<SEC-DOCUMENT>0001140361-14-020012.txt : 20140512
<SEC-HEADER>0001140361-14-020012.hdr.sgml : 20140512
<ACCEPTANCE-DATETIME>20140512090038
ACCESSION NUMBER:		0001140361-14-020012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140512
DATE AS OF CHANGE:		20140512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOTIME INC
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		14831479

	BUSINESS ADDRESS:	
		STREET 1:		1301 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		5105213390

	MAIL ADDRESS:	
		STREET 1:		1301 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>BIOTIME, INC 10-Q 3-31-2014
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Thomson Reuters
    Document created using Disclosure Solutions PROFILE 2.6.0.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div>
<hr style="BORDER-BOTTOM: black 1px solid; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; BORDER-TOP: black 4px solid">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 12pt">Washington, D.C. 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 12pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Mark One)</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;<a name="hangingindent"><!--Anchor--></a></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt; FONT-WEIGHT: bold">x</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">For the quarterly period ended March 31, 2014</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OR</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt; FONT-WEIGHT: bold">o</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">For the transition period from _________&#160;to ________</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Commission file number<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 1-12830</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 24pt; FONT-WEIGHT: bold">BioTime, Inc.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">California</div>
</td>
<td style="WIDTH: 1.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">94-3127919</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation or organization)</div>
</td>
<td style="WIDTH: 1.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(IRS Employer Identification No.)</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1301 Harbor Bay Parkway, Suite 100</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Alameda, California 94502</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Address of principal executive offices)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(510) 521-3390</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.<font style="FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt"> T</font> Yes<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt"> o</font> No</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">&#160; x</font> Yes<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt"> o</font> No</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.81%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Large accelerated filer</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: 40.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 22.21%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Accelerated filer</div>
</td>
<td style="WIDTH: 18.97%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt">T</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.81%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Non-accelerated filer</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: 40.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</div>
</td>
<td style="WIDTH: 22.21%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><a name="TAB2"><!--Anchor--></a>Smaller reporting company&#160;</div>
</td>
<td style="WIDTH: 18.97%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt"> o</font> Yes<font style="FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt"> T</font> No</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">APPLICABLE ONLY TO CORPORATE ISSUERS:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 72,149,329 common shares, no par value, as of May 9, 2014</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="part_1_2_1"><!--Anchor--></a>PART 1--FINANCIAL INFORMATION</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this Report under Item 1 of the Notes to Financial Statements, and under Risk Factors in this Report. Words such as &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; and similar expressions identify forward-looking statements.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">References to &#8220;we&#8221; means BioTime, Inc. and its subsidiaries unless the context otherwise indicates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The description or discussion, in this Form 10-Q, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left"><a name="item_1_3_1"><!--Anchor--></a><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.</font><font style="FONT-SIZE: 5.14pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Statements</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED BALANCE SHEETS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">March 31, 2014</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">(unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,637,834</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,495,478</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Inventory</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">236,588</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">178,694</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; MARGIN-LEFT: 72pt; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Trade accounts and grants receivable, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">818,275</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">998,393</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,554,114</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,277,405</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Total current assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">9,246,811</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">7,949,970</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Equipment, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,959,150</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,997,733</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred license and consulting fees</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">418,958</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">444,833</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deposits</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">428,827</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">129,129</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Other&#160;long-term assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">56,062</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">44,840,087</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">46,208,085</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">TOTAL ASSETS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">57,949,895</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">57,729,750</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,443,063</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,722,624</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred license and subscription revenue, current portion</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">177,594</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">235,276</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Total current liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,620,657</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,957,900</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LONG-TERM LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred rent, net of current portion</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">28,054</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">35,997</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred tax liability, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,928,522</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,277,548</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 19px">
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Other long-term liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,441</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">195,984</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Total long-term liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,965,017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,509,529</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Commitments and contingencies</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3,500,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">211,943,421</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">203,456,401</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Contributed capital</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">93,972</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">93,972</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated other comprehensive income/(loss)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(44,341</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">62,899</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated deficit</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(153,877,561</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(145,778,547</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Treasury stock at cost:&#160; 10,546,137 and </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10,697,715 </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">shares at March 31, 2014 and at December 31, 2013, respectively</font></div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(42,372,546</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(43,033,957</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total shareholders' equity</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">19,242,945</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">14,800,768</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Noncontrolling interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">26,121,276</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">27,461,553</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total equity</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">45,364,221</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">42,262,321</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL LIABILITIES AND EQUITY</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">57,949,895</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">57,729,750</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">2</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt"><a name="OLE_LINK1"><!--Anchor--></a>&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Three Months Ended</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">March 31, 2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">March 31, 2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REVENUES:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">License fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">294,504</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">349,824</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Royalties from product sales</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">97,886</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">107,599</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Grant income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">575,659</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">90,326</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sale of research products</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">98,586</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">66,724</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total revenues</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,066,635</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">614,473</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cost of sales</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(131,914</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(182,749</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total revenues, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">934,721</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">431,724</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXPENSES:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,405,393</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(5,395,488</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3,667,171</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3,416,145</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(12,072,564</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,811,633</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loss from operations</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(11,137,843</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,379,909</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER INCOME/(EXPENSES):</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Interest (expense)/income, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,384</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">943</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loss on sale of fixed assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,576</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,523</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other income/(expense), net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">77,746</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(28,056</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total other income/(expenses), net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">60,786</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(28,636</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LOSS BEFORE INCOME TAX BENEFIT</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(11,077,057</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,408,545</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Income tax benefit</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,349,026</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NET LOSS</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(9,728,031</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,408,545</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss attributable to noncontrolling interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">1,629,017</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">689,282</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,099,014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(7,719,263</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Foreign currency translation (loss)/gain</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(104,590</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">148,437</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Unrealized&#160;loss on available-for-sale securities, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(2,650</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">COMPREHENSIVE LOSS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,206,254</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(7,570,826</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BASIC AND DILUTED LOSS PER COMMON SHARE</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(0.14</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(0.15</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">58,257,427</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">51,175,649</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">3</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font>&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Three Months Ended</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">March 31, 2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">March 31, 2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss attributable to BioTime, Inc.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,099,014</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(7,719,263</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Depreciation expense</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">256,945</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">113,356</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,367,998</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">642,573</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of deferred consulting fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">16,279</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">16,280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of deferred license fees</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">27,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">27,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of deferred rent</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(5,040</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(2,222</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of deferred license, royalty and subscription revenues</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(42,996</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, Serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Amortization of stock-based prepaid rent</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">21,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, Serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Net loss allocable to noncontrolling interest</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,629,017</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(689,282</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">801,554</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">691,946</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred income tax benefit</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,349,026</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Loss on sale or write-off of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,576</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,523</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Deferred revenues</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(57,402</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Accounts receivable, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(24,441</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(82,916</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Grant receivable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">202,122</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">371,886</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Inventory</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(57,894</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,981</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(375,224</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(243,798</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,276,211</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(101,319</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Other long-term liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(185,717</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(7,806</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 21.6pt; FONT-SIZE: 10pt">Net cash used in operating activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(10,357,271</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(7,021,682</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Purchase of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(231,921</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(496,128</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Security deposit paid, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(299,697</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(54,423</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Proceeds from the sale of equipment</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4,000</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cash used in investing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(527,618</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(550,551</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Employee options exercised</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">12,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Director options exercised</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">46,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Proceeds from issuance of common shares</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,182,559</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">11,699,340</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Fees&#160;paid on sale of common shares</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(212,046</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(319,625</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Proceeds from sale of treasury shares</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">599,472</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,602,921</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Proceeds from sale of preferred stock</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3,500,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Proceeds from sale of common shares of subsidiary</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">130,502</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Net cash provided by financing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">12,128,485</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">13,113,138</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Effect of exchange rate changes on cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(101,240</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,463</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NET CHANGE IN CASH AND CASH EQUIVALENTS:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,142,356</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,546,368</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS:</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">At beginning of the period</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,495,478</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4,349,967</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">At end of the period</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,637,834</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">9,896,335</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cash paid during the period for interest</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,472</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common shares issued for consulting services</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">77,280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common shares issued for rent</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">242,720</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">4</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1. Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">General</font> &#8211; BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (&#8220;hES&#8221;) cell and induced pluripotent stem (&#8220;iPS&#8221;) cell technology.&#160; Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.&#160; hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products.&#160; BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use.&#160; Asterias Biotherapeutics, Inc. (&#8220;Asterias&#8221;) acquired the stem cell assets of Geron Corporation (&#8220;Geron&#8221;) that had been used in Geron&#8217;s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction.&#160; OncoCyte Corporation (&#8220;OncoCyte&#8221;) is developing products and technologies to diagnose cancer.&#160; ES Cell International Pte Ltd. (&#8220;ESI&#8221;), a Singapore private limited company, and BioTime&#8217;s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets.&#160; OrthoCyte Corporation (&#8220;OrthoCyte&#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries.&#160; ReCyte Therapeutics, Inc. (&#8220;ReCyte Therapeutics&#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.&#160; Cell Cure Neurosciences Ltd. (&#8220;Cell Cure Neurosciences&#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.&#160; LifeMap Sciences, Inc. (&#8220;LifeMap Sciences&#8221;) markets, sells and distributes <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, the leading human gene database and an integrated database suite that includes <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, the <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Discovery</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries.&#160; Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.&#160; BioTime&#8217;s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, from the sale of products for research, and from research grants.&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime&#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X.&#160; In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made.&#160; The&#160;consolidated balance sheet as of December 31, 2013 is derived from the Company&#8217;s annual audited financial statements as of that date.&#160; The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) except for the&#160;consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements.&#160; Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods.&#160; It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&#8217;s Form 10-K for the year ended December 31, 2013.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">5</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Principles of consolidation</font> &#8211; BioTime&#8217;s consolidated financial statements include the accounts of its subsidiaries.&#160; The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.</div>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" border="0" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 33px">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsidiary</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Field of Business</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BioTime </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Country</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias Biotherapeutics, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">71.6%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ES Cell International Pte Ltd</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research, including clinical grade cell lines</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">produced under cGMP</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">100%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Singapore</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OncoCyte Corporation</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cancer diagnostics</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">75.3%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OrthoCyte Corporation</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Orthopedic diseases, including chronic back pain and osteoarthritis</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">100%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cell Cure Neurosciences Ltd.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Age-related macular degeneration</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Multiple sclerosis</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Parkinson&#8217;s disease</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">62.5%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ReCyte Therapeutics, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">94.8%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr style="HEIGHT: 13px">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime Asia, Limited</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">81%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hong Kong</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Sciences, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Genetic, disease, and stem cell databases</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">73.2%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Sciences, Ltd.</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell database</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1)</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">LifeMap Solutions, Inc.</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">Mobile health software</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">(1)</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-RIGHT: #000000 2px solid">USA</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; TEXT-INDENT: -27pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 27pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">All material intercompany accounts and transactions have been eliminated in consolidation.&#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the accounting and reporting requirements of SEC Regulation S-X.&#160; As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&#8220;BioTime Asia&#8221;), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime&#8217;s condensed consolidated balance sheets.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Certain significant risks and uncertainties</font> &#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition.&#160; Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Use of estimates</font> &#8211; The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ from those estimates.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">6</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Revenue recognition</font> &#8211; BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition.&#160; Royalty revenues consist of product royalty payments.&#160; License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods.&#160; Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable.&#160; Royalties consist primarily of royalties earned on sales of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place.&#160; When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&#160; When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&#160; If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned.&#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Accounts receivable and allowance for doubtful accounts</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> &#8211;&#160; Total trade receivables amounted to approximately $600,400 and </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$575,900 </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">and grants receivable amounted to approximately $334,700 and $</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">539,300</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> as of March 31, 2014 and December 31, 2013, respectively.&#160; Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013.&#160; BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience.&#160; An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position.&#160;&#160;If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</font></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents.&#160; BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions.&#160; Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Inventory &#8211;</font> Inventories are stated at the lower of cost or market.&#160; Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Equipment</font> &#8211; Equipment is stated at cost.&#160; Equipment is being depreciated using the straight-line method over a period of 36 to 120 months.&#160; See Note 3.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Intangible assets</font> &#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&#160; Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business.&#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition. See Note 8.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&#160; BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">7</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Warrants to purchase common stock </font>&#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity.&#160; None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&#160; If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the &#8220;FASB&#8221;) regarding goodwill and other intangible assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets.&#160; Additionally, we have carved out the loss on sale of fixed assets amount from other expenses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Research and development</font> &#8211; BioTime complies with FASB requirements governing accounting for research and development costs.&#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Foreign currency translation gain and Comprehensive loss &#8211;</font> In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date.&#160; Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period.&#160; Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet.&#160; For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that&#160;are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense),&#160;amounted to $10,212 and $21,977, respectively.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect.&#160; Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized.&#160; The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.&#160; For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities.&#160; For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias&#8217; tax provision with BioTime&#8217;s.&#160; BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively.&#160; BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions.&#160; Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.&#160; Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws.&#160; Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&#160; No tax benefit had been recorded through <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">September 30, 2013</font> because of the net operating losses incurred and a full valuation allowance had been provided.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stock-based compensation &#8211;</font> BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&#160; In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments.&#160; BioTime has applied the provisions of this guidance in such valuations as well.&#160; Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model.&#160; BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables.&#160; These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">8</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Impairment of long-lived assets &#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&#160; If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&#160; The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products.&#160; See Note 5.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Loss per share</font> &#8211; Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period.&#160; Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive.&#160; Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Effect of recently issued and recently adopted accounting pronouncements </font>&#8211; There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2. Inventory</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime held $223,665 and $165,771 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2014 and December 31, 2013, respectively.&#160; Finished goods products of $12,923 were held by a third party on consignment at March 31, 2014 and December 31, 2013.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3. Equipment</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following:</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2014</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment, furniture and fixtures</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4,645,077</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4,431,586</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated depreciation</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,685,927</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1,433,853</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,959,150</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,997,733</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Depreciation expense amounted to $256,945 and $113,356 for the three months ended March 31, 2014 and 2013, respectively.&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">9</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4. Intangible assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2014</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">54,719,918</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">54,719,918</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated amortization</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(9,879,831</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,511,833</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">44,840,087</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">46,208,085</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis.&#160; BioTime recognized $1,367,998 and $642,573 in amortization expense of intangible assets during the three months ended March 31, 2014 and 2013, respectively.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5. Royalty Obligation and Deferred License Fees</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products.&#160; BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing.&#160; The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired.&#160; BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">WARF License&#8212;Research Products</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;).&#160; The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development.&#160; BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF.&#160; The royalty will range from 2% to 4%, depending on the kind of products sold.&#160; The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product.&#160; BioTime paid licensing fees, totaling $295,000 in cash and BioTime stock, and reimbursed WARF for certain costs associated with preparing, filing, and maintaining the licensed patents.&#160; In addition, BioTime pays WARF $25,000 annually as a license maintenance fee.&#160; The licensing fees less the amortized portion were included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ReCyte Therapeutics Licenses from ACT</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc. (&#8220;ACT&#8221;), under which ReCyte Therapeutics acquired exclusive worldwide rights to use ACT&#8217;s &#8220;<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ACTCellerate</font>&#8482;&#8221; technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells.&#160; ReCyte Therapeutics paid ACT a $250,000 license fee.&#160; ReCyte Therapeutics has assigned its rights under the License Agreement to BioTime.&#160; BioTime will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology.&#160; Once a total of $1,000,000 of royalties has been paid, no further royalties will be due.&#160; The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later.&#160; The $250,000 license fee less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On August 15, 2008, ReCyte Therapeutics entered into a License Agreement and a Sublicense Agreement with ACT under which ReCyte Therapeutics acquired world-wide rights to use an array of ACT technology (the &#8220;ACT License&#8221;) and technology licensed by ACT from affiliates of Kirin Pharma Company, Limited (the &#8220;Kirin Sublicense&#8221;).&#160; The ACT License and Kirin Sublicense permit the commercialization of products in human therapeutic and diagnostic product markets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The technology licensed by ReCyte Therapeutics covers methods to transform cells of the human body, such as skin cells, into an embryonic state in which the cells will be pluripotent.&#160; Under the ACT License, ReCyte Therapeutics paid ACT a $200,000 license fee and will pay a 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the ACT technology to third parties.&#160; Once a total of $600,000 of royalties has been paid, no further royalties will be due.&#160; The license will expire in twenty years or upon the expiration of the last-to-expire of the licensed patents, whichever is later.&#160; The $200,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">10</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under the Kirin Sublicense, ReCyte Therapeutics has paid ACT a $50,000 license fee and will pay a 3.5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the Kirin Technology to third parties.&#160; ReCyte Therapeutics will also pay to ACT or to an affiliate of Kirin Pharma Company, Limited (&#8220;Kirin&#8221;), annually, the amount, if any, by which royalties payable by ACT under its license agreement with Kirin are less than the $50,000 annual minimum royalty due.&#160; Those payments by ReCyte Therapeutics will be credited against other royalties payable to ACT under the Kirin Sublicense.&#160; The license will expire upon the expiration of the last to expire of the licensed patents, or May 9, 2016 if no patents are issued.&#160; The $50,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ReCyte Therapeutics License from RGI</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On February 29, 2009, ReCyte Therapeutics entered into a Stem Cell Agreement with Reproductive Genetics Institute (&#8220;RGI&#8221;).&#160; In partial consideration of the rights and licenses granted to ReCyte Therapeutics by RGI, BioTime issued to RGI 32,259 common shares, having a market value of $50,000 on the effective date of the Stem Cell Agreement.&#160; This $50,000 payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OncoCyte License from SBMRI</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Through BioTime&#8217;s acquisition of the assets of Cell Targeting, Inc. during March 2011, BioTime acquired a royalty-bearing, exclusive, worldwide license from the Sanford-Burnham Medical Research Institute (&#8220;SBMRI&#8221;) to use certain patents pertaining to homing peptides for preclinical research investigations of cell therapy treatments, and to enhance cell therapy products for the treatment and prevention of disease and injury in conjunction with BioTime&#8217;s own proprietary technology or that of a third party.&#160; BioTime assigned the SBMRI license to OncoCyte during July 2011.&#160; OncoCyte will pay SBMRI a royalty of 4% on the sale of pharmaceutical products, and 10% on the sale of any research-use products that OncoCyte develops using or incorporating the licensed technology; and 20% of any payments OncoCyte receives for sublicensing the patents to third parties.&#160; The royalties payable to SBMRI may be reduced by 50% if royalties or other fees must be paid to third parties in connection with the sale of any products.&#160; An annual license maintenance fee is payable each year during the term of the license, and after commercial sales of royalty bearing products commence, the annual fee will be credited towards OncoCyte's royalty payment obligations for the applicable year.&#160; OncoCyte will reimburse SBMRI for 25% of the costs incurred in filing, prosecuting, and maintaining patent protection, subject to OncoCyte&#8217;s approval of the costs.&#160; OncoCyte incurred no royalty expenses to date as of March 31, 2014.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cell Cure Neurosciences License from Hadasit</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit Medical Research Services and Development, Ltd. (&#8220;Hadasit&#8221;) under which Cell Cure Neurosciences received an exclusive license to use certain of Hadasit&#8217;s patented technologies for the development and commercialization for hES cell-derived cell replacement therapies for retinal degenerative diseases.&#160; Cell Cure Neurosciences paid Hadasit 249,058 New Israeli Shekels as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;) exercises its option to license <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> or <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font> under the terms of a Research and Exclusive License Option Agreement (the &#8220;Teva License Option Agreement&#8221;), Cell Cure Neurosciences will pay Hadasit 30% of all sublicensing payments made by Teva to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">11</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If Teva does not exercise its option and Cell Cure Neurosciences instead commercializes <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> or <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font> itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> or <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font>, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology.&#160; Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents to companies other than Teva.&#160; Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year.&#160; If Cell Cure Neurosciences or a sublicensee other than Teva paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If Teva does not exercise its option under the Teva License Option Agreement and instead Cell Cure Neurosciences or a sublicensee other than Teva conducts clinical trials of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> or <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font>, Hadasit will be entitled to receive certain milestone payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents.&#160; Hadasit will receive $250,000 upon the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial.&#160; These milestone payments are creditable by Cell Cure Neurosciences against sublicensing receipts that are payable to Hadasit at the time of each milestone payment for said milestone payment, except that the $1 million milestone payment shall only be creditable by Cell Cure Neurosciences if it received the sublicensing receipts in the amount of $50 million.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime License for the University of Utah</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Through the merger of Glycosan into OrthoCyte during March 2011, BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products.&#160; Under the License Agreement, the scope of which was expanded by an amendment during August 2012, BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents.&#160; Commencing in 2014, BioTime will be obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount.&#160; The minimum royalty amounts are $2,500 in 2014 and $30,000 each year thereafter during the term of the License Agreement.&#160; BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses.&#160; BioTime will also pay a $225,000 milestone fee within six months after the first sale of a &#8220;tissue engineered product&#8221; that utilizes a licensed patent.&#160; A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime License from Cornell University</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On August 23, 2011, BioTime entered into a License Agreement with Cornell University for the worldwide development and commercialization of technology for the differentiation of hES cells into vascular endothelial cells.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cornell will be entitled to receive a nominal initial license fee and nominal annual license maintenance fees.&#160; The obligation to pay annual license maintenance fees will end when the first human therapeutic products developed under the license is sold.&#160; BioTime will pay Cornell a milestone payment upon the achievement of a research product sale milestone amount, and will make milestone payments upon the attainment of certain FDA approval milestones for therapeutic products developed under the license, including (i) the first Phase II clinical trial dosing of a human therapeutic product, (ii) the first Phase III clinical trial dosing of a human therapeutic product; (iii) FDA approval of the first human therapeutic product for age-related vascular disease; and (iv) FDA approval of the first human therapeutic product for cancer.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime will pay Cornell royalties on the sale of products and services using the license, and will share with Cornell a portion of any cash payments, other than royalties, that BioTime receives for the grant of sublicenses to non-affiliates.&#160; The potential royalty percentage rates to be paid to Cornell will be in the low to mid-single digit range depending on the product.&#160; BioTime will also reimburse Cornell for costs related to the patent applications and any patents that may issue that are covered by the license.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">12</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In conjunction with the License Agreement, BioTime also entered into a Sponsored Research Agreement under which scientists at Weill Cornell Medical College will engage in certain research for BioTime over a three year period beginning August 2011.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias License from WARF</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products.&#160; The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells.&#160; The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire.&#160; Asterias may terminate the license agreement at any time by giving WARF prior written notice.&#160; WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time.&#160; WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias License from the University of California</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Geron assigned to Asterias its Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents.&#160; Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement.&#160; The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement.&#160; Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias&#8217; affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent.&#160; The license agreement will terminate on the expiration of the last-to-expire of the university's issued licensed patents.&#160; If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024.&#160; The university may terminate the agreement in the event of Asterias&#8217; breach of the agreement.&#160; Asterias can terminate the agreement upon 60 days' notice.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias Sublicense from Geron</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado&#8217;s University License Equity Holdings, Inc. relating to telomerase (the &#8220;Telomerase Sublicense&#8221;).&#160; The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of VAC1 and VAC2 as immunological treatments for cancer.&#160; Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents.&#160; The Telomerase Sublicense will expire concurrently with the expiration of Geron&#8217;s license.&#160; That license will terminate during April 2017 when the licensed patents expire.&#160; The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party. See Note 8.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">13</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, future amortization of deferred license fees described above was as follows:</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 80%; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 45pt; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" align="left">
<tr>
<td style="WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deferred License</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fees</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2014</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">83,615</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2015</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">111,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">111,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2017</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">111,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Thereafter</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">111,843</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 68%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Total</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">528,458</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; CLEAR: both; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6. Accounts Payable and Accrued Liabilities</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2014</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accounts payable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,527,330</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3,887,950</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accrued bonuses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">229,905</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">600,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other accrued liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,685,828</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,234,674</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,443,063</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">6,722,624</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7. Equity</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Preferred Shares</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime is authorized to issue 2,000,000 shares of preferred stock.&#160; The preferred shares may be issued in one or more series as the board of directors may by resolution determine.&#160; The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.&#160; The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, BioTime has 70,000 outstanding preferred shares.&#160; On March 4, 2014, BioTime sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock (&#8220;Series A Preferred&#160;Stock&#8221;) for $3.5 million.&#160; The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares.&#160; Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In connection with the sale of the Series A Preferred Stock, BioTime also entered into an Option Agreement with each purchaser of Series A Preferred Stock entitling them, for a period of five years, to exchange their shares of Series A Preferred Stock for shares of common stock of BioTime&#8217;s subsidiary LifeMap Sciences, Inc. held by BioTime at the ratio of 12.5 shares of LifeMap Sciences common stock for each share of BioTime Series A Preferred Stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">14</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion.&#160; The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval.&#160; Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted.&#160; The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares.&#160; After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Common Shares</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime is authorized to issue 125,000,000 common shares with no par value.&#160; As of March 31, 2014, BioTime had issued 69,617,329 common shares and outstanding 59,071,192 common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014 and 2013, BioTime recognized stock-based compensation expenses of $801,554 and $691,946, respectively, due to stock options granted to employees and directors.&#160; During the three months ended March 31, 2014 and 2013, BioTime granted 1,205,000 and 1,090,000 options, respectively, under its 2012 Equity Incentive Plan.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, 45,000 options and no warrants were exercised.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8. </font>Asset Contribution Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On January 4, 2013, BioTime and Asterias entered into an Asset Contribution Agreement with Geron Corporation (&#8220;Geron&#8221;) pursuant to which BioTime and Geron agreed to concurrently contribute certain assets to Asterias in exchange for shares of Asterias common stock.&#160; The transaction closed on October 1, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Transfer of BioTime Assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under the Asset Contribution Agreement, BioTime contributed to Asterias 8,902,077 BioTime common shares registered for re-sale under the Securities Act of 1933, as amended, warrants to subscribe for and purchase 8,000,000 additional BioTime common shares (the &#8220;BioTime Warrants&#8221;) exercisable for a period of five years at a price of $5.00 per share, subject to pro rata adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions; a 10% common stock interest in BioTime&#8217;s subsidiary OrthoCyte; a 6% ordinary share interest in BioTime&#8217;s subsidiary Cell Cure Neurosciences; and a quantity of certain hES cell lines produced under &#8220;good manufacturing practices&#8221; sufficient to generate master cell banks, and non-exclusive, world-wide, royalty-free licenses to use those cell lines and certain patents pertaining to stem cell differentiation technology for any and all purposes.&#160; In return, Asterias issued to BioTime 21,773,340 shares of its Series B common stock, par value $0.0001 per share (&#8220;Series B Shares&#8221;), and warrants to purchase 3,150,000 Series B Shares, exercisable for a period of three years from the date of issue at an exercise price of $5.00 per share.&#160; In addition, BioTime cancelled Asterias&#8217; obligations to repay the principal amount of a loan in the amount of $5,000,000 arising from cash financing provided to Asterias by BioTime during 2013 prior to the closing of the asset contribution transaction under the Asset Contribution Agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Because Asterias is a subsidiary of BioTime, the transfer of assets from BioTime was accounted for as a transaction under common control.&#160; Non-monetary assets received by Asterias were recorded at their historical cost basis amounts with BioTime.&#160; Monetary assets were recorded at fair value.&#160; The difference between the value of assets contributed by BioTime and the fair value of consideration issued to BioTime was recorded as an additional contribution by BioTime, in additional paid-in capital.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">15</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The assets transferred by BioTime and the related consideration paid were recorded as follows:</div>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Consideration transferred to BioTime:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Asterias Series B shares</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">52,164,568</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Warrants to purchase Asterias Series B shares</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,012,481</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Excess of contributed assets&#8217; value over consideration</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4,800,063</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total consideration issued</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">58,977,112</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Assets transferred by BioTime:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime common shares, at fair value</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">34,985,163</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime Warrants, at fair value</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">18,276,406</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cancellation of outstanding obligation to BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,000,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Investment in affiliates, at cost</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">415,543</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Geron asset acquisition related transaction costs paid by BioTime</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">300,000</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total assets transferred</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">58,977,112</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The fair value of the Asterias Series B shares issued was estimated at $2.40 based on the Asterias enterprise value as determined on January 4, 2013, at the time the Asset Contribution Agreement was negotiated and executed by its parties, and as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.&#160; The fair value of the warrants to purchase Asterias Series B shares was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions:&#160; expected term equal to the contractual term of three years, which is equal to the contractual life of the warrants; risk-free rate of 0.63%; 0% expected dividend yield; 69.62% expected volatility based on the average historical common stock volatility of BioTime and Geron, which were used as Asterias&#8217; common stock does not have a trading history; a stock price of $2.40; and an exercise price of $5.00.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime common shares were valued at $3.93 using the closing price per BioTime common shares on the NYSE MKT on October 1, 2013.&#160; The fair value of the BioTime Warrants was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of five years, which is equal to the contractual life of the warrants; risk-free rate of 1.42%; 0% expected dividend yield; 77.63% expected volatility based on historical common stock volatility of BioTime; a stock price of $3.93; and an exercise price of $5.00.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The investment in OrthoCyte and Cell Cure Neurosciences stock represents a non-monetary asset and was recorded at BioTime&#8217;s historical cost because BioTime is a common parent to Asterias and those two BioTime subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Geron Assets Acquisition</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under the Asset Contribution Agreement, Geron contributed to Asterias certain patents, patent applications, trade secrets, know-how and other intellectual property rights with respect to the technology of Geron directly related to the research, development and commercialization of certain products and know-how related to hES cells; certain biological materials, reagents, laboratory equipment; as well as clinical trial documentation, files and data, primarily related to GRNOPC1 clinical trials for spinal cord injury and VAC1 clinical trials for acute myelogenous leukemia. Asterias assumed all obligations related to such assets that would be attributable to periods, events or circumstances after the Asset Contribution Agreement closing date, including those related to an appeal filed in the United States District Court in Civil Action No. C12-04813 (the &#8220;ViaCyte Appeal&#8221;) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office&#8217;s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving US patent 7,510,876 (ViaCyte) and US patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving US patent 7,510,876 (ViaCyte) and US patent application 12/543,875 (Geron).&#160; Asterias also assumed the patent interferences upon which the ViaCyte Appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte, Inc. patent filings in Australia and in the European Patent Office.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">As consideration for the acquisition of assets from Geron, Asterias issued to Geron 6,537,779 shares of Series A common stock, par value $0.0001 per share (&#8220;Series A Shares&#8221;), which Geron had agreed to distribute to its stockholders, on a pro rata basis, subject to applicable legal requirements and certain other limitations (the &#8220;Series A Distribution&#8221;).&#160; Asterias is also obligated to distribute to the holders of its Series A Shares the 8,000,000 shares of BioTime Warrants contributed to Asterias by BioTime.&#160; Asterias will distribute the BioTime Warrants as promptly as practicable after notice from Geron that the Series A Distribution has been completed.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">16</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In addition, Asterias agreed to bear certain transaction costs in connection with the Geron asset acquisition.&#160; Such transaction costs were allocated to acquisition of assets in the amount of $1,519,904 and issuance of equity in the amount of $541,800.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The assets contributed to Asterias by Geron did not include workforce or any processes to be applied to the patents, biological materials, and other assets acquired, and therefore did not constitute a business.&#160; Accordingly, the acquisition of the Geron assets has been accounted for as an acquisition of assets in accordance with the relevant provisions of Accounting Standards Codification (ASC) 805-50.&#160; Total consideration payable by Asterias, including transaction costs, has been allocated to the assets acquired based on relative fair values of those assets as of the date of the transaction, October 1, 2013, in accordance with ASC 820, Fair Value Measurement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The assets acquired from Geron and the related consideration were recorded as follows:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Consideration paid to Geron:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div></div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Asterias Series A shares, net of share issuance costs of $541,800</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">15,121,222</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Obligation to distribute BioTime Warrants</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">18,276,406</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Transaction and other costs</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,519,904</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total consideration paid</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">34,917,532</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Assets acquired from Geron (preliminary allocation):</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Patents and other intellectual property rights related to hES cells</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">29,017,009</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(11,558,243</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">IPR&amp;D expensed upon acquisition</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">17,458,766</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 88%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total assets and in-process research and development acquired</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">34,917,532</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The fair value of the Asterias Series A shares issued was estimated at $2.40 based on the estimated Asterias enterprise value as determined by parties at the time the Asset Contribution Agreement was negotiated and executed by its parties on January 4, 2013, as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The fair value of the obligation to distribute BioTime Warrants equals the fair value of such warrants, which was computed as noted above under &#8220;Transfer of BioTime Assets.&#8221;&#160; Because the fair value of the BioTime Warrants is expected to always be equal to the fair value of the obligation to distribute them at any date on which those values are determined, the remeasurement of those values will not result in a charge or credit on the statement of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The difference between the fair value of assets contributed by Geron and the fair value of consideration issued to Geron was recorded as an additional contribution by Geron, in additional paid-in capital, because the fair value of the assets transferred by Geron was more reliably determined.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Assets acquired from Geron consist primarily of patents and other intellectual property rights related to hES cells which Asterias intends to license to various parties interested in research, development and commercialization of hES cells technologies, and IPR&amp;D, which includes biological materials, reagents, clinical trial documentation, files and data related primarily to certain clinical trials previously conducted by Geron, which Geron discontinued in November 2011.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</div>

<div>
<div style="TEXT-INDENT: 36pt">Intangible assets related to IPR&amp;D represent the value of incomplete research and development projects which the company intends to continue.&#160; In accordance with the accounting rules in ASC 805, such assets, when acquired in conjunction with acquisition of a business, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&amp;D are expensed upon acquisition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The values of the acquired assets were estimated at October 1, 2013 based upon a preliminary review of those assets which took into account factors such as the condition of the cells, cell lines and other biological materials being contributed, the stage of development of particular technology and product candidates related to patents, patent applications, and know-how, the intended use of these assets and the priority assigned to the development of product candidates to which those assets relate, and the assessment of the estimated useful lives of patents.&#160; The amounts allocated to patents and other intellectual property rights that Asterias intends to license were capitalized as intangible assets and are being amortized over an estimated useful life period of 10 years.&#160; The amounts allocated to IPR&amp;D were expensed at the time of acquisition of the related assets in accordance with the requirements of ASC 805-50.&#160; The allocation was based on the relative fair value of assets eligible for capitalization and the fair value of assets representing IPR&amp;D before assessing the deferred tax liability arising from the difference in book versus tax basis on Geron intangible assets acquired, which management estimated to be approximately equal.&#160; Accordingly, $17,458,766 was capitalized as of December 31, 2013, and $17,458,766 was expensed.&#160; These amounts are preliminary as management has not yet completed a detailed assessment and valuation of the acquired assets.&#160; Such assessment and valuation is expected to be completed during the quarter ending June 30, 2014.&#160; Accordingly, the amounts included in capitalized intangible assets and expensed IPR&amp;D as of December 31, 2013 are subject to adjustments which could be material.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">17</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias is also obligated to pay Geron royalties on the sale of products, if any, that are commercialized in reliance upon patents acquired from Geron, at the rate of 4% of net sales.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stock and Warrant Purchase Agreement with Romulus</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On January 4, 2013, in connection with entering into the Asset Contribution Agreement, Asterias entered into a Stock and Warrant Purchase Agreement with Romulus Films, Ltd (&#8220;Romulus&#8221;) pursuant to which Romulus agreed to purchase 2,136,000 Series B Shares and warrants to purchase 350,000 additional Series B Shares for $5,000,000 in cash upon the consummation of the acquisition of assets under the Asset Contribution Agreement.&#160; On October 1, 2013, the shares and warrants were issued in exchange for $5,000,000 in cash.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9. Unaudited Pro Forma Interim Financial Information &#8211; Three Months Ended March 31, 2014 and 2013</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013.&#160; The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 5.5pt">Three Months Ended March 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">2014</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Revenues, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">934,721</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">493,705</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss available to common shareholders</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,099,014</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(</font>22,572,852</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss per common share &#8211; basic and diluted</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(0.14</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(</font>0.38</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10. Subsequent Events</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In May 2014, BioTime raised $6,380,640 of additional equity capital through the sales of BioTime common shares&#160;in &#8220;at-the-market&#8221; transactions through Cantor Fitzgerald &amp; Co., as BioTime's sales agent.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On May 5, 2014, BioTime was awarded an SBIR Phase 1 Small Business Grant in the amount of $224,911 from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH). Under this grant entitled &#8220;Cell Targeting Peptides for Isolating Patient Specific Stem Cells&#8221; BioTime will work on streamlining <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup></font>cell line development and developing improved assays for monitoring stem cell differentiation.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Solutions, Inc.&#8212;Mobile Health Software Products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On May 6, 2014, LifeMap Solutions, Inc. (&#8220;Solutions&#8221;), a newly formed subsidiary of LifeMap Sciences, entered into a Co-Development and Option Agreement (the &#8220;Agreement&#8221;) with the Icahn School of Medicine at Mount Sinai, a nonprofit education corporation (&#8220;Mt Sinai&#8221;), pursuant to which Solutions and Mt Sinai have agreed to work cooperatively to develop internet, web-based, mobile user or consumer software products to provide users with information that may potentially aid them in improving lifestyle and healthcare decisions and outcomes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Solutions and Mt Sinai will license to each other, on a non-exclusive, royalty free basis, certain &#8220;background&#8221; intellectual property for joint use in product development.&#160; Solutions will pay Mt Sinai for the use of Mt Sinai personnel based on their direct salaries plus an overhead charge, but Mt Sinai has agreed to waive collection of the first $1,000,000 of overhead charges.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Solutions will have an option to acquire a world-wide license to use Mt Sinai&#8217;s background intellectual property and other intellectual property developed by Mt Sinai alone or jointly with Solutions in the joint development project for the purpose of developing and commercializing the product.&#160; The terms of the license agreement that will be executed if Solutions exercises its option under the Agreement (the &#8220;License Agreement&#8221;) are subject to negotiation by the parties, but will include certain provisions specified in the Agreement, including the obligation of Solutions to pay Mt Sinai: (a) royalties on net sales, (b) a percentage of any consideration received by Solutions from its sublicensees and distributors of the product; (c) all reasonable patent and licensing costs incurred prior to the effective date of the definitive License Agreement in connection with the licensed patent rights and certain other Mount Sinai technology and background intellectual property, and all reasonable attorney&#8217;s fees, expenses, official fees, and other charges incident to the preparation, prosecution, and maintenance of licensed patent rights: and (d) up to 5% of the then current equity value of Solutions at the time of a &#8220;Significant Transaction.&#8221;&#160; The percentage to be paid is subject to dilution based on future investment in Solutions and the amount of personnel cost overhead charges waived by Mt Sinai under the Agreement.&#160; The term &#8220;Significant Transaction&#8221; will mean the first to occur of a single transaction, or series of related transactions, consisting of or resulting in any of the following:&#160; (i) an assignment, other than to LifeMap Sciences, of the definitive license agreement; (ii) an initial public offering of securities by Solutions (or its successor) or other transaction resulting in any of Solutions&#8217; securities being traded on a nationally recognized stock exchange or automated quotation system; (iii) a sale, license or other disposition of all or substantially all of Solutions&#8217; assets; or (iv) a reorganization, consolidation or merger of Solutions, or sale or transfer of the securities of Solutions, where the holders of Solutions&#8217; outstanding voting securities before the transaction beneficially own less than fifty percent (50%) of the outstanding voting securities, or hold less than fifty percent (50%) of the voting power of the voting security holders of the surviving entity after the transaction.&#160; A Significant Transaction shall not be deemed to occur as a result of a bona fide, arm&#8217;s-length equity financing for cash in which Solutions issues securities (other than through an initial public offering described in clause (ii) above) representing more than fifty percent (50%) of the voting power of its security holders to venture capital or other similar professional investors who do not actively manage day-to-day operations of Solutions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Sciences Stock Purchase Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Also on May 6, 2014, BioTime entered into a Stock Purchase Agreement with LifeMap Sciences to provide financing for Solutions&#8217; product development costs under the Agreement with Mt Sinai.&#160; BioTime will purchase 2,500,000 shares of LifeMap Sciences common stock for $5,000,000 in four tranches during 2014.&#160; LifeMap Sciences will use the proceeds from the sale to provide capital to Solutions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime will also have an option to purchase up to an additional 9,500,000 shares of LifeMap Sciences common stock for $2.00 per share in two tranches related to the attainment of certain product development milestones by Solutions.&#160; If BioTime exercises its option it may pay for those LifeMap Sciences shares in up to three installments for each tranche, in cash or in BioTime common shares at the then current market value determined as of the date the option is exercised based on the average closing price of BioTime common shares on the NYSE MKT for the preceding 20 trading days.&#160; The number of shares of LifeMap Sciences common stock that BioTime may purchase will be reduced to the extent that LifeMap Sciences raises capital from other sources for product development under the Agreement with Mt Sinai.</div>

<br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">These condensed consolidated financial statements were approved by management and the Board of Directors, and were issued on May 12<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">,</font> 2014 (unaudited).&#160; Subsequent events have been evaluated through that date.</div>

<div style="TEXT-ALIGN: left"><a name="item_1_3_2"><!--Anchor--></a><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">18</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.59%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.</div>
</td>
<td style="WIDTH: 93.41%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management's Discussion and Analysis of Financial Condition and Results of Operations</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal">The following Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our condensed consolidated financial statements for the three months ended March 31, 2014 and 2013, and highlight certain other information which, in the opinion of management, will enhance a reader's understanding of our financial condition, changes in financial condition and results of operations.&#160; In particular, the discussion is intended to provide an analysis of significant trends and material changes in our financial position and the operating results of our business during the quarter ended March 31, 2014 as compared to the quarter ended March 31, 2013.&#160; This discussion should be read in conjunction with our Condensed Consolidated Financial Statements for the three months ended March 31, 2014 and 2013 and related notes included elsewhere in this Quarterly Report on Form 10-Q.&#160; These historical financial statements may not be indicative of our future performance.&#160; This Management's Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks described throughout this filing, particularly in "Item 1A. Risk Factors."</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We are a biotechnology company focused on the emerging field of regenerative medicine.&#160; Our core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.&#160; Products made from these &#8220;pluripotent&#8221; stem cells are being developed by us and our subsidiaries, for use in a variety of fields of medicine.&#160; Four of our subsidiaries, Asterias Biotherapeutics, Inc. (&#8220;Asterias&#8221;), Cell Cure Neurosciences, Ltd (&#8220;Cell Cure Neurosciences&#8221;), OrthoCyte Corporation (&#8220;OrthoCyte&#8221;), and ReCyte Therapeutics, Inc. (&#8220;ReCyte&#8221;) are focused on developing cell based therapeutic products for diseases such as neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular disease.&#160; Our commercial strategy targets near-term opportunities such as:&#160; </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Renevia</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8482; a product currently in clinical trials in Europe to facilitate cell transplantation; </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ReGlyde</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8482; and </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Premvia</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8482; for tendon and dermatological applications, respectively; </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PanC-Dx</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8482;, a family of novel blood and urine-based cancer screens; our current line of research products including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> cell lines,</font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">associated </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ESpan</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8482; culture media, human embryonic stem cell lines derived by our subsidiary ESI under current good manufacturing practices (&#8220;cGMP&#8221;); </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> hydrogel products; the LifeMap Database Suite and mobile health software products.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#8220;Regenerative medicine&#8221; refers to an emerging field of therapeutic product development that may allow all human cell and tissue types to be manufactured on an industrial scale.&#160; This new technology is made possible by the isolation of human embryonic stem (&#8220;hES&#8221;) cells, and by the development of &#8220;induced pluripotent stem (&#8220;iPS&#8221;) cells&#8221; which are created from regular cells of the human body using technology that allows adult cells to be &#8220;reprogrammed&#8221; into cells with pluripotency similar to hES-like cells.&#160; These pluripotent hES and iPS cells have the unique property of being able to branch out into each and every kind of cell in the human body, including the cell types that make up the brain, the blood, the heart, the lungs, the liver, and other tissues.&#160; Unlike adult-derived stem cells that have limited potential to become different cell types, pluripotent stem cells may have vast potential to supply an array of new regenerative therapeutic products, especially those targeting the large and growing markets associated with age-related degenerative disease.&#160; Unlike pharmaceuticals that require a molecular target, therapeutic strategies in regenerative medicine are generally aimed at regenerating affected cells and tissues, and therefore may have broader applicability.&#160; Regenerative medicine represents a revolution in the field of biotechnology with the promise of providing therapies for diseases previously considered incurable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The field of regenerative medicine includes a broad range of disciplines, including tissue banking, cellular therapy, gene therapy, and tissue engineering.&#160; Our commercial efforts in regenerative medicine include the development and sale of products designed for research applications in the near term as well as products designed for diagnostic and therapeutic applications in the medium and long term.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We have also developed and licensed manufacturing and marketing rights to <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a physiologically balanced blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications.&#160; Hypovolemia is a condition caused by low blood volume, often from blood loss during surgery or from injury.&#160; <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> maintains circulatory system fluid volume and blood pressure and helps sustain vital organs during surgery or when a patient has sustained substantial blood loss due to an injury.&#160; <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is the only blood plasma volume expander that contains lactate, multiple electrolytes, glucose, and a medically approved form of starch called hetastarch.&#160; <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is sterile, so its use avoids the risk of infection.&#160; Health insurance reimbursements and HMO coverage now include the cost of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> used in surgical procedures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ Health Corporation (&#8220;CJ Health&#8221;), a subsidiary of Cheil Jedang Corp. (&#8220;CJ&#8221;), under license from us.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">19</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The following table shows our subsidiaries, their respective principal fields of business, our percentage ownership as at March 31, 2014, and the country where their principal business is located:</div>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsidiary</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Field of Business</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BioTime </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Country</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias Biotherapeutics, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">71.6%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ES Cell International Pte Ltd</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research, including clinical grade cell lines</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">produced under cGMP</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">100%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Singapore</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OncoCyte Corporation</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cancer diagnostics</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">75.3%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OrthoCyte Corporation</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Orthopedic diseases, including chronic back pain and osteoarthritis</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">100%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cell Cure Neurosciences Ltd.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Age-related macular degeneration</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Multiple sclerosis</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Parkinson&#8217;s disease</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">62.5%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ReCyte Therapeutics, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">94.8%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime Asia, Limited</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">81%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hong Kong</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Sciences, Inc.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Genetic, disease, and stem cell databases</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">73.2%</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">LifeMap Sciences, Ltd.</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell database</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1)</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">LifeMap Solutions, Inc.</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 49.98%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">Mobile health software</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top; BORDER-RIGHT: medium none">(1)</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 9.9%; VERTICAL-ALIGN: top; BORDER-RIGHT: #000000 2px solid">USA</td>
</tr>
</table>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional Information</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Espy</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">, HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">,</font> and<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> PentaLyte</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> are registered trademarks of BioTime, Inc., and<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Renevia</font>&#8482;, <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ESpan</font>&#8482; and <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">ESI BIO</font>&#8482; are trademarks of BioTime, Inc.<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160; ACTCellerate</font>&#8482; is a trademark licensed to us by Advanced Cell Technology, Inc<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">. ReCyte</font>&#8482; is a trademark of ReCyte Therapeutics, Inc.<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160; PanC-Dx</font>&#8482; is a trademark of OncoCyte Corporation.&#160; <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Yeda Research and Development Co. Ltd.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We were incorporated in 1990 in the state of California.&#160; Our principal executive offices are located at 1301 Harbor Bay Parkway, Alameda, California 94502.&#160; Our telephone number is (510) 521-3390.</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">20</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The following table shows the approximate percentages of our total research and development expenses of $8,405,393 and $5,395,488 allocated to our primary research and development projects during the three months ended March 31, 2014 and 2013, respectively</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Program</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Asterias</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">hESC-based cell therapeutic programs</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">30.9</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime and ESI</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> hEPCs, cGMP hES cell lines, <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">and related research products</font></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">9.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">12.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> technology</font></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hydrogel therapeutic products and <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> research</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">15.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">21.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">OncoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cancer diagnostics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">11.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">13.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">OrthoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Orthopedic therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">ReCyte Therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cardiovascular therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5.2</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime Asia</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.2</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Cell Cure Neurosciences</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><em style="FONT-STYLE: normal">A</em>ge related macular degeneration (<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font>), and neurological disease therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">15.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">23.2</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">LifeMap Sciences</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Database development and sales</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">9.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">11.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">High Content Screening</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">0.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Revenue recognition</font> &#8211; We comply with SEC Staff Accounting Bulletin guidance on revenue recognition.&#160; Royalty revenues consist of product royalty payments.&#160; License fee revenues consist of fees under license agreements and are recognized when earned and reasonably estimable and also include subscription and advertising revenue from our online databases based upon respective subscription or advertising periods.&#160; We recognize revenue in the quarter in which the royalty reports are received rather than the quarter in which the sales took place.&#160; When we are entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which we have no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&#160; When we receive up-front nonrefundable licensing or similar fees pursuant to agreements under which we do have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&#160; If the performance period cannot be reasonably estimated, we amortize nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.&#160; Grant income and the sale of research products are recognized as revenue when earned.&#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Patent costs</font> &#8211; Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;) regarding goodwill and other intangible assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Intangible assets</font> &#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&#160; Acquired in-process research and development intangible assets are accounted depending on whether they were acquired as part of an acquisition of a business, or assets that do not constitute a business.&#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as Asterias&#8217; acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&amp;D are expensed upon acquisition.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Research and development </font>&#8211; We comply with FASB requirements governing accounting for research and development costs.&#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, and license fees paid to acquire patents or licenses to use patents and other technology from third parties.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">21</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stock-based compensation</font> &#8211; We have adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&#160; We utilize the Black-Scholes Merton option pricing model.&#160; Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables.&#160; These variables include, but are not limited to, expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.&#160; In management&#8217;s opinion, the existing valuation models may not provide an accurate measure of the fair value of employee stock options because the option-pricing model value may not be indicative of the fair value that would be established in a willing buyer/willing seller market transaction.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Treasury stock</font> &#8211; We account for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&#160; We have the intent and ability to register any unregistered shares to support the marketability of the shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Impairment of long-lived assets</font> &#8211; Our long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&#160; If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&#160; The value of the warrants is being amortized over the lives of the warrants, and deferred license fees over the estimated useful lives of the licensed technologies or licensed research products.&#160; The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired.&#160; We will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.&#160; See also Note 5 to the condensed consolidated interim financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Principles of consolidation</font> &#8211; Our consolidated financial statements include the accounts of our wholly-owned subsidiaries, OrthoCyte, and ESI, and the accounts of our majority owned subsidiaries, Asterias, ReCyte Therapeutics, OncoCyte, BioTime Asia, Cell Cure Neurosciences, and LifeMap Sciences.&#160; All material intercompany accounts and transactions have been eliminated in consolidation.&#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. and with the accounting and reporting requirements of SEC Regulation S-X.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">22</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Comparison of Three Months Ended March 31, 2014 and 2013</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$ Increase/</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">% Increase/</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">License fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">294,504</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">349,824</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(55,320</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(15.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Royalty from product sales</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">97,886</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">107,599</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(9,713</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(9.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Grant income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">575,659</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">90,326</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">485,333</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">537.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sales of research products and services</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">98,586</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">66,724</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">31,862</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">47.8</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Total revenues</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,066,635</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">614,473</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">452,162</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">73.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cost of sales</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(131,914</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(182,749</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(50,835</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(27.8</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 14.4pt; FONT-SIZE: 10pt">Total revenues, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">934,721</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">431,724</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">502,997</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">116.5</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our license fee revenues amounted to $294,504 and $349,824 for the three months ended March 31, 2014 and 2013, respectively.&#160; License fee revenues for the three months ended March 31, 2014 and 2013 include subscription and advertising revenues of $294,504 and $313,356 from LifeMap Science&#8217;s online database business primarily related to its<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> database.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under our license agreements with Hospira and CJ, our licensees report sales of<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and pay us the royalties due on account of such sales within 90 days after the end of each calendar quarter.&#160; We recognize such revenues in the quarter in which the sales report is received, rather than the quarter in which the sales took place.&#160; For example, royalties on sales made during the fourth quarter of 2013 were not recognized until the first quarter of fiscal year 2014.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our royalty revenues from product sales for the three months ended March 31, 2014 primarily consist of royalties $61,981 of royalties </font>earned by Asterias from the non-exclusive license agreement with Stem Cell Technologies, Inc. which Asterias acquired as part of consideration received from Geron under the Asset Contribution Agreement. <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Royalty revenues on sales of</font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> made by Hospira and CJ during the period beginning October 1, 2013 and ending December 31, 2013 were $35,905 compared with $107,599 for the three months ended March 31, 2013.&#160; This 67% decrease in royalties on sales of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">is attributable to a decrease&#160;in the U.S. and in the Republic of Korea.&#160; The blood volume expander marketing continues to contract and hospitals continue to shift their purchases to albumin products.&#160; Hospira has reported that they have seen a rapid decline in the price of hetastarch-based plasma expanders in the market which could continue to have a negative impact on revenues from the sale of</font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">.&#160; The FDA also required&#160;certain new&#160;safety labeling changes for the entire class of hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> which may have contributed to the decline in <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">sales.&#160; The labeling changes were approved by the FDA in November 2013 and include a boxed warning stating that the use of hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">, increases the risk of mortality and renal injury requiring renal replacement therapy in critically ill adult patients, including patients with sepsis, and that </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> should not be used in critically ill adult patients, including patients with sepsis.&#160; New warning and precaution information is also required along with new information about contraindications, adverse reactions, and information about certain recent studies.&#160; See &#8220;Risk Factors.&#8221;&#160; We expect royalty revenues from sales of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> to continue to decline as a percentage of total revenue.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Based on sales of<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> that occurred during the first quarter of 2014, we received royalties of $37,712 from Hospira and we have received $14,767 from CJ Health during the second quarter of 2014.&#160; Total royalties of $52,479 for the quarter decreased 49% from royalties of $103,033 received during the same period last year.&#160; These royalties will be reflected in our financial statements for the second quarter of 2014.</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">23</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Total grant revenue for the first three months in 2014 increased by approximately 537% to $575,659.&#160; Grant revenue in the first three months of 2014 included $425,770 recognized through Cell Cure Neurosciences, and $149,889 from various grants awarded to us by the National Institutes of Health&#160;(''NIH'')&#160;that will expire at various time during the current year.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Despite the increase in revenues, cost of sales has declined.&#160; This is entirely attributed to the increase in grant revenues by $485,333 which is not associated with any cost of sales.</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$ Increase/</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">% Increase/</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development expenses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,405,393</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(5,395,488</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3,009,905</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">55.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3,667,171</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3,416,145</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">251,026</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">7.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Interest (expense)/income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(8,384</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">943</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">9,327</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">989.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 51%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other income/(expense)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">77,746</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(28,056</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">105,802</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">377.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Research and development expenses &#8211;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> Research and development expenses increased approximately 56% to $8,405,393 for the three months ended March 31, 2014, from $5,395,488 for the three months ended March 31, 2013.&#160; The increase is the result of the ramp-up of Asterias&#8217; operations following its acquisition of stem cell assets from Geron and us through the Asset Contribution Agreement. </font>The principal components of the&#160;increase in research and development expenses during the three months ended March 31, 2014 is attributable to an increase of $1,288,531 in employee compensation, including stock based compensation, and related costs allocated to research and development expenses and reflects, in part, Asterias hiring <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">additional management and scientific personnel, certain Asterias executives and other employees who had been employed on a part-time basis during the first quarter of 2013 becoming employed by Asterias on a full-time basis</font>, an increase of $725,425 in amortization of intangible assets resulting from Asterias&#8217; acquisition of Geron&#8217;s stem cell assets, an increase of $303,118 in consulting services, an increase of $302,886 in patents, licenses, and trademark related fees arising primarily from assets that Asterias acquired from Geron, an increase of $179,736 in laboratory expenses and supplies at Asterias, an increase of $132,937 in depreciation expenses allocated to research and development expenses again largely related to Asterias&#8217; asset acquisition, , and an increase of $57,204 in travel, lodging, and meals allocated to research and development expenses.&#160; These increases were offset in part by a decrease $25,476 in ESI&#8217;s research and development expenses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The following table shows the amount of our total research and development expenses allocated to our primary research and development projects during the three months ended March 31, 2014 and 2013.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Program</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Asterias</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">hESC-based cell therapeutic programs</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,599,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">193,444</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime and ESI</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> hEPCs, cGMP hES cell lines, <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">and related research products</font></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">823,451</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">691,611</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">technology</font></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">199,447</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hydrogel therapeutic products and <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> research</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,315,231</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,163,340</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">OncoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cancer diagnostics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">929,725</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">704,917</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">OrthoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Orthopedic therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">224,716</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">249,954</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">ReCyte Therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Cardiovascular therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">433,408</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">313,615</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">12,160</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">21,633</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime Asia</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Stem cell products for research</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">8,565</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Cell Cure Neurosciences</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-Plus</font>, and neurological disease therapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,261,054</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1,252,917</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">LifeMap Sciences</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Database development and sales</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">781,424</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">596,045</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">High Content Screening</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">25,078</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">24</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">General and administrative expenses &#8211;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> General and administrative expenses increased to $3,667,171 for the three months ended March 31, 2014 from $3,416,145 for the three months ended March 31, 2013.&#160; The increase is the result, in part, of the ramp-up of Asterias&#8217; operations following its acquisition of stem cell assets from Geron and us through the Asset Contribution Agreement, including the hiring of additional management and administrative personnel, and certain Asterias executives and other employees who had been employed on a part-time basis during the first quarter of 2013 becoming employed by Asterias on a full-time basis.</font>&#160; The principal components of the increase in total general and administrative costs on a consolidated basis were:&#160; $370,138 in employee compensation, including stock-based compensation, and related costs allocated to general and administrative expenses; an increase of $167,059 in general consulting expenses; an increase of $121,247 in marketing and advertisement related expenses; an increase of $87,137 in rent and facilities maintenance related expenses allocated to general and administrative expenses; an increase of $87,091 in travel, lodging and meals allocated to general and administrative expenses; an increase of $52,200 in investor and public relations expenses; and an increase of $23,226 in Cell Cure Neurosciences general and administrative expenses.&#160; These increases are in part offset by decreases of $432,054 and $165,562 in legal and accounting fees, respectively, related to transactions under the Asset Contribution Agreement, including preparing registration statements for filing with the SEC and a proxy statement for a special meeting of our shareholders, that we incurred in 2013, and a decrease of $76,522 in stock-based compensation to consultants.&#160; General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, shipping expenses, marketing costs, legal and accounting costs, and other miscellaneous expenses which are allocated to general and administrative expense.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Interest income/(expense) &#8211;</font> During the three months ended March 31, 2014, we incurred $8,384 of net interest expense.&#160; During the three months ended March 31, 2013, we earned $943 of interest on cash balances held in interest bearing accounts during 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Other income/(expense) &#8211;</font> Other income in 2014 consists primarily of $127,368 in gain on embedded derivatives earned by Cell Cure Neurosciences through a research contract, based in U.S. dollars, with an Israeli company, offset by a $31,582 decrease in leasehold improvement liability due to the early termination of a Cell Cure lease, $17,881 in charitable donations made,&#160;and $10,212 of foreign currency transaction expense.&#160; Other expense in 2013 consists primarily of $21,976 of foreign currency transaction loss.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Income Taxes &#8211; </font>A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&#160; No tax benefit had been recorded through September 30, 2013 because of the net operating losses incurred and a full valuation allowance had been provided.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">At March 31, 2014, we had $6,637,834 of cash and cash equivalents on hand. Subsequent to March 31, 2014 we raised an aggregate of $6,316,834 of additional equity capital through the sale of BioTime common shares in &#8220;at-the-market&#8221; transactions through Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as the sales agent.&#160; Offers and sales of our common shares for our account through Cantor are made under a <font style="FONT-STYLE: italic">Controlled Equity Offering</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> Sales Agreement and have been registered under the Securities Act of 1933, as amended (the "Securities Act").&#160; The sales made through Cantor for our account after March 31, 2014 were made after an amendment to the sales agreement to provide for the issuance and sale by us of additional common shares having an aggregate offering price of up to $15,000,000. </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under the sales agreement, Cantor may sell our common shares by any method permitted by law deemed to be an "at-the-market" offering as defined in Rule 415 under the Securities Act, including, but not limited to, sales made directly on NYSE MKT, on any other existing trading market for our common shares or to or through a market maker.&#160; Cantor may also sell our shares under the sales agreement by any other method permitted by law, including in privately negotiated transactions.&#160; Cantor has agreed in the sales agreement to use its commercially reasonable efforts to sell shares in accordance with our instructions (including any price, time or size limit or other customary parameters or conditions we may impose).&#160; The offering pursuant to the sales agreement will terminate upon the sale of all shares subject to the sales agreement or the earlier termination of the sales agreement as permitted by its terms.&#160; Cantor has also acted as a sales agent for certain of our subsidiaries that have sold BioTime common shares to raise capital for their operations.&#160; The offer and sale of those shares has also been registered under the Securities Act.&#160; We contributed the BioTime common shares to the subsidiaries in exchange for subsidiary capital stock.&#160; The proceeds of the sale of BioTime shares by our subsidiaries belong to those subsidiaries.&#160; There is no assurance that we or our subsidiaries will be able to sell additional common shares through Cantor at prices acceptable to us.&#160; </font>See "Cash generated by financing activities" for additional information about sales of our equity securities through the <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Controlled Equity Offering</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> and other transactions during the quarter ended March 31, 2014.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">25</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In April 2014, Michael D. West, who was Asterias' Vice President of Technology Integration and is our Chief Executive Officer and a member of our Board of Directors, replaced Thomas Okarma as Asterias' President and Chief Executive Officer.&#160; In addition, Richard LeBuhn, Judith Segall, and Robert W. Peabody, who is both Asterias' and BioTime's Chief Financial Officer, were appointed to the Asterias Board of Directors and two other directors left the Asterias Board.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Dr. West and Mr. Peabody are working with Asterias' current management and its Board of Directors to better align Asterias' expenditures with available capital resources, and will continue to explore synergistic opportunities at Asterias and BioTime that may advance product development in a cost effective manner.&#160; For example, insight that we have <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">gained from our </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"> technology might help Asterias </font>improve the purity and efficiency of production of the hES derived progenitor cells that it may use in some of its product development programs.&#160; <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Asterias' management is continuing to evaluate the opportunities for Asterias' stem cell assets in order to select the best paths for the advancement of its key product programs, including paths that can be followed with Asterias' current financial assets and those that would be open if Asterias were to obtain the funding it is seeking in the form of research grants, cooperative development arrangements, and new equity capital.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">We expect that as a result of this review of the key programs at Asterias there will be a more focused allocation of capital to programs that receive third party funding or other support, and a reduced level of current expenditures on other programs.&#160; If third party funding or support is not received, we would expect Asterias to concentrate its resources on those product development programs that provide the best opportunity for near-term progress.</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias is seeking funding for its operations from third parties in the form of research and development grants or cooperative arrangements for the development of certain of Asterias&#8217; product candidates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has applied for a Strategic Partnership 3 Track &#8220;A&#8221; Award from the California Institute for Regenerative Medicine (CIRM) which is intended to support a Phase 1/2a clinical trial of our OPC1 product candidate in subjects with neurologically complete cervical spinal cord injury.&#160; The grant would also help support Asterias&#8217; efforts to develop a commercial process to manufacture OPC1.&#160; The purpose of the Strategic Partnership Award Initiative is to create incentives for industry to advance the development of stem cell-based therapeutics.&#160; As part of a Strategic Partnership 3 Track &#8220;A&#8221; Award, CIRM will provide up to $10,000,000 ($15,000,000 in extraordinary cases) to support an approved project.&#160; We expect that CIRM will notify applicants of the decision on their applications during the first half of 2014.&#160; Geron was granted a non-recourse loan for its thoracic spinal cord injury study of OPC1 in 2011 from CIRM, but returned the loan funds after announcing the termination of its human embryonic stem cell programs.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias is in the process of applying for a grant from a large United Kingdom based charitable organization to fund Phase 1/2a clinical development of our VAC2 product candidate.&#160; The proposed grant would fund both the Phase 1/2a clinical trial of VAC2 in cancer patients and the cGMP manufacturing costs of VAC2.&#160; The terms under which funding may be provided by the charitable organization are currently under discussion.&#160; Asterias anticipates that it will receive notification of whether the grant has been approved during the first half of 2014.&#160; This same charitable organization had awarded a similar grant for VAC2 to Geron but that grant was withdrawn after Geron terminated the program in November 2011.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias is in early-stage discussions with a United Kingdom based technology innovation center seeking their support for the development of advanced manufacturing processes for VAC2.&#160; Methods developed at the technology innovation center would be incorporated in future commercial manufacturing processes for the product.&#160; An alliance with the technology innovation center would be on a specific project basis and would require multiple approvals from different committees and boards at the center.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias is also in early stage discussions with an academic institution to form a collaboration to develop hES cell derived cardiomyocytes for the treatment of heart failure and acute myocardial infarction.&#160; The academic institution has received funding to develop the project through the IND filing stage.&#160; Asterias would either fund the Phase I study itself, to the extent that it has sufficient capital resources for that purpose or would seek funding for the study from a third party.&#160; In a collaboration, Asterias might contribute assistance in preparing and filing the IND, materials for use in the project such as cGMP hES cell banks, and a license of relevant patents and know-how relating to the development of hES cell-derived cardiomyocytes and hES cell-derived therapeutics generally, in exchange for which it would acquire an ownership interest in the resulting therapeutic products or in a joint venture company to be formed and co-owned with the academic institution for the purpose of developing the product.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">There can be no assurance that Asterias will receive any of grants that it is seeking or that Asterias will reach an agreement for support in the manufacture of VAC2 or the development of hES cell derived cardiomyocytes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Because our revenues are not presently sufficient to cover our operating expenses, we will continue to need to obtain additional equity capital or debt in order to finance our operations.&#160; The future availability and terms of equity or debt financing are uncertain.&#160; The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our planned operations.&#160; Sales of additional equity securities by us or our subsidiaries could result in the dilution of the interests of present shareholders.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">26</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash generated by operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, we received $1,171,914 of cash in our operations.&#160; Our sources of that cash primarily consisted of $97,886 in royalty revenues on product sales by licensees, $118,874 of research grant payments from the NIH, $658,907 in foreign research grants to Cell Cure Neurosciences, and $296,247 from the sale of research products and subscription and advertisement revenues.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash used in operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, our total research and development expenditures were $8,405,393 and our general and administrative expenditures were $3,667,171.&#160; Net loss attributable to BioTime for the three months ended March 31, 2014 amounted to $8,099,014.&#160; Net cash used in operating activities during this period amounted to $10,357,271.&#160; The difference between the net loss and net cash used in operating activities during the three months ended March 31, 2014 was primarily attributable to the amortization of $1,367,998 in intangible assets, $801,554 in stock-based compensation paid to employees, consultants and directors, and $202,122 in grant receivables.&#160; This overall difference was offset to some extent by $1,349,026 in deferred income tax benefit, $1,276,211 in accounts payable and accrued liabilities, $185,717 in other long term liabilities, $57,894 in inventory, and net loss of $1,629,017 allocable to the noncontrolling interest in our subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from investing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, we used $527,618 for investing activities.&#160; The primary components of this cash were approximately $231,921 used in the purchase of equipment, and a lease security deposit of $300,000 for Asterias&#8217; facilities in Fremont, California.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash generated by financing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, we raised gross proceeds of $8,782,031 from the sale of 2,311,768 BioTime common shares at a weighted average price of $3.80 per share in the open market through our <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Controlled Equity Offering</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> facility with Cantor and through the sale of BioTime common shares held by our majority owned subsidiaries, LifeMap Sciences, OncoCyte, and Cell Cure Neurosciences.&#160; The proceeds of the sale of BioTime shares by our subsidiaries belong to those subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On March 4, 2014, BioTime received $3,500,000 from the sale of 70,000 shares of a newly authorized Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).&#160; The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares.&#160; Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.&#160; See Note 7 to the condensed consolidated interim financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Contractual obligations</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, our contractual obligations for the next five years and thereafter were as follows:</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 39%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="19">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 19.8pt">Principal Payments Due by Period</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; PADDING-BOTTOM: 2px; WIDTH: 39%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Obligations <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">Total</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">Less Than</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">1 Year</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">1-3 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">4-5 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">After</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.1pt">5 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="19">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 39%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Operating leases <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">12,026,101</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">940,963</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3,243,018</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2,579,280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5,262,840</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">This table does not include payments to key employees that could arise if they were involuntary terminated or if their employment terminated following a change in control.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top"></td>
</tr>

<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(2)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Includes the lease of our principal office and laboratory facilities in Alameda, California, and leases of the offices and laboratory facilities of our subsidiaries Asterias, ESI, LifeMap Sciences, and Cell Cure Neurosciences.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">27</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Future capital needs</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The completion of the acquisition of Geron&#8217;s stem cell related assets by our subsidiary Asterias will continue to result in an increase in our operating expenses and losses on a consolidated basis, and will increase our need for additional capital.&#160; Asterias will use the acquired stem cell assets for the research and development of products for regenerative medicine.&#160; Asterias&#8217; research and development efforts will involve substantial expense, including but not limited to hiring additional research and management personnel, and the lease of additional research or manufacturing space that will add to our losses on a consolidated basis for the near future.&#160; Also, Asterias is now a public company.&#160; As a public company, Asterias will incur costs associated with audits of its financial statements, filing annual, quarterly, and other periodic reports with the SEC, holding annual shareholder meetings, and public relations and investor relations.&#160; These costs will be in addition to those incurred by us for similar purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We and our subsidiaries will need to continue to sell BioTime common shares from time to time through our sales agreements with Cantor, and our subsidiaries may also seek to raise capital through the sale of their capital stock.&#160; We and our subsidiaries will also seek funding for our research and development programs from other sources such as research grants and other arrangements with third parties.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We are consolidating the sales and marketing of our research products in a new ESI BIO division.&#160; As part of this plan, we expect to shift our sales and marketing efforts from a website based effort to one that utilizes more sales personnel who may be employees or independent sales representatives.&#160; We also plan to expand our product offerings.&#160; This effort will require additional expenditures for the development of new research products and the addition of assets and personnel for sales and marketing purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The amount and pace of research and development work that we and our subsidiaries can do or sponsor, and our ability to commence and complete the clinical trials that are required in order for us to obtain FDA and foreign regulatory approval of products, depend upon the amount of money we and our subsidiaries have.&#160; Future research and clinical study costs are not presently determinable due to many factors, including the inherent uncertainty of these costs and the uncertainty as to timing, source, and amount of capital that will become available for our projects.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The market value and the volatility of our stock price, as well as general market conditions, could impact our ability to raise capital on favorable terms, or at all.&#160; Any equity financing that we or our subsidiaries obtain may further dilute or otherwise impair the ownership interests of our current shareholders.&#160; If we and our subsidiaries fail to generate positive cash flows or fail to obtain additional capital when required, we and our subsidiaries could modify, delay or abandon some or all of our respective research and development programs.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;<a name="item_1_3_3"><!--Anchor--></a></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.</div>
</td>
<td style="WIDTH: 93.18%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quantitative and Qualitative Disclosures about Market Risk</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Foreign Currency Exchange Risk</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We are exposed to some foreign exchange currency risks because we have subsidiaries that are located in foreign countries.&#160; We do not engage in foreign currency hedging activities.&#160; Because we translate foreign currencies into United States dollars for reporting purposes, currency fluctuations have an impact on our financial results.&#160; We believe that our exposure to currency exchange fluctuation risk is mitigated by the fact that our foreign subsidiaries pay their financial obligations almost exclusively in their local currency.&#160; As of March 31, 2014 and as of December 31, 2013, currency exchange rates did not have a material impact on our intercompany transactions with our foreign subsidiaries.&#160; However, a weakening of the dollar against the foreign exchange used in the home countries of our foreign subsidiaries could increase our cost of providing additional financing to our foreign subsidiaries in the future.&#160; Conversely, a strengthening of the dollar would decrease our cost of making additional investments in those subsidiaries.&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Credit Risk</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We place some of our cash in U.S. banks and invest most of our cash in money market funds.&#160; Deposits with banks may temporarily exceed the amount of insurance provided on such deposits.&#160; We will monitor the cash balances in the accounts and adjust the cash balances as appropriate, but if the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.&#160; Our investments in money market funds are not insured or guaranteed by the United States government or any of its agencies.&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our foreign subsidiaries deposit their cash in local banks, but if the amount of a deposit at any time exceeds the amount at a bank under the national banking insurance laws, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">28</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Interest Rate Risk</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We invest most of our cash in money market funds.&#160; The primary objective of our investments will be to preserve principal and liquidity while earning a return on our invested capital, without incurring significant risks.&#160; Our future investment income is not guaranteed and may fall short of expectations due to changes in prevailing interest rates, or we may suffer losses in principal if the net asset value of a money market fund falls below $1 per share.&#160;<a name="item_1_3_4"><!--Anchor--></a></div>

<div>&#160;</div>

<div>
<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4.</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Controls and Procedures</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Evaluation of Disclosure Controls and Procedures</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">It is management&#8217;s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;).&#160; Our management, including our principal executive officer, our principal operations officer, and our principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Quarterly Report on Form 10-Q.&#160; Following this review and evaluation, management collectively determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer, our chief operations officer, and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Changes in Internal Controls</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

<div style="TEXT-ALIGN: right"><a name="part_1_2_2"><!--Anchor--></a><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II - OTHER INFORMATION</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 1.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Legal Proceedings.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">From time to time, we and our subsidiaries may be involved in routine litigation incidental to the conduct of our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has assumed Geron&#8217;s position as appellant in an appeal filed in the United States District Court in Civil Action No. C12-04813 (the &#8220;ViaCyte Appeal&#8221;) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office&#8217;s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 12/543,875 (Geron).&#160; Asterias has also assumed the interference proceedings upon which the appeal is based.&#160; The rulings related to interference proceedings involving patent filings relating to definitive endoderm cells.&#160; Geron had requested that the Board of Patent Appeals and Interferences declare this interference after ViaCyte was granted patent claims that conflicted with subject matter Geron filed in a patent application having an earlier priority date.&#160; Those Geron patent applications are among the patent assets that Geron contributed to Asterias.&#160; Asterias also assumed the USPTO interferences upon which the appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte patent filings in Australia.&#160; Asterias has agreed to assume all liabilities relating to the ViaCyte Appeal and the related interference proceedings, including the costs of litigation, other than expenses incurred by Geron prior to October 1, 2013.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If Asterias is not successful in the ViaCyte Appeal, ViaCyte would retain its patent claims directed to definitive endoderm.&#160; Definitive endoderm is an early pre-cursor of numerous cell types including liver and <font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#946;</font>-cells of the pancreas that could potentially treat diabetes, and it is likely that the derivation of any of the endodermal lineage cells from embryonic stem cells would necessarily pass through the definitive endoderm stage.&#160; As a result, Asterias would be unable to develop and commercialize those cell types without a license from ViaCyte, and may be unable to realize value from the Geron patent applications at issue in the appeal.<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</font></div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">29</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 1A.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Risk Factors</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our business is subject to various risks, including those described below.&#160; You should consider the following risk factors, together with all of the other information included in this report, which could materially adversely affect our proposed operations, our business prospects, and financial condition, and the value of an investment in our business.&#160; There may be other factors that are not mentioned here or of which we are not presently aware that could also affect our business operations and prospects.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Business Operations</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have incurred operating losses since inception and we do not know if we will attain profitability</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our comprehensive net losses for the three months ended March 31, 2014 and for the fiscal years ended December 31, 2013, 2012, and 2011 were $8,206,254, $43,760,366, $21,362,524, and $17,535,587, respectively, and we had an accumulated deficit of $153,877,561 as of March 31, 2014 and $145,778,547, $101,895,712, and $80,470,009, as of December 31, 2013, 2012, and 2011, respectively.&#160; We primarily finance our operations through the sale of equity securities, licensing fees, royalties on product sales by our licensees, research grants, and subscription fees and advertising revenue from database products.&#160; Ultimately, our ability to generate sufficient operating revenue to earn a profit depends upon our and our subsidiaries&#8217; success in developing and marketing or licensing products and technology.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will spend a substantial amount of our capital on research and development but we might not succeed in developing products and technologies that are useful in medicine</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We are attempting to develop new medical products and technologies.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Many of our experimental products and technologies have not been applied in human medicine and have only been used in laboratory studies <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">in vitro</font> or in animals.&#160; These new products and technologies might not prove to be safe and efficacious in the human medical applications for which they were developed.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The experimentation we are doing is costly, time consuming, and uncertain as to its results.&#160; We incurred research and development expenses amounting to $8,405,393, during the three months ended March 31, 2014, and $26,609,423, $18,116,688, and $13,699,691 during the fiscal years ended December 31, 2013, 2012, and 2011, respectively, excluding $17,458,766 charged as in process research and development expenses during 2013 in accordance with ASC 805-50 on account of Asterias&#8217; acquisition of certain assets f<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">rom Geron.&#160; See Note 8 to condensed consolidated interim financial statements.</font></td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">If we are successful in developing a new technology or product, refinement of the new technology or product and definition of the practical applications and limitations of the technology or product may take years and require the expenditure of large sums of money.&#160; Future clinical trials of new therapeutic products, particularly those products that are regulated as drugs or biological, will be very expensive and will take years to complete.&#160; We may not have the financial resources to fund clinical trials on our own and we may have to enter into licensing or collaborative arrangements with larger, well-capitalized pharmaceutical companies in order to bear the cost.&#160; Any such arrangements may be dilutive to our ownership or economic interest in the products we develop, and we might have to accept a royalty payment on the sale of the product rather than receiving the gross revenues from product sales.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asterias&#8217; operations will result in an increase in our operating expenses and losses on a consolidated basis</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Asterias will use the stem cell assets that it has acquired from Geron for the research and development of products for regenerative medicine.&#160; Asterias&#8217; research and development efforts will involve substantial expense, including but not limited to hiring additional research and management personnel, and possibly the rent of additional research or manufacturing space that will add to our losses on a consolidated basis for the near future.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Asterias has become a public company.&#160; As a public company, Asterias will incur costs associated with audits of its financial statements, filing annual, quarterly, and other periodic reports with the SEC, holding annual shareholder meetings, listing its common shares for trading, and public relations and investor relations.&#160; These costs will be in addition to those incurred by BioTime for similar purposes.</td>
</tr>
</table>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">30</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">As a developer of therapeutic products derived from hES or iPS cells, Asterias will face substantially the same kind of risks that affect our business, as well as the risks related to our industry generally.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our success depends in part on the uncertain growth of the stem cell industry, which is still in its infancy</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The success of our business of selling products for use in stem cell research depends on the growth of stem cell research, without which there may be no market or only a very small market for our products and technology.&#160; The likelihood that stem cell research will grow depends upon the successful development of stem cell products that can be used to treat disease or injuries in people or that can be used to facilitate the development of other therapeutic products.&#160; The growth in stem cell research also depends upon the availability of funding through private investment and government research grants.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">There can be no assurance that any safe and efficacious human medical applications will be developed using stem cells or related technology.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Government-imposed bans, restrictions and religious, moral, and ethical concerns with respect to use of embryos or hES cells in research and development could have a material adverse effect on the growth of the stem cell industry, even if research proves that useful medical products can be developed using hES cells.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will increase of our investment in LifeMap Sciences to provide funding for the development of new software products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our subsidiary LifeMap Sciences has formed a new subsidiary, LifeMap Solutions, Inc., to develop the new personal mobile health software products intended to connect users with their complex personal health information and other big data.&#160; We have agreed to invest at least $5,000,000 in LifeMap Sciences to provide funding for the project, and unless additional financing can be obtained from third parties, we may need to increase our investment significantly during the next few calendar years to fund the development and commercialization of the planned products.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The field of mobile health products, including both hardware and software products, is new, and there is no certainty that LifeMap Solutions will be successful in developing its planned new products or that it will be successful in commercializing any products that it does develop.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The field of mobile health products is subject to increasing competition, including from large computer and internet technology companies that have much greater financial and marketing resources than we and LifeMap Solutions have.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The FDA has also taken an interest in the field of on-line or mobile health products and there is a risk that the FDA could determine that LifeMap Solutions&#8217; products should be regulated as medical devices under existing laws and regulations, or the FDA could promulgate new regulations that might subject LifeMap Solutions&#8217; products to FDA clinical trial and approval procedures, as a prerequisite for permission to use and market the new mobile health products in the United States.&#160; Foreign regulatory authorities could make similar determinations or could adopt their own rules regulating the use and marketing of LifeMap Solution&#8217;s products.</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sales of our products to date have not been sufficient to generate an amount of revenue sufficient to cover our operating expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is presently the only plasma expander product that we have on the market, and it is being sold only in the U.S. and South Korea.&#160; The royalty revenues that we have received from sales of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> have not been sufficient to pay our operating expenses.&#160; This means that we need to successfully develop and market or license additional products and earn additional revenues in sufficient amounts to meet our operating expenses.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We are also bringing our first stem cell research products to the market, but there is no assurance that we will succeed in generating significant revenues from the sale of those products.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sales of the products we may develop will be adversely impacted by the availability of competing products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Sales of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> have already been adversely impacted by the availability of other products that are commonly used in surgery and trauma care and sell at low prices.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">In order to compete with other products, particularly those that sell at lower prices, our products will have to provide medically significant advantages.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Physicians and hospitals may be reluctant to try a new product due to the high degree of risk associated with the application of new technologies and products in the field of human medicine.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Competing products are being manufactured and marketed by established pharmaceutical companies.&#160; For example, B. Braun presently markets <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hespan</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, an artificial plasma volume expander, and Hospira and Teva sell a generic equivalent of <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hespan</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.&#160; Hospira also markets <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Voluven</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a plasma volume expander containing a 6% low molecular weight hydroxyethyl starch in saline solution.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Competing products for the diagnosis and treatment of cancer are being manufactured and marketed by established pharmaceutical companies, and more cancer diagnostics and therapeutics are being developed by those companies and by other smaller biotechnology companies.&#160; Other companies, both large and small, are also working on the development of stem cell based therapies for the same diseases and disorders that are the focus of the research and development programs of our subsidiaries.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">There also is a risk that our competitors may succeed at developing safer or more effective products that could render our products and technologies obsolete or noncompetitive.</td>
</tr>
</table>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">31</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sales of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> could be adversely affected by safety and use labeling changes required by the FDA</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Sales of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> could be adversely affected by certain safety labeling changes required by the FDA for the entire class of hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">.&#160; The labeling changes were approved by the FDA in November 2013 and include a boxed warning stating that the use of hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">, increases the risk of mortality and renal injury requiring renal replacement therapy in critically ill adult patients, including patients with sepsis, and that </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> should not be used in critically ill adult patients, including patients with sepsis.&#160; New warning and precaution information is also required along with new information about contraindications, adverse reactions, and information about certain recent studies.&#160; The new warning and precautions include statements to the effect that the use of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> should be avoided in patients with pre-existing renal dysfunction, and the coagulation status of patients undergoing open heart surgery in association with cardiopulmonary bypass should be monitored as excess bleeding has been reported with hydroxyethyl starch solutions in that population and use of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> should be discontinued at the first sign of coagulopathy.&#160; The liver function of patients receiving hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> should also be monitored.&#160; The approved revised label may adversely affect </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> sales since some users of plasma volume expanders might elect to abandon the use of all hydroxyethyl starch products, including </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We and our subsidiaries will need to issue additional equity or debt securities in order to raise additional capital needed to pay our operating expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We plan to continue to incur substantial research and product development expenses, largely through our subsidiaries, and we and our subsidiaries will need to raise additional capital to pay operating expenses until we are able to generate sufficient revenues from product sales, royalties, and license fees.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">It is likely that additional sales of equity or debt securities will be required to meet our short-term capital needs, unless we receive substantial revenues from the sale of our new products or we are successful at licensing or sublicensing the technology that we develop or acquire from others and we receive substantial licensing fees and royalties.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Sales of additional equity securities by us or our subsidiaries could result in the dilution of the interests of present shareholders.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The amount and pace of research and development work that we and our subsidiaries can do or sponsor, and our ability to commence and complete clinical trials required to obtain regulatory approval to market our therapeutic and medical device products, depends upon the amount of money we have</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">At March 31, 2014, we had $6,637,834 of cash and cash equivalents on hand.&#160; There can be no assurance that we or our subsidiaries will be able to raise funds on favorable terms or at all, or that any funds raised will be sufficient to permit us or our subsidiaries to develop and market our products and technology.&#160; Unless we and our subsidiaries are able to generate sufficient revenue or raise additional funds when needed, it is likely that we will be unable to continue our planned activities, even if we make progress in our research and development projects.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We may have to postpone or limit the pace of our research and development work and planned clinical trials of our product candidates unless our cash resources increase through a growth in revenues or additional equity investment or borrowing.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The condition of certain cells, cell lines and other biological materials that Asterias acquired from Geron could impact the time and cost of commencing Asterias&#8217; research and product development programs</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The cells, cell lines and other biological materials that Asteria acquired are being stored under cryopreservation protocols intended to preserve their functionality.&#160; Asterias has successfully completed the&#160;verification of the viability of three lots of OPC1 cells that it intends to use in clinical trials.&#160; However, the functional condition of the other materials cannot be certified until they are tested in an appropriate laboratory setting by qualified scientific personnel using validated equipment.&#160; Asterias intends to perform that testing on the cells that it intends to use in its research and development programs as the need arises.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">To the extent that the cells Asterias plans to use are not sufficiently functional for its purposes, Asterias would need to incur the time and expense of regenerating cell lines from cell banks, or regenerating cell banks from&#160;cell stocks, which could delay and increase the cost of its research and development work using those cells.</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">32</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Any cell-based products that receive regulatory approval may be difficult and expensive to manufacture on a commercial scale</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">hES derived therapeutic cells have only been produced on a small scale and not in quantities and at levels of purity and viability that will be needed for wide scale commercialization.&#160; If we are successful in developing products that consist of hES cells or other cells or products derived from hES or other cells, we will need to develop, alone or in collaboration with one or more pharmaceutical companies or contract manufacturers, technology for the commercial production of those products.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Our hES cell or other cell based products are likely to be more expensive to manufacture on a commercial scale than most other drugs on the market today.&#160; The high cost of manufacturing a product will require that we charge our customers a high price for the product in order to cover our costs and earn a profit.&#160; If the price of our products is too high, hospitals and physicians may be reluctant to purchase our products, especially if lower priced alternative products are available, and we may not be able to sell our products in sufficient volumes to recover our costs of development and manufacture or to earn a profit.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asterias has assumed certain obligations and potential liabilities with regard to clinical trials conducted by Geron, and we do not yet know the scope of any resulting expense</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has assumed Geron&#8217;s obligations to obtain information and prepare reports about the health of patients who participated in clinical trials of Geron&#8217;s GRNOPC1 cell replacement therapy for spinal cord damage and its GRNVAC1 immunological therapy for certain cancers.&#160; Although the future cost of patient health information gathering and reporting is not presently determinable, we do not expect that the cost will be material to our financial condition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has also assumed any liabilities to those patients that might arise as result of any injuries they may have incurred as a result of their participation in the clinical trials.&#160; We are not aware of any claims by patients alleging injuries suffered as a result of the Geron clinical trials, but if any claims are made and if liability can be established, the amount of any liability that Asterias may incur, depending upon the nature and extent of any provable injuries incurred, could exceed any insurance coverage that we or Asterias may obtain and the amount of the liability could be material to our financial condition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business could be adversely affected if we lose the services of the key personnel upon whom we depend</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">BioTime stem cell research programs, and to a lesser extent, the programs of BioTime&#8217;s subsidiaries, are directed primarily by our Chief Executive Officer, Dr. Michael West.&#160; BioTime&#8217;s subsidiaries are directed by their respective management teams.&#160; The loss of the services of Dr. West or members of senior management&#160;of BioTime and its&#160;subsidiaries could have a material adverse effect on us.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we make strategic acquisitions, we will incur a variety of costs and might never realize the anticipated benefits</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We have made several strategic acquisitions during the past few years, including ESI in 2010, Glycosan BioSystems, Inc. and Cell Targeting, Inc. in 2011, and XenneX, Inc. in 2012.&#160; Asterias acquired Geron&#8217;s stem cell related assets during 2013.&#160; If appropriate opportunities become available, we might attempt to acquire approved products, additional drug candidates, technologies or businesses that we believe are a strategic fit with our business.&#160; If we pursue any transaction of that sort, the process of negotiating the acquisition and integrating an acquired product, drug candidate, technology or business might result in operating difficulties and expenditures and might require significant management attention that would otherwise be available for ongoing development of our business, whether or not any such transaction is ever consummated.&#160; Moreover, we might never realize the anticipated benefits of any acquisition.&#160; Future acquisitions could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities, or impairment expenses related to goodwill, and impairment or amortization expenses related to other intangible assets, which could harm our financial condition.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">33</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure of our internal control over financial reporting could harm our business and financial results</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting.&#160; Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with accounting principles generally accepted in the U.S. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of the financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.&#160; Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.&#160; Our growth and entry into new products, technologies and markets will place significant additional pressure on our system of internal control over financial reporting.&#160; Any failure to maintain an effective system of internal control over financial reporting could limit our ability to report our financial results accurately and timely or to detect and prevent fraud.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Operating our business through subsidiaries, some of which are located in foreign countries, also adds to the complexity of our internal control over financial reporting and adds to the risk of a system failure, an undetected improper use or expenditure of funds or other resources by a subsidiary, or a failure to properly report a transaction or financial results of a subsidiary.&#160; We allocate certain expenses among BioTime itself and one or more of our subsidiaries, which creates a risk that the allocations we make may not accurately reflect the benefit of an expenditure or use of financial or other resources by BioTime as the parent company and the subsidiaries among which the allocations are made.&#160; An inaccurate allocation may impact our consolidated financial results, particularly in the case of subsidiaries that we do not wholly own since our financial statements include adjustments to reflect the minority ownership interests in our subsidiaries held by others.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business and operations could suffer in the event of system failures</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.&#160; Such events could cause interruption of our operations.&#160; For example, the loss of data for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs.&#160; To the extent that any disruption or security breach was to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Industry</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We will face certain risks arising from regulatory, legal, and economic factors that affect our business and the business of other biotechnology and pharmaceutical development companies.&#160; Because we are a small company with limited revenues and limited capital resources, we may be less able to bear the financial impact of these risks than is the case with larger companies possessing substantial income and available capital.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we do not receive regulatory approvals we will not be permitted to sell our therapeutic and medical device products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The therapeutic and medical device products that we and our subsidiaries develop cannot be sold until the FDA and corresponding foreign regulatory authorities approve the products for medical use.&#160; The need to obtain regulatory approval to market a new product means that:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We will have to conduct expensive and time-consuming clinical trials of new products.&#160; The full cost of conducting and completing clinical trials necessary to obtain FDA and foreign regulatory approval of a new product cannot be presently determined, but could exceed our current financial resources.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Clinical trials and the regulatory approval process for a pharmaceutical or cell-based product can take several years to complete.&#160; As a result, we will incur the expense and delay inherent in seeking FDA and foreign regulatory approval of new products, even if the results of clinical trials are favorable.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Data obtained from preclinical and clinical studies is susceptible to varying interpretations that could delay, limit, or prevent regulatory agency approvals.&#160; Delays in the regulatory approval process or rejections of an application for approval of a new product may be encountered as a result of changes in regulatory agency policy.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Because the therapeutic products we are developing with hES and iPS technology involve the application of new technologies and approaches to medicine, the FDA or foreign regulatory agencies may subject those products to additional or more stringent review than drugs or biologicals derived from other technologies.</td>
</tr>
</table>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">34</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">A product that is approved may be subject to restrictions on use.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The FDA can recall or withdraw approval of a product if problems arise.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We will face similar regulatory issues in foreign countries.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical trial failures can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future therapeutic or diagnostic product candidates</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Clinical trial failures or delays can occur at any stage of the trials, and may be directly or indirectly caused by a variety of factors, including but not limited to:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">delays in securing clinical investigators or trial sites for our clinical trials;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">delays in obtaining IRB and other regulatory approvals to commence a clinical trial;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">slower than anticipated rates of patient recruitment and enrollment, or failing to reach the targeted number of patients due to competition for patients from other trials;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">limited or no availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payors for the use of agents used in our clinical trials;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">negative or inconclusive results from clinical trials;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">unforeseen side effects interrupting, delaying or halting clinical trials of our product candidates and possibly resulting in the FDA or other regulatory authorities denying approval of our product candidates;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">unforeseen safety issues;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">uncertain dosing issues;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">approval and introduction of new therapies or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications obsolete;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">inability or unwillingness of medical investigators to follow our clinical protocols; and</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">unavailability of clinical trial supplies.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">35</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government-imposed bans or restrictions and religious, moral, and ethical concerns about the use of hES cells could prevent us from developing and successfully marketing stem cell products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Government-imposed bans or restrictions on the use of embryos or hES cells in research and development in the United States and abroad could generally constrain stem cell research, thereby limiting the market and demand for our products.&#160; During March 2009, President Obama lifted certain restrictions on federal funding of research involving the use of hES cells, and in accordance with President Obama&#8217;s Executive Order, the NIH has adopted new guidelines for determining the eligibility of hES cell lines for use in federally funded research.&#160; The central focus of the proposed guidelines is to assure that hES cells used in federally funded research were derived from human embryos that were created for reproductive purposes, were no longer needed for this purpose, and were voluntarily donated for research purposes with the informed written consent of the donors.&#160; The hES cells that were derived from embryos created for research purposes rather than reproductive purposes, and other hES cells that were not derived in compliance with the guidelines, are not eligible for use in federally funded research.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">California law requires that stem cell research be conducted under the oversight of a stem cell research oversight committee (&#8220;SCRO&#8221;).&#160; Many kinds of stem cell research, including the derivation of new hES cell lines, may only be conducted in California with the prior written approval of the SCRO.&#160; A SCRO could prohibit or impose restrictions on the research that we plan to do.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The use of hES cells gives rise to religious, moral, and ethical issues regarding the appropriate means of obtaining the cells and the appropriate use and disposal of the cells.&#160; These considerations could lead to more restrictive government regulations or could generally constrain stem cell research, thereby limiting the market and demand for our products.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete with us, which could limit opportunities for us to generate revenues by licensing our technology and selling products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and in other countries.&#160; If we are unsuccessful at obtaining and enforcing patents, our competitors could use our technology and create products that compete with our products, without paying license fees or royalties to us.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The preparation, filing, and prosecution of patent applications can be costly and time consuming.&#160; Our limited financial resources may not permit us to pursue patent protection of all of our technology and products throughout the world.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Even if we are able to obtain issued patents covering our technology or products, we may have to incur substantial legal fees and other expenses to enforce our patent rights in order to protect our technology and products from infringing uses.&#160; We may not have the financial resources to finance the litigation required to preserve our patent and trade secret rights.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is no certainty that our pending or future patent applications will result in the issuance of patents</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We have filed patent applications for technology that we have developed, and we have obtained licenses for a number of patent applications covering technology developed by others, that we believe will be useful in producing new products, and which we believe may be of commercial interest to other companies that may be willing to sublicense the technology for fees or royalty payments.&#160; In the future, we may also file additional new patent applications seeking patent protection for new technology or products that we develop ourselves or jointly with others.&#160; However, there is no assurance that any of our licensed patent applications, or any patent applications that we have filed or that we may file in the future covering our own technology, either in the United States or abroad, will result in the issuance of patents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In Europe, the European Patent Convention prohibits the granting of European patents for inventions that concern &#8220;uses of human embryos for industrial or commercial purposes.&#8221;&#160; The European Patent Office is presently interpreting this prohibition broadly, and is applying it to reject patent claims that pertain to human embryonic stem cells.&#160; However, this broad interpretation is being challenged through the European Patent Office appeals system.&#160; As a result, we do not yet know whether or to what extent we will be able to obtain patent protection for our human embryonic stem cell technologies in Europe.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">36</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The Supreme Court decisions in <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Mayo Collaborative Services v. Prometheus Laboratories, Inc. </font>and <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Association for Molecular Pathology v. Myriad Genetics</font> will need to be considered in determining whether certain diagnostic methods and reagents can be patented, since the Court denied patent protection for the use of a mathematical correlation of the presence of a well-known naturally occurring metabolite as a means of determining proper drug dosage, and found that DNA sequences isolated from humans were not patent eligible.&#160; Our subsidiary OncoCyte is developing <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PanC-Dx</font>&#8482; as a cancer diagnostic test, based on the presence of certain genetic markers for a variety of cancers.&#160; Because <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">PanC-Dx</font>&#8482; combines an innovative methodology with newly discovered compositions of matter, we are hopeful that this Supreme Court decision will not preclude the availability of patent protection for OncoCyte&#8217;s new product.&#160; However, like other developers of diagnostic products, we are evaluating this new Supreme Court decision and new guidelines issued by the USPTO for the patenting of products that test for biological substances.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The process of applying for and obtaining patents can be expensive and slow</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The preparation and filing of patent applications, and the maintenance of patents that are issued, may require substantial time and money.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">A patent interference proceeding may be instituted with the USPTO for patents or applications filed before March 16, 2013 when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent.&#160; At the completion of the interference proceeding, the USPTO may determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO&#8217;s decision is subject to appeal.&#160; This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">After March 16, 2013 a derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Post Grant Review under the new America Invents Act will make available after March 16, 2013 opposition-like proceedings in the United States.&#160; As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries.&#160; As with the USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our patents may not protect our products from competition</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We or our subsidiaries have patents in the United States, Canada, the European Union countries, the United Kingdom, Australia, Israel, Russia, South Africa, India, China, South Korea, Japan, Hong Kong, and Singapore, and have filed patent applications in other foreign countries for our plasma volume expander, stem cell products, <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and other hydrogels, certain genes related to the development of cancer, and other technologies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We might not be able to obtain any additional patents, and any patents that we do obtain might not be comprehensive enough to provide us with meaningful patent protection.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">There will always be a risk that our competitors might be able to successfully challenge the validity or enforceability of any patent issued to us.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">In addition to interference proceedings, the USPTO can re-examine issued patents at the request of a third party seeking to have the patent invalidated.&#160; This means that patents owned or licensed by us may be subject to re-examination and may be lost if the outcome of the re-examination is unfavorable to us.&#160; As of September 16, 2012 our patents may be subject to inter partes review (replacing the inter partes reexamination proceeding), a proceeding in which a third party can challenge the validity of one of our patents.</td>
</tr>
</table>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">37</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be subject to patent infringement claims that could be costly to defend, which may limit our ability to use disputed technologies, and which could prevent us from pursuing research and development or commercialization of some of our products, require us to pay licensing fees to have freedom to operate, and/or result in monetary damages or other liability for us</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The success of our business depends significantly on our ability to operate without infringing patents and other proprietary rights of others.&#160; If the technology that we use infringes a patent held by others, we could be sued for monetary damages by the patent holder or its licensee, or we could be prevented from continuing research, development, and commercialization of products that rely on that technology, unless we are able to obtain a license to use the patent.&#160; The cost and availability of a license to a patent cannot be predicted, and the likelihood of obtaining a license at an acceptable cost would be lower if the patent holder or any of its licensees is using the patent to develop or market a product with which our product would compete.&#160; If we could not obtain a necessary license, we would need to develop or obtain rights to alternative technologies, which could prove costly and could cause delays in product development, or we could be forced to discontinue the development or marketing of any products that were developed using the technology covered by the patent.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Our business depends on several critical technologies that are based in part on technology licensed from third parties.&#160; Those third-party license agreements impose obligations on us, including payment obligations and obligations to pursue development of commercial products under the licensed patents or technology.&#160; If a licensor believes that we have failed to meet our obligations under a license agreement, the licensor could seek to limit or terminate our license rights, which could lead to costly and time-consuming litigation and, potentially, a loss of the licensed rights.&#160; During the period of any such litigation, our ability to carry out the development and commercialization of potential products, and our ability to raise any capital that we might then need, could be significantly and negatively affected.&#160; If our license rights were restricted or ultimately lost, we would not be able to continue to use the licensed technology in our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The price and sale of our products may be limited by health insurance coverage and government regulation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Success in selling our pharmaceutical and cell-based products and medical devices may depend in part on the extent to which health insurance companies, HMOs, and government health administration authorities such as Medicare and Medicaid will pay for the cost of the products and related treatment.&#160; Presently, most health insurance plans and HMOs will pay for </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"> when it is used in a surgical procedure that is covered by the plan.&#160; However, until we actually introduce a new product into the medical marketplace, we will not know with certainty whether adequate health insurance, HMO, and government coverage will be available to permit the product to be sold at a price high enough for us to generate a profit.&#160; In some foreign countries, pricing or profitability of health care products is subject to government control, which may result in low prices for our products.&#160; In the United States, there have been a number of federal and state proposals to implement similar government controls, and new proposals are likely to be made in the future.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to our Dependence on Third Parties</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to enter into and maintain successful strategic alliances for our therapeutic product candidates, we may have to reduce or delay our product development or increase our expenditures</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">An important element of our strategy for developing, manufacturing and commercializing our therapeutic product candidates will be entering into strategic alliances with pharmaceutical companies or other industry participants to advance our programs and enable us to maintain our financial and operational capacity.&#160; We will face significant competition in seeking appropriate alliances.&#160; We may not be able to negotiate alliances on acceptable terms, if at all.&#160; If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our product development or research programs, or we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If we are able to enter into product development and marketing arrangements with pharmaceutical companies, we may license product development, manufacturing, and marketing rights to the pharmaceutical company or to a joint venture company formed with the pharmaceutical company.&#160; Under such arrangements we might receive only a royalty on sales of the products developed or an equity interest in a joint venture company that develops the product.&#160; As a result, our revenues from the sale of those products may be substantially less than the amount of revenues and gross profits that we might receive if we were to develop, manufacture, and market the products ourselves.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">38</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may become dependent on possible future collaborations to develop and commercialize many of our product candidates and to provide the regulatory compliance, sales, marketing and distribution capabilities required for the success of our business</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We may enter into various kinds of collaborative research and development and product marketing agreements to develop and commercialize our products.&#160; The expected future milestone payments and cost reimbursements from collaboration agreements could provide an important source of financing for our research and development programs, thereby facilitating the application of our technology to the development and commercialization of our products, but there are risks associated with entering into collaboration arrangements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">There is a risk that we could become dependent upon one or more collaborative arrangements for product development or as a source of revenues from the sale of any products that may be developed by us alone or through one of the collaborative arrangements.&#160; A collaborative arrangement upon which we might depend might be terminated by our collaboration partner or they might determine not to actively pursue the development or commercialization of our products.&#160; A collaboration partner also may not be precluded from independently pursuing competing products and drug delivery approaches or technologies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">There is a risk that a collaboration partner might fail to perform its obligations under the collaborative arrangements or may be slow in performing its obligations.&#160; In addition, a collaboration partner may experience financial difficulties at any time that could prevent it from having available funds to contribute to the collaboration.&#160; If a collaboration partner fails to conduct its product development, commercialization, regulatory compliance, sales and marketing or distribution activities successfully and in a timely manner, or if it terminates or materially modifies its agreements with us, the development and commercialization of one or more product candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have very limited experience in marketing, selling or distributing our products, and we may need to rely on marketing partners or contract sales companies</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Even if we are able to develop our products and obtain necessary regulatory approvals, we have very limited experience or capabilities in marketing, selling or distributing our products.&#160; We rely entirely on Hospira and CJ Health for the sale of </font><font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">.&#160; We currently have only limited sales, marketing and distribution resources for selling our stem cell research products, and no marketing or distribution resources for selling any of the medical devices or therapeutic products that we are developing.&#160; Accordingly, we will be dependent on our ability to build our own marketing and distribution capability for our new products, which would require the investment of significant financial and management resources, or we will need to find collaborative marketing partners or sales representatives, or wholesale distributors for the commercial sale of our products.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">If we market products through arrangements with third parties, we may pay sales commissions to sales representatives or we may sell or consign products to distributors at wholesale prices.&#160; As a result, our gross profit from product sales may be lower than it would be if we were to sell our products directly to end users at retail prices through our own sales force.&#160; There can be no assurance we will able to negotiate distribution or sales agreements with third parties on favorable terms to justify our investment in our products or achieve sufficient revenues to support our operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not have the ability to independently conduct clinical trials required to obtain regulatory approvals for our product candidates</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We will need to rely on third parties, such as contract research organizations, data management companies, contract clinical research associates, medical institutions, clinical investigators and contract laboratories to conduct any clinical trials that we may undertake for our products.&#160; We may also rely on third parties to assist with our preclinical development of product candidates.&#160; If we outsource clinical trials we may be unable to directly control the timing, conduct and expense of our clinical trials.&#160; If we enlist third parties to conduct clinical trials and they fail to successfully carry out their contractual duties or regulatory obligations or fail to meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">39</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to the Asset Contribution Agreement</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asterias has been substituted for Geron in an appeal of two adverse patent rulings, and if the appeal is not successful, Asterias may not realize value from the Geron patent applications at issue in the appeal and might be precluded from developing therapies to treat certain diseases, such as diabetes</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias has been substituted for Geron as a party in interest in an appeal filed by Geron in the United States District Court for the Northern District of California, appealing two adverse rulings in favor of ViaCyte (formerly Novocell Inc.) by the United States Patent and Trademark Office&#8217;s Board of Patent Appeals and Interferences.&#160; These rulings related to interference proceedings involving patent filings relating to definitive endoderm cells.&#160; Geron had requested that the Board of Patent Appeals and Interferences declare this interference after ViaCyte was granted patent claims that conflicted with subject matter Geron filed in a patent application having an earlier priority date.&#160; Those Geron patent applications are among the patent assets that Geron contributed to Asterias.&#160; Asterias will assume all liabilities arising with respect to the ViaCyte Appeal, other than expenses incurred by Geron relating to the ViaCyte Appeal prior to the closing of the asset contribution transaction.&#160; Appeals of this nature may involve costly and time-consuming legal proceedings and if Asterias is not successful in the appeal, these rulings may prevent or limit development of Asterias product candidates in certain fields such as diabetes treatment and Asterias may be unable to realize value from the patent applications at issue in the appeal.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We could be liable to indemnify Geron from certain liabilities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We and Asterias have agreed to indemnify Geron from and against certain liabilities relating to (a) the distribution of shares of Asterias Series A common stock to Geron stockholders, (b) Asterias&#8217; distribution of certain BioTime warrants to the holders of Asterias Series A common stock, and (c) any distribution of securities by Asterias to the holders of the Asterias Series A common stock within one year following Asterias&#8217; acquisition of Geron&#8217;s stem cell assets.&#160; That indemnification obligation will last through the fifth anniversary of the earliest to occur of the date on which all of the BioTime warrants have either expired, or been exercised, cancelled or sold.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We and Asterias have also agreed to indemnify Geron, from and against certain expenses, losses, and liabilities arising from, among other things, breaches of our or Asterias&#8217; representations, warranties and covenants under the Asset Contribution Agreement.&#160; The maximum damages that may be recovered by either party for a loss under this indemnification related to representations, warranties and covenants, with certain exceptions, is limited to $2,000,000.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asterias&#8217; operations may divert our management&#8217;s attention away from ongoing operations and could adversely affect ongoing operations and business relationships</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Now that Asterias has acquired Geron&#8217;s stem cell assets and is conducting its own research and development programs, our management will be required to provide more management attention to Asterias.&#160; The diversion of our management&#8217;s attention away from our other operations could adversely affect our operations and business relationships that do not relate to Asterias.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Pertaining to Our Common Shares</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Ownership of our common shares will entail certain risks associated with the volatility of prices for our common shares and the fact that we do not pay dividends on our common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we are engaged in the development of pharmaceutical and stem cell research products, the price of our common shares may rise and fall rapidly</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The market price of our common shares, like that of the shares of many biotechnology companies, has been highly volatile.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The price of our common shares may rise rapidly in response to certain events, such as the commencement of clinical trials of an experimental new drug, even though the outcome of those trials and the likelihood of ultimate FDA approval remain uncertain.</td>
</tr>
</table>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">40</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Similarly, prices of our common shares may fall rapidly in response to certain events such as unfavorable results of clinical trials or a delay or failure to obtain FDA approval.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The failure of our earnings to meet analysts&#8217; expectations could result in a significant rapid decline in the market price of our common shares.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 11pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Changes in the price of our common shares will affect the price at which our warrants may trade.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current economic and stock market conditions may adversely affect the price of our common shares</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The stock market has been experiencing extreme price and volume fluctuations which have affected the market price of the equity securities without regard to the operating performance of the issuing companies.&#160; Broad market fluctuations, as well as general economic and political conditions, may adversely affect the market price of our common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we do not pay dividends, our common shares may not be a suitable investment for anyone who needs to earn dividend income</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We do not pay cash dividends on our common shares.&#160; For the foreseeable future, we anticipate that any earnings generated in our business will be used to finance the growth of our business and except for the semi-annual payment of dividends due on our Series A Preferred Stock, and will not be paid out as dividends to our shareholders.&#160; This means that our common shares may not be a suitable investment for anyone who needs to earn income from their investments.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities analysts may not initiate coverage or continue to cover our common shares and this may have a negative impact on the market price of our common shares</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The trading market for our common shares will depend, in part, on the research and reports that securities analysts publish about our business and our common shares.&#160; We do not have any control over these analysts.&#160; There is no guarantee that securities analysts will cover our common shares.&#160; If securities analysts do not cover our common shares, the lack of research coverage may adversely affect the market price of those shares and our warrants.&#160; If securities analysts do cover our common shares, they could issue reports or recommendations that are unfavorable to the price of our common shares, and they could downgrade a previously favorable report or recommendation, and in either case our share prices could decline as a result of the report.&#160; If one or more of these analysts does not initiate coverage, ceases to cover our common shares or fails to publish regular reports on our business, we could lose visibility in the financial markets, which could cause our share prices or trading volume to decline.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The market price of our common shares could be impacted by the issuance of the common shares and warrants to Asterias and to an investor</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Under the Asset Contribution Agreement, we issued to Asterias 8,902,077 common shares and 8,000,000 common share purchase warrants.&#160; We have also issued 1,350,000 common shares and 649,998 warrants to an investor under a Stock and Warrant Purchase Agreement.&#160; Asterias and the investor may sell the common shares they received from us.&#160; Those sales may take place from time to time on the NYSE MKT and may create downward pressure on the trading price of our common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Asterias expects to distribute the warrants it receives from us to the future holders of its Series A common stock.&#160; The warrants we issued to Asterias will be exercisable for a period of five years at an exercise price of $5.00 per share, subject to adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions.&#160; The warrants we issued to the investor will be exercisable for a period of three years at an exercise price of $5.00 per share, subject to adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions.&#160; During the period that the warrants are outstanding, the actual or potential exercise of those warrants and sale of the underlying common shares may create downward pressure on the trading price of our common shares.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">41</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">You may experience dilution of your ownership interests because of the future issuance of additional common shares and preferred shares by us and our subsidiaries</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present shareholders.&#160; We are currently authorized to issue an aggregate of 127,000,000 shares of capital stock consisting of 125,000,000 common shares and 2,000,000 &#8220;blank check&#8221; preferred shares.&#160; As of May 6, 2014, there were 72,149,329 common shares outstanding of which 10,546,137 were held by certain of our subsidiaries for resale in &#8220;at-the-market&#8221; transactions, 5,536,301 common shares reserved for issuance upon the exercise of outstanding options under our employee stock option plans; and 9,751,615 shares reserved for issuance upon the exercise of common share purchase warrants.&#160; Our Board of Directors has designated 300,000 preferred shares as Series A Convertible Preferred Stock, of which 70,000 shares were outstanding as of March 31, 2014 and are convertible at the election of the holders into 875,000 common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The operation of some of our subsidiaries has been financed in part through the sale of capital stock in those subsidiaries to private investors.&#160; Sales of additional subsidiary shares could reduce our ownership interest in the subsidiaries, and correspondingly dilute our shareholder&#8217;s ownership interests in our consolidated enterprise.&#160; Our subsidiaries also have their own stock option plans and the exercise of subsidiary stock options or the sale of restricted stock under those plans would also reduce our ownership interest in the subsidiaries, with a resulting dilutive effect on the ownership interest of our shareholders in our consolidated enterprise.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We and our subsidiaries may issue additional common shares or other securities that are convertible into or exercisable for common shares in order to raise additional capital, or in connection with hiring or retaining employees or consultants, or in connection with future acquisitions of licenses to technology or rights to acquire products, or in connection with future business acquisitions, or for other business purposes.&#160; The future issuance of any such additional common shares or other securities may create downward pressure on the trading price of our common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">We may also issue preferred shares having rights, preferences, and privileges senior to the rights of our common shares with respect to dividends, rights to share in distributions of our assets if we liquidate our company, or voting rights.&#160; Any preferred shares may also be convertible into common shares on terms that would be dilutive to holders of common shares.&#160; Our subsidiaries may also issue their own preferred shares with a similar dilutive impact on our ownership of the subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The market price of our common shares could be impacted by prices at which we sell shares in our subsidiaries</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The operation of some our subsidiaries has been financed in part through the sale of capital stock in those subsidiaries, and our subsidiaries may sell shares of their capital stock in the future for financing purposes.&#160; The prices at which our subsidiaries may sell shares of their capital stock could impact the value of our company as a whole and could impact the price at which our common shares trade in the market.&#160; A sale of capital stock of one of our subsidiaries at a price that the market perceives as low could adversely impact the market price of our common shares.&#160; Even if our subsidiaries sell their capital stock at prices that reflect arm&#8217;s length negotiation with investors, there is no assurance that those prices will reflect a true fair market value or that the ascribed value of the subsidiaries based on those share prices will be fully reflected in the market value of our common shares.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 2.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Unregistered Sales of Equity Securities and Use of Proceeds</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Previously reported.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 3.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Default Upon Senior Securities</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">None.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 4.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Mine Safety Disclosures</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Not Applicable.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 80px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 5.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Other Information</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">None.</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">42</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.14%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item_1_3_11"><!--Anchor--></a>Item 6.</div>
</td>
<td style="WIDTH: 93.86%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Exhibit</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Numbers</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Articles of Incorporation with all amendments.(1)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">By-Laws, As Amended. (2)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Specimen of Series A Convertible Preferred Stock Certificate (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Certificate of Determination of Series A Convertible Preferred Stock (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Preferred Stock Purchase Agreement, dated March 4, 2014, between BioTime and certain investors (3) </div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Option Agreement, dated March 4, 2014, between BioTime and certain investors (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.3</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Amendment No. 1 to <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Controlled Equity Offering</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> Sales Agreement, dated March 26, 2014, between BioTime, Inc. and Cantor Fitzgerald &amp; Co (4)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">31</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Rule 13a-14(a)/15d-14(a) Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">32</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Section 1350 Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">Interactive Data File</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.INS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Instance Document *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.SCH</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Schema *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.CAL</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Calculation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.LAB</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Label Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.PRE</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Presentation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.DEF</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Definition Document *</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K/A-1 for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 29, 2014</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(2)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to Registration Statement on Form S-1, File Number 33-48717 and Post-Effective Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 22, 1992, and August 27, 1992, respectively.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2014</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(4)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 26, 2014</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">*</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Filed herewith</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt"><a name="part_1_2_3"><!--Anchor--></a><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">43</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center"></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 49.5pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 29.7pt; FONT-SIZE: 10pt">BIOTIME, INC.</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 49.5pt; FONT-SIZE: 10pt">Date: May 12, 2014</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">/s/ Michael D. West</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Michael D. West</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 49.5pt; FONT-SIZE: 10pt">Date: May 12, 2014</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">/s/ Robert W. Peabody</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Robert W. Peabody</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 51.05%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 40.45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">44</div>

<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Exhibit</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Numbers</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Articles of Incorporation with all amendments.(1)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">By-Laws, As Amended. (2)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Specimen of Series A Convertible Preferred Stock Certificate (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Certificate of Determination of Series A Convertible Preferred Stock (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Preferred Stock Purchase Agreement, dated March 4, 2014, between BioTime and certain investors (3) </div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Option Agreement, dated March 4, 2014, between BioTime and certain investors (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">10.3</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Amendment No. 1 to <font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Controlled Equity Offering</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> Sales Agreement, dated March 26, 2014, between BioTime, Inc. and Cantor Fitzgerald &amp; Co (4)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><a name="A31.1"><!--Anchor--></a><a href="ex31.htm">31</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Rule 13a-14(a)/15d-14(a) Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><a name="A32"><!--Anchor--></a><a href="ex32.htm">32</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Section 1350 Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">Interactive Data File</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.INS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Instance Document *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.SCH</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Schema *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.CAL</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Calculation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.LAB</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Label Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.PRE</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Presentation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.99%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">101.DEF</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.01%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">XBRL Taxonomy Extension Definition Document *</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(1)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K/A-1 for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 29, 2014</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(2)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to Registration Statement on Form S-1, File Number 33-48717 and Post-Effective Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 22, 1992, and August 27, 1992, respectively.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(3)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2014</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(4)</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 26, 2014</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">*</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Filed herewith</div>
</td>
</tr>
</table>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">45</div>

<hr style="HEIGHT: 2px; COLOR: #000000" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>ex31.htm
<DESCRIPTION>EXHIBIT 31
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Thomson Reuters
    Document created using Disclosure Solutions PROFILE 2.6.0.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<hr style="HEIGHT: 4px; COLOR: #000000" noshade="noshade">
 Exhibit 31</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATIONS</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">I, Michael D. West, certify that:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1.&#160;&#160;I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.&#160;&#160;The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(a)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the periodic reports are being prepared;</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(b)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
</td>
</tr>
</table>

<div>&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(c)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(d)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">5.&#160;&#160;The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(a)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(b)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.91%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Date:&#160;&#160;May 12, 2014</div>
</td>
<td style="WIDTH: 76.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.91%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 76.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 23.91%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">/s/ Michael D. West</div>
</td>
<td style="WIDTH: 76.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.91%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Michael D. West</div>
</td>
<td style="WIDTH: 76.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.91%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
<td style="WIDTH: 76.09%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>
</div>

<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATIONS</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">I, Robert W. Peabody, certify that:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1.&#160;&#160;I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">4.&#160;&#160;The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(a)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the periodic reports are being prepared;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(b)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(c)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(d)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;5.&#160;&#160;The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(a)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(b)</div>
</td>
<td style="WIDTH: 91.67%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Date:&#160;&#160;May 12, 2014</div>
</td>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 24%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 24%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.1pt">/s/ Robert W. Peabody</div>
</td>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 24%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Robert W. Peabody</div>
</td>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 24%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<hr style="HEIGHT: 2px; COLOR: #000000" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Thomson Reuters
    Document created using Disclosure Solutions PROFILE 2.6.0.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<hr style="HEIGHT: 4px; COLOR: #000000" noshade="noshade">
Exhibit 32<!--Anchor--></div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">AS ADOPTED PURSUANT TO</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">In connection with the Quarterly Report on Form 10-Q of BioTime, Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Michael D. West, Chief Executive Officer, and Robert W. Peabody, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">1.</div>
</td>
<td style="WIDTH: 93.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">2.</div>
</td>
<td style="WIDTH: 93.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;Date: May 12, 2014</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">/s/ Michael D. West</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Michael D. West</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
</tr>
</table>

<div><br>
</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">/s/ Robert W. Peabody</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Robert W. Peabody</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<hr style="HEIGHT: 2px; COLOR: #000000" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>btx-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:btx="http://biotimeinc.com/20140331" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="btx-20140331.xsd" />
  <xbrli:context id="c20140101to20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140509">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_LifemapSciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_EsCellInternationalPteLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:EsCellInternationalPteLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_OrthocyteCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OrthocyteCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_CellCureNeurosciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:CellCureNeurosciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_LifemapSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_LifemapSolutionsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSolutionsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_OncocyteCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_BiotimeAsiaLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:BiotimeAsiaLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_RecyteTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:RecyteTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:BiotimeLicenseForUniversityOfUtahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncWithKirinSublicenseIMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AsteriasLicenseUniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:WarfMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:WarfMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncWithKirinSublicenseIiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:OncocyteLicenseFromSbmriMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:CellCureNeurosciencesLicenseFromHadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AsteriasSublicenseFromGeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:WarfMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:WarfMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AsteriasSublicenseFromGeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncWithKirinSublicenseIMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AdvancedCellTechnologyIncWithKirinSublicenseIiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:BiotimeLicenseForUniversityOfUtahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:CellCureNeurosciencesLicenseFromHadasitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:CellCureNeurosciencesLicenseFromHadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:CellCureNeurosciencesLicenseFromHadasitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:CellCureNeurosciencesLicenseFromHadasitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:AsteriasLicenseUniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_ReproductiveGeneticsInstituteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:ReproductiveGeneticsInstituteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:OncocyteLicenseFromSbmriMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIiClinicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:TevaLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="btx:PaymentPhaseAxis">btx:PhaseIiClinicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIiiClinicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:TevaLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="btx:PaymentPhaseAxis">btx:PhaseIiiClinicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIClinicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">btx:TevaLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="btx:PaymentPhaseAxis">btx:PhaseIClinicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_PrivateFundingAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="btx:PrivateFundingAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_PrivateFundingAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="btx:PrivateFundingAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:GeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LegalEntityAxis_RomulusFilmsLtdMember_StatementClassOfStockAxis_CommonClassBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:RomulusFilmsLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:GeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_RomulusFilmsLtdMember_StatementClassOfStockAxis_CommonClassBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:RomulusFilmsLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131001_StatementClassOfStockAxis_Warrants1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:Warrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LegalEntityAxis_GeronMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:GeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131001_StatementClassOfStockAxis_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130929to20131001_StatementClassOfStockAxis_Warrants1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:Warrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-29</xbrli:startDate>
      <xbrli:endDate>2013-10-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LegalEntityAxis_GeronMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:GeronMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140501to20140531_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140504to20140505_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-04</xbrli:startDate>
      <xbrli:endDate>2014-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140504to20140506_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-04</xbrli:startDate>
      <xbrli:endDate>2014-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140506_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>iso4217:ILS</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>btx:Tranche</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>btx:Intallment</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20140101to20140331">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20140101to20140331">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20140101to20140331">2014-03-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20140101to20140331">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20140101to20140331">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20140101to20140331">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20140101to20140331">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20140101to20140331">BIOTIME INC</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20140101to20140331">0000876343</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20140509" unitRef="U001" decimals="0">72149329</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20140101to20140331">2014</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20140101to20140331">Q1</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20140101to20140331">10-Q</dei:DocumentType>
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="0">6722624</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20140331" unitRef="U002" decimals="0">5443063</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts Payable and Accrued Liabilities Disclosure [Text Block]-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;6. Accounts Payable and Accrued Liabilities&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following:&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accounts payable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,527,330&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,887,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accrued bonuses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;229,905&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;600,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Other accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,685,828&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,234,674&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,443,063&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,722,624&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <!--Trade accounts receivable-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20131231" unitRef="U002" decimals="0">575900</us-gaap:AccountsReceivableNetCurrent>
  <!--Trade accounts receivable-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20140331" unitRef="U002" decimals="0">600400</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20131231" unitRef="U002" decimals="0">3887950</us-gaap:AccountsPayableCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20140331" unitRef="U002" decimals="0">2527330</us-gaap:AccountsPayableCurrent>
  <!--Accrued Bonuses, Current-->
  <us-gaap:AccruedBonusesCurrent contextRef="c20140331" unitRef="U002" decimals="0">229905</us-gaap:AccruedBonusesCurrent>
  <!--Accrued Bonuses, Current-->
  <us-gaap:AccruedBonusesCurrent contextRef="c20131231" unitRef="U002" decimals="0">600000</us-gaap:AccruedBonusesCurrent>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20140331" unitRef="U002" decimals="0">1685927</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20131231" unitRef="U002" decimals="0">1433853</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated other comprehensive income/(loss)-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20140331" unitRef="U002" decimals="0">-44341</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive income/(loss)-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20131231" unitRef="U002" decimals="0">62899</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Contributed capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20140331" unitRef="U002" decimals="0">93972</us-gaap:AdditionalPaidInCapital>
  <!--Contributed capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20131231" unitRef="U002" decimals="0">93972</us-gaap:AdditionalPaidInCapital>
  <!--Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs-Geron [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c20140101to20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">541800</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20130101to20130331" unitRef="U002" decimals="0">691946</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">801554</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allowance for Doubtful Accounts Receivable, Current-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20131231" unitRef="U002" decimals="0">116800</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Allowance for Doubtful Accounts Receivable, Current-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20140331" unitRef="U002" decimals="0">116800</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20130101to20130331" unitRef="U002" decimals="0">642573</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140331" unitRef="U002" decimals="0">1367998</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Deferred Charges-->
  <us-gaap:AmortizationOfDeferredCharges contextRef="c20130101to20130331" unitRef="U002" decimals="0">-42996</us-gaap:AmortizationOfDeferredCharges>
  <!--Amortization of Deferred Charges-->
  <us-gaap:AmortizationOfDeferredCharges contextRef="c20140101to20140331" unitRef="U002" decimals="0">-280</us-gaap:AmortizationOfDeferredCharges>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0">9751615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="U001" decimals="0">5491301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0">816612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Treasury Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember" unitRef="U001" decimals="0">2360968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20130331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="U001" decimals="0">4771301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Treasury Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember" unitRef="U001" decimals="0">10546137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20140331" unitRef="U002" decimals="0">9246811</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20131231" unitRef="U002" decimals="0">7949970</us-gaap:AssetsCurrent>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20140331" unitRef="U002" decimals="0">57949895</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20131231" unitRef="U002" decimals="0">57729750</us-gaap:Assets>
  <!--Basis of Accounting, Policy [Policy Text Block]-->
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;General&lt;/font&gt; &amp;#8211; BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (&amp;#8220;hES&amp;#8221;) cell and induced pluripotent stem (&amp;#8220;iPS&amp;#8221;) cell technology.&amp;#160; Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.&amp;#160; hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products.&amp;#160; BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use.&amp;#160; Asterias Biotherapeutics, Inc. (&amp;#8220;Asterias&amp;#8221;) acquired the stem cell assets of Geron Corporation (&amp;#8220;Geron&amp;#8221;) that had been used in Geron&amp;#8217;s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction.&amp;#160; OncoCyte Corporation (&amp;#8220;OncoCyte&amp;#8221;) is developing products and technologies to diagnose cancer.&amp;#160; ES Cell International Pte Ltd. (&amp;#8220;ESI&amp;#8221;), a Singapore private limited company, and BioTime&amp;#8217;s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets.&amp;#160; OrthoCyte Corporation (&amp;#8220;OrthoCyte&amp;#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries.&amp;#160; ReCyte Therapeutics, Inc. (&amp;#8220;ReCyte Therapeutics&amp;#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.&amp;#160; Cell Cure Neurosciences Ltd. (&amp;#8220;Cell Cure Neurosciences&amp;#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.&amp;#160; LifeMap Sciences, Inc. (&amp;#8220;LifeMap Sciences&amp;#8221;) markets, sells and distributes &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;GeneCards&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, the leading human gene database and an integrated database suite that includes &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;GeneCards&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, the &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Discovery&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries.&amp;#160; Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.&amp;#160; BioTime&amp;#8217;s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hextend&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, from the sale of products for research, and from research grants.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime&amp;#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X.&amp;#160; In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made.&amp;#160; The&amp;#160;consolidated balance sheet as of December 31, 2013 is derived from the Company&amp;#8217;s annual audited financial statements as of that date.&amp;#160; The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) except for the&amp;#160;consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements.&amp;#160; Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods.&amp;#160; It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&amp;#8217;s Form 10-K for the year ended December 31, 2013.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <!--Business Acquisition, Pro Forma Revenue-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20130101to20130331" unitRef="U002" decimals="0">493705</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Business Acquisition, Pro Forma Revenue-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">934721</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Net loss available to common shareholders-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8099014</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Net loss available to common shareholders-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20130101to20130331" unitRef="U002" decimals="0">-22572852</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Geron asset acquisition related transaction costs paid by BioTime-Asterias Biotherapeutics [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Transaction and other costs-Geron [Member]-->
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c20140101to20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">1519904</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20140331" unitRef="U002" decimals="0">6637834</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U002" decimals="0">5495478</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20121231" unitRef="U002" decimals="0">4349967</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20130331" unitRef="U002" decimals="0">9896335</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, Policy [Policy Text Block]-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cash and cash equivalents&lt;/font&gt; &amp;#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20130101to20130331" unitRef="U002" decimals="0">5546368</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20140331" unitRef="U002" decimals="0">1142356</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Exercise price of warrant (in dollars per share)-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U003" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <!--Exercise price of warrant (in dollars per share)-Warrants1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="c20131001_StatementClassOfStockAxis_Warrants1Member" unitRef="U003" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <!--Exercise price of warrant (in dollars per share)-Asterias Biotherapeutics [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U003" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <!--Number of warrants issued (in shares)-Asterias Biotherapeutics [Member]-Common Class B [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0">3150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Number of warrants issued (in shares)-Romulus Films, Ltd. [Member]-Common Class B [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20140331_LegalEntityAxis_RomulusFilmsLtdMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0">350000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Number of warrants issued (in shares)-Asterias Biotherapeutics [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20140331" unitRef="U002" xsi:nil="true" />
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20131231" unitRef="U002" xsi:nil="true" />
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20140331" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20131231" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common shares, par value (in dollars per share)-Asterias Biotherapeutics [Member]-Common Class B [Member]-->
  <us-gaap:CommonStockNoParValue contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U003" decimals="4">0.0001</us-gaap:CommonStockNoParValue>
  <!--Common shares, par value (in dollars per share)-Common Class A [Member]-Geron [Member]-->
  <us-gaap:CommonStockNoParValue contextRef="c20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember" unitRef="U003" decimals="4">0.0001</us-gaap:CommonStockNoParValue>
  <!--Common shares, outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20131231" unitRef="U001" decimals="0">56714424</us-gaap:CommonStockSharesOutstanding>
  <!--Common shares, outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20140331" unitRef="U001" decimals="0">59071192</us-gaap:CommonStockSharesOutstanding>
  <!--Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20140331" unitRef="U002" decimals="0">211943421</us-gaap:CommonStockValue>
  <!--Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20131231" unitRef="U002" decimals="0">203456401</us-gaap:CommonStockValue>
  <!--Common shares, issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20131231" unitRef="U001" decimals="0">67412139</us-gaap:CommonStockSharesIssued>
  <!--Common shares, issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20140331" unitRef="U001" decimals="0">69617329</us-gaap:CommonStockSharesIssued>
  <!--Common shares, authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20140331" unitRef="U001" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common shares, authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20131231" unitRef="U001" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130101to20130331" unitRef="U002" decimals="0">-7570826</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8206254</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Concentration Risk, Credit Risk, Policy [Policy Text Block]-->
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Concentrations of credit risk&lt;/font&gt; &amp;#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents.&amp;#160; BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions.&amp;#160; Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <!--Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]-->
  <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following table reflects BioTime&amp;#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"&gt;&lt;tr style="height: 33px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Subsidiary&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Field of Business&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;BioTime &lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ownership&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Country&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias Biotherapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;71.6%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ES Cell International Pte Ltd&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research, including clinical grade cell lines&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;produced under cGMP&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Singapore&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OncoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cancer diagnostics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;75.3%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OrthoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Orthopedic diseases, including chronic back pain and osteoarthritis&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cell Cure Neurosciences Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Age-related macular degeneration&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Multiple sclerosis&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Parkinson&amp;#8217;s disease&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;62.5%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ReCyte Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;94.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime Asia, Limited&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;81%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hong Kong&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Genetic, disease, and stem cell databases&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;73.2%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell database&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;"&gt;LifeMap Solutions, Inc.&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;"&gt;Mobile health software&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;"&gt;(1)&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
  <!--Consolidation, Policy [Policy Text Block]-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Principles of consolidation&lt;/font&gt; &amp;#8211; BioTime&amp;#8217;s consolidated financial statements include the accounts of its subsidiaries.&amp;#160; The following table reflects BioTime&amp;#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"&gt;&lt;tr style="height: 33px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Subsidiary&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Field of Business&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;BioTime &lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ownership&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Country&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias Biotherapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;71.6%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ES Cell International Pte Ltd&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research, including clinical grade cell lines&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;produced under cGMP&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Singapore&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OncoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cancer diagnostics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;75.3%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OrthoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Orthopedic diseases, including chronic back pain and osteoarthritis&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cell Cure Neurosciences Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Age-related macular degeneration&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Multiple sclerosis&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Parkinson&amp;#8217;s disease&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;62.5%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ReCyte Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;94.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime Asia, Limited&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;81%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hong Kong&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Genetic, disease, and stem cell databases&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;73.2%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell database&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;"&gt;LifeMap Solutions, Inc.&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;"&gt;Mobile health software&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;"&gt;(1)&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;All material intercompany accounts and transactions have been eliminated in consolidation.&amp;#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (&amp;#8220;GAAP&amp;#8221;) and with the accounting and reporting requirements of SEC Regulation S-X.&amp;#160; As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&amp;#8220;BioTime Asia&amp;#8221;), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime&amp;#8217;s condensed consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Cost of sales-->
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cost of sales&lt;/font&gt; &amp;#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations.&lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <!--Cost of Revenue-->
  <us-gaap:CostOfRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">131914</us-gaap:CostOfRevenue>
  <!--Cost of Revenue-->
  <us-gaap:CostOfRevenue contextRef="c20130101to20130331" unitRef="U002" decimals="0">182749</us-gaap:CostOfRevenue>
  <!--Overhead charges-Subsequent Event [Member]-->
  <us-gaap:CostOfServicesOverhead contextRef="c20140504to20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">1000000</us-gaap:CostOfServicesOverhead>
  <!--Deferred Costs-->
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">528458</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <!--Deferred Charges, Policy [Policy Text Block]-->
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred license and consulting fees&lt;/font&gt; &amp;#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&amp;#160; The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products.&amp;#160; See Note 5.&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <!--Deferred rent, net of current portion-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">28054</us-gaap:DeferredRentCreditNoncurrent>
  <!--Deferred rent, net of current portion-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">35997</us-gaap:DeferredRentCreditNoncurrent>
  <!--Deferred income tax benefit-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1349026</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred income tax benefit-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred Revenue Disclosure [Text Block]-->
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;5. Royalty Obligation and Deferred License Fees&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products.&amp;#160; BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing.&amp;#160; The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired.&amp;#160; BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;WARF License&amp;#8212;Research Products&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (&amp;#8220;WARF&amp;#8221;).&amp;#160; The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development.&amp;#160; BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF.&amp;#160; The royalty will range from 2% to 4%, depending on the kind of products sold.&amp;#160; The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product.&amp;#160; BioTime paid licensing fees, totaling $295,000 in cash and BioTime stock, and reimbursed WARF for certain costs associated with preparing, filing, and maintaining the licensed patents.&amp;#160; In addition, BioTime pays WARF $25,000 annually as a license maintenance fee.&amp;#160; The licensing fees less the amortized portion were included in deferred license fees in BioTime&amp;#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ReCyte Therapeutics Licenses from ACT&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc. (&amp;#8220;ACT&amp;#8221;), under which ReCyte Therapeutics acquired exclusive worldwide rights to use ACT&amp;#8217;s &amp;#8220;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ACTCellerate&lt;/font&gt;&amp;#8482;&amp;#8221; technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells.&amp;#160; ReCyte Therapeutics paid ACT a $250,000 license fee.&amp;#160; ReCyte Therapeutics has assigned its rights under the License Agreement to BioTime.&amp;#160; BioTime will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology.&amp;#160; Once a total of $1,000,000 of royalties has been paid, no further royalties will be due.&amp;#160; The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later.&amp;#160; The $250,000 license fee less the amortized portion is included in deferred license fees in BioTime&amp;#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On August 15, 2008, ReCyte Therapeutics entered into a License Agreement and a Sublicense Agreement with ACT under which ReCyte Therapeutics acquired world-wide rights to use an array of ACT technology (the &amp;#8220;ACT License&amp;#8221;) and technology licensed by ACT from affiliates of Kirin Pharma Company, Limited (the &amp;#8220;Kirin Sublicense&amp;#8221;).&amp;#160; The ACT License and Kirin Sublicense permit the commercialization of products in human therapeutic and diagnostic product markets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The technology licensed by ReCyte Therapeutics covers methods to transform cells of the human body, such as skin cells, into an embryonic state in which the cells will be pluripotent.&amp;#160; Under the ACT License, ReCyte Therapeutics paid ACT a $200,000 license fee and will pay a 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the ACT technology to third parties.&amp;#160; Once a total of $600,000 of royalties has been paid, no further royalties will be due.&amp;#160; The license will expire in twenty years or upon the expiration of the last-to-expire of the licensed patents, whichever is later.&amp;#160; The $200,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&amp;#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Under the Kirin Sublicense, ReCyte Therapeutics has paid ACT a $50,000 license fee and will pay a 3.5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the Kirin Technology to third parties.&amp;#160; ReCyte Therapeutics will also pay to ACT or to an affiliate of Kirin Pharma Company, Limited (&amp;#8220;Kirin&amp;#8221;), annually, the amount, if any, by which royalties payable by ACT under its license agreement with Kirin are less than the $50,000 annual minimum royalty due.&amp;#160; Those payments by ReCyte Therapeutics will be credited against other royalties payable to ACT under the Kirin Sublicense.&amp;#160; The license will expire upon the expiration of the last to expire of the licensed patents, or May 9, 2016 if no patents are issued.&amp;#160; The $50,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&amp;#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ReCyte Therapeutics License from RGI&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On February 29, 2009, ReCyte Therapeutics entered into a Stem Cell Agreement with Reproductive Genetics Institute (&amp;#8220;RGI&amp;#8221;).&amp;#160; In partial consideration of the rights and licenses granted to ReCyte Therapeutics by RGI, BioTime issued to RGI 32,259 common shares, having a market value of $50,000 on the effective date of the Stem Cell Agreement.&amp;#160; This $50,000 payment less the amortized portion is included in deferred license fees in BioTime&amp;#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OncoCyte License from SBMRI&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Through BioTime&amp;#8217;s acquisition of the assets of Cell Targeting, Inc. during March 2011, BioTime acquired a royalty-bearing, exclusive, worldwide license from the Sanford-Burnham Medical Research Institute (&amp;#8220;SBMRI&amp;#8221;) to use certain patents pertaining to homing peptides for preclinical research investigations of cell therapy treatments, and to enhance cell therapy products for the treatment and prevention of disease and injury in conjunction with BioTime&amp;#8217;s own proprietary technology or that of a third party.&amp;#160; BioTime assigned the SBMRI license to OncoCyte during July 2011.&amp;#160; OncoCyte will pay SBMRI a royalty of 4% on the sale of pharmaceutical products, and 10% on the sale of any research-use products that OncoCyte develops using or incorporating the licensed technology; and 20% of any payments OncoCyte receives for sublicensing the patents to third parties.&amp;#160; The royalties payable to SBMRI may be reduced by 50% if royalties or other fees must be paid to third parties in connection with the sale of any products.&amp;#160; An annual license maintenance fee is payable each year during the term of the license, and after commercial sales of royalty bearing products commence, the annual fee will be credited towards OncoCyte's royalty payment obligations for the applicable year.&amp;#160; OncoCyte will reimburse SBMRI for 25% of the costs incurred in filing, prosecuting, and maintaining patent protection, subject to OncoCyte&amp;#8217;s approval of the costs.&amp;#160; OncoCyte incurred no royalty expenses to date as of March 31, 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cell Cure Neurosciences License from Hadasit&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit Medical Research Services and Development, Ltd. (&amp;#8220;Hadasit&amp;#8221;) under which Cell Cure Neurosciences received an exclusive license to use certain of Hadasit&amp;#8217;s patented technologies for the development and commercialization for hES cell-derived cell replacement therapies for retinal degenerative diseases.&amp;#160; Cell Cure Neurosciences paid Hadasit 249,058 New Israeli Shekels as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;If Teva Pharmaceutical Industries Ltd. (&amp;#8220;Teva&amp;#8221;) exercises its option to license &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; or &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-Plus&lt;/font&gt; under the terms of a Research and Exclusive License Option Agreement (the &amp;#8220;Teva License Option Agreement&amp;#8221;), Cell Cure Neurosciences will pay Hadasit 30% of all sublicensing payments made by Teva to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;If Teva does not exercise its option and Cell Cure Neurosciences instead commercializes &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; or &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-Plus&lt;/font&gt; itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; or &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-Plus&lt;/font&gt;, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology.&amp;#160; Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents to companies other than Teva.&amp;#160; Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year.&amp;#160; If Cell Cure Neurosciences or a sublicensee other than Teva paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;If Teva does not exercise its option under the Teva License Option Agreement and instead Cell Cure Neurosciences or a sublicensee other than Teva conducts clinical trials of &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; or &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OpRegen&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-Plus&lt;/font&gt;, Hadasit will be entitled to receive certain milestone payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents.&amp;#160; Hadasit will receive $250,000 upon the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial.&amp;#160; These milestone payments are creditable by Cell Cure Neurosciences against sublicensing receipts that are payable to Hadasit at the time of each milestone payment for said milestone payment, except that the $1 million milestone payment shall only be creditable by Cell Cure Neurosciences if it received the sublicensing receipts in the amount of $50 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime License for the University of Utah&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Through the merger of Glycosan into OrthoCyte during March 2011, BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products.&amp;#160; Under the License Agreement, the scope of which was expanded by an amendment during August 2012, BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents.&amp;#160; Commencing in 2014, BioTime will be obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount.&amp;#160; The minimum royalty amounts are $2,500 in 2014 and $30,000 each year thereafter during the term of the License Agreement.&amp;#160; BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses.&amp;#160; BioTime will also pay a $225,000 milestone fee within six months after the first sale of a &amp;#8220;tissue engineered product&amp;#8221; that utilizes a licensed patent.&amp;#160; A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime License from Cornell University&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On August 23, 2011, BioTime entered into a License Agreement with Cornell University for the worldwide development and commercialization of technology for the differentiation of hES cells into vascular endothelial cells.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cornell will be entitled to receive a nominal initial license fee and nominal annual license maintenance fees.&amp;#160; The obligation to pay annual license maintenance fees will end when the first human therapeutic products developed under the license is sold.&amp;#160; BioTime will pay Cornell a milestone payment upon the achievement of a research product sale milestone amount, and will make milestone payments upon the attainment of certain FDA approval milestones for therapeutic products developed under the license, including (i) the first Phase II clinical trial dosing of a human therapeutic product, (ii) the first Phase III clinical trial dosing of a human therapeutic product; (iii) FDA approval of the first human therapeutic product for age-related vascular disease; and (iv) FDA approval of the first human therapeutic product for cancer.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime will pay Cornell royalties on the sale of products and services using the license, and will share with Cornell a portion of any cash payments, other than royalties, that BioTime receives for the grant of sublicenses to non-affiliates.&amp;#160; The potential royalty percentage rates to be paid to Cornell will be in the low to mid-single digit range depending on the product.&amp;#160; BioTime will also reimburse Cornell for costs related to the patent applications and any patents that may issue that are covered by the license.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In conjunction with the License Agreement, BioTime also entered into a Sponsored Research Agreement under which scientists at Weill Cornell Medical College will engage in certain research for BioTime over a three year period beginning August 2011.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias License from WARF&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products.&amp;#160; The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells.&amp;#160; The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire.&amp;#160; Asterias may terminate the license agreement at any time by giving WARF prior written notice.&amp;#160; WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time.&amp;#160; WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias License from the University of California&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Geron assigned to Asterias its Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents.&amp;#160; Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement.&amp;#160; The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement.&amp;#160; Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias&amp;#8217; affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent.&amp;#160; The license agreement will terminate on the expiration of the last-to-expire of the university's issued licensed patents.&amp;#160; If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024.&amp;#160; The university may terminate the agreement in the event of Asterias&amp;#8217; breach of the agreement.&amp;#160; Asterias can terminate the agreement upon 60 days' notice.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias Sublicense from Geron&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado&amp;#8217;s University License Equity Holdings, Inc. relating to telomerase (the &amp;#8220;Telomerase Sublicense&amp;#8221;).&amp;#160; The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of VAC1 and VAC2 as immunological treatments for cancer.&amp;#160; Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents.&amp;#160; The Telomerase Sublicense will expire concurrently with the expiration of Geron&amp;#8217;s license.&amp;#160; That license will terminate during April 2017 when the licensed patents expire.&amp;#160; The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party. See Note 8.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of March 31, 2014, future amortization of deferred license fees described above was as follows:&lt;/div&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; margin-left: 45pt; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Deferred License&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fees&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;83,615&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,843&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;528,458&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <!--Deferred license and subscription revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20140331" unitRef="U002" decimals="0">177594</us-gaap:DeferredRevenueCurrent>
  <!--Deferred license and subscription revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20131231" unitRef="U002" decimals="0">235276</us-gaap:DeferredRevenueCurrent>
  <!--Deferred Tax Assets, Operating Loss Carryforwards-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20140331" unitRef="U002" decimals="0">1349000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Deferred Tax Assets, Operating Loss Carryforwards, Domestic-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c20140331" unitRef="U002" decimals="0">1151000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <!--Deferred Tax Assets, Operating Loss Carryforwards, State and Local-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c20140331" unitRef="U002" decimals="0">198000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <!--Deferred tax liability, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">6928522</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deferred tax liability, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">8277548</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deposits Assets, Noncurrent-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">428827</us-gaap:DepositsAssetsNoncurrent>
  <!--Deposits Assets, Noncurrent-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">129129</us-gaap:DepositsAssetsNoncurrent>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20140101to20140331" unitRef="U002" decimals="0">256945</us-gaap:Depreciation>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20130101to20130331" unitRef="U002" decimals="0">113356</us-gaap:Depreciation>
  <!--BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20140101to20140331" unitRef="U003" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20130101to20130331" unitRef="U003" decimals="2">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Earnings Per Share, Policy [Policy Text Block]-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Loss per share&lt;/font&gt; &amp;#8211; Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period.&amp;#160; Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive.&amp;#160; Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20140101to20140331" unitRef="U002" decimals="0">-101240</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20130101to20130331" unitRef="U002" decimals="0">5463</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Percentages of outstanding voting securities owns before transaction beneficially (in hundredths)-Subsequent Event [Member]-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="1">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Fair Value Assumptions, Expected Volatility Rate-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U004" decimals="4">0.6962</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <!--Fair Value Assumptions, Expected Volatility Rate-Warrants1 [Member]-->
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="c20130929to20131001_StatementClassOfStockAxis_Warrants1Member" unitRef="U004" decimals="4">0.7763</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <!--Fair Value Assumptions, Risk Free Interest Rate-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U004" decimals="4">0.0063</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <!--Fair Value Assumptions, Risk Free Interest Rate-Warrants1 [Member]-->
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="c20130929to20131001_StatementClassOfStockAxis_Warrants1Member" unitRef="U004" decimals="4">0.0142</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <!--Fair Value Assumptions, Expected Term-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember">P3Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <!--Fair Value Assumptions, Expected Term-Warrants1 [Member]-->
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="c20130929to20131001_StatementClassOfStockAxis_Warrants1Member">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <!--Fair Value Assumptions, Expected Dividend Rate-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U004" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <!--Fair Value Assumptions, Expected Dividend Rate-Warrants1 [Member]-->
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="c20130929to20131001_StatementClassOfStockAxis_Warrants1Member" unitRef="U004" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <!--Fair Value of Financial Instruments, Policy [Policy Text Block]-->
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of financial instruments&lt;/font&gt; &amp;#8211; The fair value of BioTime&amp;#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <!--Intangible assets, useful life-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20140331">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Intangible assets, useful life-BioTime License For The University of Utah [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Intangible assets, useful life-Advanced Cell Technology Inc., with Kirin Sublicense I [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Intangible assets, useful life-Advanced Cell Technology, Inc. [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140331" unitRef="U002" decimals="0">54719918</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231" unitRef="U002" decimals="0">54719918</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231" unitRef="U002" decimals="0">8511833</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140331" unitRef="U002" decimals="0">9879831</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20131231" unitRef="U002" decimals="0">46208085</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140331" unitRef="U002" decimals="0">44840087</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Foreign Currency Transaction Gain (Loss), before Tax-->
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">10212</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <!--Foreign Currency Transaction Gain (Loss), before Tax-->
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c20130101to20130331" unitRef="U002" decimals="0">21977</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <!--Foreign Currency Transactions and Translations Policy [Policy Text Block]-->
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Foreign currency translation gain and Comprehensive loss &amp;#8211;&lt;/font&gt; In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date.&amp;#160; Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period.&amp;#160; Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet.&amp;#160; For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that&amp;#160;are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense),&amp;#160;amounted to $10,212 and $21,977, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <!--Loss on sale of fixed assets-->
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8576</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <!--Loss on sale of fixed assets-->
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c20130101to20130331" unitRef="U002" decimals="0">-1523</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">3667171</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20130101to20130331" unitRef="U002" decimals="0">3416145</us-gaap:GeneralAndAdministrativeExpense>
  <!--Intangible assets-->
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Intangible assets&lt;/font&gt; &amp;#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&amp;#160; Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business.&amp;#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&amp;#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&amp;#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) are expensed upon acquisition. See Note 8.&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <!--Grants Receivable, Current-->
  <us-gaap:GrantsReceivableCurrent contextRef="c20131231" unitRef="U002" decimals="0">539300</us-gaap:GrantsReceivableCurrent>
  <!--Grants Receivable, Current-->
  <us-gaap:GrantsReceivableCurrent contextRef="c20140331" unitRef="U002" decimals="0">334700</us-gaap:GrantsReceivableCurrent>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20140101to20140331" unitRef="U002" decimals="0">934721</us-gaap:GrossProfit>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20130101to20130331" unitRef="U002" decimals="0">431724</us-gaap:GrossProfit>
  <!--Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Impairment of long-lived assets &amp;#8211;&lt;/font&gt; BioTime&amp;#8217;s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&amp;#160; If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&amp;#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <!--Loss on sale or write-off of equipment-->
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c20130101to20130331" unitRef="U002" decimals="0">1523</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <!--Loss on sale or write-off of equipment-->
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c20140101to20140331" unitRef="U002" decimals="0">8576</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c20130101to20130331" unitRef="U002" decimals="0">-8408545</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">-11077057</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1349026</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax, Policy [Policy Text Block]-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income taxes &amp;#8211;&lt;/font&gt; BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect.&amp;#160; Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized.&amp;#160; The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.&amp;#160; For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities.&amp;#160; For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias&amp;#8217; tax provision with BioTime&amp;#8217;s.&amp;#160; BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively.&amp;#160; BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions.&amp;#160; Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.&amp;#160; Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws.&amp;#160; Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&amp;#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&amp;#160; No tax benefit had been recorded through &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;September 30, 2013&lt;/font&gt; because of the net operating losses incurred and a full valuation allowance had been provided.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Other long term liabilities-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-185717</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <!--Other long term liabilities-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c20130101to20130331" unitRef="U002" decimals="0">-7806</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20140101to20140331" unitRef="U002" decimals="0">24441</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20130101to20130331" unitRef="U002" decimals="0">82916</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1276211</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20130101to20130331" unitRef="U002" decimals="0">-101319</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20140331" unitRef="U002" decimals="0">375224</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20130101to20130331" unitRef="U002" decimals="0">243798</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20130101to20130331" unitRef="U002" decimals="0">-2981</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20140101to20140331" unitRef="U002" decimals="0">57894</us-gaap:IncreaseDecreaseInInventories>
  <!--Intangible Assets Disclosure [Text Block]-->
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;4. Intangible assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;54,719,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;54,719,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(9,879,831&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,511,833&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;44,840,087&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;46,208,085&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis.&amp;#160; BioTime recognized $1,367,998 and $642,573 in amortization expense of intangible assets during the three months ended March 31, 2014 and 2013, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <!--Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]-->
  <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Patent costs &amp;#8211;&lt;/font&gt; Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&amp;#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) regarding goodwill and other intangible assets.&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20140331" unitRef="U002" decimals="0">44840087</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231" unitRef="U002" decimals="0">46208085</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Interest (expense)/income, net-->
  <us-gaap:InterestIncomeExpenseNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8384</us-gaap:InterestIncomeExpenseNet>
  <!--Interest (expense)/income, net-->
  <us-gaap:InterestIncomeExpenseNet contextRef="c20130101to20130331" unitRef="U002" decimals="0">943</us-gaap:InterestIncomeExpenseNet>
  <!--Cash paid during the period for interest-->
  <us-gaap:InterestPaid contextRef="c20140101to20140331" unitRef="U002" decimals="0">8472</us-gaap:InterestPaid>
  <!--Cash paid during the period for interest-->
  <us-gaap:InterestPaid contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:InterestPaid>
  <!--Inventory, Policy [Policy Text Block]-->
  <us-gaap:InventoryPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventory &amp;#8211;&lt;/font&gt; Inventories are stated at the lower of cost or market.&amp;#160; Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method.&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <!--Inventory, Finished Goods, Net of Reserves-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20131231" unitRef="U002" decimals="0">165771</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory, Finished Goods, Net of Reserves-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20140331" unitRef="U002" decimals="0">223665</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2. Inventory&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime held $223,665 and $165,771 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2014 and December 31, 2013, respectively.&amp;#160; Finished goods products of $12,923 were held by a third party on consignment at March 31, 2014 and December 31, 2013.&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Inventory-->
  <us-gaap:InventoryNet contextRef="c20140331" unitRef="U002" decimals="0">236588</us-gaap:InventoryNet>
  <!--Inventory-->
  <us-gaap:InventoryNet contextRef="c20131231" unitRef="U002" decimals="0">178694</us-gaap:InventoryNet>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20140331" unitRef="U002" decimals="0">5620657</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="0">6957900</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Noncurrent-->
  <us-gaap:LiabilitiesNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">6965017</us-gaap:LiabilitiesNoncurrent>
  <!--Liabilities, Noncurrent-->
  <us-gaap:LiabilitiesNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">8509529</us-gaap:LiabilitiesNoncurrent>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20140331" unitRef="U002" decimals="0">57949895</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20131231" unitRef="U002" decimals="0">57729750</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--License fees-->
  <us-gaap:LicensesRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">294504</us-gaap:LicensesRevenue>
  <!--License fees-->
  <us-gaap:LicensesRevenue contextRef="c20130101to20130331" unitRef="U002" decimals="0">349824</us-gaap:LicensesRevenue>
  <!--Noncontrolling interest-->
  <us-gaap:MinorityInterest contextRef="c20140331" unitRef="U002" decimals="0">26121276</us-gaap:MinorityInterest>
  <!--Noncontrolling interest-->
  <us-gaap:MinorityInterest contextRef="c20131231" unitRef="U002" decimals="0">27461553</us-gaap:MinorityInterest>
  <!--BioTime Ownership (in hundredths)-LifeMap Sciences, Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_LifemapSciencesLtdMember" unitRef="U004" xsi:nil="true" id="Item-1" />
  <!--BioTime Ownership (in hundredths)-ES Cell International Pte., Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_EsCellInternationalPteLtdMember" unitRef="U004" decimals="0">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-OrthoCyte Corporation [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_OrthocyteCorporationMember" unitRef="U004" decimals="0">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_CellCureNeurosciencesLtdMember" unitRef="U004" decimals="3">0.625</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-LifeMap Sciences, Inc. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_LifemapSciencesIncMember" unitRef="U004" decimals="3">0.732</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-LifeMap Solutions, Inc [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_LifemapSolutionsIncMember" unitRef="U004" xsi:nil="true" id="Item-2" />
  <!--BioTime Ownership (in hundredths)-OncoCyte Corporation [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_OncocyteCorporationMember" unitRef="U004" decimals="3">0.753</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-Asterias Biotherapeutics [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U004" decimals="3">0.716</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-BioTime Asia, Limited [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_BiotimeAsiaLimitedMember" unitRef="U004" decimals="2">0.81</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-ReCyte Therapeutics, Inc. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20140331_LegalEntityAxis_RecyteTherapeuticsIncMember" unitRef="U004" decimals="3">0.948</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20130101to20130331" unitRef="U002" decimals="0">-550551</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-527618</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20140101to20140331" unitRef="U002" decimals="0">12128485</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20130101to20130331" unitRef="U002" decimals="0">13113138</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net loss attributable to BioTime, Inc.-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130331" unitRef="U002" decimals="0">-7719263</us-gaap:NetIncomeLoss>
  <!--Net loss attributable to BioTime, Inc.-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8099014</us-gaap:NetIncomeLoss>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-10357271</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20130101to20130331" unitRef="U002" decimals="0">-7021682</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net loss allocable to non-controlling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1629017</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss allocable to non-controlling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20130331" unitRef="U002" decimals="0">-689282</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--New Accounting Pronouncements, Policy [Policy Text Block]-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Effect of recently issued and recently adopted accounting pronouncements &lt;/font&gt;&amp;#8211; There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130101to20130331" unitRef="U002" decimals="0">-28636</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">60786</us-gaap:NonoperatingIncomeExpense>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20140101to20140331" unitRef="U002" decimals="0">12072564</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20130101to20130331" unitRef="U002" decimals="0">8811633</us-gaap:OperatingExpenses>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-11137843</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130101to20130331" unitRef="U002" decimals="0">-8379909</us-gaap:OperatingIncomeLoss>
  <!--Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1. Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;General&lt;/font&gt; &amp;#8211; BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (&amp;#8220;hES&amp;#8221;) cell and induced pluripotent stem (&amp;#8220;iPS&amp;#8221;) cell technology.&amp;#160; Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.&amp;#160; hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products.&amp;#160; BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use.&amp;#160; Asterias Biotherapeutics, Inc. (&amp;#8220;Asterias&amp;#8221;) acquired the stem cell assets of Geron Corporation (&amp;#8220;Geron&amp;#8221;) that had been used in Geron&amp;#8217;s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction.&amp;#160; OncoCyte Corporation (&amp;#8220;OncoCyte&amp;#8221;) is developing products and technologies to diagnose cancer.&amp;#160; ES Cell International Pte Ltd. (&amp;#8220;ESI&amp;#8221;), a Singapore private limited company, and BioTime&amp;#8217;s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets.&amp;#160; OrthoCyte Corporation (&amp;#8220;OrthoCyte&amp;#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries.&amp;#160; ReCyte Therapeutics, Inc. (&amp;#8220;ReCyte Therapeutics&amp;#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.&amp;#160; Cell Cure Neurosciences Ltd. (&amp;#8220;Cell Cure Neurosciences&amp;#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.&amp;#160; LifeMap Sciences, Inc. (&amp;#8220;LifeMap Sciences&amp;#8221;) markets, sells and distributes &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;GeneCards&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, the leading human gene database and an integrated database suite that includes &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;GeneCards&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, the &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Discovery&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries.&amp;#160; Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.&amp;#160; BioTime&amp;#8217;s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hextend&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt;, from the sale of products for research, and from research grants.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime&amp;#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X.&amp;#160; In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made.&amp;#160; The&amp;#160;consolidated balance sheet as of December 31, 2013 is derived from the Company&amp;#8217;s annual audited financial statements as of that date.&amp;#160; The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) except for the&amp;#160;consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements.&amp;#160; Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods.&amp;#160; It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&amp;#8217;s Form 10-K for the year ended December 31, 2013.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Principles of consolidation&lt;/font&gt; &amp;#8211; BioTime&amp;#8217;s consolidated financial statements include the accounts of its subsidiaries.&amp;#160; The following table reflects BioTime&amp;#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"&gt;&lt;tr style="height: 33px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Subsidiary&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Field of Business&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;BioTime &lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ownership&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Country&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias Biotherapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;71.6%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ES Cell International Pte Ltd&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research, including clinical grade cell lines&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;produced under cGMP&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Singapore&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OncoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cancer diagnostics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;75.3%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;OrthoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Orthopedic diseases, including chronic back pain and osteoarthritis&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cell Cure Neurosciences Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Age-related macular degeneration&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Multiple sclerosis&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Parkinson&amp;#8217;s disease&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;62.5%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;ReCyte Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;94.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px;"&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime Asia, Limited&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell products for research&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;81%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hong Kong&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Genetic, disease, and stem cell databases&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;73.2%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences, Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stem cell database&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;"&gt;LifeMap Solutions, Inc.&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;"&gt;Mobile health software&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;"&gt;(1)&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;All material intercompany accounts and transactions have been eliminated in consolidation.&amp;#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (&amp;#8220;GAAP&amp;#8221;) and with the accounting and reporting requirements of SEC Regulation S-X.&amp;#160; As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&amp;#8220;BioTime Asia&amp;#8221;), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime&amp;#8217;s condensed consolidated balance sheets.&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Certain significant risks and uncertainties&lt;/font&gt; &amp;#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition.&amp;#160; Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Use of estimates&lt;/font&gt; &amp;#8211; The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160; Actual results could differ from those estimates.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Revenue recognition&lt;/font&gt; &amp;#8211; BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition.&amp;#160; Royalty revenues consist of product royalty payments.&amp;#160; License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods.&amp;#160; Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable.&amp;#160; Royalties consist primarily of royalties earned on sales of &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hextend&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place.&amp;#160; When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&amp;#160; When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&amp;#160; If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&amp;#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned.&amp;#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cash and cash equivalents&lt;/font&gt; &amp;#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt; &amp;#8211;&amp;#160; Total trade receivables amounted to approximately $600,400 and &lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$575,900 &lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;and grants receivable amounted to approximately $334,700 and $&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;539,300&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt; as of March 31, 2014 and December 31, 2013, respectively.&amp;#160; Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013.&amp;#160; BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience.&amp;#160; An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&amp;#8217;s operating results or financial position.&amp;#160;&amp;#160;If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Concentrations of credit risk&lt;/font&gt; &amp;#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents.&amp;#160; BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions.&amp;#160; Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventory &amp;#8211;&lt;/font&gt; Inventories are stated at the lower of cost or market.&amp;#160; Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Equipment&lt;/font&gt; &amp;#8211; Equipment is stated at cost.&amp;#160; Equipment is being depreciated using the straight-line method over a period of 36 to 120 months.&amp;#160; See Note 3.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Intangible assets&lt;/font&gt; &amp;#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&amp;#160; Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business.&amp;#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&amp;#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&amp;#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) are expensed upon acquisition. See Note 8.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Treasury stock &amp;#8211;&lt;/font&gt; BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&amp;#160; BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Warrants to purchase common stock &lt;/font&gt;&amp;#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity.&amp;#160; None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&amp;#160; If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cost of sales&lt;/font&gt; &amp;#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Patent costs &amp;#8211;&lt;/font&gt; Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&amp;#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) regarding goodwill and other intangible assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Reclassification&lt;/font&gt; &amp;#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets.&amp;#160; Additionally, we have carved out the loss on sale of fixed assets amount from other expenses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Research and development&lt;/font&gt; &amp;#8211; BioTime complies with FASB requirements governing accounting for research and development costs.&amp;#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Foreign currency translation gain and Comprehensive loss &amp;#8211;&lt;/font&gt; In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date.&amp;#160; Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period.&amp;#160; Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet.&amp;#160; For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that&amp;#160;are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense),&amp;#160;amounted to $10,212 and $21,977, respectively.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income taxes &amp;#8211;&lt;/font&gt; BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect.&amp;#160; Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized.&amp;#160; The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.&amp;#160; For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities.&amp;#160; For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias&amp;#8217; tax provision with BioTime&amp;#8217;s.&amp;#160; BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively.&amp;#160; BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions.&amp;#160; Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.&amp;#160; Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws.&amp;#160; Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&amp;#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&amp;#160; No tax benefit had been recorded through &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;September 30, 2013&lt;/font&gt; because of the net operating losses incurred and a full valuation allowance had been provided.&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stock-based compensation &amp;#8211;&lt;/font&gt; BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&amp;#160; In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments.&amp;#160; BioTime has applied the provisions of this guidance in such valuations as well.&amp;#160; Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model.&amp;#160; BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables.&amp;#160; These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&amp;#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&amp;#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&amp;#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Impairment of long-lived assets &amp;#8211;&lt;/font&gt; BioTime&amp;#8217;s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&amp;#160; If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&amp;#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred license and consulting fees&lt;/font&gt; &amp;#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&amp;#160; The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products.&amp;#160; See Note 5.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Loss per share&lt;/font&gt; &amp;#8211; Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period.&amp;#160; Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive.&amp;#160; Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of financial instruments&lt;/font&gt; &amp;#8211; The fair value of BioTime&amp;#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Effect of recently issued and recently adopted accounting pronouncements &lt;/font&gt;&amp;#8211; There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">56062</us-gaap:OtherAssetsNoncurrent>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">0</us-gaap:OtherAssetsNoncurrent>
  <!--Foreign currency translation (loss)/gain-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20130101to20130331" unitRef="U002" decimals="0">148437</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Foreign currency translation (loss)/gain-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-104590</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-2650</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Other income/(expense), net-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20140101to20140331" unitRef="U002" decimals="0">77746</us-gaap:OtherNonoperatingIncome>
  <!--Other income/(expense), net-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20130101to20130331" unitRef="U002" decimals="0">-28056</us-gaap:OtherNonoperatingIncome>
  <!--Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross-->
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c20140331" unitRef="U002" decimals="0">12923</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <!--Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross-->
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c20131231" unitRef="U002" decimals="0">12923</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <!--Other Liabilities, Noncurrent-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20140331" unitRef="U002" decimals="0">8441</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other Liabilities, Noncurrent-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20131231" unitRef="U002" decimals="0">195984</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other Accrued Liabilities, Current-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c20140331" unitRef="U002" decimals="0">2685828</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--Other Accrued Liabilities, Current-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="0">2234674</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20130331" unitRef="U002" decimals="0">496128</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20140331" unitRef="U002" decimals="0">231921</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20140331" unitRef="U002" decimals="0">3500000</us-gaap:PreferredStockValue>
  <!--Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20131231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockValue>
  <!--Preferred shares, authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20140331" unitRef="U001" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred shares, authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20131231" unitRef="U001" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock dividend rate (in hundredths)-Series Preferred A Stock [Member]-->
  <us-gaap:PreferredStockDividendRatePercentage contextRef="c20140101to20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U004" decimals="INF">0.03</us-gaap:PreferredStockDividendRatePercentage>
  <!--Preferred shares, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20140331" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Preferred shares, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20131231" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Preferred shares, issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20131231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred shares, issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20140331" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesIssued>
  <!--Preferred share dividend (in dollars per shares)-Series Preferred A Stock [Member]-->
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="c20140101to20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U003" decimals="INF">1.50</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <!--Preferred shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20131231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20140331" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred shares outstanding (in shares)-Series Preferred A Stock [Member]-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20140331" unitRef="U002" decimals="0">1554114</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20131231" unitRef="U002" decimals="0">1277405</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Reclassification, Policy [Policy Text Block]-->
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Reclassification&lt;/font&gt; &amp;#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets.&amp;#160; Additionally, we have carved out the loss on sale of fixed assets amount from other expenses.&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <!--Proceeds from sale of common shares of subsidiary-->
  <us-gaap:ProceedsFromMinorityShareholders contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromMinorityShareholders>
  <!--Proceeds from sale of common shares of subsidiary-->
  <us-gaap:ProceedsFromMinorityShareholders contextRef="c20130101to20130331" unitRef="U002" decimals="0">130502</us-gaap:ProceedsFromMinorityShareholders>
  <!--Proceeds from issuance of common shares-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20130101to20130331" unitRef="U002" decimals="0">11699340</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common shares-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">8182559</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common shares-Romulus Films, Ltd. [Member]-Common Class B [Member]-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140101to20140331_LegalEntityAxis_RomulusFilmsLtdMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U002" decimals="0">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common shares-Subsequent Event [Member]-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140501to20140531_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">6380640</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from sale of preferred stock-->
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">3500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <!--Proceeds from sale of preferred stock-->
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <!--Proceeds from the sale of equipment-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--Proceeds from the sale of equipment-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20140101to20140331" unitRef="U002" decimals="0">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--Proceeds from sale of treasury shares-->
  <us-gaap:ProceedsFromSaleOfTreasuryStock contextRef="c20130101to20130331" unitRef="U002" decimals="0">1602921</us-gaap:ProceedsFromSaleOfTreasuryStock>
  <!--Proceeds from sale of treasury shares-->
  <us-gaap:ProceedsFromSaleOfTreasuryStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">599472</us-gaap:ProceedsFromSaleOfTreasuryStock>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-9728031</us-gaap:ProfitLoss>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130331" unitRef="U002" decimals="0">-8408545</us-gaap:ProfitLoss>
  <!--Property, Plant and Equipment, Useful Life-Maximum [Member]-Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20140331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">P120M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property, Plant and Equipment, Useful Life-Minimum [Member]-Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20140331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">P36M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property, Plant and Equipment, Policy [Policy Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Equipment&lt;/font&gt; &amp;#8211; Equipment is stated at cost.&amp;#160; Equipment is being depreciated using the straight-line method over a period of 36 to 120 months.&amp;#160; See Note 3.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20131231" unitRef="U002" decimals="0">2997733</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20140331" unitRef="U002" decimals="0">2959150</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231" unitRef="U002" decimals="0">4431586</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20140331" unitRef="U002" decimals="0">4645077</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following:&lt;/div&gt;&lt;div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Equipment, furniture and fixtures&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,645,077&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,431,586&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,685,927&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,433,853&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,959,150&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,997,733&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Property, Plant and Equipment Disclosure [Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;3. Equipment&lt;/div&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following:&lt;/div&gt;&lt;div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Equipment, furniture and fixtures&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,645,077&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,431,586&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,685,927&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,433,853&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,959,150&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,997,733&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Depreciation expense amounted to $256,945 and $113,356 for the three months ended March 31, 2014 and 2013, respectively.&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Recognition of Deferred Revenue-->
  <us-gaap:RecognitionOfDeferredRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">-57402</us-gaap:RecognitionOfDeferredRevenue>
  <!--Recognition of Deferred Revenue-->
  <us-gaap:RecognitionOfDeferredRevenue contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</us-gaap:RecognitionOfDeferredRevenue>
  <!--Research and Development Expense-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">8405393</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20130331" unitRef="U002" decimals="0">5395488</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense, Policy [Policy Text Block]-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Research and development&lt;/font&gt; &amp;#8211; BioTime complies with FASB requirements governing accounting for research and development costs.&amp;#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20140331" unitRef="U002" decimals="0">-153877561</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20131231" unitRef="U002" decimals="0">-145778547</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Grant income-->
  <us-gaap:RevenueFromGrants contextRef="c20130101to20130331" unitRef="U002" decimals="0">90326</us-gaap:RevenueFromGrants>
  <!--Grant income-->
  <us-gaap:RevenueFromGrants contextRef="c20140101to20140331" unitRef="U002" decimals="0">575659</us-gaap:RevenueFromGrants>
  <!--Revenue Recognition, Policy [Policy Text Block]-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Revenue recognition&lt;/font&gt; &amp;#8211; BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition.&amp;#160; Royalty revenues consist of product royalty payments.&amp;#160; License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods.&amp;#160; Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable.&amp;#160; Royalties consist primarily of royalties earned on sales of &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Hextend&lt;/font&gt;&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174;&lt;/sup&gt; and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place.&amp;#160; When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&amp;#160; When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&amp;#160; If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&amp;#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned.&amp;#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--Royalties from product sales-->
  <us-gaap:RoyaltyRevenue contextRef="c20130101to20130331" unitRef="U002" decimals="0">107599</us-gaap:RoyaltyRevenue>
  <!--Royalties from product sales-->
  <us-gaap:RoyaltyRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">97886</us-gaap:RoyaltyRevenue>
  <!--Sale of research products-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">98586</us-gaap:SalesRevenueGoodsNet>
  <!--Sale of research products-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130101to20130331" unitRef="U002" decimals="0">66724</us-gaap:SalesRevenueGoodsNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">1066635</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20130101to20130331" unitRef="U002" decimals="0">614473</us-gaap:SalesRevenueNet>
  <!--Schedule of Business Acquisitions, by Acquisition [Table Text Block]-->
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013.&amp;#160; The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 5.5pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.1pt;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Revenues, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;934,721&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;493,705&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Net loss available to common shareholders&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,099,014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(&lt;/font&gt;22,572,852&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(0.14&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(&lt;/font&gt;0.38&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <!--Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]-->
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following:&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accounts payable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,527,330&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,887,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accrued bonuses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;229,905&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;600,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Other accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,685,828&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,234,674&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,443,063&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,722,624&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <!--Schedule of Finite-Lived Intangible Assets [Table Text Block]-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;March 31, 2014&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;54,719,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;54,719,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(9,879,831&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,511,833&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;44,840,087&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;46,208,085&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20140101to20140331" unitRef="U002" decimals="0">801554</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20130101to20130331" unitRef="U002" decimals="0">691946</us-gaap:ShareBasedCompensation>
  <!--BioTime have option to purchase additional shares (in shares)-Subsequent Event [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="c20140101to20140331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0">9500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20140101to20140331" unitRef="U001" decimals="0">1205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20130101to20130331" unitRef="U001" decimals="0">1090000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share price (in dollars per share)-Subsequent Event [Member]-->
  <us-gaap:SharePrice contextRef="c20140331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2">2.00</us-gaap:SharePrice>
  <!--Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stock-based compensation &amp;#8211;&lt;/font&gt; BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&amp;#160; In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments.&amp;#160; BioTime has applied the provisions of this guidance in such valuations as well.&amp;#160; Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model.&amp;#160; BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables.&amp;#160; These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&amp;#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&amp;#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&amp;#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Awarded grant amount-Series Preferred A Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U002" decimals="-5">3500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Awarded grant amount-Subsequent Event [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140504to20140505_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">224911</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Common shares issued for consulting services-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Common shares issued for consulting services-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20130101to20130331" unitRef="U002" decimals="0">77280</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Shares, Other-Reproductive Genetics Institute [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_ReproductiveGeneticsInstituteMember" unitRef="U001" decimals="0">32259</us-gaap:StockIssuedDuringPeriodSharesOther>
  <!--Common stock purchase during period, value-Subsequent Event [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140504to20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock Issued During Period, Shares, New Issues-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0">21773340</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Stock Issued During Period, Shares, New Issues-Common Class A [Member]-Geron [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="0">6537779</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Stock Issued During Period, Shares, New Issues-Romulus Films, Ltd. [Member]-Common Class B [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20140331_LegalEntityAxis_RomulusFilmsLtdMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0">2136000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Stock Issued During Period, Shares, New Issues-Asterias Biotherapeutics [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">8902077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Common stock purchase during period (in shares)-Subsequent Event [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20140504to20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0">2500000</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20140101to20140331" unitRef="U001" decimals="0">45000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Stock Issued During Period, Value, Other-Reproductive Genetics Institute [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_ReproductiveGeneticsInstituteMember" unitRef="U002" decimals="0">50000</us-gaap:StockIssuedDuringPeriodValueOther>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140331" unitRef="U002" decimals="0">45364221</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231" unitRef="U002" decimals="0">42262321</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20140331" unitRef="U002" decimals="0">19242945</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20131231" unitRef="U002" decimals="0">14800768</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Note Disclosure [Text Block]-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;7. Equity&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Preferred Shares&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime is authorized to issue 2,000,000 shares of preferred stock.&amp;#160; The preferred shares may be issued in one or more series as the board of directors may by resolution determine.&amp;#160; The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.&amp;#160; The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of March 31, 2014, BioTime has 70,000 outstanding preferred shares.&amp;#160; On March 4, 2014, BioTime sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock (&amp;#8220;Series A Preferred&amp;#160;Stock&amp;#8221;) for $3.5 million.&amp;#160; The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares.&amp;#160; Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In connection with the sale of the Series A Preferred Stock, BioTime also entered into an Option Agreement with each purchaser of Series A Preferred Stock entitling them, for a period of five years, to exchange their shares of Series A Preferred Stock for shares of common stock of BioTime&amp;#8217;s subsidiary LifeMap Sciences, Inc. held by BioTime at the ratio of 12.5 shares of LifeMap Sciences common stock for each share of BioTime Series A Preferred Stock.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion.&amp;#160; The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval.&amp;#160; Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted.&amp;#160; The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares.&amp;#160; After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Common Shares&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime is authorized to issue 125,000,000 common shares with no par value.&amp;#160; As of March 31, 2014, BioTime had issued 69,617,329 common shares and outstanding 59,071,192 common shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;During the three months ended March 31, 2014 and 2013, BioTime recognized stock-based compensation expenses of $801,554 and $691,946, respectively, due to stock options granted to employees and directors.&amp;#160; During the three months ended March 31, 2014 and 2013, BioTime granted 1,205,000 and 1,090,000 options, respectively, under its 2012 Equity Incentive Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;During the three months ended March 31, 2014, 45,000 options and no warrants were exercised.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Subsequent Events [Text Block]-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;10. Subsequent Events&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In May 2014, BioTime raised $6,380,640 of additional equity capital through the sales of BioTime common shares&amp;#160;in &amp;#8220;at-the-market&amp;#8221; transactions through Cantor Fitzgerald &amp;amp; Co., as BioTime's sales agent.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On May 5, 2014, BioTime was awarded an SBIR Phase 1 Small Business Grant in the amount of $224,911 from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH). Under this grant entitled &amp;#8220;Cell Targeting Peptides for Isolating Patient Specific Stem Cells&amp;#8221; BioTime will work on streamlining &lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;PureStem&lt;sup style="line-height: 1; font-size: smaller; vertical-align: text-top;"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;cell line development and developing improved assays for monitoring stem cell differentiation.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Solutions, Inc.&amp;#8212;Mobile Health Software Products&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On May 6, 2014, LifeMap Solutions, Inc. (&amp;#8220;Solutions&amp;#8221;), a newly formed subsidiary of LifeMap Sciences, entered into a Co-Development and Option Agreement (the &amp;#8220;Agreement&amp;#8221;) with the Icahn School of Medicine at Mount Sinai, a nonprofit education corporation (&amp;#8220;Mt Sinai&amp;#8221;), pursuant to which Solutions and Mt Sinai have agreed to work cooperatively to develop internet, web-based, mobile user or consumer software products to provide users with information that may potentially aid them in improving lifestyle and healthcare decisions and outcomes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Solutions and Mt Sinai will license to each other, on a non-exclusive, royalty free basis, certain &amp;#8220;background&amp;#8221; intellectual property for joint use in product development.&amp;#160; Solutions will pay Mt Sinai for the use of Mt Sinai personnel based on their direct salaries plus an overhead charge, but Mt Sinai has agreed to waive collection of the first $1,000,000 of overhead charges.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Solutions will have an option to acquire a world-wide license to use Mt Sinai&amp;#8217;s background intellectual property and other intellectual property developed by Mt Sinai alone or jointly with Solutions in the joint development project for the purpose of developing and commercializing the product.&amp;#160; The terms of the license agreement that will be executed if Solutions exercises its option under the Agreement (the &amp;#8220;License Agreement&amp;#8221;) are subject to negotiation by the parties, but will include certain provisions specified in the Agreement, including the obligation of Solutions to pay Mt Sinai: (a) royalties on net sales, (b) a percentage of any consideration received by Solutions from its sublicensees and distributors of the product; (c) all reasonable patent and licensing costs incurred prior to the effective date of the definitive License Agreement in connection with the licensed patent rights and certain other Mount Sinai technology and background intellectual property, and all reasonable attorney&amp;#8217;s fees, expenses, official fees, and other charges incident to the preparation, prosecution, and maintenance of licensed patent rights: and (d) up to 5% of the then current equity value of Solutions at the time of a &amp;#8220;Significant Transaction.&amp;#8221;&amp;#160; The percentage to be paid is subject to dilution based on future investment in Solutions and the amount of personnel cost overhead charges waived by Mt Sinai under the Agreement.&amp;#160; The term &amp;#8220;Significant Transaction&amp;#8221; will mean the first to occur of a single transaction, or series of related transactions, consisting of or resulting in any of the following:&amp;#160; (i) an assignment, other than to LifeMap Sciences, of the definitive license agreement; (ii) an initial public offering of securities by Solutions (or its successor) or other transaction resulting in any of Solutions&amp;#8217; securities being traded on a nationally recognized stock exchange or automated quotation system; (iii) a sale, license or other disposition of all or substantially all of Solutions&amp;#8217; assets; or (iv) a reorganization, consolidation or merger of Solutions, or sale or transfer of the securities of Solutions, where the holders of Solutions&amp;#8217; outstanding voting securities before the transaction beneficially own less than fifty percent (50%) of the outstanding voting securities, or hold less than fifty percent (50%) of the voting power of the voting security holders of the surviving entity after the transaction.&amp;#160; A Significant Transaction shall not be deemed to occur as a result of a bona fide, arm&amp;#8217;s-length equity financing for cash in which Solutions issues securities (other than through an initial public offering described in clause (ii) above) representing more than fifty percent (50%) of the voting power of its security holders to venture capital or other similar professional investors who do not actively manage day-to-day operations of Solutions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;LifeMap Sciences Stock Purchase Agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Also on May 6, 2014, BioTime entered into a Stock Purchase Agreement with LifeMap Sciences to provide financing for Solutions&amp;#8217; product development costs under the Agreement with Mt Sinai.&amp;#160; BioTime will purchase 2,500,000 shares of LifeMap Sciences common stock for $5,000,000 in four tranches during 2014.&amp;#160; LifeMap Sciences will use the proceeds from the sale to provide capital to Solutions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime will also have an option to purchase up to an additional 9,500,000 shares of LifeMap Sciences common stock for $2.00 per share in two tranches related to the attainment of certain product development milestones by Solutions.&amp;#160; If BioTime exercises its option it may pay for those LifeMap Sciences shares in up to three installments for each tranche, in cash or in BioTime common shares at the then current market value determined as of the date the option is exercised based on the average closing price of BioTime common shares on the NYSE MKT for the preceding 20 trading days.&amp;#160; The number of shares of LifeMap Sciences common stock that BioTime may purchase will be reduced to the extent that LifeMap Sciences raises capital from other sources for product development under the Agreement with Mt Sinai.&lt;/div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;These condensed consolidated financial statements were approved by management and the Board of Directors, and were issued on May 12&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;,&lt;/font&gt; 2014 (unaudited).&amp;#160; Subsequent events have been evaluated through that date.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Trade and Other Accounts Receivable, Policy [Policy Text Block]-->
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt; &amp;#8211;&amp;#160; Total trade receivables amounted to approximately $600,400 and &lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$575,900 &lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;and grants receivable amounted to approximately $334,700 and $&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;539,300&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt; as of March 31, 2014 and December 31, 2013, respectively.&amp;#160; Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013.&amp;#160; BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience.&amp;#160; An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&amp;#8217;s operating results or financial position.&amp;#160;&amp;#160;If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20140331" unitRef="U002" decimals="0">42372546</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20131231" unitRef="U002" decimals="0">43033957</us-gaap:TreasuryStockValue>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20140331" unitRef="U001" decimals="0">10546137</us-gaap:TreasuryStockShares>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20131231" unitRef="U001" decimals="0">10697715</us-gaap:TreasuryStockShares>
  <!--Use of Estimates, Policy [Policy Text Block]-->
  <us-gaap:UseOfEstimates contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Use of estimates&lt;/font&gt; &amp;#8211; The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160; Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <!--Weighted Average Number of Shares Outstanding, Basic and Diluted-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20140101to20140331" unitRef="U001" decimals="0">58257427</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Weighted Average Number of Shares Outstanding, Basic and Diluted-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20130101to20130331" unitRef="U001" decimals="0">51175649</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Business Acquisitions ProForma Information [Text Block]-->
  <btx:BusinessAcquisitionsProformaInformationTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;9. Unaudited Pro Forma Interim Financial Information &amp;#8211; Three Months Ended March 31, 2014 and 2013&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013.&amp;#160; The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 5.5pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.1pt;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Revenues, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;934,721&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;493,705&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Net loss available to common shareholders&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,099,014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(&lt;/font&gt;22,572,852&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(0.14&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(&lt;/font&gt;0.38&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</btx:BusinessAcquisitionsProformaInformationTextBlock>
  <!--Asset Contribution Agreement [Text Block]-->
  <btx:AssetContributionAgreementTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8. &lt;/font&gt;Asset Contribution Agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On January 4, 2013, BioTime and Asterias entered into an Asset Contribution Agreement with Geron Corporation (&amp;#8220;Geron&amp;#8221;) pursuant to which BioTime and Geron agreed to concurrently contribute certain assets to Asterias in exchange for shares of Asterias common stock.&amp;#160; The transaction closed on October 1, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Transfer of BioTime Assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Under the Asset Contribution Agreement, BioTime contributed to Asterias 8,902,077 BioTime common shares registered for re-sale under the Securities Act of 1933, as amended, warrants to subscribe for and purchase 8,000,000 additional BioTime common shares (the &amp;#8220;BioTime Warrants&amp;#8221;) exercisable for a period of five years at a price of $5.00 per share, subject to pro rata adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions; a 10% common stock interest in BioTime&amp;#8217;s subsidiary OrthoCyte; a 6% ordinary share interest in BioTime&amp;#8217;s subsidiary Cell Cure Neurosciences; and a quantity of certain hES cell lines produced under &amp;#8220;good manufacturing practices&amp;#8221; sufficient to generate master cell banks, and non-exclusive, world-wide, royalty-free licenses to use those cell lines and certain patents pertaining to stem cell differentiation technology for any and all purposes.&amp;#160; In return, Asterias issued to BioTime 21,773,340 shares of its Series B common stock, par value $0.0001 per share (&amp;#8220;Series B Shares&amp;#8221;), and warrants to purchase 3,150,000 Series B Shares, exercisable for a period of three years from the date of issue at an exercise price of $5.00 per share.&amp;#160; In addition, BioTime cancelled Asterias&amp;#8217; obligations to repay the principal amount of a loan in the amount of $5,000,000 arising from cash financing provided to Asterias by BioTime during 2013 prior to the closing of the asset contribution transaction under the Asset Contribution Agreement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Because Asterias is a subsidiary of BioTime, the transfer of assets from BioTime was accounted for as a transaction under common control.&amp;#160; Non-monetary assets received by Asterias were recorded at their historical cost basis amounts with BioTime.&amp;#160; Monetary assets were recorded at fair value.&amp;#160; The difference between the value of assets contributed by BioTime and the fair value of consideration issued to BioTime was recorded as an additional contribution by BioTime, in additional paid-in capital.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The assets transferred by BioTime and the related consideration paid were recorded as follows:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Consideration transferred to BioTime:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Asterias Series B shares&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;52,164,568&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Warrants to purchase Asterias Series B shares&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,012,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Excess of contributed assets&amp;#8217; value over consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,800,063&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total consideration issued&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;58,977,112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Assets transferred by BioTime:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;BioTime common shares, at fair value&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,985,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;BioTime Warrants, at fair value&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,276,406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Cancellation of outstanding obligation to BioTime&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,000,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Investment in affiliates, at cost&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;415,543&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Geron asset acquisition related transaction costs paid by BioTime&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;300,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total assets transferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;58,977,112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The fair value of the Asterias Series B shares issued was estimated at $2.40 based on the Asterias enterprise value as determined on January 4, 2013, at the time the Asset Contribution Agreement was negotiated and executed by its parties, and as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.&amp;#160; The fair value of the warrants to purchase Asterias Series B shares was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions:&amp;#160; expected term equal to the contractual term of three years, which is equal to the contractual life of the warrants; risk-free rate of 0.63%; 0% expected dividend yield; 69.62% expected volatility based on the average historical common stock volatility of BioTime and Geron, which were used as Asterias&amp;#8217; common stock does not have a trading history; a stock price of $2.40; and an exercise price of $5.00.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;BioTime common shares were valued at $3.93 using the closing price per BioTime common shares on the NYSE MKT on October 1, 2013.&amp;#160; The fair value of the BioTime Warrants was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of five years, which is equal to the contractual life of the warrants; risk-free rate of 1.42%; 0% expected dividend yield; 77.63% expected volatility based on historical common stock volatility of BioTime; a stock price of $3.93; and an exercise price of $5.00.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The investment in OrthoCyte and Cell Cure Neurosciences stock represents a non-monetary asset and was recorded at BioTime&amp;#8217;s historical cost because BioTime is a common parent to Asterias and those two BioTime subsidiaries.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Geron Assets Acquisition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Under the Asset Contribution Agreement, Geron contributed to Asterias certain patents, patent applications, trade secrets, know-how and other intellectual property rights with respect to the technology of Geron directly related to the research, development and commercialization of certain products and know-how related to hES cells; certain biological materials, reagents, laboratory equipment; as well as clinical trial documentation, files and data, primarily related to GRNOPC1 clinical trials for spinal cord injury and VAC1 clinical trials for acute myelogenous leukemia. Asterias assumed all obligations related to such assets that would be attributable to periods, events or circumstances after the Asset Contribution Agreement closing date, including those related to an appeal filed in the United States District Court in Civil Action No. C12-04813 (the &amp;#8220;ViaCyte Appeal&amp;#8221;) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office&amp;#8217;s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving US patent 7,510,876 (ViaCyte) and US patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving US patent 7,510,876 (ViaCyte) and US patent application 12/543,875 (Geron).&amp;#160; Asterias also assumed the patent interferences upon which the ViaCyte Appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte, Inc. patent filings in Australia and in the European Patent Office.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As consideration for the acquisition of assets from Geron, Asterias issued to Geron 6,537,779 shares of Series A common stock, par value $0.0001 per share (&amp;#8220;Series A Shares&amp;#8221;), which Geron had agreed to distribute to its stockholders, on a pro rata basis, subject to applicable legal requirements and certain other limitations (the &amp;#8220;Series A Distribution&amp;#8221;).&amp;#160; Asterias is also obligated to distribute to the holders of its Series A Shares the 8,000,000 shares of BioTime Warrants contributed to Asterias by BioTime.&amp;#160; Asterias will distribute the BioTime Warrants as promptly as practicable after notice from Geron that the Series A Distribution has been completed.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In addition, Asterias agreed to bear certain transaction costs in connection with the Geron asset acquisition.&amp;#160; Such transaction costs were allocated to acquisition of assets in the amount of $1,519,904 and issuance of equity in the amount of $541,800.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The assets contributed to Asterias by Geron did not include workforce or any processes to be applied to the patents, biological materials, and other assets acquired, and therefore did not constitute a business.&amp;#160; Accordingly, the acquisition of the Geron assets has been accounted for as an acquisition of assets in accordance with the relevant provisions of Accounting Standards Codification (ASC) 805-50.&amp;#160; Total consideration payable by Asterias, including transaction costs, has been allocated to the assets acquired based on relative fair values of those assets as of the date of the transaction, October 1, 2013, in accordance with ASC 820, Fair Value Measurement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The assets acquired from Geron and the related consideration were recorded as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Consideration paid to Geron:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Asterias Series A shares, net of share issuance costs of $541,800&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,121,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Obligation to distribute BioTime Warrants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,276,406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Transaction and other costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,519,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total consideration paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,917,532&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Assets acquired from Geron (preliminary allocation):&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Patents and other intellectual property rights related to hES cells&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;29,017,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(11,558,243&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;IPR&amp;amp;D expensed upon acquisition&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17,458,766&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total assets and in-process research and development acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,917,532&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The fair value of the Asterias Series A shares issued was estimated at $2.40 based on the estimated Asterias enterprise value as determined by parties at the time the Asset Contribution Agreement was negotiated and executed by its parties on January 4, 2013, as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The fair value of the obligation to distribute BioTime Warrants equals the fair value of such warrants, which was computed as noted above under &amp;#8220;Transfer of BioTime Assets.&amp;#8221;&amp;#160; Because the fair value of the BioTime Warrants is expected to always be equal to the fair value of the obligation to distribute them at any date on which those values are determined, the remeasurement of those values will not result in a charge or credit on the statement of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The difference between the fair value of assets contributed by Geron and the fair value of consideration issued to Geron was recorded as an additional contribution by Geron, in additional paid-in capital, because the fair value of the assets transferred by Geron was more reliably determined.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Assets acquired from Geron consist primarily of patents and other intellectual property rights related to hES cells which Asterias intends to license to various parties interested in research, development and commercialization of hES cells technologies, and IPR&amp;amp;D, which includes biological materials, reagents, clinical trial documentation, files and data related primarily to certain clinical trials previously conducted by Geron, which Geron discontinued in November 2011.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-indent: 36pt;"&gt;Intangible assets related to IPR&amp;amp;D represent the value of incomplete research and development projects which the company intends to continue.&amp;#160; In accordance with the accounting rules in ASC 805, such assets, when acquired in conjunction with acquisition of a business, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&amp;#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&amp;#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&amp;amp;D are expensed upon acquisition.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The values of the acquired assets were estimated at October 1, 2013 based upon a preliminary review of those assets which took into account factors such as the condition of the cells, cell lines and other biological materials being contributed, the stage of development of particular technology and product candidates related to patents, patent applications, and know-how, the intended use of these assets and the priority assigned to the development of product candidates to which those assets relate, and the assessment of the estimated useful lives of patents.&amp;#160; The amounts allocated to patents and other intellectual property rights that Asterias intends to license were capitalized as intangible assets and are being amortized over an estimated useful life period of 10 years.&amp;#160; The amounts allocated to IPR&amp;amp;D were expensed at the time of acquisition of the related assets in accordance with the requirements of ASC 805-50.&amp;#160; The allocation was based on the relative fair value of assets eligible for capitalization and the fair value of assets representing IPR&amp;amp;D before assessing the deferred tax liability arising from the difference in book versus tax basis on Geron intangible assets acquired, which management estimated to be approximately equal.&amp;#160; Accordingly, $17,458,766 was capitalized as of December 31, 2013, and $17,458,766 was expensed.&amp;#160; These amounts are preliminary as management has not yet completed a detailed assessment and valuation of the acquired assets.&amp;#160; Such assessment and valuation is expected to be completed during the quarter ending June 30, 2014.&amp;#160; Accordingly, the amounts included in capitalized intangible assets and expensed IPR&amp;amp;D as of December 31, 2013 are subject to adjustments which could be material.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Asterias is also obligated to pay Geron royalties on the sale of products, if any, that are commercialized in reliance upon patents acquired from Geron, at the rate of 4% of net sales.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stock and Warrant Purchase Agreement with Romulus&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On January 4, 2013, in connection with entering into the Asset Contribution Agreement, Asterias entered into a Stock and Warrant Purchase Agreement with Romulus Films, Ltd (&amp;#8220;Romulus&amp;#8221;) pursuant to which Romulus agreed to purchase 2,136,000 Series B Shares and warrants to purchase 350,000 additional Series B Shares for $5,000,000 in cash upon the consummation of the acquisition of assets under the Asset Contribution Agreement.&amp;#160; On October 1, 2013, the shares and warrants were issued in exchange for $5,000,000 in cash.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</btx:AssetContributionAgreementTextBlock>
  <!--Maximum percentages of current equity value of solutions at time of significant transaction-Subsequent Event [Member]-->
  <btx:MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction contextRef="c20140504to20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2">0.05</btx:MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction>
  <!--Number of tranches-Subsequent Event [Member]-->
  <btx:NumberOfTranches contextRef="c20140506_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">4</btx:NumberOfTranches>
  <!--Number of tranches related to the attainment of certain product development-Subsequent Event [Member]-->
  <btx:NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment contextRef="c20140101to20140331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">2</btx:NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment>
  <!--Number of installments for each tranche-Subsequent Event [Member]-->
  <btx:NumberOfInstallmentsForEachTranche contextRef="c20140101to20140331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="INF">3</btx:NumberOfInstallmentsForEachTranche>
  <!--Number of trading days-Subsequent Event [Member]-->
  <btx:NumberOfTradingDays contextRef="c20140101to20140331_SubsequentEventTypeAxis_SubsequentEventMember">P20D</btx:NumberOfTradingDays>
  <!--Common shares issued for rent-->
  <btx:CommonSharesIssuedForRent contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</btx:CommonSharesIssuedForRent>
  <!--Common shares issued for rent-->
  <btx:CommonSharesIssuedForRent contextRef="c20130101to20130331" unitRef="U002" decimals="0">242720</btx:CommonSharesIssuedForRent>
  <!--Amortization of deferred consulting fees-->
  <btx:AmortizationOfDeferredConsultingFees contextRef="c20140101to20140331" unitRef="U002" decimals="0">16279</btx:AmortizationOfDeferredConsultingFees>
  <!--Amortization of deferred consulting fees-->
  <btx:AmortizationOfDeferredConsultingFees contextRef="c20130101to20130331" unitRef="U002" decimals="0">16280</btx:AmortizationOfDeferredConsultingFees>
  <!--Amortization of deferred rent-->
  <btx:AmortizationOfDeferredRent contextRef="c20140101to20140331" unitRef="U002" decimals="0">-5040</btx:AmortizationOfDeferredRent>
  <!--Amortization of deferred rent-->
  <btx:AmortizationOfDeferredRent contextRef="c20130101to20130331" unitRef="U002" decimals="0">-2222</btx:AmortizationOfDeferredRent>
  <!--Security deposit received-->
  <btx:SecurityDepositReceived contextRef="c20130101to20130331" unitRef="U002" decimals="0">-54423</btx:SecurityDepositReceived>
  <!--Security deposit received-->
  <btx:SecurityDepositReceived contextRef="c20140101to20140331" unitRef="U002" decimals="0">-299697</btx:SecurityDepositReceived>
  <!--Increase (decrease) in Grant receivable-->
  <btx:IncreaseDecreaseInGrantReceivable contextRef="c20130101to20130331" unitRef="U002" decimals="0">-371886</btx:IncreaseDecreaseInGrantReceivable>
  <!--Increase (decrease) in Grant receivable-->
  <btx:IncreaseDecreaseInGrantReceivable contextRef="c20140101to20140331" unitRef="U002" decimals="0">-202122</btx:IncreaseDecreaseInGrantReceivable>
  <!--Amortization Of Deferred License Fees And Royalty Fees-->
  <btx:AmortizationOfDeferredLicenseFeesAndRoyaltyFees contextRef="c20140101to20140331" unitRef="U002" decimals="0">27375</btx:AmortizationOfDeferredLicenseFeesAndRoyaltyFees>
  <!--Amortization Of Deferred License Fees And Royalty Fees-->
  <btx:AmortizationOfDeferredLicenseFeesAndRoyaltyFees contextRef="c20130101to20130331" unitRef="U002" decimals="0">27375</btx:AmortizationOfDeferredLicenseFeesAndRoyaltyFees>
  <!--Amortization of Stock Based Prepaid Rent-->
  <btx:AmortizationOfStockBasedPrepaidRent contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</btx:AmortizationOfStockBasedPrepaidRent>
  <!--Amortization of Stock Based Prepaid Rent-->
  <btx:AmortizationOfStockBasedPrepaidRent contextRef="c20140101to20140331" unitRef="U002" decimals="0">21146</btx:AmortizationOfStockBasedPrepaidRent>
  <!--Proceeds From Employee Options Exercised-->
  <btx:ProceedsFromEmployeeOptionsExercised contextRef="c20140101to20140331" unitRef="U002" decimals="0">12500</btx:ProceedsFromEmployeeOptionsExercised>
  <!--Proceeds From Employee Options Exercised-->
  <btx:ProceedsFromEmployeeOptionsExercised contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</btx:ProceedsFromEmployeeOptionsExercised>
  <!--Proceeds From Director Options Exercised-->
  <btx:ProceedsFromDirectorOptionsExcercised contextRef="c20140101to20140331" unitRef="U002" decimals="0">46000</btx:ProceedsFromDirectorOptionsExcercised>
  <!--Proceeds From Director Options Exercised-->
  <btx:ProceedsFromDirectorOptionsExcercised contextRef="c20130101to20130331" unitRef="U002" decimals="0">0</btx:ProceedsFromDirectorOptionsExcercised>
  <!--Fees paid on sale of common shares-->
  <btx:FeesPaidOnSaleOfCommonShares contextRef="c20140101to20140331" unitRef="U002" decimals="0">212046</btx:FeesPaidOnSaleOfCommonShares>
  <!--Fees paid on sale of common shares-->
  <btx:FeesPaidOnSaleOfCommonShares contextRef="c20130101to20130331" unitRef="U002" decimals="0">319625</btx:FeesPaidOnSaleOfCommonShares>
  <!--Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted-->
  <btx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="c20130101to20130331" unitRef="U003" decimals="2">-0.38</btx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <!--Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted-->
  <btx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="c20140101to20140331" unitRef="U003" decimals="2">-0.14</btx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <!--Warrants exercised-->
  <btx:WarrantsExercised contextRef="c20140101to20140331" unitRef="U001" decimals="0">0</btx:WarrantsExercised>
  <!--Period of option agreement-Series Preferred A Stock [Member]-->
  <btx:LifeOfWarrants contextRef="c20140101to20140331_PrivateFundingAxis_PreferredStockMember">P5Y</btx:LifeOfWarrants>
  <!--Preferred shares, Convertible, Conversion Ratio-Series Preferred A Stock [Member]-->
  <btx:PreferredSharesConvertibleConversionRatio contextRef="c20140101to20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U004" decimals="2">12.50</btx:PreferredSharesConvertibleConversionRatio>
  <!--Share conversion price (in dollars per share)-Series Preferred A Stock [Member]-->
  <btx:PricePerShareOfOptionsToPurchaseCompany contextRef="c20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U003" decimals="INF">4.00</btx:PricePerShareOfOptionsToPurchaseCompany>
  <!--Preferred shares sold-Series Preferred A Stock [Member]-->
  <btx:PreferredSharesSold contextRef="c20140331_PrivateFundingAxis_PreferredStockMember" unitRef="U001" decimals="0">70000</btx:PreferredSharesSold>
  <!--Trade accounts and grants receivable net current-->
  <btx:TradeAccountsAndGrantsReceivableNetCurrent contextRef="c20140331" unitRef="U002" decimals="0">818275</btx:TradeAccountsAndGrantsReceivableNetCurrent>
  <!--Trade accounts and grants receivable net current-->
  <btx:TradeAccountsAndGrantsReceivableNetCurrent contextRef="c20131231" unitRef="U002" decimals="0">998393</btx:TradeAccountsAndGrantsReceivableNetCurrent>
  <!--Deferred license and consulting fees-->
  <btx:DeferredLicenseAndConsultingFees contextRef="c20140331" unitRef="U002" decimals="0">418958</btx:DeferredLicenseAndConsultingFees>
  <!--Deferred license and consulting fees-->
  <btx:DeferredLicenseAndConsultingFees contextRef="c20131231" unitRef="U002" decimals="0">444833</btx:DeferredLicenseAndConsultingFees>
  <!--Schedule Of Expected Amortization Deferred License Expense [Table Text Block]-->
  <btx:ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of March 31, 2014, future amortization of deferred license fees described above was as follows:&lt;/div&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; margin-left: 45pt; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Deferred License&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fees&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;83,615&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;111,843&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 68%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;528,458&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</btx:ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock>
  <!--Treasury stock [Policy Text Block]-->
  <btx:TreasuryStockPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Treasury stock &amp;#8211;&lt;/font&gt; BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&amp;#160; BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.&lt;/div&gt;&lt;/div&gt;</btx:TreasuryStockPolicyTextBlock>
  <!--Certain significant risks and uncertainties [Policy Text Block]-->
  <btx:CertainSignificantRisksAndUncertaintiesPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Certain significant risks and uncertainties&lt;/font&gt; &amp;#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition.&amp;#160; Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.&lt;/div&gt;&lt;/div&gt;</btx:CertainSignificantRisksAndUncertaintiesPolicyTextBlock>
  <!--Warrants to purchase common stock [Policy Text Block]-->
  <btx:WarrantsToPurchaseCommonStockPolicyTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Warrants to purchase common stock &lt;/font&gt;&amp;#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity.&amp;#160; None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&amp;#160; If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;</btx:WarrantsToPurchaseCommonStockPolicyTextBlock>
  <!--Annual minimum royalty due-Advanced Cell Technology Inc., with Kirin Sublicense II [Member]-->
  <btx:AnnualMinimumRoyaltyDue contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" unitRef="U002" decimals="0">50000</btx:AnnualMinimumRoyaltyDue>
  <!--Annual minimum royalty due-Cell Cure Neurosciences License From Hadasit [Member]-Minimum [Member]-->
  <btx:AnnualMinimumRoyaltyDue contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MinimumMember" unitRef="U002" decimals="0">100000</btx:AnnualMinimumRoyaltyDue>
  <!--Annual minimum royalty due-Asterias License, University of California [Member]-->
  <btx:AnnualMinimumRoyaltyDue contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember" unitRef="U002" decimals="0">5000</btx:AnnualMinimumRoyaltyDue>
  <!--Royalty, Percentage-Asterias License, University of California [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember" unitRef="U004" decimals="2">0.01</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-Advanced Cell Technology Inc., with Kirin Sublicense I [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember" unitRef="U004" decimals="2">0.05</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-Advanced Cell Technology, Inc. [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember" unitRef="U004" decimals="2">0.08</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-Minimum [Member]-WARF [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember_RangeAxis_MinimumMember" unitRef="U004" decimals="2">0.02</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-Maximum [Member]-WARF [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember_RangeAxis_MaximumMember" unitRef="U004" decimals="2">0.04</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-Advanced Cell Technology Inc., with Kirin Sublicense II [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" unitRef="U004" decimals="3">0.035</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-BioTime License For The University of Utah [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U004" decimals="2">0.03</btx:RoyaltyPercentage>
  <!--Royalty, Percentage-OncoCyte License From SBMRI [Member]-->
  <btx:RoyaltyPercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember" unitRef="U004" decimals="2">0.04</btx:RoyaltyPercentage>
  <!--License Fee, Amount Paid-Advanced Cell Technology, Inc. [Member]-->
  <btx:LicenseFeeAmountPaid contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember" unitRef="U002" decimals="0">250000</btx:LicenseFeeAmountPaid>
  <!--License Fee, Amount Paid-Advanced Cell Technology Inc., with Kirin Sublicense I [Member]-->
  <btx:LicenseFeeAmountPaid contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember" unitRef="U002" decimals="0">200000</btx:LicenseFeeAmountPaid>
  <!--License Fee, Amount Paid-Advanced Cell Technology Inc., with Kirin Sublicense II [Member]-->
  <btx:LicenseFeeAmountPaid contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" unitRef="U002" decimals="0">50000</btx:LicenseFeeAmountPaid>
  <!--Royalty, Maximum Payment-Advanced Cell Technology, Inc. [Member]-->
  <btx:RoyaltyMaximumPayment contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncMember" unitRef="U002" decimals="0">1000000</btx:RoyaltyMaximumPayment>
  <!--Royalty, Maximum Payment-BioTime License For The University of Utah [Member]-->
  <btx:RoyaltyMaximumPayment contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U002" decimals="0">2500</btx:RoyaltyMaximumPayment>
  <!--Royalty, Maximum Payment-Advanced Cell Technology Inc., with Kirin Sublicense I [Member]-->
  <btx:RoyaltyMaximumPayment contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember" unitRef="U002" decimals="0">600000</btx:RoyaltyMaximumPayment>
  <!--Annual License Maintenance Fee-WARF [Member]-->
  <btx:AnnualLicenseMaintenanceFee contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember" unitRef="U002" decimals="0">25000</btx:AnnualLicenseMaintenanceFee>
  <!--Annual License Maintenance Fee-Asterias Sublicense From Geron [Member]-->
  <btx:AnnualLicenseMaintenanceFee contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember" unitRef="U002" decimals="0">10000</btx:AnnualLicenseMaintenanceFee>
  <!--Deferred License Fees Amortization Expense Year Four-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearFour contextRef="c20140331" unitRef="U002" decimals="0">111000</btx:DeferredLicenseFeesAmortizationExpenseYearFour>
  <!--Deferred License Fees Amortization Expense Year Three-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearThree contextRef="c20140331" unitRef="U002" decimals="0">111000</btx:DeferredLicenseFeesAmortizationExpenseYearThree>
  <!--Deferred License Fees Amortization Expense After Year Five-->
  <btx:DeferredLicenseFeesAmortizationExpenseAfterYearFive contextRef="c20140331" unitRef="U002" decimals="0">111843</btx:DeferredLicenseFeesAmortizationExpenseAfterYearFive>
  <!--Deferred License Fees Amortization Expense Year Two-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearTwo contextRef="c20140331" unitRef="U002" decimals="0">111000</btx:DeferredLicenseFeesAmortizationExpenseYearTwo>
  <!--Amended License Agreement Amount-Cell Cure Neurosciences License From Hadasit [Member]-->
  <btx:AmendedLicenseAgreementAmount contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember" unitRef="U005" decimals="0">249058</btx:AmendedLicenseAgreementAmount>
  <!--Amended License Agreement Amount-Asterias Sublicense From Geron [Member]-->
  <btx:AmendedLicenseAgreementAmount contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember" unitRef="U002" decimals="0">65000</btx:AmendedLicenseAgreementAmount>
  <!--Amended License Agreement Amount-WARF [Member]-->
  <btx:AmendedLicenseAgreementAmount contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_WarfMember" unitRef="U002" decimals="0">295000</btx:AmendedLicenseAgreementAmount>
  <!--Fees for sublicense, percentage-Asterias Sublicense From Geron [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember" unitRef="U004" decimals="2">0.01</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Advanced Cell Technology Inc., with Kirin Sublicense I [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIMember" unitRef="U004" decimals="1">0.2</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Advanced Cell Technology Inc., with Kirin Sublicense II [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" unitRef="U004" decimals="1">0.2</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-OncoCyte License From SBMRI [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember" unitRef="U004" decimals="1">0.2</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Asterias License, University of California [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember" unitRef="U004" decimals="3">0.075</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Cell Cure Neurosciences License From Hadasit [Member]-Minimum [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MinimumMember" unitRef="U004" decimals="1">0.1</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Cell Cure Neurosciences License From Hadasit [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember" unitRef="U004" decimals="1">0.3</btx:FeesForSublicensePercentage>
  <!--Fees for sublicense, percentage-Cell Cure Neurosciences License From Hadasit [Member]-Maximum [Member]-->
  <btx:FeesForSublicensePercentage contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember_RangeAxis_MaximumMember" unitRef="U004" decimals="1">0.3</btx:FeesForSublicensePercentage>
  <!--Deferred License Fees Amortization Expense Next Twelve Months-->
  <btx:DeferredLicenseFeesAmortizationExpenseNextTwelveMonths contextRef="c20140331" unitRef="U002" decimals="0">83615</btx:DeferredLicenseFeesAmortizationExpenseNextTwelveMonths>
  <!--Notice period to terminate agreement-Asterias Sublicense From Geron [Member]-->
  <btx:NoticePeriodToTerminateAgreement contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasSublicenseFromGeronMember">P90D</btx:NoticePeriodToTerminateAgreement>
  <!--Notice period to terminate agreement-Asterias License, University of California [Member]-->
  <btx:NoticePeriodToTerminateAgreement contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember">P60D</btx:NoticePeriodToTerminateAgreement>
  <!--Reduction for any patent that have licensed two or more-BioTime License For The University of Utah [Member]-->
  <btx:ReductionForAnyPatentThatHaveLicensedTwoOrMore contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U002" decimals="0">2500</btx:ReductionForAnyPatentThatHaveLicensedTwoOrMore>
  <!--Payment upon issuance of first five license-BioTime License For The University of Utah [Member]-->
  <btx:PaymentUponIssuanceOfFirstFiveLicense contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U002" decimals="0">5000</btx:PaymentUponIssuanceOfFirstFiveLicense>
  <!--Minimum royalty amount each year and thereafter-BioTime License For The University of Utah [Member]-->
  <btx:MinimumRoyaltyAmountEachYearAndThereafter contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U002" decimals="0">30000</btx:MinimumRoyaltyAmountEachYearAndThereafter>
  <!--Sublicensing receipts for creditable milestone payments.-Cell Cure Neurosciences License From Hadasit [Member]-->
  <btx:SublicensingReceiptsForCreditableMilestonePayments contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember" unitRef="U002" decimals="-6">50000000</btx:SublicensingReceiptsForCreditableMilestonePayments>
  <!--Milestone payments-Teva License Agreement [Member]-Phase II Clinical [Member]-->
  <btx:MilestonePayments contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIiClinicalMember" unitRef="U002" decimals="0">250000</btx:MilestonePayments>
  <!--Milestone payments-Teva License Agreement [Member]-Phase III Clinical [Member]-->
  <btx:MilestonePayments contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIiiClinicalMember" unitRef="U002" decimals="-6">1000000</btx:MilestonePayments>
  <!--Milestone payments-BioTime License For The University of Utah [Member]-->
  <btx:MilestonePayments contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U002" decimals="0">225000</btx:MilestonePayments>
  <!--Milestone payments-Teva License Agreement [Member]-Phase I Clinical [Member]-->
  <btx:MilestonePayments contextRef="c20140101to20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_TevaLicenseAgreementMember_PaymentPhaseAxis_PhaseIClinicalMember" unitRef="U002" decimals="0">250000</btx:MilestonePayments>
  <!--Reimbursement to SBMRI for cost incurred (in hundredths)-OncoCyte License From SBMRI [Member]-->
  <btx:ReimbursementToSbmriForCostIncurredInHundredths contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember" unitRef="U004" decimals="2">0.25</btx:ReimbursementToSbmriForCostIncurredInHundredths>
  <!--Reduction in royalties-Asterias License, University of California [Member]-->
  <btx:ReductionInRoyalties contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_AsteriasLicenseUniversityOfCaliforniaMember" unitRef="U004" decimals="1">0.5</btx:ReductionInRoyalties>
  <!--Reduction in royalties-OncoCyte License From SBMRI [Member]-->
  <btx:ReductionInRoyalties contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember" unitRef="U004" decimals="1">0.5</btx:ReductionInRoyalties>
  <!--Fees for research use-OncoCyte License From SBMRI [Member]-->
  <btx:FeesForResearchUse contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_OncocyteLicenseFromSbmriMember" unitRef="U004" decimals="1">0.1</btx:FeesForResearchUse>
  <!--Fees for research use-BioTime License For The University of Utah [Member]-->
  <btx:FeesForResearchUse contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_BiotimeLicenseForUniversityOfUtahMember" unitRef="U004" decimals="INF">0.3</btx:FeesForResearchUse>
  <!--Fees for research use-Cell Cure Neurosciences License From Hadasit [Member]-->
  <btx:FeesForResearchUse contextRef="c20140331_FiniteLivedIntangibleAssetsByMajorClassAxis_CellCureNeurosciencesLicenseFromHadasitMember" unitRef="U004" decimals="2">0.05</btx:FeesForResearchUse>
  <!--Assets Acquired and Related Consideration recorded [Table Text Block]-->
  <btx:AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The assets acquired from Geron and the related consideration were recorded as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Consideration paid to Geron:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Asterias Series A shares, net of share issuance costs of $541,800&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,121,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Obligation to distribute BioTime Warrants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,276,406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Transaction and other costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,519,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total consideration paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,917,532&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Assets acquired from Geron (preliminary allocation):&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Patents and other intellectual property rights related to hES cells&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;29,017,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(11,558,243&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;IPR&amp;amp;D expensed upon acquisition&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17,458,766&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total assets and in-process research and development acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,917,532&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</btx:AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock>
  <!--Assets Transferred and Related Consideration Recorded [Table Text Block]-->
  <btx:AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock contextRef="c20140101to20140331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The assets transferred by BioTime and the related consideration paid were recorded as follows:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Consideration transferred to BioTime:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Asterias Series B shares&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;52,164,568&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Warrants to purchase Asterias Series B shares&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,012,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Excess of contributed assets&amp;#8217; value over consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;4,800,063&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total consideration issued&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;58,977,112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Assets transferred by BioTime:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;BioTime common shares, at fair value&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;34,985,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;BioTime Warrants, at fair value&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,276,406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Cancellation of outstanding obligation to BioTime&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,000,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Investment in affiliates, at cost&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;415,543&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Geron asset acquisition related transaction costs paid by BioTime&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;300,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;"&gt;Total assets transferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;58,977,112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</btx:AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock>
  <!--IPR and D expensed upon acquisition, asset contribution agreement-Geron [Member]-->
  <btx:IprAndDExpensedUponAcquisitionAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">17458766</btx:IprAndDExpensedUponAcquisitionAssetContributionAgreement>
  <!--Warrant Expiration term-Common Class B [Member]-Asterias Biotherapeutics [Member]-->
  <btx:WarrantExpirationTerm contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember">P3Y</btx:WarrantExpirationTerm>
  <!--Warrant Expiration term-Asterias Biotherapeutics [Member]-->
  <btx:WarrantExpirationTerm contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember">P5Y</btx:WarrantExpirationTerm>
  <!--Total assets and in process research and development acquired, asset contribution agreement-Geron [Member]-->
  <btx:TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">34917532</btx:TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement>
  <!--Market Value of BioTime Common Shares-Common [Member]-->
  <btx:MarketValueOfBiotimeCommonShares contextRef="c20131001_StatementClassOfStockAxis_CommonClassCMember" unitRef="U003" decimals="2">3.93</btx:MarketValueOfBiotimeCommonShares>
  <!--Royalty rate on net sales of products-Common Class A [Member]-Geron [Member]-->
  <btx:RoyaltyRateOnNetSalesOfProducts contextRef="c20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember" unitRef="U004" decimals="2">0.04</btx:RoyaltyRateOnNetSalesOfProducts>
  <!--Percentage of Subsidiary Stock Contributed-Cell Cure Neurosciences, Ltd. [Member]-->
  <btx:PercentageOfSubsidiaryStockContributed contextRef="c20140331_LegalEntityAxis_CellCureNeurosciencesLtdMember" unitRef="U004" decimals="2">0.06</btx:PercentageOfSubsidiaryStockContributed>
  <!--Percentage of Subsidiary Stock Contributed-OrthoCyte Corporation [Member]-->
  <btx:PercentageOfSubsidiaryStockContributed contextRef="c20140331_LegalEntityAxis_OrthocyteCorporationMember" unitRef="U004" decimals="1">0.1</btx:PercentageOfSubsidiaryStockContributed>
  <!--Total consideration received, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:TotalConsiderationReceivedAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">58977112</btx:TotalConsiderationReceivedAssetContributionAgreement>
  <!--Total consideration received, asset contribution agreement-Geron [Member]-->
  <btx:TotalConsiderationReceivedAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">34917532</btx:TotalConsiderationReceivedAssetContributionAgreement>
  <!--Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired-Geron [Member]-->
  <btx:DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">-11558243</btx:DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired>
  <!--Common shares issued to subsidiary upon consummation of asset contribution-Asterias Biotherapeutics [Member]-->
  <btx:CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">34985163</btx:CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution>
  <!--Fair Value of Shares Issued-Asterias Biotherapeutics [Member]-Common Class B [Member]-->
  <btx:FairValueOfSharesIssued contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember_StatementClassOfStockAxis_CommonClassBMember" unitRef="U003" decimals="2">2.40</btx:FairValueOfSharesIssued>
  <!--Fair Value of Shares Issued-Common Class A [Member]-Geron [Member]-->
  <btx:FairValueOfSharesIssued contextRef="c20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember" unitRef="U003" decimals="2">2.40</btx:FairValueOfSharesIssued>
  <!--Obligation to distribute Warrants, Consideration Transferred, asset contribution agreement-Geron [Member]-->
  <btx:ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">18276406</btx:ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement>
  <!--Series B common stock, Consideration Transferred, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:SeriesBCommonStockConsiderationTransferredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">52164568</btx:SeriesBCommonStockConsiderationTransferredAssetContributionAgreement>
  <!--Warrants to purchase Series B common shares, Consideration Transferred, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">2012481</btx:WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement>
  <!--Warrants issued to subsidiary upon consummation of asset contribution-Asterias Biotherapeutics [Member]-->
  <btx:WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">18276406</btx:WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution>
  <!--Total assets transferred, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:TotalAssetsTransferredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">58977112</btx:TotalAssetsTransferredAssetContributionAgreement>
  <!--Investments in affiliates, at cost-Asterias Biotherapeutics [Member]-->
  <btx:InvestmentsInAffiliatesAtCost contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">415543</btx:InvestmentsInAffiliatesAtCost>
  <!--Cancellation of outstanding obligation, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:CancellationOfOutstandingObligationAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">5000000</btx:CancellationOfOutstandingObligationAssetContributionAgreement>
  <!--Series A common stock, Consideration Transferred, asset contribution agreement-Geron [Member]-->
  <btx:SeriesCommonStockConsiderationTransferredAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">15121222</btx:SeriesCommonStockConsiderationTransferredAssetContributionAgreement>
  <!--Patents and other intellectual property rights related to hES cells, asset contribution agreement-Geron [Member]-->
  <btx:PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_GeronMember" unitRef="U002" decimals="0">29017009</btx:PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement>
  <!--Class of Warrant or Right, Number of Securities to be issued-Common Class A [Member]-Geron [Member]-->
  <btx:ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued contextRef="c20140331_LegalEntityAxis_GeronMember_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="0">8000000</btx:ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued>
  <!--Excess of contributed asset's value over consideration, asset contribution agreement-Asterias Biotherapeutics [Member]-->
  <btx:ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement contextRef="c20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">4800063</btx:ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement>
  <!--Amount of Contribution From Investor-Asterias Biotherapeutics [Member]-->
  <btx:AmountOfContributionFromInvestor contextRef="c20140101to20140331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">5000000</btx:AmountOfContributionFromInvestor>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>btx-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<xs:schema targetNamespace="http://biotimeinc.com/20140331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://biotimeinc.com/20140331" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20140331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20140331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20140331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20140331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" id="OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies">
        <link:definition>060100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/Inventory" id="Inventory">
        <link:definition>060200 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/Equipment" id="Equipment">
        <link:definition>060300 - Disclosure - Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060400 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" id="RoyaltyObligationAndDeferredLicenseFees">
        <link:definition>060500 - Disclosure - Royalty Obligation and Deferred License Fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
        <link:definition>060600 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/Equity" id="Equity">
        <link:definition>060700 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AssetContributionAgreement" id="AssetContributionAgreement">
        <link:definition>060800 - Disclosure - Asset Contribution Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" id="UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013">
        <link:definition>060900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061000 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" id="OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies-->
        <link:definition>070100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" id="OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables">
        <!--Parent Role: Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies-->
        <link:definition>080100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquipmentTables" id="EquipmentTables">
        <!--Parent Role: Equipment-->
        <link:definition>080300 - Disclosure - Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: Intangible assets-->
        <link:definition>080400 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" id="RoyaltyObligationAndDeferredLicenseFeesTables">
        <!--Parent Role: Royalty Obligation and Deferred License Fees-->
        <link:definition>080500 - Disclosure - Royalty Obligation and Deferred License Fees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
        <!--Parent Role: Accounts Payable and Accrued Liabilities-->
        <link:definition>080600 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AssetContributionAgreementTables" id="AssetContributionAgreementTables">
        <!--Parent Role: Asset Contribution Agreement-->
        <link:definition>080800 - Disclosure - Asset Contribution Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" id="UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables">
        <!--Parent Role: Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013-->
        <link:definition>080900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails" id="OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails">
        <!--Parent Role: Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies-->
        <link:definition>090100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/InventoryDetails" id="InventoryDetails">
        <!--Parent Role: Inventory-->
        <link:definition>090200 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquipmentDetails" id="EquipmentDetails">
        <!--Parent Role: Equipment-->
        <link:definition>090300 - Disclosure - Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <!--Parent Role: Intangible assets-->
        <link:definition>090400 - Disclosure - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" id="RoyaltyObligationAndDeferredLicenseFeesDetails">
        <!--Parent Role: Royalty Obligation and Deferred License Fees-->
        <link:definition>090500 - Disclosure - Royalty Obligation and Deferred License Fees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
        <!--Parent Role: Accounts Payable and Accrued Liabilities-->
        <link:definition>090600 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquityDetails" id="EquityDetails">
        <!--Parent Role: Equity-->
        <link:definition>090700 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AssetContributionAgreementDetails" id="AssetContributionAgreementDetails">
        <!--Parent Role: Asset Contribution Agreement-->
        <link:definition>090802 - Disclosure - Asset Contribution Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" id="UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details">
        <!--Parent Role: Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013-->
        <link:definition>090900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091000 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="BusinessAcquisitionsProformaInformationTextBlock" id="btx_BusinessAcquisitionsProformaInformationTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetContributionAgreementAbstract" id="btx_AssetContributionAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AssetContributionAgreementTextBlock" id="btx_AssetContributionAgreementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" id="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfTranches" id="btx_NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" id="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfInstallmentsForEachTranche" id="btx_NumberOfInstallmentsForEachTranche" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfTradingDays" id="btx_NumberOfTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AsteriasBiotherapeuticsMember" id="btx_AsteriasBiotherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifemapSolutionsIncMember" id="btx_LifemapSolutionsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RecyteTherapeuticsIncMember" id="btx_RecyteTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EsCellInternationalPteLtdMember" id="btx_EsCellInternationalPteLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifemapSciencesLtdMember" id="btx_LifemapSciencesLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifemapSciencesIncMember" id="btx_LifemapSciencesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OncocyteCorporationMember" id="btx_OncocyteCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiotimeAsiaLimitedMember" id="btx_BiotimeAsiaLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CellCureNeurosciencesLtdMember" id="btx_CellCureNeurosciencesLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrthocyteCorporationMember" id="btx_OrthocyteCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonSharesIssuedForRent" id="btx_CommonSharesIssuedForRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfDeferredConsultingFees" id="btx_AmortizationOfDeferredConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AmortizationOfDeferredRent" id="btx_AmortizationOfDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="SecurityDepositReceived" id="btx_SecurityDepositReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInGrantReceivable" id="btx_IncreaseDecreaseInGrantReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" id="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AmortizationOfStockBasedPrepaidRent" id="btx_AmortizationOfStockBasedPrepaidRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromEmployeeOptionsExercised" id="btx_ProceedsFromEmployeeOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromDirectorOptionsExcercised" id="btx_ProceedsFromDirectorOptionsExcercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FeesPaidOnSaleOfCommonShares" id="btx_FeesPaidOnSaleOfCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" id="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlan2011Member" id="btx_StockOptionPlan2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrivateOutsideFundingTable" id="btx_PrivateOutsideFundingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrivateFundingAxis" id="btx_PrivateFundingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrivateFundingLineItems" id="btx_PrivateFundingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashInflowsDomain" id="btx_CashInflowsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrancheOneMember" id="btx_TrancheOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrancheTwoMember" id="btx_TrancheTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CertainInvestorsMember" id="btx_CertainInvestorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsExercised" id="btx_WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="btx_EquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlan2010Member" id="btx_StockOptionPlan2010Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifeOfWarrants" id="btx_LifeOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PreferredSharesConvertibleConversionRatio" id="btx_PreferredSharesConvertibleConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PricePerShareOfOptionsToPurchaseCompany" id="btx_PricePerShareOfOptionsToPurchaseCompany" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PreferredSharesSold" id="btx_PreferredSharesSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="TradeAccountsAndGrantsReceivableNetCurrent" id="btx_TradeAccountsAndGrantsReceivableNetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseAndConsultingFees" id="btx_DeferredLicenseAndConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TreasuryStockPolicyTextBlock" id="btx_TreasuryStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" id="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WarrantsToPurchaseCommonStockPolicyTextBlock" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OncocyteLicenseFromSbmriMember" id="btx_OncocyteLicenseFromSbmriMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdvancedCellTechnologyIncWithKirinSublicenseIMember" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarfMember" id="btx_WarfMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReproductiveGeneticsInstituteMember" id="btx_ReproductiveGeneticsInstituteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdvancedCellTechnologyIncMember" id="btx_AdvancedCellTechnologyIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AnnualMinimumRoyaltyDue" id="btx_AnnualMinimumRoyaltyDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RoyaltyPercentage" id="btx_RoyaltyPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LicenseFeeAmountPaid" id="btx_LicenseFeeAmountPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="RoyaltyMaximumPayment" id="btx_RoyaltyMaximumPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AnnualLicenseMaintenanceFee" id="btx_AnnualLicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearFour" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearThree" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CellCureNeurosciencesLicenseFromHadasitMember" id="btx_CellCureNeurosciencesLicenseFromHadasitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseAfterYearFive" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearTwo" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AmendedLicenseAgreementAmount" id="btx_AmendedLicenseAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="FeesForSublicensePercentage" id="btx_FeesForSublicensePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" id="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TevaLicenseAgreementMember" id="btx_TevaLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiotimeLicenseForUniversityOfUtahMember" id="btx_BiotimeLicenseForUniversityOfUtahMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AsteriasLicenseUniversityOfCaliforniaMember" id="btx_AsteriasLicenseUniversityOfCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AsteriasSublicenseFromGeronMember" id="btx_AsteriasSublicenseFromGeronMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NoticePeriodToTerminateAgreement" id="btx_NoticePeriodToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PaymentPhaseAxis" id="btx_PaymentPhaseAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentPhaseDomain" id="btx_PaymentPhaseDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReductionForAnyPatentThatHaveLicensedTwoOrMore" id="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PhaseIClinicalMember" id="btx_PhaseIClinicalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PhaseIiClinicalMember" id="btx_PhaseIiClinicalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PhaseIiiClinicalMember" id="btx_PhaseIiiClinicalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentUponIssuanceOfFirstFiveLicense" id="btx_PaymentUponIssuanceOfFirstFiveLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MinimumRoyaltyAmountEachYearAndThereafter" id="btx_MinimumRoyaltyAmountEachYearAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="SublicensingReceiptsForCreditableMilestonePayments" id="btx_SublicensingReceiptsForCreditableMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MilestonePayments" id="btx_MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ReimbursementToSbmriForCostIncurredInHundredths" id="btx_ReimbursementToSbmriForCostIncurredInHundredths" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ReductionInRoyalties" id="btx_ReductionInRoyalties" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="FeesForResearchUse" id="btx_FeesForResearchUse" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="btx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" id="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" id="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetContributionAgreementTable" id="btx_AssetContributionAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Warrants1Member" id="btx_Warrants1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IprAndDExpensedUponAcquisitionAssetContributionAgreement" id="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="WarrantExpirationTerm" id="btx_WarrantExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" id="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="MarketValueOfBiotimeCommonShares" id="btx_MarketValueOfBiotimeCommonShares" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="RoyaltyRateOnNetSalesOfProducts" id="btx_RoyaltyRateOnNetSalesOfProducts" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PercentageOfSubsidiaryStockContributed" id="btx_PercentageOfSubsidiaryStockContributed" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="TotalConsiderationReceivedAssetContributionAgreement" id="btx_TotalConsiderationReceivedAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" id="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" id="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="FairValueOfSharesIssued" id="btx_FairValueOfSharesIssued" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="GeronMember" id="btx_GeronMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RomulusFilmsLtdMember" id="btx_RomulusFilmsLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" id="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" id="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" id="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" id="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TotalAssetsTransferredAssetContributionAgreement" id="btx_TotalAssetsTransferredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="InvestmentsInAffiliatesAtCost" id="btx_InvestmentsInAffiliatesAtCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CancellationOfOutstandingObligationAssetContributionAgreement" id="btx_CancellationOfOutstandingObligationAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AssetContributionAgreementLineItems" id="btx_AssetContributionAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" id="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" id="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" id="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" id="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AmountOfContributionFromInvestor" id="btx_AmountOfContributionFromInvestor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>btx-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreementDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreementDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#EquipmentDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to TradeAccountsAndGrantsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAssetsNoncurrent" xlink:title="calculation: Assets to DepositsAssetsNoncurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DeferredLicenseAndConsultingFees" xlink:title="calculation: Assets to DeferredLicenseAndConsultingFees" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="MinorityInterest" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to MinorityInterest" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="TreasuryStockValue" xlink:title="calculation: StockholdersEquity to TreasuryStockValue" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="StockholdersEquity" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to StockholdersEquity" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRevenueCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LiabilitiesCurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to OtherLiabilitiesNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="DeferredRentCreditNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to DeferredRentCreditNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="DeferredTaxLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to DeferredTaxLiabilitiesNoncurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LiabilitiesNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: ProfitLoss to IncomeTaxExpenseBenefit" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RevenueFromGrants" xlink:title="calculation: SalesRevenueNet to RevenueFromGrants" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RoyaltyRevenue" xlink:title="calculation: SalesRevenueNet to RoyaltyRevenue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="SalesRevenueGoodsNet" xlink:title="calculation: SalesRevenueNet to SalesRevenueGoodsNet" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="LicensesRevenue" xlink:title="calculation: SalesRevenueNet to LicensesRevenue" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="SalesRevenueNet" xlink:title="calculation: GrossProfit to SalesRevenueNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfRevenue" xlink:title="calculation: GrossProfit to CostOfRevenue" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncome" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncome" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestIncomeExpenseNet" xlink:title="calculation: NonoperatingIncomeExpense to InterestIncomeExpenseNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="calculation: NonoperatingIncomeExpense to GainLossOnSaleOfPropertyPlantEquipment" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: ProfitLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="ProfitLoss" xlink:title="calculation: NetIncomeLoss to ProfitLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to NetIncomeLossAttributableToNoncontrollingInterest" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="NetIncomeLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to NetIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromSaleOfTreasuryStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromSaleOfTreasuryStock" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromMinorityShareholders" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromMinorityShareholders" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromEmployeeOptionsExercised" xlink:label="ProceedsFromEmployeeOptionsExercised" xlink:title="ProceedsFromEmployeeOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromEmployeeOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromEmployeeOptionsExercised" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FeesPaidOnSaleOfCommonShares" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FeesPaidOnSaleOfCommonShares" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromDirectorOptionsExcercised" xlink:label="ProceedsFromDirectorOptionsExcercised" xlink:title="ProceedsFromDirectorOptionsExcercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromDirectorOptionsExcercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromDirectorOptionsExcercised" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to EffectOfExchangeRateOnCashAndCashEquivalents" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDeferredConsultingFees" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDeferredConsultingFees" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:label="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:title="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDeferredLicenseFeesAndRoyaltyFees" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredRent" xlink:label="AmortizationOfDeferredRent" xlink:title="AmortizationOfDeferredRent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDeferredRent" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDeferredRent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ImpairmentOfLongLivedAssetsHeldForUse" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLossAttributableToNoncontrollingInterest" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfStockBasedPrepaidRent" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfStockBasedPrepaidRent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInGrantReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInGrantReceivable" order="14.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="13.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfIntangibleAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDeferredCharges" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDeferredCharges" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="RecognitionOfDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to RecognitionOfDeferredRevenue" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="15.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DeferredIncomeTaxExpenseBenefit" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherNoncurrentLiabilities" order="18.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="SecurityDepositReceived" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to SecurityDepositReceived" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsGross" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearFour" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:label="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseAfterYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearTwo" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccruedBonusesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:label="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:label="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="calculation: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:label="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="IprAndDExpensedUponAcquisitionAssetContributionAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="calculation: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to IprAndDExpensedUponAcquisitionAssetContributionAgreement" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:label="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="calculation: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" order="3.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>btx-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreementDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreementDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquityDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#EquityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#EquipmentDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/InventoryDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#InventoryDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreementTables" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreementTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentTables" xlink:type="simple" xlink:href="btx-20140331.xsd#EquipmentTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20140331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreement" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreement" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Equity" xlink:type="simple" xlink:href="btx-20140331.xsd#Equity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilities" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFees" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssets" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Equipment" xlink:type="simple" xlink:href="btx-20140331.xsd#Equipment" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Inventory" xlink:type="simple" xlink:href="btx-20140331.xsd#Inventory" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20140331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Inventory" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Equipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Equity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreementTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="AccountsReceivableNetCurrent" xlink:title="definition: MinorityInterestLineItems to AccountsReceivableNetCurrent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="GrantsReceivableCurrent" xlink:title="GrantsReceivableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="GrantsReceivableCurrent" xlink:title="definition: MinorityInterestLineItems to GrantsReceivableCurrent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="definition: MinorityInterestLineItems to AllowanceForDoubtfulAccountsReceivableCurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestTable" xlink:title="definition: MinorityInterestLineItems to MinorityInterestTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="LegalEntityAxis" xlink:title="definition: MinorityInterestTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="EsCellInternationalPteLtdMember" xlink:title="definition: EntityDomain to EsCellInternationalPteLtdMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="definition: EntityDomain to OncocyteCorporationMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="definition: EntityDomain to OrthocyteCorporationMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="definition: EntityDomain to CellCureNeurosciencesLtdMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="definition: EntityDomain to RecyteTherapeuticsIncMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="definition: EntityDomain to BiotimeAsiaLimitedMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="definition: EntityDomain to LifemapSciencesIncMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesLtdMember" xlink:title="definition: EntityDomain to LifemapSciencesLtdMember" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSolutionsIncMember" xlink:title="definition: EntityDomain to LifemapSolutionsIncMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="TreasuryStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to TreasuryStockMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/InventoryDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="RoyaltyPercentage" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to RoyaltyPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmendedLicenseAgreementAmount" xlink:label="AmendedLicenseAgreementAmount" xlink:title="AmendedLicenseAgreementAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmendedLicenseAgreementAmount" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmendedLicenseAgreementAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualLicenseMaintenanceFee" xlink:label="AnnualLicenseMaintenanceFee" xlink:title="AnnualLicenseMaintenanceFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AnnualLicenseMaintenanceFee" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AnnualLicenseMaintenanceFee" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LicenseFeeAmountPaid" xlink:label="LicenseFeeAmountPaid" xlink:title="LicenseFeeAmountPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="LicenseFeeAmountPaid" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to LicenseFeeAmountPaid" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyMaximumPayment" xlink:label="RoyaltyMaximumPayment" xlink:title="RoyaltyMaximumPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="RoyaltyMaximumPayment" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to RoyaltyMaximumPayment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForSublicensePercentage" xlink:label="FeesForSublicensePercentage" xlink:title="FeesForSublicensePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FeesForSublicensePercentage" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FeesForSublicensePercentage" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualMinimumRoyaltyDue" xlink:label="AnnualMinimumRoyaltyDue" xlink:title="AnnualMinimumRoyaltyDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AnnualMinimumRoyaltyDue" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AnnualMinimumRoyaltyDue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="StockIssuedDuringPeriodSharesOther" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to StockIssuedDuringPeriodSharesOther" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="StockIssuedDuringPeriodValueOther" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to StockIssuedDuringPeriodValueOther" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForResearchUse" xlink:label="FeesForResearchUse" xlink:title="FeesForResearchUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FeesForResearchUse" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FeesForResearchUse" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionInRoyalties" xlink:label="ReductionInRoyalties" xlink:title="ReductionInRoyalties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReductionInRoyalties" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ReductionInRoyalties" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReimbursementToSbmriForCostIncurredInHundredths" xlink:label="ReimbursementToSbmriForCostIncurredInHundredths" xlink:title="ReimbursementToSbmriForCostIncurredInHundredths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReimbursementToSbmriForCostIncurredInHundredths" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ReimbursementToSbmriForCostIncurredInHundredths" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="MilestonePayments" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to MilestonePayments" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SublicensingReceiptsForCreditableMilestonePayments" xlink:label="SublicensingReceiptsForCreditableMilestonePayments" xlink:title="SublicensingReceiptsForCreditableMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="SublicensingReceiptsForCreditableMilestonePayments" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to SublicensingReceiptsForCreditableMilestonePayments" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MinimumRoyaltyAmountEachYearAndThereafter" xlink:label="MinimumRoyaltyAmountEachYearAndThereafter" xlink:title="MinimumRoyaltyAmountEachYearAndThereafter" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="MinimumRoyaltyAmountEachYearAndThereafter" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to MinimumRoyaltyAmountEachYearAndThereafter" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentUponIssuanceOfFirstFiveLicense" xlink:label="PaymentUponIssuanceOfFirstFiveLicense" xlink:title="PaymentUponIssuanceOfFirstFiveLicense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="PaymentUponIssuanceOfFirstFiveLicense" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to PaymentUponIssuanceOfFirstFiveLicense" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:label="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:title="ReductionForAnyPatentThatHaveLicensedTwoOrMore" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ReductionForAnyPatentThatHaveLicensedTwoOrMore" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NoticePeriodToTerminateAgreement" xlink:label="NoticePeriodToTerminateAgreement" xlink:title="NoticePeriodToTerminateAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="NoticePeriodToTerminateAgreement" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to NoticePeriodToTerminateAgreement" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsAbstract" xlink:label="DeferredCostsAbstract" xlink:title="DeferredCostsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredCostsAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredCostsAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:label="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredLicenseFeesAmortizationExpenseYearTwo" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredLicenseFeesAmortizationExpenseYearThree" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredLicenseFeesAmortizationExpenseYearFour" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredLicenseFeesAmortizationExpenseAfterYearFive" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredCostsCurrentAndNoncurrent" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to DeferredCostsCurrentAndNoncurrent" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="27.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarfMember" xlink:label="WarfMember" xlink:title="WarfMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="WarfMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to WarfMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncMember" xlink:label="AdvancedCellTechnologyIncMember" xlink:title="AdvancedCellTechnologyIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncWithKirinSublicenseIMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncWithKirinSublicenseIiMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReproductiveGeneticsInstituteMember" xlink:label="ReproductiveGeneticsInstituteMember" xlink:title="ReproductiveGeneticsInstituteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ReproductiveGeneticsInstituteMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to ReproductiveGeneticsInstituteMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteLicenseFromSbmriMember" xlink:label="OncocyteLicenseFromSbmriMember" xlink:title="OncocyteLicenseFromSbmriMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="OncocyteLicenseFromSbmriMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to OncocyteLicenseFromSbmriMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLicenseFromHadasitMember" xlink:label="CellCureNeurosciencesLicenseFromHadasitMember" xlink:title="CellCureNeurosciencesLicenseFromHadasitMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CellCureNeurosciencesLicenseFromHadasitMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CellCureNeurosciencesLicenseFromHadasitMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TevaLicenseAgreementMember" xlink:label="TevaLicenseAgreementMember" xlink:title="TevaLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TevaLicenseAgreementMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TevaLicenseAgreementMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeLicenseForUniversityOfUtahMember" xlink:label="BiotimeLicenseForUniversityOfUtahMember" xlink:title="BiotimeLicenseForUniversityOfUtahMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="BiotimeLicenseForUniversityOfUtahMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to BiotimeLicenseForUniversityOfUtahMember" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasLicenseUniversityOfCaliforniaMember" xlink:label="AsteriasLicenseUniversityOfCaliforniaMember" xlink:title="AsteriasLicenseUniversityOfCaliforniaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AsteriasLicenseUniversityOfCaliforniaMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to AsteriasLicenseUniversityOfCaliforniaMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasSublicenseFromGeronMember" xlink:label="AsteriasSublicenseFromGeronMember" xlink:title="AsteriasSublicenseFromGeronMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AsteriasSublicenseFromGeronMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to AsteriasSublicenseFromGeronMember" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseAxis" xlink:label="PaymentPhaseAxis" xlink:title="PaymentPhaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="PaymentPhaseAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to PaymentPhaseAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseDomain" xlink:label="PaymentPhaseDomain" xlink:title="PaymentPhaseDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PaymentPhaseAxis" xlink:to="PaymentPhaseDomain" xlink:title="definition: PaymentPhaseAxis to PaymentPhaseDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseDomain" xlink:label="PaymentPhaseDomain_2" xlink:title="PaymentPhaseDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PaymentPhaseAxis" xlink:to="PaymentPhaseDomain_2" xlink:title="definition: PaymentPhaseAxis to PaymentPhaseDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIClinicalMember" xlink:label="PhaseIClinicalMember" xlink:title="PhaseIClinicalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIClinicalMember" xlink:title="definition: PaymentPhaseDomain to PhaseIClinicalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiClinicalMember" xlink:label="PhaseIiClinicalMember" xlink:title="PhaseIiClinicalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIiClinicalMember" xlink:title="definition: PaymentPhaseDomain to PhaseIiClinicalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiiClinicalMember" xlink:label="PhaseIiiClinicalMember" xlink:title="PhaseIiiClinicalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIiiClinicalMember" xlink:title="definition: PaymentPhaseDomain to PhaseIiiClinicalMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquityDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingLineItems" xlink:label="PrivateFundingLineItems" xlink:title="PrivateFundingLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:title="definition: PrivateFundingLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: PrivateFundingLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: PrivateFundingLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: PrivateFundingLineItems to CommonStockSharesAuthorized" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: PrivateFundingLineItems to CommonStockSharesIssued" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: PrivateFundingLineItems to CommonStockSharesOutstanding" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: PrivateFundingLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: PrivateFundingLineItems to AllocatedShareBasedCompensationExpense" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: PrivateFundingLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="WarrantsExercised" xlink:title="definition: PrivateFundingLineItems to WarrantsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: PrivateFundingLineItems to PreferredStockSharesAuthorized" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: PrivateFundingLineItems to PreferredStockSharesOutstanding" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesSold" xlink:label="PreferredSharesSold" xlink:title="PreferredSharesSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredSharesSold" xlink:title="definition: PrivateFundingLineItems to PreferredSharesSold" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: PrivateFundingLineItems to StockIssuedDuringPeriodValueNewIssues" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockDividendRatePercentage" xlink:title="definition: PrivateFundingLineItems to PreferredStockDividendRatePercentage" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockDividendRatePerDollarAmount" xlink:title="definition: PrivateFundingLineItems to PreferredStockDividendRatePerDollarAmount" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PricePerShareOfOptionsToPurchaseCompany" xlink:title="definition: PrivateFundingLineItems to PricePerShareOfOptionsToPurchaseCompany" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="PreferredSharesConvertibleConversionRatio" xlink:title="definition: PrivateFundingLineItems to PreferredSharesConvertibleConversionRatio" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifeOfWarrants" xlink:label="LifeOfWarrants" xlink:title="LifeOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrivateFundingLineItems" xlink:to="LifeOfWarrants" xlink:title="definition: PrivateFundingLineItems to LifeOfWarrants" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateOutsideFundingTable" xlink:label="PrivateOutsideFundingTable" xlink:title="PrivateOutsideFundingTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PrivateFundingLineItems" xlink:to="PrivateOutsideFundingTable" xlink:title="definition: PrivateFundingLineItems to PrivateOutsideFundingTable" order="20.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingAxis" xlink:label="PrivateFundingAxis" xlink:title="PrivateFundingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="PrivateOutsideFundingTable" xlink:to="PrivateFundingAxis" xlink:title="definition: PrivateOutsideFundingTable to PrivateFundingAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CashInflowsDomain" xlink:label="CashInflowsDomain" xlink:title="CashInflowsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PrivateFundingAxis" xlink:to="CashInflowsDomain" xlink:title="definition: PrivateFundingAxis to CashInflowsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CashInflowsDomain" xlink:label="CashInflowsDomain_2" xlink:title="CashInflowsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PrivateFundingAxis" xlink:to="CashInflowsDomain_2" xlink:title="definition: PrivateFundingAxis to CashInflowsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheOneMember" xlink:label="TrancheOneMember" xlink:title="TrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashInflowsDomain" xlink:to="TrancheOneMember" xlink:title="definition: CashInflowsDomain to TrancheOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheTwoMember" xlink:label="TrancheTwoMember" xlink:title="TrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashInflowsDomain" xlink:to="TrancheTwoMember" xlink:title="definition: CashInflowsDomain to TrancheTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CertainInvestorsMember" xlink:label="CertainInvestorsMember" xlink:title="CertainInvestorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashInflowsDomain" xlink:to="CertainInvestorsMember" xlink:title="definition: CashInflowsDomain to CertainInvestorsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashInflowsDomain" xlink:to="PreferredStockMember" xlink:title="definition: CashInflowsDomain to PreferredStockMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="PrivateOutsideFundingTable" xlink:to="LegalEntityAxis" xlink:title="definition: PrivateOutsideFundingTable to LegalEntityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="definition: EntityDomain to OrthocyteCorporationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="definition: EntityDomain to OncocyteCorporationMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="definition: EntityDomain to RecyteTherapeuticsIncMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="definition: EntityDomain to LifemapSciencesIncMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="definition: EntityDomain to BiotimeAsiaLimitedMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="PrivateOutsideFundingTable" xlink:to="PlanNameAxis" xlink:title="definition: PrivateOutsideFundingTable to PlanNameAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2010Member" xlink:label="StockOptionPlan2010Member" xlink:title="StockOptionPlan2010Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2010Member" xlink:title="definition: PlanNameDomain to StockOptionPlan2010Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2011Member" xlink:label="StockOptionPlan2011Member" xlink:title="StockOptionPlan2011Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2011Member" xlink:title="definition: PlanNameDomain to StockOptionPlan2011Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementLineItems" xlink:label="AssetContributionAgreementLineItems" xlink:title="AssetContributionAgreementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: AssetContributionAgreementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="CommonStockNoParValue" xlink:title="definition: AssetContributionAgreementLineItems to CommonStockNoParValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: AssetContributionAgreementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:title="definition: AssetContributionAgreementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="definition: AssetContributionAgreementLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantExpirationTerm" xlink:label="WarrantExpirationTerm" xlink:title="WarrantExpirationTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantExpirationTerm" xlink:title="definition: AssetContributionAgreementLineItems to WarrantExpirationTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmountOfContributionFromInvestor" xlink:label="AmountOfContributionFromInvestor" xlink:title="AmountOfContributionFromInvestor" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="AmountOfContributionFromInvestor" xlink:title="definition: AssetContributionAgreementLineItems to AmountOfContributionFromInvestor" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PercentageOfSubsidiaryStockContributed" xlink:label="PercentageOfSubsidiaryStockContributed" xlink:title="PercentageOfSubsidiaryStockContributed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="PercentageOfSubsidiaryStockContributed" xlink:title="definition: AssetContributionAgreementLineItems to PercentageOfSubsidiaryStockContributed" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: AssetContributionAgreementLineItems to ProceedsFromIssuanceOfCommonStock" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="definition: AssetContributionAgreementLineItems to AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FairValueOfSharesIssued" xlink:label="FairValueOfSharesIssued" xlink:title="FairValueOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueOfSharesIssued" xlink:title="definition: AssetContributionAgreementLineItems to FairValueOfSharesIssued" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MarketValueOfBiotimeCommonShares" xlink:label="MarketValueOfBiotimeCommonShares" xlink:title="MarketValueOfBiotimeCommonShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="MarketValueOfBiotimeCommonShares" xlink:title="definition: AssetContributionAgreementLineItems to MarketValueOfBiotimeCommonShares" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: AssetContributionAgreementLineItems to FiniteLivedIntangibleAssetUsefulLife" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyRateOnNetSalesOfProducts" xlink:label="RoyaltyRateOnNetSalesOfProducts" xlink:title="RoyaltyRateOnNetSalesOfProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="RoyaltyRateOnNetSalesOfProducts" xlink:title="definition: AssetContributionAgreementLineItems to RoyaltyRateOnNetSalesOfProducts" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: AssetContributionAgreementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:label="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:title="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:label="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:title="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalConsiderationReceivedAssetContributionAgreement" xlink:label="TotalConsiderationReceivedAssetContributionAgreement" xlink:title="TotalConsiderationReceivedAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalConsiderationReceivedAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to TotalConsiderationReceivedAssetContributionAgreement" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="definition: AssetContributionAgreementLineItems to CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="definition: AssetContributionAgreementLineItems to WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CancellationOfOutstandingObligationAssetContributionAgreement" xlink:label="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:title="CancellationOfOutstandingObligationAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to CancellationOfOutstandingObligationAssetContributionAgreement" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_InvestmentsInAffiliatesAtCost" xlink:label="InvestmentsInAffiliatesAtCost" xlink:title="InvestmentsInAffiliatesAtCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="InvestmentsInAffiliatesAtCost" xlink:title="definition: AssetContributionAgreementLineItems to InvestmentsInAffiliatesAtCost" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: AssetContributionAgreementLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsTransferredAssetContributionAgreement" xlink:label="TotalAssetsTransferredAssetContributionAgreement" xlink:title="TotalAssetsTransferredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalAssetsTransferredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to TotalAssetsTransferredAssetContributionAgreement" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to SeriesCommonStockConsiderationTransferredAssetContributionAgreement" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:label="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:title="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="definition: AssetContributionAgreementLineItems to BusinessCombinationAcquisitionRelatedCosts" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:label="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:label="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="definition: AssetContributionAgreementLineItems to DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:label="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="IprAndDExpensedUponAcquisitionAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to IprAndDExpensedUponAcquisitionAssetContributionAgreement" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:label="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="definition: AssetContributionAgreementLineItems to TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueAssumptionsExpectedTerm" xlink:title="definition: AssetContributionAgreementLineItems to FairValueAssumptionsExpectedTerm" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: AssetContributionAgreementLineItems to FairValueAssumptionsRiskFreeInterestRate" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueAssumptionsExpectedDividendRate" xlink:title="definition: AssetContributionAgreementLineItems to FairValueAssumptionsExpectedDividendRate" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: AssetContributionAgreementLineItems to FairValueAssumptionsExpectedVolatilityRate" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementTable" xlink:label="AssetContributionAgreementTable" xlink:title="AssetContributionAgreementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AssetContributionAgreementLineItems" xlink:to="AssetContributionAgreementTable" xlink:title="definition: AssetContributionAgreementLineItems to AssetContributionAgreementTable" order="37.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetContributionAgreementTable" xlink:to="LegalEntityAxis" xlink:title="definition: AssetContributionAgreementTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="definition: EntityDomain to OrthocyteCorporationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="definition: EntityDomain to CellCureNeurosciencesLtdMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_GeronMember" xlink:label="GeronMember" xlink:title="GeronMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="GeronMember" xlink:title="definition: EntityDomain to GeronMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RomulusFilmsLtdMember" xlink:label="RomulusFilmsLtdMember" xlink:title="RomulusFilmsLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="RomulusFilmsLtdMember" xlink:title="definition: EntityDomain to RomulusFilmsLtdMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetContributionAgreementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: AssetContributionAgreementTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_Warrants1Member" xlink:label="Warrants1Member" xlink:title="Warrants1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="Warrants1Member" xlink:title="definition: ClassOfStockDomain to Warrants1Member" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: SubsequentEventLineItems to ProceedsFromIssuanceOfCommonStock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: SubsequentEventLineItems to StockIssuedDuringPeriodValueNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfServicesOverhead" xlink:label="CostOfServicesOverhead" xlink:title="CostOfServicesOverhead" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CostOfServicesOverhead" xlink:title="definition: SubsequentEventLineItems to CostOfServicesOverhead" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:label="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:title="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:title="definition: SubsequentEventLineItems to MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: SubsequentEventLineItems to EquityMethodInvestmentOwnershipPercentage" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchasedDuringPeriodShares" xlink:title="definition: SubsequentEventLineItems to StockRepurchasedDuringPeriodShares" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="StockRepurchasedDuringPeriodValue" xlink:title="StockRepurchasedDuringPeriodValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchasedDuringPeriodValue" xlink:title="definition: SubsequentEventLineItems to StockRepurchasedDuringPeriodValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranches" xlink:label="NumberOfTranches" xlink:title="NumberOfTranches" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTranches" xlink:title="definition: SubsequentEventLineItems to NumberOfTranches" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="definition: SubsequentEventLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SharePrice" xlink:title="definition: SubsequentEventLineItems to SharePrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:label="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:title="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:title="definition: SubsequentEventLineItems to NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfInstallmentsForEachTranche" xlink:label="NumberOfInstallmentsForEachTranche" xlink:title="NumberOfInstallmentsForEachTranche" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfInstallmentsForEachTranche" xlink:title="definition: SubsequentEventLineItems to NumberOfInstallmentsForEachTranche" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTradingDays" xlink:title="definition: SubsequentEventLineItems to NumberOfTradingDays" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>btx-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:label xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityDomain_lbl" xml:lang="en-US" id="dei_EntityDomain_lbl">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:title="label: EntityDomain to dei_EntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="dei_LegalEntityAxis_lbl">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:title="label: LegalEntityAxis to dei_LegalEntityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Trade accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl">Accrued bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl1">Accrued Bonuses, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl1" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl">Accumulated other comprehensive income/(loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Contributed capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl">Transaction costs allocated to issuance of equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl1">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl">Allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDeferredCharges_lbl">Amortization of deferred license, royalty and subscription revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:title="label: AmortizationOfDeferredCharges to us-gaap_AmortizationOfDeferredCharges_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDeferredCharges_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfDeferredCharges_lbl1">Amortization of Deferred Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl1" xlink:title="label: AmortizationOfDeferredCharges to us-gaap_AmortizationOfDeferredCharges_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">General</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl">Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xlink:title="label: BusinessAcquisitionProFormaInformationAbstract to us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="BusinessAcquisitionsProFormaRevenue" xlink:title="BusinessAcquisitionsProFormaRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl">Revenues, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:title="label: BusinessAcquisitionsProFormaRevenue to us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1">Business Acquisition, Pro Forma Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1" xlink:title="label: BusinessAcquisitionsProFormaRevenue to us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="BusinessAcquisitionsProFormaNetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl">Net loss available to common shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:title="label: BusinessAcquisitionsProFormaNetIncomeLoss to us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl">Geron asset acquisition related transaction costs paid by BioTime</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl">Transaction and other costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:title="label: BusinessCombinationAcquisitionRelatedCosts to us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">At beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">At end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">NET CHANGE IN CASH AND CASH EQUIVALENTS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAbstract_lbl">CASH AND CASH EQUIVALENTS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:title="label: CashAndCashEquivalentsAbstract to us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl">Exercise price of warrant (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockNoParValue_lbl">Common shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:title="label: CommonStockNoParValue to us-gaap_CommonStockNoParValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common shares, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common shares, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Common shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl">Common Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common shares, authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassCMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl">Common [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl">COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentrations of credit risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:label="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl">BioTime's ownership of outstanding shares of its subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:title="label: ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock to us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xlink:title="label: ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock to us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl">Principles of consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl1">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl">Cost of sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl">Cost of sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfRevenue_lbl1" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl1">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl1" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfServicesOverhead" xlink:label="CostOfServicesOverhead" xlink:title="CostOfServicesOverhead" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfServicesOverhead_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfServicesOverhead_lbl" xml:lang="en-US" id="us-gaap_CostOfServicesOverhead_lbl">Overhead charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfServicesOverhead" xlink:to="us-gaap_CostOfServicesOverhead_lbl" xlink:title="label: CostOfServicesOverhead to us-gaap_CostOfServicesOverhead_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsAbstract" xlink:label="DeferredCostsAbstract" xlink:title="DeferredCostsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredCostsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredCostsAbstract_lbl">Amortization of deferred license fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsAbstract" xlink:to="us-gaap_DeferredCostsAbstract_lbl" xlink:title="label: DeferredCostsAbstract to us-gaap_DeferredCostsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCostsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredCostsAbstract_lbl1">Deferred Costs [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsAbstract" xlink:to="us-gaap_DeferredCostsAbstract_lbl1" xlink:title="label: DeferredCostsAbstract to us-gaap_DeferredCostsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:title="label: DeferredCostsCurrentAndNoncurrent to us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1">Deferred Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xlink:title="label: DeferredCostsCurrentAndNoncurrent to us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_DeferredChargesPolicyTextBlock_lbl">Deferred license and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:title="label: DeferredChargesPolicyTextBlock to us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DeferredChargesPolicyTextBlock_lbl1">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xlink:title="label: DeferredChargesPolicyTextBlock to us-gaap_DeferredChargesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureAbstract_lbl">Royalty Obligation and Deferred License Fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xlink:title="label: DeferredRevenueDisclosureAbstract to us-gaap_DeferredRevenueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRentCreditNoncurrent_lbl">Deferred rent, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:title="label: DeferredRentCreditNoncurrent to us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="DeferredRevenueDisclosureTextBlock" xlink:title="DeferredRevenueDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureTextBlock_lbl">Royalty Obligation and Deferred License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xlink:title="label: DeferredRevenueDisclosureTextBlock to us-gaap_DeferredRevenueDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1">Deferred Revenue Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xlink:title="label: DeferredRevenueDisclosureTextBlock to us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl">Deferred license and subscription revenue, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl">Deferred income tax benefit, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsDomestic to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsDomestic to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl">Deferred income tax benefit, state taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl1">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl">Deferred tax liability, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:title="label: DeferredTaxLiabilitiesNoncurrent to us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl1">Deposits Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl1" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl">BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalents to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Percentages of outstanding voting securities owns before transaction beneficially (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl">Expected volatility (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl1">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl1">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedTerm_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:title="label: FairValueAssumptionsExpectedTerm to us-gaap_FairValueAssumptionsExpectedTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssumptionsExpectedTerm_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedTerm_lbl1">Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl1" xlink:title="label: FairValueAssumptionsExpectedTerm to us-gaap_FairValueAssumptionsExpectedTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl">Dividend yield (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: FairValueAssumptionsExpectedDividendRate to us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl1">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: FairValueAssumptionsExpectedDividendRate to us-gaap_FairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair value of financial instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Intangible assets, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Intangible assets, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1">Finite-Lived Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl">Foreign currency transaction loss included in other income/(expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl">Foreign currency translation gain/loss and Comprehensive net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:title="label: ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl1">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl1" xlink:title="label: ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl">Loss on sale of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">Intangible assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="GrantsReceivableCurrent" xlink:title="GrantsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_GrantsReceivableCurrent_lbl">Grants receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:title="label: GrantsReceivableCurrent to us-gaap_GrantsReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrantsReceivableCurrent_lbl1" xml:lang="en-US" id="us-gaap_GrantsReceivableCurrent_lbl1">Grants Receivable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl1" xlink:title="label: GrantsReceivableCurrent to us-gaap_GrantsReceivableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="us-gaap_GrossProfit_lbl">Total revenues, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl">Loss on sale or write-off of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">LOSS BEFORE INCOME TAX BENEFIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl">Other long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherNoncurrentLiabilities to us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl">Patent costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xlink:title="label: IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend to us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xlink:title="label: IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend to us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNet_lbl">Interest (expense)/income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:title="label: InterestIncomeExpenseNet to us-gaap_InterestIncomeExpenseNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="us-gaap_InterestPaid_lbl">Cash paid during the period for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:title="label: InterestPaid to us-gaap_InterestPaid_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl">Inventory of finished products on-site</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:title="label: InventoryFinishedGoodsNetOfReserves to us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xml:lang="en-US" id="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xlink:title="label: InventoryFinishedGoodsNetOfReserves to us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract_lbl">Inventory [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrent_lbl">Total long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:title="label: LiabilitiesNoncurrent to us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrent_lbl1">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl1" xlink:title="label: LiabilitiesNoncurrent to us-gaap_LiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl">LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">TOTAL LIABILITIES AND EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="us-gaap_LicensesRevenue_lbl">License fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:title="label: LicensesRevenue to us-gaap_LicensesRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="us-gaap_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:title="label: MaximumMember to us-gaap_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="us-gaap_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:title="label: MinimumMember to us-gaap_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestTable_lbl">Noncontrolling Interest [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" xlink:title="label: MinorityInterestTable to us-gaap_MinorityInterestTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="us-gaap_MinorityInterest_lbl">Noncontrolling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:title="label: MinorityInterest to us-gaap_MinorityInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestLineItems_lbl">Noncontrolling Interest [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" xlink:title="label: MinorityInterestLineItems to us-gaap_MinorityInterestLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">BioTime Ownership (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss attributable to BioTime, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl">Net loss attributable to noncontrolling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1">Net loss allocable to non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Effect of recently issued and recently adopted accounting pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other income/(expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">OTHER INCOME/(EXPENSES):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl">Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl">Foreign currency translation (loss)/gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1">Foreign currency translation (loss)/gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl">Unrealized loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1">Unrealized loss on available-for-sale securities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl2" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl2">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl2" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncome_lbl">Other income/(expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:title="label: OtherNonoperatingIncome to us-gaap_OtherNonoperatingIncome_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xml:lang="en-US" id="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl">Inventory held by third party on consignment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:title="label: OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment to us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xml:lang="en-US" id="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xlink:title="label: OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment to us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl1">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred shares, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred shares, authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePercentage_lbl">Preferred stock dividend rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:title="label: PreferredStockDividendRatePercentage to us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNoParValue_lbl">Preferred shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:title="label: PreferredStockNoParValue to us-gaap_PreferredStockNoParValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl">Preferred share dividend (in dollars per shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:title="label: PreferredStockDividendRatePerDollarAmount to us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred shares, issued and outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Series Preferred A Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl">Reclassification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromMinorityShareholders_lbl">Proceeds from sale of common shares of subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:title="label: ProceedsFromMinorityShareholders to us-gaap_ProceedsFromMinorityShareholders_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Additional equity capital raised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from issuance of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2">Proceeds from issuance of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl">Proceeds from sale of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:title="label: ProceedsFromIssuanceOfPreferredStockAndPreferenceStock to us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl">Proceeds from the sale of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl">Proceeds from sale of treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfTreasuryStock" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:title="label: ProceedsFromSaleOfTreasuryStock to us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProfitLoss_lbl1" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl1">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Equipment useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Equipment, furniture and fixtures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Equipment, furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Equipment, furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="us-gaap_RangeAxis_lbl">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:title="label: RangeAxis to us-gaap_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeMember_lbl" xml:lang="en-US" id="us-gaap_RangeMember_lbl">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:title="label: RangeMember to us-gaap_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_RecognitionOfDeferredRevenue_lbl">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl" xlink:title="label: RecognitionOfDeferredRevenue to us-gaap_RecognitionOfDeferredRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RecognitionOfDeferredRevenue_lbl1" xml:lang="en-US" id="us-gaap_RecognitionOfDeferredRevenue_lbl1">Recognition of Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl1" xlink:title="label: RecognitionOfDeferredRevenue to us-gaap_RecognitionOfDeferredRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="us-gaap_RevenueFromGrants_lbl">Grant income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" xlink:title="label: RevenueFromGrants to us-gaap_RevenueFromGrants_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">Revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="us-gaap_RoyaltyRevenue_lbl">Royalties from product sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xlink:title="label: RoyaltyRevenue to us-gaap_RoyaltyRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueGoodsNet_lbl">Sale of research products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:title="label: SalesRevenueGoodsNet to us-gaap_SalesRevenueGoodsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNet_lbl1" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl1">Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl1" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNetAbstract_lbl">REVENUES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xlink:title="label: SalesRevenueNetAbstract to us-gaap_SalesRevenueNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl">Unaudited Pro Forma Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl1">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl1" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl">BioTime have option to purchase additional shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weighted-average assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockOptionsMember_lbl" xml:lang="en-US" id="us-gaap_StockOptionsMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsMember" xlink:to="us-gaap_StockOptionsMember_lbl" xlink:title="label: StockOptionsMember to us-gaap_StockOptionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Awarded grant amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Proceeds from sales of preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl">Common shares issued for consulting services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesOther_lbl">Common shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:title="label: StockIssuedDuringPeriodSharesOther to us-gaap_StockIssuedDuringPeriodSharesOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1">Stock Issued During Period, Shares, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesOther to us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="StockRepurchasedDuringPeriodValue" xlink:title="StockRepurchasedDuringPeriodValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" id="us-gaap_StockRepurchasedDuringPeriodValue_lbl">Common stock purchase during period, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:title="label: StockRepurchasedDuringPeriodValue to us-gaap_StockRepurchasedDuringPeriodValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Stock issued during period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="us-gaap_StockRepurchasedDuringPeriodShares_lbl">Common stock purchase during period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:title="label: StockRepurchasedDuringPeriodShares to us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueOther_lbl">Common shares issued, market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:title="label: StockIssuedDuringPeriodValueOther to us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueOther_lbl1">Stock Issued During Period, Value, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xlink:title="label: StockIssuedDuringPeriodValueOther to us-gaap_StockIssuedDuringPeriodValueOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl">EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl">Total equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="TradeAndOtherAccountsReceivablePolicy" xlink:title="TradeAndOtherAccountsReceivablePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl">Accounts receivable and allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:title="label: TradeAndOtherAccountsReceivablePolicy to us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl1" xml:lang="en-US" id="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl1">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl1" xlink:title="label: TradeAndOtherAccountsReceivablePolicy to us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockValue_lbl">Treasury stock at cost: 10,546,137 and 10,697,715 shares at March 31, 2014 and at December 31, 2013, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:title="label: TreasuryStockValue to us-gaap_TreasuryStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockValue_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockValue_lbl1">Treasury Stock, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl1" xlink:title="label: TreasuryStockValue to us-gaap_TreasuryStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockShares_lbl">Treasury stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:title="label: TreasuryStockShares to us-gaap_TreasuryStockShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl">Treasury Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockMember_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl1">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl1" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BusinessAcquisitionsProformaInformationTextBlock" xlink:label="BusinessAcquisitionsProformaInformationTextBlock" xlink:title="BusinessAcquisitionsProformaInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl" xml:lang="en-US" id="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl">Entire disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProformaInformationTextBlock" xlink:to="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl" xlink:title="label: BusinessAcquisitionsProformaInformationTextBlock to btx_BusinessAcquisitionsProformaInformationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl1" xml:lang="en-US" id="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl1">Business Acquisitions ProForma Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProformaInformationTextBlock" xlink:to="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl1" xlink:title="label: BusinessAcquisitionsProformaInformationTextBlock to btx_BusinessAcquisitionsProformaInformationTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl2" xml:lang="en-US" id="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl2">Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProformaInformationTextBlock" xlink:to="btx_BusinessAcquisitionsProformaInformationTextBlock_lbl2" xlink:title="label: BusinessAcquisitionsProformaInformationTextBlock to btx_BusinessAcquisitionsProformaInformationTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementAbstract" xlink:label="AssetContributionAgreementAbstract" xlink:title="AssetContributionAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetContributionAgreementAbstract_lbl1" xml:lang="en-US" id="btx_AssetContributionAgreementAbstract_lbl1">Asset Contribution Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementAbstract" xlink:to="btx_AssetContributionAgreementAbstract_lbl1" xlink:title="label: AssetContributionAgreementAbstract to btx_AssetContributionAgreementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementTextBlock" xlink:label="AssetContributionAgreementTextBlock" xlink:title="AssetContributionAgreementTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetContributionAgreementTextBlock_lbl" xml:lang="en-US" id="btx_AssetContributionAgreementTextBlock_lbl">The entire disclosure for Asset Contribution Agreement pursuant to which the entity contributes certain assets in exchange for shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementTextBlock" xlink:to="btx_AssetContributionAgreementTextBlock_lbl" xlink:title="label: AssetContributionAgreementTextBlock to btx_AssetContributionAgreementTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetContributionAgreementTextBlock_lbl1" xml:lang="en-US" id="btx_AssetContributionAgreementTextBlock_lbl1">Asset Contribution Agreement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementTextBlock" xlink:to="btx_AssetContributionAgreementTextBlock_lbl1" xlink:title="label: AssetContributionAgreementTextBlock to btx_AssetContributionAgreementTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetContributionAgreementTextBlock_lbl2" xml:lang="en-US" id="btx_AssetContributionAgreementTextBlock_lbl2">Asset Contribution Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementTextBlock" xlink:to="btx_AssetContributionAgreementTextBlock_lbl2" xlink:title="label: AssetContributionAgreementTextBlock to btx_AssetContributionAgreementTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:label="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:title="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" />
    <link:label xlink:type="resource" xlink:label="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl" xml:lang="en-US" id="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl">Represents maximum percentages of current equity value of solutions at time of significant transaction during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:to="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl" xlink:title="label: MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction to btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl1" xml:lang="en-US" id="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl1">Maximum percentages of current equity value of solutions at time of significant transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:to="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl1" xlink:title="label: MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction to btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl2" xml:lang="en-US" id="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl2">Maximum percentages of current equity value of solutions at time of significant transaction (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:to="btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl2" xlink:title="label: MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction to btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranches" xlink:label="NumberOfTranches" xlink:title="NumberOfTranches" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfTranches_lbl" xml:lang="en-US" id="btx_NumberOfTranches_lbl">Refers to number of tranches.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranches" xlink:to="btx_NumberOfTranches_lbl" xlink:title="label: NumberOfTranches to btx_NumberOfTranches_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranches_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfTranches_lbl1" xml:lang="en-US" id="btx_NumberOfTranches_lbl1">Number of tranches</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranches" xlink:to="btx_NumberOfTranches_lbl1" xlink:title="label: NumberOfTranches to btx_NumberOfTranches_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranches_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfTranches_lbl2" xml:lang="en-US" id="btx_NumberOfTranches_lbl2">Number of tranches</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranches" xlink:to="btx_NumberOfTranches_lbl2" xlink:title="label: NumberOfTranches to btx_NumberOfTranches_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:label="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:title="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl" xml:lang="en-US" id="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl">Represents number of tranches related to the attainment of certain product development during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:to="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl" xlink:title="label: NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment to btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl1" xml:lang="en-US" id="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl1">Number of tranches related to the attainment of certain product development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:to="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl1" xlink:title="label: NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment to btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl2" xml:lang="en-US" id="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl2">Number of tranches related to attainment of certain product development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:to="btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl2" xlink:title="label: NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment to btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfInstallmentsForEachTranche" xlink:label="NumberOfInstallmentsForEachTranche" xlink:title="NumberOfInstallmentsForEachTranche" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInstallmentsForEachTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfInstallmentsForEachTranche_lbl" xml:lang="en-US" id="btx_NumberOfInstallmentsForEachTranche_lbl">Represents number of installments for each tranche.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstallmentsForEachTranche" xlink:to="btx_NumberOfInstallmentsForEachTranche_lbl" xlink:title="label: NumberOfInstallmentsForEachTranche to btx_NumberOfInstallmentsForEachTranche_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInstallmentsForEachTranche_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfInstallmentsForEachTranche_lbl1" xml:lang="en-US" id="btx_NumberOfInstallmentsForEachTranche_lbl1">Number of installments for each tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstallmentsForEachTranche" xlink:to="btx_NumberOfInstallmentsForEachTranche_lbl1" xlink:title="label: NumberOfInstallmentsForEachTranche to btx_NumberOfInstallmentsForEachTranche_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInstallmentsForEachTranche_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfInstallmentsForEachTranche_lbl2" xml:lang="en-US" id="btx_NumberOfInstallmentsForEachTranche_lbl2">Number of installments for each tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstallmentsForEachTranche" xlink:to="btx_NumberOfInstallmentsForEachTranche_lbl2" xlink:title="label: NumberOfInstallmentsForEachTranche to btx_NumberOfInstallmentsForEachTranche_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfTradingDays_lbl" xml:lang="en-US" id="btx_NumberOfTradingDays_lbl">Represents number of trading days require for average closing price of BioTime common shares on the NYSE MKT.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="btx_NumberOfTradingDays_lbl" xlink:title="label: NumberOfTradingDays to btx_NumberOfTradingDays_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTradingDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfTradingDays_lbl1" xml:lang="en-US" id="btx_NumberOfTradingDays_lbl1">Number of trading days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="btx_NumberOfTradingDays_lbl1" xlink:title="label: NumberOfTradingDays to btx_NumberOfTradingDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfTradingDays_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfTradingDays_lbl2" xml:lang="en-US" id="btx_NumberOfTradingDays_lbl2">Number of trading days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="btx_NumberOfTradingDays_lbl2" xlink:title="label: NumberOfTradingDays to btx_NumberOfTradingDays_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl1" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl1">Asterias Biotherapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl1" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSolutionsIncMember_lbl" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSolutionsIncMember_lbl1" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl1">LifeMap Solutions, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl1" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LifemapSolutionsIncMember_lbl2" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl2">LifeMap Solutions, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl2" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_RecyteTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RecyteTherapeuticsIncMember_lbl" xml:lang="en-US" id="btx_RecyteTherapeuticsIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecyteTherapeuticsIncMember" xlink:to="btx_RecyteTherapeuticsIncMember_lbl" xlink:title="label: RecyteTherapeuticsIncMember to btx_RecyteTherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RecyteTherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RecyteTherapeuticsIncMember_lbl1" xml:lang="en-US" id="btx_RecyteTherapeuticsIncMember_lbl1">ReCyte Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecyteTherapeuticsIncMember" xlink:to="btx_RecyteTherapeuticsIncMember_lbl1" xlink:title="label: RecyteTherapeuticsIncMember to btx_RecyteTherapeuticsIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_EsCellInternationalPteLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EsCellInternationalPteLtdMember_lbl" xml:lang="en-US" id="btx_EsCellInternationalPteLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EsCellInternationalPteLtdMember" xlink:to="btx_EsCellInternationalPteLtdMember_lbl" xlink:title="label: EsCellInternationalPteLtdMember to btx_EsCellInternationalPteLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EsCellInternationalPteLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EsCellInternationalPteLtdMember_lbl1" xml:lang="en-US" id="btx_EsCellInternationalPteLtdMember_lbl1">ES Cell International Pte., Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EsCellInternationalPteLtdMember" xlink:to="btx_EsCellInternationalPteLtdMember_lbl1" xlink:title="label: EsCellInternationalPteLtdMember to btx_EsCellInternationalPteLtdMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSciencesLtdMember_lbl" xml:lang="en-US" id="btx_LifemapSciencesLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesLtdMember" xlink:to="btx_LifemapSciencesLtdMember_lbl" xlink:title="label: LifemapSciencesLtdMember to btx_LifemapSciencesLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSciencesLtdMember_lbl1" xml:lang="en-US" id="btx_LifemapSciencesLtdMember_lbl1">LifeMap Sciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesLtdMember" xlink:to="btx_LifemapSciencesLtdMember_lbl1" xlink:title="label: LifemapSciencesLtdMember to btx_LifemapSciencesLtdMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSciencesIncMember_lbl" xml:lang="en-US" id="btx_LifemapSciencesIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesIncMember" xlink:to="btx_LifemapSciencesIncMember_lbl" xlink:title="label: LifemapSciencesIncMember to btx_LifemapSciencesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSciencesIncMember_lbl1" xml:lang="en-US" id="btx_LifemapSciencesIncMember_lbl1">LifeMap Sciences, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesIncMember" xlink:to="btx_LifemapSciencesIncMember_lbl1" xlink:title="label: LifemapSciencesIncMember to btx_LifemapSciencesIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OncocyteCorporationMember_lbl" xml:lang="en-US" id="btx_OncocyteCorporationMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteCorporationMember" xlink:to="btx_OncocyteCorporationMember_lbl" xlink:title="label: OncocyteCorporationMember to btx_OncocyteCorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteCorporationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OncocyteCorporationMember_lbl1" xml:lang="en-US" id="btx_OncocyteCorporationMember_lbl1">OncoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteCorporationMember" xlink:to="btx_OncocyteCorporationMember_lbl1" xlink:title="label: OncocyteCorporationMember to btx_OncocyteCorporationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BiotimeAsiaLimitedMember_lbl" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BiotimeAsiaLimitedMember_lbl1" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl1">BioTime Asia, Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl1" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BiotimeAsiaLimitedMember_lbl2" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl2">BioTime Asia, Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl2" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl1" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl1">Cell Cure Neurosciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl1" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl2" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl2">Cell Cure Neurosciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl2" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:label xlink:type="resource" xlink:label="btx_OrthocyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OrthocyteCorporationMember_lbl" xml:lang="en-US" id="btx_OrthocyteCorporationMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrthocyteCorporationMember" xlink:to="btx_OrthocyteCorporationMember_lbl" xlink:title="label: OrthocyteCorporationMember to btx_OrthocyteCorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OrthocyteCorporationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OrthocyteCorporationMember_lbl1" xml:lang="en-US" id="btx_OrthocyteCorporationMember_lbl1">OrthoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrthocyteCorporationMember" xlink:to="btx_OrthocyteCorporationMember_lbl1" xlink:title="label: OrthocyteCorporationMember to btx_OrthocyteCorporationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CommonSharesIssuedForRent" xlink:label="CommonSharesIssuedForRent" xlink:title="CommonSharesIssuedForRent" />
    <link:label xlink:type="resource" xlink:label="btx_CommonSharesIssuedForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommonSharesIssuedForRent_lbl" xml:lang="en-US" id="btx_CommonSharesIssuedForRent_lbl">The fair value of common shares issued for rent in noncash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuedForRent" xlink:to="btx_CommonSharesIssuedForRent_lbl" xlink:title="label: CommonSharesIssuedForRent to btx_CommonSharesIssuedForRent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommonSharesIssuedForRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommonSharesIssuedForRent_lbl1" xml:lang="en-US" id="btx_CommonSharesIssuedForRent_lbl1">Common shares issued for rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuedForRent" xlink:to="btx_CommonSharesIssuedForRent_lbl1" xlink:title="label: CommonSharesIssuedForRent to btx_CommonSharesIssuedForRent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredConsultingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfDeferredConsultingFees_lbl" xml:lang="en-US" id="btx_AmortizationOfDeferredConsultingFees_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred consulting fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredConsultingFees" xlink:to="btx_AmortizationOfDeferredConsultingFees_lbl" xlink:title="label: AmortizationOfDeferredConsultingFees to btx_AmortizationOfDeferredConsultingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredConsultingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfDeferredConsultingFees_lbl1" xml:lang="en-US" id="btx_AmortizationOfDeferredConsultingFees_lbl1">Amortization of deferred consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredConsultingFees" xlink:to="btx_AmortizationOfDeferredConsultingFees_lbl1" xlink:title="label: AmortizationOfDeferredConsultingFees to btx_AmortizationOfDeferredConsultingFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredRent" xlink:label="AmortizationOfDeferredRent" xlink:title="AmortizationOfDeferredRent" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfDeferredRent_lbl" xml:lang="en-US" id="btx_AmortizationOfDeferredRent_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredRent" xlink:to="btx_AmortizationOfDeferredRent_lbl" xlink:title="label: AmortizationOfDeferredRent to btx_AmortizationOfDeferredRent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfDeferredRent_lbl1" xml:lang="en-US" id="btx_AmortizationOfDeferredRent_lbl1">Amortization of deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredRent" xlink:to="btx_AmortizationOfDeferredRent_lbl1" xlink:title="label: AmortizationOfDeferredRent to btx_AmortizationOfDeferredRent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SecurityDepositReceived_lbl" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl">The net cash inflow/(outflow) associated with security deposit received during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SecurityDepositReceived_lbl1" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl1">Security deposit received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl1" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SecurityDepositReceived_lbl2" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl2">Security deposit paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl2" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl">The increase (decrease) during the reporting period for amounts due under the terms of governmental, corporate, or foundation grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl1" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl1">Increase (decrease) in Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl1" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl2" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl2">Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl2" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:label="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:title="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred license fees and royalty fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:to="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl" xlink:title="label: AmortizationOfDeferredLicenseFeesAndRoyaltyFees to btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl1" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl1">Amortization Of Deferred License Fees And Royalty Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:to="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl1" xlink:title="label: AmortizationOfDeferredLicenseFeesAndRoyaltyFees to btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl2" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl2">Amortization of deferred license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:to="btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl2" xlink:title="label: AmortizationOfDeferredLicenseFeesAndRoyaltyFees to btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of amortization of stock based prepaid rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl1">Amortization of Stock Based Prepaid Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl2">Amortization of stock-based prepaid rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromEmployeeOptionsExercised" xlink:label="ProceedsFromEmployeeOptionsExercised" xlink:title="ProceedsFromEmployeeOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromEmployeeOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProceedsFromEmployeeOptionsExercised_lbl" xml:lang="en-US" id="btx_ProceedsFromEmployeeOptionsExercised_lbl">The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromEmployeeOptionsExercised" xlink:to="btx_ProceedsFromEmployeeOptionsExercised_lbl" xlink:title="label: ProceedsFromEmployeeOptionsExercised to btx_ProceedsFromEmployeeOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromEmployeeOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromEmployeeOptionsExercised_lbl1" xml:lang="en-US" id="btx_ProceedsFromEmployeeOptionsExercised_lbl1">Proceeds From Employee Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromEmployeeOptionsExercised" xlink:to="btx_ProceedsFromEmployeeOptionsExercised_lbl1" xlink:title="label: ProceedsFromEmployeeOptionsExercised to btx_ProceedsFromEmployeeOptionsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromEmployeeOptionsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromEmployeeOptionsExercised_lbl2" xml:lang="en-US" id="btx_ProceedsFromEmployeeOptionsExercised_lbl2">Employee options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromEmployeeOptionsExercised" xlink:to="btx_ProceedsFromEmployeeOptionsExercised_lbl2" xlink:title="label: ProceedsFromEmployeeOptionsExercised to btx_ProceedsFromEmployeeOptionsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromDirectorOptionsExcercised" xlink:label="ProceedsFromDirectorOptionsExcercised" xlink:title="ProceedsFromDirectorOptionsExcercised" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDirectorOptionsExcercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProceedsFromDirectorOptionsExcercised_lbl" xml:lang="en-US" id="btx_ProceedsFromDirectorOptionsExcercised_lbl">The cash inflow associated with the amount received from holders exercising their Director options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDirectorOptionsExcercised" xlink:to="btx_ProceedsFromDirectorOptionsExcercised_lbl" xlink:title="label: ProceedsFromDirectorOptionsExcercised to btx_ProceedsFromDirectorOptionsExcercised_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDirectorOptionsExcercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromDirectorOptionsExcercised_lbl1" xml:lang="en-US" id="btx_ProceedsFromDirectorOptionsExcercised_lbl1">Proceeds From Director Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDirectorOptionsExcercised" xlink:to="btx_ProceedsFromDirectorOptionsExcercised_lbl1" xlink:title="label: ProceedsFromDirectorOptionsExcercised to btx_ProceedsFromDirectorOptionsExcercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDirectorOptionsExcercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromDirectorOptionsExcercised_lbl2" xml:lang="en-US" id="btx_ProceedsFromDirectorOptionsExcercised_lbl2">Director options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDirectorOptionsExcercised" xlink:to="btx_ProceedsFromDirectorOptionsExcercised_lbl2" xlink:title="label: ProceedsFromDirectorOptionsExcercised to btx_ProceedsFromDirectorOptionsExcercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl">The cash outflow associated with fee paid on sale of common shares during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl1" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl1">Fees paid on sale of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl1" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl2" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl2">Fees paid on sale of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl2" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:title="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted to btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US" id="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl1">Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl1" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted to btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl2" xml:lang="en-US" id="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl2">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl2" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted to btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2011Member" xlink:label="StockOptionPlan2011Member" xlink:title="StockOptionPlan2011Member" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockOptionPlan2011Member_lbl" xml:lang="en-US" id="btx_StockOptionPlan2011Member_lbl">Name of stock option plan originating in 2011.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2011Member" xlink:to="btx_StockOptionPlan2011Member_lbl" xlink:title="label: StockOptionPlan2011Member to btx_StockOptionPlan2011Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2011Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockOptionPlan2011Member_lbl1" xml:lang="en-US" id="btx_StockOptionPlan2011Member_lbl1">Stock Option Plan 2011 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2011Member" xlink:to="btx_StockOptionPlan2011Member_lbl1" xlink:title="label: StockOptionPlan2011Member to btx_StockOptionPlan2011Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2011Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockOptionPlan2011Member_lbl2" xml:lang="en-US" id="btx_StockOptionPlan2011Member_lbl2">2011 Stock Option Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2011Member" xlink:to="btx_StockOptionPlan2011Member_lbl2" xlink:title="label: StockOptionPlan2011Member to btx_StockOptionPlan2011Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateOutsideFundingTable" xlink:label="PrivateOutsideFundingTable" xlink:title="PrivateOutsideFundingTable" />
    <link:label xlink:type="resource" xlink:label="btx_PrivateOutsideFundingTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrivateOutsideFundingTable_lbl1" xml:lang="en-US" id="btx_PrivateOutsideFundingTable_lbl1">Private Outside Funding [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivateOutsideFundingTable" xlink:to="btx_PrivateOutsideFundingTable_lbl1" xlink:title="label: PrivateOutsideFundingTable to btx_PrivateOutsideFundingTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingAxis" xlink:label="PrivateFundingAxis" xlink:title="PrivateFundingAxis" />
    <link:label xlink:type="resource" xlink:label="btx_PrivateFundingAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrivateFundingAxis_lbl1" xml:lang="en-US" id="btx_PrivateFundingAxis_lbl1">Private Funding [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivateFundingAxis" xlink:to="btx_PrivateFundingAxis_lbl1" xlink:title="label: PrivateFundingAxis to btx_PrivateFundingAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingLineItems" xlink:label="PrivateFundingLineItems" xlink:title="PrivateFundingLineItems" />
    <link:label xlink:type="resource" xlink:label="btx_PrivateFundingLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrivateFundingLineItems_lbl1" xml:lang="en-US" id="btx_PrivateFundingLineItems_lbl1">Private Funding [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivateFundingLineItems" xlink:to="btx_PrivateFundingLineItems_lbl1" xlink:title="label: PrivateFundingLineItems to btx_PrivateFundingLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CashInflowsDomain" xlink:label="CashInflowsDomain" xlink:title="CashInflowsDomain" />
    <link:label xlink:type="resource" xlink:label="btx_CashInflowsDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CashInflowsDomain_lbl1" xml:lang="en-US" id="btx_CashInflowsDomain_lbl1">Cash Inflows [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashInflowsDomain" xlink:to="btx_CashInflowsDomain_lbl1" xlink:title="label: CashInflowsDomain to btx_CashInflowsDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheOneMember" xlink:label="TrancheOneMember" xlink:title="TrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="btx_TrancheOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TrancheOneMember_lbl1" xml:lang="en-US" id="btx_TrancheOneMember_lbl1">Tranche one [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrancheOneMember" xlink:to="btx_TrancheOneMember_lbl1" xlink:title="label: TrancheOneMember to btx_TrancheOneMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheTwoMember" xlink:label="TrancheTwoMember" xlink:title="TrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="btx_TrancheTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TrancheTwoMember_lbl1" xml:lang="en-US" id="btx_TrancheTwoMember_lbl1">Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrancheTwoMember" xlink:to="btx_TrancheTwoMember_lbl1" xlink:title="label: TrancheTwoMember to btx_TrancheTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TrancheTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TrancheTwoMember_lbl2" xml:lang="en-US" id="btx_TrancheTwoMember_lbl2">Tranche two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrancheTwoMember" xlink:to="btx_TrancheTwoMember_lbl2" xlink:title="label: TrancheTwoMember to btx_TrancheTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CertainInvestorsMember" xlink:label="CertainInvestorsMember" xlink:title="CertainInvestorsMember" />
    <link:label xlink:type="resource" xlink:label="btx_CertainInvestorsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CertainInvestorsMember_lbl1" xml:lang="en-US" id="btx_CertainInvestorsMember_lbl1">Certain investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertainInvestorsMember" xlink:to="btx_CertainInvestorsMember_lbl1" xlink:title="label: CertainInvestorsMember to btx_CertainInvestorsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsExercised_lbl" xml:lang="en-US" id="btx_WarrantsExercised_lbl">Number of warrants exercised during the period that is attributable to transactions involving issuance of stock not separately disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsExercised_lbl1" xml:lang="en-US" id="btx_WarrantsExercised_lbl1">Warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl1" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsExercised_lbl2" xml:lang="en-US" id="btx_WarrantsExercised_lbl2">Warrants exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl2" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl">Name of equity incentive plan originating in 2013 plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl1">2013 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EquityIncentivePlanMember_lbl2" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl2">2013 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl2" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2010Member" xlink:label="StockOptionPlan2010Member" xlink:title="StockOptionPlan2010Member" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2010Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockOptionPlan2010Member_lbl" xml:lang="en-US" id="btx_StockOptionPlan2010Member_lbl">Name of stock option plan originating in 2010.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2010Member" xlink:to="btx_StockOptionPlan2010Member_lbl" xlink:title="label: StockOptionPlan2010Member to btx_StockOptionPlan2010Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2010Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockOptionPlan2010Member_lbl1" xml:lang="en-US" id="btx_StockOptionPlan2010Member_lbl1">Stock Option Plan 2010 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2010Member" xlink:to="btx_StockOptionPlan2010Member_lbl1" xlink:title="label: StockOptionPlan2010Member to btx_StockOptionPlan2010Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2010Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockOptionPlan2010Member_lbl2" xml:lang="en-US" id="btx_StockOptionPlan2010Member_lbl2">2010 Stock Option Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2010Member" xlink:to="btx_StockOptionPlan2010Member_lbl2" xlink:title="label: StockOptionPlan2010Member to btx_StockOptionPlan2010Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifeOfWarrants" xlink:label="LifeOfWarrants" xlink:title="LifeOfWarrants" />
    <link:label xlink:type="resource" xlink:label="btx_LifeOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifeOfWarrants_lbl" xml:lang="en-US" id="btx_LifeOfWarrants_lbl">The life of the warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifeOfWarrants" xlink:to="btx_LifeOfWarrants_lbl" xlink:title="label: LifeOfWarrants to btx_LifeOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifeOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifeOfWarrants_lbl1" xml:lang="en-US" id="btx_LifeOfWarrants_lbl1">Period of option agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifeOfWarrants" xlink:to="btx_LifeOfWarrants_lbl1" xlink:title="label: LifeOfWarrants to btx_LifeOfWarrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl">The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl1" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl1">Preferred shares, Convertible, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl1" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl2" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl2">Common stock conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl2" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:label xlink:type="resource" xlink:label="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xml:lang="en-US" id="btx_PricePerShareOfOptionsToPurchaseCompany_lbl">Price of a single share of a number of saleable stocks of a company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PricePerShareOfOptionsToPurchaseCompany" xlink:to="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xlink:title="label: PricePerShareOfOptionsToPurchaseCompany to btx_PricePerShareOfOptionsToPurchaseCompany_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xml:lang="en-US" id="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1">Share conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PricePerShareOfOptionsToPurchaseCompany" xlink:to="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xlink:title="label: PricePerShareOfOptionsToPurchaseCompany to btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesSold" xlink:label="PreferredSharesSold" xlink:title="PreferredSharesSold" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PreferredSharesSold_lbl" xml:lang="en-US" id="btx_PreferredSharesSold_lbl">Total number of preferred shares of an entity that have been sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesSold" xlink:to="btx_PreferredSharesSold_lbl" xlink:title="label: PreferredSharesSold to btx_PreferredSharesSold_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesSold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PreferredSharesSold_lbl1" xml:lang="en-US" id="btx_PreferredSharesSold_lbl1">Preferred shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesSold" xlink:to="btx_PreferredSharesSold_lbl1" xlink:title="label: PreferredSharesSold to btx_PreferredSharesSold_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesSold_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_PreferredSharesSold_lbl2" xml:lang="en-US" id="btx_PreferredSharesSold_lbl2">Preferred shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesSold" xlink:to="btx_PreferredSharesSold_lbl2" xlink:title="label: PreferredSharesSold to btx_PreferredSharesSold_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl">Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1">Trade accounts and grants receivable net current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2">Trade accounts and grants receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseAndConsultingFees_lbl" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFees_lbl">Carrying amounts as of the balance sheet of deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFees" xlink:to="btx_DeferredLicenseAndConsultingFees_lbl" xlink:title="label: DeferredLicenseAndConsultingFees to btx_DeferredLicenseAndConsultingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseAndConsultingFees_lbl1" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFees_lbl1">Deferred license and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFees" xlink:to="btx_DeferredLicenseAndConsultingFees_lbl1" xlink:title="label: DeferredLicenseAndConsultingFees to btx_DeferredLicenseAndConsultingFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:label="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl">Tabular disclosure of the estimated aggregate amortization expense for deferred license fees subject to amortization for each of the five succeeding fiscal years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1">Schedule Of Expected Amortization Deferred License Expense [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2">Amortization of deferred license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TreasuryStockPolicyTextBlock" xlink:label="TreasuryStockPolicyTextBlock" xlink:title="TreasuryStockPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl">Disclosure of accounting policy for an entity's treasury stock, including common shares issued to subsidiaries for future potential working capital needs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl1" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl1">Treasury stock [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl1" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl2" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl2">Treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl2" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:label="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:title="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl">Disclosure of accounting policy for certain significant risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:to="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:title="label: CertainSignificantRisksAndUncertaintiesPolicyTextBlock to btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl1" xml:lang="en-US" id="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl1">Certain significant risks and uncertainties [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:to="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl1" xlink:title="label: CertainSignificantRisksAndUncertaintiesPolicyTextBlock to btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl2" xml:lang="en-US" id="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl2">Certain significant risks and uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:to="btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl2" xlink:title="label: CertainSignificantRisksAndUncertaintiesPolicyTextBlock to btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:label="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="WarrantsToPurchaseCommonStockPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl">Disclosure of accounting policy for an entity's warrants to purchase common stock, including common shares issued to subsidiaries for future potential working capital needs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1">Warrants to purchase common stock [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteLicenseFromSbmriMember" xlink:label="OncocyteLicenseFromSbmriMember" xlink:title="OncocyteLicenseFromSbmriMember" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteLicenseFromSbmriMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OncocyteLicenseFromSbmriMember_lbl" xml:lang="en-US" id="btx_OncocyteLicenseFromSbmriMember_lbl">Stem cell agreement with reproductive genetics institutes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteLicenseFromSbmriMember" xlink:to="btx_OncocyteLicenseFromSbmriMember_lbl" xlink:title="label: OncocyteLicenseFromSbmriMember to btx_OncocyteLicenseFromSbmriMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteLicenseFromSbmriMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OncocyteLicenseFromSbmriMember_lbl1" xml:lang="en-US" id="btx_OncocyteLicenseFromSbmriMember_lbl1">OncoCyte License From SBMRI [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteLicenseFromSbmriMember" xlink:to="btx_OncocyteLicenseFromSbmriMember_lbl1" xlink:title="label: OncocyteLicenseFromSbmriMember to btx_OncocyteLicenseFromSbmriMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIMember" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl">ReCyte Therapeutics (subsidiary) agreement that permits the commercialization of products in human therapeutic and diagnostic product markets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:to="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl" xlink:title="label: AdvancedCellTechnologyIncWithKirinSublicenseIMember to btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl1" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl1">Advanced Cell Technology Inc., with Kirin Sublicense I [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:to="btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl1" xlink:title="label: AdvancedCellTechnologyIncWithKirinSublicenseIMember to btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl">ReCyte Therapeutics (subsidiary) agreement that permits the commercialization of products in human therapeutic and diagnostic product markets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:to="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl" xlink:title="label: AdvancedCellTechnologyIncWithKirinSublicenseIiMember to btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl1" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl1">Advanced Cell Technology Inc., with Kirin Sublicense II [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:to="btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl1" xlink:title="label: AdvancedCellTechnologyIncWithKirinSublicenseIiMember to btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarfMember" xlink:label="WarfMember" xlink:title="WarfMember" />
    <link:label xlink:type="resource" xlink:label="btx_WarfMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarfMember_lbl" xml:lang="en-US" id="btx_WarfMember_lbl">BioTime commercial license and option agreement with Wisconsin Alumni Research Foundation (WARF).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarfMember" xlink:to="btx_WarfMember_lbl" xlink:title="label: WarfMember to btx_WarfMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarfMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarfMember_lbl1" xml:lang="en-US" id="btx_WarfMember_lbl1">WARF [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarfMember" xlink:to="btx_WarfMember_lbl1" xlink:title="label: WarfMember to btx_WarfMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReproductiveGeneticsInstituteMember" xlink:label="ReproductiveGeneticsInstituteMember" xlink:title="ReproductiveGeneticsInstituteMember" />
    <link:label xlink:type="resource" xlink:label="btx_ReproductiveGeneticsInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ReproductiveGeneticsInstituteMember_lbl" xml:lang="en-US" id="btx_ReproductiveGeneticsInstituteMember_lbl">ReCyte Therapeutics (subsidiary) stem cell agreement with reproductive genetics institute.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReproductiveGeneticsInstituteMember" xlink:to="btx_ReproductiveGeneticsInstituteMember_lbl" xlink:title="label: ReproductiveGeneticsInstituteMember to btx_ReproductiveGeneticsInstituteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ReproductiveGeneticsInstituteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ReproductiveGeneticsInstituteMember_lbl1" xml:lang="en-US" id="btx_ReproductiveGeneticsInstituteMember_lbl1">Reproductive Genetics Institute [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReproductiveGeneticsInstituteMember" xlink:to="btx_ReproductiveGeneticsInstituteMember_lbl1" xlink:title="label: ReproductiveGeneticsInstituteMember to btx_ReproductiveGeneticsInstituteMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncMember" xlink:label="AdvancedCellTechnologyIncMember" xlink:title="AdvancedCellTechnologyIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdvancedCellTechnologyIncMember_lbl" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncMember_lbl">ReCyte Therapeutics (subsidiary) license agreement with Advanced Cell Technology, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncMember" xlink:to="btx_AdvancedCellTechnologyIncMember_lbl" xlink:title="label: AdvancedCellTechnologyIncMember to btx_AdvancedCellTechnologyIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdvancedCellTechnologyIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdvancedCellTechnologyIncMember_lbl1" xml:lang="en-US" id="btx_AdvancedCellTechnologyIncMember_lbl1">Advanced Cell Technology, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvancedCellTechnologyIncMember" xlink:to="btx_AdvancedCellTechnologyIncMember_lbl1" xlink:title="label: AdvancedCellTechnologyIncMember to btx_AdvancedCellTechnologyIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualMinimumRoyaltyDue" xlink:label="AnnualMinimumRoyaltyDue" xlink:title="AnnualMinimumRoyaltyDue" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualMinimumRoyaltyDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AnnualMinimumRoyaltyDue_lbl" xml:lang="en-US" id="btx_AnnualMinimumRoyaltyDue_lbl">The minimum amount of annual royalty due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualMinimumRoyaltyDue" xlink:to="btx_AnnualMinimumRoyaltyDue_lbl" xlink:title="label: AnnualMinimumRoyaltyDue to btx_AnnualMinimumRoyaltyDue_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualMinimumRoyaltyDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AnnualMinimumRoyaltyDue_lbl1" xml:lang="en-US" id="btx_AnnualMinimumRoyaltyDue_lbl1">Annual minimum royalty due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualMinimumRoyaltyDue" xlink:to="btx_AnnualMinimumRoyaltyDue_lbl1" xlink:title="label: AnnualMinimumRoyaltyDue to btx_AnnualMinimumRoyaltyDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RoyaltyPercentage_lbl" xml:lang="en-US" id="btx_RoyaltyPercentage_lbl">The percentage of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="btx_RoyaltyPercentage_lbl" xlink:title="label: RoyaltyPercentage to btx_RoyaltyPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RoyaltyPercentage_lbl1" xml:lang="en-US" id="btx_RoyaltyPercentage_lbl1">Royalty, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="btx_RoyaltyPercentage_lbl1" xlink:title="label: RoyaltyPercentage to btx_RoyaltyPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RoyaltyPercentage_lbl2" xml:lang="en-US" id="btx_RoyaltyPercentage_lbl2">Royalty rate on sale of products and services (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="btx_RoyaltyPercentage_lbl2" xlink:title="label: RoyaltyPercentage to btx_RoyaltyPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LicenseFeeAmountPaid" xlink:label="LicenseFeeAmountPaid" xlink:title="LicenseFeeAmountPaid" />
    <link:label xlink:type="resource" xlink:label="btx_LicenseFeeAmountPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LicenseFeeAmountPaid_lbl" xml:lang="en-US" id="btx_LicenseFeeAmountPaid_lbl">The total amount paid related to license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeAmountPaid" xlink:to="btx_LicenseFeeAmountPaid_lbl" xlink:title="label: LicenseFeeAmountPaid to btx_LicenseFeeAmountPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LicenseFeeAmountPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LicenseFeeAmountPaid_lbl1" xml:lang="en-US" id="btx_LicenseFeeAmountPaid_lbl1">License Fee, Amount Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeAmountPaid" xlink:to="btx_LicenseFeeAmountPaid_lbl1" xlink:title="label: LicenseFeeAmountPaid to btx_LicenseFeeAmountPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LicenseFeeAmountPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LicenseFeeAmountPaid_lbl2" xml:lang="en-US" id="btx_LicenseFeeAmountPaid_lbl2">Licensing fees paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeAmountPaid" xlink:to="btx_LicenseFeeAmountPaid_lbl2" xlink:title="label: LicenseFeeAmountPaid to btx_LicenseFeeAmountPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyMaximumPayment" xlink:label="RoyaltyMaximumPayment" xlink:title="RoyaltyMaximumPayment" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyMaximumPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RoyaltyMaximumPayment_lbl" xml:lang="en-US" id="btx_RoyaltyMaximumPayment_lbl">Maximum amount of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyMaximumPayment" xlink:to="btx_RoyaltyMaximumPayment_lbl" xlink:title="label: RoyaltyMaximumPayment to btx_RoyaltyMaximumPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyMaximumPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RoyaltyMaximumPayment_lbl1" xml:lang="en-US" id="btx_RoyaltyMaximumPayment_lbl1">Royalty, Maximum Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyMaximumPayment" xlink:to="btx_RoyaltyMaximumPayment_lbl1" xlink:title="label: RoyaltyMaximumPayment to btx_RoyaltyMaximumPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyMaximumPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RoyaltyMaximumPayment_lbl2" xml:lang="en-US" id="btx_RoyaltyMaximumPayment_lbl2">Maximum royalty payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyMaximumPayment" xlink:to="btx_RoyaltyMaximumPayment_lbl2" xlink:title="label: RoyaltyMaximumPayment to btx_RoyaltyMaximumPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualLicenseMaintenanceFee" xlink:label="AnnualLicenseMaintenanceFee" xlink:title="AnnualLicenseMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US" id="btx_AnnualLicenseMaintenanceFee_lbl">Annual payment related to license maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualLicenseMaintenanceFee" xlink:to="btx_AnnualLicenseMaintenanceFee_lbl" xlink:title="label: AnnualLicenseMaintenanceFee to btx_AnnualLicenseMaintenanceFee_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualLicenseMaintenanceFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AnnualLicenseMaintenanceFee_lbl1" xml:lang="en-US" id="btx_AnnualLicenseMaintenanceFee_lbl1">Annual License Maintenance Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualLicenseMaintenanceFee" xlink:to="btx_AnnualLicenseMaintenanceFee_lbl1" xlink:title="label: AnnualLicenseMaintenanceFee to btx_AnnualLicenseMaintenanceFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualLicenseMaintenanceFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AnnualLicenseMaintenanceFee_lbl2" xml:lang="en-US" id="btx_AnnualLicenseMaintenanceFee_lbl2">Annual license maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualLicenseMaintenanceFee" xlink:to="btx_AnnualLicenseMaintenanceFee_lbl2" xlink:title="label: AnnualLicenseMaintenanceFee to btx_AnnualLicenseMaintenanceFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl">Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1">Deferred License Fees Amortization Expense Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl">Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1">Deferred License Fees Amortization Expense Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLicenseFromHadasitMember" xlink:label="CellCureNeurosciencesLicenseFromHadasitMember" xlink:title="CellCureNeurosciencesLicenseFromHadasitMember" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl" xml:lang="en-US" id="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl">Acquisition of the assets for cell targeting, inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLicenseFromHadasitMember" xlink:to="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl" xlink:title="label: CellCureNeurosciencesLicenseFromHadasitMember to btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl1" xml:lang="en-US" id="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl1">Cell Cure Neurosciences License From Hadasit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLicenseFromHadasitMember" xlink:to="btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl1" xlink:title="label: CellCureNeurosciencesLicenseFromHadasitMember to btx_CellCureNeurosciencesLicenseFromHadasitMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl">Amount of amortization expense expected to be recognized after the fifth fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1">Deferred License Fees Amortization Expense After Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl">Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1">Deferred License Fees Amortization Expense Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmendedLicenseAgreementAmount" xlink:label="AmendedLicenseAgreementAmount" xlink:title="AmendedLicenseAgreementAmount" />
    <link:label xlink:type="resource" xlink:label="btx_AmendedLicenseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmendedLicenseAgreementAmount_lbl" xml:lang="en-US" id="btx_AmendedLicenseAgreementAmount_lbl">Refers to amended license agreement amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedLicenseAgreementAmount" xlink:to="btx_AmendedLicenseAgreementAmount_lbl" xlink:title="label: AmendedLicenseAgreementAmount to btx_AmendedLicenseAgreementAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmendedLicenseAgreementAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmendedLicenseAgreementAmount_lbl1" xml:lang="en-US" id="btx_AmendedLicenseAgreementAmount_lbl1">Amended License Agreement Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedLicenseAgreementAmount" xlink:to="btx_AmendedLicenseAgreementAmount_lbl1" xlink:title="label: AmendedLicenseAgreementAmount to btx_AmendedLicenseAgreementAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmendedLicenseAgreementAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmendedLicenseAgreementAmount_lbl2" xml:lang="en-US" id="btx_AmendedLicenseAgreementAmount_lbl2">Amended license agreement amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedLicenseAgreementAmount" xlink:to="btx_AmendedLicenseAgreementAmount_lbl2" xlink:title="label: AmendedLicenseAgreementAmount to btx_AmendedLicenseAgreementAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForSublicensePercentage" xlink:label="FeesForSublicensePercentage" xlink:title="FeesForSublicensePercentage" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForSublicensePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FeesForSublicensePercentage_lbl" xml:lang="en-US" id="btx_FeesForSublicensePercentage_lbl">Percentage of fees for sublicense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForSublicensePercentage" xlink:to="btx_FeesForSublicensePercentage_lbl" xlink:title="label: FeesForSublicensePercentage to btx_FeesForSublicensePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForSublicensePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FeesForSublicensePercentage_lbl1" xml:lang="en-US" id="btx_FeesForSublicensePercentage_lbl1">Fees for sublicense, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForSublicensePercentage" xlink:to="btx_FeesForSublicensePercentage_lbl1" xlink:title="label: FeesForSublicensePercentage to btx_FeesForSublicensePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForSublicensePercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_FeesForSublicensePercentage_lbl2" xml:lang="en-US" id="btx_FeesForSublicensePercentage_lbl2">Fees for sublicense (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForSublicensePercentage" xlink:to="btx_FeesForSublicensePercentage_lbl2" xlink:title="label: FeesForSublicensePercentage to btx_FeesForSublicensePercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:label="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl">Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseNextTwelveMonths to btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl1">Deferred License Fees Amortization Expense Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseNextTwelveMonths to btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl2">2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseNextTwelveMonths to btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TevaLicenseAgreementMember" xlink:label="TevaLicenseAgreementMember" xlink:title="TevaLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_TevaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TevaLicenseAgreementMember_lbl" xml:lang="en-US" id="btx_TevaLicenseAgreementMember_lbl">Research and exclusive License option agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TevaLicenseAgreementMember" xlink:to="btx_TevaLicenseAgreementMember_lbl" xlink:title="label: TevaLicenseAgreementMember to btx_TevaLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TevaLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TevaLicenseAgreementMember_lbl1" xml:lang="en-US" id="btx_TevaLicenseAgreementMember_lbl1">Teva License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TevaLicenseAgreementMember" xlink:to="btx_TevaLicenseAgreementMember_lbl1" xlink:title="label: TevaLicenseAgreementMember to btx_TevaLicenseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeLicenseForUniversityOfUtahMember" xlink:label="BiotimeLicenseForUniversityOfUtahMember" xlink:title="BiotimeLicenseForUniversityOfUtahMember" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeLicenseForUniversityOfUtahMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BiotimeLicenseForUniversityOfUtahMember_lbl" xml:lang="en-US" id="btx_BiotimeLicenseForUniversityOfUtahMember_lbl">License from the university of Utah.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeLicenseForUniversityOfUtahMember" xlink:to="btx_BiotimeLicenseForUniversityOfUtahMember_lbl" xlink:title="label: BiotimeLicenseForUniversityOfUtahMember to btx_BiotimeLicenseForUniversityOfUtahMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeLicenseForUniversityOfUtahMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BiotimeLicenseForUniversityOfUtahMember_lbl1" xml:lang="en-US" id="btx_BiotimeLicenseForUniversityOfUtahMember_lbl1">BioTime License For The University of Utah [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeLicenseForUniversityOfUtahMember" xlink:to="btx_BiotimeLicenseForUniversityOfUtahMember_lbl1" xlink:title="label: BiotimeLicenseForUniversityOfUtahMember to btx_BiotimeLicenseForUniversityOfUtahMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasLicenseUniversityOfCaliforniaMember" xlink:label="AsteriasLicenseUniversityOfCaliforniaMember" xlink:title="AsteriasLicenseUniversityOfCaliforniaMember" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl" xml:lang="en-US" id="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl">Exclusive agreement with the regents of the university of California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasLicenseUniversityOfCaliforniaMember" xlink:to="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl" xlink:title="label: AsteriasLicenseUniversityOfCaliforniaMember to btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl1" xml:lang="en-US" id="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl1">Asterias License, University of California [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasLicenseUniversityOfCaliforniaMember" xlink:to="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl1" xlink:title="label: AsteriasLicenseUniversityOfCaliforniaMember to btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl2" xml:lang="en-US" id="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl2">Asterias License From University of California [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasLicenseUniversityOfCaliforniaMember" xlink:to="btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl2" xlink:title="label: AsteriasLicenseUniversityOfCaliforniaMember to btx_AsteriasLicenseUniversityOfCaliforniaMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasSublicenseFromGeronMember" xlink:label="AsteriasSublicenseFromGeronMember" xlink:title="AsteriasSublicenseFromGeronMember" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasSublicenseFromGeronMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AsteriasSublicenseFromGeronMember_lbl" xml:lang="en-US" id="btx_AsteriasSublicenseFromGeronMember_lbl">Exclusive sublicense under certain patents owned by the university of Colorado's university license equity holdings, inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasSublicenseFromGeronMember" xlink:to="btx_AsteriasSublicenseFromGeronMember_lbl" xlink:title="label: AsteriasSublicenseFromGeronMember to btx_AsteriasSublicenseFromGeronMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasSublicenseFromGeronMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AsteriasSublicenseFromGeronMember_lbl1" xml:lang="en-US" id="btx_AsteriasSublicenseFromGeronMember_lbl1">Asterias Sublicense From Geron [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasSublicenseFromGeronMember" xlink:to="btx_AsteriasSublicenseFromGeronMember_lbl1" xlink:title="label: AsteriasSublicenseFromGeronMember to btx_AsteriasSublicenseFromGeronMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NoticePeriodToTerminateAgreement" xlink:label="NoticePeriodToTerminateAgreement" xlink:title="NoticePeriodToTerminateAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_NoticePeriodToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NoticePeriodToTerminateAgreement_lbl" xml:lang="en-US" id="btx_NoticePeriodToTerminateAgreement_lbl">The notice period to be given in order to terminate agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodToTerminateAgreement" xlink:to="btx_NoticePeriodToTerminateAgreement_lbl" xlink:title="label: NoticePeriodToTerminateAgreement to btx_NoticePeriodToTerminateAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NoticePeriodToTerminateAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NoticePeriodToTerminateAgreement_lbl1" xml:lang="en-US" id="btx_NoticePeriodToTerminateAgreement_lbl1">Notice period to terminate agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodToTerminateAgreement" xlink:to="btx_NoticePeriodToTerminateAgreement_lbl1" xlink:title="label: NoticePeriodToTerminateAgreement to btx_NoticePeriodToTerminateAgreement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseAxis" xlink:label="PaymentPhaseAxis" xlink:title="PaymentPhaseAxis" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentPhaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentPhaseAxis_lbl" xml:lang="en-US" id="btx_PaymentPhaseAxis_lbl">Disclosure of payments for each clinical phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentPhaseAxis" xlink:to="btx_PaymentPhaseAxis_lbl" xlink:title="label: PaymentPhaseAxis to btx_PaymentPhaseAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentPhaseAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentPhaseAxis_lbl1" xml:lang="en-US" id="btx_PaymentPhaseAxis_lbl1">Payment Phase [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentPhaseAxis" xlink:to="btx_PaymentPhaseAxis_lbl1" xlink:title="label: PaymentPhaseAxis to btx_PaymentPhaseAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseDomain" xlink:label="PaymentPhaseDomain" xlink:title="PaymentPhaseDomain" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentPhaseDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentPhaseDomain_lbl" xml:lang="en-US" id="btx_PaymentPhaseDomain_lbl">Disclosure of payments for each clinical phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentPhaseDomain" xlink:to="btx_PaymentPhaseDomain_lbl" xlink:title="label: PaymentPhaseDomain to btx_PaymentPhaseDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentPhaseDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentPhaseDomain_lbl1" xml:lang="en-US" id="btx_PaymentPhaseDomain_lbl1">Payment Phase [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentPhaseDomain" xlink:to="btx_PaymentPhaseDomain_lbl1" xlink:title="label: PaymentPhaseDomain to btx_PaymentPhaseDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:label="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:title="ReductionForAnyPatentThatHaveLicensedTwoOrMore" />
    <link:label xlink:type="resource" xlink:label="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl" xml:lang="en-US" id="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl">Reduction in payment granted to any patent that licensed two or more sublicenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:to="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl" xlink:title="label: ReductionForAnyPatentThatHaveLicensedTwoOrMore to btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl1" xml:lang="en-US" id="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl1">Reduction for any patent that have licensed two or more</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:to="btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl1" xlink:title="label: ReductionForAnyPatentThatHaveLicensedTwoOrMore to btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIClinicalMember" xlink:label="PhaseIClinicalMember" xlink:title="PhaseIClinicalMember" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PhaseIClinicalMember_lbl" xml:lang="en-US" id="btx_PhaseIClinicalMember_lbl">Disclosure of payments for each clinical phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIClinicalMember" xlink:to="btx_PhaseIClinicalMember_lbl" xlink:title="label: PhaseIClinicalMember to btx_PhaseIClinicalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIClinicalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PhaseIClinicalMember_lbl1" xml:lang="en-US" id="btx_PhaseIClinicalMember_lbl1">Phase I Clinical [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIClinicalMember" xlink:to="btx_PhaseIClinicalMember_lbl1" xlink:title="label: PhaseIClinicalMember to btx_PhaseIClinicalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiClinicalMember" xlink:label="PhaseIiClinicalMember" xlink:title="PhaseIiClinicalMember" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIiClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PhaseIiClinicalMember_lbl" xml:lang="en-US" id="btx_PhaseIiClinicalMember_lbl">Disclosure of payments for each clinical phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIiClinicalMember" xlink:to="btx_PhaseIiClinicalMember_lbl" xlink:title="label: PhaseIiClinicalMember to btx_PhaseIiClinicalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIiClinicalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PhaseIiClinicalMember_lbl1" xml:lang="en-US" id="btx_PhaseIiClinicalMember_lbl1">Phase II Clinical [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIiClinicalMember" xlink:to="btx_PhaseIiClinicalMember_lbl1" xlink:title="label: PhaseIiClinicalMember to btx_PhaseIiClinicalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiiClinicalMember" xlink:label="PhaseIiiClinicalMember" xlink:title="PhaseIiiClinicalMember" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIiiClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PhaseIiiClinicalMember_lbl" xml:lang="en-US" id="btx_PhaseIiiClinicalMember_lbl">Disclosure of payments for each clinical phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIiiClinicalMember" xlink:to="btx_PhaseIiiClinicalMember_lbl" xlink:title="label: PhaseIiiClinicalMember to btx_PhaseIiiClinicalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PhaseIiiClinicalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PhaseIiiClinicalMember_lbl1" xml:lang="en-US" id="btx_PhaseIiiClinicalMember_lbl1">Phase III Clinical [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseIiiClinicalMember" xlink:to="btx_PhaseIiiClinicalMember_lbl1" xlink:title="label: PhaseIiiClinicalMember to btx_PhaseIiiClinicalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentUponIssuanceOfFirstFiveLicense" xlink:label="PaymentUponIssuanceOfFirstFiveLicense" xlink:title="PaymentUponIssuanceOfFirstFiveLicense" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl" xml:lang="en-US" id="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl">The amount of payment to be made upon issuance of first five licenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentUponIssuanceOfFirstFiveLicense" xlink:to="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl" xlink:title="label: PaymentUponIssuanceOfFirstFiveLicense to btx_PaymentUponIssuanceOfFirstFiveLicense_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl1" xml:lang="en-US" id="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl1">Payment upon issuance of first five license</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentUponIssuanceOfFirstFiveLicense" xlink:to="btx_PaymentUponIssuanceOfFirstFiveLicense_lbl1" xlink:title="label: PaymentUponIssuanceOfFirstFiveLicense to btx_PaymentUponIssuanceOfFirstFiveLicense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MinimumRoyaltyAmountEachYearAndThereafter" xlink:label="MinimumRoyaltyAmountEachYearAndThereafter" xlink:title="MinimumRoyaltyAmountEachYearAndThereafter" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl" xml:lang="en-US" id="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl">Minimum royalty payable each year and thereafter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumRoyaltyAmountEachYearAndThereafter" xlink:to="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl" xlink:title="label: MinimumRoyaltyAmountEachYearAndThereafter to btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl1" xml:lang="en-US" id="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl1">Minimum royalty amount each year and thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumRoyaltyAmountEachYearAndThereafter" xlink:to="btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl1" xlink:title="label: MinimumRoyaltyAmountEachYearAndThereafter to btx_MinimumRoyaltyAmountEachYearAndThereafter_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SublicensingReceiptsForCreditableMilestonePayments" xlink:label="SublicensingReceiptsForCreditableMilestonePayments" xlink:title="SublicensingReceiptsForCreditableMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl" xml:lang="en-US" id="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl">Receipts from sublicensing creditable milestone payments per the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicensingReceiptsForCreditableMilestonePayments" xlink:to="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl" xlink:title="label: SublicensingReceiptsForCreditableMilestonePayments to btx_SublicensingReceiptsForCreditableMilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl1" xml:lang="en-US" id="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl1">Sublicensing receipts for creditable milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicensingReceiptsForCreditableMilestonePayments" xlink:to="btx_SublicensingReceiptsForCreditableMilestonePayments_lbl1" xlink:title="label: SublicensingReceiptsForCreditableMilestonePayments to btx_SublicensingReceiptsForCreditableMilestonePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:label xlink:type="resource" xlink:label="btx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MilestonePayments_lbl" xml:lang="en-US" id="btx_MilestonePayments_lbl">Payment made in phases per the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="btx_MilestonePayments_lbl" xlink:title="label: MilestonePayments to btx_MilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MilestonePayments_lbl1" xml:lang="en-US" id="btx_MilestonePayments_lbl1">Milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="btx_MilestonePayments_lbl1" xlink:title="label: MilestonePayments to btx_MilestonePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReimbursementToSbmriForCostIncurredInHundredths" xlink:label="ReimbursementToSbmriForCostIncurredInHundredths" xlink:title="ReimbursementToSbmriForCostIncurredInHundredths" />
    <link:label xlink:type="resource" xlink:label="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl" xml:lang="en-US" id="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl">Amount reimbursed for cost incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursementToSbmriForCostIncurredInHundredths" xlink:to="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl" xlink:title="label: ReimbursementToSbmriForCostIncurredInHundredths to btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl1" xml:lang="en-US" id="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl1">Reimbursement to SBMRI for cost incurred (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursementToSbmriForCostIncurredInHundredths" xlink:to="btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl1" xlink:title="label: ReimbursementToSbmriForCostIncurredInHundredths to btx_ReimbursementToSbmriForCostIncurredInHundredths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionInRoyalties" xlink:label="ReductionInRoyalties" xlink:title="ReductionInRoyalties" />
    <link:label xlink:type="resource" xlink:label="btx_ReductionInRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ReductionInRoyalties_lbl" xml:lang="en-US" id="btx_ReductionInRoyalties_lbl">Reduction in royalty fees as applicable to the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReductionInRoyalties" xlink:to="btx_ReductionInRoyalties_lbl" xlink:title="label: ReductionInRoyalties to btx_ReductionInRoyalties_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ReductionInRoyalties_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ReductionInRoyalties_lbl1" xml:lang="en-US" id="btx_ReductionInRoyalties_lbl1">Reduction in royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReductionInRoyalties" xlink:to="btx_ReductionInRoyalties_lbl1" xlink:title="label: ReductionInRoyalties to btx_ReductionInRoyalties_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ReductionInRoyalties_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ReductionInRoyalties_lbl2" xml:lang="en-US" id="btx_ReductionInRoyalties_lbl2">Reduction in royalties (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReductionInRoyalties" xlink:to="btx_ReductionInRoyalties_lbl2" xlink:title="label: ReductionInRoyalties to btx_ReductionInRoyalties_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForResearchUse" xlink:label="FeesForResearchUse" xlink:title="FeesForResearchUse" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForResearchUse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FeesForResearchUse_lbl" xml:lang="en-US" id="btx_FeesForResearchUse_lbl">The percentage fee for the use of research findings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForResearchUse" xlink:to="btx_FeesForResearchUse_lbl" xlink:title="label: FeesForResearchUse to btx_FeesForResearchUse_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForResearchUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FeesForResearchUse_lbl1" xml:lang="en-US" id="btx_FeesForResearchUse_lbl1">Fees for research use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForResearchUse" xlink:to="btx_FeesForResearchUse_lbl1" xlink:title="label: FeesForResearchUse to btx_FeesForResearchUse_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FeesForResearchUse_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_FeesForResearchUse_lbl2" xml:lang="en-US" id="btx_FeesForResearchUse_lbl2">Fees for research use (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesForResearchUse" xlink:to="btx_FeesForResearchUse_lbl2" xlink:title="label: FeesForResearchUse to btx_FeesForResearchUse_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="btx_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="btx_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to btx_DocumentAndEntityInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:label="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl" xml:lang="en-US" id="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl">Tabular disclosure of the assets acquired and related consideration recorded under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl" xlink:title="label: AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xml:lang="en-US" id="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl1">Assets Acquired and Related Consideration recorded [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xlink:title="label: AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xml:lang="en-US" id="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl2">Assets Acquired from Geron and Related Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xlink:title="label: AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:label="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl" xml:lang="en-US" id="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl">Tabular disclosure of the assets transferred and related consideration recorded under the asset contribution agreement..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl" xlink:title="label: AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xml:lang="en-US" id="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl1">Assets Transferred and Related Consideration Recorded [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl1" xlink:title="label: AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xml:lang="en-US" id="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl2">Assets Transferred by BioTime and Related Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:to="btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl2" xlink:title="label: AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock to btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementTable" xlink:label="AssetContributionAgreementTable" xlink:title="AssetContributionAgreementTable" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetContributionAgreementTable_lbl" xml:lang="en-US" id="btx_AssetContributionAgreementTable_lbl">A table or schedule providing information pertaining to Asset Contribution Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementTable" xlink:to="btx_AssetContributionAgreementTable_lbl" xlink:title="label: AssetContributionAgreementTable to btx_AssetContributionAgreementTable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetContributionAgreementTable_lbl1" xml:lang="en-US" id="btx_AssetContributionAgreementTable_lbl1">Asset Contribution Agreement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementTable" xlink:to="btx_AssetContributionAgreementTable_lbl1" xlink:title="label: AssetContributionAgreementTable to btx_AssetContributionAgreementTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_Warrants1Member" xlink:label="Warrants1Member" xlink:title="Warrants1Member" />
    <link:label xlink:type="resource" xlink:label="btx_Warrants1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_Warrants1Member_lbl" xml:lang="en-US" id="btx_Warrants1Member_lbl">Warrants to purchase stock at a contracted price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants1Member" xlink:to="btx_Warrants1Member_lbl" xlink:title="label: Warrants1Member to btx_Warrants1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_Warrants1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_Warrants1Member_lbl1" xml:lang="en-US" id="btx_Warrants1Member_lbl1">Warrants1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants1Member" xlink:to="btx_Warrants1Member_lbl1" xlink:title="label: Warrants1Member to btx_Warrants1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_Warrants1Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_Warrants1Member_lbl2" xml:lang="en-US" id="btx_Warrants1Member_lbl2">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants1Member" xlink:to="btx_Warrants1Member_lbl2" xlink:title="label: Warrants1Member to btx_Warrants1Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:label="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="IprAndDExpensedUponAcquisitionAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl">Amount of IPR and D expensed upon acquisition under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:to="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl" xlink:title="label: IprAndDExpensedUponAcquisitionAssetContributionAgreement to btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl1">IPR and D expensed upon acquisition, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:to="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl1" xlink:title="label: IprAndDExpensedUponAcquisitionAssetContributionAgreement to btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl2">IPR&amp;D expensed upon acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:to="btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl2" xlink:title="label: IprAndDExpensedUponAcquisitionAssetContributionAgreement to btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantExpirationTerm" xlink:label="WarrantExpirationTerm" xlink:title="WarrantExpirationTerm" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantExpirationTerm_lbl" xml:lang="en-US" id="btx_WarrantExpirationTerm_lbl">Period in which warrant issued expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExpirationTerm" xlink:to="btx_WarrantExpirationTerm_lbl" xlink:title="label: WarrantExpirationTerm to btx_WarrantExpirationTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantExpirationTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantExpirationTerm_lbl1" xml:lang="en-US" id="btx_WarrantExpirationTerm_lbl1">Warrant Expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExpirationTerm" xlink:to="btx_WarrantExpirationTerm_lbl1" xlink:title="label: WarrantExpirationTerm to btx_WarrantExpirationTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantExpirationTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantExpirationTerm_lbl2" xml:lang="en-US" id="btx_WarrantExpirationTerm_lbl2">Warrant expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExpirationTerm" xlink:to="btx_WarrantExpirationTerm_lbl2" xlink:title="label: WarrantExpirationTerm to btx_WarrantExpirationTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:label="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl">Total assets and in process research and development acquired under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl" xlink:title="label: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl1">Total assets and in process research and development acquired, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl1" xlink:title="label: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl2">Total assets and in-process research and development acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:to="btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl2" xlink:title="label: TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement to btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MarketValueOfBiotimeCommonShares" xlink:label="MarketValueOfBiotimeCommonShares" xlink:title="MarketValueOfBiotimeCommonShares" />
    <link:label xlink:type="resource" xlink:label="btx_MarketValueOfBiotimeCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MarketValueOfBiotimeCommonShares_lbl" xml:lang="en-US" id="btx_MarketValueOfBiotimeCommonShares_lbl">This line item represents the market value of the common stock at the end of the day trading on the NYSE.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketValueOfBiotimeCommonShares" xlink:to="btx_MarketValueOfBiotimeCommonShares_lbl" xlink:title="label: MarketValueOfBiotimeCommonShares to btx_MarketValueOfBiotimeCommonShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MarketValueOfBiotimeCommonShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MarketValueOfBiotimeCommonShares_lbl1" xml:lang="en-US" id="btx_MarketValueOfBiotimeCommonShares_lbl1">Market Value of BioTime Common Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketValueOfBiotimeCommonShares" xlink:to="btx_MarketValueOfBiotimeCommonShares_lbl1" xlink:title="label: MarketValueOfBiotimeCommonShares to btx_MarketValueOfBiotimeCommonShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MarketValueOfBiotimeCommonShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_MarketValueOfBiotimeCommonShares_lbl2" xml:lang="en-US" id="btx_MarketValueOfBiotimeCommonShares_lbl2">Market value of BioTime common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketValueOfBiotimeCommonShares" xlink:to="btx_MarketValueOfBiotimeCommonShares_lbl2" xlink:title="label: MarketValueOfBiotimeCommonShares to btx_MarketValueOfBiotimeCommonShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyRateOnNetSalesOfProducts" xlink:label="RoyaltyRateOnNetSalesOfProducts" xlink:title="RoyaltyRateOnNetSalesOfProducts" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyRateOnNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RoyaltyRateOnNetSalesOfProducts_lbl" xml:lang="en-US" id="btx_RoyaltyRateOnNetSalesOfProducts_lbl">This line item represents the royalty rate at which Geron will be paid on net sales from patents acquired from Geron.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRateOnNetSalesOfProducts" xlink:to="btx_RoyaltyRateOnNetSalesOfProducts_lbl" xlink:title="label: RoyaltyRateOnNetSalesOfProducts to btx_RoyaltyRateOnNetSalesOfProducts_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyRateOnNetSalesOfProducts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RoyaltyRateOnNetSalesOfProducts_lbl1" xml:lang="en-US" id="btx_RoyaltyRateOnNetSalesOfProducts_lbl1">Royalty rate on net sales of products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRateOnNetSalesOfProducts" xlink:to="btx_RoyaltyRateOnNetSalesOfProducts_lbl1" xlink:title="label: RoyaltyRateOnNetSalesOfProducts to btx_RoyaltyRateOnNetSalesOfProducts_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyRateOnNetSalesOfProducts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RoyaltyRateOnNetSalesOfProducts_lbl2" xml:lang="en-US" id="btx_RoyaltyRateOnNetSalesOfProducts_lbl2">Royalty rate on net sales of products (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRateOnNetSalesOfProducts" xlink:to="btx_RoyaltyRateOnNetSalesOfProducts_lbl2" xlink:title="label: RoyaltyRateOnNetSalesOfProducts to btx_RoyaltyRateOnNetSalesOfProducts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PercentageOfSubsidiaryStockContributed" xlink:label="PercentageOfSubsidiaryStockContributed" xlink:title="PercentageOfSubsidiaryStockContributed" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSubsidiaryStockContributed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfSubsidiaryStockContributed_lbl" xml:lang="en-US" id="btx_PercentageOfSubsidiaryStockContributed_lbl">This line item represents the percentage of subsidiary stock contributed by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSubsidiaryStockContributed" xlink:to="btx_PercentageOfSubsidiaryStockContributed_lbl" xlink:title="label: PercentageOfSubsidiaryStockContributed to btx_PercentageOfSubsidiaryStockContributed_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSubsidiaryStockContributed_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfSubsidiaryStockContributed_lbl1" xml:lang="en-US" id="btx_PercentageOfSubsidiaryStockContributed_lbl1">Percentage of Subsidiary Stock Contributed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSubsidiaryStockContributed" xlink:to="btx_PercentageOfSubsidiaryStockContributed_lbl1" xlink:title="label: PercentageOfSubsidiaryStockContributed to btx_PercentageOfSubsidiaryStockContributed_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSubsidiaryStockContributed_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfSubsidiaryStockContributed_lbl2" xml:lang="en-US" id="btx_PercentageOfSubsidiaryStockContributed_lbl2">Percentage of subsidiary stock contributed (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSubsidiaryStockContributed" xlink:to="btx_PercentageOfSubsidiaryStockContributed_lbl2" xlink:title="label: PercentageOfSubsidiaryStockContributed to btx_PercentageOfSubsidiaryStockContributed_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalConsiderationReceivedAssetContributionAgreement" xlink:label="TotalConsiderationReceivedAssetContributionAgreement" xlink:title="TotalConsiderationReceivedAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl">Total consideration received under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalConsiderationReceivedAssetContributionAgreement" xlink:to="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl" xlink:title="label: TotalConsiderationReceivedAssetContributionAgreement to btx_TotalConsiderationReceivedAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl1">Total consideration received, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalConsiderationReceivedAssetContributionAgreement" xlink:to="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl1" xlink:title="label: TotalConsiderationReceivedAssetContributionAgreement to btx_TotalConsiderationReceivedAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl2">Total consideration issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalConsiderationReceivedAssetContributionAgreement" xlink:to="btx_TotalConsiderationReceivedAssetContributionAgreement_lbl2" xlink:title="label: TotalConsiderationReceivedAssetContributionAgreement to btx_TotalConsiderationReceivedAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:label="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl" xml:lang="en-US" id="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:to="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl" xlink:title="label: DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired to btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl1" xml:lang="en-US" id="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl1">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:to="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl1" xlink:title="label: DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired to btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl2" xml:lang="en-US" id="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl2">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:to="btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl2" xlink:title="label: DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired to btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:label xlink:type="resource" xlink:label="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xml:lang="en-US" id="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl">The fair value of common shares issued to subsidiary upon consummation of asset contribution in noncash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xlink:title="label: CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xml:lang="en-US" id="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1">Common shares issued to subsidiary upon consummation of asset contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xlink:title="label: CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xml:lang="en-US" id="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2">BioTIme common shares, at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xlink:title="label: CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FairValueOfSharesIssued" xlink:label="FairValueOfSharesIssued" xlink:title="FairValueOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="btx_FairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FairValueOfSharesIssued_lbl" xml:lang="en-US" id="btx_FairValueOfSharesIssued_lbl">This line item represents the fair value of share issued based on Black Sholes Merton valuation assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfSharesIssued" xlink:to="btx_FairValueOfSharesIssued_lbl" xlink:title="label: FairValueOfSharesIssued to btx_FairValueOfSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FairValueOfSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FairValueOfSharesIssued_lbl1" xml:lang="en-US" id="btx_FairValueOfSharesIssued_lbl1">Fair Value of Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfSharesIssued" xlink:to="btx_FairValueOfSharesIssued_lbl1" xlink:title="label: FairValueOfSharesIssued to btx_FairValueOfSharesIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FairValueOfSharesIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_FairValueOfSharesIssued_lbl2" xml:lang="en-US" id="btx_FairValueOfSharesIssued_lbl2">Fair value of shares issued (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfSharesIssued" xlink:to="btx_FairValueOfSharesIssued_lbl2" xlink:title="label: FairValueOfSharesIssued to btx_FairValueOfSharesIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_GeronMember" xlink:label="GeronMember" xlink:title="GeronMember" />
    <link:label xlink:type="resource" xlink:label="btx_GeronMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_GeronMember_lbl" xml:lang="en-US" id="btx_GeronMember_lbl">Refers to competitor of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeronMember" xlink:to="btx_GeronMember_lbl" xlink:title="label: GeronMember to btx_GeronMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_GeronMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_GeronMember_lbl1" xml:lang="en-US" id="btx_GeronMember_lbl1">Geron [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeronMember" xlink:to="btx_GeronMember_lbl1" xlink:title="label: GeronMember to btx_GeronMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_GeronMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_GeronMember_lbl2" xml:lang="en-US" id="btx_GeronMember_lbl2">Geron [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeronMember" xlink:to="btx_GeronMember_lbl2" xlink:title="label: GeronMember to btx_GeronMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RomulusFilmsLtdMember" xlink:label="RomulusFilmsLtdMember" xlink:title="RomulusFilmsLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_RomulusFilmsLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RomulusFilmsLtdMember_lbl" xml:lang="en-US" id="btx_RomulusFilmsLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RomulusFilmsLtdMember" xlink:to="btx_RomulusFilmsLtdMember_lbl" xlink:title="label: RomulusFilmsLtdMember to btx_RomulusFilmsLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RomulusFilmsLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RomulusFilmsLtdMember_lbl1" xml:lang="en-US" id="btx_RomulusFilmsLtdMember_lbl1">Romulus Films, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RomulusFilmsLtdMember" xlink:to="btx_RomulusFilmsLtdMember_lbl1" xlink:title="label: RomulusFilmsLtdMember to btx_RomulusFilmsLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RomulusFilmsLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RomulusFilmsLtdMember_lbl2" xml:lang="en-US" id="btx_RomulusFilmsLtdMember_lbl2">Romulus Films, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RomulusFilmsLtdMember" xlink:to="btx_RomulusFilmsLtdMember_lbl2" xlink:title="label: RomulusFilmsLtdMember to btx_RomulusFilmsLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:label="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:title="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl">The amount of obligation to distribute warrants received under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:to="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl" xlink:title="label: ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement to btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl1">Obligation to distribute Warrants, Consideration Transferred, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:to="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl1" xlink:title="label: ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement to btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl2">Obligation to distribute BioTIme Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:to="btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl2" xlink:title="label: ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement to btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl">The amount of Series B common stock received under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xlink:title="label: SeriesBCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl1">Series B common stock, Consideration Transferred, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xlink:title="label: SeriesBCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl2">Asterias Series B shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xlink:title="label: SeriesBCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:label="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:title="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl">The amount of warrants to purchase Series common B shares received under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:to="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl" xlink:title="label: WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement to btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl1">Warrants to purchase Series B common shares, Consideration Transferred, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:to="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl1" xlink:title="label: WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement to btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl2">Warrants to purchase Asterias Series B shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:to="btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl2" xlink:title="label: WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement to btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xml:lang="en-US" id="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl">The fair value of warrants issued to subsidiary upon consummation of asset contribution in noncash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" xlink:title="label: WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xml:lang="en-US" id="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1">Warrants issued to subsidiary upon consummation of asset contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" xlink:title="label: WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xml:lang="en-US" id="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2">BioTime Warrants, at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:to="btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" xlink:title="label: WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution to btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsTransferredAssetContributionAgreement" xlink:label="TotalAssetsTransferredAssetContributionAgreement" xlink:title="TotalAssetsTransferredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsTransferredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TotalAssetsTransferredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_TotalAssetsTransferredAssetContributionAgreement_lbl">Total assets transferred under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsTransferredAssetContributionAgreement" xlink:to="btx_TotalAssetsTransferredAssetContributionAgreement_lbl" xlink:title="label: TotalAssetsTransferredAssetContributionAgreement to btx_TotalAssetsTransferredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsTransferredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TotalAssetsTransferredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_TotalAssetsTransferredAssetContributionAgreement_lbl1">Total assets transferred, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsTransferredAssetContributionAgreement" xlink:to="btx_TotalAssetsTransferredAssetContributionAgreement_lbl1" xlink:title="label: TotalAssetsTransferredAssetContributionAgreement to btx_TotalAssetsTransferredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TotalAssetsTransferredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TotalAssetsTransferredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_TotalAssetsTransferredAssetContributionAgreement_lbl2">Total assets transferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalAssetsTransferredAssetContributionAgreement" xlink:to="btx_TotalAssetsTransferredAssetContributionAgreement_lbl2" xlink:title="label: TotalAssetsTransferredAssetContributionAgreement to btx_TotalAssetsTransferredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_InvestmentsInAffiliatesAtCost" xlink:label="InvestmentsInAffiliatesAtCost" xlink:title="InvestmentsInAffiliatesAtCost" />
    <link:label xlink:type="resource" xlink:label="btx_InvestmentsInAffiliatesAtCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InvestmentsInAffiliatesAtCost_lbl" xml:lang="en-US" id="btx_InvestmentsInAffiliatesAtCost_lbl">Cost of the investment at close of period. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesAtCost" xlink:to="btx_InvestmentsInAffiliatesAtCost_lbl" xlink:title="label: InvestmentsInAffiliatesAtCost to btx_InvestmentsInAffiliatesAtCost_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InvestmentsInAffiliatesAtCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InvestmentsInAffiliatesAtCost_lbl1" xml:lang="en-US" id="btx_InvestmentsInAffiliatesAtCost_lbl1">Investments in affiliates, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesAtCost" xlink:to="btx_InvestmentsInAffiliatesAtCost_lbl1" xlink:title="label: InvestmentsInAffiliatesAtCost to btx_InvestmentsInAffiliatesAtCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InvestmentsInAffiliatesAtCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InvestmentsInAffiliatesAtCost_lbl2" xml:lang="en-US" id="btx_InvestmentsInAffiliatesAtCost_lbl2">Investment in affiliates, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesAtCost" xlink:to="btx_InvestmentsInAffiliatesAtCost_lbl2" xlink:title="label: InvestmentsInAffiliatesAtCost to btx_InvestmentsInAffiliatesAtCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CancellationOfOutstandingObligationAssetContributionAgreement" xlink:label="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:title="CancellationOfOutstandingObligationAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl">The amount of cancellation of outstanding obligation under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:to="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl" xlink:title="label: CancellationOfOutstandingObligationAssetContributionAgreement to btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl1">Cancellation of outstanding obligation, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:to="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl1" xlink:title="label: CancellationOfOutstandingObligationAssetContributionAgreement to btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl2">Cancellation of outstanding obligation to BioTime</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:to="btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl2" xlink:title="label: CancellationOfOutstandingObligationAssetContributionAgreement to btx_CancellationOfOutstandingObligationAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementLineItems" xlink:label="AssetContributionAgreementLineItems" xlink:title="AssetContributionAgreementLineItems" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetContributionAgreementLineItems_lbl" xml:lang="en-US" id="btx_AssetContributionAgreementLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementLineItems" xlink:to="btx_AssetContributionAgreementLineItems_lbl" xlink:title="label: AssetContributionAgreementLineItems to btx_AssetContributionAgreementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetContributionAgreementLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetContributionAgreementLineItems_lbl1" xml:lang="en-US" id="btx_AssetContributionAgreementLineItems_lbl1">Asset Contribution Agreement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetContributionAgreementLineItems" xlink:to="btx_AssetContributionAgreementLineItems_lbl1" xlink:title="label: AssetContributionAgreementLineItems to btx_AssetContributionAgreementLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl">The amount of Series A common stock received under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl" xlink:title="label: SeriesCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl1">Series A common stock, Consideration Transferred, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" xlink:title="label: SeriesCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl2">Asterias Series A shares, net of issuance cost of $541,800</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:to="btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" xlink:title="label: SeriesCommonStockConsiderationTransferredAssetContributionAgreement to btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:label="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl">Patents and other intellectual property rights related to hES cells acquired under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:to="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl" xlink:title="label: PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement to btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl1">Patents and other intellectual property rights related to hES cells, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:to="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl1" xlink:title="label: PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement to btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl2">Patents and other intellectual property rights related to hES cells</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:to="btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl2" xlink:title="label: PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement to btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl" xml:lang="en-US" id="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl">The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:to="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued to btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl1" xml:lang="en-US" id="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl1">Class of Warrant or Right, Number of Securities to be issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:to="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued to btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl2" xml:lang="en-US" id="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl2">Number of warrants to be issued by Asterias to Series A common shareholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:to="btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl2" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued to btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:label="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:title="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl" xml:lang="en-US" id="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl">Excess of contributed asset's value over consideration under the asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:to="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl" xlink:title="label: ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement to btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl1" xml:lang="en-US" id="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl1">Excess of contributed asset's value over consideration, asset contribution agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:to="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl1" xlink:title="label: ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement to btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl2" xml:lang="en-US" id="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl2">Excess of contributed asset's value over consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:to="btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl2" xlink:title="label: ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement to btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmountOfContributionFromInvestor" xlink:label="AmountOfContributionFromInvestor" xlink:title="AmountOfContributionFromInvestor" />
    <link:label xlink:type="resource" xlink:label="btx_AmountOfContributionFromInvestor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmountOfContributionFromInvestor_lbl" xml:lang="en-US" id="btx_AmountOfContributionFromInvestor_lbl">This line item represents the amount of contribution received from investor in relation to asset contribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountOfContributionFromInvestor" xlink:to="btx_AmountOfContributionFromInvestor_lbl" xlink:title="label: AmountOfContributionFromInvestor to btx_AmountOfContributionFromInvestor_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmountOfContributionFromInvestor_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmountOfContributionFromInvestor_lbl1" xml:lang="en-US" id="btx_AmountOfContributionFromInvestor_lbl1">Amount of Contribution From Investor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountOfContributionFromInvestor" xlink:to="btx_AmountOfContributionFromInvestor_lbl1" xlink:title="label: AmountOfContributionFromInvestor to btx_AmountOfContributionFromInvestor_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmountOfContributionFromInvestor_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmountOfContributionFromInvestor_lbl2" xml:lang="en-US" id="btx_AmountOfContributionFromInvestor_lbl2">Amount of contribution from investor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountOfContributionFromInvestor" xlink:to="btx_AmountOfContributionFromInvestor_lbl2" xlink:title="label: AmountOfContributionFromInvestor to btx_AmountOfContributionFromInvestor_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>btx-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreementDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreementDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquityDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#EquityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#EquipmentDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/InventoryDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#InventoryDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreementTables" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreementTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentTables" xlink:type="simple" xlink:href="btx-20140331.xsd#EquipmentTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20140331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" xlink:type="simple" xlink:href="btx-20140331.xsd#UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AssetContributionAgreement" xlink:type="simple" xlink:href="btx-20140331.xsd#AssetContributionAgreement" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Equity" xlink:type="simple" xlink:href="btx-20140331.xsd#Equity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="btx-20140331.xsd#AccountsPayableAndAccruedLiabilities" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" xlink:type="simple" xlink:href="btx-20140331.xsd#RoyaltyObligationAndDeferredLicenseFees" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssets" xlink:type="simple" xlink:href="btx-20140331.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Equipment" xlink:type="simple" xlink:href="btx-20140331.xsd#Equipment" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Inventory" xlink:type="simple" xlink:href="btx-20140331.xsd#Inventory" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20140331.xsd#OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20140331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20140331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to TradeAccountsAndGrantsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DeferredLicenseAndConsultingFees" xlink:title="presentation: AssetsAbstract to DeferredLicenseAndConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to DepositsAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="DeferredRentCreditNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to DeferredRentCreditNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="DeferredTaxLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to DeferredTaxLiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to OtherLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to LiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="TreasuryStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to TreasuryStockValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="MinorityInterest" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockNoParValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockNoParValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockNoParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="TreasuryStockShares" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to TreasuryStockShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="LicensesRevenue" xlink:title="presentation: SalesRevenueNetAbstract to LicensesRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: SalesRevenueNetAbstract to RoyaltyRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RevenueFromGrants" xlink:title="presentation: SalesRevenueNetAbstract to RevenueFromGrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueGoodsNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueGoodsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="SalesRevenueNetAbstract" xlink:title="presentation: IncomeStatementAbstract to SalesRevenueNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: IncomeStatementAbstract to CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainLossOnSaleOfPropertyPlantEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ProfitLoss" xlink:title="presentation: IncomeStatementAbstract to ProfitLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: IncomeStatementAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: IncomeStatementAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasicAndDiluted" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredConsultingFees" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:label="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:title="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredLicenseFeesAndRoyaltyFees" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredLicenseFeesAndRoyaltyFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfDeferredRent" xlink:label="AmortizationOfDeferredRent" xlink:title="AmortizationOfDeferredRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredRent" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredRent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredCharges" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredCharges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfStockBasedPrepaidRent" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfStockBasedPrepaidRent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLossAttributableToNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DeferredIncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RecognitionOfDeferredRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to RecognitionOfDeferredRevenue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInGrantReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInGrantReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherNoncurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="SecurityDepositReceived" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to SecurityDepositReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromEmployeeOptionsExercised" xlink:label="ProceedsFromEmployeeOptionsExercised" xlink:title="ProceedsFromEmployeeOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromEmployeeOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromEmployeeOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ProceedsFromDirectorOptionsExcercised" xlink:label="ProceedsFromDirectorOptionsExcercised" xlink:title="ProceedsFromDirectorOptionsExcercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromDirectorOptionsExcercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromDirectorOptionsExcercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FeesPaidOnSaleOfCommonShares" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FeesPaidOnSaleOfCommonShares" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSaleOfTreasuryStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromSaleOfTreasuryStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromMinorityShareholders" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromMinorityShareholders" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to EffectOfExchangeRateOnCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to StockIssuedDuringPeriodValueIssuedForServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CommonSharesIssuedForRent" xlink:label="CommonSharesIssuedForRent" xlink:title="CommonSharesIssuedForRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonSharesIssuedForRent" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to CommonSharesIssuedForRent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Inventory">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Equipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="DeferredRevenueDisclosureTextBlock" xlink:title="DeferredRevenueDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="DeferredRevenueDisclosureTextBlock" xlink:title="presentation: DeferredRevenueDisclosureAbstract to DeferredRevenueDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreement">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementAbstract" xlink:label="AssetContributionAgreementAbstract" xlink:title="AssetContributionAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementTextBlock" xlink:label="AssetContributionAgreementTextBlock" xlink:title="AssetContributionAgreementTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementAbstract" xlink:to="AssetContributionAgreementTextBlock" xlink:title="presentation: AssetContributionAgreementAbstract to AssetContributionAgreementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BusinessAcquisitionsProformaInformationTextBlock" xlink:label="BusinessAcquisitionsProformaInformationTextBlock" xlink:title="BusinessAcquisitionsProformaInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionsProformaInformationTextBlock" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionsProformaInformationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:label="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:title="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CertainSignificantRisksAndUncertaintiesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CertainSignificantRisksAndUncertaintiesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="TradeAndOtherAccountsReceivablePolicy" xlink:title="TradeAndOtherAccountsReceivablePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="TradeAndOtherAccountsReceivablePolicy" xlink:title="presentation: AccountingPoliciesAbstract to TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TreasuryStockPolicyTextBlock" xlink:label="TreasuryStockPolicyTextBlock" xlink:title="TreasuryStockPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="TreasuryStockPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to TreasuryStockPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:label="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="WarrantsToPurchaseCommonStockPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to WarrantsToPurchaseCommonStockPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="presentation: AccountingPoliciesAbstract to IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PriorPeriodReclassificationAdjustmentDescription" xlink:title="presentation: AccountingPoliciesAbstract to PriorPeriodReclassificationAdjustmentDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DeferredChargesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to DeferredChargesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:label="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:label="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="presentation: DeferredRevenueDisclosureAbstract to ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreementTables">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementAbstract" xlink:label="AssetContributionAgreementAbstract" xlink:title="AssetContributionAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:label="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementAbstract" xlink:to="AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="presentation: AssetContributionAgreementAbstract to AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:label="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementAbstract" xlink:to="AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" xlink:title="presentation: AssetContributionAgreementAbstract to AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="TreasuryStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to TreasuryStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="EsCellInternationalPteLtdMember" xlink:title="presentation: EntityDomain to EsCellInternationalPteLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="presentation: EntityDomain to OncocyteCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="presentation: EntityDomain to OrthocyteCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="presentation: EntityDomain to CellCureNeurosciencesLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="presentation: EntityDomain to RecyteTherapeuticsIncMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="presentation: EntityDomain to BiotimeAsiaLimitedMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="presentation: EntityDomain to LifemapSciencesIncMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesLtdMember" xlink:title="presentation: EntityDomain to LifemapSciencesLtdMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSolutionsIncMember" xlink:title="presentation: EntityDomain to LifemapSolutionsIncMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="LegalEntityAxis" xlink:title="presentation: MinorityInterestTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: MinorityInterestLineItems to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="GrantsReceivableCurrent" xlink:title="GrantsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="GrantsReceivableCurrent" xlink:title="presentation: MinorityInterestLineItems to GrantsReceivableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="presentation: MinorityInterestLineItems to AllowanceForDoubtfulAccountsReceivableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="MinorityInterestLineItems" xlink:title="presentation: MinorityInterestTable to MinorityInterestLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="MinorityInterestTable" xlink:title="presentation: AccountingPoliciesAbstract to MinorityInterestTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: AccountingPoliciesAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: AccountingPoliciesAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="presentation: AccountingPoliciesAbstract to ForeignCurrencyTransactionGainLossBeforeTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/InventoryDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoodsNetOfReserves" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoodsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="presentation: InventoryDisclosureAbstract to OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="Depreciation" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarfMember" xlink:label="WarfMember" xlink:title="WarfMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="WarfMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to WarfMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncMember" xlink:label="AdvancedCellTechnologyIncMember" xlink:title="AdvancedCellTechnologyIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncWithKirinSublicenseIMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncWithKirinSublicenseIMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:label="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:title="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AdvancedCellTechnologyIncWithKirinSublicenseIiMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to AdvancedCellTechnologyIncWithKirinSublicenseIiMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReproductiveGeneticsInstituteMember" xlink:label="ReproductiveGeneticsInstituteMember" xlink:title="ReproductiveGeneticsInstituteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ReproductiveGeneticsInstituteMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to ReproductiveGeneticsInstituteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteLicenseFromSbmriMember" xlink:label="OncocyteLicenseFromSbmriMember" xlink:title="OncocyteLicenseFromSbmriMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="OncocyteLicenseFromSbmriMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to OncocyteLicenseFromSbmriMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLicenseFromHadasitMember" xlink:label="CellCureNeurosciencesLicenseFromHadasitMember" xlink:title="CellCureNeurosciencesLicenseFromHadasitMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CellCureNeurosciencesLicenseFromHadasitMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CellCureNeurosciencesLicenseFromHadasitMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TevaLicenseAgreementMember" xlink:label="TevaLicenseAgreementMember" xlink:title="TevaLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TevaLicenseAgreementMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TevaLicenseAgreementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeLicenseForUniversityOfUtahMember" xlink:label="BiotimeLicenseForUniversityOfUtahMember" xlink:title="BiotimeLicenseForUniversityOfUtahMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="BiotimeLicenseForUniversityOfUtahMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to BiotimeLicenseForUniversityOfUtahMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasLicenseUniversityOfCaliforniaMember" xlink:label="AsteriasLicenseUniversityOfCaliforniaMember" xlink:title="AsteriasLicenseUniversityOfCaliforniaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AsteriasLicenseUniversityOfCaliforniaMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to AsteriasLicenseUniversityOfCaliforniaMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasSublicenseFromGeronMember" xlink:label="AsteriasSublicenseFromGeronMember" xlink:title="AsteriasSublicenseFromGeronMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="AsteriasSublicenseFromGeronMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to AsteriasSublicenseFromGeronMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseAxis" xlink:label="PaymentPhaseAxis" xlink:title="PaymentPhaseAxis" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentPhaseDomain" xlink:label="PaymentPhaseDomain" xlink:title="PaymentPhaseDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIClinicalMember" xlink:label="PhaseIClinicalMember" xlink:title="PhaseIClinicalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIClinicalMember" xlink:title="presentation: PaymentPhaseDomain to PhaseIClinicalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiClinicalMember" xlink:label="PhaseIiClinicalMember" xlink:title="PhaseIiClinicalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIiClinicalMember" xlink:title="presentation: PaymentPhaseDomain to PhaseIiClinicalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PhaseIiiClinicalMember" xlink:label="PhaseIiiClinicalMember" xlink:title="PhaseIiiClinicalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentPhaseDomain" xlink:to="PhaseIiiClinicalMember" xlink:title="presentation: PaymentPhaseDomain to PhaseIiiClinicalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentPhaseAxis" xlink:to="PaymentPhaseDomain" xlink:title="presentation: PaymentPhaseAxis to PaymentPhaseDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="PaymentPhaseAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to PaymentPhaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="RoyaltyPercentage" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to RoyaltyPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmendedLicenseAgreementAmount" xlink:label="AmendedLicenseAgreementAmount" xlink:title="AmendedLicenseAgreementAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmendedLicenseAgreementAmount" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmendedLicenseAgreementAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualLicenseMaintenanceFee" xlink:label="AnnualLicenseMaintenanceFee" xlink:title="AnnualLicenseMaintenanceFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AnnualLicenseMaintenanceFee" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AnnualLicenseMaintenanceFee" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LicenseFeeAmountPaid" xlink:label="LicenseFeeAmountPaid" xlink:title="LicenseFeeAmountPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="LicenseFeeAmountPaid" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to LicenseFeeAmountPaid" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyMaximumPayment" xlink:label="RoyaltyMaximumPayment" xlink:title="RoyaltyMaximumPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="RoyaltyMaximumPayment" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to RoyaltyMaximumPayment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForSublicensePercentage" xlink:label="FeesForSublicensePercentage" xlink:title="FeesForSublicensePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FeesForSublicensePercentage" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FeesForSublicensePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AnnualMinimumRoyaltyDue" xlink:label="AnnualMinimumRoyaltyDue" xlink:title="AnnualMinimumRoyaltyDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AnnualMinimumRoyaltyDue" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AnnualMinimumRoyaltyDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="StockIssuedDuringPeriodSharesOther" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to StockIssuedDuringPeriodSharesOther" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="StockIssuedDuringPeriodValueOther" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to StockIssuedDuringPeriodValueOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FeesForResearchUse" xlink:label="FeesForResearchUse" xlink:title="FeesForResearchUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FeesForResearchUse" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FeesForResearchUse" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionInRoyalties" xlink:label="ReductionInRoyalties" xlink:title="ReductionInRoyalties" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReductionInRoyalties" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to ReductionInRoyalties" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReimbursementToSbmriForCostIncurredInHundredths" xlink:label="ReimbursementToSbmriForCostIncurredInHundredths" xlink:title="ReimbursementToSbmriForCostIncurredInHundredths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReimbursementToSbmriForCostIncurredInHundredths" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to ReimbursementToSbmriForCostIncurredInHundredths" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="MilestonePayments" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to MilestonePayments" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SublicensingReceiptsForCreditableMilestonePayments" xlink:label="SublicensingReceiptsForCreditableMilestonePayments" xlink:title="SublicensingReceiptsForCreditableMilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="SublicensingReceiptsForCreditableMilestonePayments" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to SublicensingReceiptsForCreditableMilestonePayments" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MinimumRoyaltyAmountEachYearAndThereafter" xlink:label="MinimumRoyaltyAmountEachYearAndThereafter" xlink:title="MinimumRoyaltyAmountEachYearAndThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="MinimumRoyaltyAmountEachYearAndThereafter" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to MinimumRoyaltyAmountEachYearAndThereafter" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PaymentUponIssuanceOfFirstFiveLicense" xlink:label="PaymentUponIssuanceOfFirstFiveLicense" xlink:title="PaymentUponIssuanceOfFirstFiveLicense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="PaymentUponIssuanceOfFirstFiveLicense" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to PaymentUponIssuanceOfFirstFiveLicense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:label="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:title="ReductionForAnyPatentThatHaveLicensedTwoOrMore" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ReductionForAnyPatentThatHaveLicensedTwoOrMore" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to ReductionForAnyPatentThatHaveLicensedTwoOrMore" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NoticePeriodToTerminateAgreement" xlink:label="NoticePeriodToTerminateAgreement" xlink:title="NoticePeriodToTerminateAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="NoticePeriodToTerminateAgreement" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to NoticePeriodToTerminateAgreement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsAbstract" xlink:label="DeferredCostsAbstract" xlink:title="DeferredCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:label="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseAfterYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredCostsCurrentAndNoncurrent" xlink:title="presentation: DeferredCostsAbstract to DeferredCostsCurrentAndNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="DeferredCostsAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to DeferredCostsAbstract" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: DeferredRevenueDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedBonusesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateOutsideFundingTable" xlink:label="PrivateOutsideFundingTable" xlink:title="PrivateOutsideFundingTable" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingAxis" xlink:label="PrivateFundingAxis" xlink:title="PrivateFundingAxis" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CashInflowsDomain" xlink:label="CashInflowsDomain" xlink:title="CashInflowsDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheOneMember" xlink:label="TrancheOneMember" xlink:title="TrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashInflowsDomain" xlink:to="TrancheOneMember" xlink:title="presentation: CashInflowsDomain to TrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TrancheTwoMember" xlink:label="TrancheTwoMember" xlink:title="TrancheTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashInflowsDomain" xlink:to="TrancheTwoMember" xlink:title="presentation: CashInflowsDomain to TrancheTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CertainInvestorsMember" xlink:label="CertainInvestorsMember" xlink:title="CertainInvestorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashInflowsDomain" xlink:to="CertainInvestorsMember" xlink:title="presentation: CashInflowsDomain to CertainInvestorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashInflowsDomain" xlink:to="PreferredStockMember" xlink:title="presentation: CashInflowsDomain to PreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateFundingAxis" xlink:to="CashInflowsDomain" xlink:title="presentation: PrivateFundingAxis to CashInflowsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateOutsideFundingTable" xlink:to="PrivateFundingAxis" xlink:title="presentation: PrivateOutsideFundingTable to PrivateFundingAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="presentation: EntityDomain to OrthocyteCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="presentation: EntityDomain to OncocyteCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="presentation: EntityDomain to RecyteTherapeuticsIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="presentation: EntityDomain to LifemapSciencesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="presentation: EntityDomain to BiotimeAsiaLimitedMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateOutsideFundingTable" xlink:to="LegalEntityAxis" xlink:title="presentation: PrivateOutsideFundingTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2010Member" xlink:label="StockOptionPlan2010Member" xlink:title="StockOptionPlan2010Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2010Member" xlink:title="presentation: PlanNameDomain to StockOptionPlan2010Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_StockOptionPlan2011Member" xlink:label="StockOptionPlan2011Member" xlink:title="StockOptionPlan2011Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2011Member" xlink:title="presentation: PlanNameDomain to StockOptionPlan2011Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateOutsideFundingTable" xlink:to="PlanNameAxis" xlink:title="presentation: PrivateOutsideFundingTable to PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PrivateFundingLineItems" xlink:label="PrivateFundingLineItems" xlink:title="PrivateFundingLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateFundingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: PrivateFundingLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesSold" xlink:label="PreferredSharesSold" xlink:title="PreferredSharesSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredSharesSold" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredSharesSold" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockDividendRatePercentage" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockDividendRatePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockDividendRatePerDollarAmount" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockDividendRatePerDollarAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PricePerShareOfOptionsToPurchaseCompany" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PricePerShareOfOptionsToPurchaseCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredSharesConvertibleConversionRatio" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredSharesConvertibleConversionRatio" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_LifeOfWarrants" xlink:label="LifeOfWarrants" xlink:title="LifeOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="LifeOfWarrants" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to LifeOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateFundingLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: PrivateFundingLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="WarrantsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to WarrantsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateFundingLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: PrivateFundingLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivateOutsideFundingTable" xlink:to="PrivateFundingLineItems" xlink:title="presentation: PrivateOutsideFundingTable to PrivateFundingLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PrivateOutsideFundingTable" xlink:title="presentation: EquityAbstract to PrivateOutsideFundingTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AssetContributionAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementAbstract" xlink:label="AssetContributionAgreementAbstract" xlink:title="AssetContributionAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementTable" xlink:label="AssetContributionAgreementTable" xlink:title="AssetContributionAgreementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="presentation: EntityDomain to OrthocyteCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="presentation: EntityDomain to CellCureNeurosciencesLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_GeronMember" xlink:label="GeronMember" xlink:title="GeronMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="GeronMember" xlink:title="presentation: EntityDomain to GeronMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RomulusFilmsLtdMember" xlink:label="RomulusFilmsLtdMember" xlink:title="RomulusFilmsLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="RomulusFilmsLtdMember" xlink:title="presentation: EntityDomain to RomulusFilmsLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: AssetContributionAgreementTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_Warrants1Member" xlink:label="Warrants1Member" xlink:title="Warrants1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="Warrants1Member" xlink:title="presentation: ClassOfStockDomain to Warrants1Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: AssetContributionAgreementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AssetContributionAgreementLineItems" xlink:label="AssetContributionAgreementLineItems" xlink:title="AssetContributionAgreementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: AssetContributionAgreementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="CommonStockNoParValue" xlink:title="presentation: AssetContributionAgreementLineItems to CommonStockNoParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: AssetContributionAgreementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" xlink:title="presentation: AssetContributionAgreementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="presentation: AssetContributionAgreementLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantExpirationTerm" xlink:label="WarrantExpirationTerm" xlink:title="WarrantExpirationTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantExpirationTerm" xlink:title="presentation: AssetContributionAgreementLineItems to WarrantExpirationTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_AmountOfContributionFromInvestor" xlink:label="AmountOfContributionFromInvestor" xlink:title="AmountOfContributionFromInvestor" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="AmountOfContributionFromInvestor" xlink:title="presentation: AssetContributionAgreementLineItems to AmountOfContributionFromInvestor" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PercentageOfSubsidiaryStockContributed" xlink:label="PercentageOfSubsidiaryStockContributed" xlink:title="PercentageOfSubsidiaryStockContributed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="PercentageOfSubsidiaryStockContributed" xlink:title="presentation: AssetContributionAgreementLineItems to PercentageOfSubsidiaryStockContributed" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: AssetContributionAgreementLineItems to ProceedsFromIssuanceOfCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="presentation: AssetContributionAgreementLineItems to AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_FairValueOfSharesIssued" xlink:label="FairValueOfSharesIssued" xlink:title="FairValueOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="FairValueOfSharesIssued" xlink:title="presentation: AssetContributionAgreementLineItems to FairValueOfSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MarketValueOfBiotimeCommonShares" xlink:label="MarketValueOfBiotimeCommonShares" xlink:title="MarketValueOfBiotimeCommonShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="MarketValueOfBiotimeCommonShares" xlink:title="presentation: AssetContributionAgreementLineItems to MarketValueOfBiotimeCommonShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: AssetContributionAgreementLineItems to FiniteLivedIntangibleAssetUsefulLife" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_RoyaltyRateOnNetSalesOfProducts" xlink:label="RoyaltyRateOnNetSalesOfProducts" xlink:title="RoyaltyRateOnNetSalesOfProducts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="RoyaltyRateOnNetSalesOfProducts" xlink:title="presentation: AssetContributionAgreementLineItems to RoyaltyRateOnNetSalesOfProducts" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="FairValueAssumptionsExpectedTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to FairValueAssumptionsExpectedTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to FairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="FairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to FairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to FairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: AssetContributionAgreementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to SeriesBCommonStockConsiderationTransferredAssetContributionAgreement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:label="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:title="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:label="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:title="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalConsiderationReceivedAssetContributionAgreement" xlink:label="TotalConsiderationReceivedAssetContributionAgreement" xlink:title="TotalConsiderationReceivedAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalConsiderationReceivedAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to TotalConsiderationReceivedAssetContributionAgreement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="presentation: AssetContributionAgreementLineItems to CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:label="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" xlink:title="presentation: AssetContributionAgreementLineItems to WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_CancellationOfOutstandingObligationAssetContributionAgreement" xlink:label="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:title="CancellationOfOutstandingObligationAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="CancellationOfOutstandingObligationAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to CancellationOfOutstandingObligationAssetContributionAgreement" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_InvestmentsInAffiliatesAtCost" xlink:label="InvestmentsInAffiliatesAtCost" xlink:title="InvestmentsInAffiliatesAtCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="InvestmentsInAffiliatesAtCost" xlink:title="presentation: AssetContributionAgreementLineItems to InvestmentsInAffiliatesAtCost" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: AssetContributionAgreementLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsTransferredAssetContributionAgreement" xlink:label="TotalAssetsTransferredAssetContributionAgreement" xlink:title="TotalAssetsTransferredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalAssetsTransferredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to TotalAssetsTransferredAssetContributionAgreement" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:label="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="SeriesCommonStockConsiderationTransferredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to SeriesCommonStockConsiderationTransferredAssetContributionAgreement" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:label="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:title="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="presentation: AssetContributionAgreementLineItems to BusinessCombinationAcquisitionRelatedCosts" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:label="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:label="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" xlink:title="presentation: AssetContributionAgreementLineItems to DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:label="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="IprAndDExpensedUponAcquisitionAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="IprAndDExpensedUponAcquisitionAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to IprAndDExpensedUponAcquisitionAssetContributionAgreement" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:label="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementLineItems" xlink:to="TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" xlink:title="presentation: AssetContributionAgreementLineItems to TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementTable" xlink:to="AssetContributionAgreementLineItems" xlink:title="presentation: AssetContributionAgreementTable to AssetContributionAgreementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetContributionAgreementAbstract" xlink:to="AssetContributionAgreementTable" xlink:title="presentation: AssetContributionAgreementAbstract to AssetContributionAgreementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="BusinessAcquisitionsProFormaRevenue" xlink:title="BusinessAcquisitionsProFormaRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionsProFormaRevenue" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionsProFormaRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="BusinessAcquisitionsProFormaNetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionsProFormaNetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:title="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: SubsequentEventLineItems to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: SubsequentEventLineItems to StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfServicesOverhead" xlink:label="CostOfServicesOverhead" xlink:title="CostOfServicesOverhead" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="CostOfServicesOverhead" xlink:title="presentation: SubsequentEventLineItems to CostOfServicesOverhead" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:label="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:title="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" xlink:title="presentation: SubsequentEventLineItems to MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: SubsequentEventLineItems to EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchasedDuringPeriodShares" xlink:title="presentation: SubsequentEventLineItems to StockRepurchasedDuringPeriodShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="StockRepurchasedDuringPeriodValue" xlink:title="StockRepurchasedDuringPeriodValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchasedDuringPeriodValue" xlink:title="presentation: SubsequentEventLineItems to StockRepurchasedDuringPeriodValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranches" xlink:label="NumberOfTranches" xlink:title="NumberOfTranches" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTranches" xlink:title="presentation: SubsequentEventLineItems to NumberOfTranches" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="presentation: SubsequentEventLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SharePrice" xlink:title="presentation: SubsequentEventLineItems to SharePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:label="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:title="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" xlink:title="presentation: SubsequentEventLineItems to NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfInstallmentsForEachTranche" xlink:label="NumberOfInstallmentsForEachTranche" xlink:title="NumberOfInstallmentsForEachTranche" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfInstallmentsForEachTranche" xlink:title="presentation: SubsequentEventLineItems to NumberOfInstallmentsForEachTranche" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20140331.xsd#btx_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfTradingDays" xlink:title="presentation: SubsequentEventLineItems to NumberOfTradingDays" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!^3Q`*UP$``*@5```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/&
MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,84'^@Y&JZJ,
MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N
M);GWYIY2E^50"1=K`RK<F6I;"1^^VADU(IN+&5#>[?9HII4'Y3N^GD&&@T>8
MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@
MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A
M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD
M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E
M6,S*L9B58S$KQV)6CL6L'(M9.1:S<BQFY5C,RK&8-<%BU@2+61,L9DW^RZP^
M]&!`F\^_/Y1FS"]%C//K$MR97YXV0W]+SH4%^>9M:`S/#O!]]C&.T*>-K38N
M-(L63C^%7758[^Z8,`BL+V!?'K:5</O$T$J>'GC0`D+=>TJ0+=FTZ5F'7P``
M`/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L
M<R"B!`(HH``"````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````",DL].PS`,QN](O$/D^^IN2`BA
MI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!
ML3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T
M'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-
M;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_
MMCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#
M`%!+`P04``8`"````"$`FM$*B](!``"-%```&@`(`7AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````O)C-3L,P$(3O2+Q#Y#MU=UU*04U[04B]\O,`5N(V$6D2V>:G;X]5
M4*`2#)=H+Y'L*)O1V#M?G.7Z?=]DK\Z'NFMS19.IREQ;=&7=[G+U]'AWL5!9
MB+8M;=.U+E<'%]1Z=7ZVO'>-C>FA4-5]R%*5-N2JBK&_T3H4E=O;,.EZUZ8[
MV\[O;4Q#O].]+9[MSFF>3N?:_ZRA5B<ULTV9*[\IR:CL\="G5_]?O-MNZ\+=
M=L7+WK7QEW?HM\X_A\JYF(I:OW,Q5\-4T,<[9"9)L])_R$E^R,I9(#D\%Y;#
M<R1'>JW@4C%)>T/0F]F8<F+J,)<*?FWBXU`?KU#$U9@:AL[YUC%,?373%7*$
M6%@-,90C;0Y!=_A2V!V^1.X8\=[&S2UM#O*&I%.88`IS@K@HHWB*W.%K:3G7
M2(XT%6`>2V\<N&](W!KH#8\*S(%,:3/^\>7',[1OC#2M#*25-!T@'$A:#4$Y
M+,TJQJR2/C,P/#.844,G5-:[\B'Z=&(,W[UU,HW:BJ1A11!6)`TK@K`RTI%L
M8"1+)S(,9.F5@@M%TM80](:E8<405BQ]M&)XM#+2F6-@YIA1Z1GBH4D_Z8:O
MG,\QBF!I/`UTTB<_$5<?````__\#`%!+`P04``8`"````"$`1X9$&CX#``""
M"@``#P```'AL+W=O<FMB;V]K+GAM;)26;V_:,!#&WT_:=XCR?LU?NK8J5+10
M#:F#:M#VI642`U83.[6=4O;I=PDCO20L:U^12^+'S]W]?.3RZBU-K%>F-)>B
M;WLGKFTQ$<F8BW7??EC<?CNS+6VHB&DB!>O;.Z;MJ\'7+Y=;J9Z74CY;("!T
MW]X8DUTXCHXV+*7Z1&9,P).55"DU$*JUHS/%:*PWC)DT<7S7/752RH6]5[A0
M']&0JQ6/V$A&><J$V8LHEE`#]O6&9]H>7*YXPA[W&5DTRZ8T!=]OB6TE5)MQ
MS`V+^W8/0KEEM1LJSZYSGL#3\\`-;&=0)7FOK)BM:)Z8!:1W4(=Z^:'OGQ9O
M%J5XY&RKWQ<5H?7VQ$4LM\6K4-I=%05@8%L^>N*QV<!SUW6K>S\87V_,X2;(
M.TB_K"#L4_Y:HDSO4!$"G2)C8;C9D8G85Y]+:&%1]0EDYMF6NN!PH2:Q5QC'
M*C>SZ6@\G8]'!*[FL[O):+B`X'IX-YS>C)&*CU3\SZF`@<I,@&3*>G_`S'P!
MGGYB,R%2"3]HYJ\*-@/%KRK3:\K,U)H*_KODC%Q3S361*W*OF`8,*4X)NRG)
MP#E-Q"N\+]4.K\`;?V]N/'[)>5:PCE><(JMGS143,"36?)DP0K5F1N.5W]'*
M\^;*7W)'$P!GMDSX>I]J@=.(K9A2#,O`4*AJY;E-G6$4R5P83>[ICI8^0`5N
MJIS%Y`[KG&.=%HY%[@:7*H0C]+YO"[QAD2ZYD<(HOLR+D4"&:\7@P-;*%];.
M0(N[!T'S<DA`>R6Y+088'"7#%$_)+4?N0WP*O!9Y\WRIV4L.>Y-QT77<AQ"3
M[WV2-@QMB''S6KQU8PO^JZ,88@J]?V-(%D5':[E@&KW_XWA$`5/I?1++6C4P
MES!O&^.MF\N:$`;3;X'9!1I9H*KV,+!^"]ANU+"A'@05^7Z+V>X^`VQ5GWT,
M#`2-$E4#"DZ]H3S!C?8Q(A`TEE:3ZMA2S,C^#[,^%ALCZY@$AL1O`=H]NS#I
M/7QL_1:OW9!@(;\&20O;_?0ZDDF`H8"@4<=.N$:HE3T\1((6I-UPX40"7!$(
M&H9:@^Q(3CV,55#RZ90=AN^4B"81?$`5/\472)FP<_A\'/P!``#__P,`4$L#
M!!0`!@`(````(0`7&=,UK`4```\6```8````>&PO=V]R:W-H965T<R]S:&5E
M=#0N>&ULE)C;CJ,X$(;O5]IW0-PGV`9C:'5ZU&$TNR/M2JO5'JYIXB2H0XB`
M/LS;;YER,#:;".9B9I)\%+__<E6!'[]\5B?O739M69\W/ET3WY/GHMZ5Y\/&
M__NO;ZO$]]HN/^_R4WV6&_^';/TO3S__]/A1-Z_M4<K.@PCG=N,?N^[R$`1M
M<915WJ[KBSS#+_NZJ?(./C:'H+TT,M_U%U6G@!$2!U5>GGV,\-#,B5'O]V4A
MO];%6R7/'09IY"GO0'][+"_M-5I5S`E7Y<WKVV55U-4%0KR4I[+[T0?UO:IX
M^'XXUTW^<H)U?](H+ZZQ^P^3\%59-'5;[[LUA`M0Z'3-:9`&$.GI<5?""I3M
M7B/W&_^9/F0A\8.GQ]Z@?TKYT8[^[[7'^N.7IMS]5IXEN`UY4AEXJ>M7A7[?
MJ:_@XF!R];<^`W\TWD[N\[=3]V?]\:LL#\<.TLUA16IA#[L?7V5;@*,09LVX
MBE34)Q``?WM5J;8&.))_]O]^E+ONN/'#>,T%"2G@WHMLNV^E"NE[Q5O;U=6_
M"%$="H,P'20$]?IW-C=(@(+Z]7W-N_SIL:D_/-@T<,OVDJLM2!\@L%I8!))0
MQK#46RN%):H@SRK*QH?=#I>WD)[W)Q$]!N_@:*&1[12A-I%="94(4#=(A'6/
M)?Z_YU<E"E9*5`Z4M"U^`;$':<RY[Y00?$`L)6#0?"4*!C-'-Q;Q$!:U(0)V
M#]H<U[)[A"4-[C-?FH)A"X[N*X0C#9&TSR5+(TY<96,@C-*$&<`2!JN;+TS!
MCK#$$89(W`M+19(XGF;CWRD1/$V'`):N>(DN!3NZ3%C,)2*HBPL><P?(QD!*
M0F:$6[K$$ET*MG4E9%@NZD)$^Y7PB5_CW^-8W$JCFF2C/G&_"!7LR'**?8L(
MRJ(DCN/0U%PO/!L3,8TB$0XKLPQ+ERA3L*/,:0=;1%#9BH8TI69GHS*;2)B(
M3*XM:10&S7S7>MH19]:,V=2,3F<8">88FUE$%-*;&:6JW\Y.:4_;[2QQ?-EJ
M!BKP9C^[B]C>+6K[%)OXN*4ESH;::D9G-HD(#U/'W\QF`.!18CJ0+5#UYOG^
M82>W!)H.H).+C!880C52,4FOS4042L,LU!:X:";0Z5!(W*&@F6MM,"(8CYU=
MD-E0DE`:A\9F6Z%JUO,MQ-9N66ARHRT<M_\5I304263NCO6KGMR@"UPW0BC2
ME-RJX$5C@F*/!R>'`DA,8*T0&9`P,!,'[R&V@8NF!9V.B]0=%YH9O'&+/-,`
MQP$\\M86MFA>T.G`2)V-O]7,51AW'Z8R&Z"<F;3;TA8-##J=&*D[,32#TH00
MD5/8F06L6$*X(2QM;-'`Z&E[8+@-;:L9U!83,9G_%@#:XO"6MD7S@N'3_+A8
M4V>?;S6C4TKA:4T0[O2<S(:@:R?\5L-CBT9&3SONF4Z*Q:H95$CA,9>,'MNP
MF6@$Z\%4DYU6U;1G]SF&+=ZRSN1$"T-&6Y<*V%.A4S&9CJ.9^\XYHT*]!L+[
M](WWV^%=:SHR4B=]6X:,=C!F*:$.DEE(G*0L,05FVZCZ]LC&F2JQVUMVNF-#
MO86/)@*!@3!YZK,9(6C*XALMABV:&CWM;$1W:FA&YY*2B+N=.[,0&L'8,T;;
M-CI#8Z:-T^%!B=GO>ELBI&6RF#M`QA"X7RV+9@>;S@Y*G%+8:@A?9U<)(S'C
M3C?*;$;`Z4PR*G;;06>$S'1P.DHH,5M=.X@0/,6K4Y056=.(6'^<I65L<H%I
M8I9H5<]N]:BCGONO<OU5]N:DQ&Q[%*TA3#M/&!<1,YNO9]3QG"DQ3BF\(D]>
MF_#\#<^G*MD<9"9/I]8KZC=UML;`DN';X=SOF:FS'N?[+9P']H=GP?`#',==
M\H/\/6\.Y;GU3G(/(<E:@`,-'NCAAZZ^]*=B+W4'!W']?X]P\"KA+(FL`=[7
M=7?]H$ZJAJ/<I_\```#__P,`4$L#!!0`!@`(````(0#1.92BK@(``"L'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)2576^;,!2&[R?M/UB^+Q_F
M.PJIVE3=*FW2-.WCV@$3K`)&MM.T_W['.*&!5%V:BX"3QR_O>8]MEM?/;8.>
MF%1<=#GV'0\CUA6BY-TVQ[]_W5^E&"E-NY(VHF,Y?F$*7Z\^?UKNA7Q4-6,:
M@4*G<EQKW2]<5Q4U:ZER1,\Z^*<2LJ4:AG+KJEXR6@Z3VL8EGA>[+>4=M@H+
M>8F&J"I>L#M1[%K6:2LB64,U^%<U[]51K2TND6NI?-SU5X5H>Y#8\(;KET$4
MH[98/&P[(>FF@;J?_9`61^UA<";?\D(*)2KM@)QKC9[7G+F9"TJK9<FA`A,[
MDJS*\8V_6,?872V'?/YPME<G]TC58O]%\O(;[QB$#6TR#=@(\6C0A]+\!)/=
ML]GW0P-^2%2RBNX:_5/LOS*^K35T.X*"3%V+\N6.J0("!1F'1$:I$`T8@&_4
M<K,R(!#Z/%SWO-1UCH/8B1(O\`%'&Z;T/3>2&!4[I47[UT+^0<J*D(,(7`\B
M/OFP2'`0@>NK"$DC/XK_;\6U90TIW5%-5TLI]@A6'AA7/37KV%^`LHDG@)#?
MC@=R,7-NS*1A*M`*6OJT"K-PZ3Y!'XH#<WO.D"FQ?H/(1L0%?Z-)R.WC)LVD
M'(<8C29)&HSZ0R&WEH%&CLRLC/5[Q,0CA'?J\?T`#0Q!GSR7I/',FV6R(5X2
MD20(O"FQ/B6"-$VRZ)68>(,0+O=FX+FW9/KD6\O$UAO),B^:`NM3(/;,9P0F
MSB#ZRYT9>.XL'75M1RUS<!:G44IFQ'I"D"",D]>>3[S%4V^7;0TS:>HQG"\Z
MB]C&1F$8>/&,@//0B%@B3@B)R=RB/>_L3N[IEGVG<LL[A1I6P5+VG`2JE/:T
MLP,M^F'';H2&4VJXK>&EQ&`[>P[`E1#Z.##GZ?B:6_T#``#__P,`4$L#!!0`
M!@`(````(0`;PWEIT@L``-9@```9````>&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;)S=6W/B1AK&\?NMVN_@XC[FX+-K/*F`SN?3[EXS&(^IV,8%3";Y]MN-
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MW[=U1CIAIW9TOP[--H/6=#/]^F6U_'FF3FP5B_7[5`\3PWM=>9>^.BO[//Y=
M'%4.=97?=)F'GMI%E;2U.H?^^'IY-?S2_T/E?M:8\6<CQ&0G=,AU64LVV++!
MD0VN;/!D@R\;`MD0RH:H;JA/&;UC\4X</J_X+,E.[#Y+*ALRV9#+AD(VE+*A
M^M#05SVZ[U9U'AO=VCZ8['I/:]U[NWT=UPVJ^+X[1V9G3E!8*&P4#@H7A8?"
M1Q&@"%%$*&(4"8H4188B1U&@*%%47<+(LOHZ,;*LAZ@+-51U9UJ_R\ATW?`Q
MTY=7,M5MYL),OG6$L8\P3INY-K?EMID;TWAMYM8T?INY,TW08JX'I@G;C!CX
MHB-,?(1)CC!IFQ']E1UA\B-,T69$7Y1M1O1%U68.?6$D7TT\C.1W)UYK(_%U
MP^%;:[)K.`SKGTX!J\U<FC&PV\R5:9PV(TXW]PCC'6'\(TRP,[OON'#7T'$P
MHA9S+3Y$W&*NQ`%+VHPX8&F+N19ULC8CZN1M1HPK18N18V%YA*FZC9%E-0T^
M(<M:&UFN&SYD6398LL&6#8YL<&6#)QM\V1#(AE`V1+(AWC5T!"W9F5TZTUU#
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M!L8_%_8O8H?\^@T='SHP2JJ/)'8YQ`H1BAA%@B)%D:'(412U.'2P"%$I7Q>C
M5-6U!2/G=R+GW<.YUC+?HJ/&M>GHZDDM[K;A'=WI\)@G@(4E;!0."A>%A\)'
M$:`(442UN*X/V.7=X$J<KS&62%"D*#(4.8H"18FBJD6=GVLC/D:TA^J^F#&&
M=V=[RV6XQ<`W;E!7NAO2]):Q>\V-?+U?#[V.&C9OQF'B,O&8^$P")B&3B$G,
M)&&2,LF8Y$P*)B63JB%UH(;ZFW8_7)IYUPL@'^<LD/=ZO<28F]^(FR/C88TZ
MLCIA8C&QF3@-^7!B'0[$]LQR3;&=D^P/U59XAMA.6TS@\WX$3$(F$9.82<(D
M99(QR9D43$HF52<Q\ZY734[(>[W(8N9=W+0>#VO4F7<D%E>QF3@-^7#>?SCS
MF\#7^U*3Z];`X][ZO"L!DY!)Q"1FDC!)F61,<B9%0PY#DCF:E%RBZB1FWO5J
MR0EYUUS.9\3$<3RL46?>D5A<Q6;B,'$;LK\N$I>9'KSN\R8"*!'*U\656<2;
MB&4)<?&6R-?%)E+>1,8D9U(P*1O2],C-^>6=\<_-IUL!E?D.=:5_^/AFW/6"
MR@EQK]=?5%@/=\EOY*U&_>M+W5/O"1.+B<W$8>(R\1I2CT"M$QK\R`%O)F02
M,8F-G=W.9,4,+N$B*9.,2<ZD8%(VY'#TS?&_ZBQAIET-P:>D77,QN-^*@SG6
MOVY':4=B<16;B</$9>(Q\1M2=\G%:'0EQH"`:X1,(B8QDX1)RB1CDC,IF)1,
MJDYB)EXO.9TPOM<K5,;X?GOXZMC.A\?#KF6L+9DPL9C83!PF+A./B=^0PR`D
MQH&`:X1,(B8QDX1)RB1CDC,IF)1,JDYB)EZO/IV0^'JQRDR\F/&.AUTK6DWB
MD5A<Q6;B,'&9>$Q\)D%#]E<*8J0(N40D2PS$S>"8:R1,4B89DYQ)T9#](1&7
M%267J#J)F76]`G5"UNL%*S/K8@?'^M?^:3Z#Q.(J-A.'B<O$8^(S"1JR[UB1
MTY!+1$QB)@F3E$G&)&=2,"D;\G?'K>HL8:9=+TE]3/MQO_PUK%>RS-3+]=0&
MJ8GZX<+6O,R8,+&8V$P<)BX3CXG/)&C(OO=&GV*/*XD1;R9FDC!)F61,<B8%
MDY))U4F,Y.O_3LI(?O>BTY;+ZU;1<>,&=26>B<7$9N(P<9EX3'PF`9.02<0D
M9I(P21M27Y>,6NY-92AR0]1WC,3536$0=;W_<7UT.P$N&]&1IZJ3F(&7JZS'
M#?6CEM766[G:VJ".'9TPL9C83!PF+A./B<\D8!(VY,-%\*<<1%PF9I(P29ED
M3'(F!9.22=5)S/#KU<33YSFC>A'2G.?(I=<&=88?%S,MKF(S<9BX3#PF/I.`
M2<@D8A(S29BD3#(F.9.B(<V-7KWV;<Z*2ZY1=1(S^2J\_R3Y^FUROB,784<U
MZDP^$HNKV$P<)BX3CXG/)&`2,HF8Q$P2)BF3C$G.I&C(X;M.!A_#4G5NQ0R^
M7(8]<K[3LAQ[*Y9BQB-<FYPPL9C83!PF+A./B<\D8!(RB9C$3!(F*9.,2<ZD
M:,CABD(&'_-4=6[%#+X:CXT1'ZYL-1<C_9WX2AKKA[_`'4PF%A.;B</$9>(Q
M\9D$3$(F$9.82<(D99(QR9D43,HV<B=6.ZI6=%A*,G,OUV6/'/#KI5=U!AYN
M4][)._@C7I]E8C&QF3A,7"8>$Y])P"1D$C&)F21,4B89DYQ)P:1D4G42,_NG
MK=".=BNT^B%/H\%0WKIO7J^_KVXOKH?B3N>D`1TS?XN)S<1AXC+QF/A,`B8A
MDXA)S"1ADC+)F.1,"B8EDZJ3F&$_;8EVM%NB;<(NLCQN7J_#/ASJF[7F]&S2
MB,ZTX_JMS54<)BX3CXG/)&`2,HF8Q$P2)BF3C$G.I&!2,JDZB9EVN40+T_G=
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M<'__?R3X^G\```#__P,`4$L#!!0`!@`(````(0!U)NRU-0,``)P)```9````
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MS'Y`\SRQG>5BR,]O2O;B[-H2-=M_XK3\2CL"R88RJ0)L&'M2TB^E&H*7G8NW
M'X<"?.=622J\:^0/MO],Z+:64.T0`E)QS<O7G(@"$@HV,R]43@5K``".5DM5
M9T!"\,MPWM-2UIGMHUD8NSX"N;4A0CY296E;Q4Y(UO[1(G2PTB;>P<0'^L-S
M[]TFP<$$SB<3+PE1&+V-XNBPABSE6.+E@K.]!9T'X*+'JH_1')R/Z='!C`G[
M7[X@4<KD0;ED-DP92(6`&C\O@R!>.,]0F.*@65UJD*E8'Q6J"LHVUP-#+AW@
M':$AG^?0_Z[ED4V)%=O1=:4'P'N$]28@EXHX-"7YI<1+1XD!"T6_'5:),QL*
M,;(%03+Z#EE9:0UTWTEC*M9O*O)K"H,>4&ZG5V*8(&=DGC_)[4IKTJ%)PB!&
M:8HF`:ZUY$J`^543@Q]<;N=7XBE_9.9VI371P'^7)G&:^-,^UA(X_J]`N6$"
M4Q@EOC]^Q^"/WL.OQ"9_X(ZVNGFT1.-#:P6NFTPFZEI+KN$;)I'G)FYRFA\&
M?OP>?"6>X`>G2:7YM<:`"R<QKO^A,;.07U,8_.HOX&QYO+[2*+')C]PIO];H
M]D=^%*?IM/O/%5'@A?&I,_2JJ`5&"L;P-+S>#?4ZWQ*^)6O2-,(JV$[M=![T
M[C@Z;L(/GEHA)^,K-(=5&<:=\0%LCCW>DF^8;VDGK(948.G.8N#A>GO5-Y+U
MP^ZR81*VQ>&RAK\@`NNZ.P-QQ9@\WJ@/C/]5R[\```#__P,`4$L#!!0`!@`(
M````(0"#)!BB'0,``-\(```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;)2676^;,!2&[R?M/R#?-V`^0Q12-4'=)FW2-.WCV@$3K`)&MM.T_W['.)!`
MVK2]@6!>7I[S'L=F>?M45]8C%9+Q)D%XYB"+-AG/6;-+T)_?]S=S9$E%FIQ4
MO*$)>J82W:X^?UH>N'B0):7*`H=&)JA4JEW8MLQ*6A,YXRUMX$[!14T47(J=
M+5M!2=X]5%>VZSBA71/6(..P$._QX$7!,IKR;%_31AD302NB@%^6K)6]6YV]
MQZXFXF'?WF2\;L%BRRJFGCM39-79XMNNX8)L*ZC["?LDZ[V[BPO[FF6"2UZH
M&=C9!O2RYMB.;7!:+7,&%>C8+4&+!-WA11HA>[7L\OG+Z$&>_;9DR0]?!,N_
MLX9"V-`FW8`MYP]:^BW70_"P??'T?=>`G\+*:4'VE?K%#U\IVY4*NAU`0;JN
M1?Z<4IE!H&`S<P/ME/$*`.!HU4S/#`B$/'7G`\M5F2`OG`61XV&06ULJU3W3
MELC*]E+Q^I\1X:.5,7&/)A[0'^^['S;QCR9P/IFX\P`'X=LHMBFK2RDEBJR6
M@A\LF'D`+ENBYS%>@',?CREF".RUO"`H;7*G71($?QF(0D*/'U>^'RSM1VA,
M=M2L+S5XK-CT"MT%;9N:@2Y+&W@':,CS'/KE7O9L6JS9>M>U&0#O`=:=@%PJ
MHDDUZ:7$C0>7$2PT_1Q6)^S!-+X.K1]*$#1D8/3]</#OTED;#<S"DV:LV+RI
M2*\I1E4`RGD5U^FU&*H\(W/=28!KHXG-9`G]P(FB";U17*DO'7GX'@[FIXQ&
M]&#R?GHMGM)/V-9&$W;T-SB<![$[D6R,!(ZOM2<=F_B>-P^\(8,1?_@1?BT>
M\WNG6,S4,1*#[\9!C`-G>'&GV!C%-?JQ1QQ%WBOPT4?@M7@,CYWYF&UM-&;J
MN$$83Y>:S;D`8\\+)O7#AJ/?\G)U)GBSH9BELJ9B1S>TJJ25\;W>+%QH_#`Z
M[&-WKEYD)N-KO("%#<;MX0;L+RW9T1]$[%@CK8H68.G,(N`19H<R%XJWW0*]
MY0IVENYG"1\2%)9&9P;B@G/57^@7#)\FJ_\```#__P,`4$L#!!0`!@`(````
M(0!P<'KU90(``.`%```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)24
M6X_:,!"%WROU/UA^WYB$)"R(L%I`M"NU4E7U\FP<AUC$<62;V[_O.(:4F[;T
MA<3D^,N9,^.,7_:R0ENNC5!UAL.@AQ&OF<I%O<KPSQ^+IV>,C*5U3BM5\PP?
MN,$ODX\?QCNEUZ;DW"(@U";#I;7-B!##2BZI"53#:WA2*"VIA:5>$=-H3O-V
MDZQ(U.NE1%)18T\8Z4<8JB@$XW/%-I+7UD,TKZ@%_Z84C3G1)'L$)ZE>;YHG
MIF0#B*6HA#VT4(PD&[VM:J7ILH*Z]V%,V8G=+F[P4C"MC"IL`#CBC=[6/"1#
M`J3).!=0@8L=:5YD^#4<S6),)N,VGU^"[\S9/3*EVGW2(O\B:@YA0YM<`Y9*
MK9WT+7=_P69RLWO1-N";1CDOZ*:RW]7N,Q>KTD*W$RC(U37*#W-N&`0*F"!*
M'(FI"@S`+Y+"308$0O?M=2=R6V:XGP;)H-</08Z6W-B%<$B,V,98)7][47A$
M>4ATA,#U"`FC_X;TCQ"X_H5$STF8I/^V0GQ9;4IS:NEDK-4.P>2!<=-0-\?A
M",CW8X$\G/;5B=LM4+&!5FXG<1R-R1;R9T?-]%9SI9C=40P["`%?G3G(ZW%S
M3ISA&*/.7!2F';<M8.HUT+A.$U\J9N\I+KQ!6(][<V*8G//WQOW+-T^]9MC&
M&D7]-$TN!;-S09@F@T'8"2Z<003GSMS$]^'<O-]:M^G:X54V4Z_Q#L-H&%U5
M`,?8,>X]]_[\(?7CU]`5_TKU2M0&5;P`C[U@`(W1_HCZA55-.VY+9>%HM;<E
M?$DYS&(O`'&AE#TMW$>@^S9/_@```/__`P!02P,$%``&``@````A`/@S9*!`
M"@``;#<``!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULG)M=;^/*#8;O
M"_0_&+Y?6Z,OQT&2@Y6B;0_0`D5Q3GOM.$IBK&T%EK/9_??EB/-%2J;DGHN3
M#?<E/<^0,Z2]UMUO/P_[V8_ZU.Z:X_U<+:+YK#YNF^?=\?5^_N<?W[[<S&?M
M>7-\WNR;8WT__U6W\]\>_OJ7N\_F]+U]J^OS#"(<V_OYV_G\?KM<MMNW^K!I
M%\U[?82_>6E.A\T9?CV]+MOW4[UY[IP.^V4<1?GRL-D=YQCA]C0E1O/RLMO6
MC\WVXU`?SQCD5.\W9UA_^[9[;VVTPW9*N,/F]/WC_<NV.;Q#B*?=?G?^U06=
MSP[;V]]?C\UI\[0'[I\JW6QM[.Z77OC#;GMJVN;EO(!P2UQHGWF]7"\ATL/=
M\PX(]+;/3O7+_?RKNJUR-5\^W'4;])]=_=D&?YZU;\WGWTZ[YW_LCC7L-N1)
M9^"I:;YKZ>_/V@3.RY[WMRX#_SK-GNN7S<?^_._F\^_U[O7M#.G.@$B#W3[_
M>JS;+>PHA%G$F8ZT;?:P`/C_[+#3I0$[LOG9_?S</9_?[N=)OLA64:)`/GNJ
MV_.WG0XYGVT_VG-S^"^*.B(7)#9!X*<)$M\L5BI:)RL((C@FQA%^&L=\$=]D
M*LOUJPN.J7&$GW;9:J'2:,P/HG:X\-/Z18LTSE8W'6__%9>X7]WV/V[.FX>[
M4_,Y@YJ&'6G?-_J$J%N(IO<]@>QA!)>)2XF`#.@@7W64^SD<1G!OH7I^/*31
M^F[Y`S*^-9JBKU%445J%3J\.^\@-%1JZK"T!P%%`QCB%KIXK*70436%?O[`&
MCQ6S)5N%=7E$`ZS3[<0JHSY57Q+[O2)84$\AUO!AL#G0XOLY5))[Y51%]*4+
MU,#.>`U5E%;A@*SAHDLE*0@.K&TZCA9#+09+56I%%UN@9MT5G$K2=10QX!(5
M>&-T)64-EW$D!<&!;9R.H\44)U6L_@O4Y(BC,M7'046`8PV7<20%P<DICKT)
MY*+33AR+G9$"-09K?=.G0D%`90V7J20%H5I1*IE&B_D12EC-H09V]>(1L@IW
MA*SAHDLE*0B.GG>"ZUK&T6*>G)3AH`:3DT=1VCM!*`B28PV7:<*8V2J#8^E>
ME,"LKX'18@[#;M8"-0B3).DJ>.&NH90H"&"LX3),&#-+UDD0D\`HZ)K34].I
M.4[NMJE;;6%$]D+(X>A016D4`9"S7":2PE(DW6Z#:IMV)2ALTG"-^A/2N[F-
M2#I&3N+.D;,$D>F&5**$PNDV',#)1TEATP[;T=HW;9,NU&"ZOJ@HA<JGRRM-
MF#!?H9-*;]*$-;G*^0Q14R3=B:<C8=\.D5)U0Q=<*!09ICC/>D0H"(FL18^!
M3%Z9>,-YIS"Z#P<P$XL/NS>%ZB4*169NB&+%.E:I4!!"A2ZQ6J]Z6;(NXUG2
M'?EZ,.W%+HR8[6ZA9UX0#>\NWH!.XD_5J%/EG,;A=&.^'@[;.6RA=&5(/=_`
M68F'LY8@,BWQ2DD26I*Z30=P(U<&-G52BC$?^=1`YX][Y6A%'LM:!"Q)0K%T
MOPZP)IXT[/(4CP]+:G18*)W$PXTZ5<YIB)_"Z?Y]/1QV_9&"'!T>2F4E'LY:
MAE;>57'EG(8D!"Z^:N;HU/P*X05I1.0*B=G06#J1PW*6H34CEBBA6&SND,]9
MC/,&+40^&1H1P:+W0.DD'@HC"TZ5<QKBIE!7S1LQC@6T`/GI,B)A?:63>"B,
M+#A5SFD<"G8]/%TCF=)J7H!\Z(U1M(JZM\$1?/Z6K</_6.,MC3[HU<XRM'Q3
MB_@BPYM`TZ;[^M7W1ZR]."E;>6%$PXO`AN8D/GT867"JG-,0/X6#,"'<2/JT
M>NSML?[`<V0$<1(/->I4.:=Q*-W/@XR-0&'WAWKPHT?<JTD4F9ID5V89VP'"
M\UA+$)3>-I5S&I+0).E&/IT'VS[EX5-]+,T&IO*LQ$-9R]"*S;&2)!2*S1PC
M2<*)8.0V'!T;RMA*/)2U"%"2A$+IWCX]4S@)T$SU*@]%_C;,6!,H8SM0>"9K
M$9@D"6'2_Q@PG:E3\WN/O_TR(CCS_LC1TU$ZB8-REHM.E2BA4%<-&`F.`7+U
M&9$(9<<)#V4M`I0DH5!7#1@)C@%R]1G1A7O/_&W0>9U%X)'&#\H#:PLK;]K;
MDD1[L0I,^/MD(Q*3A7%".&L1X"0)A=-M?/)5D6#3'ZE`%(E05N(KT%H$*$E"
MH>"UKX#2:I:I7N=-4.3N/_B'47Y5H"),E+4(3)*$,NE6/CU1V/BA#/S5EK!Y
MH4A&IX/227RB1ITJYQ2\N-LL"J7[]'0H[.I0!AY*L394)%+KQY'"23S4J%/E
MG((7OP"E^_1T*.SJ)%/]ZD.1J[YUN@K?BJQ[M6A'!4]H+4/+QZ$ID20T;;IK
M3R?$'D\($_;14I%(@X!)FY5X*&L1H"0)@4JO&C`Z]=A[$".",^X+UM4,0CF)
M@W*6BTZ5**%0NFM/SE2*/9YDJE>+1N1J\89=*Z41!!>ALPA(D\>+]*KQHE.S
MRSWA=X81B7FRXX+/D[4(4)*$Y@GV_(H\:?5H\:%(A+(2#V4M`I0DH5"Z84\O
M/FSO$-T?EG[QH<@5WRI1Y")D;S#+%/5A+5I+\#+T3%;.:4A""77[GDZHU;P6
MV4>:18HB,6U6XM-F+4,KQMM=C$NAKIHT4IP'8%=]VGI-V8A$*#M7>"AK"2+S
M3$D2"L4F#3W$JY7^#M^%K_;9;S.E.!J,E&5_?LA8ARM-H!5<='ZG$M:Y'XU*
MV*E*E%!HW=&GER?V?T*:\,\!4FE(,"W-2GPFK24@YYF4)!1*=_3I4-C_1\I3
M&A(,E)5X*&L1H"0)@<K8\#&Y/#M'=J?T;DTC"HNJ5YY&,U*>`Y'8!5:)$@I]
MU7"2#0PG_#L*A1&%I&Q]I9.X3#K+Y4R*$@K%QA.=27WWRA\L9C@ID#)-6#,K
MC$B$LQ.'A[,6`4Z24#C=^X.S-Q%.>[$:3?B'<1F*\`L>6;I62<0'2R,)FCEQ
M2E>KOE/EG(;X*9R>#`*XD8QI-8-*^><[&8K$C%F)SYBU#*T8F[D8ET+!:X=0
M$S.FO=B`V2]'%(EP5N+AK$6`DR043K?_(&,3X7!HH'VN5XXHPG)<KS*5*]:J
MR\P.'QXN=+I1><Z_T%,YGR%\RL8&EI%J')A24G9^BJP_I?0N1ROQ3-8RM&)3
MC9*$0NDN?WW"<#:`8Q$,3KW+41H@L(=G5N+AK"6(S`83YS0DH7"ZVU\/AS/"
M2#6B"*M115F:*][ZRLP.&YXN](J3/%KG;-<JYS1*E[,)1:['3@T72.J?8>B;
MRK[IL6^JB(GL.#P(U-OQ_^-QBRX,N\KY8%X8D6[EK@I5[WN57N6RT#?I!YBZ
MZ[7K9$B$#R3A$S&'^O1:E_5^W\ZVS8=^V"B#[R`XJWL0ZFNL=Y?9"W7[V#V7
MPNWQ;3FD_YI'\$15]U`4]\C=LU9+]U?PK-/[YK7^Y^;TNCNVLWW]`LN#+T?`
MMISP:2G\Y=R\=\_T/#5G>,JI^^,;/-56P],TT0+$+TUSMK\`Q-(])_?P/P``
M`/__`P!02P,$%``&``@````A`$5'9&:Z!0``Z!4``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C,N>&ULG%C;CN)&$'V/E'^P_+X8WV"P@-6`\4V)%$6;Y-EC
M#%B#,;(]E_W[5%]Q=S$,.R_C\7'5Z:[3U5U%S[^_UT?CM6R[JCDM3'LT-HWR
M5#3;ZK1?F/_\B+X]F$;7YZ=M?FQ.Y<+\67;F]^7OO\W?FO:Y.Y1E;P##J5N8
MA[X_!Y;5%8>RSKM1<RY/\&77M'7>PVN[M[IS6^9;ZE0?+6<\GEAU7IU,QA"T
M]W`TNUU5E&%3O-3EJ6<D;7G,>YA_=ZC.G6"KBWOHZKQ]?CE_*YKZ#!1/U;'J
M?U)2TZB+(-V?FC9_.D+<[[:7%X*;OB#ZNBK:IFMV_0CH+#91'//,FEG`M)QO
M*XB`R&ZTY6YA/MI!9GNFM9Q3@?ZMRK=N\+_1'9JWN*VV?U2G$M2&=2(K\-0T
MS\0TW1((G"WD'=$5^*LUMN4N?SGV?S=O25GM#STLMP\1D<""[<^P[`I0%&A&
MCD^8BN8($X"_1EV1U`!%\O>%Z<#`U;8_+$QW,O*G8]<&<^.I[/JH(I2F4;QT
M?5/_QXQL3L5(7$X"3T[B3&\Z>-P!GMS!'SWXOC=YF,*H-T:"KW2Z\!0CS4:V
M-YZ0V=[PFW`_>(H!;]K#].DX\!3CW(X(]A-U@*<8X+Z(9MP1GMS1=>Z)R(94
MH2.2?\20UV*RV(K3!`KS/E_.V^;-@%T):]J=<[+'[8"0D-1QX<EDE,GT42Y!
M$A&61T*S,"%N<.]@`[PNO?%T;KU"TA;<9H5M;-5B+2Q(AA+:4`<V.A#I0*P#
MB0ZD.I`-``MDD=K`=D#:D&WUB]H0&J*-B&HE@(M8CB:$L!`NH0YL="#2@5@'
M$AU(=2`;`(H0L*61$!X(<?U\$3E!O!8F[&Z9$Z[OJ8&NN,W02#-92Q,I!D(V
M"(D0$B,D04B*D&R(*)K`E)$F7T@.0@,B@9A2)6_\H*G$C6ZI)$VD2@C9("1"
M2(R0!"$I0K(AHJ@$<2&5OG"\$!JJDHANQ1$86.KF^A-5M[4T$FXA0C8(B1`2
M(R1!2(J0;(@HHD#]442YO8V(M1H[1VA#0<_)-4)"A&P0$B$D1DB"D!0AV1!1
M`H5JJ00J^I)?/$`)C:H`0U@K0PK%FINHZ:`5H%`:B738("1"2(R0!"$I0C*.
MT%-?T83TW'K!_<*Y06A431@RT(2;>+0<.V-;.UA#^5W*@9"((Y?B%4L;4N2!
MU57W7"*_"]84(=F051$'^I\KXHQ(/]@?JN)YU<!NAW)]9<>X$";K10B)*@U#
M!M)P$TC<P>FAG;JA-!*1;!`2<62@C[2Y09U((T&=(B0;4BLBD3;MIDH_FO-'
M*D&'+&2B-*I.`H*A![K,U!5>7ZS$[$,.^3`SZ>@XVG&\$58VS<B9ZTT=K0.,
MA(DCNZ48#Y<(JYO#I<**#>?-W.G85T/)A`D=3A69-(7#?7HEY89BLAX2ZKC0
M9&4SR'<EM,90R*$)^RU%SK*-@"Y)%0G'B>2*!72A3X3CA2L5T(4K$XZ42XV9
M]'_#F,6/@4]B9VVC$CN'E$2:C%7UU[:T$J*%'/HLD9CC!`Y9F6[N!.42L_+A
M(:T<1\OF&$\BN6L2*;?2)J%U\IG@^F@2Z@*0;G.X`)\(SYO38=(Q2$DZ!(4V
M@Y2DX]`E42)NY0^3#G$EF"L5T(4K4[C4F$GO.(SYSJ3C+><P=@ZI2:?5IS7<
MP]#R,)-;*>309TG''+7UUHIJ)+@^6F]:HF(\B40X?G*F79T$.M:8U8>9SQ:`
M72>QVX"Z;/?ENCP>.Z-H7LA5$:S8<BYA=H^U\@)H]6&SZK@?0+=[!9\$T!QB
M?#T-H&6Z@C\$&YHT&G_\$$`7<<5^%D!-QG@\"Z"@8ASNX1[I4:_QK\C]W!7[
ME1/`;V+,LW(#^&&(\4<O>(1UA`^6'`'NV<[YOOPS;_?5J3..Y0[$'=.6IF4W
M=>REYT7[J>GAAHW6[P/<J)90$<8CZ']V3=.+%S*`O*-=_@\``/__`P!02P,$
M%``&``@````A`*5ZS_$.!0``+!4``!D```!X;"]W;W)K<VAE971S+W-H965T
M,S`N>&ULG%A=;ZM&$'VOU/^`>+^&Q<8$R_95`*6]4BM553^>,5[;*,!:0.+D
MWW>&P9A=R!KW/B0QG#T^9V9V9N^NOW_DF?'.RRH5Q<9D,]LT>)&(?5H<-^;?
M?[U\>S*-JHZ+?9R)@F_,3UZ9W[<__[2^B/*U.G%>&\!05!OS5-?GE655R8GG
M<3439U[`FX,H\[B&C^71JLXEC_?-HCRS'-M>6GF<%B8QK,HI'.)P2!,>B>0M
MYT5-)"7/XAKT5Z?T7%W9\F0*71Z7KV_G;XG(ST"Q2[.T_FQ(32-/5C^.A2CC
M70:^/]@B3J[<S8<!?9XFI:C$H9X!G45"AYY]R[>`:;O>I^``PVZ4_+`QG]DJ
M<N:FM5TW`?HGY9>J][=1G<3EES+=_Y86'*(-><(,[(1X1>B//3Z"Q=9@]4N3
M@3]*8\\/\5M6_RDNO_+T>*HAW2XX0F.K_6?$JP0B"C0SQT6F1&0@`'X:>8JE
M`1&)/YK?EW1?GS;F?#ES/7O.`&[L>%6_I$AI&LE;58O\7P*QEHI(G)9D#NK;
M]\[#)(N6!'[?2)PGE[G+^U(LLM5$*8KK>+LNQ<6`T@/AU3G&0F8K8+Z&A\QT
M`?LJ7A`H)'E&EHT)>P9"44&2W[<+WUU;[Y"8I,4$0PR3$>$5@5E`VH@>-+&T
M0&\G&N+9%SV>RZLV!*.V*VM`#X"[$^LH0H8(3W$3#2&.W[%(8B'IT\4B>&-"
M(CIM"W_9\391"0@#U7?#R(CP+B+2(23U(*6O'NMC#IM0'W)<!+B^0M^3-0:$
M63;%`CT1_\F(D!`:GY&.0W(!)(^[P$6JBR=98T`8<N&->*#W\/.K7$57!&Z:
M6P0D]4M9O3[V"%8KZ%:95$&$T:@*[R(B'4)2[SVB'L%RS+U;4$@\02CDT(2;
MRE$P(6$T!B,]BV0`CP)*B[R_!7"1;`24*L5#&'*R])?,F_=Z2&,V)(C.B$3B
M+9C#YK=T2S[\_^,#%ZD^E+X=$(9\N+[M,>:K'94@.A\2R=)CBX6SZ.(E^6#0
M?_H)T>^'!JTZ4.0%+8@L++"FNJ^F/+0`G0$M1#:`<ZU747<,T!3L=U/7GLOZ
M`D8@OVFG3S9SW5OP6@=]Q-)G_D*9*U'+,>Y1-H#3;[H!FI6R`45>P`ATW=;V
M6`XDB.T/VVW4LDRQ@!-PN@5$JT6D'`D"1B"WR<&@@*XOOYX$W?HQB!Q_''S3
MQ=.8!`'=$')M)?D!NSMMP_N02`N1+4".'K"`:'6J#2P0:#SY[2:X"XGP/P?P
M5>,LL@4<@;TL3#L;,1J<_6PL?/58T8)H-XR=*UK`N,K&:Z2%R$9P&/:,W.E'
M-#K[!EQ;/=VQ_GP=-4``K0$=1#:`0[!G8&(F:'3*1@:9(!`UUCF=-N3>&S*"
M:*WH(+(5G(./6Z'I*5NY'0.:@@@8@3R;&M1,'2)A"]`:(8YQB&3$4:;TM)PT
MJY1&RY1>&K0@&+AX:&8SI1&'[?MQD;0YM!#9AS*L)_H8&=I,/3<Y_9&L#,2P
M?:DU0>O'(;*)AP:V,S*PF7ID:D$T[1A<9RB[HGM_FSJ*Q4@+D?5#9?=WA;Y#
MP7W28%HS]<34@OK!<YFB,!P!*1"\O+HW+^ARBJY=<EX>><BSK#(2\8873PY4
M<?>TNQ1[=O#"0GD>L!5<DL!SJWL!=U7G^,A_C\MC6E1&Q@]`:<\\\%72;1=]
MJ,6YN>S9B1INJ9H_3W`KR>&:Q9X!^"!$??V`7]#=<V[_`P``__\#`%!+`P04
M``8`"````"$`T,B4I]L+```M5P``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6R<W%MOVLP6!N#[+>W_@+@/,#Y@0$D^U?A\D+:V]N&:$B=!#3@"VK3_
M_IOQC(%9=N:%]*)IG<?+QFMY/%Z`[__ZO7T;_*KVATV]>QBRT60XJ';K^FFS
M>WD8_O<_T=UL.#@<5[NGU5N]JQZ&?ZK#\*_'?_[C_J/>_SB\5M5QP"/L#@_#
MU^/Q?3$>']:OU79U&-7OU8[_YKG>;U='_M_]R_CPOJ]63\U*V[>Q-9E,Q]O5
M9C>4$1;[:V+4S\^;=174ZY_;:G>40?;5V^K(]__PNGD_M-&VZVO";5?['S_?
M[];U]IV'^+YYVQS_-$&'@^UZD;[LZOWJ^QM_W;^9LUJWL9O_=,)O-^M]?:B?
MCR,>;BQWM/N:Y^/YF$=ZO'_:\%<@#OM@7ST_#+^Q1>FPX?CQOCE`_]M4'X>+
M?P\.K_5'O-\\%9M=Q8\VSY/(P/>Z_B%H^B06\97'G;6C)@/_V@^>JN?5S[?C
MO^N/I-J\O!YYNEW^BL0+6SS]":K#FA]1'F9DN2+2NG[C.\#_'FPWHC3X$5G]
M;GY^;)Z.KP]#>SIRO8G-.!]\KP[':"-"#@?KGX=CO?V_1,TK.@6Q5!";[[WZ
MO75S$$<%X3_/0:R9R]SI#;O"=[IY/?QG&V4VFKFN,YUYU[^@J8K"?[91YE<?
M#4^MS$\QM;)MW;X+?'O-"^$_VRALY%BN-[LE,XP7E,ROJ*PO)YB=RH3_HSTB
MT]'-V6%MI8A_J#B6._+89&[?D![&"TV^JG/%6;.K=V<LSX'FE`I6Q]7C_;[^
M&/!QBK^XP_M*C'IL(;;1GDRR]$^GUV=G%S^M1)1O(LS#D*>?GS@'/B3\>N1%
M?#_^Q4_CM3)^US!=+%LASED1-I`+Y)DG%H1T0=0NN-SP5`\;MV'/AFPX:46[
MX90NR.B"O%WP:="B%6W0\F+!F!_^4PYX86@YZ!_(VD,MM#C4;5B_77#>$TL_
M`,NN\$AR@BZQYGJ44!+^(BYR[.DFNL+$74/V-X$BA2*#(H>B@*(T"2W'_-32
M<BS.,YL/4.9<B[6T7-,%2[H@H`M"N4!/VXRDK6L<9Z*;N,=8I(J2*TS:9TBI
M93W&)ON3=XUK$5-<8<H^<RY(+8G\.JTET9P\H;7DT05+NB"@"T*YX#P`1G1!
M3!<D[8++TY0<W[0U[1B2T04Y75"T"R["6F08+7L,.V]:.Y1\8J(=RNO.!['6
MPY!OYCP$6;9>I[XT_.^3<72QA"*`(H0B@B*&(H$BA2*#(H>B@*(T"2WQ?'ZI
M)=Y\#@G-!\J+9+H62:<O#=^!3Q,.10!%"$4$12S%M)D?S>83:^*1ZV=R*2SF
M>;9-Q^$4;B:#(H>BN-R1J6M[GG<^D9NY67DI+&9/)Y/SZ*MEG-\<:!F_[E07
M:^F9GY(]\"69-X?SO.UF[Y;R=X:B"`QKAW#M"(H8BD0*?K\BYLLLO".%G<((
M&10Y%`78B](40<NSZ*]<WDJ8SVRA]?RZ=#KA2V-(XA**`(H0B@B*6`IU9O,S
MX?)D:`HRN10V<[LBA5O)H,BA**`HI9"OQ=9W5,LWOTW7\BW.:X<GRYQWL1;-
M.[EA\Z4QY1V*`(H0B@B*&(H$BA2*#(H<BD(*0X66IAA:XD6'I9-Y?#/3K$93
M3RZ`OD*FW&,28!)B$BDB+S#D5B<V_3(Q_3+%6\XPR3$I,"F-1$^ZZ%Y</[R+
M]EGG/">WG;Y"QF3+.`82X"@A)A$F<0]Q&;EH)SW(\<[WD\W%(.U#^DU*ADF.
M28%):21Z"8ANQPTE()LC^N2=SN%$5Y37B2&_2TP"3$),(DQB1=20T%SGR<PS
MP5%23#),<DP*3$HCT=,O.B67Z;]N(B^ZRG0DH,T<7R%C&<@X!A+@*"$F$28Q
M)@DFJ2*>O`&8C$@[):._GY!Y4HZW46!2&HE>`:+!\X4*D'VARX&`V61(])E$
M:H+"9I;KDK%BJ1'&IO-YY^XX4,90)2$F$28Q)@DF*289)CDF!2:E(C(#S;S_
MLSMZ\6[K5^I`K$8F@#8I>K^)#2X(,HXAQP&.$F(281)CDF"28I)ADBNB$NBP
MV47^FGE'@8.41J*/!J(#](710#:.+D<#MSL:2&1(\9)!$F`28A)A$F.2*,(G
MW*+;8XW(O#'%(3),<DP*L".E,81>`*(U](4"D!TEO0!H%Y^9VDZRQ8=)@$FH
MB,J+/9J3/8EPC!B3!),4DPR3'),"D])(]"(0[:++(C"W?YCL+ETFWW'(A=Y7
M2#O[73+/7O8A_1XJP"3$),(DQB3!),4DPR3'I,"D-!*]`$3?Z+(`KKPMD.VF
MRT)P;3(H^LS4DU*C`"0!CA)B$F$28Y)@DF*289)C4BARNO^8D,-?&F-H16!]
MK278K$;>T+5)I\U72!L-]!-]B4F`28A)A$F,28))BDF&28Y)@4EI)'H9W-8D
MM'J:A#:YR?45,J8?-PEQE!"3J(=T.H!Q#R(G5M)'.DW"/J37?89)CDF!26DD
M>@G<UB2T>IJ$-GU30"%C"<`^8H"CA)A$BJA!4WP^578!U=_\;5S2V8AQT$0/
M.AW9X1V9AJ8X2H9)CDF!26DD>C7PZ[LV.3#/#BW!:8>`OFN@D+$:9!P#"7"4
M$)-(D?82JI^>,0Z0&`.D.$"&28Y)@4EI)'K2:9L0)+W;'G1M>DM@263(Z!*3
M`),0DTB1-NDCSYM:\\L_M`S@OB<TY'0^U<85<@%)\5YFF.28%)B41J(7!D_?
M+:.!X/IH8#,R+OKBBQ(<&0L#D@!'"3&),(D543TZBTT==TH&N`2'23'),,DQ
M*3`IC43/_]<ZAE:W8VC3]UU]A8QU@#N&.$J(281)K(BL`VO"+&=&.N$)CI)B
MDF&28U)@4AJ)7@9?ZQM:/7U#^NE(7R%C&<#68H"CA)A$F,2*R#)P>,-^,B4#
M7(*CI)ADF.28%)B41J*7P6V=0ZO;.;19YV91(F/Z(0G4I@Q10DPB3&)%U-5@
M-O<\QLCM0X+#I)ADF.3:SMC.G'F=]V4*'*8T$KT`:.<0S!-[.H8.&31]"[8#
MEY@$F(281)C$BL@"X,><?_>S.P#`EY3B+668Y)@4F)1&HN5??&3PANE@P^ET
MD-XG*&0X=9>8!)B$F$28Q(K(_/,//7A3AW[*(\%A4DPR3'),"DQ*(]'S3[N%
MU[US8'>[AC;]YI>OD+$.<-<01PDQB3")%5$7@M[/E>$H*289)CDF!2:ED>AE
M<%O'T.YV#&WZ331?(6/Z<<<01PDQB3")%9'I=QC_[CZ=!>(@*289)CDF!2:E
MD>C9IQW"*P>!;J?0MLC4R;=A&W")28!)B$F$2:R(F@PT@X#>24IPD!23#),<
MDP*3TDCT*KBM96AW6X9VYXN@"AG'`-B9"W"4$),(DU@1=0GHOQ?`85),,DQR
M3`I,2B/1\\^SI$T%KQP%Q&KZE-!U.J.`1,8Z@"2P(0DQB3"),4DP23'),,D5
MD37)7&8QBPZR!0Y3&HE>!U_K$-K=#F'G$NHK9*P#W"'$44),(DQB3!),4DPR
M3')%5!WTWJ84.$QI)'H=T!:AN35@=UN#=N>#!`H9\X];@SA*B$F$28Q)@DF*
M289)KLAI')C/Z6>%"ARE-!(]_;0U>.7EH*=%V'DGT8;]OR4F`28A)A$F,28)
M)BDF&2:Y(K(,K/F$>9,):<`4.$QI)'H=T`ZAJ`/\'6.[VRGL?%/$5\@X',#.
M6X"CA)A$F,28))BDF&28Y(K(.KAC_'YU9M$[U@+'*8U$*P3GME9AP_5YH=V9
M%RID*@!,`DQ"3"),8DP23%),,DQR1=3UP'/<F3<E;\44.$QI)'K^O]8JY(^A
MI/<'-BU47R%C'>!6(8X28A)A$F.28))BDF&2*R*_#OO)6T8XC'A:Z.>?X9!U
M()\&*A]=N*WV+]6R>GL[#-;U3_&DSQG_4LUIZ>DII-\<\9`\LMQGBV7S/"VR
M/&8+_AC`KD_9@C_\K[L\YT\Y[5ON6PN_;[M+:['L6QY8"_[8+QY_?-HA_K#2
M]]5+5:[V+YO=8?!6/?.7.!F)IT7NY>-.Y7^.]7OS`,?O]9$_IK3YYRM_+&W%
M'Y0X&7'\7-?']C]B`Z<'W3[^#0``__\#`%!+`P04``8`"````"$``E".3,X"
M```^!P``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R<55UOVC`4?9^T
M_V#YG7P'"")4+56W29LT3?MX-HY#K,9Q9)O2_OM=QY`F8475>`#L'!^?<ZY]
ML[YY%C5Z8DISV>0X]`*,6$-EP9M]CG_]?)@M,=*&-`6I9<-R_,(TOME\_+`^
M2O6H*\8,`H9&Y[@RIEWYOJ85$T1[LF4-/"FE$L3`4.U]W2I&BFZ1J/TH".:^
M(+S!CF&EWL,ARY)3=B_I0;#&.!+%:F)`OZYXJ\]L@KZ'3A#U>&AG5(H6*':\
MYN:E(\5(T-67?2,5V=7@^SE,"#US=X,+>L&IDEJ6Q@,ZWPF]])SYF0],FW7!
MP8&-'2E6YO@V7&WGV-^LNWQ^<W;4@_](5_+X2?'B*V\8A`UEL@782?EHH5\*
M.P6+_8O5#UT!OBM4L)(<:O-#'C\SOJ\,5#L%0];7JGBY9YI"H$#C1:EEHK(&
M`?"-!+<G`P(AS]WOD1>FRG$\]])%$(<`1SNFS0.WE!C1@S92_'&@\$3E2*(3
M20SJ3\^C]Y+X3E#G[YX8LEDK>41P9F!+W1)[`L,5$%MC"4AR,GJK;SD%BY;D
MUK+D&`X[+-=0G:=-FB1K_PDBI2?,W24F'".V9X2M!,CK-8+QH<9_AWZ68L%6
MBBV"U7;G)H"[UQ9-]KU$+-(>,E(""0V5G-.ZKL@N@E0'`N)T&H[#0/"]R`EB
M>PTQT@@;#35>UV;!<!@'^\9IUGMW`3I,UI4UBY-%-*W;$)!D\2)X(SVP-U1F
MTXOA*EY7:!=-%,Z#B4*'<0IGRR#+@G`:WP@21>DB6J:OYV`4X/Q_9-I%8YEI
M\AJ#"])APJ!+<A9X81*,/M-<I_AXV?MV@EV_<O=9,+5G6U;7&E%YL+TH@GWZ
MV;Y-WD;V:DSF[Z!]=LW&[Q]`^VK)GGTC:L\;C6I6`F7@+2!(Y1J@&QC9=EUD
M)PTTKNYO!>\I!E<O\`!<2FG.`WNQ^S??YB\```#__P,`4$L#!!0`!@`(````
M(0!3?$6E#`8``*<8```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG)G;
M;MM&$(;O"_0="-['XIZYAN4@9)`V0`,410_7M$191"11(.DX>?O.<M;:`V59
M3!#$5OQQ^'-F9_[E^N[]]_TN^59W?=,>EBFYR=*D/JS:=7-X7*;__/WI79XF
M_5`=UM6N/=3+]$?=I^_O?_WE[KGMOO;;NAX2B'#HE^EV&(ZWBT6_VM;[JK]I
MC_4!?K)INWTUP,?N<=$?N[I:CQ?M=PN:97*QKYI#BA%NNVMBM)M-LZH_MJNG
M?7T8,$A7[ZH!]/?;YMB_1-NOK@FWK[JO3\=WJW9_A!`/S:X9?HQ!TV2_NOW\
M>&B[ZF$'S_V=\&KU$GO\,`F_;U9=V[>;X0;"+5#H])GU0B\@TOW=NH$G,&E/
MNGJS3#^0VY+Q='%_-R;HWZ9^[KWODW[;/O_6->L_FD,-V88ZF0H\M.U7@WY>
MF_^"BQ>3JS^-%?BS2];UIGK:#7^US[_7S>-V@'(+>"+S8+?K'Q_K?@49A3`W
M5)A(JW8'`N#?9-^8I0$9J;Z/7Y^;];!=IDS>")4Q`GCR4/?#I\:$3)/54S^T
M^_\0(C84!J$V"'RU00B='839(/#5!:&Y($*^+66!CS5FZ6,U5/=W7?N<P-(#
MX?VQ,@N9W$)DDQX&23Z?'LB+N>:#N6B\%.@>:OKMGN9WBV]0AI5%BC-(2)1G
M"'U"%B#OI!'2YFN\K,W`RY2GR4D;RTYA1_D%(E"^$\)#HKQ$!-(@9==+,S"D
MU[LO(^&-"T3TF%,IF<I9+,TG!->"*Y?Z0!JDX'II!HZDT4@:(A++S:3(W7W'
MM)8^0%0NM9,>"(/$^\*N6W+FHD@@BP0B@@)SDE,E0J#T`:USIEV$0*#\&8'F
MHDB@>WY<=XB@0"($)R0BRH"@2O',/4,@4842+[>$@2-I+BQ*0P2E:<IE3J*5
M6?J$TEQKY=HJD&:<TYLHEZ49.)(FPZH5B-AUIX4FPMT8%UY(:*78*X75<Z09
M.)*F(FF(H#1.<BWBE@@`SO/7A!$8N=<G;:0C:=&="\M8;32'=@C%EP%!J(:_
M)R(H*(D\XG)%1SH2YP+C:K,,BA,RD]&L*2T@QF'CRAW*FF4+!$>Z/WRY"VQE
M(6-SQG.>9?DD:P$C:99GN6NF4*`9U5=W`L'!'@B,>K"PC,V;Z4)8<Z>B83-$
MC*):>0T3"IQE$03G._SK;#.J6V$9&+2.B?5AF/-(*,_,:R]_UQF%V=Q%?<O=
M.+"%1L;FD7.6R0@I;1A$I*)44C>L0YD_91=DZA?<W<#*#.Q`*>$YJBVV3U`F
MJ'+3,Q0YRS#(U#%XM,X*R]@<0B-(,>D5WS.D%DIGKN5">;-,@^#`#U:B>VZ;
M.V3.+S.;O$M(*&^6<9"I<_`H-85E,'LTST14^S(`F`"[/?51((W.<HZ1#H<S
MCYW#,G;E:WC#H%&;EP$"SJ*$%R64-\L[*+X3!#,P]@[+H+R<\VA&EL'/">P7
M<I?:4-HL_Z!3__#&*JXYR[QD3HJ,N*KAF@N07&1:O.:Z=)9[C'186!%EIK",
MWQ)B4EETH5>8,']FD'OC^?*V@.+8]WM61#.WL(Q_<U<[FS\,<QX)Y0'CRS/N
MH=]\LS5OTI%[Q*U96`;+S$1F_IR:T\K$,!?W+_2,;Y`,+GPCD5/C$/%L'D,O
M4U1("=&<<1HMAS*$,L:%Y)F#PF3.L@\ZM0\1SV?+H$3-M)JL1-\\0B"4%EG'
M=;L$BK/?GS2Q?16608GO8)<PG348!0E)<^V&5:AQEG_0J7_$+Q:%9:PV(E@.
M0UBZZMEEB)%>*"Z4RN'`X+18`Y'FV"=N&/[F<AROB@:/R\(HH[#,2R(I4U3P
M:$&4$<0RQF#'\(K46:["IJXBHX8M+(,2";P!4QWO>,J0X7F6*>G,,\SE+&]A
M4V^)2UE8!@5222CQ]WI8[I!17,(A@YNQH<!9[L+0%?QNB5_9"LN@0"Z8Y'0R
M<D+&[*F9QX0"9[D+G"#'8SO>T1>6P;,UV(N>>WF*F+,O3WC4C(>HQ^JQ_E)U
MC\VA3W;U!BPFNU'0,QT>-..'H3V.AZ4/[0`'Q..W6_B%0`TGJ=D-P)NV'5X^
MF*/LTZ\8[O\'``#__P,`4$L#!!0`!@`(````(0"?3JD`+@,``#(*```8````
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG)9=;YLP%(;O)^T_(.X;,`0H49*J
M2=5MTB9-TSZN'3#!*F!D.TW[[W=LY\M.RM+U(@GU>UX>O\?83.]>VL9[)EQ0
MULU\-`I]CW0%*VFWGOF_?C[>W/J>D+@K<<,Z,O-?B?#OYA\_3+>,/XF:$.F!
M0R=F?BUE/PD"4=2DQ6+$>M+!2,5XBR5<\G4@>DYPJ8O:)HC",`U:3#O?.$SX
M-1ZLJFA!'EBQ:4DGC0DG#9;`+VK:B[U;6UQCUV+^M.EO"M;V8+&B#96OVM3W
MVF+R9=TQCE<-S/L%C7&Q]]879_8M+3@3K)(CL`L,Z/F<\R`/P&D^+2G,0,7N
M<5+-_'LT62+D!_.I#N@W)5MQ\ML3-=M^XK3\2CL":4.?5`=6C#TIZ9=2_0N*
M@[/J1]V![]PK284WC?S!MI\)7=<2VIW`C-3$)N7K`Q$%)`HVHRA13@5K```^
MO9:JI0&)X!?]O:6EK&=^G(Z2+(P1R+T5$?*1*DO?*S9"LO:/$>D9'4RBG0E\
M[TQ0]&Z3>&<"WT>3Z#9!2?IOE,!,2Z?T@"6>3SG;>K#T`%ST6"UD-`%G%<_X
MS7@@%U5SKXIT*:@%]/1YGHZGP3.TH=A)%N>2R%8L+RCR@R0`O`,CQ';*>+EU
M>S8EACGXWH$MB0^V&G]A)##+@\2A7PXI+#2([!1-Q1?#&AU&5$6@.[E_FCB(
M1I+K;$-[;'EYS,*"Z;\?2Q4Y6*E]ZX61I!H+-C+U9RN60PH+$>(_11Q.3(D=
MM,R^\<)(#%IV`<R,)TZB%E)J(UW73%7DH-TZ:$;R-IH9'T3+_@=-%3EHQR?,
M/`I&<GF=71ZS$E.GY,GN,=Q$);9Q,F?U+(S$)`4;K%Y@CF8YK+'P\O?@*;&#
MAYQ&&HG!2_,497'D!+JT)-D812@^2BPX!/O$:7C7+3==Y6`Z.^MBIS&<21YF
M".6.9FEKT@R-Q]%Q%[1!G3-BN,MPF)_EZ&[`.\VNSV$R3E'L/,_JI4#Y[#5I
MGF7HN$L:0'/JF_.LQVOR#?,U[837D`HVXG"4P4//S9EO+B3K];FU8A+.:OVS
MAG<S`H=:.`)QQ9C<7ZBWBL/;WOPO````__\#`%!+`P04``8`"````"$`)2$4
M4*MW``"N=P$`%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W;;AS9E:;O!YAW
M"`CRE`0D)9$4*:E.C11%JMB62)FDJFP,YB*8&23#E2?G02KZRA?]!C,W#?0`
MA7F`>8AZE'J2^?ZU]MX1&1&D6&4;:&/<:-MB9L0^K.._#GOGE__RPWB4?2CF
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M)_S?\V>[VT^WFU_MK>9S7L\.RL6`(?Y0Y'-1)7N5+]M+V=C8W-K8WFR.$9;Q
M73$:;7P_F7Z<9*=%OD`:AMGA8K$JYLT7/CN:-C\*8WP[':TFRWQ^S8)&"-T-
MC\55GQ2SZ7R)*&:GRWRY:CW^V1^*UF=A)AL_VV.;E]-YFV+]P:!@`7P]]*7<
MM)+I>#QEP\OIX/M>=GJ5SXM%=KQ:FDJPL.9K27[J!#]`?%OK_.Q6\0NOOROF
MY905=@[PNQ:GTNQGU[,V>S>?;/RNN=X^:C4TU3H8Y:W=?':1CQ:M@=(L874W
MR=/>\=&K_:/3_5<9_SH]?G/XJG_&'R_[;_I'>_O9Z3?[^V>GV8/5)%\-2QCQ
M,'OP_O15=O]A<Y&OBD'2V.WFEWOO3T[VC\ZR_NDIP[6^S1=79C4&^D?QIU7Y
M(1\5DV6+'8>3#WS<(2IG\WQ89/G`+-7"QKJ4-B^R>3$H&.Y\5/2R2;%L3OUN
M7LSR<I@5/V`/%XB-C-=T>57,LT'0RGRQ*-I+.9LN4=7;G]EG)S/QK7/J5\5%
M@=X/LU$YT-Q.@>EDL1J9-ET4;;UYA:XMRO9JCFW%&/_+C64Q'V?=:SY$JR>7
M);0(#W2NZ^SXK/_F)DX%/KXY[+\\?'-X=KC?8B9**]^PR&;YM<ANVX(S\Y5M
M-3\O1^6R[-I:!SD6J_/%8%[.EC@06`GW5_`Q4MWL3MNSK+-F5-XXY9OCH]<;
M9_LG;[-;]I/8)!-M!,NF%Y]:0GIIF?\`?WT%UYWDKEB7&>OBTQTD\HU57+[E
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MFI6@T7'Q^,%HNEBT/$/]Y6%Q40[*EAD^`WDN5B".A7QXEB_!G(OEY]GFD][.
MTUWV^LQXSY^[+YZQT9TD4\LN@>+]UJYOEP!7+1.`J^EH".KYS!S1LB4K1U/V
M"L&FHY$P3SE!:XM%>T?F'^3+VD.<F86MV9RL?_0JZU:X7^&?WX%_0-;%L@1-
MWNBOVYJ<U#A[4$ZR(1O,YYAQ]-+HTN)K>X2:]FL(UZ<[O!?4^Q>\LR;DM[S7
MT.Q?NL7&ZW?;7^.E3V^N\4+="MRRM8;.W/+D#3)T>@;4>[M_!+X[/LB.W^V?
M],\.`8$FC7O';]^=['\#-#S\=C][<WQZ)Q!8#]M:(/!D_]O]H_?[IY\WK<N;
M`("Z$,_)]#H'#X',+N;3<3:;3X>KP3);`!!;\/"U!7!NBYISG/*"W`^Z2GB%
M!PHCM09Q2Q"P1NO;/<R2ANF<?_W53F^___MW0MMM&IS$=<GE#4$ZHZE!Q^8^
M7A<3(J*1HZKAN)Q8W"JWUGS25Q.!;?/;-UAJ)RF9`$(L`%9KL\=GW^R?*.8]
M?KO_^$%<^L,6_\"59@.S!V&VAX^="9TDL)GE;0-'+LH?Y-H[4;:#H^A=XNB=
MP_IVW3G=Z063Z9?[!\<G%M>SQ^RL__OLY?[1_L'A69->A^;A,N&Y<UAPT?9A
M1_MGIB?--X^*92:_B%=S-VNH>#D%.=W)D\1QL_[9V<GAR_=G_9=O6.IQ%I(2
M/7'H47/6@^F\*"\G`:@.KC-E-Q9X<"%I]]./+\GN--][/\$5CPS`V:)Y.O^0
MER,M>H-DSH:Q;5&`P0W&=_*B;3R:T[SLGQ[NF:%Y=?CFO2).8P<VB#CT[=OC
M(R+//HR15?NT)_IN__#U-QJD_RU&[/5^=O3^[4N&PJS51\/.O3_#ZAV].CQZ
M_3DQ;G,-?ZT-W>N??I,=O#G^[D[&LO;TP<GQVVB!CUYG_;VSPV\MNFKIVHW2
M]+*<GI5C(#B2VI*&_O"/JT4(!Y`\@F)DC^2.0N)NX5P;+I.T\J3%YZL%Z@I;
M@MT``Y%I*S^8-+262\#*9*6+7=#?IBSTQ\H?_=F?P;8"J=;#U$^]`*CT2)I=
MW18]-R=*[\4(O,L!W?B20-:=5Q9F`(2:/[LV^]T5W;:,<'-^0\@;Y[FX`&TM
M>]&UE$I01J/IH&9S-NX"7RV7%F89`/7!^<:?YH93H.LF]S;[N&[WY]E'#$BQ
M,;VXD#\54.[T=VF"&SWR%<("/%B72/,F1N1:D-R2SI2K^$26R(%%]5"3"J+U
M)W6C^5)3_0^/OMT_/<,RW:;^[U9@%WA_*\U.W3I?@R,L742`7@X[#?6[^710
M%,.`!(@9DE>^D2%[RM%%&U"2D%M8MJJR`9_:Y\'A$:G%3^QS?SP;3:\+]FFY
MGP4)NF(^*!'ZYO"O2OA"3O#33ZYO5K`\GPR,DDAX%?\W)S@@#V<4S&J@Y=8W
MUB>*.&>98ES+G#2GZ7X)#8_Y%D7&=WMI;7&&5DFCE<.2E'YS@"2YL_GT0TDA
M)CN_SB[*"911='LS5_<O+B"[B>$/2"0JF"E1G_F_R?0`/>Z:UA7"V?NF?X3C
M/CS*3"\4$-L_%!5_VW^S3Y324M^[/]E?@MHNR\E$F\+<2-*!O:3MFP3A29+M
MMS]S^O[=NS<6.9$H?75XN@=V>0]8$=R("("=@"S?6D357K@H8Y9["(QB2=5Z
M,C#6C4F%M8E/][[9?_4>*,BT1\='&SYUI5Q0\$XF9:\N_#$QI574O.FBF'\@
M2&LYIQO?[?)(Q_/+?!+\?"][F2]*2PB^4TB&RQ<R)8$(\4]7X['*3S#JE`(0
M8G8*E"W)'*E`%XRVR/9NBE_M2&C^_6:ZI;:X^2C[^\V[+J9SU5MC)/CS7_YG
M%M`:W,OR[+R<+HO!U60ZFEY>P\7Q+)]<(]67^:4CM^7':4:.R/.Q/#TNADH5
M92DV%A,P"!9IUV+11W&>SS"(\])X=*&JE^;%_TJ*+\IB9.HS+\@V6V1)?M!F
M*"?%%YF2L,;)T>@ZNUJ-\TE&[G=^/9V4`[)_Q3A[\/-?_N-J__3GO_SOAQGU
M/P]URPF+$>(9H3`S]H<@I*?+=[6GJZT_^NG'C,)N>Q5L%*.Z$*IER7-2GEAX
M1U0R\5J$35P-Q7/D%*$9+G6!++(2@]'GJY+=IE4N+=>37:PF(&*&(H):9L-5
MH8>']94,\63FQ:7K?R3QJ;6R:1-_MF-#BLAFE.'IN"!ZDT)`L-4%9MGM!GD"
M],072S4Q,L'I>CX=.L[4)@LT&N]^-?UH>HVIGQLF9(HQBS&S(_[5V*WI\FRR
MLM0\_YX4'P.]BA6YQ2@A"ZT]"J`DA_I4)FAK'D>DG8W@LI'`TAHU"@<A`W]@
M;];$SQGC$X$V-$<?SLQ+I);):E\O/.0QN8F/F/#D`T"E"FS:5\55SS1H<Z^+
M.4S:F\XI)'GT(=FS3VT`8_I5CD\LBDG"/.'[?U\8PXSV:RNO4Y#]48<<^_XZ
MR+NV?^=:?6>1GQ?D8J<?9?%,O1:?PXL5&6CTNX>G'<1_S2F^S*3,T$2<N"+5
MM<PN"-]7,%^?C*^)!>9``6HJDPL289)3$?>84?:N<>!-<L0OC"+H>=B>%I-6
MKY&3LHCC8G:97TZF2!9&>U#,-0?RO2>%MGS1Q"C..MXQZ9OE\)$Q</_T4!.Q
M?&P^%@O.X*GG5'!Y:E12TX*?P:3Y'H/D_?P7&,+;RHHP]X=2O3*FL9BI[\F%
MLUXIF/&+S#V+U*HKL9@77MY(O$R[LQ3$6#AW8.],4;H-Z2_*J*%-`8Y%^VX"
MQF\Z*.C,#A030`11)2:RC<5TCJ+"S6`P?-%F,GA)-#TI;-(SLV.F+CRM%("1
ML^/;NZTBIZ`W+PM:>-`3DYCIAWPQH`0T-QI$:M&Q0C\1A*FM%<)\-+MM!DQ.
MI*'?JX6X$30GJ`B93&!0<EO:FLG*GB3W2-*^P-,C28M*6&YX(.X0HW.XF.?%
M*,2Q>+IJ@BA$6!X<&$*%M-1$.\E%>+=BE%LJY`G1E01%330/6J,"`?&(E@GM
MJFU6YQ)(!IB5E];745!UNRH(56DI@'25O3"9L$?@PSAW!E2N)"*F])B_2:EN
M6<Y([RP&],_0,6"B\J:\*-[FL^PT$+(F)\VOC(1!NGO9PI:DS;*_4"I<8#TG
MQ1ZV)(!",(G^_QW_A7XL^R-E'ZD*?W5OL0)J>QG_WF/:O_[L'S][M*,_9;SF
MHM&8QK5-?3(_H+[FS^R1BCR?E_KT(A^70`8;<<O&D>05_@'2,YWKP\>V@.77
M/_U?1TRU5<5Y-VV2O\^T/6/VB#8ZLS<&;P1`LF&^S(4P3&003')<!9Y!UBQ]
MM:!6"%00TG#A0=;_2>1[+=XZD:/(OL($R2*'T+;&\/]OQ5`MGY\O9OD`C9K)
MG\T_%/>^K@0-4U)A[AI<0=,3]DUN4&K?B>7=_;[-1[E9`>>*8QC,A,';*-HA
M'PUO:@V@$3*"*<P&2V/R+/3TR.T(1Q87V%O^]T[1A6QXT]B:DP^5IGSX05@$
M7&2*66TVN7H]G7R$N65I(P@&".@`D/1()(U""+ZE(19)HRM+SVN`6(,","P!
MRN2D(16C6""FA\)F\$?!I]EK_#DC,X21-S>.*U#0(WM;:``&9A`?NQK*K`7+
M5^XF+:P"9N"PZEF;5HBL&E=N]IT'>I7/B?L+\";S"$KQ6B#$@@Z)[",>BTJU
M9$.-(33E90\.7O4?9OE,Z\E'8<VX;W@2X@^##=:"@]_,Y]ZL=BX\4%`@F\[$
M?>AII/Q(<XFOWC!\C-4:L4='8!P%:T;*N)RN%BP\"#FL/Q]-Z=4D(EF,P3AT
MNN)"J$M`7F.G";L#P20'),3P4(`$,8XNE4N,30\-*OC7Q"MKR!,%-N";N>I*
M"*`%&0I#NO4PR<!J53^)J6V#J_3NLEP0+XOU(%MNSXK?7D20GJA0X2(QE)4#
M[.I#%<@E_Q7B18OT0;25T?-7IB!*?L_?]NI$%.3&?!'S(50:-.8UI:;=](QR
MV,N^*7X@9`_)MG^::+(W@>!U0D9>K`7#KD7&VJ27``?Z^M#=A'%J9O4,UJ1N
M7?0'P::Y5$'3!+TM,<G\(?A!`H>D!Z'Y0'D!FOX[V^G<K-]Y0%JN<2%D9RQ9
M4;46F+#*%%4]8U9>EF:)!LNK.<E^DO`Z$8"DL,:W[49!NK&WG2!ZYU<NRM+2
M%\33E<6[^^S954XZR_(!;&5&1L@RYL'DF%Z3H2'19H8`>Y'3#CL?&I%E,6VS
MY02K3E@DU^!Z=\`Q#)K=-GYG=")I)9.J`/9TX_>RT8?NV*8S^CWXU&*!.`L$
M49*L5N%](%Z#U&44IA.L!\^#C\>X%&HEM#6;JZU>>(@Q)K!:*.>*<K,Q)625
M-YCSLD@=*@(,8`4EUF#M=(09#3X[=VHDQF<U&%E1<$S3MG:'R/[TXYI\=LGE
MJV:7J+*.T5(FV[?GZ4[C1#Z9K%ARZ%RO;:(FI02K9B19IU0C+`<ZJ9#<V)PI
MYAVE%;<WF2X3867#<;OF"Q"@8)?K+L#G0['):,],2:-N7*S@[[4.A?":#B0$
M.%6=I=G#!^0(&RD=.\\C&9$3NIA.EZR"\`.0C+X12R^")-AZ%*&:-5BW#A6W
M:X1*XMXAU!5"0-R+F2R,Y'YE/<?R8E23"$?)F"7MJ0P3%H`4Y-)>PI/0ONY_
M&-**BA"X5%`00(`KK+4?BT_PG3RF)7V4Q#O=W[,8MOA!ZXF,^S52ULL^7I7T
MBWU$4M:D[3:QDAA%ID"X"$,N5G/ZM:Y$GK$WR5<$03,!)0MRXWQMN,V8:3@K
MJJ0#"?P[8*]6.9)*2V&]HF5`XY`84EG82TKCHJSA1$07$%-1?DWEHDOH9#[H
M%W0COZ'7_QCSV\FB-31M;>#.`26=DDQ2A0*'[#>$O#9'W9Q&T_C;R$17!?<1
M+9O04HUWE?"A/=7"I"*URHG9B^I;*-:Y[+!(LXE!PDTRFRGO:$:JQ"WA/_D8
M8+#J69;"5K>.`\&/U$D65^5,:3X5LV6QY1;GT]7E%18<>S''-V)2ZFEU,K^.
M[NK]HMYRJV]:2W*P4!F-TYBB;Q6%#V(-YV5`YLU7`W^:'Q_'C32_L-.",4*O
M5A"S]=T)_>8@)PBO(`%4JMHC(ZX`C--E1-^:NTWVW\JF1S0:7&Z*_K`Y5D_B
M=3.*QES/LXN.,;]W>Z;=4Z1*R#>7_?ZTW_QH_[8\>//ATQ22WX`/72;ET@?D
MM2T-"4#$0BB32,Z<T*HYIH^$D*\4]F2#UV_?-1])V??F%[$>4"\4-)_9LY0_
MTFPE`#Q::P6=Z?+F,/:0U3/DP)116/2"G;#MHB"J&I[G'!F@FNX^CY);,:7L
M<24OT9KWAI2QY92;T_<OBXT8\W2E7IO/OVUE79M/O*->`/B;3DSOPYZ:#WG.
MNOEI1R;?\[?-![^-:7J&C]6#FHBH^)-2^6E[-?+&A#[&D`-_F$EHGE+_L?+0
MG#0)Z49TD=AGY2HLI2UC[PJ2!HIT11(!#Z7Z=ZK$M_!GT/3Y2E4!@[(.+>4N
M\ID7.IJKB(%_?U'F/8)>JQ8U'TI+K=D#9H]S-A__AC-UV6_YK^87S9BZFQNO
M2?XB_ZF`XYM`1$.).6;(6H+:'EXULN8BJLW$@9I/I'%(=01N'G8TB+Z=<BZO
M4,%P1)"RF%XL/Q+;W#A8JB!8X4[\O6$>2VE\Y$C-Z'J#0\F8G+H+DWU-+Z8Q
MN];7QY1Q4%WU7^7%^(?GM2APQ_.&6H4U.:MI29%5A:T00[+(!JH=P81(F,>B
MI_ZT[U?U'RRGT(AM=*#@;LC;@8UY%S'.WC\Z]2K=ZW[_G:%5;:'"5!6"UN=$
MFR3'9/?FZLV;5U$V6)<R8$3*,63L&S!9C[WHNBFM2[@&A-A+],,]ANFH)D:+
MWZ._)10Y>RJU]FZJT%73K&FB523C`O2-]BP];9:EUN0IB86+6H).L-?`8Y;;
MB5*+7&&B#F:)NB51!7@8.`#%-&"%YX9TH"A0\`S:+/00);PEX"11#9!,[XI;
M-W3K"V8'5`<E65).N8R\`,*6T;L42W=^$$P)ZD"`"#B[LC-KT>^BI?0QL%`C
M2FR*FI>+[WT_8'./!BV)*HA[QNIKF1AT+C)!>VOB1--8E/2/`%'%(?4.$#6>
M3-4X$[/BN7<!-NF-EECTO$[WY%&D<Z<K8JHXGOLG\BKDDZ5F$R+G6.Q?3CT%
ME:#TY\:..`6[2;"'5#E'X0,L1@!X)ASYU"O1;42[;U(16Y^`E/2W*<$]M!39
MX@N]PA@UZ9J>6Y!-DCL$UW["HI8`CZEOT<V3L&&4&U8B^C16$$#>[2L)`!AL
M^K&K9).`HL9/:6RRNE^@]_1R4Y=`_#WSE)ZM&HLDQ[QH67X\XWDA%:IET(E.
M1$X;BX8^#<O?D%44U)O#@L&4?;#<'D2,D]Q,U'SH8`/K'A0UJ*U&QMK30@.G
MU<>V,,%)':HFBN/\6@4:9U`Q[)AFP@T32XXAD,K*/]#MHV"L2F^S4-]2181H
M-IR-]M<E*4I/;6IGTINU?<5S,CK?;BDW7B(]2-,"3ZZ4@G6[OT8/XQ!;#&=L
MTKN(UOA\-5^X`0F4A.+TDT$'%TTQ(4"AM!*C_[I(+;('FB4BKE2F>.@"<*GB
MZ<3L5/#^>>U8F1))?J1;YJ0G)ELK3GC4*J]D.]F:DDOJ5-%<3DSNE$G]GFTK
M]IY4!%L1MI-C7U@T?F9RY/93(BKM[LY@5^:\EJ-RYPZU0'[7[DGE6Z/'5,-.
MS)JZBGZ/D4X+T,K)P*S&H>7<1*NR<(PB#RSM",D;263G00/7@I1S"]N0*U*:
MYJ9W,+=L7UG(P.-?M/<H25VKK`I,;#&<PB&;12(-+=.D%;CP')(L=)\F0]0Q
M&EK2>53]AB46?^Z2`Q:`AXE^#3]%E6?Y]8E?V<`@@RG.RLQ.+>MB)F2D<I.A
M'@&9TR44K_?XOB3[B<6:9)<K++.*%<A%V%!]7"W9#XNJ0FLW12Q$0"7"1<^@
MJUD\@,/U%*;,>N]-=0"U_2XBCQ%0`I=1A%[3A10F,+4"7%R5):.G*XS*1.%W
MJK:Q34LERL4%BNBB!.\\7<UL7\ECK<V$O:%XG2I]M43?L:Q`,&48-]4%0U`?
M<L)NY;`PE?GZ2,:MOH`@"&R4><+8+)7R*V&8,+LVJG[AZ03#22NQJ0PFM**Y
M>!B)O4:PJJ(8QF*7JAR:/?]G6;#1MW1#YX8)VCK/0)I1W$(X\:<560]D@3]=
MS$RQPW$S5W`0HH_"E3BP-15-@HQP>!#<*GG"]'F,TCFH\V\YG9)V&=&N(#'X
M3N(2<268&$-7+D=,`A1"UC5AMIIM,"46$"P-9D9.VWYX0:2F)D.3Y!D>D$,Z
MCD,K^74!]TW&*14-<!4),HBM6,FN(<CR!&XRSFE'\^QY0)-60+^)I%)4:S[`
M]%@PZ2@_*8"\!*Z]M>^P453P[[C3X13EL=CV%V\V'7@T@?)CE[`(IIM>"PF8
M.ZB3SNV!MGJ8SLTDNOJ7`JN"[.>R*HE(T3%P\BPR"<>IDYZL?UT"C-EI]A$!
M8<T#$M,3B:S@Z\C!'X`AM,E)PMMKU7*T%LN8=RU(FWE+NH.CE%CGZ`A(+1K"
M5&4S=(!,::`4?E.492EY]:=:AC4?7)4X&8>##7N.`A+0<*K"I4B+1*;#;*B&
M\@0<;_-"$',^R!^:7^'4J\[QAYXG*SB%4-^T*$QI#$KC];('YP_M(P<ED6[I
M@;@]M>5@@64U$H=8!AM`E`4Y4M[!6ZX<)@P+N"=A>3#@,`99G*`.>$*CO?O0
M&[0C>UV[C\%&T3NQ;01<P7H(`B.(CK9)0$%NL6;A:KY(O#N)[CT9L-L'K1S2
MD`32FN6++UY=#Y6))'K4;JO\7%Q<`#?K'6Q[-QUPJU>6W"TR,4.3Q+HJ+Z]P
MH2,N4>3:,3\_Z5*$L;.CG2$%A`QSD1)GUL!@`&05/0V!K/4JX*\1+.NW1^"M
M[*Y,`]U72&T;<_=CKLP-E5E?,P4Z7F"&4I'&<+HZ7U)TKE)K0#;([C<LH(Y#
M0P_A6C6V97#83;U%P#\8HF>7]W>Y`>HI-T!IDOL[SW9Z+\(?WL(2/(.OX^91
MMK>?]IZE4;9?]+;UAR&(]?R6S=.J"5JK0KK[20)T*N5T&0;!1C@O-1XJQ%-=
M)`H[*.<+S65A9[1C-?`&3V\E';,T:+*YN=M[_HLVH"7'J0MXN[)X2<H45AF3
M%$RFL+3B;NU8TUI'?TB\U*LI&@ZIN23]*\K(QM;'$7%F.5!:QYE,1VK9)\SH
MAKTAQ60!^OX*W(T`#Q!?11QT,8+=M9,^(645[<L,T)YJR0(U2-#(:#T;45(_
MEB@-LBV2<Q8"E:G25^=\QKF,+%>N6JO.N>Z"62D&6GH-W:ER@V-U.(DZ5>0X
MK:,"8S",#F@*7;(AS_/)]_/5;$F?WP71^>02L4-%"I`6:-FKC?&5^MQ5\C$&
M4+Q631W;:"#(3S_B6`?EG!NV"&4ADAB8'%#<$/#:3MG2>)@"5O$)KHDT>.ZX
M5SZM,^ZCQ6U0D.8#GE8@H;L@0"_-[/[>E,EUBZFGSQEGH/S%,E-RT4S:@:==
M8*FW,+GALCBY7D.-V<,HLT#`>JX2V'++/'QK(5MEM+60FRQM734L8QARPF9,
M)!)A"XB@M;_81QHLY%A1D&O,*Q4%_B/4*`E))048*WL=!P$,6VZG8J/($)M\
MM13S")4%1DZ,T2&^[7Z/Z3'L`[9(QL-JT&I:D3F51JJ(99;.,BPQ_I54IL&_
MR#C5A^;-*Z#E:)BCS$GS%,3A=KB'!OE2#*8T6MQH2Q3219O&]OB7@CQIFF5<
M&!!<KB4R.:$NI+;L%)T*=BK*R,$GL7\FY'@9(61/:D(>*SN+7L9%,U,V(@LB
MH2;/!`(!-)G&4<21!<"`,,F$%'V(=&H6UOE_4<X7RXUR0I>E_4N-RFH+.C@\
M./:S+079B[8*[.,\9Y)JVW?U%PNH-JU]:G=K7\<LZ0S=4YX1'V)-N:*0;A9&
MC)8;E@T8V]2V._81$#3DV]Y5K+2Y]22T06J*4YHBC]3`M=W!(HQ%_3+/P*KF
MIX;KD#R=+2$+*;\^`@,Y)^&%`7(G=C(M6GS]29@A#5F?S@;&9',7D@U>C:I8
MH!I927ULBID>A$?57*B#\'!,!G_BK4.`!4&/DK/*Y5P,T.[[\0!G.=D`B*E%
M$=,68*,DI-X(TEZ@1#5(.!,:LBEFU*6EYF@`H-(6Q7^1*U1*)!T8Q0W,='(2
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M!RF78,]7RJWQ7/]T+WO^9&=CYPG'>F3LVPI2L\!WT3`9T,-W)_\M'\^^>.7U
M:B0@I).AJQ*8->%]5%FOYRWK=:8PE'/OV$9=^%G/"4>G9!H;(0024]W0@C^P
MZV"%*V(3FWR35/QB1:@$5(TM7=G'J7IN:([RFTVIF>F^&[16A9#:$EQH3*-2
MF_Q:(592$9<3:\_05,["M*&"FE0$`;^"6KC<%:DN_Q/)#.UYMO#9#-MK"N`.
MLX;?)`W^:(MPW^5S1=46\L6(4?IDU&G1<JWYP#M.123PL@\2".EFB"9PLPYF
MV`5B"#@#9!'LE:$SS07MLV>,AC\CNAQ9DZ*;D>;@`*Q(-H;@M4;,%HN_&CRT
M'`$P*VPNR^;W*G@(8]%B=2N!T^D+K*[V9>X?_N?X!HODP%^+,K)&FA[7(M0E
M6=#P6"QRE<:+:O689H!BL&3Q+?,3:4'I82/97[4!V60;1;SO6+LY'H/!OECY
MR`KON<%4(#!G0XR@WGT=C258"]8]K=7X&&_%HG\&E$AJ*0+B<!3$JE`2ZS"F
M!Q]F6&I#(S=>Z@OY+KT0[('94A8B#Y7TR3"4!PVLJNI):$GYVC6;-UL'[336
M1)/+BBF;RIU+Y"W18WJ*3E9%";N$QRCB89HY>#T14TPW6%RTVTO26@*OQCZ#
MJJ9<J[<P?EREEF'XVY?>>3@G44F+N85([X"9***&]NJIJ&9H)+IQ$RBOBLL$
MSNP%FSX1"=*D#H'Z.3DY]V3:V4"P)&[J:@5BY2OCW?GF*A$%M:-;<OR,)(`Y
MK!4HA`7PEYD:93\ME+$%IL(>B^+D.GEZM!*K(1(=I(BS[QD!#7,*%!WJY'GV
MDDY/DI-Z4NB^?_K2_!(65WV./'K):3]+(8CU458;2+8E?2>I%=^/[ID`QJX;
MXE)H9L<Q8B13-9JA+9U-_%@,8WAHU+>W9Y+8<._1H^S,?\&`55IJ3'I7)=C@
MA8X%AC>@CJ2RZC.:\YW!!!XP@4X<J79M3)&K,E0AJ]9/29@1O<T?:?[3X0SZ
M-`4;%3!IQ79("]<8\Z3URUI#).=3.VWCQ!TDO0&VUSV_P<)4#18W(0-^*/:Z
M>:N"V%H#/%+NI/O:;QUKFFYHLR<WA0VN/6O2OB;&'HH:SB98@?DZRF)1.LH)
M571+!F$K103="*[[#_6GGE<W,$M5;<,RD)[MU@HMQO4CL_%;=ZAI'^3GPL\D
M^/RQB.M5,?U@A4E4B?`K4!'-^""@U$K/4V'8OEX1.T034`E&I?TMIAUPY$"W
M.+CL-.Z0U>6Q9@WV`/.-4WUBZJ%"&_1>])&\KI?KW*R),EJ))"U>FI3'7]5@
M/NR%RU6J1UK/I%\(RZN.D(VDU:\\6%Q"Q&VWW2+*'H?/5B3[[.@-V97JOCI;
M&D&-FMWPA*:DW0TG:U@PG15+I0@M(DJ_[<E\M1\SE'2U%J10:8;%\V0Y^J<,
M`<M%">?JJ%E;ID%;+<[3!4&B@X3%H179U8\!:EIWWQJVA=[0H3O<Z1^"*4GT
M)UL5M2QDQJBX5J8@Z&8)#=PGBOF!3NE]0X("*#1,?[,,NG6ZR.YO/GG:VWGA
M=0833)3S_N;3Y[VGV\_6T__&&V%R4GFJ,J4AMGJ[.T^T6XNUV&\]X*"1W5Q2
M7[!>5U#Q_TRQOB.,.!RJC:V5/+8)4J'*!W?,*O%N(.H.2IP7@UR:"_?Y[_"F
M6&LVR6-_I<-T$Y%!XX#<PQ7-<J/Y\J<?]4:ZR-G$22;]T:_B%R:W@R?>=FT$
MC74%Z(OF1[?+YOB)B*`D#WNLJ5;R@86]K<TM8\_]K<W>BV<-QK6LTZ'76,WB
MW@P1$205>_PI6:Q&^/RZUA]FR#3F*Y%(=?J<>U@@#L!PJ:!9'5MG!:(]IZ=7
MR<4`75*A7?>%^POH1?5\\%\1=",'8F@^&NC<K[3535';Y@1K%KVYAA_E'WD?
M92+)YJ;6[9FT\5LK%IEAB'4JGXMT",+B!M'\W=H)8.#;:J`PY**P7RA*NPB-
M$=0$D%VKKX_*[_E!%0G9Q!)?EDVI7>-!$(Q;#*3K'%`%'J7,H'342BU=NF00
M(,%#>GO]<+*Q1;HCZQ;;RF1PN-X./14M[,:\!9D`\11RXH;T`R?)CH:X%F=3
MH>WZ:!J#._?2"-H`M(YE&_QI_CW))Y@J>1Z(9SA@"8M]+D&S%SC:R)G/RC"J
M8^Z<,R'<'V\^V39MF\`8X='69LG&%&HTJ"A-]DN4WA"E-T2O!5]B8$SG+?=2
M_,`527ZMFL'G_`>#2E7[9ER&6]UDRPP?4]S"NL3.=7.S%P76!0J)%D8EE#DJ
M$Z37QBB?`!1=WD@W(@@I4!9;>?I<#7!Q*JIROD%=6&)G=2T`".^H9J<EQB$"
M/]0N@K[8[T<IWP*;X2AK(I?+:17!BUHB2^8WTM/F2M3&9-?6'\Q0KZJ=T#T4
M`;U%^7%.`4SI?>@3D2S?L(PNIV`K%<%99(P21W;=8]RF*,_2D(?:\B)Y$23-
MW>*';F?C:I/`%U%#EWP[KZ)YYE[)<L&1<ROGB;"O$3P8*K@?)T>-V;=^4HIT
M5:S;(<FUI=3$*E3+_BB*M*3+=$N1#4_Y;9-L^XGF[1-0SU)";FT\96&82^?0
M,WY6DFH:1_I`S=HT%6438#;GC!'I`1(KWY$GCR?%#Y#!>&*RR9.\'LDCG5TC
M@[&#!]<"T#IU=0<2=M2>:Y-4X\G>:E=OJUYB:\F23KHQD#5T`[ZT7P&J5G^S
M=)H2QCH8>A0P:FJ*8I_TS4F9_)*,ECOL5^:ZQKP@_2)0#6TR_OW-WO93?GF*
M1@1ES:0T5EZ/TOY)_&;'CT,_:X5C?>3-G<W:R*F673<H]S=?/.]ZQJD/G?UZ
MPU^ZJ^W>UG/_Z;#.75G@[6BTHTT$(G5N:$O]&EV+7=O0T[6)TZ8;&SHB$X`0
M1;ZDVT43`R"\'?L^U3T*_JMH9/#-@IP'*,@ZI1^<+(SI(41>.%-V)*1?3(!S
MHBK,L+>,K*$`@GT`K:XU)02QB[];`G6J;'+'3P"L8ZTA%[0+L%39&38<LC-5
MO&ZP-8Q5]=LYL4.(;UNJNUP9M6#+O6BE"G/U2P0QVC*S(XS1,8=UAI`FL@L3
ML&I^O%XGF#1X@170'?.+"%=E;>*'F`$5)L+U\[W0I$UX(!LE/:6BF'*L?N7"
M),0#_'+NCALG-;2'%'NMY46`AA.)NH+4*1!8@/WENBA#+%AR2J'AW[;[A(*D
MH!5#$86.?:^Y4=4JT'W:[,$H\F/1^9K97"I%EP;'W5BM*$W`JZR2@^2R>'O>
MFB%$%5+5@C/5=BJWPE%3A5=`'"9\28_P]QNG`\`9G[RE+QTR.F%9#->=0/;Q
M%))HCN"8/JLJ_MYCPT8K>LN<=6P[LIOA-6\\2>$)M5B.QS+[W)24:W-;,&9Y
M`,A4E2Q8APN"'A;V-V+H?WD&8)\.BU0IQ_J!N=#M9PZ'GP66U`4G"UHR+R7X
M9NPZL_A.CLL^BEX1R0-A*3R0?ZD?BJLHE2!H?:G<;0;E_"P2*06C".!I+-J)
M.FJ:&B+Z6A.AFS5=\4^D0R?_($*G)J!U_CL,&`_RA:1"X^)K0#C,$G3'$YH,
MB*`!**TJ;?%PK4,,5N6*O=.<<1K75&#W<B/^TH0_8[A>^TF(-ZQ'0@0M,S4M
MT6Y.`X7B(DWNYRR"<)C/3U7(1NA4/QJ#7Q1R4VD*.:W:-4RJ-%F?$]-FL475
M=1E-VUDS)DX(7[O(T@Y*,7M2LK7PAZ2BI:UDXHV!-4&J"Z*:GVLXHG9^J;)<
M4N^B9?`/4_.%9,1^9M1[""R`]1)#$#IKKVL]4;>CK6HSDH804U<IBX_L6F:L
MZO90X#Q1"U,6.@CYMK;=]>ZX<(^2`O.8LJ.>>6U8,?5]Q4X$:$&=S\-+.4.5
M=D*[G)]?L3:%^E+"\%J?3OB1=5FKM"FNB4V8U5BN:+()YJ30XH6,G*L:.?7F
M\DP#/7V)7PI%:\XUZ#+3E1TPEW>OY1"3CGN8Z>48J2ES5H-)'ME0]8$1W>FL
M^%)?U*@>W*OR8.PU.-]J2"<F$[B;TLO-K7BKFMOY2K[6M:!:34OD7L4,0TQP
MRQHIL55+GAO>N-.#EA$C.`QD-RG7'ZGT6?4-X/9JN7,)H]I0,?'!(J9,15S8
M6N8])MKIS[[R.#YDZ&0^\11DXN:P1:<%=#6[0E1;4VW.:*;2(D6EVD*QKT&@
MZPU:>BB8(/TSKMFX["\$+*%<`J340VL[D`[>.'+%0+93-8H%<H9Q&'1M7ZG&
M(+36:.G7)E,+VTZ+^V_TJWALQWVYXTJZ(`>&;"UO6GV)?,J+VH_4(I'6*"P"
M24WLT9CCL7P(2A(CW*`?,;^^$?/K50<!X]9Z2^JW*<5@R$FNW;SB*GUI79JV
M6F&ZV\DX&=+YOV@Z?MS"-:D6+'MI`A8,-;-00_7;>TH_(?/D_W6E5`A=8#"?
M84J7]D/?4&)M?Z$9"``3W;/D)`G>@PB3L*[K_3&>XGSH&,9^P0B;P>DLG:3&
M(\6^&[5%"U;(,'#Q&M]@Q)!_RXR:/(9J2^KQTJF7C;B[.HT;$A"9<8?(5%NR
MB(E5*+4@%,&Q1:>E88_:#PM7^PR_:+W3>_J"Z/C)YAJ)7O2>$=7N\M/#B5@V
M36][]TGOQ>[S&KW".!Q:X'>=F^,\I_U_ET1W'&6]/-'2D8,49,B$5&G+>@.V
MRFUG:/JZV:V[ZN#!M>"8A,8HQ52W]35?",_>,`&."2U=@R,H^V6HL<MIP2N2
MK=#Y7)7C]85T+AK[-,-6A>J75*;A6I+OE7-RQ*,@TW[,1HJ/D'^R(-4^`;.?
M],DQ%G@@!FC0)GV6M\-:%CO!-?-+Y>"!=%H=;7-L7KT;Q^N*B"L=%22YQG:E
MW&G0WV2VB!#!0BB.M3K6$)W\-]5*(UDW#2J"6_+!%MP2K-C4?7W+3QIM/:*,
MJR,=W.[\Y>/EUUW7=UMI[/[6UG9O=W?'K,/]S=T=B;X$MHRO!^GUB@.T])^%
MF$XV:'B$AE@*B`K6IBE.<%U]W^'LJ0'>_BCG7`ZW.NU1M\,23,I<+ZT7X&SV
MCKR.\#LQC26H96`.:%BV4K"Z0R1G<34J&F[U7FQM$^7!V5CU(RN?X`*M^BIL
M<T;ATIMG[[B*%OWW8ZMYD[#IBUL8L_VHZCYOOM^_*UE4*+1F=[KD=3&E-4[*
M1-#DH7\C>Z*"=`XXBQH&(%#=Q-*<^D&ZDO=A\ZLZ6YK?I1W?M)#F"_>;'_1K
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MZD._`.+I41R"($<HT!CVH^I`L._U282;TPP(=[K+29Y].K)S1&N'^_AM(N7<
M3`+5#$$:J[J1C,(C)V?(HTH(`8JX%GLT!8Y:?[U_C_D<YW!0W2YX9?ULG10K
M-U^%C0(<X^T#W],E2:>9[ED?^/4GM+#CH$WFUVX-L,A=)&2S_G4,:M<W"3_"
M(231*[+)BG6>RO(#@W7SI0LTAW8*0Q%+E6U1:,=:QLH9Z+S?BF17/@?E:8\8
M#*-)//&=TCV)&9"ZA2&^ZY\<Q,MK?O[+_SHI0OS]+B":ILH=3[)_Y?<#E9S`
MN5"G>%ZE[.$4[!+6ABHYN?Y$\JC$8LZQW8V4]>-E'$[L[Y2V`A)QZH0?U)B4
M65K)`9"9Y*ZD2\='M&!UZ$;ALPV$Q((R`7;8,5(Y<"=P,K0NLD(3<D`BHA6/
M<]5$]+Q07M(LW333^$0:0C*D[?C?.!A]7.$&SHBLB8;$KQM%D<,6I*%C?B@&
MHT$&K;8&>;P-2Y.C`$D1X2&KKIU=X^J4$?-YX5M/0[FAKCJU_!^Q.U*[K@EU
MZ6.5'?<TP@FV2''--IU5+>Z07J*E=J^U56F&E$"JA?UKBI#HM`B6@YU8`"W*
M1B[Z7+IPBQ70>$GWHCVS]1MIV-/?Z,;FR*FP&H[D&)Y,-.*00&@9)TD<+ZT)
MB?M:7T+DGW4H2:QPR-6!<.L0.B>_JU/AX00)"V81HDM%$I/P.J:'_BI_HXDZ
M#")1B=RK$]YZJY,!#9V]5N(7#^]OO=BQ(C&#6>)6!(ZR;`4`))&/Z)WSJ]V&
MSBF)4MQ6Z$:N#N*9+0//SL@H3RYUG%5GT'V@^K%E<3CH$1[`E",6)6/EL5)U
MB+'PN4&JMN1T"!,IS>-`2#/&@"8;66SRGY'=ZQ3@&*<NH&#^Z$)9@$Z5PFE#
M<B[EL$%"WLSW6EJ5+P*=K*YPE\A>ZH2*W27^:UG-+N5YXT"%!(A^1*>_=]9E
M.E?X3Q)'P7!V#=,PHF'4IKGLQ]^ALMNHSY+"U7Z0CQ7(3O9PGA)+SQMTS1C=
MDQ)NI`^5(.3$VXA##T/5P.KY:1OSWY6Z^`_^J;GI!EH6/__;_V&JNI>71'JZ
M#\:JK9RKF>U18S.5#54682\,F("+Z/.2RAB<11^-@JW?Z=4C)I%=FS#%8DW(
M'A+IK19!FJ/@=;UFE6V.=UW:J7#R!V&_3C.)9)L!["?(6EVSD^W$#S__33)`
M[%%FTT0M6BH@S%JE@,^I&BC%:>X]5+Z-4F$+&*#$8DW*?;J",-X;!`U!][3A
MF![R5V6EM#UOT:#AOZ<^K7B%0_6,+?R<6C?UO`#H(N'L*W`$QR>D>LN/".=U
MC#_X/2M*FK9*>R0QU`Q)3A$%0H676527>0G90ZO:@5O5\&*_\GH&W;NX>)NA
MX/W_=&;B&#2SNEQ!BDW:.1PL=4GA)W5>1C_GPEMB),JZX,T&>I+@WUG-3;DW
M.K0;R=6I3N`KUR<R8B5SZ7R4/@X:8<>DM+#:8TE<*9GH45-DZL>X''AK2O#;
M$C>4O;.?J1-$G!$?Z`9GNVD]S>-/51NN([[:&LP;-I\-*-`D#C_>_EV'J(>2
MZ?9O/&A+U<\.1"<><%D;0$M6;Z!`%ZNM<*Q"J2Z/,-MH9R^PEPXFC4;2%5_8
M.3_`7=5;%F`>LY2&_&17U>]0_?0Y--:>:K56F4P'56AXS:)*T]^;7]!<-8IV
M7N`-'."\D)Z2=0V&)HHB_M?84!G`;.=O;_\T>45F1R];3WXC456`:2``G^,'
M!6)_6/:@=O9'N4JLE]+)"_N1/8AX(U0W%,55(E/]9KI!+@.45#P>\I+=16A%
M[BX6F]`#.)U`PG61QM4&9!LK],BPG59==U^IO?(_CTW?6$XW_AJ;WB$[@5G_
M:+:]TIZF_>E6(;GBNAJU,4I3B[8?_5./U.NVKD=.[;,$ASHUJ4LMS3[Y`1!<
M'/HGDX+)<#.:G)24S>>XT4>!?NT)A]<Q\/'6&"*8E9I]""G-L>$(W1Q7@`N!
MMY)W\)'NMY43CA8UG?OVU(BO1C7"$">%3,_]($*^`+)"DW*\&@?T1W]#Q'/J
ML$P6D4EO)`XNPN^Z4JY!)\_4"(/M(J41K9\&BNT1HI\O7O;-5UEY[-NPY-\`
M.,*XM[#QA?4U[XK<@-L0M5H]U6NH<1615I'$<EK_H(:GBWUO`BPTUW/R^K`C
M]#PHSN>6MMLRFCWAO[M&:D#14R6Y%.<U$><))3*K>2I<U*D0_403U1]:F_G%
MXL)2=2PDXK9#NL1URCC7B1[2?$2D:_%""+OD:0.+:"G6!2.>>^E:J23Y]6&5
MD@A%<]29C[/MK=[6S@M5'JO&'$[JT&^*/XZ'':T+VE):43YB0&,U?FTM=@!+
MQ#N(X?)%[!$'^`<5JO@#+1'<.W(_??GVI"5+9^%T03W?8BF$ZMXA$2OTBV!-
M37S.<G[J6*?90X8BE)(\^T*E<K-B9,I'<#K/TW@;YZ2Y[=V4HB!T3#F*I-3Q
MUXM/<_WPX7#C)37IJWQ,PSAGF!"]E%->EU/;IH4S"(^R^3&7%NT):>5XN1]/
M7/%;DPC1C.8DY-C.%Q,E<&T#!EBS)%#I4#/>&BW'8ED.6=1\A@NB.RH"48NC
M")=9KD+[M>>"HOE$(FUZT1`#4ZN_(F13PL]PV3?V4UM"O-*Y]1O"ZLQ3P8,Y
MVDV'5L>PE`1+7^M@D-B'(<1H3Y^8BDABH@K+M2;!"@S_5V7`Q&\-D;Y,L8.Q
M@KD"XT6SIX#\1O[9@L?_Q]Z9[=9UG7G^50X,N2T!I"Q2LY,8H"G99I=D"2*=
MH!#4Q>$@B3')P^8AY2CHBWJ'ZML&Z@GJ(?(H]23]^W_#6FM/AY03]Y6!#-0^
M>Z_A6]\\K7+'><+'C8(-&07=]V4@Y*&LZWSS"U1PPBEE%1$VTE4;.F!$#!Z%
MR"?1`VTP<*VU>FGN"MO:K,9($;9EY#`9_`@'*DVB&>`:V`1[S#DJ?1U22DU&
M;'NUK5DD#UD'TK!^4ZPBLY&R'M14T?Z$@2J=+D[:=#K^!<B$G<YO"X>!7Y";
M)-CS]UK^<V@,UB+(JJ?:,')33A!C^#'.W^(+,O8=4;OB14O4")Y0%N0O0SVA
MB/G").@-NX!246XNZ;>KWB]Y/I1HY*C)OVOSJ$IW5@)S8.J/]C'$X.*7G_GI
MR`NZB1(/%@N,[IH'IZR[C8"=OGB`JIQ,YX_"IM8Q[^BA?6(_BL[E$"B7*^4>
MS.]M"7'D`W=F[*RSS(ZZE'O&H)-3R;P1)N_&/.,#'[BQ]>VK"]I+'EVQ_KAE
MJRM!OI\?DI1PV=='IKZ5D=350/"@D7QV*(T4L,#`+W%RV!^<@/J/\O3%N%,L
MYAYR_]WPOMK'S^">)XM(8K(+PA1EC&]-*+B.ZUK\U,*+3T`>F>)&3ZJ`SEJQ
M`CJ4\7&F^_E*T4FC1MG>PATA31O+UF:''BV]^?[YK@F-<GFB21""/KI<P0M=
M3.KDR!0'4_5RPNA1!F"Z3MR0*829VJCQC83LILH_'SX!`7Z>^9V3Q[/=]T<4
MF>,T41BH$(0M00L-9"XH5_`1=2Z&=08`(2[S"76]=C$%HL.8F`9*AFZ'"&TH
M&[`#K/2QAXVBQ7A%Y>MXN3GYJMWVT-RNH-EY.]NC7B.<ED7N[)P=XMJUYC0%
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M0!JUQ=CBHOD-;W_#VU^L3QC>?H+XF%\7/P3;,=NQEM0@P%`_Z*!1H:T_SA1W
M[H8".C+*]$LEH,G@-W>J'`K(J!1J,H'CWK])[E_-?7FD.N-/$*I(TBY";46>
MQ*/IX@IBTS22%6$S9OHE3I3':X7HT\:5)ZA_:1HVR42,('8B:4WW-`\V&G!S
MN)[);,!N/JI>!@G#LE'+]4(82WK_C%$AB&74(&V'Q@EP0(*,^GU89HDVC/B=
M.CHX%&GOJ54H3;BJ"*9.F(%2U]5,<ZYT6W4\DO$^C8]RJ5B2&4:XM?W6D?6#
M*PF#*\!],GM&1-CZK`@*";I.\B!#.:;F0'$@.0X(IFGHT"/=Q8Z@[J$#6\/+
M&KV(SB1EFQ"&^5CFV.4U7)2'^P_I.U7?-$!/*8MFD*7^\XN/41E\6'3+L:N9
M?Y-&OTFC?U0:)1M*:AWCFQD&&-R$AW=&C'T*N4MXTVZ.F5%63BS5/"#PV1RT
MA`OLRO%ZO9_2V)S-QG4E?+,\.C).1,&LNCM22NFEK]CO$DV>,@Y?[+E!<"EA
M9$VNTIS<XCI%>H;F*!;<@4_(LYJ35W9X=*:>Q;DWOO>[JF,+OG_BZ(B`G1XE
MKXV,!E\_)8P7H8SXKO^AW86K;<NC4^&!,X5VOY9D<4'8.CI8G`,208G_4XJE
MNY9N;0C<)YIF8B."BB\^MI2'TMG13G]I`MR>->$901EQ9!>G&?V?.IF,O1<Q
M)YYO9W`.0S3AH,%&A"K<7TNWB]0`@;G<!TLQ.V"IC*[!3Z7HWB;14`VL!F^K
MZ0(V/E<46Q#B9ILC-J'[P#*'2G.,[S-PR!,J3$.AN2YKT+F-R+'+KS,@E8))
MC@(-_^,9SLT+O-"6V/CCY?Q]WQV=(4V]3;K@.WP.0.^[DX]X[%&>K)[E%5>?
M+;8_$MH.67M-Z#*(RCG%^#*$Q*U?.,@O<2VH66AJ&D!47R0#R?LFD^HMA>S'
MDM.74"B9HAX6H<KF'*4IV]2IQ1V>$L9W9B%5$6H^-(J.C48**_KF9@W2&M\$
M`Z'"^ZNS_7SQZ7+'G<FYZ()$0[%1);YA0]L=U9<E/.@M89_-D"'D'?^!IY:4
M.E;5H/A!1]"J5]&PJKX#F`/B-.RRE&V#>B[<5RI*U$AY5%TUR_"GEX;C^!N<
MH;<TH&?I0KC*H>=;5&22[`?>:Y\&MEOW72>OL3.F(&QLP;&B\T'P31AM</":
M.VG#*;9F08V21VOK%-I,G;Y-!BI4[*JAPH/-^\&#@Q!J34F?^G)M!:4$QB'1
MDF)AR9"%92OAPV^S"TX7$SJ/?JN(1G_N[-00O$4=O#K!M%(3)-*,\Q`;L<"G
M^Q4+9VQ6J+!5F4JX]O-"KA3K;NSV2?P:<9W#8_)+O+"1L%M[/@:#<CS*MHWR
MFLI\/:))H)C*@N._1B_/F:.$(.?;%P:+S.>JU;BTW!@B:UBU1U:B%YB.8[=#
MAXK9E(TXCFMU6T@4W9<T,H(BO%A+C$N$3E"P!)O(JK:/L`-5G:1$9'$R*GM.
M/L)DR4:>7XH5T)5,B1#Z_E(_*V+56G7:D]VMM;YXNTZ'#W;H5QM\]'([RY_F
MJ[@'P[GU//*GV8,TDI`7Z>,=D16FS]$40JE.]63[J/JJ)/33K,+2&"H[8AH#
M;50_OA@/2FX/YBANN9K0TKKDQ(1&?7(E6NCWW@E,!:^\=8'./P.#4BO!S`_S
MI1J$XPOGZC8^(2_?:V^&B>VYTE4:,E6T2H9A#+B>97<%]BA.9QPL?U^=)V`T
ML,<.:MA=%&CR966"022WLQO2+&E%*B@X`0P3^PMW#_""<<ZW]%&N&W3..L(!
M7TJ(D#Y6+N-FB28K"U=JKO5V^BN!RIC?LRGJ")DQJH,V6)NOH/X>,^A&>.A'
M:QTW*+Y]ME6M@O)Y"223<G2$##NH0FX%&-K"TMO'=QJP3BKE"\^9$<>9!#U7
MC1^/CM97I+E`^@;#_4[#,5YGYQTA,+D2(SKNR%C/H'`AC$B@\J2>V\<??OGP
M%)6CJTVRGB+N$JTZJHC..7EX0=RN0M*WW]RXL6$1\_!)J_S,T<5XO:124@%)
M;06FB5R=4%M9B%1&F'(20HC[@E)QSQ#C5:EO221G-.4I"=6%ML]+_VZ?`$<J
M0378)N<0-P]`\RATF9N42T\.%%*;VV+%'$Z/#^G\<_8..7?()>?8%%8V/*@3
M#NB-2]D2/J04R9F_Q+TGZB1J,)=.P\6A-5<@S4]Y.$A+:+;J!F&;R8'HXM*@
MIY.PJA_X#>9XPVP&J+$SDJFG]P>RI$H=TQ5ZHF<71K&DWW^3)E.L@&!YGLUB
M.3N(=JQ*COE/1RJ^3CADSN0V]CV9"LZ:T"!T6!Q$6B&%NPENB2C>P(2MJH^#
MN2,Y:9JZ<;AH(-:=O1H5&P,P9*__LF_SMJA<O"^/RYO#Q"%=*+@^#(!70!AU
M:-`.2,J(LHPR`WG>))L*MX<9/BY($B@VJN.+XX@>K)-GR9&T]5K90,`[.8-G
MP9(-KUJA;[[CY.#4PA_/WYW1T!9N+@PL9Y",0KB^!]Z$4"NJ-P?G??)S;8:7
MLFE(_E07@['5L0.\L,0G8,F.]1`\+Z/MP'%J7X0L:1,BO.,^,3IH:'$C.LFJ
MR09++^T#V(WZ7><61!??DS7\O8(@)+-_S_T(FN][3*=4>OR3`7XYF4TFH2?4
MULJE$^2-`P4UK,!L=;7$CAAK^>H<Y,1EG_H#>H]=Y26E8%)DJY?8\5MUTRY>
MP%;EJ\*;_(92>8'P=[,4\'=P@^/UC"9W;W4,FL3(P%CX`F?6\MT0!BD'G.$7
M(A`K"Z[OCHRNB1<,#]ZK%[U)-O"13Z-A<Q7]P(S><0[.ID%;A[AI5R8!9.2J
M57,(-K!>+=ET('EBQ2POJA*^C>-NI0&7ZY73RI5I#'O3*J`[NZ^3-CMJ5B:;
M!6%J'C>X^SNW?YP!P/*HN[\XAE3L9ALL`J&W_2B`73<VKK)R+IP342LQD((1
MR&SEBL-3K\XPHKAJ!MV7&8F/%?P*OLO7[A,DI9G:7@[!KZ`*\=7).@:Y3N)Z
M.7$&!CQ8Q!62_-.X9AD@)'*+O$R5Z!AYU`W@$N!F$_9002T?S9W-ZK6N9A?I
MT$E?X%EE><9BV@R&9GH3X.:Q<0D^0),A/EX#P')\)G;%%;0Y*UX1#MW@0`OH
M]C%ZR<+S$9)[&(\QC&=I^]&%9']^]M/%%9U0>49<32V38#CZARMR.MPQ9C^R
M.^DB"_,]&"-SCZT:L$\*UA=M99&FJ<:QS)MMD@S!.7HI]D?X3O=-(Q^R.(!Z
MNT0[Y5!=*YGWF.N-4B1Y.78X-;4=VD"DZ?XF%5G;KWYM@^$"XX[()&X-O3RN
M&FI*$(YG,7LG*QE+0<F>!W)4@.`L[)A`3#@V3-'CD;>XH,^/7!;GBM68FLCZ
MN<#V'1<4G!T2B,")[#HT=TM]U#4.]II)KUK:P3?+<S.M#W0CK]=RW)V]OKJ0
MU\O8'F0;8DDHTQ=7;2)R=2TDIKG"8C<U!.1:FZ^#U<[7&Q4?LX"6P.:TJ;0N
MSK-_;+VJ#_`'I$Z"LJ*N1*2P<E,(\'<CI;7+N-^Z;\D4-B%Z^[&XM'/MA4J:
M+:>-,'`&:RM7-0+0*2W9^-RE6I&KA7-=H[GG`IWT7>["L0J?<I]%FCD<9?@N
MR5['!H.-!N,TW9B_:\5^WWL7*X('$\,`]9`QDC<!BMXZO"=8+(<(.E-=:3:=
MC>!@G<^"F)IB!D>`8&..&'J[@#EULMQ/$4J4F)KG&MS0C0]"B^)!]5LGSM0V
M'X\\U@@K0%^B/,701Q.$.YX%N0UEGI30*0JSD*#<+XXA(,`D+$#_-Y[=)NV#
M(9,?L'5WP:H1$::,WU,!6!&-1(0*(,W&T*JJ,+32J=+426X9JR`D1C0_Y$\F
M0M=B3`0QS!@%F<!CP:"<U_)?,AO<6KT-6LRLX(4"?0'%37&<[/#/!0*#J@*?
M7%=OD3T:60L=#H_V+_&2J2N3_BD1.DR-=4)-_;'8R:;7AE]`?+SZ!#JI3G8E
M3I.:DWN@2@57=>D'HJG_LN!D9I)IL$T-**[)LCA@'4>C6ZP!^+,KO+]Z$RW[
MB@(0E!Y?J6C8SKWHPAR%8K[9;VV9D9R&E#1!P0#'F$3V`;-Q"[B*^'#&C6N8
MPSX)E0=1;63N@5+JFE1LGI(=JV3.-CV)Q>-KKB3:E#SK<,JNFC>\"W1=/VQG
M\][F@]QO79\I\_4]C59803(N*SD4N-N#=95&3SO?='`8IUA/3:ICF];^Z!X!
M_H_++_`L8]\.KQC)"=MN.$:[IG#TM9#RMG2UP-5H/Q<*2BLFJXP+GT"B?QZ#
MF_#AQ?FQ2A6VC)^$OM.'"ZO#:GYZ$0J4.A3#;[ZG21W8#3WNG!W<[6([=4@$
M1J3&UZS\\FBWY+PI&S]/;:]^4U_`N6])@,MR.B*FM,J:N$$/JW*7XUK]'[>V
M-XQ7\,>F#/_CT],KOYQ"`K]H+J[:A/.S([]'%]O(<//[Q;%@VQRMF\TR8F$+
MQ6[1(5P]KVQ)QADE%<JAKHXWV`#T85-S%0DQ:-E"K'QEN0)J;QEH7+NKMZ7@
M$UL1/YO/4"M25+9&>[!C3VLS!:-@IX3<*M^/K$PD:.^\*KIV.,@>!#NZOO#A
M>3\OU(/:TM6L.A%MEYL9-`VA@QLZVK&:Y(X]PSPS!O#PG"@\]KA&9>*+LM+&
MX)Y>L.!BIA8:0.%(I@05T$&,873[V7.%L_A'S^Y&&Z$C51H@R&;^Z>]C1&GC
M+JO.4<]0-](TLV(/SRXP/;[J1A7T#6_4Z<N(-:,!X)H7Y)BY;#PSG8.TSI%T
M=@4MZHR:RKJ9;GK$U#J+2\-K1L,8M&X+RA`!6]-./"`P>G&TN'A'0O'?S+2@
M!N88]@,"VZLJGK,61A?+]\?G4EFD(CA7`C0V$VS:;3>W1E$FY.37Q7P6YI.N
M$],*>E'LGWIF7DW(HHJ)*8CW`'UW5FYV>3)B@6I/GF1S'S^?YW[$'2$X`IC?
M-Z?7QIM"4IP?0.9.";(!Y-+E/]Y\?OE57U;\*PZ6V7-EPO1_>98])X.9]W__
M=J0W-4C-L2M1H__VGF[T[#^D`[D:QRQGKR-56LC$0[NS]@47NNEZ**HW?^EW
M*]I?/[JKB7[9[#>]*(`&D#X!3-K2WXQ3QO8PKW-[L#BZ@T"GA\E_IZ\**(N.
M,4=`8]#;7YPA^P:0>P4VXBP;KJ$_CDON\:<KP/K8+UBX_-C_\C77_/BEV+MV
MS4O_]XRBR+CWFY=UNQ82W(-*FR;V)+DLRF?>$?A)#&E=8E,[:![;3*;9P4I#
M_809(67%2<P^0T%6>3`4(CK=7U`B;[1%]\<#7!W*-(<W6BN%A2X2@NL<'CE7
M+ITC1[X:;(.[(6R&>GU2W8AD9*P#LAZL7U@#(,JT6CL7.%N-8/CAT*P,&*2#
M2O-'$GT@6/\NK8#TXK#Z&M]A2`:2!6=W5&3^;8&I`T_<`X<]O,X8=;!)]7?"
M88H7@QM!R)&QCLB"(^MWB=\=)L]F!%+`U^04:PP`FT\&-B*3]H)MR^DB]5`7
M.I[9C706#.6XQH!IWIV`)D?*:5]=BH.+U=_YI4<@*8"UB(J9%IJC)=NMQVC:
MC<]\0\:>2"\]_7%TO:NK'6""H/@J;TLE)[";&0CX#G.4NBAK^<Y!-42UZRB_
MA?9>[[MZ78AIURYP53^`\F+Y\>__:;]:L;?DWBW:M2DOQ-)361W\'_%F%+4U
M*U_-?$A=5&2T-CNXPO.(7$8\A<I*.N5Y68%=4G8$UFN&C;MDP*(J.*"%&_&F
M<%VGD4!4>$B:I^&M0/4<5[/_4V@YN2Q(%?Z+H\DN_D*UYHS9!JU[K>]$LF3P
M_5#!/\LH&IU37^H:0XUEZ=R0(4MD[EL/[L*YFDWPFMIA@$[-ZQ:RT>L;FT"U
MLQUS9IFR;MM;M9\!ZNU8?'VRO8GV.@6;E1'WLXFF]K;,=%-83O'4\&&RF=^#
MTGS/;+-`G<+F`,+2&>4NA/EPTL3S["I/G0\:9D7RR0F$H_6U!*G?4%S:GYNN
M+PH_)L1\\9$`_-NCE_/SV6XT]PBK-6\URK,//.F>6IVL/THY4)M="^N>9PX[
MM9>Q<\T6Y<F4AB3D?I&I,=TV0C:&[6QR1N8`%_S*+C;M?9S`1(?B]$FK%MPB
MC8AH`7S:!`W$F!!W6=(V)JW?2;SU/O18;R'F&;(A+K:T66?SP[_0A"*5=&%P
M0T9&=7<DT14J(KFCGLDT'%!;A55&*F(%2#0C],X&!D>PQ>B->)FD(X<S+'A!
M"H':947M@+.=T;EDG;L=X(R>8#\HPXZ<#[FD13GYRX)0:[';V\5<O^VUV0?<
M37*&-D+>N^F8Z`6HNL15V-7RM13F?9BC8<E<2J<X%A:TP75C];`X/1U6\:.9
M>25,\.H7,]&D:I`FX,E&8@)^O`UO]Y.9$WI7!NW%0`N`A<?ETXED^,4I_&#V
MSG$:1/-5?MG/F!2`1ON[^4*6IYSHR$(&^+*W@M>.TB+G$T386;F00YCM"2D&
M=3I)"VDYJO;-1!:QFVR3]`FB,7WO+7MHK^G6\BBET#V(R8*J2M:N0QDL+,TC
M/F1.8!>AK!C!P7T<D5A^8M8TG2I9RWPC!AG#VZ4N>1"SLA,3:`X@8(K/"GCP
MO4N6R[W^7GU!G3(&I[,SP,Z>`P$NE3JJ$#,X-N$14PV,)%>OO,=IPR&1^0X:
M4RPUK3/INU=GAKI#QJX6]YRJ%"B^\!N1S511H#>XL.-#L[K.D0C86U93@2G9
M\M*</ZE'PO=:Q!U(C3&RM7'*\L*5TFQ@_@%'4M9,VRG%XB%I8^>KU\$[AE(%
MGV["P[==;=PU$?6)5NF&URF81[4#6Q><UISU0@V'O"OMEJ%(W[N3@O\]G5/"
MF'KTE*M.'Z_=WWS:H6:XM)3BQD)X2"LJ[DK=>+K9?7&`V\^NU$K2X/\IEYCE
MVL#4Q3L<:V#44OK+.K>N\3=[)FUEZ1XVO*C>4`TTOO7DWL;:PX</;,&W'G$M
M[-,'CV2C6O82>O\)1I]\T#`%&[!<&9O9A_R0M\#[MCV906D;X.T_N)V<9&-M
M\UY>Y'(XXSJ)IV&$G9L&TU^P>T+E'\7RVK2;)!&]A#3$'[%E7E./\0]!?FWV
MP)?3WC$,%N6=MWXQ3,95#P=S;8D/R*PK6ECM\=5'[57OKG#P/,%O]@FSO*JM
M&UR/N=_8%"!S\4X#0G2PT+KPPZZ:Q*G+/=ED[IY+SQ`SD<T:WOO_>T>1TI(T
MXH(GL5E4Y%];&"ZD9A,9@($X!!$J(4OFSF)!R[)D)$RQ2+J&1GDEF8)H)H6;
ME>X0SM6*=?\OF^:O5P>7BWUT"'?ZWA\<[1Z)WDO<78W@<1@-7'P_EM2153"L
MQU`W:X`H:W^R]O0>;K?'CU/0=5D,Q/Q./DL=FG9_<;1NT6@G$F?4&+GFO\75
M>JF%;SSE9E#3-I$WAT>']+/5W1OR`(L18(*9Z]K&TR&E%3E[4MQ_:?*@<>1Q
M)I##R-#4($+^^J>8P7P603HF8DPGBB"$%E>-33?DJ_7^L&>]=Y5<9?%WM%P-
MG&CCS&UYCA\;,:JFM1=20,P&S*?^KT;:PFWGY\?XR\/9'WR?C9'1(CQP[%E2
MKL&]2I^7<[%14;0X$](]0<^`0=_`?955O1K@T><8%CC'9/F:R)70O&Z$B2)N
MKQ^9JW.A@K%FEB0D,KF,J(PRFK$.B`F".XXO')@N%49ERUP'B:MSW=".#V6I
MDKWE%2D4,LDOA2PE[^QT+B2TE#0+!@%FH4XG8SWZ)MOU+YQ"]%=^JT3]B-`9
M`GJP6!JB*O=BH1HL]R";6,BJ+!H43).H$F"9TMY/L6NBSH9M4M483JH[J&W7
MXHDKH'C2FI*VS4U8.#0!=IJ(O+G!Y=!<B?N@]8%+&.VZP^V;#AXH'SM4C]FM
M>R`PU[(7!Y1QRO*9JSZB#P==2Y.%`N^O;43G_=YWRK&Q-G&C1%6K(0A!*5E&
MU)DQ9?>ARFLF3AJ]YJ;(+@"5]-_P+U4<87]580*^-S5U=K2Z"<Y#<8Q/!M`Y
M_",3:Q7FTYTGHA@MKS[W!#93[VC%;0E[M@FK(JJY1.#R!YIB=]DG,8,\N0@0
MHS3<!Z65'\VQ:B:Q?R$1W,<F-L%:^+$$1$/N02EZ<15C'TB.;^`FPNS"V!6;
M,&8;_BYFCY6ZHF]SAJ@)L6>[SNU81-%#6\'[S0X;+C48LVUH<:(#5'D*3MHC
M,@*+U1)64#?`_3,<"*)0%BASN*L-EQ^YGP1EK.&XRI7\\M]23VX!_5BE9GO9
MFVDP*''K1CW?$VI&D?*!4LRY^@N/D`!N*KR.*>!1SHC%-0<MXM;K=5Q]P\M-
MV<60L`7/NE4Q>WPFAU9V`I:6J80.=2YSA#>OR4Q<!X%#<@RP0)N+Q>?Y1F9E
M'FLN/BO`NLLV,[0'P.FH\G9GR^V$E:$-0M$%00N',7DT4'!2HHN*"G^ZZ<>D
M'>K>13^64/)`,-/NQ#?BI)'3W7/KJ\\6S^Z^$M9;_\VMT!Q#@>M"?0"$/(V.
M4@-?)G>Q(&M_AOPF`7/-Z]O.,%UG!A"M0=DM18Z!^_/ME-NDQ#)K9J/-*[KL
M?Q#*MK&W]M:$1+66=7@9HJ%;Q?;^@`[](3X/WAL0H\AS"E?2_!9!HD%9<9@Q
MGUN;=Y&Z;O.**;=CF.$"5X?#.N[P<0G5FFJ?O>N*`121`TN"\;&FS3;+WS@[
M>H>C%N6#U<!BD)6T37?6(P7`?"\9ZQ4O-H\KOTOID%8=H<L#BY[(%]<@DWN2
M`T?96`SF&3XFT@H'*@'OBHHIND9UADDX"\`@^+EMPA/AY[-OZ('P$T$77#[H
MAR]1L0!U])"64B!!>4HU`9G';LYY<Q*V*1B6C`G1\M6I&_!?(03DEC@0L-`2
M3[N^2ML8&J:Y+TLSD2S?1)$,?V7/Q=E^UB:7)PQ^-P,;?EHW]=(<D]#8O;N/
M[G_^NQG*>EE/*ORSC\=')X>_FSUZ>O<1-_^6W[DF'!+%<"#_P+PM@7ES>)/J
M43NRT-WC9@`TWS%Q\@;AC9%A[LIX.7J!F%^A"''`Y#PV6.D%S"4R"!#I(PJD
MQ^0?94"X^:(3\EBG:"4,@4FU;B"><IDYN=MRMD:C*B?#^W>?WF\*)U)]\KFE
MW8X/$X#[X5]WG\]>_LO>F+D-HNP)BPJ/3<3.$9.W&CW^?\'=B@DWP]QJO^81
MH^AU?/._!'$W[C[8O`9Q'S\6<M?E-@A8$/>3D'4,JW3TGXQ5.M)Z]:'X7C%]
MC9%.F+&!TM@,&-)F\*GE1U]SM1&ZNEOI&F`6=V?/4E9#$4^4,CT\$!ZN&X9M
M89JNC\D:56>=_$CLW/1V,BD&5.1R-A2.K0.R'[UZN2\6;^HB\O$J_S=Q4!9X
M$*ZQL(IE<5HCSRBR"1>J.`8>#V7QR`7RT]GBY_7W-#/0]E;5J$3!B.GTX3=.
MLZDQJ^%PODAW#Q-7+3J%FU@Z0=V9@;NY*9C4Y(*\;,[B9C&E,/<4!16VS++F
M9NQT9^"$23CLUT(PE953;*K+Z@E26CT?Z:@D9"(/U,@0LCRVVS=`Z5I,7NJB
MT4O1_`\7Y,F`%::HV17FR$6M'/MY;DE>IUBEW2U_]^:'5Z])6>\.Y=GIP\HZ
M&^V/2G$?>W\N)6.F8CT5_JF'[,G1U4]'I\=S^8!M@ZQ'TE9"!)]&51ZCHD52
M5WX]75F2&@;*CQ=E["-/+ET#SY`/+)S,#X!F$6(T$Y3PXPN@H`0N]/:FX9,A
M^82KN]C5<C18-EG4`'GXKSE%F5KGYT<`FP1C5@N'D#)!)8,TAEU`SZ3/+)Z&
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M%%!VA(E#K*2&Y(/?+,YKIPE'18[>.5LVQDPV$\-&5E(LA&^`O*GV6Z3&7,#4
M\$F#(8'1S[FL"#SG#FH_0D>7@0#9LERXQELA"T)[::TV4#:HN98@C7HN??V/
MUA[>?XSK\NE8(D[J>U(V;^RRW.*^'>2EO,)@B`/<YU(,M<9T2J39XHRRE$Q7
M+3%EB)=LLPOJ-^7!YW".83V-<S]P<Y\:.Y)I(=8+\6WJEUTGD`S)XP-&%SB,
MR<((RDT^L.O.V:W@(IX;I85W\$NJ@%"L4\C;7;Y.H0GE-X[?!(<=5(V4N/-$
M#"9UAZ+#3DGT:G!W5F=I(.UJ6,I@3)`:4&)X*=E4?YOKWCB[M^D[L](V]P+[
M:5G"K/8U"B3K/[(O#YS4;:YN(#^DK\CL5%=9@X$5`_95W9"'!%5DZ(0AU?\'
MX@`4@]3(H+N^NT(PV94L&P[TL]R5B,`%:4LN],8))JBQ\3`3)M]X2J3M@5,K
M+$:23J<F7,/V&W[R\,'&VI-[]P;`V!.=NIA=<<"^N4/RH3@01O?>.-3*_P2M
M:V8RA8A3<)9RE"'^D.`2U>?G)^K=PK]T8LYV()=QI:<J=[$@`P>N+Y@?9,,(
M)/LJ>R77P8)QN-@EJE"B7`),;DB(HUGAJ7?*&-#,/<#J47->RXHUI+&H^H(U
MBXF!DA+V52<6B&-Q@%@O7QP:Z$M9&'H"=Q$0;C+_OE+4S%>RY>-*T*$@J(7_
MX1+5`,]Q)JW=WMK=OC-[<N_A^L-[VL.8KS!+0B"YE#(=3:6/JRK"5LX/Y-#!
M,P.)'WK"N+H+3--19D*U:VT+K@?ET<2C&I?1F`V.K_6#T^Y[[D&,/<^>;%*:
M^*ULZ#\JYP4GSGQYY?QR%;:6A5=YDFA2U'DA2+U`U^BM]9F_I1IA\?.PO&F[
M\YEY%<%@0YB!ZS7/H;(C9Z%K,P(60A?[ISD)#5&<A_#\5E!DGSN]*E5T(IN&
M@?:99__#O>;T*RG9?(-755<E+M9`1]OLO[?5PY$&U+?/P1-$EX6``[E`]CL#
M`+GNX(KD#4RW1L\NUE)_6:7(['+^5^3GW$JB$"!MM*V)R4"I^XO%3Q3.D]L!
M:^(C$]MRZ3@70"/3/2:2V8G?HGE83W_JVUR_^_#AD[7-!_?[/^V\?O,_YJ?G
MOWMF3@V28`E3GTM;J.RC_TG'(ZTS.SY;#QX*#KL-:DC=,4,GEK8'`5:2%>J)
M)*?P\U/<UM6M749#F3FZP(6&HV',@0V#*B[A2UO'/]MOK<,;^LA!LU_-C3TX
MO%%X5W/V&O)U+QOH.!C&3-_T"Z>JVO%^P]3/R*)%;;5JS9(-82P`RT*'G^S"
M:?@NVB-"Y9OP)@TGU9/\I*A\\@463SBVS,G/JA=&L'<\A$.DFP0"LYS.,.:E
M+,C.UBFF[2.GE>$2AR@AC^ZF+F82_UJ<)$(1#([=S1>F;0(3D0U9_U*`R#Y'
MX<?G+8<`I$P&,;-I*!P#9%^`PAHF&G;!"T>E3<-'VMAN=\_!-&"H)3A8+3%7
M77JDV>6]-;SK_*CK('0E9#JX:]^X>*TOB9TWH5UTKI5''SLP`0X"1;RQKL;*
M'L7QT<U5@)]G,X"9HYLS/8W2B`S;,RY-V$;XH`!_Z(3&Y7ZA>`@,*KQ)]O49
MZA7B,XOO^?,#XD'NJ.1+9H7#V5@CR)+<]H8>OR*:"!`=O/?6#AE+*W(@23?4
M90CG&E]?UY^VVI7'BHGTL/@*33:95DMW)!E6?J$39\<IJ*\"7R:*YCK]M-$X
MA,?T0W+(_$`]N-W81";*L`'ISD!RYKI838$$BV4%7A8"_;G$X/"!3%AIO#$A
M[I"'*@[!^_'^6&84W^LC<9#FH'/)TIQWQC7S4.VE@E]<*5K(L9O^B2^J=3<*
M'%*80\SJ-4;O7@K?R'3QD&I]8*K`NWC?-"L@"!C@E\<D+I+Z@X-PG;[O/,;&
M4`N_V$Q>,8C%L8\:L"A7X.@%2'.!PUDG-@DD6F]0YN]*EBT@4P'Y*(P8J7(&
M'98+2[(]MFH%O#X/(VRF.F]PA^*"/3R"?4+;[8YLT$Z%!@:K6@_PHKFP@ONB
MY[,-A5=E8U35XFIY]/9*^7,?.!H+=O,_ULU>)R#U0:O_?O&STB%O=$8=U<N.
MR=59\R`<+LR4U4D-3,C9[?`^VP'US]H'J7P-;Q(+'+,%5V`<1EX@'4C<TSU'
M*4BG*ED\JE<.N/!>4EDQTPHZYUG*^5"A#ZQ[R<1Q:*["BH$4;5^\A&NLP?N.
M21CT*4V;/:$MN,F+X#NPFO@6IH#=<Y5\%"B&9#P<`[T42A<(8VP3HA(A,TY*
M7$=:1+LD?N^N3HD9U2=2/XQG,CDV%@.$`'\1/R0'BB5))^F$(4(\382I]'W&
M>7Q^9TF@/.@<>^./@+E>%T7#LKT`C^?<7\W;@$L_M/3('D:6QHO)!Z7]Q,".
M,<5-8H^7R]1P-'(]Z0Z=:1*V3'JJN1QXT;U,4&#KE_I$(=WMV--PZ13'/POY
M2KHR^X='#>E`X!+:^U%7;N(]LTD3@'(5,S-@.^]X"W`M'"38;]RSCMJKMU9E
ME"VJD)AQ(#P:ZCG#6#TF()`FF<893/"`CO>7@4+BI)-'$'=(*RHDO:_EE3Y'
MUQ=CJW$>!$FZT2I?50&G^9(-M;7*446UB&/14(5`%H<Q.HC)3XZ3H0^N,+;M
MO9H$"2A^L<&=R@@YW5"RH7`]9[!_'X"=0QA_M:-'GS%31-B[9;XEEBVGWRTJ
MH1Y@IS]^],B3+[H"D8-XEC=11LN<^TX^_0\3(8(^1'/-140M6^3LFD7+\29[
MY"->H)2KH+-49\K5#.4%9=N@$%TZD9\<:Q,\>PQ;\YL?6>@V^EW/6`-0==Y(
M)M:XI-E3J6S7FNB(_^<5?4VX.\GZ0@S`:`N)_88::^IR038V,DZX";<&O8#(
M&-R-QML`2BG]39W/"S_94$;(!_*NZO[B7/V8B+*X7;GU+'[K.1*FX*`7HNJ_
MS\QM#`MP9:Z&_&V[HLIC<^:9<"S,,17&JAJ`4N[](%9D;.3!YP*!/(,J>QE:
MG+N6/R5\"!M<76PQ8T&[+355-W0Q7_.;!=TPK@9IKJ]&O"*0(W*R$["`X\,F
M.7X.ST7/EEC*1&B\B9+8AW[H2/C9)Z]W]NWQR2F"_L7EH=43Q#8LU$U:;J_V
M*GYMHG,E=7=S;>/^(TNRCSC0-Q'?<^VVJ1`JG]R/6H0F`;K_K1AID[\OR,V7
M[^M],E(7KTY!0W'KEE`]9:;AS>Z3$?VL@JP(CB/KJ5ZARG@ZFY`AG4%>RA?>
M`A;7J20;KGM`)C^>S>EK*HGYF@#FMUPI-<=:$BJ<<C#6Y12_\,X98(@]KI/A
MIMQ&LN(OW].+6@58O59C!G"5*?0=9+_N;"O*#9_>)1GC4W?ZW__^'__`7O<D
M:BV<(*JZ*K,CJ11)`L['#51IPX>:Z?T24_<S-:*C9U`&L[AZYR;O*B1J*QOA
ML=&FKXG%,`5*>5P75AE$5@V"@UK^^%)++B?\`[F3N4-OU>C&Y!3&'`XW8^W5
ME<8O<#ZW%RT)='%@O6L."4BY#@PC\2H_CTYQ09O=3Y.F?2.P(K^']>$B`%F'
M`=U5*-I'RML%,^[T?WJC!*(KN7%@T/T??X`[4GB#>/G0E)NSW-(^*.+L_0]O
M$UQ_2L7UQH/!+YM<8_AX<^W)P\W^3V4VY:>VDU"D^!\6O3@PLCL\IKW82)3B
MWMV1Z>[=O?^D/]%N3?1^KL;"`X$R>&$%W6W<HT_A=0/NJ$7)QUX;JHLYD81#
M.I6NW7]R;^T1>?,PUX9/1U@[U`ZPJU*&"5*]_LWQ8D_:>@NNY=__$S9)G>#\
M<AU>O*ZLIZ-+I$T;JI0/WL>CR`%3%59X^;=WY$O3;<(B.HC%NXCR94Y!6V*?
M%0UU<&/>Q=>_O_P:GJY-XEB",9+FE&N3@C^'FXN+$EG>_6;GS>RUB?>-V:X:
M@LR^B3#V[#O">>;'E@QQG5.[Y)K#!VM/-S9J8=P/)HV,;Z<K@_>^LQ;[)T13
M#ZWR*?L2S6[_L//=RUTRJIQ\AU\;*7]/>AO7TO#R]W?$30_!0VNB[RWNC7JE
MQ0):RX?=DZ<=I^&[V>LCTNCI)VD!]!U:7[`\/>;_^&JVZQ=N'*`Z$`K0MU:G
M60"D7AW**Y"WB)2DH_DI.4HV`#%A?>,8#)3UG]?\#^Z@RRTLH3/IT'_X;'D%
MS:@D^/SRLR^__OWR;_Z83M_ZYX%Z#[,3-*D_?+:A)Q??(MK\G6T2H/8OCO7T
M[9P&91_]\::-PPT4()=-051B<:&'7]H"+F=_/3WY:GG.;8Q_^,RXU,6'H\^^
M_OM_S09KS=5LV-2_RF*^+CZ4CCM!:D2X%P1-.OA1?R@LA*<3TY'B`R?310WZ
M&;?XJ3MC,OZA2A*4GE`I`/N7]8K(TK4J>O'!07=HV?S?__Y_7BZ(S7+[D&/3
M[N+M)<A/SX-(E.USHR`;FCXXV4P,[)6H.9ET1Z@3IOTS)R9AR[:P)_#`6F<N
MB*&,4YIS@8KX(,QXD1Z[O5A_!O<_65A^K;'65U8-TJC=F9Q5%'%36DOBQ\[!
M_#T4327*PA(TC?`(7XG07BJG9+:+AG5L*UV<`?VW!*2.<#T97.%:W98$+^-]
MW]U0-=[-[=MB\VW$*T[5FLIDE%0NI5$'#:D;@0=2_H^X*.<2F_MHW[MST#C>
MCPPW$6%$"1]IO/R]S,-CZ7*867Q%2`2QR]M%UTN#1:OGF!:@!C/ENA`6H*Y*
M(D"F#S04QJDF9GGY41%X,/6](8Q=87K(!5">1J,?*#N#OX]93N/PL+A@NIW8
MNK5/,[<BC9SPVF*C-Y>4E3)ON"M*KV4)R"GIG8'@=?M4&W%C%\J]9(C@-[PG
M0:3DG?J!BC89`$NPRX8S:[ZLV!8I([4<H\80W]<(X&]Y+M8F4^ZDXR;"I>Z9
M[!)+:&@PWW-L0TD8^<H`)DF'%@LE#'@%.@9N6790@RQS>9I@2KTFAG[1QBTZ
MG=!$7-U465%OW!%+MKL[Q\M2FL5)A'^#([`K5ZS,OHW7:>NY4,M0KK"?`+SA
M!U"CX]GHP03:0_5$OG)HW`71V=7.#/PT+*[DQ0'J)/Q$8P@SPSE6ZUJ69P6-
MJCA?T(G7A-=:E#22+!K0,XT72"%$V..?$.)I\=4GOMK1V%RN3DLVX@4IE7QH
M^G6=60N/`2!MW+E78X46]T'RL1>D?A--J!S.^)G8,\PS^[%E$:'L7:!F*Y<K
M75JR4,E0-SQ#A5",*SC-*M#C][<%'`OW["2N`8$F9P`(UGV!*BUI?#6[/;\S
MZ_AQX&"NCW%IZCZ*C5S`;"TC`8H4BHO51#!RP(Y`=<.#.I&Y;2S?M]P?`"'I
M_$H2EEK[LKCF_+A8]8`I.1A4%4C34E?/S:5NG_I1ZM`S>33L((L!I.TWWCD_
M0H8BRL%9B:^PJ8Y31\L*U"&LX6N(@AC#PD[:<2.2^A&1ZP@-$090>GNF*D/7
M@GXT4N5J/_`C7(#\Q45:E&+.*9BP'_2YAW:<*\GY?\#Q(",Y;8>N]V<#[52S
M`EE15F+_T+>G<Q&XW!5&;>-[_LI6>?OP#MX;#>L7O6AP_@OPHI5J6!8E)%WQ
M(13D$@&0KKN+FFDIFRRUR;>+[)H]!F]PCTFA5DL?Q#?;$)59;4916:(9S=J[
M96?-4MBT5E[-@"H(A%<#=HS'*!&\,+H17M!RGQ7;DZPS0B<#Q[FABP0V:':]
M:(*23K`<\=WX'3AX]`;/9>>5#)@T;X`;1IH8+I`([_"!.Q3T;W!<Q!L45]PK
M7\$S==6R4G,M@"86R5Q`2%)32UR,J'PQ3$-5@3BN+VD0NR;9!E9D6PA[;KQ`
M".S^4@81+D:'(CAB/:3;K-W9QX$\)8N+.]I-K*K)S1S;7QD%\NE,8%%.`":#
MT?454Q<A/KMNLM-?K;H#F3?ZAO+9_[HBV],<ELN/TNOS+FA.#!^T+CQP.5`6
M"[O+NA([69@;OTFC)E(MJ$B)T\.&36O=YL&BM(V7[39H+A#KW:V@L^9Z-Z*L
MPG[>0RQB:'=&<J0QMSRG*;@!>KTA`FA@W\YNZ0`(+KW2E#MTH-HV+(@.ILUH
M$?K2``UZ0K]GY&V(=;%GKK2AI`,7D.'8V^.W)-H'N<]N<UL7Y^VK7#F5[4^+
MO-E8L=1S\AX*%+K+_]ANV8!T=?&!6C,(")16-8"74O3V)MJG"&2<H2EKF1,^
ML\;IJ#.8OG"@)'<Y,8),M66R7Q!\9(/HJJ_YQ:E$P/H)%R#C0`CV2J8(W%I+
MDK9D/G6(VR/9Y90\)15.60FL;?Z;3AKH>XHZ<3O$-182CR?6P<;N4;<\2=2&
M3$/22BRE[;JC[(/?"-S75^$.8.)2KHS"5LI?DB.MK`.$&`:.E"*XBO-Y:1-T
MQ"?/RP"MTA>ST#R*J+M9=#<6_]?D*'9(9>#?[]NY$9]Y/8@A]0WO+8N9N=.J
M6-_IDP&+6EO98S[#,5UQ'BP!X)@^B)78Q8)R[N(=O&)9&*V"[1K3B-CRF5*P
M"9%SJ6Y)Y79QKX;%`CK#=@6\P?K276B1-V%G-X[REO)-8PEV`VEMRF2W@0T&
ML_EEN8C8V)-=*%===6*X(J,$2/%G+JH<&1QJ9V\6W!P:4]@>J%+,Z[J.)&--
M!7WZR\"PV6E@)V&LFE-Q1P-%D>:NL:'_H969L0*4TV0>.]9Z9[,LBH(%.L:=
MZL4=-6?B^F39`VYUR=X:'$(<-@MV:,`X,.:Y#Y:BAQ.MT-U=Y@J([5@*E[$E
M$(`/$^:)'!&*0S^5@&CU1_<HRR](Z4K-BY6W.*2!<HKLN[#)+$Z/A6(>[TZV
M1S;IZ+:H8)CQY2!"M9S2H:(8HK)O#L7B-N_IO.Q/W?24ZEYMMWQ3NC#[,U=A
M#IU$.,-XU%R<:5?,*NS6HN+"2OMN<$#F[2?=T',RG#Q<3UI";2A/=KICN',]
M,^ASMCTN#I93`P^VI<Y5%83%!D."(Y>4<%BRDI,LQR1,Q":K0]:'ME>JI9_E
ME2]N%-FW$9_E>!0#V-AT;^;L=HD*6AGG;@V4*.X$4AI96SB,"C)E@PB<)=*!
M.2),&K"'5YW;J[Y1/:HP[[5'RTS3\K7M*G!]@3#1M186OFN%O[)GKE`7P)K7
MJ&@X2I>SV_G7(%06T84^L%_C/*9-GI)KF:6"&JG7?W4[K%$EP*5%I0XX;G%?
M8=J9TVWL(J<?.5"&S[2@0<@JXGB@I/4?EJ[9GSUVFQ<=>L$I9PN#6/QL=J6(
MZ7!QM7^IQ+)(91S,M*UKQ<E`-"C[GJ$#N)1VTI]S3QZ"*PY@*5'3_S7R/=RK
MFL25[&?L`P(J3`V0J4GM#_:FUXB^__NW5%$J8.)&\`%^'>G9BM2`M._@XU]Z
MJ!.(;)-K?7$$QUO*#R%7BW[J#XB['Z^L2JN&MT?MD*Q]C%.>Q7)J>-O>10ZT
MVPO]H5XHR(I:[85S_5^_[?3:J?0K[GZ!GWHD@OG<&KEK;O'%,Y4:!X6*FLLS
M+J0\%\7%68L0X$!TL."(1\?]-0EO3QBY')!=<&#BC[I>T^^D8U^MO5$Y>KBR
M/`P".?=!"6>$SPKAM==+HP$*;,492J13JGR=B^((8W>RA61I>]"T<S%6AEW,
M0<C2Q"QOMKP!8WN>[4YFMR?`L3-(G9YZ\XUW;YTUQ94Z_%)(^")L8%U/-SE=
M81JOFYO9>-B_>&YZ@!4Y5JL_6KJW"4M802O4II3%VL6;J`2!&U4G9_^TMS0W
M/;N&26KF)[O1&"5UXE=)'YJ$P/BT,&C/4>KO]->DRV>6O;F\,[O]X^ZSV:T!
M@08?W!,?7)$H4?`.<1E\,UP-^+'>'ATJ]Z"_K97?F/HRSG[IGHH@OKR`TD7G
MT`SZ#2[#/[]0<'('A]#RW_IS[5G[I91ZQB.//XA!]%^T)(56BO9?V/HT@?HZ
M+AM?L[;XEX::E0^L6O*/9XA7>E]#'F,":ESBR>1&XIFPXRAH^,/GJ/^NC/KA
M?'D[_-B#PVX6]M)*I/YM]K]G+_%-G%Z=SOX<C_H`J1]A)F;2>O^E+^X_4C2>
MC+O^+_7SG$!SSLF&7C'G%QL8`N/CE<19&`J\^F)^?H2C_0#DG5A_,IY710#=
M!F#O4<SA3"QX"*5=R_)PQ#LS%0-]^S6:K&6!WIV<Z15X:]V0MIO0^-2R:HNV
MF[QM*2O;5^CY/QS1XV99T@)(2YU>T)LC6PYRLX`I^NE,K2J!M;4\IO?6"W5Z
M`<&FWN[;2=<,/GQ]Y>K_O#$@\S)"QFJOF=$]/YX8,8TA6U@1'N%`8=RMOCR:
MZ#J!6:!->N55^*71$Y[/+Y3EPZ6N:'Z[,K=7,BC-L5XF"9V';-AF`AAK.T%D
MRCFM%_421W5>_C=`W**13YU74>AMO=,`V:'SK?+*/LYN7R\_\E5@@G9[O'P/
MPH0EC"9VMDZB\8`+UPGRNCE2M;B2])Q(+:J:10IE9TF-G68HURZN\!YD%'WG
M:;PB0QD%A&M*]?<JB3>BJET/BUYAG+?4^/,6<0CU"1J@\V".->5/3/+8+`_J
M0^33=,7<17\4Z0>WAPK"G[;>?#O)`*Z3'=?Q^:U#.L_("6/\;:_4N5U#UE.?
MP;(/8-*6#_$OQYCV2N[,:-'.Y"Y^V7#3X[W!:6_.81F@<CR8?-HI=9M3Y%GD
M1U'NZ31%RN7+-]-S30@&6+?'R+[5$-_/#_&RH$%-B,B=%[M];-C#HU,&*2D0
MDR-X2NC.;%NYCP>(RZFIXL5/>/,&KZ;4*IO&V).Q2$-!LHG8N?F0?KR<OY]<
M5U$KRA@"7'>`;=0UE/@S>LY-;:\,TR">'<%W1YCFDY]]J_C0T?H+EGLHO2/K
M:\,&6J5&?H&F9'>']D_PB_OCSY-;>(4/PL0BEZ5VT]U9Q,`_@$&8EJMUI2TX
MM%30DT"WF@#DD?_^HK;.SJ[`CGR]S8L@TZ+_MI^%C`"E85AB0O^5Y#">7Z,F
M+G;)VT`--3N9PU-4.&>_;F^^5G)G35?-&;C/J[\(5(.25$]J"-W-`,D*03WV
M/GF,ENKMCOG^#&7Y<I*JT:LEVEVS@3?R<)N]P"'Z\LU)NOI(WQP=G^Y?<7^/
MA*^\X\Z`!#O+W,#(4":*;W"%&OV2/%H<AYAL4V=2:$0G++<6&=#N2??N)^;@
M*<&7,LS`[Y)2*$\HDDXL7"+2,)$O6^'(XLI]V.(<L:U:;9P.S]RIILY<8'9:
MP^E`F?ZG%<("CU(_(HO)P@CF'H\O<8P3B^(E!7'[P_S@/0-1\G0CL`(2UDA&
M89A"4/UOOGAT3P'7`:)_\73\^9;W-G"/*9LCJ\1],TD-1F+3NLK-?4FI8$RY
M'*25P9&OU=Y>X]OS)::Z.JE(U5==LZ93003`KJCXOS`C>P4]#C]O_*VM,W#%
M&$'3URZU0_MEG9_(,\IW-UQ<6D`9HUS)G<QH6G'U81\3W<CR6.&2ZVI)N5G-
M_HJ=<K/E>#I6/2-R0"ST/26#ZYN!!$OEKJPX.GPX3=A;\M`B(^<%_WR<_KZ;
M>6P]Y:8#DZS7\.;F8[,=R\?Z[A#7%[>!UZ#"T$EA>*:`E2DXJ!:D9QX<V2X'
M7P\,Q<1!6W8SAH6%!MMTK@3+\"->P9(>CFL<IL5,5.I>SP;NS5XVI9S]U5&(
M>G?&+9RJO[C?_S'V.84H\?/V"7&=V3>3RMEJU:TSR-;D(%D87*N)I]TV*^&U
M2A=TN@A>$ID?(516H/\/5]8MB0.FU$74>Q,59N0CY-8^60NN_>#Q+[JP=`@G
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MA')$MR5*,02JGI5=X,7`=CT&\<2;FXP='+&%UUY#EY7!VY2MJMW-9Y9137J#
M^HQB!I)4TLS1R<>^9L)0)9;&;$N"Y(WE^`T^7QOW+E1AKJ4K6;)_3"D/S*0-
M/1"Q7A;9)&^&^-%>_<^!A-@U^OH4A76XP%F3S7GC3,[^KNJP*W,MIS\#7"57
ML?^6''-=`_W+Y?+RZ_\G`````/__`P!02P,$%``&``@````A`)E]I7,9#```
MJ',```T```!X;"]S='EL97,N>&ULW%W[;^+8%?Z]4O\'R]-6NU(3P)@`V9#5
M0.+N2-/IJI.JE;I59<`D;OR@QLPF6_5_[SG7KW.QC:^#[<MTHDG`<,_YSG<>
M]^7'S?<OKJ-\L8*=[7LS=7#95Q7+6_EKVWN<J7]Y,"XFJK(+36]M.KYGS=17
M:Z=^?_OK7]WLPE?'^OQD6:$"(KS=3'T*P^UUK[=;/5FNN;OTMY8'GVS\P#5#
M>!L\]G;;P#+7.VSD.CVMW[_JN:;MJ9&$:W<E(L0U@^?]]F+ENULSM)>V8X>O
M3):JN*OK#X^>'YA+!Z"^#'1SE<AF;W+B77L5^#M_$UZ"N)Z_V=@K*X]RVIOV
M0-+MC;=W#3?<*2M_[X4S54L/*=$G']8S]4I5(I,7_AI`_.[?>S_\[C?1GW>_
M?_>N_\]OO_O[GZWU/W[Z)O_93]^JO40-D0D^."[SLG]4+'P<2>[%%MS>;'R/
M&`)>9P1=/WO^SYZ!GT$P@'GXM=N;W2_*%].!(P.$M_(=/U!"\#+8QXYXIFM%
MWUB8CKT,;/S:QG1MYS4ZK.$!%ACQ]UP;W(0'>Y&&;O4L$4UBTP1A<#8-\0BU
MR0633#QXW";S7P4V<;I&U;I.X8_3Q:PX;E=CNO)QD>/P%%VIKXB>X'$Y4PT#
M:LB@WT=:J<-:4C9=]$%?9\JN1IU9-C2&QKA1R[A8S/L-%0Z-)JFL4&B\']]U
M1F?SRLJLB\MP5QF`"=<LBS:D[I'\'AOXTT6<=-RA->HQ&,"%[QW[T8NZV]U^
M"R.Z56!O0V0NH7=\F>]_6&8V53K%8+0WBF"#B1UTT[;CI*.TX0C',7#D]@8&
MC*$5>`:\4>+7#Z];&,5X,+9%IGK1]RJ^_1B8KP.-<2G68.<[]AI1/"[8V"GN
MNQ97]\;BGNDER$11E`@UC,6X!:'W\^FB>:2+Z;1IH9H!/PT+?3_"GX:%&O!O
MT1BG<?72FP*9RE-"&^<Z_<OQ=#J=#*XFD\E4'PYTG9&\C"/:]M;6BX73G\9H
MRB,8`8+I<#*]T@!(7Y\P59TB&`*`\6@T&0VFF@[_6?5L'T'3G(Y4V5XE""1Y
ME2"0Y%4VW.XU4/GC3(&5!\FY2A!(\BI!(,FKXX8K\%BZ5PD"25XE""1YE2T2
M-9BKL*(G.5<)`DE>)0@D>;6QP6=<@:?2O4H02/(J0="U5Y-IU>+^WF!+!OF1
M66/CXU@7#N+KZV*S1IBG+OU@#1/U=#\!5]RC8[<WCK4)848:V(]/^#?TM_![
MZ8<A;%3<WJQM\]'W3`=>]I(6R=\C+6$K!W9M9FKX9*^>01FW/!QQ$ZEH2T-:
M]72<3>ACO3_61]I5-&%K2+5KK>V]F[<NU5T8ET`C<EMM..'02Y7$X9"M5O70
M"['[!%LP5S-/"S:`F$A"0K!%$S9F*[>B-I(68C:2!H(VDA:B-D+J%"57PN3:
MW\,NXJ&##6/2[[-97^UX*19(@!=$3&6;/)^530H8K6PCRFE"'M277&[,-?QA
MH^,"2RM:Y.VL:%!@944+41OYN"FT.%VZP/)<@.2`;^[KHC"(8E+*XSJ$B_31
M,CW-44`#8$0;$MS0L*K#$95*7!_!@=^1R>TH$<55&&!'B6V=G_K06^8R<I@H
M+,*/:),68U\4PDEQ(*JD13LC'Z6!<`:(1"%DS+>&'@0S+2V3Q*L1M9_D"PBH
MJK>\#G@7Q52B[*"'R7<+QT(PGE'`!&5E.<YGG#+\;9/.4F#A__;F94-.3X*S
MA_#\'3S["5_"[EK\,IJ11&\`8EDCK;218FZWSNNGO;NT`H.=2,94L*.XBY>]
MF[.I5/:>[8:Z%MNZ4",Q/P9^:*U"=J(;VWTMPS,LP3.(!8G@.46_7J(?>!+F
MXQ3]L#1>Z$3@1:I^""YA_4W&`Y[2%P<UN(`&]3$\32*`!=`$`3A!!@(\!3'F
M`,)3!@)86$H00(!F"`#.D:@X)0\&I)I!#&0J07];*J'&)%9R*ENTLJS\@OXC
M5AI<^3V)9E)O(=`SFN'-$0`GJ2PKL;)*#'$[9%I&`;PY0H$!O6XS7=Z@K.9+
M(X047<"0,0)EX!@CS44EJ;F@,P-PG)%Y@^,0$A18BF1#`#A2(!!'#"3UOP.*
M05(/3*-!4A=,(7!]<(<Y03W!]9"2,``>*5F1C1,&7(_1(0T$@JP*2:)!DU4B
M*099-3)SA2:K1!((LBHD]82L$DDQR*J1Q!6R2B2!`(Q(J9#4$[)*),4@JT9F
MKAC**I$$@JP*23PQ;+E$]NBR:;2(2M9/QV];/U5>-I4+J8.R21/X/6D>S9ZB
MF2/X@LVER%0:3T$Q\4H27#M5GOS`_@4FF7CQYPH.6(&*%PN']HH>^3DPMP_6
M"TQ%HYWQE\W!6B^;7<8KQ.(8^676!&NWR(&XZJ7M`VY+V<R8@[5^5:FDC2@7
M9TV0GQ.P(*QX*1!><J6=#[)2(BHMQQ6ARAV%`]J+P^7M&&C0"IO<-(@V0Z"A
MY,::(]M7T+U+QT!<518NN(K#I\@\7BY*JEMIN+:0KW`=WCFA@4[YC+B!"B05
MS9";0^4#)UI^3\*FM3!B6R#Y[*Y"5UP&.\)<G(@'D'/1)A<<-UN5YNT2YGAP
MN:K1$7,P?2JH\4,>7*[`GF,D\I#/+!+YNB/+V65UAZ?NO+Q=$J`\H><%N23A
M><C`.=\5=I3P0N!@B>V<P/'Q"4/C_W]PQZ<1M6>ZZ/5X=GE0VV$%IQ$V.P-\
M9I6=C\VFV*P[,2FIDCRX''-2NW$AR#D^I4(6JITYEL^IL$,?U$BVUXU/(>9R
MSNZ(N;)A$=]AY_PJ-13%,.?<_15@SD6!5,PE@<L7UAS-D@.71_=U!"Z/.<>H
MU"`H2S8>\]<0N!#.K6PM%*?)&[4UT[EPRO%L'K[C$U[<J]Q6$;!]`(,=B>H!
M(:^]=$&<CN+QHD)V86ENY['88GXM,*>3KXFE"-Y(=S/*<^97;R="I2I:0(/#
M1Q)-I)J5,D1!L@NOZFUZHO.2J>!QE((>HWAJQPQ70KN.&4YYOD3P]@L7C!P?
MU4%4DE#MXSLQ?CB`;_5>CB^XJ*WWIIJ#)RORA:X[%XK4@3P^D4+PIL`3=>RY
M[<=C)IQV&L1)X=1.0%<7@)+H.0Y')'@Z[T5DEM$2%KE>+H]/A,96<U"D^N=+
MA_32Q@5G'M^YTLI%0T6'T47V<#1VB:<D6S@\9Y@M)9-Q8*[V@+O4O74F(3BW
M$^NR##CE`\_FK#@]M$@Y._D53G<E-P_@;QV0GARKX&W'X2DJ_=\J%\K[%9Y?
MFFXW(]3EWG;@)HEXUBN>N+S:[^#^7//H8'RJZ3%9Z6*2AGE$9$'8U)4%$J+1
MF@9+)U063-;KR@+UD:PA6$MDP7T5:LM*=S_A)N><+-AYK(LKW:P<\MR/!+G7
MB_R(Q9;8B":+X**R,C]BOA,_@LEU965^Q`L"B"PPN:ZLS(^`D,C204E=69D?
MP0M4%H1;75FI'W6>^Y$@]U>%?N1C%<^@%\%%965^Y&-U*!BK5%;F1SY6T>2Z
MN#(_@E3*/7Q05U;F1[Y.Z()U@MJ8^9'G?B3(_6%%Y2->$XSX2$KF.WA%.,*U
M+!&.(BF9U_@H'PI&>20E\Q<?W[I@?$=2,D^!/&*1#A^(6Y3Z:,BSJPNR.S?7
M26_`!PSV,R(PX'E;J[T#ST'S\2EJ[`H1/*V7&(37`PI)>K)6S\H";OB3"N+S
M`;M1$4'W+UO'],S0#UX5O"HD%<<[?20H[@^^GW+$2]#@K0B@'^"9<_`X.P5X
MB3MQCB"\M**.F#07>'KP$O$Z8J!UA(://QS&UA$#K2,Q?%'%\9.(F`_>=I]Z
MB*^EV'6+B/AH>\_6FH\<ODIH`%)$TB=K'P9F&G]\2FF"Q'S"VT2E,O@2P>[Z
M=#AF_`1WA4I(Q#4FDCLX@!<!_J=]2&C$5D2()EB7'NP0[C>:)#$G`F&)X'CP
MX4JM5,1!11&4\5<S\#!;N-0]B-$2B[+KWF#TOW[);AG&>`_QJ8SL9F+I?`"(
M6EL;<^^$#^F',S5[_4=V)U\(IOA;/]I?_)")F*G9ZX]XBV3(8EB,A7+S<0>W
MW86_RCZP9^I_[N?CZ=V]H5U,^O/)A3ZT1A?3T?SN8J0OYG=WQK2O]1?_!<KP
M$9;7\`S$$QX1R1YE"5>^#?3KG0,/D@QB8V/PG[-C,Y6\B>"S[2N`#0O*B1&]
M7?J(S=O_`0``__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL
M+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$
M;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8
MRTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;
M'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',
M3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ
M`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>
M3!<QM6)M85W?_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?
M!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;
MU69]>\W!&Y#%-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'
M3#C;+85O`'RCFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.
M1H)BS0!O$ER8L4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?
M_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY
M$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^
M%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`
M]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N
M,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7
MZ0RN=FRS=Q=U."O3>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!
M7/A%7$\J\'1`&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P
M:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:
M!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W
M1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[
M6MEX3RAC`S5GY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5
M#D*<0-]>\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.
M&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y
M:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<
ME,7*DB):#QL,^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN
M)B>+T5';:S76&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ
M-PEJ</MA[;ZDL%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'P
MKTD!=G1=2R83XJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J
M@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N
M_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!
MT0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>
M94FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3S
MS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!
MS`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4
M(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>
M,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;Q
MT7UP]`Y\-I@Q)4TPP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(
M````(0`-V)KI6`4``!T9```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;)29V6ZK2!"&[T>:=T#<'T-C@Q?9/@IFF2.=D4:C6:X);MLHAK:`Q,G;3S7-
MUNU,%\E%$A<?/U5_+U0ZV^_O^=5XHV65L6)GDIEM&K1(V3$KSCOS[[^B;RO3
MJ.JD."975M"=^4$K\_O^UU^V=U:^5!=*:P,4BFIG7NKZMK&L*KW0/*EF[$8+
MN')B99[4\+$\6]6MI,FQN2F_6HYM>U:>9(4I%#;E%`UV.F4I#5CZFM.B%B(E
MO28UY%]=LEO5J>7I%+D\*5]>;]]2EM]`XCF[9O5'(VH:>;KY<2Y8F3Q?H>YW
MLDC23KOY\""?9VG)*G:J9R!GB40?:UY;:PN4]MMC!A5PVXV2GG;F$]G$9&U:
M^VUCT#\9O5>CWXWJPNYQF1U_9@4%MV&<^`@\,_;"T1]''H*;K8>[HV8$_BB-
M(STEK]?Z3W;_C6;G2PW#[4)%O+#-\2.@50J.@LS,<;E2RJZ0`'PW\HQ/#7`D
M>6]^WK-C?=F9<V_F+NTY`=QXIE4=95S2--+7JF;YOP(BK900<5J1.63?7G>^
M++)H19:]B+.<D87MX8E8HJC&HR"ID_VV9'<#)AZD7=T2/HW)!G0[<T0IO5W_
MYQ;8Q$6>N,K.A!4#1E0PQ&][=^%MK3<8EK1E_$>&R,2A(_@8<-F@"XQDB2(;
M=DQW4R0"\'V4RU)^4OS(#+E8X$QO#XS;V)[/YTSG`H>Y"UTJ?A<84G'D1`Z/
MQ-*5D4`@3N/J@BR]A7P]5*\K]T?*];4MWQ^+ZV._AB0E+V#N3O>"PY(7:N"@
M!@(1&"?B+E9RLN$$)IK`Q'I&*AM6W?2R.2R5K08.:B`0`;%=\%D?=H%AUKB+
MM>Q#U#'=5(N[P.<W207!KC6](`Y+!:F!@QH(1&!4D!J(U$#<!4;9N\,\E;+W
MOI(]AW<F>#/L!>ZPTIM-QA<,9-`SR@H[H$2`$B%*1"@1ZPC)(]C(IX\PA^&=
M-JK?=8<=0'@DF'6S!ZW(RG%=94(>Q@0AWGH]7PP#*'9S@6B,#E$B&C_&FZ]L
M3WU*K-.03.+]W>C-I]_:.:R:-)?7I"\837T'E`@$X35&.\YB3939&J(2$4K$
M.D*R:/T5BSBL6J2L)%\P.HM0(D")4!#"1&(W7_)01:A&K",DCP@TI.-YQ#NH
M!52HGT_-7:I;RIO;;R&=73@2X$C8(DN[F7?VS%8RB7"-6(O(CO'N:[3R)CHF
M>C9YGU*:09\(2.L8B@2X2M@BO6,/AJ%/B;5/D0WC+9IBV!RF'3+%1&,G&Z8T
MPCX1D-8P%`EPE;!%VIW-_6Q1XBJQ%I$]XQW>USWC=ZG+4NE!?2(@K6<H$N`J
M88N(UZZP3'FG1KA*K$5DSW@3.?(,F5^BY81*^\;IH2WPB8"T7J%(@*N$/<+_
M^%1>.U%_<4A506(M(KL$Q8Q=XMO7A-7([U)FEJ>,IL^/)0#2NH4B`:X2XDB$
M(W&+B#6]5M:T[!EO7:?/+-'H2C/+4QHAG^BZX:;A/.!(@",ACD0X$K>(6,M#
M>RV[Q'O7D4L37XRBXY7=&IX@&GBB:XM;MU`DP%5"'(EP).X1OIJ'6F2W>!NK
MN#5A'8KF5W9+[>2)KD-NW4*1`%<)<23"D;A'N%M#+;);O*$=N87L[:+]E5U2
MMDP?#FW1W0I%`EPEQ)$(1_@9LYJNZPU]FW!+G"*+$]*<EF=ZH-=K9:3LE9\0
MN]`?]]'^]/JI.356XC[9P'DF',\H\8!LX,CR,>X[&_\SG8.S@1,6X*U>"`ZG
M;\F9_IZ4YZRHC"L]06KV;`EOAE(<;XL/-;LUY[O/K(9CZ>;7"_P;@L(9DST#
M^,18W7W@#^C_L;'_#P``__\#`%!+`P04``8`"````"$`1.033KP#``"6#0``
M&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)2779.:,!2&[SO3_\#DOD+0
MU>J(G86=;3O3SG3Z>1TA:F:!T"2NN_^^)P2!!+5ZHP(O[WERDI,<EQ]>BMQ[
MID(R7D8(CP+DT3+E&2NW$?KU\_'=>^1)1<J,Y+RD$7JE$GU8O7VS/'#Q)'>4
M*@\<2AFAG5+5PO=ENJ,%D2->T1*>;+@HB()+L?5E)2C)ZI>*W`^#8.H7A)7(
M."S$-1Y\LV$I?>#IOJ"E,B:"YD0!O]RQ2A[=BO0:NX*(IWWU+N5%!19KEC/U
M6ILBKT@7G[<E%V2=P[A?\(2D1^_Z8F!?L%1PR3=J!':^`1V.>>[/?7!:+3,&
M(]!I]P3=1.@>+Q(\1?YJ62?H-Z,'V?OMR1T_?!0L^\)*"MF&>5)D_8/F-%4T
M@YE#GIZ1->=/^M7/<"N`(+(6Z"#R[S',?:BC^&V8_N]CR,=ZVKX)+Z,;LL_5
M=W[X1-EVIR#2':1!9V.1O3Y0F<(T0*Q1>*==4YZ#!7QZ!=/K"=)(7@P=R]0N
M0N/IZ&X6C#'(O365ZI%I2^2E>ZEX\<>(<&-E3,+&!+X/S?/;3<:-"7P?38(1
MG@33_X/X9E!UOAZ((JNEX`</5BM@RXKHM8\7X'LZ*9`-K;W7X@A!-<%X)<S,
M\RI8^L^0^[11Q$8!GZT"VXKDJ-#3!PPM"&3F>A`MUB!ZMC19;&[TXX9.7*,(
M:^H)GDW?M\\M#,A!'T,OEC&LT\MYT2]%:-(;];AU-WQ&`>NES<O$5B27%!8A
MA.D37B;38AA!+^Z='3<VBC[9U%8D0T7';I&!R?5D6FR3S>RXL5'TR;HYJ[.:
M#!5GR*:WD&FQ339WR(RB3X:=0DB&DC-HLUO0M-A&PTY]Q49BL;FE,)2<8=/G
MYM6;@Q8[;&X5&,E%MJ'D#-O\%C8M=M@Z6U.A1F*Q.:62#"6=B54(&':,ZQ-7
MJQTZIP;C1F/A.?62G-"<X].;<&]BK]OEL-FZ^YL)=BHR;C1]SH[!%&TCF=8[
M\2S$D_DX[`K,SN--AP(V6[S%UQF;66XT?;[0+=T3FFX,-I_>M'MYO+P78ZVV
MYSETJ[?16'QN^9[0G..[Z:S`P\,B="NXT5A\7?!F@J\^,'0;=D/^M-K)GU.B
M<>T8(8O/J:7DA*8;@CV_-YT;T/D.^)P:C1O-[-B&]%9^D[S_'QRFZS5=7$'%
MEB8TSZ67\KWN8C%8MW?;MKSIE]L'T.!69$N_$K%EI?1RNH%7@]$,$B=,BVPN
M%*_J'G'-%;2V]<\=_/^AT',%(Q!O.%?'"]W1M?^H5O\```#__P,`4$L#!!0`
M!@`(````(0!1P"-=P0<``/D?```9````>&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;*Q9VV[;1A!]+]!_$/@>B;N\Z`++@461;8$6*(JT?:8IRB(LB0))Q\G?
M=Y8[>]_(<M(^5/'A[.R<G2NY=Q^_G(Z3SW77-^UY'9!I&$SJ<]7NFO/3.OC[
M4_%A$4SZH3SORF-[KM?!U[H//M[__-/=:]L]]X>Z'B:@X=RO@\,P7%:S65\=
MZE/93]M+?88G^[8[E0/\V3W-^DM7E[MQT>DXHV&8SDYE<PZXAE5WBXYVOV^J
M>MM6+Z?Z/'`E77TL!["_/S277F@[5;>H.Y7=\\OE0]6>+J#BL3DVP]=1:3`Y
M5:O?GLYM5SX>@?<7$I>5T#W^X:@_-577]NU^F(*Z&3?4Y;R<+6>@Z?YNUP`#
M=NR3KMZO@P>R*B(:S.[OQ@/ZIZE?>^W?D_[0OO[2-;O?FW,-IPU^8AYX;-MG
M)OK;CD&P>.:L+D8/_-E-=O6^?#D.?[6OO];-TV$`=R?`B!%;[;YNZ[Z"$P4U
M4YHP355[!`/@_Y-3PT(#3J3\L@XH;-SLAL,ZB-)I,@\C`N*3Q[H?BH:I#";5
M2S^TIW^Y$$%57$F$2N`7E3`3KBR(<0'\BEVG)`Y3MN>59?!T-!9^Q3X0QU<6
MI+@`?G$!G<Y)N(SFWHUF_'#&L]Z60WE_U[6O$PA@H-]?2I8.9`6ZQ"'SG>6Q
M?^O4X;B9D@>F91V`Q7"@/83*Y_LXC.]FG\&]%<IL7!EB2F1"@OF2J=W:0&X#
MA0;,@)&D!4[_'V@Q+8R6,&@C`,636AR$A%BRM8'<!@H-,#A`S-D<(L@B?_P+
M3[!%ZP"B3WHB"A/3Q@W*Z$*6LS(I(GDX2.X@A8X85&`KFXK*HYNCC&D!;A#@
MDESLD$.A:^2DB"3G(+F#%#IBD`-[;'+,3^],(:9E)">,VB`"^TJZ$;%S1@J)
M95L'R1VDT!&#"Y0`G<OU6&/"ILF(Q#)C,@?9.DCN((6.&/;-WV,?$S;MXPBP
MUT[4SF`A(P\4U2A2N8,4B(REPC"832-:?;U^H$S8-!B1I6%Q9.9S)H6DR1Q)
M(`HE44I3<UF.0F2LUPDE:9RD"U.F0)FQS1N\P"*=%^L;;Q<GMLCDQY$$"H<T
M-")V,9)"DA]'4MZK6:O($:$C&1H2&B^L5"E03<J"T^!"X)Q<,E/628=#4SUO
M6C`..HW'>1'LARV0*3')C7H!@HTU=E8USI24I(=0,I=YE`MHP;OK(H1AU(J#
M0LBXWB*L3VIA.+9YF(:0X*?V,A)\!UO>>*$6"Z,WXQ[KP/*E%729DA(+MPBE
M>EJZT2JD4AZNB^5\3HB5NX70[O$QZ[+V"23*Q^((/#Z&T4TZF?=J@S9"2WD2
M&7&@+4*0D8)VCE"JG%P(*8\#66O5S'_#3&S$NG<X9'EG;J9[1J24,'.+D)YK
M`E*#42$6>@Z>]<W;+<<NJUN.D)E%5J'*B)12EG/HC2J("Q->!J-XN4B(FUFH
MRN,8B-IWT&/25I'@D.68I>T8*:7H<<AP#$*\"I(%G:?PZF&J*MC@!38D'E>Q
MMJNYZK:B3K!9ZRY#R'`9#4U#,K%09<X6(2--N"[T3P)U#_XS-15BF<<]K#%K
ME-[(&VSC.A4.F>ZA5FO)B)12[N&0X1Z$N'MBDB2Q4\)1D<<YK!5K3+AS5`&[
MK4GQ?F[4+X1,7UF%-2-22A'D4!II)0VA>*S1D==57"3QN`HLL`F2'^I13*&5
M;!RRO&DY(2-22I'ET%L]"J6N]RC4[KJ8>N80\NX>-6H9::NIPZD"&R$%A4W.
M)O;<I63D.;A0[D*%`1FC%O4,(M_QLC2J,5TK()U0%-EQK*04)1QEM/G>E2H,
MR*1D31;72PQU)P@!*0,R%]JZ4.Y"A0&99KYK@J#N!($0=`\9,%%DIXX44L>+
MFA2[7"A74"$@]P6*LM;KU#WO,*X-:N,J*T!X#S>G\<B)>2FE&'#HC3D"=\0^
M11)"":56^!5"R*U^[/O@=]#DO5ROYZ,B>PR/[)<.):5H<EUZPT*I].H\(51Y
MZIEGGM#KV4TMB[KCA8"@D&JA:,TYF9)2%+DNO66A5,I;%KAMN;2_7!8HX^E9
ME+5K*SA_J&>-"JVXQ9$`\DAC:T_NN!`ZFV*+XX:>L>Y[%2Y,><^"^9?,$[ML
M%D*[Q\>LGULG$(5J++GMO8KRJ<"(8X1,)]MCOUBHS9`(Z3,D0OJKEI#R9"+K
MSPZC-PL.[^H&`PZ9PT9D3_942BG'<0@R47G<XSB4PD\>RY#,P]#27@CMKN-8
MU[5I@O6^CQR0X>(%>%QEQJ>`P!P5G[$UHF=*2M)$2'<40N`H79<U;1=B(;12
MN2.EBKK1]R+/Q/'N(C0JL6CSL<'T;FP5_`P7ZFDI(-7]<H32Y3@WDWF<+.:I
M5<\*L<[C2FL"&5\-R`]\W8%K/7MR%I#I9;O]*RGE9:X+OF7ISK+(Y;@PX9^W
MOE&%A)"6L_SVD-]HG>KNJ<[JX[&?5.T+NQF$=_O[.PGCM24-5P^@"0RTGL!,
MO&*CJ^\)W'7"!.A[0N&)3]MVOH+OQ.Z*+8U6;`)RG\"%ZH-/TP8V]^\-6WOT
M;"*XF/7@#_'J`5YMW(TW\0IN-SQXLH*;`@^>KN`+/>`S>8)P\7HIG^H_RNZI
M.?>38[V'X^=MH.-7M]@3\$OC8SO`E>OXT?$`5^PU?,(-6<#NVW80?[`-Y*7]
M_7\```#__P,`4$L#!!0`!@`(````(0`1$\OBU`0``(\0```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;*Q87:^C-A!]K]3_@'C?\!$@!"59)0':E5JI
MJK;M,R%.@B[@").;>_]]QY_!ADWO5OMRN1QFCN=X[!D[J\]O36V]HHY4N%W;
MWLRU+=26^%BUY[7]U]?\4VQ;I"_:8U'C%JWM=T3LSYN??UK=<?="+@CU%C"T
M9&U?^OZ:.`XI+Z@IR`Q?40M?3KAKBAY>N[-#KATJCLRIJ1W?=2.G*:K6Y@Q)
M]Q$.?#I5)4IQ>6M0VW.2#M5%#_&32W4EDJTI/T+7%-W+[?JIQ,T5*`Y57?7O
MC-2VFC+Y<FYQ5QQJT/WF!44IN=G+B+ZIR@X3?.IG0.?P0,>:E\[2`:;-ZEB!
M`CKM5H=.:WOK);D7V,YFQ2;H[PK=R>!_BUSP_9>N.OY6M0AF&_)$,W#`^(6:
M?CE2")R=D7?.,O!'9QW1J;C5_9_X_BNJSI<>TAV"(BHL.;ZGB)0PHT`S\T/*
M5.(:`H"_5E/1I0$S4KRQY[TZ]I>U/8]FX<*=>V!N'1#I\XI2VE9Y(SUN_N%&
MGJ#B)+X@@:<@\9=/'>;"`9["P5O.XC`,HG@!PSX9*A">\!2>P<R/0R^,:+Q/
M'.$K$PI/.60T"_QP$3.E3SPCX0E/Z?D\6(?/,4M96O3%9M7ANP7[`&:17`NZ
MJ[P$V&2N^-@J>]]*'F2-DFPIR]J&#0QY(;#B7C>!ZZ^<5U@EI;#9C6T\W6(O
M+>B2H+2I"60FD`\`!Q0I69#V'R"+LE!9,J"=!!XZ#95[:2%=4A/(3"`?`)H&
M6(FFACELQNEM)#-!G=8V+$65"3\PYGDG;(9&@9$*9:)TC)!LA.1#1),"0YE2
M:$7XSE5&64`;."IQGF>*$T;/Q"D3)6Z$9",D'R*:.(CG!XBC+$R<#&HG$!A7
MR?47D9$H923=TA&2C9!\B&A:H`0,M3Q?:]18#UD@K+FP+;P?(>D(R49(/D2T
M^!9Z?/^S7%$6/7".P+0,IGIA3+6T43,M:/0$Q;I7IHRD6RX05E8T<?0`-*K%
M,]I]^DM5ONPP!`<%;R(I<ZBYO!)3#ET:1S1IOKG=I8V,,14TD(?!A"P-:<I(
MNN4"&4N#WOM,VE=\_98TZ*%2&R71M0EDR5J.[WJF+O5=1IAR)(0Z^A#F&YLJ
M$T8>HXWGD1?JRG-AX+-ST+#O>$`\%#J1JX$@9JTK$E!(,_JZ`4G&T/N'@=(D
MH(B?@&CGS"3D,QJHDJ[K&AHD43060;OJ8"'^APC>@Z$LRX!VGH!47HP)WC\,
MI$\J(,B,A#()\3Q,B^`CA1.9H&WUXR)X$]9$<.B1";,>>,I`1IP*2,L$MXJ>
M94(0362"=M2!"%[OOK,D>*(M#Q,D(%C'CVT0&RMD+QV7*B6I@**Y@C()!7*I
MQ<'<7&I\N*DLT:YJ"H33OBAYLBY\O/[!Q<8L$@*"1`[%&N>&_</JD4W.%>FU
MTUC+F7",(J8_].,@-'H`O6W1H,)!@OGMB1_%&]2=T1[5-;%*?*,W(]B;FY6"
M^;4M72303"`X$X^3C!5<`X=KWI9M"P/?T>O?!,_.3^`H.N;?S1,XV(WQ;9!L
M0=CXPRY(X+`T@8<)'#PF\"B!A@^XHR*%Z^"U.*/?B^Y<M<2JT0DFQ67KON,7
M2O[2B[YQP#U<!%D+N<#%'T$)=.DB.F'<RQ<Z@/HI8?,O````__\#`%!+`P04
M``8`"````"$`"`<D@T(-``"I20``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6RLG%%OX[@5A=\+]#\8?M_8LBTY"9(L)A;9+M`"1;%MGSV.DQ@3QX'M
MF<S^^QY*O"(O#]<3&?.RV?EX2=][1/&(LN2;7[]O7P;?UOO#9O=Z.RPNQL/!
M^G6U>]B\/MT.__.[_>5R.#@<EZ\/RY?=Z_IV^,?Z,/SU[J]_N7G?[;\<GM?K
MXP`CO!YNA\_'X]OU:'18/:^WR\/%[FW]BI;'W7Z[/.*?^Z?1X6V_7CXTG;8O
MH\EX7(VVR\WKL!WA>O^1,7:/CYO5NMZMOF[7K\=VD/WZ97E$_H?GS=M!1MNN
M/C+<=KG_\O7ME]5N^X8A/F]>-L<_FD&'@^WJ^K>GU]U^^?D%=7\O9LN5C-W\
M@X;?;E;[W6'W>+S`<*,V4:[Y:G0UPDAW-P\;5.!D'^S7C[?#3\6UO9P,1W<W
MC4#_W:S?#]'_#P[/N_>_[3</_]B\KJ$VCI,[`I]WNR\N]+<'A]!Y1+UM<P3^
MM1\\K!^77U^._]Z]_WV]>7H^XG"7J,@5=OWP1[T^K*`HAKF8E&ZDU>X%">"_
M@^W&30THLOS>_'W?/!R?;X?3ZJ*<CZ<%P@>?UX>CW;@AAX/5U\-QM_U?&U3X
MH=I!)GX0_,T,<J+CU'?$7^EX^I-FO@/^^@[5Q>2R+,K*I7OBD]#:U(F_ON.D
M#'6>Z%CYCOA[,L51*VQSG.KE<7EWL]^]#S#Y4=#A;>E.I>(:@\@!:C^R.V1_
M=L1PJ-P@G]PHMT.<M3@8!TRS;W>3V?AF]`U38^5C[CFFT!$+B7#SP`U;I\"D
MP$9@A(JZLG"L?T)9;A17EB1T+R"J,ZE!(J1+G0*3`AL!50.F75K#%&=@_MR1
M(^$ZW0XQ`:,CD>A\[V/BH%E21A?2U4'$$+$Q4:7@H])2W#+0<Y:Y45`;.D;%
MI=/,!YTJK@OIBB-BB-B8J.*0ST\HSHW2%"=)W7N"SXW*G20'J@N2;C410\3&
M1-6")2"NY?1<<\$Z94]FW1FS(%(3,41L3%1^<YV?6Z[F**;G1'*CZ,0]T5I/
M$ZV[H$YK(H:(C8FJQ5WD1$OO::U=L$[9DTAK(C410\3&1.5WI?,[TQK<*#IQ
M3[36Z0+4!75:$S%$;$Q4+046SH^+W43KI`5%<C.J&1E&5B&=IO.S:$XTFD_[
M3_"B]44LE2+?O2`M>YE,\1`E'6M&AI%52-?D_"VJZ?0\+UHW5)E[%$M/J):.
M(<HPL@KI-)UY16F>.=T+[X&Q\ITMQ@MYE2K?107E"1D9/E1I%=(EX5C')?U`
M>1>=3'J/PJ<M"D(U(\/(*J33=&Z4*C\^8]*[<9("/$+2D8?.4^F[J"`](>,N
M6-SP00RKD*[).5A4TP^D]WX73YK8`INKX45!J&9D&%F%=)K.G*(TW:2OL%3V
M]-/">UR<?V=[L?*7J?)=5%">D)'A8^7C*%V2\[.HI!\H[]TOSCPV1*\\H;H@
M9!A9A72:SJJB-)OEYIQ)[RTO+J!SP5CZJU3Z+BI(3\@4A*Q"JJ9)+Y-MHO7I
M*B@<Z`6CFI%A9!72:>9,UH7WG/43-EE!:KTIDRW*(D1UTC,RC*Q"NJ9>)CMA
MDQ442\\FRU&&D55(I^D<+9WU6%?[*N^-,9KTD\XKHTE?)CO?18@*RG<=!1F.
ML@KIDIPA1B6=7F\FWC[CS#V*E2=42\<091A9A72:SKVB-,]<Z=U]K,1C!2'G
MX+%END\-42)SS<@PL@KIDGIY[(0]5E#0=,&H9F08685TFLZJ$N7/N/DQ\8X7
MSYS.!&/ETUVK=`Q5UHP,(ZN0+LF97U32#^:\M\HX<W+/Q810S<@PL@KI-)UY
M16DV'EN=L=QX$XP+Z'PQEC[=Q$ZZJ##I"1F.L@JIFMP=P+BFT](WT=IC!87I
ML&!4,S*,K$(ZS9S']E=^RA8K2"\WZ3XV1'7*,S*,K$*ZI%X6.V6+%10KSQ;+
M48:154BGF;'8,VZ13=EB!6GETWULB`K*L\5RE%5(E^3L,#J/?S#G770RYSV*
ME2=43PD91E8AG>;/L5AWNR?-WR,D&%ELNHV5CJ'*FI%A9!72)?6RV"E;K*"0
MTX)1S<@PL@KI-',6ZZKJ>5TY98\5I*5/][$A*DSZSIP%&8ZR"NF:>GGLE#U6
M4"P]>RQ'&496(9VF\[/HW&P\]HS-U-3[8N2Q@K3TZ3XV1(G.-2/#R"JD:IKU
M\M@F6J\W@B+I&=6,#".KD$[SYWCLC#U6D%*^2K>Q(:I3GI%A9!72)?7RV!E[
MK*!8>?98CC*,K$(ZS8S'%F?<O)FQR0K2TJ?[V!`5I&>3Y2BKD*X)GQB?R*=-
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MI$OJY;`E.ZR@D,""4<W(,+(*Z30S#GO.:L,.6W9&&<_Y=!,;HH+R74=!AJ.L
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M?+J+#5$B<\W(,+(*J9+FO3RVB=;+C:`@\X)1S<@PL@KI-#,>6[A-;\])/V>3
M%80%,5S2S]-M;(CJI&=D&%F%=$V]3';.)BLHEIY-EJ,,(ZN03C-GLOV7FSE[
MK""M?+J-#5%!>?98CK(*Z9*<^47?^)R^43SW5AE]KR,H5MY'!51SE&%D%=)I
M.B>,TFR^F#I#>3=,<M*V"/^-IGRZBW7WI-$OE%U[XFYM1_V2/9@)47+`K*#F
M/31=8V*Z;8T7KL/Q>;/Z<K_#)^&DS1RB*=[2:]_=F[,7>Z0JG*3K:1<DB=8R
M$@:,*DSV.B9$24<K*%-AQJ^+,E3X^^[MSRJ$JW<ELEO//;IJWU8<%U1>%R!I
MUKZ/6SE#?9/DE#,2530C7TZK(ED.K40T+][J`]K+RN=LY1[A)E3S$N8X_>Q%
M"`AEM<-@0R/(^"AL'MPP15&,Q\G&R<I`E>NEBTB,/C/[XF/#?C[WJ#LVB<2+
M$"`9UQ[AV`@R@MH#D2^B_23<ADR+N.QE[4VT7B4\"D<B72%"@&1<>Q0?"4$G
MCH0,Q$?B,FO\X>SYT/K0#)+4YB\$H%XX$2Z3&;*0CE?=(:D]P@9.:C:"9C+5
M+F?)-;/U(;FCE%P%M$_X7<CZ)ZO#QQ=#O`R?+O<>N?NZ4;'I9C9$266U1V[/
M%#K2<B%155-_.;F<E8DGN#?T&R^)#G#[QGW[)O=VO7]:+]8O+X?!:O?5O4V/
M<_/NIL/MJ_[W\^FU<W6D1RTSM#36F[94\VNW\<CTJ2[1TJS7U.<*+<TQ3UOF
M8WQ.<X)2"WZ'`-=ZF<^93]#2G)YIGPI]VC.%6M`'2U=FM`H:M)./^D`#;-AS
M?4JT-#Y.?2JT-`<E;2G1![>C,Z.5Z(,[P+D6:(T;J;D6:(U[E[D6:(U;@)F6
M"EKCKENF988^^&(NTU*B3[N`4CW0&E\IY?I`Z_;$I#[0&B=-K@^TQO</F989
M^N`1A5P+^N#2*=<"K7'',-<"K?%]=JX%6N-KX5P+M,8WL9F6*?K@<:U<"_K@
M":E<"[3&<T:9EAFTQJ,]N19HC2=D<BW0&@^E9%JFZ(,G5W,MZ(.'17,MT!K/
M7.9:H#4><\RU0&L\5Y=K@=9X0"_3,D$?^'VN!7WPW'RN!5KC\?-<"[3&$]^Y
M%FB-YZ8S+5-HC6^P,BT%^N!]IDS+!'WP&%NN!5KC19Q<"[3&NR^Y%FB-5TAR
M+=`:;VUD6@KTP;N=N1;TP>N4N19HC7LJN19HC?<`<RW0&F_8Y5J@-=Y@R[2@
M2[8'.F3C(7-6Y0(JXVWHS"<44!GO%.=:H#)>X^46[+"NW?XIUU*A)5<]?@#G
M4VZL>_?QF9'NW2'.<7<R9?BGV?4GV#>G=._6LQS'$<R5<(_CUQ0PZM99_%#.
MV_)I_<_E_FGS>AB\K!]A_>/FZF[?_M1.^X^CWR-]WAWQ$SG-=ND9/XFTQB^L
MC-VETN-N=Y1_(-%1]R-+=_\'``#__P,`4$L#!!0`!@`(````(0"HT4M\^`4`
M`"P8```8````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK)AM;Z,X$,??GW3?
M`?%^PT,@":CIJ@G/NI-.I[V[UY20!#7$$=!V]]OO&&RP/6FN7?5-*3_&8\_?
M8WOBNZ_?ZY/V4C9M1<YKW9J9NE:>"[*KSH>U_L^WZ,M*U]HN/^_R$SF7:_U'
MV>I?[W__[>Z5-$_ML2P[#3R<V[5^[+J+;QAM<2SKO)V12WF&+WO2U'D'K\W!
M:"]-F>_Z1O7)L$US8=1Y==8'#W[S'A]DOZ^*,B#%<UV>N\%)4Y[R#L;?'JM+
MR[W5Q7O<U7GS]'SY4I#Z`BX>JU/5_>B=ZEI=^.GA3)K\\01Q?[><O."^^Q?D
MOJZ*AK1DW\W`G3$,%,?L&9X!GN[O=A5$0&77FG*_UA\L/[-<W;B_ZP7ZMRI?
M6^%_K3V2U[BI=G]4YQ+4AGFB,_!(R!,U37<406,#M8[Z&?BKT7;E/G\^=7^3
MUZ2L#L<.IMN%B&A@_NY'4+8%*`IN9G8_C(*<8`#P5ZLKFAJ@2/Z]?[Y6N^ZX
MUFUWYB[-N07FVF/9=E%%7>I:\=QVI/YO,++HH$8G-G,"3^9DOIB<W&@X9PWA
MR7OW;O;DL`;P9`T6,WOE6NZ"#O=&3_"UCQ.>?(CV^UHN6$MXLI;NS'+,_^MP
MR9K!\WVAP8KL1PC/CX4&BO4-X?G!T"Q(MV'V:=X-,WLK.&-(GCX7@[S+[^\:
M\JK!`H?T:"\YW2XLGSKE63A,R)B7;Z4EI!+U\D#=K'40`#*NA;7T<F_/[3OC
M!?*_8#8;;&/)%EMN03.4N@U4$*H@4D&L@D0%J0HR`1@@RZ@-+(K/T(:ZH=KP
MJ#8<"&(I0G`+WB100:B"2`6Q"A(5I"K(!"`)`8O\,X2@;M8Z;`!"DLSER#?,
M1C1R9)/M:#*J@TB(2(1(C$B"2(I()A)))!CR9XA$W8!(L-L)*JE+B1G=4FDT
M&55")$0D0B1&)$$D1203B:02Q/49*E$WO4H\N@TCT+&@FYHZHQ%O%B`2(A(A
M$B.2()(BDHE$$@4.*$F4ZR4`WVNIM1P[(\ZXQ6P1"1`)$8D0B1%)$$D1R40B
M!0I'JA3H+YXVU(VL`"/R[+O*QC$:C;./2(A(A$B,2()(BD@F$DD46M"+1_#M
MV:?6<NR,"+./2(!(B$B$2(Q(@DB*2"82*5`H<Z1`?W'VJ1M9`48$!1`)!N)Z
M?7'B6$O;D[,C'`UX=D0#6?1E?%^/Q,AM,A)AV[&5;2<=C;CK3'0M:41KL"LB
MS9:P>73'JGC:$-C?H&*YDB5SB(V58]2+K%'O&)`@$D8!1[""IVW45@[I<++B
M`44,B6)QJZG'A*/%4"*:EN(YG0RXYTSR+&M%"S=QY0P)-6GUC5S>T@I^=(QB
M#?4?'+F\SXW%$$S3)(-:T&XG*]XP8,@%_:>&]D))-6YE]3*XSM+R/&LE&T7<
MR!Z'%>,.$VYUL\.46]WJ,.-&?8>RT+0PO"7T^Y)R*"\EG0?D0E$UR357Y-I:
MH]6D,T-3;H7<BBZ4Z4?(4E65-9037-D+8NYK/FJ?<#3UF'(D]ZC,8\:MWNI1
M5IJ6ETAI^$D.0='5SS/Z`UL!*UC%[&9(S&['E(7:6J/1)/J`7#C))H5Q<C.K
M59_<CK-R3'.%IH$9B<F-.DS8&&YWF'(KUN'"-E?F2CG[,VYT);EIK8HD=S^\
MB["25]29H2EEMA9"`48A1A%&,48)1BE&F83D](,\0UK,86_YZ'4`]:.</PR!
M`%/RS)6%MZ478+3A)%F`48A1A%&,48)1BA&]]9L&,>@SW.(--R=UV1S*;7DZ
MM5I!GND-G4WWU1$/UX>;A0]U,*P=E2]]*`6O\)4/E=,5;CEP#]GKH7JR7'Y#
MJ7Q)/!]J#NP+SE^?'K'X2^:!JVL?X!;TH5\S2A<;>CMZQ='&]N$:`7>PF?OP
MTQGS!\=_`+WQAPV$?35J"/JJO>=OKD:P]?SMU0^!YT/1AWN&(LBG)0[^$GD^
M+73PA]CSX^&#,>H$=[67_%#^F3>'ZMQJIW(/F6+VVTHSW/8.+QTK4AY)![>T
M?;URA%OY$NZ_3+KO[PGI^`OT;(SW_/<_`0``__\#`%!+`P04``8`"````"$`
M*'_]>_T%```E&```&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*R8WX^C
M-A#'WROU?T"\7P@0D@5MMMJ$WVJEJKJVSRQQ$K0ACH"]O?OO.P8;;$\NS9WV
MY;A\&,]XOAZ;63_^]K4^&5](TU;TO#;MV=PTR+FDN^I\6)M_?XX_/9A&VQ7G
M77&B9[(VOY'6_.WIUU\>WVGSVAX)Z0SP<&[7YK'K+H%EM>61U$4[HQ=RAC=[
MVM1%!S^;@]5>&E+L^D'UR7+F\Z55%]79'#P$S3T^Z'Y?E22DY5M-SMW@I"&G
MHH/YM\?JT@IO=7F/N[IH7M\NGTI:7\#%2W6JNF^]4].HRR`[G&E3O)P@[Z_V
MHBB%[_X'<E]794-;NN]FX,X:)HIS]BW?`D]/C[L*,F"R&PW9K\UG.\AMS[2>
M'GN!_JG(>RO]WVB/]#UIJMWOU9F`VK!.;`5>*'UEIMF.(1ALH=%QOP)_-L:.
M[(NW4_<7?4])=3AVL-P>9,02"W;?0M*6H"BXF3G]-$IZ@@G`OT9=L=(`18JO
M_?.]VG7'M>G,9_9BO@1KXX6T75PQCZ91OK4=K?\=;&PVI]&'PWW`D_MPES-O
M-7=MYN3&0)</A"<?:"_&X#?&+?@X>(J`-^/`+/HDX2GB>+.%XZT>_F^&2SX2
MGGRD<U=F*SX.GB+B79G!MNQG"L^[,O.Y/3Q%G#LSLZ'4AI5G-<>7_E9NUE`Y
M?2&&15<\/3;TW8#=#<717@IV5M@!\RI*<%C`L2B_5Y-02,S+,W.S-B%QJ+<6
M-M*7)\?V'ZTO4/PEM]E@&UNUV`H+5I_,;:B#2`>Q#A(=I#K(=)!+P`)91FU@
M2WR$-LP-TT9DM1%`$DL30EB((:$.(AW$.DATD.H@TT$N`44(V.(?(01SLS9A
MWT]%XLS5S#?<1C9:J";;T614!Y$(D1B1!)$4D0R17":*2##ECQ")N0&1X+2;
M5$);B1O=4FDT&55")$(D1B1!)$4D0R27B:(2Y/41*C$WO4HBNPTG$'C2S=$/
MF-%(#`L1B1")$4D021')$,EEHH@"'RA%E.O??W'6,FLU=TX6XQ&S121$)$(D
M1B1!)$4D0R27B9(H?%&51'_R:\/<J`IPHJZ^HQT<H]&X^HA$B,2()(BDB&2(
MY#)11&'=O/P)OKWZS%K-G1-I]1$)$8D0B1%)$$D1R1#)9:(D"GV.DNA/KCYS
MHRK`B:0`(N%`/+]O3A;VRM':DV@T$-41#V39]_!]/Y(@M^E(Y&-'^V)EHY%P
MG<NN%8U8#W9%I-D*#H_N6)6O&PKG&W0L5ZK$A=QX.\:\J!KUC@%)(F$4"@0[
M6#I&774C19.52"CF2!9+6$T14X&60XLXMS7/V60@/.>*9U4KUKC).V<HJ$FK
MS_3R/:W@CYM1K*'_@T^NB+FQ.8)EDF3P5!FVDY48&'+D@?[2P*4Z,!)6]E",
MRX4W7ZU4FUC8...L$APO%58WXV7"BL=;N+;WH,TI%S9]/%5FUA;>DOF^DAR:
M2T7E`7G04DEB:4)L[=%J4IFCJ;(B8<6VR?@GB/.@B\H'JN6MG02)\.6.TJ<"
M31$S@92(KM;/YL+J>Q%5I5ESB92&/\<A*;;W13W_P$'`VU6YMCF2:]O5JF%K
MCT:3Z`/RX#LF*:P-C/A`[V'8X;[GVYZF22QLY-)&\5)A=3->)JQ$/'^U<K5#
M)1<V5TJ;]:E(<.^'3Q#>[LHJ<S05S-9&*,0HPBC&*,$HQ2C#*%>06GQ094@+
M%PZ6'[T*8'ZT;P]'(,!4.J[>G+.;+S9PDBS$*,(HQBC!*,4HPXA=]TV3&/09
MKN^&6Y.:-`>R):=3:Y3TC5W-.>Q0'?%P;[A9!M`#P\[1^2J`-O`*?PB@:[K"
M[05<0/9ZZ)YL3UQ-:F]2/X!^`_N";V_`/J_X3>Z#JVLOX/KSN=\S6H@-NQ:]
MXFCC!'"%@`-LW`#^;,;\>1$\@][XQ0;2OIHU)'W5W@\V5S/8^L'VZHO0#Z#A
MPY&A`0I8>X/?Q'[`FAS\(O&#9'AAC3K!)>VE.)`_BN90G5OC1/90*?/^6&F&
M:][A1\<;E!?:P?ULWZL<X3J>P-W7G)WZ>TH[\0,B6^,%_]-_````__\#`%!+
M`P04``8`"````"$`=QH)1(0"``!Z!@``&````'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;)1536_;,`R]#]A_$'2O%3MITAIQBG1%MP(;,`S[."LR;0NU+$-2
MFO;?CY)2+VZZ+;W8%O7X'DF1\O+J4;7D`8R5NBMHFDPH@4[H4G9U07]\OSV[
MH,0ZWI6\U1T4]`DLO5J]?[?<:7-O&P!'D*&S!6V<ZW/&K&A`<9OH'CK<J;11
MW.'2U,SV!G@9G%3+LLEDSA27'8T,N3F%0U>5%'"CQ59!YR*)@98[C-\VLK?/
M;$J<0J>XN=_V9T*K'BDVLI7N*9!2HD1^5W?:\$V+>3^F,RZ>N</BB%Y)8;35
ME4N0CL5`CW.^9)<,F5;+4F(&ONS$0%70=9I?+RA;+4-]?DK8V8-O8AN]^VAD
M^5EV@,7&8_('L-'ZWD/O2F]"9W;D?1L.X*LA)51\V[IO>O<)9-TX/.US3,CG
ME9=/-V`%%A1IDNS<,PG=8@#X)$KZSL""\,?PWLG2-?AU2<D&K+N5GHH2L;5.
MJU_[S3U%=,[VSOC>.T_GR?EB,DU1ZS\D+`82\KKACJ^61N\(]@I*VI[[SDMS
M)'X]$<S`8]<>7%#L98S58O$?5M-LR1ZP8&(/N8X0?`Z0=$`PU!R$4>QT80_V
MPKZB/I+K:#B4^1/(2&;Z%AD/+NCL(/@LG0_A1^6(P8(/"<X&Q$@9:4Y/T(-1
M^9#VJ+01<PCYBS)"3E?VX*`\U#9:#G6R=/%ZCO.W*'GP6"E:PJ",2K<8TX8I
MFV)`_^Y.[S7FCY9Q)A<O,HFS'F="@:GA`[2M)4)O_1QGV.6#=;ABUIGOQ)?V
M6;X.5P\;-G#T>U[#%VYJV5G20H64DV2!$9EX><2%TWV8Q(UV./SAL\$['K#3
M)PF"*ZW=\P*%V?#76/T&``#__P,`4$L#!!0`!@`(````(0"O)O.J)0X```Q+
M```8````>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK%Q=;QNY%7TOT/\@Z#V6
M1M+,2(;M131DV@6V0%%LVV=%EFTAEF5(2K+[[WO((8>\'[$U2OM0;\Z]O'-Y
M>,E#SH=N?OEC]SSXMCD<M_N7VV%Q-1X.-B_K_?WVY?%V^._?/WV8#P?'T^KE
M?O6\?]G<#O_<'(>_W/WU+S??]X<OQZ?-YC1`A)?C[?#I='J]'HV.ZZ?-;G6\
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M%;/YS>@;QG\=?):*#_5HHH<;;!?6<,!FP`@=Z'J!\>.]<+74LQ<NBNM%O/XR
M`JE;$Y9R](A-#`=L!I"443@\Y1E2ULL_\NP:W0Y1+AG/"YK2,OCD3C/JTG0N
M7=H"L3E"$D=@GO@%7+LHZ`EZG'6%ETQP>JLKG4O7%8'8'"%=P=7_#UUQ47Q7
M8@K+@.1Y%^68#4+G%)L9@=@<(9E7-/.WJ\8YTP0#,NM*O1&($8C-$9)-3;/Q
MB\BB_RKBPM`\`T*)+!B1G5-'I$!LCI#4W78B6__>)M(YTP0#DA$I$",0FR,D
MFP7-QFOB&$70<R%S86B>`:%$\L6L<^J(%(C-$9)Z@?$^GTGO35.,4,:EA(R$
M+(%H3DXOLM%U?%Y0ET4K.UBL(C'+"%%"IZPRDU=L:"1D"43S=^*1Y?]V=1:M
MU)`T`Y1S*B`3&R8O2R":DQ.&+"=?HU7_&BV"P.2D=IJ3B4+)Q2LV3-D:"5D"
MT0Y@S/(.O$.J\V:%&J"40%,(R$C($HCFY!9Z3NKT`E)=')9M@)!A4MJRY)7:
M>:5*%9!U.N_"^Y[3#CAMR#KP#JE!2?*QS\7%[_Z:0D!&0I9`-">WZ&<YN4IU
M&XZ>BVD1M"-/MI.3G-.*<]IY)4X%9&-XA5,G$RS_HKQR1X/3TW;]9;E'A[`T
M*5Q/L0</._.@-7GV`:JZY:PI!&0D9`E$J7:R\$:JO^]??Y0JSEE=KD%<\EQ;
M"$MDY+`I!&02E(\'VQC;Z#5UL4CZ$Z9=?DWKR[0/0N=>@-QBFLV]FM6)[L7V
MPD;UJMBFTD8O,MNKM&.BW5;DL<8A.M17'+3SBVTBA3)`;N5(%%1\YZ%[,3DU
MT:OR)TQW4BX7^?\8L3;Z8])EUTYZ0LEPNLA*>(IK<#:4V9:5\"2H:U;"`7*G
MZBP+O@`'+S?%,B^VI)@8:]*>L6DAV6BE5TJ%1/NKZ7COFI<B/FFA:39C`^3F
M7]8W-EHF-O33TR]>-D(^%LW>"2X;K>*G2C<H>#YP+<1*EZTJS43SJMF\--&K
M*]V2%;>-'N<5*ZJ2=W]:_,S,=0'9XM5"M"+KM)2T(NUNDZ$A\V+SVP0OK$[^
MWA"OVS:&FZY9??QHGK*=!E^KXZKUSCR5.Y!)"TTQGBF+F@U3$[QH4=0I5\^*
MB;'JL%+A;B+OLWJU-"=HM;MM0U;M[_0M;#+R4FXA["@[&9VT$-:,")D`3=,=
M,!LAWY#FY+8,Y^<4-A@I@>6DA4A.+>36L6P(&'4F-LS3S&/1--UNX?PTV[U%
M?H2:M!!)LX4(=<$KSREO2')R4I#GQ$OXK(V=#T)G;("FV<8N0(Q1+BNQH;_=
MWRZ]$?*Q:/;*KF&6"<=Y$Q#ZP!><`+DK9Z.?Y*M=<((76W#8JFQB^"),P,6L
MSG<*"U935KUVE:8U98!M%=Z>CE.Y)8B0?T(2NM5Z02.[Z1B]T@RU$6H?K>1W
MP*>*G%?9]N6\FI)R[N/BF4`FYP&B<C[GBA>\9IF<DUB442>BV2SU,^)GY-RM
MXDS/`D17[CG7,]V+ZUGP@F8[/1M?\3`VAL$BFVIYGL2$]M[I'^O]3ZFYNW/`
M>Z_I]#P5>*A"U8M-%A/"8W?6]KZ>%F1RL2EKH_]9^H[52Y#Q4SL['Y`ME*WX
MNEU)-CIL56Q"0^:5)-I39I*7(^,#JR<;S;ABNE2=@M!"<)K,"N'G^MZ*?*YG
MTZ#[M#+9D#6ZEUAE0ZRY+P39]V"&$*:^_W!1=1+.^]Y?5MJ-`.EP@.IN96VP
MP_'S(T%&0I9`=)R<M+-<W9VE=X2@W1"0W%K(W0*1M=-,HS6C;Y'669+2C.TI
MWD[%>],Y$:'LKJ:$C(0L@6A.RDZA<(M!SSMP,[E7B!#9K"_8Y&N25R>J$K($
MHAWH)?0S*?01RDD-7@DRTLL2B.:D"'VQN(!4J?70:C\M**E,^YKDE4CM&D;(
M$B_:`:;U[U2J%'+<?@YIQJLU$C(2L@2B.8$_/J$O>%#DU@"FNQ&BG*:-0*N[
MR2MVR4C($HCFST3S'4Y;^4.X>+7E+$"I*AL)&0E9`M&<W.K/%LFIV]SWG?VM
MBI!L`T1)Y9N96><5NVDD9`E$.\`4Z1U2I?+,`I23*B`CO2R!:$Z*\ES"J92B
M68`HIVSKUR2OQ&G7,$*6>)'\RUXRY;VI3$4HXU1"1D*60#0G3:8N>*)92IF*
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M\K-4\NHXE9`E$,V_ETA54J0BE',J14IZ60+1G!21*MPC]+ZD2I6J.K%)*^ID
MS,]2R2N1VC6,D"5>M`,8L_-5JG+>K%`#E),J(!,;)B]+()J36__9OO\"E7(;
M,)YLIRPYI_PL%1NF9(V$+(%H_KU4JI(J%:&40",A(R%+()J3HE*73'ZI4E4G
M-CFG_"B5O&)1&@E9`M'\>ZE4)54J0CFG4J6DER40S4E1J4LXE2)5=5J3<\J/
M4LDK<=HUC)`E7B3_NI=(>6\Z]R.4<2HA(R%+()J3(E+I4Y:S/R>II4A%"(M3
MMT.=C/E)*GE%`HV$+(%H_KU$JI8B%:&<4RE2TLL2B.:DB=0%-_QJ*5(1HJ3R
MHU3R2J1*D2)>M`-.4#)!>/LH50?YR6Y.12@G-7@ER$@O2R":DR)2TW%_Y7?%
MS50J0I14?I9*7HG43MXB9(D7[4`OE:JE2D4H,=A(R$C($HCFI*A4<<'G"[64
MJ0A14OEA*GE%!HV$+(%H!WK)5"UE*D(YJ5*FI)<E$,U)D:F).XGWW*/64J<B
M1$@M^&$J>252I4X1+]*!>2^=\MY4IR*4D2HA(R%+()J3HE.75.I<"E6$**G\
M-)6\.E(E9`E$.]!+J.92J"*4DRJ%2GI9`M&<%*&ZX);?7.I4A"BG_#"5O!*G
M4J>(%\T?X<_7J;GS9H4:H)Q3`9G8,'E9`M&<%)VZY!'J7.I4A)!AVE$5_#25
MO!*I4J>(%^U`+YV:2YV*4**KD9"1D"40S4G1J0MV_G,I4Q&BG/+35/)*G(98
MJ9>6>-'\>\G47,I4A-+5&@D9"5D"T9P4F;K@U(]?'!"SJA.;O$[Y:2HV3%TR
M$G(_:.##>Z\V__8'"MIOXG>;P^.FV3P_'P?K_5?WXP.0D+N;#FY_&6$YK_#3
M"/[%2&&I8?%OE0C+'!;_=JBP+.(/+0C+&!;_JI^PN!]G\*_D"<L$%O_&H+!,
M8?%OXPG+#!9/B;"4L/B=.+?4:(/M-0I86-`&^U;-`MZP>]0LX`W;,LT"WK`Y
MTBS@#;L.Q5*A#<[]F@5M<*)6+#6XQKE6LX!KG!@U"[C&N4VS@&L<B!1+A3:X
M(:E9T`9W^C0+N,;]-LT"KG$G2[.`:]Q/TBS@&G=J%$N)-GA2HEG0!L\@-`NX
MQI,`S0*N<8M=L53@&NNM9@'7N(6L6$JTP2-<S8(V>#:J6<`UGE!J%G"-9W^:
M!5SC"9QF`=?8=RN6&=K@W1+-@C;MBPM\ELS`-=Z=T-J`:[R4H%G`-5X-T"S@
M&@_=%4N!-GA76K%,86E?]1>Y@6N\U:6TF8%KO"ZE6<`U7EK2+."Z?0N87Z=`
M&WP;I[0IT`9?\&H6<(WO:#4+N,;+O9H%7.,S4<T"KO$!IF)QTT?#T4#U!YDJ
MRQ@8?5S`,3Y<5ZY<@./V>T?.U[2X7N(=:MD&K[M?&]6"%]LQREH;_+[/1YU[
M7%ZYQA*#I?ICJ-3XL^N/D%N9[-+-%@UW\TO#)Y/K)=XUEI'P.=RU^VQ,6O`I
M'++5+,M)!1(UXO'1#DC4+!86VUI&W9C@MXA>5X^;?ZP.C]N7X^!Y\X#M0OO"
M_:']-:/P]GWX]/7S_H1?(?)?P3[A5Z<V^'V;L?M@ZV&_/\5_H".C[G>L[OX'
M``#__P,`4$L#!!0`!@`(````(0";GZL;H@<```\B```8````>&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULG%K;;MM&$'TOT'\0^!Z+>^'-L!R$#-(6:(&BZ.69
MEBB+B"0*)!TG?]]9SHK<&5*TY#PXEGAV>/;,SIPEUP\?OQ_VBV]%W935<>6)
M.]];%,=UM2F/SROOG[^_?(B]1=/FQTV^KX[%ROM1--['QY]_>GBMZJ_-KBC:
M!40X-BMOU[:G^^6R6>^*0][<5:?B"%>V57W(6_A8/R^;4UWDFV[08;^4OA\N
M#WEY]##"?7U-C&J[+=?%YVK]<BB.+0:IBWW>`O]F5YZ:<[3#^IIPA[S^^G+Z
ML*X.)PCQ5.[+]D<7U%L<UO>_/1^K.G_:P[R_"YVOS[&[#Z/PAW)=5TVU;>\@
MW!*)CN><+),E1'I\V)0P`R/[HBZV*^^3N,]TXBT?'SJ!_BV+U\;Y?='LJM=?
MZG+S>WDL0&W(D\G`4U5]-=#?-N8K&+P<C?[29>#/>K$IMOG+OOVK>OVU*)]W
M+:0[@!F9B=UO?GPNFC4H"F'N9&`BK:L]$("?BT-IE@8HDG_O_G\M-^UNY:GP
M+HA\)0"^>"J:]DMI0GJ+]4O35H?_$"1L*`PB;1`%[.UU>6V0)1+JYO<Y;_/'
MA[IZ7<"B@5LVI]PL07$/@<W$%,B#-/JI7IHI3-$$^62BK#Q8[3"\@?1\>Q2^
M?EA^`TG7%I-.8"@B.R-,)H!>SQ$F[G*<%OU,Q8`-%9,$PRW%+R!VSTVR^XX1
M4=!#"!-0R&5R5FN>D1FT\K1#0/A#?"2)&%@+/4DF7S:'(!SA1B['>6X&#!EW
M[BO\L)\[<D-,TJ7U0^PGB2\X.0*)(I'(4/51"#N8HLO.**@O%M(YIV805S#J
MXR-+Q,#/BPK.(0C'D'*<5]"`N8(QXX:8L%-0!F&B6?HS%R"$4L&0`\(LNH69
M`7-F"6.&&&0F5!@E">.>N8A0RR"ZD%AC=1.-9%X\,XA1%#ZCB!A+,901FT+&
MKL?#>")=0OG-\S)@SDLP7HBQ28V4TS*Z!9E=ODYX">BVKG#SQ#HT9\;Z66I!
M2.U#X.M!$J1&`1+^]7.CW$Q'OCFI`OLX:2IB6#58KA848%>13M8L10QBYZ!E
MDEPH"<'<X;J>W(WB.K*NEEJ03;$0>J!@2:)SX"0&D:F&IG'?KB&V>ZHAZQJI
M0)#52(02.C-KBQG%A'$BXTO)OLDXQ(1S"*9/:D%(,/9%$#"),X(($Y$X&E,9
M3?=V9'RC3+#74_F8-*G9P$&5G^53.O$EFT%F,?,9OLDOQ(1A"-9T4PNRP@71
MB!8QC$`.U45%N\DOQ(1A"-9M4PNRH@61]H?E9(L"P\Q+]BZW$-CJ8>7U'B_D
M4':VL2`(<MN#1HMN#D(%O,DUQ(1M2&X;%F0%E%IKAL@H(I:)4U>$G;S).CHT
M:WE.XT?U+`C925\*CL@(0D4BCH?%2=DQ\YBO6#DV#<565FHQ_=J+$YY9@I!)
M/$A+J;W+,R1V>[>I*$8@M1A+$38%4C)(1B%2J\C9<U&:IK\[/>\Z:Y/H"BY-
M/?0'FV;$6)I"1J$4@U98QS;.&>,+Y30#RO,FYY!CY]"\RUC,^=YQ$(V,C4*B
MV'ELH>1N,@[S.,YW?DYWM>I1X_!5$,EH)!\!15!*X27GE<Q`KLPS>@#MAFRQ
MI5WHE0=<+G;#60B5\B8[D1-V(OD6QH)LHB4L,=XP,PK122CD8)>4'W.5-SH.
MNH!;)X+[?RH1=.8'N]"$;2,R"@FT=M8+I7>3F<@I,V'W3BT(Z6G?9V:8V>NS
M7FQ>][A=9EZU#LU=9,@'%H@%6=4":"]\AY,Q2.`'P5!!1#;%?.2ZZNA&L7<&
MDK<9"YJKCED(Y<E,Y0T=QV8B%$M?JA"$.L*KPE%^+6`^OZ;7.R[R!B]T!E(5
M:LB,S2^"[+(+Q^M.(6">%W.-*_,Z=@\QVB@H!"&_6,0R"%CJ,P(1(DP2Y3PF
MT\2:3GZ]@-CWJ8#<?Q6";('`+LMWGGO0?BD$&F/H-$_*C]G'&PE&VZ#\N&TH
M!"&_($ETQ/9B&4&(T)=NXZ;T;G(-->$:BKN&!2$]!64QL0(QSOP*9'YQY0J<
M\`TU[(%MA2"(W]ZFUC45J/K`>8:BTC''N)+@A',H[AP*02BA@!48ZYC)G%&,
M@A>30@VMGC#5S$2N8]J-8F;BW`&EM"!;*\(7TBE4%)1``GWIW;-^EY-THSA)
MUDY2"[)R"M@#.*]P+4E\PD$(O`D)57A)S)N<1*-)D'T@5RBUH#FGFX709)ON
M?G5#U.@%I.'P9][4@JPX.@ET-(AC]<,X"-'PMB8)AT5-^3%GF6^(>L)1-&MW
MJ07AS<-013%_],L()(F3$%[C3[]6-0<>KGY7%@MZ!LTS-Y8N]/Q^?Q9"=;S)
M6/2$L6AN+!:$.L9C6['7>=^DM)BA&/G>/D/2:`A4OB%!MM><7>/RXY*-,UU)
ME.>[[$5/V`O?'*06Q&6RA>+:2Q2Y[]8I/^8N;Y3)A*OHH0"M?@C"LT*VFS4'
M].;9&B]*+2/GW1T2P_-W/)\^%/5SD17[?;-85R_F;%W"64'_;7_N_TF:HU[V
M?0I_#]`=GB_["W`<?\J?BS_R^KD\-HM]L860_ET$B:SQ0!\_M-6I.Q5_JEHX
MB.]^W<$?7A1PE.S?`7A;5>WY@SFH[O^4X_%_````__\#`%!+`P04``8`"```
M`"$`PRPM,&P%``"W$P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RL
MF-F.XC@4AN]'FG>(<M]D7XB@6@4A)-&,-!KUS%RG@H&H"$9):NFW[^-X(;9I
M5*VIOFB*C^/?/K^/EV3Q];T]&:^HZQM\7IK.S#8-=*[QKCD?EN8_W[(OL6GT
M0W7>52=\1DOS.^K-KP^__[9XP]US?T1H,$#AW"_-XS!<$LOJZR-JJWZ&+^@,
MO^QQUU8#?.T.5G_I4+4;&[4GR[7MT&JKYFQ2A:3[B`;>[YL:I;A^:=%YH"(=
M.E4#C+\_-I>>J[7U1^3:JGM^N7RI<7L!B:?FU`S?1U'3:.ND.)QQ5SV=(.]W
MQZ]JKCU^T>3;INYPC_?##.0L.E`]Y[DUMT#I8;%K(`-BN]&A_=)\=)+2<4WK
M83$:]&^#WOK)WT9_Q&_;KMG]T9P1N`WS1&;@">-G$EKL"(+&EM8Z&V?@K\[8
MH7WU<AK^QF\Y:@['`:8[@(Q(8LGN>XKZ&AP%F9D;$*4:GV``\+_1-J0TP)'J
M??Q\:W;#<6EZX2R(;,^!<.,)]4/6$$G3J%_Z`;?_T2"'25$1EXG`)Q-QHZO(
MG88>:PB?K*'CS!S?#DGG=]KYK!U\\@YGOAM$\3CJ.PU!=DPW$@T_UB$LE[$=
M?/Y:AW/6T"$SR[R[EZ)%YV><[K0:JH=%A]\,6$,P`_VE(BO228@8GVB:K)CZ
MG\T\3#E1>20R2Q/2@$GMH5Q?'WS;6UBO4&(UBUGI,8X<L>81I)Z(;*J"C0HR
M%6Q5D*N@4$$Y`1;8(KR!NOL,;X@,\89GM>+@:I:K&,$C>)-4!1L59"K8JB!7
M0:&"<@(D(V`=:49X4"RW=P->$Z35TH2U)&K"C=6:8#'3(%_Q0H0(,S2RT4BF
MD:U&<HT4&BFG1/($AJQY0G;(7UPX1`9,@H;")5\UB<7<,TF$"),TLM%(II&M
M1G*-%!HIIT0R"=+Z#).(S&@2SV[%"'0L;'/C0*D<$<2;I1K9:"33R%8CN48*
MC913(ID2*J;<7T4D6LZ=$5]L*&N-I!K9:"33R%8CN48*C913(B4*I^%GS#Z1
MD1U@9.*`1E)*@CD]C)S(G<O5L1$!O#HR2L+Q9C2>/UM--A=D4GBNLF45(HA+
MEU-IR2-R8=;/WUD$U3,<F_IYA:'`X8"Z420>I$9/7R(B.\3(Q"&-I(S`]%W7
MD*OL/1L1Q%/)*)FZI$GGHA6Y";BVHZ@6XG>N6DY5)8/@IG/7H&_X\C.#X+;'
M'2(JLD.,P,<U^SB4:V0M@O@X4TH"./RNS5REV88%.6/MN8$;>9XM*V<L9+S"
MTUK3^LH_TE<A]>7%<30/E+[*:5^2M^3")YE[H\HF)H[ALHL,!7!,7OV((SG9
M]35*^,A02&_\Y+*WX<BEMKGSN:WLZ!D7"L7>M^7($RCG0E?M@B.J'=KDGSS(
MD@N-VK)-Y(+XOQ>I0Z^9<-1S$U8<P01-W(OE@:VO4;QARE!X37K#D4_="^,@
M=A6EC,4$DZK3Q7.N=!4O.&+BKN>'D;+IE9*X[!^Y5VK^P?,@I$WV.+Z$/[[A
MP:.ONIX9@DKD+JUUE#(4DJ[YDXJKK5\>%8Y>!K[OV:&RA65<?%J*=%23(>1<
MZ6Y_!8^B_841C$@]4\C3/DDYF)0G?7JGCW,MZ@YHC4ZGWJCQ"WDR=R(8O<#T
MM<$J3."X!H,4GD<)'%HW>)S`7JWS,DI@Q]8YO)9X'(M+T5^1UQ4WXE=N`@\=
MNL[*2^#FK?-'/WD$(_0?5GX"M]`;/$C@(G:#1\GJ5@+K*%G?XFF4P(5!UTGC
M!(Y(G6=1`@>ESK=1LAVY)1R"UR:7ZH#^K+I#<^Z-$]K#Y-GC#:"C+U[HEX$=
M=$]X@!<FXYEWA!=D"+9.FRRE/<8#_P(=6^*5V\,/````__\#`%!+`P04``8`
M"````"$`)H1@:M0%```%%@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6RLF%V/FS@4AN]7VO^`N&_X)@%-IIH$"*!=:;7J[EXSA"1H0HB`Z;3_OL?8
M!MLGC696[44S>3A^C5\?VR=^^/RM.6M?JZZOV\M:MQ:FKE67LMW7E^-:_^=+
M\FFE:_U07/;%N;U4:_U[U>N?'W__[>&M[5[Z4U4-&BA<^K5^&H9K:!A]>:J:
MHE^TU^H"3PYMUQ0#?.V.1G_MJF(_-FK.AFV:OM$4]46G"F'W'HWV<*C+*FK+
MUZ:Z#%2DJ\[%`._?G^IKS]6:\CUR3=&]O%X_E6US!8GG^EP/WT=176O*,#M>
MVJYX/L.XOUEN47+M\0N2;^JR:_OV,"Q`SJ`OBL<<&($!2H\/^QI&0&S7NNJP
MUI^L,+=<W7A\&`WZMZ[>>N%OK3^U;[NNWO]17RIP&^:)S,!SV[Z0T&Q/$#0V
M4.MDG(&_.FU?'8K7\_!W^Y96]?$TP'1[,"(RL'#_/:KZ$AP%F87M$:6R/<,+
MP/]:4Y/4`$>*;^/G6[T?3FO=\1?>TG0L"->>JWY(:B*I:^5K/[3-?S3(8E)4
MQ&8B\,E$[.4L<J>APQK")VMH60O+-7W2^9UV+FL'G[S#A6M[R]7XUG<:@NPX
MW.74\'T=PG(9V\'GQSH,6$.+S"SS[MX0#3H_XW1'Q5`\/G3MFP9K"&:@OQ9D
M15HA$>,330<[3?W/9AZFG*@\$9FU#L.`2>TA7;\^VBO[P?@**5:RF`V.L>2(
M+8\@^41D(Q7$*DA4L%-!JH),!;D`#+!E\@;R[E=X0V2(-WQ4&PX$LQ0C>`1O
M$JD@5D&B@IT*4A5D*L@%(!D!ZP@9X4"RW-X->$Z05FL=UI*0$XX\T`V+$8-<
M.60[A4QF(!(CDB"R0R1%)$,D%XGD";PR\H3LD!]<.$0&3(*&@DOJRF%!]UR:
M0B:7$(D121#9(9(BDB&2BT1R"<;U*UPB,J-+?'0;1J!CP3<U=:8@WBQ")$8D
M062'2(I(AD@N$LD47S'E_C(BT?+8&1F/_W&?W"(2(1(CDB"R0R1%)$,D%XDT
M4#@.?\7L$QG9`4;DV?>4C6,*FF8?D1B1!)$=(BDB&2*Y2"132(DLGKCW9Y]$
MRV-G1)A]1")$8D021':(I(ADB.0BD08*-8HTT/]96A`9V0%&!`<0B2CQ@K$6
M<:VE'<C9$4\!/#L22ORQ,!Z7U0[)IA,1MAU;V7:R*8A+YZ*TY!$IN6Z8M%C"
MYC&<ZO)ET\+^!@7*C2QQ8&RL^B(JLD>C,"#!)(PBCF`%S]NHK1S2\1S%!Y0P
M))K%H^8>4XY\6A&:EJ*<S0%<.9>49:](G2:N')I0LU=?VNO/O(+"?S*+EGMP
MY/(^-Q9#,$VS#2M?SICM',4;1@QYX/_<T%8:QCS*HC9X]M)Q3%D\X3'V]%8[
MW%_*H^[VE_$HVI^S6BT#3^DOYS%C?[+-I`H4;;Z1>J*=M&B4[*3(@]II=F6U
ME$>\M::HV4Z*?/HSD/P"B%F4;U/O["`PE7T^X4*^8!W23KG0K)UQ1+5]D_R3
M7S*7M&6;2&4HVJ1FX_M6+JLOQ61D2$[&E?QB6VN*FMVCR'<F'V(6Y;O4/7_E
MK6Q%*6$QGIAY2#SE2K-XQA$3MQW77RI;82Z)R_Z1FA'Y!Y<$D#1DX^.+^0.[
M(*M"12\I@DSD+FWAUH3LE0**&/))U]//5[R*:4.?;F:>ZSJFK^QG"1<74Q'U
ME[ZKOXQ'T?[\I6W[ZDE#KH#&P8S]47OIE0[]C=]4W;':5N=SKY7M*[FNL<B!
M.&%ZE[3Q0RCAP""5+T.H8F[P50B'/N9I$,+1=X-;9DAV>OPD#^`6Z]8#N-YZ
M&O-1?25R[75#:&.'\.,5=[!Q0O@%A_F3&SZ!=_C!Q@WAQ\P-[H50S]_@0;BY
M.8)M$&YO/HB"$&H/K`1G<4A.6OPD"4)RWN('NR#<T0?&Y!-<PEV+8_5GT1WK
M2Z^=JP/,NCF>D1V]QJ-?!G96/K<#7+^-Q^8)KELKV'--L@8/;3OP+]"S,5W@
M/OX```#__P,`4$L#!!0`!@`(````(0!<&L<LI`T``-U$```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;*R<ZV_CR`W`OQ?H_V#X^\76RX\@R6$CS;0'
MM$!17-O/7D=)C(VCP/;>[O[W)34<S9"<\^NN'^K;WW`HDO,@-9)R]_/W[=OH
MMW:WWW3O]^/L9CH>M>_K[FGS_G(__L^O]J?%>+0_K-Z?5F_=>WL__M'NQS\_
M_/4O=]^ZW9?]:]L>1J#A?7\_?CT</FXGD_WZM=VN]C?=1_L.+<_=;KLZP#]W
M+Y/]QZY=/?6=MF^3?#J=3;:KS?O8:;C=G:.C>W[>K-NF6W_=MN\'IV37OJT.
M8/_^=?.Q]]JVZW/4;5>[+U\_?EIWVP]0\7GSMCG\Z)6.1]OU[2\O[]UN]?D-
M_/Z>E:NUU]W_0ZG?;M:[;M\]'VY`W<09JGU>3I83T/1P][0!#S#LHUW[?#_^
ME-W:^6P\>;CK`_3?3?MM'_WW:/_:??O;;O/TC\U["]&&<<(1^-QU7U#TER=$
MT'FB>MM^!/ZU&SVUSZNO;X=_=]_^WFY>7@\PW!5XA([=/OUHVOT:(@IJ;O(*
M-:V[-S``_G^TW>#4@(BLOM^/<[CPYNGP>C\N9C?5?%ID(#[ZW.X/=H,JQZ/U
MU_VAV_[/"66DRBDI2`G\DI(\"TJ.="RI(_Q2Q_*L?F!:;S7\^@M6-V5>S1>]
MV4>N.*.>\$L]BYM%596SQ1R4Z8X3%Z\^_,WJL'JXVW7?1C"G(2+[CQ6ND.P6
ME/FX.PW#2/S>0,`(H))/J.5^#(L18KR'V?/;0S$M[R:_P8BO2>91RV1<HO82
M.+RHMI'`2&`C,`&/!K=@'OP);J$6=,L;].A!\#,7/G@)WZ61P$A@(\!\@&DH
M?2A@8:67A!\)['0_AHD8C43%;7PDF5A(#%8]B`Q^*&(4L3%AKL"EI"NXNB^<
M9:@%?(..D7/"\D<2.N;<(#(XIXA1Q,:$.0?V_`G.H9;>.6_4(Q&X;N3NC(]E
M/0CY;HTB1A$;$^8+;`&Q+\?G&@ISDXF4PXJI%6D4,8K8F##[YMP^W*YFL"8N
MG$BHA1M.A,=Z+F(]"`VQ5L0H8F/"?,':)=IZC\<:A;G)1*)8*](H8A2Q,6'V
M+;E]5Z8&U,(-)\)CO1"Q'H2&6"MB%+$Q8;YD,$G.#W8OS8WV*`JW1HU&1B/+
M$#<3\UDT)S#F.58P%T[PS.5%V"I]^!X]XF%?BK`'*=^QT<AH9!GB/F%^BWPZ
M/L\SEPV9Y83BT"O4^(Y!RFAD&>)F8O**S,30AUKJ_$J(<F`<^2$M1AMY-I61
M'Z1"Y!4RF4*6(>X2C'7LTHG(H[28](1"3.M,H48CHY%EB)N)V4A$_HKJ`+M(
M^X<\%T=>E9V#5(B\0L:K#[&P#'&7,(%%+IV(/*6[>,[$&;`OANM,H48CHY%E
MB)N)N>E\,RF3Q68Z!-$*)4HF2^+,"X7PDJ802T-"94#6H[[^YG9CSCK?;LIP
ML=V$(%]$AA=R20Y2P7*'*D@G0\<\%T69R4@JZV^%JCR;E=5,9#CKA7+<H[E[
MF,8B]W`K.EWY9Y3\8C<=JF#3&*PM,E$QU]01I(*;KN/,W1_CO9@AJ5G>^Y1/
ML[Q<B)5DO:;^H("YE(O\ZURZP0WV\+I9?WGLP$!(6HF%4L`%W5UFKX3O4!Z!
MO9&'XH:G#E*#AX2J^>"T\6C1>U@NIG`$)*:$]3)ZT/)$ZL[@#((<_+7[Z!V\
MP%N=P_MKW(_%>(K95P>IX*W3-8L7JIZVU'$V<]-VL9S/,[F:K=>>&&.1Z'&,
MLRJ,L0]!8HRAQ!D&61<`.:'E,%:U1@TA6)K>;4-H%@;9>JG$`&)JC5;="3,I
M$4>K+7=(C(Z\B0A2WLR&4+S:/`IG#]9W3`3^HCR?ZSSO$5]%8L.J@U2PW.DZ
ML1U2Q\IMAT6Y7%297EFD*C$P,&LO&!B4%IN$0V)@9.F+939TC+=!0FQ@G!1M
M@]DBG\_*J5B!UJM*#)4H#,[;VG-=('C$ABR71660"D/F=+%E0HC2%>Q[\#^>
M"RUIJA+#@\G\_'5#J3]>-U0?L"R5B]Q2YX-4<,4A-CR$7)8J,S@255LX*4H,
M#J;MR)/KDA05#;&#A/A8R3(I'Z2"@P[-0F8V)#4K^SVZ2`Z5ZY4:*K!`.OC'
M<A0J%(O-(;[8<C$(=3Y(!6<=.I6C2.IXCB+M>HBQC%(1N#A']5JXVQZ%^K76
MJ-'(:&098F54D2HR</>]\'R@UR,<H'(#MN%02>6R5O0=@YN-1D8CRQ#W290-
MQ_-NH<L#CX)-M4:-1D8CRQ`W4Y0'N#DLKXB\KAL*0CSRLH8-4L.*T<AH9!GB
M+F'*C?:[$Y%W"3H^F2D(Q9%7J-%21B/+$#<34VYD)D8>K+AXSKO,S>PG!#9'
M<UYD\[H8I$+D%3):RC+$71)EP(G(Z_1?$(HCKU"CI8Q&EB%N)J9*$?DK3F8*
MEW%9Y`GQR,M:V7<,7C8:&8TL0]PE3(Z12R<B3SDY2N8%H6!3K5&CD='(,L3-
MQ`P6F8ES/B^OV&Y<)F2A)\1#+XO]8I`*DUXAHZ4L0\PG-#_VZ7CH>VF>HCR*
M0J]1HY'1R#+$S4SEV"DL^`MS;$D)-9H['O'0RQN1(#6$7B.CD66(^W11CBUU
MCO4H#CU)!=1H*:.198B;F<BQ5^STI<ZQ'K'(%^(FIPY2(?)#<O;(:"G+$'<)
MKGC!I$=I,>D)A3#7<$C:2P74:&0TL@QQ,S&AB?TFNV;24V*,)_V0*Z,D6\C;
M.QQF]#SV22&CI2Q#W*>+DFRIDZQ'P:9:HT8CHY%EB)OYYR394B=9CV"ZA/*F
MD/>=0<K/\$8CHY%EB+MT49(M=9+U*(Z\RKN-EC(:68:XF9C0HDE_(B%1^HNG
MMD,P3Z/XREO=T@N%\)*FX)TAH6CZ6X_TXP^\X8OM=N<4R</SZ&"U[\7W%H_`
MGL@!><\7I`8/".'/T%&?)WLI=ZZ455F>Y;F8?M8+Z8,E."^\QDV==GM%\MB\
MD#=802JXZ73%!TPD=?S\SZO2YP]P**-\BL_(SWH.TBL1(TG)F(^DO)/Q'<-!
M>D,H/F+RR!TQP;`ME_)E/DLR\`/!8HL*#W[DY/Q#9TR]0N&M2\K\C*F0=P_4
M$7["@+J.)\Z8J",]!X'SZFQ>R6W3>NV),<;T'&TK;GE>^ARDHB0?;3<>\4&6
ME7N0"FX[7;#4/#(D%3\:(90:4\S$RJ.3&P[E[]@#AS!VP[Y1%+(`K@8I;VY#
M"%9BZ)C8<%Q'_XQR.<WFTZG0;KWVQ,")@L$?-!S/"Y4N'#QB`U7*:C-(!3>=
M+C90#L%`!<^+4I1/EG3ALAP"F^?!=;Y$DQ5'F*#G;4*ZWH"'J5C#\=$MQ89?
M!ZG@-G6,$B))S9;].7<V+ZO%?";V,^M5)8925"#]&H27N2$\^+C9/XH\_VEL
MI8L4C_@HR_0?I(*[3A=:'PV6<,Y01_CIWZ?^G5V(5"7V83!+KMDXT_@0G)C<
MJ$5LOH3"8-650HU&1B/+$)NC^%:G-/^*-SU[-=Q^CUA57,JB)T@-PZ:1T<@R
MQ%T2]<SQR.-6)R+O411YC1J-C$:6(6YFHD2YXD4XV(25_81XY&4=YCL&+QN-
MC$:6(>Z2J$E.1-X5"7!CZ8?^$<JCWIE@4ZU1HY'1R#+$S<0T+=(LWMY>>/`$
MSP95Y`GQR(L=I_8=@Y>-1D8CRQ!W"3-RY-*)R+O\S2)/*-A48_4FC@HT,AI9
MAKB9B<Q_S9S7I0`4D61LV.N+4I:J0<I/N48CHY%EB+N$.?7\R+L,S")/*(Z\
M0@W6)7PPC$:6(6YF(E%G^.#DTDFO\_.,$)_TLEP.4B'T0T>/C):R#'&?1.H]
M,>EUBH6J1P2UUJC1R&AD&6)FSA,I-D=X8>A[/3S'>L1#'\I1]T9KD/)Q;C0R
M&EF&N$\7Y=BYSK$>1;->HT8CHY%EB)N9R+'XU/_2R.L<.T_EV$K>>@2I$/FA
MHT=&2UF&N$L7Y=BYSK$>Q9%7:;?14D8CRQ`W$S-AM"WBC<$5CS3GJ$;,>4)L
MSE?B1JWV'8.7C49&(\L0=PGS8>32\>T&TYJT7"74VDO%9BHIHZ4L0]S,1(Z]
MX@4*^`I9V9_*L96\[_0=8Y>&CF'.*X3?/8?=V+GDOF-V'])NV]U+6[=O;_O1
MNON*WRC#C=W#W8#=!]2/\QR^H.YOTU1+`2W](95J*:&EMU>U5-#2%ZBJ908M
M_0VQ;)E!"]0+X*IJF4-+_Y*L:EE`2W\"K5J6T-(?),J6^10LZ(^:5`M^1=Z_
M4RY;9M`'[IQ2MD$?N%E)M4!$H>9/M4!$H<Q.M4!$H5I-M4!$H4!,M)30QQW,
M2ZM+Z.-*)M4"L89'/BEM$&MX<I)J@5C#PXI$2P6QAEOE1$L!?>`M@E0+](%G
M\8F6$F(-C[]3+1!K>(B<:H%8PW/;5`O$&AY_)EH*Z`/O4Z5:H`^\EI1J@5C#
MFT"I%H@UU(6I%H@UO,.2:H%8PZL@B98,+(`/IU(M8`%\JY1J`0L@5:1:P`+X
MRB;14D"L(;&G6B#6\%)<H@6,3MH,0YT<:1CHY#AG<&WXU#!QA0RN#1_LI5I@
MS.`;.=W29/-;_$@GT5(N;_'YE6Z!/QKQ*:7K$2^?D'^$BR?E<;HDY#^5MY_2
M6QVNV$2'1QC!Y`#BSHCRDV$=PQ^7^%B]M/]<[5XV[_O16_L,&_NT/R/=N3]/
MX?YQH.\Z/G<'^+,2_2<>K_!G1%KX9&:*QXW/77?P_\`+#'^8Y.'_````__\#
M`%!+`P04``8`"````"$`.$YG9$(%``"3$P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6RLF%UOHS@4AN]7VO^`N)_P'0A*,BHA?&E76JUF=Z\I<1+4
M@".@3?OOYQAL!^PTRJQZ,YX\/7[M\W+\`<OO[]5)>4--6^)ZI1HS75507>!=
M61]6ZC\_HF^>JK1=7N_R$Z[12OU`K?I]_?MORPMN7MHC0IT""G6[4H]==_8U
MK2V.J,K;&3ZC&OZRQTV5=_"S.6CMN4'YKN]4G313U^=:E9>U.BCXS2,:>+\O
M"Q3BXK5"=3>(-.B4=S#_]EB>6Z96%8_(57GS\GK^5N#J#!+/Y:GL/GI15:D*
M/SW4N,F?3Y#WNV'G!=/N?TCR55DTN,7[;@9RVC!1.>>%MM!`:;W<E9`!L5UI
MT'ZE/AE^9ABJME[V!OU;HDL[^K_2'O$E;LK='V6-P&UX3N0)/&/\0D+3'4'0
M69-Z1_T3^*M1=FB?OYZZO_$E0>7AV,'C=B`CDIB_^PA16X"C(#,S':)4X!-,
M`/Y5JI*4!CB2O_?MI=QUQY5J.C/'U2T#PI5GU'912215I7AM.US]-P3U&7$1
MDXI`2T6L^57D3D>+=H26=C2<F><X]MQS8?@[/6W:$UHVY,PV'=?KYWVG(\CV
M"4/+AG0?FNN<=H26=C0?FZI+.T++1GPP25BD_5RA_;4D%[0CM&S(QY(TH`"'
M>B"52`OB;IK:4%!]?89YEZ^7#;XHL.BA9-IS3K80PR>RK#*'9\-K];-2A1HE
M*D]$9J6"`U"%+:ROM[6M&TOM#=9$06,".4:(V+`(L@"(;"B"K0@B$<0B2$20
MBB`;`0ULX=[`0OD*;X@,\89E%3!P-<N<6K5A$:Q+*(*M""(1Q")(1)"*(!N!
MB1&P\+_"""*S4F$OX$5B6M8T\X#&C(/L:<B&AW!W)+*52"216"*)1%*)9&,R
M,0FF_!4F$1DP"3:^D4M"?00TZ)Y+/(2[))&M1"*)Q!)))))*)!N3B4N0E^22
M!?O.+^XW1*9WB6474`(#CWQSA-+A0:Q;*)&M1"*)Q!)))))*)!N3B2EP6$U,
MN7TM8'LMB9[F3HG-MYB-1$*);"4222262"*15"+9F$P2A<-UDNC_/&V(S-0!
M2D8.2"0<B+,8CB?#-1?3ZMCR`%8=T4#F_>6N/Y%B23;A9%1XIK!GI3R(26=C
MZ8E'Y,XOG\@S<M/JCF7Q$F`H<#BR;A2)!:D-YS$1F3I$R<@AB824P..[KB%3
MV*&W/(BE$@UD[)(DG?!>Y&Y@ZH:@FO*_,]5LK#HQ"*Y+=PWZ@<^?&02W9>80
M49DZ1`DTU^PM8>?=\"`VSW`@#NQAUV[F7"@M&F3TM>?8KK%8&-XT)J(Q)E_%
ML318\LA@Z0.#9>/!)NZ22^!=>Q^JOUYE:B]%#AR@5Z,LP:C--8H;S-"U=+<,
MD37!+IRFY0J&LJAI/0NK/F91%O<]8>@Z8LK0=$3A$68LZK,1ITZ3>Z>TTN&5
M#)(B"YW5\>.K'EYAQ:)F")XW=\K6IT9MKD%7TP<I![8IWL^4RIIV=+QA3[4]
M6]<]Z3%0J5%ARP,F3.KN@"F+H@/.3=W3/>&4)V_RQ`:G'W"P?'@S']Y\*M0<
MT`:=3JU2X%?RUFVX,'^.AT\"P=R'<PS\$'CB^K";W^">#YN8S#/7AZU,YO#)
MX:F?H*`?D$\1-^(#TX?[N:P36#[<267^9/M/8(3\A\#VX7IV@SL^W%!N<-</
M;B6P<?W-+1ZZ/IRDLD[H^7!VR#QR?3A!9!Z[?MQSC3L$GT3.^0']F3>'LFZ5
M$]K#P]/[H[$9/JH,/SIZ`CSC#CZ&](?!$3Y^(7BEU,GRVF/<L1\PL,8_IZU_
M`@``__\#`%!+`P04``8`"````"$`TD0U,D0%``",$P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6RLF-N.HT80AN\CY1T0]VO,R=C(]FILS$F)%$6;
MY)K!;1N-H2U@#OOVJ0:Z37=Y+">:FV7]3?5?U$_U`9;?/\JS]D;JIJ#52C<G
M4UTC54[W175<Z7_]"+_-=:UILVJ?G6E%5OI/TNC?U[_^LGRG]4MS(J350*%J
M5OJI;2^^833YB919,Z$74L%?#K0NLQ9^UD>CN=0DVW>#RK-A3:<SH\R*2N\5
M_/H1#7HX%#D):/Y:DJKM16IRSEJX_^947!JN5N:/R)59_?)Z^9;3\@(2S\6Y
M:']VHKI6YGYRK&B=/9^A[@_3R7*NW?U`\F61U[2AAW8"<D9_H[CFA;$P0&F]
MW!=0`;-=J\EAI3^9?FJ:NK%>=@;]79#W9O1_K3G1]Z@N]K\5%0&WX3FQ)_!,
MZ0L+3?8,P6`#C0Z[)_!'K>W)(7L]MW_2]Y@4QU,+C]N%BEAA_OYG0)H<'`69
MB>4RI9R>X0;@7ZTL6&N`(]E'=WTO]NUII=OFQ+%<;VY"O/9,FC8LF*:NY:]-
M2\M_^JBN)*%B#2IPY2JSB>M-[4[DSD![&`C78:!I3N:NZ\SF'J2_,](91L)U
M&&D]E!%4NX+ARC-:CV6<#2/A*C*:SG3&?+ISH]XP#*X\X8,EPASM;A6N(N$C
MIBZ&<7#E&1\LT83^Z]N!-6+_I*W)YT4:?3=US1ED;;9>UO1=@QD/[=)<,K9^
MF#X3Y6W9^R0:];,^A09E*D],9J5#_="!#4RNM[4SG2Z--Y@0^1"SP3&F'+'E
M$:S[F6R@@IT*0A5$*HA5D*@@'0$#;!'>P"3Y"F^8#/.&5[7AX&J6I1C!(_B0
M0`4[%80JB%00JR!103H"DA$PZ;_""":STF$=$$UB66J3##'C($<Q1X0(=Q#9
M(1(B$B$2(Y(@DHZ)9!+<\E>8Q&3`)%BJ1BZYL@6;(>B>2R)$N(3(#I$0D0B1
M&)$$D71,))>@+N22#>O.?UQOF$SG$J]N,Q!(//)-G5<BB`\+$-DA$B(2(1(C
MDB"2CHED"FQ4DBFWSP1\K671<NT#<<02LT4D0&2'2(A(A$B,2()(.B92H;"U
M2H7^S]V&R<@.#&3D`")!3]Q%OSV9GK609]5.!/#N"'LRZTYVW8X4(=E8D''C
M*6M6(H*X=#J6ECQB!WZ\(T_8*:L]%?G+AD*#PY9UHTEL**W?CYF([-!`1@XA
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M5_+^K:<D]9%LR?G<:#E]9:_;I@=W+W#_+6`S\V$/`S<4'GL^K.0W^-R'!0SS
MU/-A&<,<OC4\=3>HZ&_8-X@;\1O+A[,YUMG8/IQ',7]R_"<P`O]AX_AP-+O!
M71].)S>XYV]N%;#U_.TM'G@^[*)8)YC[NUOQH>?#[H'C(\^/.FX(A^!;R"4[
MDM^S^EA4C78F!WAXTVY;K/NO*?V/=EC]GVD+'T&ZC>`$7[T(O$Y.V>0Z4-KR
M'Y#8$-_1UO\"``#__P,`4$L#!!0`!@`(````(0`IWO<MU0,``%T/```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)1776_:,!1]G[3_$.5]!)N/$@1,
M[:INDS9IFO;Q;!(#49,XLDUI__WNM=.,V$DA+X%<CL_UN=<^V*N/ST4>/'&I
M,E&N0S(:AP$O$Y%FY7X=_O[U\&$1!DJS,F6Y*/DZ?.$J_+AY_VYU$O)1'3C7
M`3"4:AT>M*Z64:22`R^8&HF*E_#+3LB":7B5^TA5DK/4#"KRB(['\ZA@61E:
MAJ6\AD/L=EG"[T5R+'BI+8GD.=,P?W7(*O7*5B37T!5,/AZK#XDH*J#89GFF
M7PQI&!3)\NN^%))M<]#]3*8L>>4V+QY]D252*+'3(Z"+[$1]S7$41\"T6:49
M*,"R!Y+OUN$M6=[1.(PV*U.@/QD_J;/O@3J(TV>9I=^RDD.UH4_8@:T0CPC]
MFF((!D?>Z`?3@1\R2/F.'7/]4YR^\&Q_T-#N&2A"8<OTY9ZK!"H*-",Z0Z9$
MY#`!>`9%ADL#*L*>S><I2_4!1X\6L]ETOK@!FBU7^B%#SC!(CDJ+XF^-JKDL
M"ZU9X+-FF<Q'LYOQA$#2"R21G9$1>,\TVZRD.`6P:B"EJABN0;($XFY%(`6Q
MMPA>A["J8:X*VO"TH8MX%3U!Z9(:<V<Q\&PPI$%$D+3)#-FNSXQ@S(RUQ:G<
MV<!Y&MJ=9C(D#8+7X?1L\C0>-[PVL\5`Q1N!TP;1$@@TUPM$,&0^I_5K:T'G
MF)[4`+D^-8)-ZJ:X-G*>A\8]79P/R83@=B8;,7NF5;N;(;0(;M/:2%M`S_I`
MC[YZ`R"XG<E&?`%QFQ8=8S(&XWE[@^&H-K^-M)5,NM<;`?KKI1AT.U<=\L40
MW-1G14(U=`:3>EN-&>:DL/;0UM.SB,D@AS!H)YDUB0X]CBD8/X\OZZGMP1!:
M,R"^&]!XUM.?089`&D=HMF4=ZM`#4W?[0^:7]>`PIV0V!,_&W6@\[]$S:.\3
M?_/7H0X]SO8WZPW_Y"ZL-]\(2)<3W/3H&60%Q/>".M2AI\,-KNF/;P>DRP\6
MW7KH(#\PZ/9BJ$.^'MKE!^@>;_?'#'-2=/G!_R-%ZS^!#O(#@W:2]?D!=?S@
M@@S?!@S!.CS?-N#V/6T99`/4MX$ZU-$6W+R.3<>7NX*CG$+94%M.SP&`#G(!
M@W:2]9T!:(<+D-EE/;X+&":W/3WG`3K(!0S:T=-W)(`;BM<>//!=6&V^"1@B
M5XY[*+"7&7O6+[C<\T\\SU60B"->5"B<WIMH<XFZI7C`=N/3Y:V]7$7-+W"Y
MJ=B>?V=RGY4JR/D..,<CO,Q(>SVR+UI4YHJQ%1IN->;K`:ZQ'$[PXQ&`=T+H
MUQ?('#47X\T_````__\#`%!+`P04``8`"````"$`1='GH^0&``"*&P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RL6=N.HT80?8^4?T"\CW&#;0RR
MO1HNFZR42%&T29X9C&TTQEC`[.S^?:KZ`MT%,^N=V3S$.T7UZ3IU;9K-AZ_5
MV?I2-&U97[8VF\UMJ[CD];Z\'+?V/Y\_WJUMJ^VRRSX[UY=B:W\K6OO#[M=?
M-L]U\]B>BJ*S`.'2;NU3UUU#QVGS4U%E[:R^%A=X<JB;*NO@S^;HM->FR/9\
M475VW/E\Y519>;$%0MC<@E$?#F5>)'7^5!673H`TQ3GKP/[V5%Y;A5;EM\!5
M6?/X=+W+Z^H*$`_EN>R^<5#;JO+PT_%2-]G#&7A_98LL5]C\CQ%\5>9-W=:'
M;@9PCC!TS#EP`@>0=IM]"0S0[593'+;V/0M3U[>=W88[Z-^R>&ZU?UOMJ7[^
MK2GW?Y27`KP-<<((/-3U(ZI^VJ,(%CNCU1]Y!/YJK'UQR)[.W=_U\^]%>3QU
M$.XE,$)BX?Y;4K0Y>!1@9NX2D?+Z#`;`_ZVJQ-0`CV1?^>]SN>].6]M;S9;^
MW&.@;CT4;?>Q1$C;RI_:KJ[^$TI,0@D05X+`KP1Q_9F[7K+E"E%>6>G)E?#[
M]NT7$@1^)0B;SWPV#SS_]=WA*2</O\/"A;OTUYS]V&Y'>(\'(\FZ;+=IZF<+
M,AS\TUXSK!<6`AI&P8-8"H0^+B^%!>*!(/>(LK6A-&%Y"[GT9><%_L;Y`O'/
MI4XTUF&F1JPT,-@(FU!!J@D<(-"S@/A1%IA+/\@"49"%VC]2@H&62TQ6&FI)
M0@6I)C!,AL2A)B_`Y.GT5W[&15L;TJ7W,UL$IDF1U-&5%J9*W*OT9H\DJ2XQ
M#`=@:O@;?(THP`08]U2\8&W:&4FEUZCT*CV5D235)085V)U2>4/R(PJGHDR(
MI$2WVPM(G.)>22U+1I)4EQB6K\:6L^4,NT9W*O/'J`:O0K%,9),'Y2F*%C%,
MNZ5DU5=`/)(D(TFJ2PPC_=>-_%Q?7S(2FJ^R$D%,*X6$B4Z.?2(>29)>,J07
M6Y((I%+)0[J&X7C&($WQA[V+&*;=0L*@(?0ISY:D2\:32J0NDBFEU=PLGE0J
MZ4G(5D/+-0@'8\(^3%.932I0MZ<6XIGDA00;Q4!^1;OII))G\DJDTHJ/&1R7
MRT#_CS@TE>H0:VWCH2$:;F`P^6C@/=B".F*BK+2,Y2@F>RG"YJ)9L329Q5*+
M0>0TK96IE2@LESM@""@OZE0]-7<:$LCDB_/TO8D.A4B#+46>5J)2Q"`<&C<2
MK$0MY"4I"0EX@65:CZ.56O^>K,72)&DK121O22.))[5\4I")TNHS=TE2.U4:
MMR4K3FA"WV/O*%HF1[XX;6-CC:3(S$B?Y%P\K46*.Y%:[GPZ;\7F+D1;RX^7
MZA0G.J&N-VC5L+Y3I_)<H/,5(L]HFCX)4\R$EID4_F"K/+Q*+%\V*GBC,"LY
ME3ADMZ$FS&R')J1S_@XWU"8]2(B\@6Z,#$#+=?N!GTB1-YR"4R7B"TV;</1K
M<?B.3?*@,!@0,2$R;!(BL$E+!)^X+E$+=3-U+--,'/2WFRF.!7`T50>SB`F1
M8:80&:Z36KI-^D+3)AS/FDWB]7<8-3>=X+`N:92%R-/.<%*+>'0T5N3"H*>=
MRH4"R[0>IRJQ?J&=/V\L0#&;#4\+D3DH_6%\\=**<8H`;]*62%=.I-:"R0(,
M%KY^4`A(3J52W]Q[-92UX0%H8X8'7D]]KFV6HQ+Q6Q)!2XK`#I5YB=(:*C15
M(G&]8KP%3XSSE79\N2FGL`.3G)(B?9Q+$;IL:-=K.O$4EC;.#2S3HS][G&/"
M4R9"9';N-9UG<B'1HO-,:KD+F5X4)E4PT`,T'PW#Q&3_LZ>Y.Y[F4F26S7I(
M<)F%8B'1(L622"SXP=L>2#*/&<5%2C95^C?-=_"I45R\.;[G9,<!2?V)\8S7
M?%IT2%>,Y4*B-8QH,>H'+73&'<FG5#V&`35LY0\@9B+@3":ME;V+NQCR>I=%
M.E`9<+VK&;0F(8NGM6B755IKG@AC[G(KHU&\V%1QA%/N/SQ67'$0,`A+$;_/
MEFD^$B5JX:"5&B(S3CC:B:VPY=25"[A(W6:@RVE/$B+4&>=.+!<`\)`ZP=!G
MA4GBDEW<ZU9%<RSBXGQNK;Q^P@MTJ.3=IA>+V_UH%<*]#8P9*G?A`9">>,*"
M,(+N/7X"@S9,)I_`2`6TJ37P=>&>SS2Z/WQUF-*/7`":V#OR0KBI'-MTOP!\
M'D>ZP2*$^\#Q@F@9PFW;A)S-PPA>2\=/X$4\Q!?6\1-X"0<64T\BM@`T?D`D
M=B7P))E\`J\)@,;7./TB^!)RS8[%GUES+"^M=2X.$&@QZAOQ+47.?7G']E!W
M\`V$7[>=X)M7`2]W<WQ5/-1UI_X`(D[_%6WW/P```/__`P!02P,$%``&``@`
M```A`!/XD1.:`P``=0T``!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
ME%?;;N(P%'Q?:?\ARGM)G'`IB%#1K;I;:5=:K?;R;!('K"9Q9)O2_OV>8T-*
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M'*&Q1?+VP%0,%06:43!!IEADL`!X=7*.1P,J0E_-^X$G>A>YP6PTF?DA`;BS
M84H_<J1TG7BOM,C_61`Y4EF2X$@"[T>2<-J7Q+,+,OX>J*:KI10'!PX-2*J2
MXA$D"R#N-@1.$+M&<.3"H8:U*MB%EU4XG2Z]%ZA<?,3<6PR\5AA2(3P0K91!
MK;\R@E$92XM+N;<#YS)!MTPX1`;!D3L^6WPXG56\5MEB8-LJ@^,*43,(-/T-
M(AB4SVG;M;6@<\P%:8#TET:PD:Z*:T?.=<+I;;?)Z1`E!->5[(BY,K7:S>JT
M>-_F<&L_/IXXJ4YO1^I&YMU&,*I[7P0$UY7L2-O(O$YK@F,."_K8"<ZJ\]N1
MFI.9W^V$0*'Z6S'HNM9QJ&V&X.4^*Q*Z":]NBYG54+`I4;=S(2?(H*`PZ(:8
MS8H..XUL0#O!^+J?8TH80IL)I!T*X>Q"()%!N6#0#3^G&,`GUGFBXA.IN3UD
M>O6PF6D-"62*W/K^A!>.VZ`((.T,.`YU[$]'"HS]^>BZHW82D(XHF%U(3S(H
M"PRZ4;Y+:4`ZXJ#'!6K'@2%J;M"D>X."07E@T'4[QZ'V!@4=>=#CP)EI#8FN
M0'AO+6K'/!@4"`;=$+L4"$%'((3X3/XXK<VTAD17(+QW$G4_C4`PSPC_NJJ-
M`5A>]=R&%KA];9L/;MODVB8P9W++OK`L4TXL]MC`!M#65:-5<[T.4*0Y/EZL
M;=/M5;]`TUO2+?M!Y987RLE8"IS^:`9NI&V;[1<M2M-[;H2&=M=\W,'?&P:M
MG8_W.Q5"G[Y@S%5_F%;_`0``__\#`%!+`P04``8`"````"$`NF(]Z`X&``!!
M&```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLF-N.HS@0AN]7VG=`
MW$\(IZ2#DHPZX:Q=:;6:W;VF"4E0AQ`!?9BWWS*VP7:ETYG1W`S37ZK*KM]E
M7'CY];TZ::]%TY;U>:6;DZFN%>>\WI7GPTK_YUOXY4'7VBX[[[)3?2Y6^O>B
MU;^N?_]M^58WS^VQ*#H-(IS;E7[LNHMG&&U^+*JLG=27X@R_[.NFRCKXLSD8
M[:4ILEWO5)T,:SJ=&556GG4:P6ONB5'O]V5>^'7^4A7GC@9IBE/6P?S;8WEI
M>;0JOR=<E37/+Y<O>5U=(,13>2J[[WU07:MR+SF<ZR9[.D'>[Z:3Y3QV_P<*
M7Y5Y4[?UOIM`.(-.%.>\,!8&1%HO=R5D0&37FF*_TA]-+S5GNK%>]@+]6Q9O
MK?!_K3W6;U%3[OXHSP6H#>M$5N"IKI^):;(C")P-Y!WV*_!7H^V*??9RZOZN
MW^*B/!P[6&X7,B*)>;OO?M'FH"B$F5@NB937)Y@`_*M5)2D-4"1[7^D6#%SN
MNN-*MV<3=SZU33#7GHJV"TL24M?RE[:KJ_^HD<E"T2`V"P)/%L2:3QY<UYD]
MS"'*#4^'><*3>;KW.4+8?M[PY$,N[O.<,4]X\B%O3G'.[.')1[HS.=AC_1SA
MR4>Z;XH+Y@A/YFB#M#=D-*%N^J'(?_A8USP,NOQ]-?E9EZV73?VFP1:%!6XO
M&=GPID>"D#JRX4D''2KKH\*"BB)1'DF8E0X)@WL+N^%U;;OVTGB%"LZ9S0;;
MF++%EEN0<B5A?14$*@A5$*D@5D&B@E0`!L@R:`-[`VE#]M@/:D/"$&UX5AL.
M1K$L10ANP5U\%00J"%40J2!60:*"5`"2$%"$2`@'A+C^LN$U0;Q6.NQPH28<
M.=$-LQ&-%)/M8#*(@4B`2(A(A$B,2()(*A))$Y@RTN0GBH.$`9%`3$$E=><P
MHULJ#2:#2H@$B(2(1(C$B"2(I"*15(*\?H5*)$RO$L]NPP@,+.CFRM6U'8RX
MFX](@$B(2(1(C$B"2"H2210X@211;F\C8BWGSH@SO%&VB/B(!(B$B$2(Q(@D
MB*0BD1*%HU-*]"</%Q)&5H`1>?5GRNH/1L/J(Q(@$B(2(1(CDB"2BD02A73@
MXHE[>_6)M9P[(\+J(^(C$B`2(A(A$B.2()**1$H4NA@I4=ZB_N#Q2<+("E!"
MNUK2)FR9B5P.<[D<_,&(ET.`2(A(A$B,2()(RDA_YDN:D!;K5XC2QY%584B0
MA1LY?4-F34WE:/5'@T$3C$*.Q@XFXFB(K)Q8\6C`(R<8I1Q=T8GT9.(NH<4S
M(9\5W;',GS<UO/?!Z,KNL2%=UI72S@Y.5SZ+C4G12+:,./`6$XZ2!Z5Z1BL>
M*L`HY$B4BLWA9OB8._9?C/WD$XQ2CJ[H15JW6WI]JR\?Z04??(-@M`.4!&,(
M2EJ09R'+LS4'*RZ/SY`+%3\X6I;RD@ZXE=G7Z,)VYI;R51!R$VM8Q0@/%W.K
MF\,EW(H.YRSL^51I&E)NT@\G;U[2#(HB7RD^44S6.XZUMC$I<NTAE2U&/D,S
M^K%-WG`!1V-AA=QQ+)F(HS%\S!W'6`E'8ZR4._:QY)Q):R?FS,_P3W(G;LK[
MB2&ID&93M9`&J[&0*/JLD*C5#,[=H=SL&:HE%@O*=;"R+*6:(Q--(F;H]B02
M9J5,0OFZ2WFLCR8A+P!I(\4%^$1XUG6*14>15'0(^>3;!59,*CJ&QD()F94K
M%AV*%>-8"4=CK%2*)>=,.DHQYSN+CC6B8NX,R46GG%9;N*CKJW4Q;$N?H=OK
M'3`K9;V58S;DL3Y:[_Y]'^%)Q-SQDW<:G;TR"?1:HU;N1Y.@"T#O&^D-454T
MAV);G$ZMEM<OY"X15FR]'#"]Z-PX'GS^P695N>O!%]`5/O/@@^$*GWO0,U_A
M#QZTF)AO%QXT7E>X.?4":"SP+]"U>*0+P;]`#P`^_2M2R2*"7\A)C'W@@O>Q
M/R(4CPVY^+UBO[$\N%_!<3:V!Y<,F#\ZWB.L/_Q@#"/`!>XE.Q1_9LVA/+?:
MJ=C#HDS[IJBA5\#TCXX=]D]U!U>W_;E_A*OZ`DZ2Z02VZ[ZN._X'&6"X_%__
M#P``__\#`%!+`P04``8`"````"$`D-_].=$/``!64@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6RL7%UOX\@1?`^0_V#X_6R1%$7)6.]!).>2`Q(@
M""[)L]:6U\+:EB%I;^_^?:K)^>CNZ?5:LO,0W]9T-[MF>J:&(Y(??O[C\>'L
M]_5NO]D^79\7%Y/SL_73S?9V\_3Y^OP_O_WRT_S\;']8/=VN'K9/Z^OS/]?[
M\Y\__O4O'[YM=U_V]^OUX0P1GO;7Y_>'P_/5Y>7^YG[]N-I?;)_73VBYV^X>
M5P?\<_?Y<O^\6Z]N!Z?'A\MR,IE=/JXV3^=CA*O=:V)L[^XV-^M^>_/U<?UT
M&(/LU@^K`_+?WV^>]R':X\UKPCVN=E^^/O]TLWU\1HA/FX?-X<\AZ/G9X\W5
MKY^?MKO5IP?P_J.8KFY"[.$?6?C'S<UNN]_>'2X0[G),-.>\N%Q<(M+'#[<;
M,*!N/]NM[Z[/E\65F\_/+S]^&#KHOYOUMSW[[[/]_?;;WW:;VW]LGM;H;8P3
MC<"G[?8+F?YZ2Q"<+S/O7X81^-?N['9]M_KZ</CW]MO?UYO/]P<,=PU&1.SJ
M]L]^O;]!CR+,15E3I)OM`Q+`_Y\];J@TT".K/X:_WS:WA_OK\VIV43>3JH#Y
MV:?U_O#+AD*>G]U\W1^VC_\;C0H?:@Q2^B#XZX.4S44YKXMZ1E%>\*R\)_Z>
M?OFI#X*_/D@QN6B*R:)J7KXZ6@?R^)L<IV7=S`?V>=Z78^\-@]&O#JN/'W;;
M;V>H</3/_GE%\Z6X0C0:A0IC.4:(X_*]8<%X4)`E1;D^Q]2$^QZU]/O'JEE\
MN/P=XW_C;=K<II`67;"@P::PO08<`RY!(++`^&D65$M'LJ`HQ")<OPU`HE6J
ME(-%<.DUX!@@4D;AZ)2G2-DN_]#/Y'1]CG*)_5Q,=3][&VXT55E'DYAVACB.
MB,016"=^0E]3%#`!XTBEFD]DGJTW>HE*-(E4,L1Q1%#!U365:G%\]5.8@4O(
MH?4(3[RH=;E'H^#69XCCB$A])E-_N6S(6";HD6FL]2Y#^@QQ'!'9-#*;82V?
M(/<C)R"%D7EZ1':DGH31*'9DACB.B-1I/\$6P)<[DHQE@AYA'9DA?88XCHAL
M%C(;ZL@3"I*BR#0](ONQDM.MBT:Q'S/$<41D7F#>O+XC!VN98H!85^90GT-.
M0#(GT@LVN$-=SHZORV+4':Q6H6?:`,D>U0MML@J.?0XY`4D"I!Z,P,O568Q:
M(]+T$._4#.J#8[)R`I(YD3*PG(9.K4[H5*\PO%.CZ"15*.I:E6D1K5*G9I`3
M5I(`QHP3^$&GDK6J5`^E[NJ*#.ISR`E(YD0+O>[4$_J4P@S)I@ZLYDIX6I)K
MLD+.47RSRHTVJ9,SR*5(L)*$2"L4(5+[(Q6A\)+#BR2J4,H>^W5=)-$JY9]!
M+H0?1E+F3X*A\B_J"]J7'^XW-U_:+;H.RX)1/!4VP'Y;[%6'9^^A65Q*NB*#
M^AQR`I*IDIJ\D.IOV^?OI8J;G)BKUR2>ZPAA>0I]V!49U">(CX?:E;I@55$L
MF3Y)R@OIOZZGO2[Q[$>(%K)8Y47=Z#HQK>;2JB\LJYG:KKI@Q>=5,4NS3]`N
ME5[2,MK@#M;75QBTUQ?;$%`N5!ZB69JZ8*:W3[:5VASTP6HVW-[1;6J]X/]3
M'>N"/8J;73LM,[(S#*&N<`W=&\9L8R5<YC+M(;JE95EH1?%65*/,2BTI?8A5
M#CV0AG68ZRZTRBNE0I)\28/?6O.E%W)6\QZJV(SU$-4FXZ9&JP^.P_3TA,;P
M8RR9/:FMSOY-I>OEFS,9(56Z:E7I2LNJ4?.R#U:Q=&M5W"Y8O*Y82>L5_:IX
MR\SUFP=.?X1D13:JYKK2M%+SN_=6F)!T,*-BN-"*N</JXWOS%!-24^>J&%:M
M'\Q3BJ)6JA&J0"AET:AAZNA,#HZR*)J4ZWAJY*VJQJ]4.,J3R[D+%O)J:4[(
M:J=M`QON'W#SFPP^EB.$+7*4T7*$,.L"U'NH2L=/+D"#H\R)M@ROS\EO,%("
M;3E"(J<1HI6`#8'JNCXX\C1Y+)DF[19>G^:XM^"W+^4(B31'2'2=M^(Y<4>9
M$TDYRVFX?3EV8U>.^P&1Z@A5;&/GK52/9K+B'1>Q%IQW'&.)[$G(=/93EOWK
M)N`014Y`#TFA;))\#5.K\U9J65*K<A_"%WX"+J8-WRDL5$TY\]JS-*UE#ZBM
MPLO3$>JEEYH`#3]/>%JC%30R3L=@E6:H"]#XNP8_?JX,.9^Q[<NKMK!#$#4H
M7()]JB,DY5P?G/8A%I-S#X&$WH!7[RWG0T#%Q!)J?6/:>4>YOL^UGGDK"!?I
MV>1"AW$A#-:EM)+-DYC(>B(-5>O!F]2<-$RIFX?DM)FG`O=#.SHJ*S59>A\+
M.Y:1?5,58G*I*>N"_:OTG8YQ=&<4;]G9#0%5*8PB3AK,1D>MBIUW5%9)HH<N
MZY,5=<9/>F\3FJ&VZ5)-"B(+@319%<+;N(\BST4"*SK5!HEH2FBNAJRSK;)5
MUL>:#X60<_?-4)=TJ>\NJB3AFOOQLC)N!`1A#S5Q9>VP+QOF1X+Z''("DN-$
MTJYRQ26MDQA43SC>P+XJFY4C1#9Y[73>053I(MU9R)1(PEE*/]"D4?!%-WF(
MG2A6&=3GD!.0R&EJ[!0*FA!'GL`-<>0,#I#8/B_4Y.N25135''("D@24T(\;
MM>/SCSN`-`\JK2GMU%MQ2GI]3C:)4'0+D!-6DI"Q2R@6)XS(N`7@]3/U$$^_
M6"CA[))5R+;/(2<@2<#:*)R0_[@7H#D;5Z:*R?.PM+=3;\4I92,2;1*A#'(I
M$JPD(03G\Y9*[(2?V^@@72E^@'CVQ2)M04;%3U8I?Q\KK01.6,G\T84Z?]H\
M'3O%*<PPQ?F`J,YN:;S(BE-2-EVR282B6X"<L)*$2+380DH#4M'MP;&,1O'#
MA<)%VZF'>/K%(B,0K8)CGQP#Y`0D"9A">GS^44G9B*@%MIUZ(\XHXQ-M0O)]
M<@N0$Y#D8XCM*>.1J^_40SQ[K(;RI*9+5B'9/H><@&3^2IE/%9$HV6P\YBK9
M=AHE.UEE`Q)M$J$,<BD2K`2AVI+U$W[2'N)(60^0'!&],4]6D4`..0%)`N\C
MZ[4IZRK9-EAQ2GI$DDTBE,NZL)*$#%D_043J7-4#Q+,O%NGV91219)7RC]N!
M`#EA)?,GQ51K[@DB4GOAQ7*?5%WM0-I@Q!EEXY$I>)_<$A]N)?D@N.9#BG.D
MA-041DT0#_'LBX6^>PN.2<'[''("DOF38+[#>'C=Y>-1%NHFLJV]%:>4#4BT
M";W?)[<`.0%)0I:H'Z_I=:[I`>+9XS1$:4BR"LGV.>0$)/-_'TVO#4TOJVR&
M1,%.TR@;D&B3"&60"]?+GVVH#5$_Y49DB*.FB*'J>+!>CTBT2@0RR(7P!@%2
MS'>8(EYX^12IYFI];>LHSR^,2+1)A#+(I4BP$B4V,U2=L"/7K"&,')``\2E2
M3M16LDM6,?\<<@*2^;^/J,],45<+;!NL."4]19)-(I2+NK"2A`Q1+^B1AF-'
M)%?U613G5$_E1*T#7;)*!*)C@)RPD@3>1]5GAJIGAR?!Z,4!X7H]'MXFM\2'
M6TD^"*ZG_`FJ/J,P:H9XB&=?3O2M>G!DJIY#3D`R?Q+1MR]9M-//;]65XK7!
MBE/*9DBNZLDM#0BWDH0,5:<%XM@)DJOZS$,\^W*2Y1^M0K)]<@R0$Y#,GQ3S
M'0;$"R_Z*6U[V3GQ>)@UB_*<K#)"T29DWR>W`#D!24*&JI\R(%Z(V=')+&IS
MRKZ<J+O?+EF%9/L<<@*2^9-@OL.`>-WE`Y+=J<^B."=&V7A$F\0G@UR*!"O!
MIS$T/;W6]>I7JX8P<L4*D)P@ZMZW2U8Q_QQR`I+YOX^F-Y:FZQ\+VF#%*>D!
M23:)4*[IPDH2LC3]A//W)M?T`/'TRXG:27;)*A'(-5U820+OH^F-H>F5_K&@
M#5:<4C8B7*Y'44]N@:,3D"2$X'K*5Y/C1:2A.&J.>(BG7T[45K(+CDS5<\@)
M2!(@>61KULL__-'LUVEZ*"70!:L$]3GD!"1S,H2Y..5EK%R9FZBY:=DL)VKW
MT26K4`)]#CD!20+OH\R-H<Q%H5;)-ECQ.LG*/%?FY!8X.@%)0H8REW1><N1>
MJ<FE.4`\_;+0]]O)*F3;YY`3D"1`NL?*_,13],;+)YBSO9+::;?!BE/*1B03
MXCZY!8Y.0(+0W-#F4^;($$<N/`'BZ9>%ON%.5B';/H><@"2!]Q'GN27.2K;:
M8,09Z0%)-HE/KLW"2O(QM/F$0_1Y+LT!XMF7A;[=3E8I_UR:A97,_WVD>6Y*
ML^KL-EAQ2LJF2S:)4*;63EA)0@B>3?D3'A^94QPU0SS$TR\+M0QTP9')8`XY
M`4D"I*QO7[/F7J#EFJ7N?=I@Q2EE(^(C<4(9Y%(DC)LD9.CZ"?=W\US6`\2S
M+XLL_RC^J:(RR*586?[O(^MS0]:KA9;U8,4I981R64]N@:,3D!P00]9/.)+"
M1U:R&>(AGGU9J*+K@B,OJ.B8\N?0F/_X39;Q,R"/Z]WG=;=^>-B?W6R_TO=6
MB@D]6AIQ_S68>7.U'#\'HUI:M%`GX8)9RSQ\0D:U+.<5H@UYJQ:L;?`9'EO.
M6J9HL7R6\QK1AN?N,Y\:/L-)1M8R0XOELVP6B#8\XZU]T$)["HOI!-$LG^6\
M0+3A(7(=#2T.@FA%*]%B^2P;]!LVSH8/6NA&RVI!O^$.QFI![^`^PFI![YC7
M63:H`VP4+1_4`?;`5@OJP/19SM#7.($P?-!"9RM&2X.^-GV6#?H:=\^6#_H:
M!P-6"_K:]%G.4%4X/C1\T.)P5FJUH-],G^4,_8:S+\L'_893/:L%_6;Z+&=@
MBK-_RP=,\;.&U0*FIL]RAJK"R;7E@ZK",;W5@JHR?98UF.*G.\,'+?2KI-4"
MIJ;/LD:%0.4L'U0(?E$S6F:H$--G68,I?GDW?-#B\)B!U0*FIL^R1H7@9V/+
M!Q6"&SRK!15B^BRG8(K'9@P?M-`3049+#::FS[)&A>"9#\L'%8*G6:P65(CI
MLYR"*1YZ,WS00L_S62U@:OHLIZ@0/+)E^:!"\#":U8(*,7V64S#%,ZN6#YCB
M<5RK!4Q-G^44%8)''"T?5`@>);5:4"&V3X'KX`5TPZ=`-'RBPFI!-'PH(F]9
M%C0*9H6@A;[%D/NT!48!7SFP6M#7^*B`T5*A!<_?6RVH1#QR;K1,48EV;K0D
M6AZXB'D-#+19&[BT>>4"5\8G8(R<"HS_^/$"K;W5Y*K%"U&Y#]Y=NZ*WI_(6
MO*4&[E8+OI2WM/"6+F]$:E$4ICU*PJJ(Y?1J:19$2W5G78!6'PLOBZMV?'%2
M=0C>;;^B=\`-VFAQ9DM;UHAF#4F/EMYLP9NWB#;X7,84\%6_Y]7G]3]7N\^;
MI_W9P_H.N]#Q[;G=^%U`_RJ=_X[%I^T!W_,;/FEQC^\WKO&EN`F]?7VWW1["
M/T#D,GX1\N/_`0``__\#`%!+`P04``8`"````"$`KOC`'C(!``!``@``$0`(
M`61O8U!R;W!S+V-O<F4N>&UL(*($`2B@``$`````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````G)%!3\,@&(;O)OZ'AGM+::<QI&6)FIU<8N*,BS>$;RNQ
M4`)HMW\OZ[HZHR>/Y'UY>+Z/:K[3;?()SJO.U(AD.4K`B$XJLZW1\VJ1WJ#$
M!VXD;SL#-=J#1W-V>5$)2T7GX-%U%EQ0X)-(,IX*6Z,F!$LQ]J(!S7T6&R:&
MF\YI'N+1;;'EXIUO`1=Y?HTU!"YYX/@`3.U$1"-2B@EI/UP[`*3`T((&$SPF
M&<'?W0!.^S\O#,E94ZNPMW&F4?><+<4QG-H[KZ9BW_=97PX:T9_@]?+A:1@U
M5>:P*P&('?;3<A^6<94;!?)VSW9OKDV\;RK\.ZND&.RH<,`#R"2^1X]VI^2E
MO+M?+1`K<C)+\ZN4%"M2TKRD9/9:X5-KO,\FH!X%_DT\`=C@_?//V1<```#_
M_P,`4$L#!!0`!@`(````(0`T,*"`P0(``-T(```0``@!9&]C4')O<',O87!P
M+GAM;""B!`$HH``!````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````````)Q6
M34_C,!"]K[3_(<H=4BA:K5`:%)H@*A5:;0-[M-QDTEJD=K"=BO+K&3<T3:F)
M1&^VY\-OYLUX[-^\K0IG#5(QP0?NQ7G/=8"G(F-\,7"?DKNSOZZC-.49+02'
M@;L!Y=X$OW_Y4RE*D)J!<M`%5P-WJ75Y[7DJ7<**JG,4<Y3D0JZHQJU<>"+/
M60J12*L5<.U=]GI_/'C3P#/(SLK&H5M[O%[K4YUF(C7XU'.R*1%PX(=E6;"4
M:HPR>&"I%$KDVHG?4BA\KRWT$=T,TDHRO0EZOM?>^K.4%C!$QT%."P6^MS_P
M[X&:I$TIDRKPU_IZ#:D6TE'L'=-VZ3ISJL#`&;AK*AGE&F$9M7JS71>ETC+X
M+^2+6@)HY7NH4!]NEVW=]II=!?W^5@-7AYK&0XT$!8<8$Z8+4)-\2J6V0.[W
MVYBW*&K$-:`=BP1K@\1<8[[(B-=L,]%&WL0PG#Q&\>,LC@BN9I/Q*`H3W-R&
MX_!Q&)]@<O$3FUF"MSW\Z)I/$_LU$[F@G+UO:XK<4L44$3F92E!8V]2*;,37
M*!-R8Y7&KQ4K36-8I2-TRA=L7@"A2GTICB;%_\2&%LC$9%ZP10W-\!-!#E)B
MP3:*IO1J(L,T%177BDSIAF[=HP$>R@HR,K::&*3:'D1HL)&AX%JR>67ZC80+
M"?!M7$^<5AG3>!=V++DSKP76D0;)5N2.6:^?57,%KQ5FBL0FH0=]TL35S<\I
MG%Y:T32TD<2DSP[FB+TNY6X2[<B[6?S&IH,KDEB#[6;+?DTW$?6[]?G(->0U
MG8*EJRDK[%G=I[Y+ZSCW7=K=R;>70'?R[39U#W6&U]5+)#J!'SN2HW:R@3J8
M(U\FQYCQ%_54)B*B&G:C\?#0GRVIA`R'QDZ^/_#O<2K*PC@9+O&-@VRG<RPP
M@_RY_JT$%U?GO7X/9W3KS/?V_Y+@`P``__\#`%!+`0(M`!0`!@`(````(0!^
M3Q`*UP$``*@5```3``````````````````````!;0V]N=&5N=%]4>7!E<UTN
M>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````````````````
M$`0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`)K1"HO2`0``C10``!H`
M````````````````-@<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M`BT`%``&``@````A`$>&1!H^`P``@@H```\`````````````````2`H``'AL
M+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0`7&=,UK`4```\6```8````
M`````````````+,-``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4
M``8`"````"$`T3F4HJX"```K!P``&0````````````````"5$P``>&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(````(0`;PWEIT@L``-9@
M```9`````````````````'H6``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L!`BT`%``&``@````A`'4F[+4U`P``G`D``!D`````````````````@R(`
M`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`@R08
MHAT#``#?"```&0````````````````#O)0``>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+`0(M`!0`!@`(````(0!P<'KU90(``.`%```9````````````
M`````$,I``!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@`
M```A`/@S9*!`"@``;#<``!D`````````````````WRL``'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`14=D9KH%``#H%0``&0``
M``````````````!6-@``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M
M`!0`!@`(````(0"E>L_Q#@4``"P5```9`````````````````$<\``!X;"]W
M;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`-#(E*?;"P``
M+5<``!D`````````````````C$$``'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"+0`4``8`"````"$``E".3,X"```^!P``&0````````````````">
M30``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0!3
M?$6E#`8``*<8```8`````````````````*-0``!X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"+0`4``8`"````"$`GTZI`"X#```R"@``&```````````
M``````#E5@``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@`
M```A`"4A%%"K=P``KG<!`!0`````````````````25H``'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L!`BT`%``&``@````A`)E]I7,9#```J',```T`````````
M````````)M(``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E;90&
M``"G&P``$P````````````````!JW@``>&PO=&AE;64O=&AE;64Q+GAM;%!+
M`0(M`!0`!@`(````(0`-V)KI6`4``!T9```9`````````````````"_E``!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A`$3D$TZ\
M`P``E@T``!@`````````````````ONH``'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+`0(M`!0`!@`(````(0!1P"-=P0<``/D?```9````````````````
M`+#N``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A
M`!$3R^+4!```CQ```!D`````````````````J/8``'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`"`<D@T(-``"I20``&0``````
M``````````"S^P``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`
M!@`(````(0"HT4M\^`4``"P8```8`````````````````"P)`0!X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`*'_]>_T%```E&```
M&`````````````````!:#P$`>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M`BT`%``&``@````A`'<:"42$`@``>@8``!@`````````````````C14!`'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0"O)O.J)0X`
M``Q+```8`````````````````$<8`0!X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"+0`4``8`"````"$`FY^K&Z('```/(@``&`````````````````"B
M)@$`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`,,L
M+3!L!0``MQ,``!D`````````````````>BX!`'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"+0`4``8`"````"$`)H1@:M0%```%%@``&0``````````
M```````=-`$`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(
M````(0!<&L<LI`T``-U$```9`````````````````"@Z`0!X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`#A.9V1"!0``DQ,``!D`
M`````````````````T@!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M+0`4``8`"````"$`TD0U,D0%``",$P``&0````````````````!\30$`>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0`IWO<MU0,`
M`%T/```9`````````````````/=2`0!X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L!`BT`%``&``@````A`$71YZ/D!@``BAL``!D`````````````````
M`U<!`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`
M$_B1$YH#``!U#0``&0`````````````````>7@$`>&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0"Z8CWH#@8``$$8```9````````
M`````````.]A`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&
M``@````A`)#?_3G1#P``5E(``!D`````````````````-&@!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"````"$`KOC`'C(!``!``@``
M$0`````````````````\>`$`9&]C4')O<',O8V]R92YX;6Q02P$"+0`4``8`
M"````"$`-#"@@,$"``#="```$`````````````````"E>@$`9&]C4')O<',O
=87!P+GAM;%!+!08`````*@`J`%@+``"<?@$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 05, 2014

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>May 06, 2014

</div>
          <div>Subsequent Event [Member]

</div>
          <div>Tranche</div>
        </th>
        <th class="th">
          <div>May 31, 2014

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Subsequent Event [Member]

</div>
          <div>Tranche

</div>
          <div>Intallment</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Additional equity capital raised</a></td>
        <td class="nump">$ 8,182,559<span></span></td>
        <td class="nump">$ 11,699,340<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,380,640<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Awarded grant amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">224,911<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesOverhead', window );">Overhead charges</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction', window );">Maximum percentages of current equity value of solutions at time of significant transaction (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentages of outstanding voting securities owns before transaction beneficially (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchase during period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchase during period, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfTranches', window );">Number of tranches</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">BioTime have option to purchase additional shares (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment', window );">Number of tranches related to attainment of certain product development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfInstallmentsForEachTranche', window );">Number of installments for each tranche</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfTradingDays', window );">Number of trading days</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">20 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents maximum percentages of current equity value of solutions at time of significant transaction during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_MaximumPercentagesOfCurrentEquityValueOfSolutionsAtTimeOfSignificantTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfInstallmentsForEachTranche">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents number of installments for each tranche.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_NumberOfInstallmentsForEachTranche</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfTradingDays">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents number of trading days require for average closing price of BioTime common shares on the NYSE MKT.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_NumberOfTradingDays</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfTranches">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to number of tranches.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_NumberOfTranches</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents number of tranches related to the attainment of certain product development during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_NumberOfTranchesRelatedToAttainmentOfCertainProductDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServicesOverhead">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indirect expenses and cost incurred associated with services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfServicesOverhead</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 18<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -Subparagraph a (1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001140361-14-020012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-14-020012-xbrl.zip
M4$L#!!0````(`!Q(K$0%<8YA7]<``#--!P`0`!P`8G1X+3(P,30P,S,Q+GAM
M;%54"0`#!\9P4P?&<%-U>`L``00E#@``!#D!``#L7>MSX[B1_WY5]S\@SB79
MK9)L44_+LS,I6^-)7.L9.[;W]E*IJRV(A"3L4@07(&TK?WVZ`9*B*.IE6T]S
M/NS*9*.?/S0:(`C^\-?GH4L>F51<>!^/K./*$6&>+1SN]3\>A:I,E<WYT5\_
M_?=__?"'<OEOS&.2!LPAW1'YS)7M"A5*1NZ%&P;`09';NYLO5]>7I'K</*X<
M5TA'^"/)^X.`6.UV@Y1)M6+5R,-`#)7PR!T+`Y!-SFV;N:$Z)N>N2S2Y(I(I
M)A^9<UPNH_3GKG0)*.NI,_S)/QX-@L`_.SEY>GHZQBO'0O9/JI5*[81[*J">
MS8XB>I=[O\TAQ]M=JA+RYRGZIYJF!@O:)_IN0JIX'B&PM4[^[^OUO3U@0UK.
MZH/BG7'#M#;-$W,S)N5*U*M6:YZQAB)IX#TR%4SR5LP^[HO'$W,/FEG5<L4J
MUZRX$<2Y3ZF?M.I1U=42HALY31S&\X7`C3P)@9QI0_L$[L:$7CC,)W0">1*,
M?'8"%$QR.VD@O"7:"*^<:6>+T`OD*-^(Z&:.(78H)7206>VBNSD-/<IME=]*
MW\(FUF03Q>W\!G`CCSSPY0QZN)/3@#W;@_P&>"?'AF[PG-!WN0CXD''//K;%
M$(GKE5I"NDSOA%Y-R`_8G<Z4[BAWK$=T]SK#H'T\4GSHN]AK]+6!9+V/1Z!"
M.99U_*R<(W)B^.BD`%'U`O8<$.Y\/+(UG56Q`I%HIVD3:N8%/!A%UY*KW,'K
M/<XDT7JQ"6-B%W6N?CSZ5(%_IZUFK5[[X23;.!9UDB,KDN0#((63E0_ND<%G
MR+*?4&V,0,6*N8SO91HQSTDUJ4'0QH*=5(/X:DIT?"GRW7QW-BKMO7"B05D0
M^:-1KK03YM&=M_''OH!JTA]I?+RE/VI6=?_\42M#GEN3/Y+T4]L;I$RDG]KJ
MZ:>VOO13W4=X5=<)KWT!U41W6UOZR8SVOYR#?@['J<DCNV=0G/&`,W7Y;+NA
MPYPO4@P[8NB'`<6YRTWODDH/YCWJELG[`97L8I3/X/R9JU]^IE*"WE_9L,OD
M%F(P[J^L/V2)`Y,;#JCQ[+O<YI&.Q(%RS3/SO*BN/UNC@XX^Q4(F//7#2:YR
M8Z-.\JPZL")J<RB]#X3]VXVOY^8%5!="==I=!5ZS14R157<"JMO/JKM5&VX2
MI0^2417*D4X7!5878C7'7P5B-XK8H@[8QSI@M_"ZR;JUR+#[F6%WJW(U.+UF
M?>I>:GLTMJYYCPVI?V]SYME,70?.?@+,8?PL8]O1IV[P?#;+P$TA8C-KS?G!
MO50=YKI70"H]W:.H>QNPPXOQ`CO?0ZAO9#`0]BA@'2%](;47#BS*LTU\#P%&
MA'="R;ZQ4`IUL.EZOIGO(="9`>O*LP\LQ+,,?$_!C;>('6YTIRQ\#^&]\>Q#
M'X1G6?@>PGNNH,+D5%UP$0R8I#X#C-M[NH8T,\1SK7P/8;XPN_G.%:?7?,@#
M=FA%UBP#WT-P[QBFKX<4L`]O#)YCXZ&%>'(5]E8*8!2,;EV0<.XYE[^'W$<[
M+D8/(Y^919'XFK'\ESOJ]<V=K_29#\/A?H(A7OQ,S!FOAT[8M0@`J\A:PMUC
M+3)^+U9DWQJ]W#M,]*;M*M"[L^C]`G$*V#5_9,Z5!QF^S[LNE!B*!>IB])7^
M*F3'I4JE*ZQK;D-0V!<A?_*X?N\J&-WT?@KH8+]1O((K)@JR1?XH4/<JU)T[
MC_BNC8-KC`_,'GC"%?T1E$8_\V#P(Y?<NP^[KHG!U3M#X`M\4Z!Q/6@LD)?V
M0X&RUZ$L6LR)AI;TN-*A+N\)Z7'ZWA"WO$\*]+T*?3]3V2LF*J^=J*P,\+';
M"_RN`;_%,E&!W_W`[TI5/=]O1*]WRL,+/+X!'N.GQ_%"AQ3#^^Y0OC?DS7=#
M@;$7("M_W]C8OW^G#E6Q*]\-T%;RRJ$]&GSI5'F<]=%%?V-R7S?QO'J"/-,3
M[QTJXP+UW6!B\S7Y=K80%##8,1CL=)GR^H798K39F=%FIY%6/%[:Z\=+NUK)
M%,_$]_*9^$'`Z;TM^^SR@N.N`JK8*;;3.\5V?XZVTA+8H3VEWNZ"X2J:OO9Y
M^KN8`VRH%Q1HW^;R>('`P]MML=]Y>)5](>^B%Q0UR+O!_C9JD%V=BQ5[B?=B
M+_'NS\GNF"^%$]IXB!]^1<N\H:S`P#!@[PQ`2_BB&'.+K6;[O=5L]U/2`WND
MD8_.^Y*QU"O6MW2$?]T.J#)EF?YUQ3LN\+>I^\X0-=M3;U&+H82LPXW<7*\7
MJ7'3J"]@OQ78%[C?+NX+U&\!]07F<\O@6\D?@>.7T,,O$QN02M9C4C)GC\^(
MUW&?,FV\%I-GXV$7L$6@BP/\9Z-CI=,I?[D/0`]TC<[P-SWM6[,Z+89#X>G+
M%_L)J/&72F;8.,;6M+%O,9#M]EF:>XSIU"[@Y1!\_IX0?+X!!!?[L%?!ZYT8
MAFZHOG!W.#ZU_J!S[^Q#2/-<\9:/Z]:2[0L,%Z=<%R@I:LP-`>E@\MTVC_0N
MBL1W6"1N]0SYHLHKJKS-@;!F52K6''A%7[]6UGYB:XE(1V^>IZW<0HAK9:N2
M*M#6N?([9XC;M_#NTJ"QP_7VHDZ>2G*=_03"RS)ZYQ"[>ZW2KK;-U\Z+W+Z]
MW)[]OGB[7&VOD@XR"%G_]+L8!O:H;*M7&LF8WH!@WH==Q7X/0<W+1_A/\DF7
MS/7]#&_2T?.-'*?V7&NW-?XW5A__&VM;;VM4ZC%:*HT"+3N)EOK*:*DTUH^6
M9H&60T%+<UUH*3"R`QB9+#S2X5[G8D(1^*T'?H<7'@J,[`A&UC,K"3UN8OU3
MI6)E`C=D5(62?8KT'U#)5,PJOI=FC[QF\:[.X,V5J%>MUME/]Y]?RKJ68>WP
M1\!'UGW8XELX9)(&8NI1P]+ZI!V<SS$E[C/SQ)![\P4N<FY6XC33^&[*[F7<
M5I\;;1]^OC0@C06QOKJ^?RGKY@S6^F4$23W()"]EW9K#&M^&<%WLOLMQ_T.Y
M?`[4#K8@7US:+Y?-#5SF2.[@#1+UR3O6RQV=CS[UJ*O`J*F6B:1.**66PY5-
M7?)/1B6Y]!R"0T!:;D1GR)#JT@P3BU4HEZVJSC?SV"3Z?!9VJ`V_U1DH5Y>8
MQI`LK4@Z]\UDDRABEI+(S\QUR[]YXLDC]Q`UX3&'7"D5,IG6R!`C[8](&E,:
MPL6:?1-&H[ELLIK]KW!#0)8<0>Q<)M6T/@F%(5A5CTSSK/P8.7?,%S+@7I_@
M0FR8HT=$F1`:NL7J_!.3VB(V6;6TLJ0#H>P+.9I61M^/;R_6X=RVF8M9&N*N
MFZ8UFN"55>2.];D*<.F9?*-#-JW)F`#O+U;EXNKFX>KK);GZUDDK,<EF*DK@
M,0D=^\ISV#/YD>5X)"+1%$"P6)%T2363S90B^K$+T8OS)7*OARQR$P98?>!K
M&CEZZ1:Z@2%/4><HV:BTCPAF47U-5R3$838?0@K\>%0Y^M2J6O5V#5?AEY,Q
MG9/22?(+7%1Y66F<VS3)<GEI,B-E6,Q4),J1"U0Q5$LJ\P\K3Y44BVEEL-3-
MDX[7%PNT*N5_3(K$=N.1T+8%9"%%;NF(=EU&(#8$+LH0.N0UIUWN\H`S58KS
M4:Q)7';'#*+VYYX3M4XUCE-95MF:5045)T!5S8"JV:I6FU6(WPOD[8:1)@YS
MC6S4Z[5*L[89(\EG@)PKL$`B_WK`V>2%"]WS_U]B\Y@5,M)\%B/RSV[P`<IA
MHH*1"Q/+'M"7>W3(W=$9^<L#S/P4^<:>R)T84N\O):*OE(B"+M+[0#2UXO]F
M9\2J^,&'HS_W@P\9CBB^3%W>]\[(KZ&"N>@H:IB(F9*S4)"Y\,1X?Q"<D:YP
M'2.[>4R6]3RJ>0)Z+E#99;W@]?H:Q]"A_^&/5K/R8279^@KW<!Y_1NH-_ZW4
M.0_(5RKM`:E9)8*`T)[ZS&PSZX^NUDJ$QA[U4QZED4?=%)8!;`I&9[@J>B08
M,)#KNN()1I>S7?)VH(V`2L?UJ8-C'W9[_;?RJ1W_'6GWQ)U@@'PK?\HJ]N+>
M$<CDET,>M>D?C[HB",0PD1NI5C:7STC5?_Y`'AG4@C!"Q>XR-Q=VNQP<E5O'
MU9<@:4AEGWMEY'A&TCR6=_])X*S#_$EY$S)L@9$%(9#J9\CK"NG`+"<6]\>*
M_H=BB1(N=U[L>QO<S>3Z,MYD%UZRFZU;J>]"CX8.ATSP_?SHP\1/4O_CD?G_
MS.A,@_E-\5%@\'7A3H\9.X)`'+EV'GHGJ8%@B2&A2^W?^A*&8J<,:!(2(`+S
M==8#MT2C5*OYI[T:),XSE<6+AHK%;K$6>67UW##MN3=08UXI_L(JZ']>Y-*T
M=1*[UC+FM;=@7K74J+9*M5IE37U]*]@J`/U^`5TKG9ZV2NW&'@+Z]:-93__;
MY]%,3XF[P@O5]`+#2_M^QBO;ZON;56-V)\WHL951I]HNM2N-S771]?M^ZP$O
M<+<8=\U*I00SPOW#W8I#0^X,Z_!F/S=XRD'>0NK;K9AMIWY=N(ZQ*X7V2HKN
M=-U8+35/&Z73ZNDF%SVV$K3=T:3`^39P7JW52\W6U$KWGN+\E2-C?89Z>SZ3
M>N.'1TMZ:7,]#Q0BC@B[+ELR1ZRJZ<XLO*SH@)TNOQNE>KU6JC0W]6!A>[#=
M'4V*#G1`':A9:E6A4*UN:O!>-VQ3@_>)WE22_!79MMH>LIS]6\E^L@=)'3;>
MB2.9S?@C<IJU4>PNH?C&@E=L^6NT&NU*9=J0//YKUG:)O7O-2J6^LK;9IY`+
M]MZ]PIFUT]-6NY&CWR3KM]9L"<=5&]56K;:29GK5XL*L=<_;JXET$=EK%*RV
MV_@&^%S&:U)OF9VQ.BVOH%XX#%V]S_XS\Z%_<!IPX97P+Y?A3[-M<8B;__\=
MW;N5PH<T-8)?+O6"DB:Y_#WD_C#?M%A&6D0B`%-0BGW,7+.&>PG?EP3+:IXV
MVM76A#O>1)G#\.`2>++JM=IIH[8A#^KS5D'-(3`>X+N>CXQP#_YF)]_!B*2^
MG^,:O8K923>]TBVOH1TDVYO>`WU^"8;*4&S7K5P'+"-R-^Q<)G-43]OMUYO9
M`<F2=T,TTZ8^#Z"6R1H#U1%B@[JWE#M77L>0O20X[5J[54TIG<]Y'<HMX=$5
ME3MW<%LZ]@U%`D'&Y`3I`1\D:E$R[_.8-^*<DOX_]6Q&.D(%JJR/7R+_,N\T
M3V_@'TMY$#-4TNP-]YBW9KUH%__<TZT6O.M@G4X,6Z_0<NQ0%TI7W=_T6T;E
M+E7P&X$,*-;9B5P^X^_I>B9NJ1M>8+MTLZC5-"82=]26*!';5KO>3)F\E,SM
M&9=]8V.N<:<5J]&HO\JX)PWIGI#D,\PO@U[HCE^I&)?1LRNJF,47(6,&TU7X
M*RHM"XJ+"<BN(G!W+%VFBGH;2U-5`;Z7P9//U1&JOU<W95>JP4TO^W6[5W:^
M>K712E<U<V5MS(:5^IA5:[;:[=-7&_$Y^C87Z4#?[+,%-L34$?'KPE"NPVRJ
M.<N"C*@-&;!2#,K5T\K*ZL/X6':X&^('PHDY1H*P9]L-';"A)\505X9AD!BH
MB?'1/!1<Q,?C5[`1^0Y*`M/\^W)TWN;L81^$QC+OF1U*O=)S&4G%CTAWQC)O
M>I=4>MSKJULF=<8&R\+<Y#$Y_K]2RL4HGT'ZW-2\:B+[SG&[U;":5GJ2_A;6
MKS>`IJ2[\;&).N`P:CLC,Y>)9:/>QIRR5['<3F?,9-Y=Z8RG5K-I5?<J?@]2
M'Q4SBN99AQO&V-#TIT?G!K-::U;:S=.]BN8V,^LF@[EJ9JVW6GN76;?:,S<Y
M3*[<,ZU*H]ZT:JVUA5-/(F9/0O7M5TPRV]5Z\]1*HS'-\6W46&)6WVK7V^U6
M93DU\J6_Z*P/E'O:;F3EODS@4H]36U4HDZ<,301>4,45]LIH9@_0*)%;X7)[
M1/X5_7_..2&Z^4UOW-@T,?_=U6-!<K:8U9IO=LX%"L8;$[;HWV<$US.Y_4:"
M_L8\)JFK-P`@`5XC9O/`:=6R/I`++I`-@0!3TN4B8/;`$Z[HCW1*IMZ(,*]/
M^TRO.@=/@E!,1X@&H!XR!W<H$$C(3+_TCP^O?"F<T`X`9(_,%?H)SW$LYR^0
MS25`#])V3Y^'!'*1+Q[,P9FK3^F0K*^UUH.%EL`]]H$H'T#;0W'NB`Q"\`&!
M7"A'PN,V^)$-R7>Q8=7*A\'E??*7]>%[?92&U@ZB&=I@C>]"%O3!7AV%3&M^
MF]-Z[)KC\?8+/&5L6ENB/W*NU^[-9P/Q*!*S+`OCFQ:780ET-$#?@ML4(!`H
MH;%DW9"#5Q+M`XZ+W*07>K8>*F%\!$?#%2!VTIHX'"*B&!$2+/X51H^TSN`<
MXXO;>W/&",8,CY\$#`P9]71XP<%AC]H!N,GK$X@EGM:FE<9CI:*@F3ATA3,R
MZH&QK"<D#O+BR1R^XH!*N"H&(H:@E%[<Q*8I>*`X2KQ0O[`/OSU`>>ISBS&B
M5-J&&+C:#DA\*NR"+$XENMIW02OM$BTCY?&8E59C`K9I@:%B:5GQ5R!)YC.0
M)7+EV<<3R(E))^!#[=]#CJM2:/=8%[-.B`:;YS0=(7TA30V4YJGO3C#48!E0
MAW09\U!;W3LGZ*S6!Z4#K45-6)KV//BC+^E0S0K+A+],M-,>2#IO?*J.Z<;J
M#&(82HWL$D#>CG_)8"!\["3*/.@>@%8!Z5&H3:2)Y7`D;"HAD"[P[H'.Z(YT
M,&Z`6V<4L)GNB@DF/`9Y)K(,E4RLTH&/.R$B!T'#:=\3^-@#%[9E6C:XLX/N
MO,*3(CP:/Y,#9:X#9Q((E_=7:07`7'(/HJF/O0-RX",>F>GR(=</($VJ-3Z)
MD#T12.!&+JYN")X2J_1&`N`":?0WI@]^3.+L0O(Q5HUA)IEYTIQ@(+$>@N=`
M#E<(>6PCH).7,6]$K"<ZW`W&;K[C8XHYGA^G0\R-,)0$*5!@UM)["P$=40)3
M4=*&%`:-)A.O5N9A?G_,H5I-.TH>,:<$(^P-&IGBD2H[=*G4JL7>Y?H<[$D;
MP)%/IJ//R#NATD<IFBA%77&H%<D=:S3V.MA3OF'O4C9G@%`U#;X9A%G+H3-?
M*4F9&STRS!__]4!M1JZ4JQ)\16W'KC,6`BZI&;/B3*`KA91WN(?3C\CMV;P3
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M(Q9`3N2YG!IZNGK"#FOCC("9JK0[2L*%\R&X&WJ@@U3F=$9==.@-</@5!!Z$
M>L6RA'1F]$&BR!@8G*)Q3#>#/_T!E9#Q]:BNRT4GQ"3+HMH22XMD<YUAI?6+
MYSK3]1`,^AFQ6`:.^:;'B-OT@([Z)>Q,]B?&XSA9C1RB!`3C"88Q$088$=Q1
MAT=@?_?E\SG,$7S4"W=T:=TE2TVF=(T!;@->'L@H0_$Y)%W$`%,P?_`1!;C"
M@VH_#6!&H*V09@Z9/Y':,]3[DCUR$2KP0`17!)<K!$[D*20?\BC<$`C9,X3/
MT5A+%6>IJ@;#%>JHPB`C^Y#Q2I!R&/SR;)B%2PI@3Q458X1"@"#MZI(B;R(Z
M4:[C1E>J*W/0FWDA0AWBZ,&<&'2#2#K1,@@XQZQ_`VO<3XD3*!9U#.A_F$O-
M1:1!E(UK_N@\TVPA,LZE<;!+IK44(^HFO2XC+W&4,'/4*`5@3LGW;\R]M+FA
MZN^`,>8YVQF4DP#$KLDMZ$WG->Z.TT%??_PTA9A]Z7LP9R+)H9FXEN/@QCS]
M2[^B;:8].!/FD(W^T]Z_-[>-)/G"\/\GXOD.>/ITQ]H1D)KW2_=.1\BRW:.S
M;4NOI9XY&Q-/3(`D*&$,`AQ<)',__9N7NN%&@A1)D3(WML<B"51E965E965E
M_A(V6U3-\8,+NH\=A%D<4-Z%:S<8RZ*RU)184'AKAQS.ADO3)9$Z#SQ$+BP3
M&-`#[(<!7C"50`H+%&%V^VQ*U-B)'ZRI'SYMTKOUX`#IY+^!H;"VAMVR3)O`
ME#GWU"UJ+4QABB;$;-Q,J%O</:-TS`PB\?L8PA:!T.[4X1?>;=!2N#W[OZ;V
MNN+-%<]TPH[0O0&#\/!JQ"*_$7#*I'\"G\[$`?1$+N!Q&I&KT'CA+>Q7H)-B
M]/>":IGCH@C(WQ/Y"V&B!#`4/-;-P]CC\QH\!<>SW+SS;!DL=PI8T9JC,V>2
M<>"!*.M/F9DMD]L"WC1["5AO*T5PR<?CS$PY09#BJ5=(DQZ<(3C<!UDB2$*.
MS/+!KR-?M,\DBO&XPX!RH)WKT96[AKE!<7^@I,`JG!-39&_3%.9_@<46X#5L
M_6CLADM0\HZ'9\LIBJ?*O9F&80+<(?^X2&R,A003G\25M!=DUW_I1*IE6[(H
MM?$'O[AS;,-1]U^X]T-K<Q_ZUC*K50]P/YQY";U$M]_B`QG3<B''<BKU?2ZG
M#GT;/SC!/<GGS(OCO)/N]L-EQE?A?D/ZY)0_9Y788'MZ((I/3FZU+%L.6?<6
M3YIA[$W3*/"@5^#$C*.@-<-`XV"]<2PD-V'3G2:;)T"H&L$JU`?6A&\RD&=C
M<2O,5=8R1%PEN-KC]/[>)=AX6JCP#H?!+]L<2H5DA"O:D1+U+WEOHS1W3F.L
MECKRJ(4)'6;@?`#C-J6V;/N06\%_J75-2YJU1V$6RY;X"UR05J-M%/*8Z]TO
MZ]ML>6ZZP%L9N>?`<8X8Y<!>219[X19;O&:\%<-+](YXY7D!T)UANV]FD];H
M\"7&M%9,]+#=Z;>:FXWI,V@:LNR<1\?SZ0J1S^=8Q8B"@![@0&W4W:K3"32J
M$]:>&>\]:`R'5#EH[8Y?<HSK!>6W6MU^:]!M/6>0?+E)EYU\$\IOZ3,G')!B
MA_7BF'++YICDIHWALZK[U\J@KQ(B,1\,E03?Q')BVIWNN2JIK2R539*3HZ9.
M<EL[EY.](:$FJH'BG795C&LD_\F>P4P8>7R5:1#QA>=FQZE^S6X3EE#)"EI-
ME,[CQ!,!#IW^P)SB1SBA!PE[$2^=*%K@KO\WQR_J/WSE(IC@/\:+%XE\BU[:
M"/.AU^X/VL;`:O7T@F.J$R;6&78[_<'QC*FU>DR==F<X[/6/9TPU=/9P,.RU
MV]T=C*E^R%]YEZ>(OSUX2=7\D:O$U=Q?'0,HP[5B\OL\>/</<`+S/6@"SQ:/
MKO0"S=,(SIAX#J)CC!/`B=6[I^MZ.&KC873!AU/#5P$G#Q\-5#!O1FZ!ML*A
MHVCEUQ*I6E+,-1O!4(GH)O`-'('HKP+20D67]+Y\7;[\/#NKV^WTVKV5NK6\
MZP,:]'I)J\U.J]WM/7/0'[ZYT=BCZPYO3/ZM)Y%R]8;"FWS?B8P4@K=GH@[J
M)?H.K'?:/EK;R*06KJ<B_^DZ^H+7#I*<&Z1&_1B+7[=B8?[S5GH#!`64&$#O
M\=CHZW=E!EC;G((6R-VY:8QN,J#-YT&VU-PM@]O-1J.YA&6*C$/GU]'(Y]Y8
M^%D%#`O683@Y8H!D\H16\ZU*(]3A)],``J6\L)=XSSAYMSBPI9]/$FHWN]FC
MZ#.'M^:L@$F3^FF,);UGL#]1!.-A3HB@E`@%,K<_$2\Z#]O1*OM=!2N2C!N-
MW3"4+E02[87'D<#QR0W&7A%HPG@831KST9H.A6^Q]TO@^7!(B5+W!^OGW=-1
M[@182H=T4\(2GCL1PJ*F;M4&5D*9J/S^.;QQHMK.ELR.<O7YXP^_F9-=UNI^
M22YAXQY)WMYV5W]^7L9^[0`7P9@PTY:WR\H,HRXTHY8[5I_#-\-S6H]+%SOG
M4I@F<0)J!AU9YL91/6I*&8ZOC?=JK)`"UD>OW^QT6IU2J@L][)/X$HU4('[8
MZ#>;P];SB`]"+:*VY:3)0QAY_P/[=[/5Q9I+^)],IB\+N"JOG?ZKU1O:O6;?
M;K>&TB#`![M#&XBV@>H,URH;[O7M3K-E-]O95GHVS)L-$Y=M)2D2LF02-O:[
MMX#KG7:G52[L2^7\Q.VU;P1:C7:GV^M4J):EW"ZQ1%>M289WW$27]/K`.V#=
MDN7(C>^>VAK*HS<$>0%QV9A:0W;7H?A"O[8!U;!*"G9W=0_[([V&>&Q.NA&#
MRO?>UAN\^7YK6WBQ#ROYSOE&N6,BS^U&9&M<))P+)B_\/V.&;)!$8(+@8Y1=
MZL8%1(M,C]RAQ-Q5?8@NS![NPFS[LOEGA@;TN_W&H-7+,&V;Y+UB1J\99])J
M]%K=SCX8'8S!WA29O5^\^*MM74;NQ$O$AS4N`,VF\&5N!_\Z7?OMY-K/9#A'
MI_/,1<#RZJN_CRK$D$/(!>0TI4D1-H9'0:QQ.OJ7.T[432$L)02I(#@.!M>I
M[MP2,>-&QHN,G2^[IBS#>*`T^9CC)1F/27?A?IM3&*]J5,2JQAA`-',0EM5#
M,"/*95'E/V!SP?M-V<B_4YB*9&%$7)KY:)D8U2RYL%0I;CWFJ]#R]X$,&/,8
MJ".\`&``!MT*.`@Q-D*0A7%0F"VLOI$3?%6-_VH]A$^(P&$KECPX,85YP_!!
M*ES*T\-D;8PF@['CGIIBBJ08<)T+UNHE:VH($9Y*`89_T(WN@Q-8?W\(<5S7
M3PA<<BNA.+"H@4.!MOA#%#]X<Z5S;>O#=.J.>>B7%+(<LSK_QQVIZ^7:19.!
M1-S!^TP"4:`)X.Y5[[)ST?7U5'0,W7Z?80EW&>P.WB<C=^K3Q)1FMDE6(D)#
M!(_A<L:HXBA,83V%`4'.S`@"QD!DL57B@7%.$:<ID6=F/KXL"%E4[$O".7`"
M&2&^D!66VB93JY(2>*1<R`IW64IL%;6:U.=X[HSEY_+25YA*F\Y@(2)`D?B-
M2PEF?I%%G1J-G_+SMJZXR%YH^&7=1YS\9OZDN)%$<APR1Z[=GG\S?I^L/<Z2
MPIUBM.U&20TKS+/+#*'D_1H#6;I6=AR`7M$WZDY,+WQN[_S%DYB?4>A/F""M
MTY97*MO>!':&Y\/!:0ZW.(<?93Z^C'/=UU0V&^?-UMZG<M?LE+;0@<RNLC+V
M-:NP/K<RI\4'ON=%>HD&\U(M6U4@>0LSN[JL\W%OJ\N1]':^<%:S]^@WO2\*
MBB"/ZX)I11A8!7WJ@AD%2#\#V`!S-Q7J2YQQ")@`,S%#-M:!^V/\-/SQ`*;Z
MN#=%ZJ??/._]=`"L?+F=:*OL_//VXF#4?JX@\'&K_:6XF2\AOSGN'KW6OUT.
M<&N"+8Y]+R"\K'NJB*QA0]=*_-X*U4RK.[%2@A0:__[IY@"$X17L"^AI.@!.
MOI)M0>'V'LSF\*K.!&6`S@=@TQS]GG!)\-42SIJ0CU^>JZ]`N?:[Y^V3T7TR
MN@]]_9<"MA^`57#TBO4Z`UA/*/49`_LA(OABY`1"F0ADCCAQ0P?>Q&R3%]'$
M)S/W9.8>BR)^50;NLK(-!V!''+T^OKAWSR285%D%B/T[-M:^U-IBWY\*I2V^
MK_'?.-%7+XASE9#$1GT`R^T5[+N]UGGW=`+:&CNY!L_![+VOZA!4627J`.S&
MH]]X_R8+8956=<H6RU([M'%DDB6S$%C7$RC?JKB6K/GU?>U>ZB+G3$(HN\$D
ME*6O]!VZ8I-D*U8/<P,O"2.C0):^_YE$*585B[EX:Z[>X>DXNI6Y&W;.!Z?S
MZ$N<1_-AS<T=A#6_]E.JC*:\B#W'MO[@RI0'8.0=_2ZYXF[^`%C\"G3OH'DZ
MD&R-F7\-P7S[+_B?TYED%PJAO+SH`1@.1Z]JL7(G4*ZJ!]NY4LBR-MK)X-W.
M37C[O'4R>`_R`J9ZK-^M@5M4NYM>P.R$N4>O?&\+:O9@>/L*=.V;YMN#8><K
MT;=;]KMOA]7K6KI5<JFT7>C+JLK*RMR;W&Q@7U:-YU,X\GS7>G`=/WF`+J?)
MDR,B<C<;3IE8[<>JJQJB7.*'-)[52WWY6I8V3>FB^IE@&&KM4!D`C+-6?Q,$
M#`$4P=PPFJB1%+K9E8#V0!+<Q"J,"2IG^)<?WM_>?/S#BQ."05'($UO$D/AA
MF5(3_6S&X0([2P5'_$V"LUKRB[(@2'32)-P1B4OL13I15BA7*K[Z1#@T9R%!
MX9B@)I@FN>3H7V.%K`3PV1TJ3A4$T%J08/K%4RF@/6""W>@RLPB.9?*?)`A?
MPN?*B@%E@F=65R45-4@9HDN";)4"^V2K'9^PAT[80]OT%;T*1\7!06*<L(>.
M?PY/V$,G[*$3]M"!+](3]M`)>^B(.7S"'OJ.+B1.V$,'>_E[BK8Y80^]Q+WO
M"7OH%!1T2LH^80\=C^XZ80^=L(>.2;F>L(=.1O<QK/\3]M`)>^ADYI[,W&-4
MQ*_*P#UA#YVPA_;7]PE[Z(0]=,(>.J:-]X0]=,(>.DKFGK"'3MA#I^/H"7OH
MQ<^C)^RA$_;0P3+VA#UTPAXZ+LU[PAXZ80\=)6=/V$,G[*'C5;LG[*$3]M`1
M\_>$/73"'CHJ?7O"'CIA#YVPAT[80R?LH1/VT-%A#QE_5H&<O`BRS@78?S.'
MLGQ]RT,U-`YG<R=8:$P:NGV*G"!VQL0\Z\%Y=*V1ZP:6ZWLS+Z`++2_(PN7D
M86M6`^+@;,S1S1J(]I"":()A\2!#L(L(BO"R<JYQ>CAP"+-<X7=W+M[%=-<_
MSV_/K3<RKJ35^/7WBXL;];'YZUL:&C5M@/!@\_A]Y,[#B#Y%[K]3+Q)4@E3<
M?KBTOKCWJ<]IN;=G_]<<[`4]\PE]Q5:[:5L(R&1+<)XL&V1ZM6V5WGO+3`OX
M2\8&V]:'VRO;J@A1T]UD;@4R/#"?,'EAEPA[9NWDEI7"&P)QB)E_L.-[R0)6
M)&%31:&/7WN1%<XILDOP5<_]Q!U[,4D4?C]'?"M<=Q*<"%&&#/PB<0F*&[!H
MWL<F/8'$97FQA$*"$0-)#LC]W(&.71!3FCR<%YQ*H!&FK0*U"598[$ZR\S1R
M?)+"^,%UDR+:T0I<L1QPEP$+%A-)L0-B7(3^BI/KZ2W^=`+^V@/P5V8R:%+Q
M,?RE#.I+*\<IH6GANN;WY361OCQRQJ0])O0H-D^2C!HV"A=@':/(SQU/R"R\
MG_K4$CWA/KI!ZL9EVA![!=&?Q1*K"UZ=@_1[H)R!+R#&M.+N(U?JUUA12:/$
M1<"DEPJ]TLSX@EC"\'LMZ:^2W8+L?^$!EDN_^'&EP%MIX/&O?S8:K1](K\P<
M/T8K[;=FNSEL=O+$B::W0T];T=.N0<^@U>\,5]%S#68.G)U@2A[`"@;U@'A2
MH+MP.CX\XO_^XY,[&[E1"68@,=^-'D$&8MU.@8?=1D?PL-OH_5.W3\W?+>;N
MQ3<OSG_/G:X8(1\M"O*0(TF-];T[=2-<(/A<01'*7^E'V/(0AO$BF'R&78`_
ME`QMY21T6X-.=Z`I7-E)";$\,>O`.:I>^-4#T>M[4:^*;:R97(%P$J"R0S4U
M=9=IW3IOTV>/5S%JM4?'AZ4*'YZ<"(Q7!%R,XQ3:`/,D>?`B,#B<B)0OZ64A
MG&QF3/+]40>DI.%MH=#Y0!3C-VG,,(Z@\\$P=1,G`BO('3\$B)TBCA*9/O/&
ML2(66S$(!BN;E/@,+='_`8)"6#S<%3`[9(-(TDX&-+\`A#QZ$W>BK:;,2/2#
M)2UCT-F,=@`8UC1%M(%'5VTRHIU);GR1_J&P`YJ#O77!9`W!).N>E^\=R]=(
M<1GBXK2MP*5YEQJ!#/<PJ%I_7^"92_C72YZG15J#1K=3)+VL^3T2WFZV5A'>
M[@Z'_4T)AX-7"!90XGP#&0K<J9=4D7M%3]XYWSY\FZ-LO./'G[>?GS7;G6&C
MU2N27]'=/D:PE@70>`;IT@1Y[\5C/XSQ!/B/&CN.>$V_]>*[3L5IXE\I:)_I
M8@M^H@K/8/<<6D"S>V%=CZ!//L*CEE0\_D.HRH_N$44S[^H`I@X\8J.(*S;'
M_6P?DAK8&9WYW%_0%@;46@MXIZSKJ<O[O9OMD/P-\H"6/#@)6#O8J%!Z_D*?
MH/);M>A$X+%ARV9G>&A3/1'4LN@&E,YCZ",G'"N&>?.FWA@V>4Q\@P,:@2H'
M#RXI]!1Q(!+'"Y(%S(V'!SX!Q4QJRSQDLK&B<>/4851"QPFJ8)]Y4I1`OT&8
M@.JSO@;A4\"G2=6E!<P@?B&?B35TML1U9)HZ%8/4Q]VR:7OR?!_/M!Y0@]X=
M(53,3<PNF*2^,,B\&9A;$1]<B8H941".88HL&+SOD;PQ&!Z0X-U[B%'E?INS
M`\@4OC)XZ@V=L5G]M`M+^>\77SY*%:1LX);"";1NA-A^]YKI.K#^CQ.D:&NW
MT<O:&&CW)]VGT4Z/]CH<+-5Z^,,X05S/2?`NI(N$5\+?89/$HP3\X*>SP+,4
MZS_BS1L+J^E1Q1DS/:EYC4$S*I4EV.TS3X.URR4EEA^<#Q)V?Y.&H@_P"N.O
M&TMN!"L^N*<O0VK?1N_.$WJ%T<LC&M.!=-+##RPU8YD+^F.>1O,PEL<@Z=L2
MJUMNE#,G^NK2N0M4D=*B:<QN5]5V$H9^)L$(***TE@DR&+:+1;[[,I4!))3X
MQEF3S)T%,U<[TH1+B]QL)G445RC/22EYQHI:S`#/5-L1H6IB)_E9C805P3H-
MBS_PLZV?<$XZ/R&@IYPY0=57+YADJ(K!+*EJEQS7'N'L_PM4&GG5Q;R"9*?B
M*L:;:I>D'X<@&+A'`!_8MN'C+O))LXA6A#Z-$C@H70WC+S&)D*2P;$+H%*S]
MB[CYV_`FJD#X^&-KV+7Q7AFO@YR8)4R^&B=@<-KB<L6;C=((.4PS.*4\*!X>
M.BG16QF'L&)Q"+0LYQ%Z\RD=:NKY*BUJAIL6_"=G5$T<+YZ,]7`%\COAS#7;
M&,\B9AI^;#'IL#VF?)^$F[5<N-21&Y#_%0:=G[8L1T#UQ>)21!VPQ=D.5BD8
M[:+X`UU5E1M4WN8W%$AXX0I*V+AC<N#);]M'M366*0*ASP7\[<7EW;%<O.+V
ME8*0-1MR\RH;7FXCD[M7;LNZF#SB[$_X7O!.*35QS6UN5LBAS*T?8SD^/7@@
M*V44J.L+]QN(;(RW"T]AY$^>O$G>!6:T3;)J=+LW1R/0@$S`VPHWXU`4Q'0&
MK5\-!I@[`.J@F9L\A!-6DF/8"J@=6L@>+#9E]@>P?_F\M<9)!)I!R-_<3R./
M@9>-W<34%64L)I4*A,,$@PYJD!(R=,&JU_'^%;0ER"P*"DR'F!6>6:2]*#8P
M/J%=*NUTW#7`O![\I+8D--(=41I'[F%VSG4*W\/?L2NL=J#0AQFJ./LMS,ZO
M47\YO)5@#S\VD1'$##SRJ/T+ATO!!\@V&Z;"FJ819L<:S]``X(`S22L4M1@C
M'!<\TL96\N3BX0?/D70>3>=BTZ9',N<]WXF)@>+E_,E6;#PVKRD7S\6PC6/6
M;Y2GI6RVEVT=7OP:-XZ=Z]F+]![V)JO9?9:FI5M;ZS8=^15*&!9P;65**O2L
M1(?"BD/W_P+G`5LT]-,;%(JL*L\?%%50B_&:$LS1@EHD1>5,T8@"":`)_R\/
M#"OKYL&)9G18PO@?(WHDUR\_K1FQ[.QCT$ATY=\5YZ&<U\(`O%>V,KQ6!+^G
M`X0"S%1N"#ZA;//<OUL9O<L>1<P9*Y,B.CW%YEY%X5FP?\GCB]!)S+!1.$%'
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M>(H7[![QV<8Q\Y9F!MTMN*SDPK#=\/RDHDRR!AY3A[$30HV(RP<I6DR`-?,"
M;Y;.E"05]&48NWJF*^9"*MLQ7<>C9_4>3YF)$)3B(`1?T\I54D=G;^'0`Q/[
M":9Y2)JLA^P/0ODK\8ZC<`I:NV1Y'K_2/D9/&JN!+[]?'8OQ#`>\C^XHHHN@
M%LE=8UCKB$<)L.0QRYWDOKCRQN/1M01&06Q=P?+SDA0:-141,JKB_',5L(H$
MG4`72A,WNZ3$P0^ER9=>S'N,_&*O?=D(4%O\?F4;]^`RI`V^MMHMN]4=TCD*
MMR\JUVMCM@9?D_.I2,>:R34GUSR5LL8A3X0ZQF]+F)1=N[`$94.G!;NS!:N*
M;F16Z>V[3U^.9IW>B;2.LJDEOTCLF:O#`<.*TVW8J8WA@(R&1S[M28IW06*B
M83J;MA&;+YPLCMR#ST:NN#I23FS;\&+[)D])Z)T`#M.3LW=I%#PX,^L3@L?#
M,E8WP>6Z@*?#=,64WN[&Z/10=U:A]1#.*&;3G2=`#8<_S,%8DX6?E+'')J"(
M6>("Y<@:=HB`:16YCC00R0<$NS60CVLC\UP&UHIN0>6+PJK%8#$Y%0*9A7XA
MB,>%R/3Z5QKPE3"IS(K:X^41L:($N<-I#N9=9)DS6KFV:6:0Q6K"8(1J80B!
MH#L5E(?<(9@?4M8^M^-H<W]J=7XJW!Z3(3HFW>OXQC$`F=%L%)[GC`V>K#.<
M]VR(D2:5#79Y$8W1+O"3J/F0O\?47/LU?WA01J1J69CX(J8Y;\I+\5MFP>LK
MZ)QUR1R;.1A\P#?0?)+H`CV>Z4M0IQG2Y3/TO(Y<%3R=#;UF40I<0Y+R#"T+
M`[L(I+%=<3N+^XRDW75@Z5!\F!`1F3B3,V)Y6IUI@J7-=,"(.@5*41&Z1$\N
M/0P=BX,'$X9$%(SX)'QRHHF>K_^(5:MR[PQ54*)>GQCJ!A*(@\%Q5$NVNE47
MLX4-M+H_R8'RQ;K'H;VT_\J;=!A+[([3I/1:78:A1&'"$V6;00F2@JP^GV,$
M.GN<5,^E="MJX)@@>>%R$"P)*MDB99OZ46W?E24%S)WGK\[$@3WP6/;SJC&A
MXR5K:0?6!<CV1$0UP2::D.'VQ71B5-QL"YX4=^!;E?1`MIWR@(CT5'-;EGPU
M-V;SHJ9J(,I?@DX8=?EM[#WFU@[RF>N'%H**Y\J$G\J%O;KD+S[Y\.$V"S%,
MNWGDSGW8F_@VEW9VV7*$=A*EU\J:"FC3"QAG<Q%6#9QTM>1\JS.T&]T!B0<C
ML'C6[8/[U?5CF;$HE`Z10L8+*PRUC-4:A^U"-"L<:!A[(SOZ-YS@0&I\X10K
MQ*G)RQV3:3JDB^;34?#*(DK2E`SS`',D2^QJ:MVYCX[PB"E#Y"J8@,8BC(*"
ML./S&4EWOZ%$T32@.<TACR"\4H[W%IEQ/?^"`ID-RH`/<3J7?6-=TS,%"IQI
M)YXY&-51@O^`O%<@$$*Z^QV>0&B;DLE`EKZ'<>YMC&<WH`VS^7K:\ZB2DIVL
MBO^@=*A4]H4`W/Q5,TE_U=-9]V^5,E,FO]0S;6%`8^R.:2$K:WJ&=79'"UYZ
ML%(JP18,)[UZ.0OCGM&-?)>0U8W250]O%?W\IWN@)3IQ$L++F,<@%9RIWU#<
MJ@0"W>B<$:TW6_CZ>]`/)SVX>ST(4NCZ4\L\?[OL#94*R#B&9P.Q-9;$;.Z[
MR@.3S>\IC9+Y'B;U)+P[%]XU=M&5@3EKQW\N[5K='V>V;#HH8.X%?<`S-'KE
M8%VU2YQD*XYY5???):N6$;+(UZ4M`-R4,L-AKY!(?)&92JU&LV^K-J6#"-VM
MB<\7.8(<NALOOU!6KB*,D17!+L3L"G^3\/VIE[2KCK)B="P>!R/@D)X\OJ.6
MSC])L.%!`ZF&,[T3%5Q25]-*5H=X1-,=NGG^\<E3TV=TAUYI+TQCZJY:3M$_
M29=*\-=7^6X5`Q'LR]<70RH<!%B8R9^!IMQ,0V)B9#LBPQ36-A_&82HJ>"R$
M-F=KJF'"B^2HS,88R$D^NF/K4A--GQ>6&OGBXH%-MHWE"J\.V5<K+U422H<[
M[9VO:YPONG?6T>K270B]PRDO#`Q50-M/E82KR)RI%\6P*!)L12ITE3B7$6[=
M1RP!$47`&B&`N>Y7QC8D',,0LS&ETYY4'L4*.'FO&SOQ*JF,ZZ3A9?@D&:-2
M(70,4H`0?W*,T(Y';/),/MP\X-WD56[D=DEKH!UF7AP+>UF\EW^1D-#9+C?Y
M`L(\IFQ`--/5_;3DEF`J>S1_;"+;?5)PY0/1Q(LAE8ZH0%KNC@ZOO(HBA/L&
M;_XRL*UJIF0X669GHKF82].-X#B+)H`)#X!XBGB[5B!%8-W!9E[XB>[@W7FB
ML04,GA4;BA_041,&_D);-JL&YTT1SD&Y[\7TEXQ3<)YC!45(C*3EJ.Z7Y%VY
MND\2)\D_`P]3!3R^X?XS<0KEJP[5AI#1(F1VN=$];.<P@M_]Q3B,85>GBR6%
MBEHS&J00YU%D3U7$AE:@9B:\O*>63S\L)EC6T2^]M/ZS.AV/;X[C,>A70BRC
M:ZDGO$?[!@>-"2M=/!#@-1HM"S%@D=D$(V[9)=E[5GO%&2V3%C]W(TPAH153
M=70K4>?9@TX6[;;4G$;2LB:Y2$O/&]'..$$S.Y/=KW/G:3#9O'ZB.!_M4`S8
MS9\'>/WGHR#*G^+V?FS974YR5_%E/[9YQ]'A!FB#NAQ/4!%Y4!"$LO@7UH`Z
M@+I<;HT3;^%$9\8+*ZTH;LRRSU>$]1[-R:.P!"JX]6,W:QU@'"7%CL@=+;-1
M3XU[WXE6"1Q[:6!-9^(B%$@#?A#R@FJ9?1):R',4XNVY=I3`FG@*<0)G821/
M-?*0PW<-$V\Z%;!!N=O=#"^4^&#2E<`YT)LM!ZLD#X@9XGV#SH+D(1:A,)H-
M*BK'O*%)B`U@X]R#24]W_F*%9I*L#7UB8"I(7F9">ZS*%C&H!\[V7L!`([Y'
M<:TB*9!>(ED7&7`!&J^A#U9$9,W!DD/59J,!06K((=L6+]#-LR*IC1#VEK-P
M>C;&A3YUQ@1JS;@IE&8';P4)>UY%(#&3(,RYX[8;Z`P21@%:5EHJCV7YZUS?
M%D$"F79`/22%XMB5+:7C15>';:#ZR`(+4+B'7*N>>DK&=L1,ERH3;5:1%A@"
M1S('DH-+?9M6@#&O5''`2SPCCD^F9<G?EX?Y%2(7=?2<-#16-"#27]#S]^":
MY[!BKK&R//116/NP9/M>$=2GL"=)#CDEQQVU(\$FY$$_\M3H%'#Q6!WK%F3"
MD_)BDM>RY)"HNRAU(GQ\?Z'/MH8+00CQ6NPPT9_>>&]+CKF%`W@8"V`IIWH*
M;&BLM+7-FOL5FX/V,B//&`"5K_*.?N^>R;@CM8!%O!7'[+[Q'C=O?HS"&AW-
M^J\4]XU!NC+QN=0LI;9D%;:C4DR$%4SH4U+H,[$:BA";#1-)<29X&CNF9!QR
MEIDWN2%6H#C3``IY'<3)\9XZN"SP8(45GD!."-6+VC!"HO,:4UB4?OA$GCAO
M<H:L\''_N$>_!F&-%<#%ED!V:0M0!PC+3DG"*"Y8BK`XB`D;5<0>)ZI,A[9?
M)3`CS#&;;,IM1``%?&HU)O`4SE)V5U*23%'A(\@`O>5SV>:8$A694;7:LC&#
M7<E)!M8R+K?$^KN+HB%E00;97H:^[][+U-#@'@670",D_)SH`65'X?0]4OQE
M\H!HIG3\%0CE(Q?L^"#KK&@>E9$LJ_1DK61"?3P2G:Q&4(S-MCZ#,BM&YN4Q
M,1$?SQ0CU2)ZJ632HF/8R*@CBT'3W(04)&I5N6D"A@(4E;A,2!*)8HFW1IP4
MP"9'P?AVS4W4-I%A&'-P";+P78G;0Z8JJL^DUT3YJ1D5%BI2*>JLS.8AY[.1
MPPT>!GYE0#HE>@LNHOLH?$I$,G_QC+"LL\HAY+DFAT(A#7`L^BN&(0SAOV:;
M^OUKLZ,.(_S*T5@<K$(K\VLE2VPKLPPHN5_Y(TD4';RT@<6-*:SZ/&*O-)VQ
M[(XW]3`R7YJ?YA%1&]%VU@A2_MB,#$^RB69V&0*H6%E4R<XQ[8M\T`MMR6K<
MN%7+,QC#0&7<?QH*&Q]DZ\>`?"XL#Q,R]<ADQD1`,&$>,$T2$:FPIAVK/E%5
MR0B9UPQ8A9>0>T'C)V3KQ1FSHSM/2BE$`PLAQG'+!>OJGGU@K$AANP7U''F@
M:@(,NX"7S7[HH3I]>%,M/^0/C5`A&U9SB*=GV-?3P(:Y=\1]DV.L`['W(R\$
MB"\TJ@8JS<AL+N`8K`YG)',@R2S5A>,884TV("SD3&1D!HJXZAJZ1&2MJ>/1
ME7>,!G5F%"K<1]P/!E8U\+K1/1G2(K>W-A%+&5B81C(!9=T]A<U>8V(5"T<1
M^KE%9&KQ42!'0@F/G.!KE,X3SE.-$<2>'V!HE:H[@[)1.H0<,B7S`[49W>:&
MT7$!M)>;@\6+ADOH$Z8U\)QC48J_NQ&ZS56^=6BL.)C0E58B*E4*_4D4`ET5
M2XP\,<.L<H15)&XV(DPW%2NYQ"Z:8?4G?=K6KE0@_!X]IV=8%S+RJ![`'"]F
M`Y0V^1!N=2)!SD7@<SRYST5-3Z(_!)Z'P.1)%(X7B4I)FRU<'U>9O`36V?-D
M"I#;$BOUB73Y<^L&#MRI(^,$O5@OL[Q)$I2"[&:-9\+Q4W`[VK^6T02\=QL[
MNRW6&XW5S/\?>924:.(,V`S3'L/C;J`R@DTGU:)FI,^?!?]HV=`K+XGQQ50+
M4"9;O_F3B-<MCSNN]D*HS9C-0Y'UG0_M-'H2=X5QXG`U6+'YT!DW`Y28OR53
M]38T':@OR^G@RA:"'*S)XP4I18N&DH%3=3UKY(.;;1C^5Z<<J\7-A\!BB*U+
MS"J[N;2M49I0`">03C>0Y#_K-GZR<]?UJ\W.TOFM2H!(^2K:V$G8?8>^>Q\K
MO*8<=X4X&@9#E2*N0K='E[C-Y8LQ\-;&CFS"O"?@*F^&/D0M2;)?BH;.Q+`6
M$):7Z,926Z^NS/?/NSJ2'0/-W$DL4$QHU4_<42(KZHKZNF5X<214RGUCYJ39
MTN:O#(1W<ZEN<@Q&GK,))XM=_0OO4"VT$T"M%@VBB9FN#5HEG6*D1X0GK13T
MCR-]O7D'L:T1]^RLLWCY4J^"/JLT_->$J=3S]1\J+&"96KR:F@B;F5VP,`;3
M]E?H:7;%$T]AZD^,<5!\2JN3'[\A7\7S@&$N"BX\BA5>-O%L1BK%M%3FQ[A_
M5/1%)ZE>PYHXB_@_U.'E&*U"`]N8UA$95<=B`6;,$14JI,>1-5&,P*&L8T\I
M;G+EC<K"<"[![(B<29A!2S`>D6KT`VNSOX8^ZKM8H#]E-`KHDAE8)?!P,7U8
M_50/KKKT!7F%'6M1+B^$E5O!N=C!W''Q;Q>735)B\$<+'8+>;)8&RAC38$Z9
M2\`RVZJ4:,.^HGLF,7V@VMPS.I.7>+H8'YC,'>.R#7<E-?DK8'<X)8GL)30L
MX!U2#_`632QF0`E548XV5S$4-M&:Y<&,)DA0B>&QS%=<;BAJL2[5WM5R8D)I
MCE4%37^A;W6R.PJK!G,!E&)U.GJ2<ON4C`*=1YY/J64ZBJ%P'"\ZGJH'@GP3
MY81T;PP@K_P'ROG$LC%DW9WS/]F9=_"X(67)XPF7N+=HJ2F7!&4)&3A(VLPR
M-(Z3R1!")P[GYJ5DIKI>)/<F$=C&=Z0NG&J\$9I;5/N'O"RV(*R43B/QPE=@
M70S^)F91^D?&"\SW#Z-[)Q!A0#;,`J@O43*,#H^D4:/XP9M+<XZUFD3'=N3Y
M6P=^P)CA[,%G7...F_9/QLB39K,H9DH>9>E:D4)M,/I<5^$=/.-.MM,]J#O9
M+9)S40(W98.]AC9JMF8AI6>705A.E*`YHQ!/\U2C!;KS_?`I_F4CLV5W7.:,
M"NKT+S\@;W^P1G1HPGJUY"^98^&LX%Y]CN?.6'X6A#]YD^3A%VO0^"E/;Y[<
M/+4S)[KW@C/L.#./975CDTC]A=$V3/(H3))PEJ>D-_BIF$7&C^KV*C@_IEO2
MYS.>ORB6H?UO]!Y\P-#^_%S\G$QJC["Y:H#9&<^T/`YQ$J'IU@]5O1PH[_*%
M>I=S,`B?(F?^EQ_XW\JQ%K7+<WG\LR&J-816K+`S_OH7JS7_IF@X9$DV<74W
MDN5E`]^Q@+.24SW_[P;]'U)@$;[PP3*]K#3UEL1^)].QYEH8.>.O]Q%66ST;
MXSD1IF8,MM)T>E`K@OI!VV`CL5\]QN<(?^WIW@(964YOA:L_;L12<W3DH:TS
MO.$+#&_0MGO-[HX6\`X%Z_G+>$K_=Y#+>,5\;#S&EUK&^R6C>KWEZ'B)]=9L
M4BW)_2VX;?'^5>^;O>]\W]S5@CN`#6[O"^ZTP]58</W3#G?:X8Y[ARL]G1[1
MMG>G,"&VYRMYD:UHM>OD0/;,]0@]^%UUT&GOT_%S.%MMGKQ.!7F'NO_>807>
MK2SZFB/?WUH"@JQ)F(Y\M^:J7Y?2@_$PK<F`@S89NJV!W>D.]J1-=BVTAC;Y
MF:XSU2<QMO_\.8W/[AUG_HN\/_J"D6VI^]Z+QWX8IY%[!Z-XYX?CK[_]/__+
MLO[S_ST[>Y^_W!5HKGBYRT"E$3=B6R+:0U[1GYUQ(Q6=7HJG,=(7>OWB3O_R
MPQA]R8UVN_D#1NCQ=W\V&JT?K(D[]F:.'^-UZV_-?K\[[%0.1[3\<D-H-UNK
MAM!J=UO]WOI#N'.^61<4\V!;URHWZ(\PCJU+)XH6TS"B`EM5E,/[_+IZ&=_-
MO+K1C+0[0U`#Q?'4Z&_S0=K6>\S/@:7RC.'*)C8:=K/;W'38LM_G#/\VH=I@
M6#PJ1'6Q.1>HI8M@0NULQ(KA8%-.9/HNLB,!=OB>,Q(H5(&;+!GG'^)!SXT_
MJ_BS3<;3&[8&W5:K=$"EG>R%\!J:9=`"[=@9;$0X96S'2OCT,T7"^5%^\GF<
M[K0&0+-);WG;.Z6S!F.;K2'\_WIT1M``QTF)<C<E!.IGBLQK-II)6(^-K6YO
MV.EFR%,M;X^DMB*I74<]MMO=W@J2WEW<7EU:%Y_?6^^O_OCS[L-[ZX_KVUOK
MYL,7Z_+ZTZ?KS];M7R^^?+#>8+%D3)"-"*>3$7#>YHG_X$28L!7?N-$M/O#.
MB;TQZ);WGI\F7#>Y/HO;YGA:/_QVUCAO&F;'BKX.9(1+9ZQLA-WU1RB?L^!!
MBYZTK9L0S*V%]0_Q+UJ6%IF6_]^J$?$;RA1=.6>_+3T;K`J]JXRS>QEL'G]/
M\.UD3B@IHV."Q'%7^0/-YJ\633GN79:?>0-QWA#C(Q5AT<`MC_*QU*-.DD3>
M*$TD?+;$R1'AN!S2XT[.'#CM('!#D%(0E0"#4.7;K3!-,/IW8N8"<MBR&<HM
MQ;^$TLB=8L9<O'FW<S^-!32FS+7EZ'VN#PT]4S*("SN`)RL`H]1&#G;+^9$<
M9A_0T4YP)%>FGO):'5D>@O/(P$#"1-;8>J/S33$Q(L8RU'&"RX,3AM_RJ89I
M)S!7[`0+W'+0+G,L5MCCB&:$U3`Q7I[CQ>60.(5JA'9EXIW)T97Q.L=G54R;
M$)`$A"I7/<U'$G,9YV9;Y/%1TMQ"$B#*V-C=3L]NMOO&>`6CNG9GV+1!L658
M-;3[W29&E6BF43=VN]>PA[U!L9V.W>\7VQDT>]!*2[5B2P`,X(*_*(2+%T_7
M*_29UII*A(`+#X1I1IG8_#?AHQ"$&^5MX!^8U_B(16>2POF.V[J>?A`M?8&&
MKH-+>`O4-?[S0;_[/#OC#)YM=0Q+?YVN#V_L:QDT()'M9P[\1B'5<(:]H64>
M0SKHF6KD"61RY$XI\1B1=QW&2.,T!\SB\1=D-CRDP01,?%AP;\]NTU$,W$(K
M]P,E+O[C$X6G%O==2BS[1.KC2N7*7C\%G)ZA*2T1F&ZC]T_=$?5SMYB[%]^\
M./\]]YYE;,=D+.S@C7/3ZJA+EV+J1\>+K+\Y?NKBF2"=\6JVK0_?<-V"_OE;
MB-ER>`ZS<);.+EGS7OH.:+!WFD,J`08V*P-(*Z[D(?9,'1O]REYUIU](M)>O
MNG_^X=X[_@=,M%L0&R4M.5*8D'_2H1GY0F.XGM[B7D#O\=CHZW<K>=]!WO>&
M/>.@6W](F_/_[T*W-G?!V'9CV!KRDFXV&LTEK%)DU.-3OV\N_RWRZ8L7?[4^
MXJYY1=!T<;(',<5.L4_9Y8$+::.QBOEE`]J8]9M):"V>[DP^89)6K..-6*16
M\9T;S?:C.K&GEY3%WV[:_UUOI2.E:W+P><JOE#6;B]1O-]V=C/0]G@<13FQ_
M^ZWL\G`5&9B0C7K,-L>R*=.?)V=+N;D+%;8]YH!=_9$!8>"@?A7$290*I)?Z
M3BG5__54M64T)1HXN:9VX)JBF7R4,SE5,^EI]E?[JS"E?YII0/B=,B@#(FT<
M3Y>^OA.QA:OFWRFBM%&]N]+>13K^QXO;=]8]9K<C^$,$"B5B1")UG1YC[G.:
MY`@J;=-F9/QO#'2+;I0QWI$1I)$HNX2Y^R[!#,NJ;6.NPTM/88%/QCM`*%B,
MZV+$`L<G\N('URTI8U3T7M02?+7JP)#`XL.4/"UN8]+8G:8^P745%A46NW#_
M0$@5_2+=G_Q)+_V!$%\KU]1-LV%N637:K$MNOAC,QS`B@2JIGU2I4K<PQ']6
M-Q*_6WQR_A5&I&=)P>*&!30+DH%B3>SU%$DM-VFVR+6+R2.*F"A.>Z?18!"H
MQF;HC__R(A!:`V#CZG`X*.E'\C7U0/S?@7(B7--]I;C9VI405K%3`/\</MNV
MP")^^(R>M@Q^R1O?WZ,P+O@!EQ!/SV]R.=WM])O#87-09QS<RY['4./B>H=C
MN!B/TUG*53,N#%B0-89E-&&VL%'H0[?9'+3;M<99T>TACKR&F`X'_>&@W=S+
MR#\7XUB6]`9/;S*5G5ZK,6@,NK5&!'WLD?HZ(2V=0:?1&/37ISZ,7##E+8[_
MPQ.*X?7_'8'EWN#%[5M;W@K<.=\*P^$V9!-&"]@`OOZ.WL4PLV?=!#4;K:;I
M;ZK?[\&,=ZW;GU9SV._O;KQ\'*$O)`3S&L?52F+BBV!B-GJ*KMC'$5;,\UC.
M<Z)GP,+"XS37EW!ZB]P'K,F-%6)P>S>.LMDS+I7X@&-@Y'$Q>SZIJMI#%%PI
M06$)K$W44\)H3DF$%^=+?6+-5A%S9%<<BBEP09*/)>XH#F&.%C&<*2?9^ULB
M35SCB\JN=<ZEA(!H1AB(,&@F1L2IQ?HR>(H08N6$(7R<<9"6X1Z6#/?(7C=7
MQY-\<6,$5\>0"V/JG`D"DNE2\Y&+..=<C=7AFC>!A*TS#`3F^C@SW5Z`Q04D
MT&X=+IGD?:P;:Z%"+>Q<_R1NHB8.`>A5"RP]RL"6';L[;%";),7T96=@=]K]
M;)@$/9(&D>MP01?51,ON=1LX:@87S,;</+A^%F/1*<&A.Q<(OJIMI.1GZD#!
M7W/C*AHF/S<EG!BY8T<`FL:N?%/$[%!A':KN-'.BKRY'-`F0:7%;OR`L33U!
M^*;SZ'@^/8MBAFB=YQO-6_G<B$T2B9<@^.P9DD#A*%X_OQ&+YZUMT$;^)`;<
M1JQ2V,6Y?G>K:<,.MW:\R\9[C]H6*1A-()JRA^P;K2G41_F=3FZNU\$M/'T]
MO1$@Z#=8E!A#!QA?]GDQ+H.NF9Q1K\M]CF8MN^6LV6VU-Q[-[U0@PB<)N9A@
MD8`XP4#^1Y?N'4H"B,4;,/?9Y\7CSYN:=J_7;_:-D\Z*WO8XCK4FI=UI]IIF
MO';=<12\1P6RPW""*+G04OZH<;+]]F#[%2:H^K*B\"@[2Z=T6-1.P4>Q%0G@
M530HL-8DI@_-A.EC/AE09<.RAI&MHG'=*E:WT"UCO0L0/-Q"R+Z"3KA8O.]B
M/2]&O_:Y4(4WFSM>5$"['X,.X?**9Z):0775J"*A--#Q6&Q15`;'+/3Z].`*
M$]9=@'5'#XO^".@[$J4X^&LN0,@HPB,T$-V8H88==0=$&-B3D-B`>ST!&[O&
M\YG24P@N[>@!%BN7+NF630MCF(9IP?5P]?R<^>3``"9@:2XR$&=SWY4PRLX(
M&!DJB&2!A!QB;H4[J>8V6.8PSZ+\&!+@S$GT_T=8L`%3EZO4X,C:X)F)BR5)
MKIWO7XJ<#"2>($SUQ,J,C!KE8@W8],B4[I&#AC!;QEYDF".5(I_P-,ZIZ@;>
MCN5*AOTU?`+:(YO'L7P"BZ)34U"L-S*"FR_GRAK1A03>HM5&DA[Q!:*"2!?2
MCP(?I3Z?J2YN+ZU!HWO6;8@X\>+",:H7UUEY;XPJ`5<W7^@3_O?>K`Y`4B),
MR(G`Y];C6@JC7;03ZV],>M/F..XOA!J.IK0M7"<%)QX_J1]\1FYNMSULFZF,
M%4WOD,@Z=E"[TU^/2+1*P=:;>B5DP6_\T_.,LR$0U3)M,]WPLPE9R[KJM)O]
M5F<Y(5=J]T*-^MZ+YV',=>G_"(-[X4&6;N/ZGCC=['4D&[V>8I/4XLD0VY\A
M9DSP%`[*,*EB[V&%6>EK*XL8*;QN5IXK*&-;>(<>/?=)6#':6*)-R"4+[E%6
M]Y)Y#[@C>=$XG6%6P)B^P(KDB:C541(7(LT=[)?*5E"U,G0`HIF&#BKT?`%I
MA5W=)$ET@W2J0!-=;YW+>F``"U*BVN2`;BSJ1K:`$WFQKLQ00J91L"$)96)2
M&F"\C##W,'O+\/"Y,K"-S2-9JU#5*>'&<@,S>J$\-1JDK!AE#!F'<1^0P>%A
M,6K,#3*:9JKADRYOEQ\2IE*Y$][NM662#?8QR5RY0VZB.RK<#EP'UST+IU/*
MLI'G^B7J*M_17UU_@O$DSSWJ9MT/M3I\D4&MM=5E/43K#>J*7;]\M<4FX66H
MZAT*H(10I_Z(Y^^<;RY%>R:1$V*H&183NDK<F4B!QX3#T*<:+3*^N\`8:@G[
M_0B]ZDYUGWQGQ<]1AYGNJ+=L7RIL_GD^JD&G,>B:_I`=DOJ=3<2:Z7W-1K_?
MZ/9?9";PCE:ZU]Z\XV(^A0QXU8]X4CSWW'$CA$VKEQ]VH9N=DKS6FFEL0NM:
MIJQL]62N[L5O2'.4X/I9:9M*)P&7OO+,5TN\"K]?7-R`O4->#Q%MS%:-*@=F
M%IU5)DOF*G@A$LUMSAC'E'\3Z(9?`%KT\X)$>8DI?%Z./Q:WHL*>+=X$BZM<
MB=5".#K.$[NM<K?,INWW-[)/Z9H6:TSI/D'1./*ZFAQ`@8N^$=3:LMBO6S*:
MF!_VR-E%Q7]][RO>;=+U.9K97#]/UR2+L&?)PM(&T9`6!KJ\O\P7I,N&E5,1
M.C5->),I[%;J$:\1XX?0G\@:SFS%<E$X@;^@;[EUX'DL\S4RK6$;9@LX$*"=
M8&YH&TR<KRX-,V>8\_<H>/1"Y()E'Q2OJ\-856B+Q9O:"+?%R[(W:Y;&Q"?D
M_!ES_@PY?X;\B^%'!X:#1RYR2[G?G)FL28XFO/.-#/44>N5DZCPY?+>:+4<\
M]7R$<8"3#$HA!4=,W8FZ-B*N&8M-##0FI[DJYP@"DCDWP=,C+W!+B\?2@*/P
MT8N5_['D\&F2+IM6C(MQG44I>3.%`8"TPC;@^!2_8?@%\=)<'7JP;S4;3FR.
M2WC\;.M!^DV#4*4A"*<[]ZD"*+CN-8I,!1EE5_D:!R)[Y5P<+LX,ET4L8;]G
M!+.8\_4()](PC<6\D3(C>#,JER@NU?^5PJD5SKXDX&;/XC[.7^AC,*@!X`-Z
M`J@*O2H7GN&<$D,J/#C#F.D2:23&80%U95L"&QJ9:Q0LZJGA1LQV\90O;ORM
M?Z=X\@P#!0[BS609;'WPGLAZYGP+`?KO6QKS7!'E\"3B#PAVX3@R;)&50^>@
MV]6>8G+;7LIBJ;_-T7UR`N>>M<PD=&/2B:Q4M*,C0;Q88Q35TDOK#$_?$4,B
MB!`?NB43XTVL`!<A1UP\H^;C-BV++=1\W&;E8[UC&0)M5-0TXJJ`QS\V;;"8
MJ=#M$Y=*YDBH-5!@H$V!C9-ON=EM&BTK_64N[A^;PT'9,RR)9`IEEM.:HVO;
MK4&C>G2X=,6HS/)O8E>I&EC+'C0:*P?6&90^4S&PSV%F)`\.7KFY@289)B),
M[Q^L4D/VN4)SZ\X3,?H&CSYKKLJP*F$3H7\O5)"6&+M$QAQ9>M*&0<>E]5BT
MY?30:,><H.6TVJ-6<811)Z-KNDU&G4YU?LW(QY+C$"((N3#A].]50"]KY#\#
M7O&YA]%!M]_,'L%K=[WWH:WGZ.D/&KUG#DR^9+V1K[VE.U)Y)-*W8*O'*5_2
M[SP3AK'3Z327C:_8X4N-:ZUY&[2&S:7SMF1<:@!@)7*=75SHPH)<2RIE2S?<
M$`9+<3-;7'JM?@^.W76&NHR*0QG\FI&">$$^W-K8*P3Z)H(CEC=1;C/D""NK
MB]*(MB(5H@4);2L:`F*H&6[EF7&&_6[+O$'>C(8#Y<1Z:2^==G\XV#4G$.@K
M2,*HUDHP'GZFP+>&@Z5+W>AI;R-82TZ[_<%PJ9B6CR"7%V?I$@#6/Y9ZA+-Q
M.R65`P[2.;RK*L2=\V(,9\EA3OXYBJR?\[;JRYWWDC)O3,EIIB1&LS3$E(S[
MJ8SC8^N=G$64;N%13!\?`Z8A&O5P!/AE`V9Q^L78]7U180/7`7V.Y\Y8?LZ5
MB6\T?LJS;6-)V[A*UX9%>$K$X*Q_WMI$$&9.=.\%9]CB+Y;91GW?Q.95NDYE
MS(L*)+L":^J%71/U)@V<=.(E[N3M/BMM;;E4TTD&:TZWJ?(/1`*5(^F016_K
MI8G[O<TKM;W$)K'2]/G.RAD?3)&VHZGGV.W8_>;0'C9W583M90INGB3Z)-%'
M*-$[JD2<*W!X;+N<B?1DGFVW=S`ZI$JFZY8O/C1"#[K@Z)NA/>C#?^WF/HW;
MPRP_N^)H>5H_I_537#\#NXL5P-LO70'\P-?/C@J+O[;C*M7DW(H:JLFQ`RY(
M?K0G@ZT5)#^`PT.G8P\Z#;LQZ.])O[V<W!X.):<5])I64,]N-0:P@KJO9`49
M6_G/=/.YE_ON0XQ/5IE/`B=&I@/DKZ'O9>`^QW\[@9&;S3B/>`W=;(CP>PPQ
MM1!L"\7:\C%(?.3$WO*DBPF%/_?Z]G`XX*#=7J=E=_MM2H(Q+\!%*H5(C,B1
M.DDC%;>_!B#@FOA\-8(VJB-#;.LRC('4*QFDFX36%^#P$Z8!??B6`*GKI11F
M:3%PD?EEZDUV=A=25]<1=W20H25'GW=XXR2,01,OP\1@*3!`GB@))!QA%A8!
MPE(KM)SF48CI)H1KD>AJ$`)\R)UD084<M6(Y,C(+S:>P7SD53\A%-F7.BTW(
M)(]!-'+9*BJ?#HB;I?Z]B2*A:P5=Z&9NL2JG$TUBZUT(_UAO\$D#,@FS]#)(
M2;K^R[W`.:+Q2#3.W-+?8-FNM526%9L(BA#H)9CD'[X)=!,)V[0=(/0Z/>V#
M^(TPZ-<EGO/@%`;KSYQY4C4(>IH3%D0(93G\_%I`INU!)CJPO)-=T[Q63.:P
MTUZ#8JRS:U$,K;&9BFV>4Z.K`!CX^QM\]7E(()U^JT@PMKM;(C?'"BBA4$:)
M+M;;S,5+)WR`O>`#"&XO`XG74<6XR5+*F$JT]\,G6>@^IE1]1K,V-U/<4B0V
M@,(&EXF_1BZ:S+4$DGT'SH^,.X_V]H/K@$$(F_#$Q:0C,*<GG!@.`X5=OI@7
M%XO4]"C&Z;'%7U@US40H_'CU\3JSW3(80:UMM%Q(RT0?MUA""4!ESL5"D%]?
M7)B7Q[*P;O&F?(]>@Y>NI_*53?:=9J_;[S=+1E#=S0L-IDX^5*O=ZW6?.9CZ
MX>GBA<./2\<Z`MYTL<,0NG.E#A9KG=]?L^^`"@S\"#)I@U"*-.)>UX;EQ@=T
M*6]<I9&7CS[.!-`N9KDGY'D8A]$\)*`(U'G_3IT(%!Z#M?K.S)TX<'3&.I)A
M%'@.OE0OVKX*"4$M9SQ>Q`956(*A90];;0ZVES44'-"K'AQ<$!)Y87%9J1A8
M+;!!:E&SCGI=[E40#U4NV`T++8%RZ0X&)=1DC=I->J^CJ/N#7C;YIJ3W/\SZ
MHA6XL,8SSX"$[<)YI6<"=Q6;W395-9C4&W;[0Q.IMBY5.@=X"6'ZH4TXUAOV
MNHUF.<=TR[LAKU8]N\:PVQIN0!XMYP]4H60)=1?!A`HU(X`0J"Y^?B/)ZP\[
MP\&P6TII:2^[)KH.S'._WQKVN^62N8IH+F(Z=8MVE/@M%B6,GIE-/NQT&QV3
MPDSC6R%HS;(5PT&K!D$Y&,2J`^XG+T!`G,42[,+5/.HU6YBTK8G*M[IUJFI(
M5ZO?Z36[W78-JJ1Q<OT$!Z3XP9M;;\"(>$B#2>1.DH?X[1G61OWDS*W;L><B
MJIEM_9%,JDO!YGM2#=^X$69N./?NN\6-4ZTU__F'>^_X'X($&J%:KTC`S)G+
M_J'WBG+NWV+OE\#SP;:+4O<'RYO\Y0>$?SP#;OV\QH`_W'+U6QH!PQXYOG63
MN.=['_J'&"G)$`)T5',@:R%43_\2RM9@U'4$Q^#+!1BAE\(<Q4NG_7&'^A]#
M_T;W!\$8$I]+/#!^=M,HC%]JY2`=2$:&BCK2T_[AM\9YK]7=-:.*NF5IF>F=
MZQ9=0'H%;_KMUMYX$_JI@$\#\EZ`-[+_:N94*=[6>HKW&C;(EU0GT/VZVH2%
M8=E.NQUA4%"1\"A>ZCES%R9E'.^1/9*$'`4U6=1<8B)MAT7RB8O8<T#3>C/,
M(=XC?Y`OT#]V+SI?R9H6LF:P\^WHBTNKZLZ8M;TKVB\N+BV3A-JZ=M@9/(]#
MZ&&A6[`;@=V&+JHW?\9T._"6/)4QW;M?H.NK%!`)FL`69`/O%O@VXYO0J_K-
M9V+"=+N-;M>0B/H='\APU[LB[L+9J3G8Y7!%@,4FPU6O;FNX>%8<=,Q+_?H]
M'\AXURN^T6["_[=7S^^J\5*57(DI31`L22@#XUB5E0Q1EPYX+FI@OSEL]=J9
M4>C&=TKHF@$7C>$0GJQ#Z!()NE88F6M+D'IU:PJBV6AW^ZW^:HU8TO6!#'A-
M86NTFKU!Z]GC94GT$1%9B&$0!F=U/%`9H;DP9/DNW$W1CUYKF'&$KTW`P0Q\
MO:GN#8:MW$QO/.XG,WX09"6`O\>RWD+]J!IH2+>3;89?/D7;["':Y@/!^>/M
M:N2B4>LO+"^.4X%2K+YS)N&<0FSTS,\S4V9E(G3,XK]HB+NB`F^Q$]U>K")1
M1>R,J-F[<(VB`^(W>1`9N;[G8L0&EU@UH-&Q`-I8%)(+<7Y0`^/5,*:"<OVR
M8I6(.N&JZXJMZ937D-"R(I.(]"L4TC$?SL0$/A<'<M!K&\?CRFYV3?5::KO7
MZ`_6(EKOLN*7PAZKGI`//-?:;O1;W9YA#A4ZV"IQZT$:#YK-7KN]'FV9DF&5
M!&[-G&R"]=X?=,J(++$JMTCFFM7;VGTP>X<UJ8SNG4#DQV!ZB=0]L@3-#9>?
M=&3I9!V??ZL4DAD1AN_<PM[C3;VQ`UN#N0NCSD&#<%G4F$E/AIJ+8&+2<CU5
ME&A"-!UX9:RI,'2AH.%0-^R=1Z(USZWLE+_#_"J<69.['$)ZF\YF#@=@W;H^
M[L`K9O:[#VW;FT4D"N)D(XY-@\8HD^-8(R\T<G\P'<<)%I8;W#OW'!&</(5H
MRG!9('AZYF(%6C];L%Q$N9F%R\]E/_^!07`>2<LT'*>QR/SA:&(,@B/;3=2,
M11.)>O`"]U<+(^Q(IM`B>DAGF",X&T6+,/#&P$=WEHD]?OAPFPD]1JA9`8&+
ME<.`2C^-/*[54WS;NREY6[/&#/'[4D8MC&&*<85PB&*?/ZJSD4-HN@%WEVM2
ME"6+L`091OQQR';DCE(/N**H3\C4M*9@II&F]3$J?)+2<6UB4C+Q8H*[ID2%
M?Z51AF9@#O/BYI8Q>&5U#JY&%M#T`H/3*9B=G/R`%:46@NC%W)63QO,P"B<+
M)@_-8ZJ,%#^$3QR]..%*QI3$Y<6ZL)E9UQX1B*T@I3A&^!LS%8V[$A4W69;>
M2>.`O25.1]"7YU`<_=P'JH@EU(?!<16"B61DQ-;L,(TSE9>K;I'$;8`I.?F"
M820^SIBJ^%$?!BTBH10&_+L+MG?F^LYLDW[--$C"HDJKI.R0L3+/40%LG&CJ
M*C-2D_/`C_O(F<55TY+A%\]VYAY-+EX)#LW+./X%YC"-2+)M"\_@XB^,/)CC
M(HEYZW@`JA*LONQ+HV"V",>8DP=:Q0NF0#.RPYR,TMM.DUWR@0S'*+F!1B:.
M>SPJFGBY"%%R4&@\YS[`LG=C3#Z,S+XK0UPX0L&DXL/ME4D`5LJ[A:Z=.:X.
MT(&/&(3LB]LVH6J9)V65S*$UZ]W5-=`FRLZAIN!4$!R/FF=,A8Y%W3LI9C(%
M1,F`&CU,W@1T>(PB+W-!SE!OB*8S"ZX\:B7#>/G$$LYK=8BZ$;:2Q!`*U%J$
M:P#2(128Q"W'VF;9&DK5MW,F325/K4>=0R76W(3,&Y+,\-&)L1QF)+P*S%TP
M*1_<678,6**0%WJ%WA$U,WF6Q%*D4G#E>TU%?$Q1^"H>S(\<%O-5'#FN?\9[
M4_G^3QLU[UP&JY1\B7<UZWB$()<B.UAJ`K(4#.YPKI+,K,OI'=G`W+NGK]RY
M!T_YJ!9XQU(ERW"6Y%LSAR=&;X721E6/\9NSU$^\.1:.'/N@-7/0`17A-2:'
M\X]D\YQX]:!IAJ22SL7T:*KL&9<7]=J5]7>)7JBL/PL^Q.E<]HXJX^Q!'`":
MF99B."SZ"!F=1\$@NS@)YQGCNM]AXQK:QF^Y:J'O.C3%O'7@K&"U6`=EAE/'
M`W(KWT>TB-1/<8I)&[3-J92V[XEM>QNKE&,\$J/Z7[S$F/6\PQK61KVA$NS,
M?F;8,J6'!5[RGQS?H6FT#5-5VL6RQ[*JDO+/@ZK\81S42"%3P5!=Q7A*1K`[
M!>66U#Q266%0T+QD.3@^380S>40#:"(X5V)#%ZTG7+!C/!&X;)6.%FJZ\#P$
MOZ8!T!#%.GE`@BV`%9+(@#ULA78?SU6#@<U)[&/T&GR</S@1:'S:U<E<G*2H
M9%UA6Z)I06WKIH@^>=8IVD.PZ>>Z13-0MVON$3?FAH[TJ>98^QN0-H(A,99\
M1F`+S).%&4%X6LQ;>_/Q_<5;SJY]Q+*L1'OD&H<ILC&X2G$`?9Q19<`1RH`;
MP_EACE*`KCY/8F[0*`3P2_E!ZLBD?AZYCUCGUC<A249^&.)!W@'E8SV&?CHC
M[!'@'\F:89P95@U.5TJS"IM,=.]BUJT[<^&O8`RG\,@!83>,"BVA,$&@=IU"
MS>$R<UW?,D2<8Q&+&Z`G(#]"-!#A!@'F6%,X&(/ACCD9=(!RQ<*`]8>ZE+_$
M9U#*M,TORO+D#1&M2^5DV_QV%"YD56>J$)_IST@3IS.J4`&H4\KY*UNW][=5
M_=4EE)27V935!$C6E!KTO'B9W5(=@&D39$Y2Q[+VL*Z]*BI3=?%(,0$>:"/8
M;%$UQP\NZ+ZRNN&\"]=N4-]C8E-B09EUK2/W`27XT>7(A=HEC`U,+N'VV92H
M,8;&3/WP:9/>K0?GT96E<5W6UJ-%J3:9Z;K;B,HPQAK!&B4)N\7=,Q+5PEG\
M/H:P130;9_\_ZO`+[S9H*=R>_5]3>UWQYHIG.F%'Z-YL#`<!-827#3SH-^31
MXRC(,/#I3!Q`3^0"QM1&LDKT"V]AOP*=%*._%U3+G*\.T-\3^0MAHLA[HGF(
M1@&>U^`I.)[EYIUGRV!Y,1U:<W3F3-PLWI2K/V5FMDQN"RG5["5@O:T4P24?
MCS,SY01!BJ=>(4UEM_*B#[)$D(0<F>6#7T>^1*2!9#SN,*`<:.=Z5#6=S0V*
M^P,E!5;AG*,)1&]4U9FJ9L-KV/K1V`V7H.0=#\^64Q1/=4TY#<,$N$/^<7$%
M&`L))C[147/"8&0KPBOTLBU9E-KX@U_<8K0)](3NA]B06:UZ@/OAS$L2!EJ;
M(R)+DDAC6B[D6$[E+2X\(Q?WV_C!">Y)/F=>'.>==+<?+C.^"O<;TB>G_#FK
M1&+08`GTS&I9MARR[BV>-,/8FZ:10%"0@#::8:!QP#2)/3CE3-ATI\GF"9@;
MMY0QZ0,3QDGF=S.<4X:(JP17>YS>W[LQ640/C,035\;>R,VA5$A&N*(=*5'_
MDO<V2G/G-,9JJ2./6B@@>"(7QFU*;=GV(;>"_U+KFI8T:X_5\!$O<T'ZG=[7
MWFC-0)A/1F##RCO<S*2O%B0A-BR%LMZUL/G-R[3\!J6O>CA0&\ZH>.<?EQ^$
M9)H).O1AP6*T'`EA%*;W#V!#T`WEC&X,C3YMM4^E"872D<<9COMN!8G50B*0
MYL'`!XE`@1!?2"S@MCG'R\N7,N:RJEQ:HY)I#J49/2_I#.-JW5]%:P("/_/+
M%NN?REYH^&7=1WQ6,G\R:J;*<<@C5;L]_V;\/EE[G"6%+,1HVXT2M&4\EF6&
M4/)^C8$<8'S)KHLQWLKE4<"1RF)J;V\".\/SX>`TAUN<PX_2??M.N/KV-97-
MQGFSM?>IW#4[I2_Q0&9796#N:U9A?6YE3HL/?,^+]!(-IZ5:MJJPSQ9F=G4-
M@^/>5I<'7NU\X:QF[]%O>E^4YSI_#3@.9S,WPE.#+(L`.U$A`LSP@^-17UT2
MQA;'5HH$%N,^,N8(OSK181QN@S\>P%0?]Z9(_?2;Y[V?#H"5+[<3;96=?]Y>
M'(S:SQ6W.VZUOS3,\B7D-\?=H]?ZM\OCH<W8O+'O!11><1^A$U5'F>X_B8-I
M=2=62C?0X]\_W1R`,+R"?0$]30?`R5>R+:@P[X/9'%[5F:`L_O\`;)JCWQ,N
M*=M!9C]0H/S+<_45*-=^][Q],KI/1O>AK__2_)X#L`J.7K%>9_*;**DI8V`_
M1!3MCIS`>E,<J`(:V`T=>!-#.UY$$Y_,W).9>RR*^%49N,NR_`[`CCAZ?7QQ
M[Y[)>/>RA,'].S8VC';:2M^?"IF0W]?X;YSHJQ?$N<1YL5$?P')[!?MNKW7>
M/9V`ML9.3MD^F+WW51V"*D$%#L!N//J-]V\2-Z$4!""+K:!V:./()!$6,`[;
M$TDA"HM!0D1\7[N7NL@YDQ'W;C`))5*"OD-7;))L1;`)-_"2,#+P%/3]SR1*
M$82",GU4GI1&T'CYQ?`*ML5AYWQP.H^^Q'DT'];<W$%8\VL_I9:6#3D`(^_H
M=\D5=_,'P.)7H'L'S=.!9&O,_&L(YMM_P?^<SB2[4`CE:%0'8#@<O:I%H">@
M7('-V3GD/`FE<3)XMW,3WCYOG0S>@[R`J1[K=VO@EM?OW41\=\+<HU>^MP4U
M>S"\?06Z]DWS[<&P\Y7HVRW[W;?#ZG4MW2JY+*^:>[Y?N=G`OJP:SZ=PY/DN
MXDO[R0-T.4V>'!&1N]EPRL1J/U9=U1#E$C^D\:Q>ZLO7LK1I2A?5SP3#4&N'
MR@"!G+7ZFR"!"*`(YH;11(VDT,VN!+0'DN`F5F%,$/K-7WYX?WOS\0\O3N[P
M)84\L44,B1^6*371SV8<+K"S5'#$WR0XJR6_*`N"1"=-PAV1N,1>I!-EA7(E
MK*ZGA]#W%V<(E#+)%C$(IQ5`U'57R#$`=5V`_2<KG3&2DH0=5Y@T#-_M!+$C
M`.XT!)2+`/J!0&'*PN7D86MJ("L1,#_!1I6#>I4C>)5`?8ETUS_/;[.@X;]?
M7-QDP+=P:!H*2C?/V*4$[DL0;50^0N$.WGZX7(+H=U&*O2C=]1DVR/1JNQQ,
M7V9:V!K[W\9*!'85$+WN)EM,W.2!^42V0$)1V#-K)[>L%-X0B$/,_(,=WTL6
M`@H,:S[BUUYD@-T1!)R:>RR'%2M,R;DL.R7!B1!ER,`ODF"10::DI"J*B:AA
M`@J)<=L<D/NY@[CF(*:N1*C'J<1:`N50714(8QGXM:5H1X=UQ7WT<%P2D2XV
MZEE%7OR5)09K)=+OB8P[P$;PO0P\UYW&6Q2P?4MKUSB,A?4OK*,%HFS6Q<%R
M/&%DP&P[7/`R+^8:T]$4=Q4V86J+VQ34A&Q70H*-TD3A2,H2)4EH9RN]_")1
MKR5<I<H435"92WQ"CZZNYJ+B90ER`%=]$86D)NZC-Z;**Q.2_?A7T8:QN,,1
MS<G']Q<"TC$"^RLP$;4EEC8^+="XEU)20H$D;BDELKP0UBLJP:>OQ$G_E0!L
MW81F@X$3U+.Z[)(H6TJPX6$$&QY.K8%^O<C#FQ.%N#4)B/2).Q,,$J3+3JJ9
MBN:F2+>>JH+H4O,A[#A-*V[/,0F.>H9$<N8L$/"0VW(G)=T$[GV8>*@3I\YC
MR(6A-!0U`E_2D+*UIVAZ%.ZU<Q^YKJ[D01#5YK@LY]'Q?-DGHL4%\,;$HS=D
MJ:0\/^00\^^":,U&:12S_I;XB6.LNJ7$NQ0-HRA2L?4F`TDN(<;?L@#<8_6%
M@+H1AU9G`K8-E@T1\*4I[,$,]&FK`D+B42K=X-P3$#`(3B3V3F9F:-3Q.Q[D
M][WI^#]%V8DX\=`07:'(&?15X:&L48Y76*@(48K"168?&H32O,O@/)/B^NIJ
MJA@1/H[3V9RW$:X7I_2_,!<-H%1<IUQ@C/'>6:HE3*S&OQ7#P+5%T"\5[W`O
M.#R)S;C.V.7Z*J-20^3#0ZZL$FN@M6I+F/%:,]8N*`DN0$C;T)A*)T\\X$LD
MH9JQAH/BXPG>]"77VA>>:H3N#>\#KQ:L*>UO/I6VP"6#AY_;!`3?+"SZ+O5]
MW!VL^]3C`UL82+DR.\O4#Z-Z"`LM?@+;W`#W%S43%M;<6130BO^@;<O%^@G%
M-G1U!V@-S;MQY,T5"K59V4%22<(:IA'BJGM&E22S@K@8R?_0D0`77CJG<2JC
M)M,3;%9F1R58Q]>T/_AZ(+&$UA!VK_S)V'.?W"PA8IW"@*$_T0<7(0$C*%"E
MUYT8C(H1\(-7(NS[Q;GPJABH2U>(-K&(IB-`<O<FO"]8?T+5A#$8[\1*=H2_
MX=^I`[H50Z&%S)#R5&(^I])`HA4W"V8O)AK.]["WH5#`]K*D469^$H9?L3S(
M.#.7?\>Y-ZH5(0A8XLMZIM0QR.T9=`US!H=I.#2#T!4MP1@.'ABQ3&(Y!QLL
M=7AC-(21I97I,MT!02BVM%1(/J'`DUX8`==E10$ZS[AN7,U:54_'QX,]KBHZ
MYBMIQAT9C,O*\8L!QSL=\2240/)K#WJ"=6KE20/V9!!-9$"$R@?7WJ/+%J_9
M6G$3OII6/(3')SQ$,@IZ5@6`%:#]1;+K.,<?(E11X7M3T_H`RWB,!:42S^?C
M2()-2<#V"G*0EAD752H29`[JDP<RGB!"M=3^MN71V<<VR^60[RM!YP`!6^,I
MCXQ^9_S@@0QIUZ(A7U28@&J]DW1171_5&]9E'/.>1\#WT.<;YRVI]@2+-,`T
M<YDO`MH7QB.1(KK,MF=;;T9O^6Q#)I?DWRP_/#PU@WK-B#=A`.*1`LT^Y:@4
MW9.I-L%91.%Y,WYK+A/1BVR[?-58OV-M',D+:2/*"CLEY^A*#6AL.-D:H6(5
M%\KWE#>N=QV93E%X\6$QP=0)/U]E=5EIK9-W;C?>.2P&HZK"X$)XA$F"]5;'
MIN3*U#&5N'F`#1OFW/>@"5R=H+!%P1O0PN,',K7X!@"M*N^>*I."PL"Z&PL6
M=:,L"Z@!'^NRP8H<N07:3@?PPA60O.CAS9+T/FU'Z&@D[8U^ETF8CI)IZJM[
MH8(=5B#VN829DF/>)H4).3F=B6N0'`O]*E0Q>B"_T:8"@O5CK]&P.XT&#6OW
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MG[E1YO8/MA7M*9]AI27DEO:G9<QXFGA'54<=B^JY(R?X&J7S9+R`%_&"DO:C
MB8L7O;)FNWREC(;B)1*\7BS29I8S5'_!,6#L1>-TAH;J.%M54G8&)WPJ3V4;
MKDUA*R+KT(UM>M_U!#^19V^$1<DBKL=)9>9<$9)K+NZ3];47ZRL,,&[,N-8<
MXS4+7Y!66V`?E2QQT4*VL[@PKX$8+F]`Y1K"DY:QHL?+.B]W(HVKK,4R-4:W
MGG'NV"2Z`'6A'>?8EKB>C_%*;H;7P?`?A08DL580L.C0S)2-_!NT!TKY-,,.
M60$Y4Q4M2RZL95J$PAU:_C[=Q(5CH(ZT%QYQOXU==R).T30VNAG#HYUPEZ+F
M4(W_:CV$3Z`M(SOG5TD,;3FABT"LOHF+.!`J20SX9.<6XH<#W'WP?MJT*S,+
M13ZBX@`2TI_"H0$[.L<!\/UC)"Y%,\("O\@Z?.(V/U:&A*&.9<@5D.P[HS`2
M]X4PX0^N,[&YX"7>]^(]+L5"X>U4H%Q/ANT0"VC_*,;IL<5?6./:#/OY>/7Q
M.A/Z-'.3A["83_'=2\D'6.E4A*%:A:I'J%*A$A&4"E,6,H_)Z($Y[*D>O<$E
MY,FU`7H47=9G=/'`$\-.-T<ZSD#HVCT4G&:K(<ZY&<,53K^?L:QF:?G`[WM"
MKV`_".X].A?1W6KUQ!8>53K>`]ZFL8LFO$_^9-0.VE]+DZ6\F+DG`RI16=8P
MLE4TKEM%':];QE`@<25`->FY*"9(F^^BM<WE*WTNJ^[-YHX7H<1E;VB%A](+
MSD!I8%5:[7WC,!5=>*1(*`V4]Q11F1:$V.6*@%A(\\$5]Q7N@N^F'-D?UDYU
MHH0#5OAK-E[9!!^)HEHV793%LC\NS!L2&]".H#W5-9XO^/H=/<!BC<\EW8I3
MGAZF=$JQBAZYQOR<^>2-9%\WGZQF<[SR%/=\L'E/PD`&&9+9$L>A6.F5W&9'
M;JQNE\;.G$1?.%>1:TA=SM5/0:LX\,S$Q9(DU\[W+T5.6O#B,)L9&35*#R38
M],B4;G5&+`1Q58E\(@U*CVMFX^'/',5?I7'SM'H"BZ)34U"L-_*,QM&]98V0
M>_EW-PJ#MW95<6\C+CA*\2@$SUW<7EJ#1O>LVQ`GP>+",7;[.BO/W*RO;K[0
M)_SO?39@&:1$A&B(VV=C7.=Z'QB<]H%\1W=X`9*"]0<'X?'7:AM078G)DP/J
M/",68H:6-I="]>(X%;=09@0IOC!-,8)0'ZE@<2'.X;U<XU8`QP$J1IYDZ0H#
M>;U6$7]<=ER2(=@8#"W*1QFNC,B]]S#2G(X+:2`_8KX#CX,&,,?[:;Z:(K/6
M\`.0D4*/GL)W7E*$_^Y$[.N%"9,W(THD6:HSOIB2BY=,MH26[R?9LA!IUL2!
M:RAB$3FO0DYC#K+'72<,,M'UIH1^IA+#+$+Y3N"XKA9;F=-3AD,[.G0ZXX4C
MU8I-"><E^;YUM#9+[*]87IZN:JE>-SPJMC\X:,>>7"2XETA:\.P>N&)=NTGB
MNSGJ`W([Y'9E^3;90(HP]1+O9<\9"-H9:D\J&0/[-=%9P43CKJ*]![RWLW>4
M#XQ@*EKH+"Y.#\VK##Y<X&[N.N.'K!;B2$2.+:(VV:U(W#&:AD\<!&O<,8O]
M2[E!34UGA"P"53IJ_[2=%=U_'"I'H4"K+UPSJ]V,H2ZYB)?F&#Y*U^ZTG\#>
MH>/`X*`ADFS832VCTE783H4MI4+81>Z"-"1U'(X1:^/$BDH1;:8DIBSP5<G.
M271602Z3E8"\C:OMH$OZV3A&T"1R;@$%.%$K-"E*=&0$#M6,-'(E,F:KHW+V
M1#"F#K-_='4`,AT-0&VD42[`Z^[!BTVCW!.AW1BQHZ5-1:("<;/4OV=#:D$"
MI'W@1@SK+=:Y=R(PRMZ%\(_U!I\T/6@7M^\RMCC848CM":_>A^&$+J!TT'_A
M/'`2PV(P,F50TY7"\DADF0;&0:X+T%?*IZIS42/5G+CQXEA__)-OVT".8%3T
MMD@SY415ZXY""=15>N%>,PB?<HFI.K4P@M]$`I%+2E')KY8%V;44!,,WHRXX
M_04<AET11>A$>"1'%RZ[G>-81MS2Y:SW31_JQ>T(1R]3;Y*`D\!5U=K-G[W7
M#8%'39!-"N;D(=J^M$(Q42,+QWU2OME0N65/9C5H1C6*4KWZR@T3H\G"YWV3
MSJ0V1@)BRJR5.-_P(SZ/E0>03A>_R%!*=Q*<RR=_#;+6PM09B]046^2J&$'L
MM!!HW7F@2-$)Z/$I4Y@6>N]0T>_T<QKKG_3RT3O*Z?3YDLOGHTCT9'4V7C`H
M@$B"OY>%DRYAJ43N`UISCT)W+;ENLVBUD-=$!;C+1<<FG!0P.K,(SR`FTTHB
M8/</LQ'SE/8_`5EW\%JM(IT*#VF"?'47,T]'(N;7_<;'&8L(0-)<SO02-X%U
M\L3IA%0:#)O)LU(WXE,_?*H@#'V@^L+/8KP3W`-$UF&&7&7A%^/$O[ARS9M3
MQX$<V4!I"J$IGN]!NZ6SE$G3R:]ZNL4I;[F=7NG-^B@(ST1S4HAS63@4AW*-
MB^*F[EVGRP26=]6I]6.ST;&[0XZ((RFF+SL#N]/N9T/%1-)YY`H7O6JB9?>Z
M#1PU>9)S3L('UR?#4X(]E/HZSBFYT6@;*?F9.E`1T-RX<CWFYZ:$$R-W[*!.
MY9L.\6;NIL-1[CZP+H2/)W;''%J+?A$]0705Q`FZOJM.A^<;S5OYW##""!$O
M8\_8XC*="#^_$8OGK6W09H0\PI3:K6:+8QQ;37O8[^=C_@Y"<7^G^\@5*PDR
M1-9TPWOFJR4N!C.?5Z2,\)Z"YOLX\D;LRDMCU[BF<Y/,]K`0-_!T.16YHX5.
MTH%^Q0MDN"@'&9.HXY#X+L\?"TTI-HT2_QFK=WD^P.9]YXGWA-S.8^K)OU&(
M)ZEN&64J#,08ES%O860C!BY>.CF1N`;`ZMTEHY%G;;I%I-P<W_N*^HZV5+Q?
MXV1GB]*`Q8TGF)*"A:4-XFE89QZ13LLC`I$9K8[ICA^'>IK8LZ3R1DFUQ`^(
MQ$`N`Y@BO#-A;X^3@`$Q2HV=KR0%.M,:@P/H%G`@0+L,K@1;U/GJTC!1TXP3
M=2',W],)$%^(W"2-@N(6AAG/(S=PIUXBTQ!T:+`M7I:]63/8?656U!ES_@PY
M?X;\B^%'!P-3?9?O^]QO#D$NX9OHSG"^D86@P0GRY+"^5;L/S<P4L?G4&98,
MIJD[42X9XIJQV,1`8XI&8'GD#5%YE[%1>'J$`2RR*R.NE0<<A8^$]\-KM01_
MI^QJ2S&.?#X17TX(R!^"#7(#X9,T+EQQ(U6AV-BWF@V*V%7C$AN)K:/M@E"Y
M%D0T`_>IC"J14$71>Z5D5,9OXT14AI[+X>+,Q!2Y6,)^$]?*G"^\,PA3$8O$
MRBP<B]_D1HO5>>*)-R[$-_XN;X3T98%'&9Q^""9E9&+A9#BGQ%#$7?X+.520
M1F+<@O+:1B[2@FQH9..\%\8U::9=O(F1ET#_3C'8(`QDT%2"R&/W,F]21(A.
M4,49>9:!^RT5D99\_3!#J'S)+AQ'ABWB))UU))K<MI>R6.KO3!:CQI2@-%$9
MP3E.=*)D0@DM>A35TDOK3,8.8GX@F_TJ01/&FU@!19&)&+&#L"P.R]"YT#N6
M(=""QV6)&7:[,[01+),3/L7I:%K7ZK6QS4+8)K?<[#:-EI7^,A?WC\WAH.P9
MED0RA3++:<W1M>W6H%$].G*7\JA*$FFJ!M;"3):5`^L,2I^I&-CG,#.2!V>B
M_+Y,LL2-VTE^T2TB"_+H&SSZK+DJCUK")@K01E2I'")$6WKLA`TS36$Q/Q9M
M.3TTVC$G;FF4[BFK8B>'DUL,HSCCB#<""8-#*4W/ZH/*)"3P2<,#'*LK)>T@
MIE.XZ$`GMO,J$B<7#L(Q+5QQS2[M5W':5[3)&_6I,,Q+^J#DIPENJ1,*3YA`
M/PPZ1]XHV/+"A9LMC"Z_E(%)<[&QJG!`'?VG;_PS2_8J$*JPU6AT>4=&^!@1
M_F%D=^$IP,7HYUB=UTCR*2R)0QDPPV(F_V:7HSPZX+#U.I(!$SD>5X5-@>;R
M/9&9H2Q4<44-=I#JQ!/Y%:HCLO2>7-_/QO^3&QX9+NZ\\2R@AZ=MK#3Q?+)J
ML>-WO@-2=SN&$PY\\\F-$AP(P\@@GAQ.QRR$-DI&\1\Z54`Q(!O<L40<A*=.
MPDKQ_9>,3'<20<-9A@;R/=$A(!/#\Q^Q$!0!@,?,P7]'BPQREKXW-;$510XX
M![%^XV,(6Y[HSI)1,7'N$!D;/TE3T:[$3]24JG.=2?)CB+Y!#J:1%A4R5OD*
MB&?LCG88]XI,_RC\%S=6NF*@+S<:>W0D?'`>/5AS^9.P/F6*WL1:X_G`G3S.
M`B(8R9.(4T2+4?8MNY.HJG%R]LB%),4S#'!F"(RD*T\6YG*=3=&ZH6.B%V<B
M@=DP5E&5>4^Y@1\&^S,>>T(.&M<9#32ZC.WBPWK!+;P8H%2NC$KR9'(>(;S+
MA>%F?`VV&:Q$L8U:T$Q!1;02P]@VP-ZTYB,"3V;VB_H35=H#"@J>6F5,._NB
M5NW<F?S;PNOFCE@(ZK#%A<FCYSX)HUDG89!7S:7,D$=YVVD(7C95%W.:QV3W
MRE/AV(FB!6E)=3"4"0$<HLC>-;0B%SIW-XOK1=D")DFB&Z0SEC$-=M:-(S/(
M\_G`J,49ZQ3T@D:8*2%3^57)^24BH=,`(0^%DQ[-8^/2*^=EX^@@(UZG&#AQ
ME>D%)X$'B>XU"H360S9Q?V)I5NFFF6KXI-&U\D/BW,TXM_*+`935@3XG9;`O
M9?!>'GX5=)X(CC""':KC/>J\;>(4XJPK$<B'-Q<"(.C&S(T(C-86<1ZY_C+A
M$S):@BHOJ``)8:C.$:R!//L&L+$P6W6?^2V]/.!7Y2?F,MKT+3)ODX)V6F_\
M@CRAZCOZS$CT@R4M5R0/">)$.Y/<^"+]0R%RM30CLGN*@RI45L.[X3FZ=A]D
M39[RZ"<G]L:DJ_W,&S+9+!4JFM`X<)+5H_)*AJXM0&X5$@<K71G`<"8#&/0Q
M('MW'J8)G:%E.%5Y6,-[ST_EKI*C5%0$B#?O=NZG_+;AHV9#$/W-V#,!?_*-
MN1!1B8UG8H?"=X0\*3B2Z5"CB4B[EM+QY/)\HU.%<\E"?%/)=2R,G"1B.P;B
MBR0D1@6U:2.;)R*!@4-LA;=!#$FE""+0W9D<71FO<WQ>PQFJKD*`&I$?'RPD
M`72Z:3;L;J=G-]M]8[R"45V[,VS:[48SPZJAW>\V[5ZS:R0Q8#=VN]>PA[U!
ML9V.W>\7VQDT>]!*2[5R"ALX'*WU,6-O3<M@3*I5V5WA0%EF_)<'BTGO'$&&
M3-&74=Z[P`;-7FMK9X=&_(8>1AC<.UT](CL3^%5BG,;9R&29KTHE?"BV8-.*
M)M_W%OE!J7AV(/@+Y;5D7RQ_5^+SA=D*0JQ,PC)1F9!WQ]EHY*4J=E+F0]9[
M"1[]%JYQ%9^+G!RY/@*1RI1OPX>!YZ+QTAC&,OCX8M55\?=__IS&9_>.,__E
MVBAR<&G6@;H()C=&M/WU5"5?W*KVWZNE`4_?:I@AG9UQ(XH#W8%@O?-AZ_OM
M__E?EO6?_^_9&6-H7XCC^.<P$-$T9V?\B"(0G^/']$.T4T.37]SI7WX8X_[4
M:+>;/\!*]OB[/QN-U@]4J&CF^#&6??NMVVOT6L;`R]K=$77M9FL5=8VZE"V-
MYGV#V_O;GS$(L9323)`OQW.)]BY%<W<ZG`_F]$ZW_3NTB0;H142PZ._)37A#
M%LIG-[F>WCG?BN-N-!O-)*2_5LY/LS/HM/LY-NR6X*-D:D<QM8;0GS4;G>XP
M+UQ[XBHOHFQ@N0@B?(-MO+6M/W7D[%]#G_9;[$'\CA[K6VVABSXM[M3B7F%U
MNJ3PH>>ZTZ-[%9W*45T'NKO=S4FKUZTQ(\\E\CN<AK7TS?ZGH!`&C2??4F:!
MWE=1"&*JGB5R_7Z_T\N-M]C'+LE=:VK.6H-&=VUZ%4Z<#6=7!=-VF\XY!0P-
MP$\N@B^@1]L55C]=_-X'G'3_>P1S6SI"U;9J6;8+ZM%H]4]LU&AS$T.EV1JV
MVKG!;]K_,;*HAK6T0Q;]81X@5QA^QK//LTT'G4XS-YS2MG=.:QW>#[O#06<#
M:B]$2&Z&ZLME=C6_8#Q_N3F+6[U!=]`:Y,WLJB[V1WL-EK=:[4ZOG^?Y:MIO
M1`P-.BX%G)QU$Z$634`#W/@.KFA<]`KR,#\6V<)=*-Z7K]/+L+`T6.*S-'YG
MV&N:DU._W\,8[%J[,<SWL-5\WF`C>0,E':-!B'='[):R920W&G0MC-6D>$V9
M2%8;J/Q7J\]OXJ^!YYN^%-/7OBF&>V$"Y*@HFN]OY&';8*FWNPW\/X/!Q79/
MG%S3*[$>#PVNO?'D=<G;Y53>TD,7^LT:4]_,+ZW&TJG/=['O$92P?`<CH"LF
MNMQS14(:#>$!S#GX/7F`8=RZE+NM7[JPJ'GK'Y](S/Z_Y0-]+QK_`FW#D0>=
MH'@OMT(K_O.&JZ]^3$G8+[YY\3^S[7+G609U3`9=??X(4GG>:%?QIYRR)?.L
MECKQB-//C1NR%3/^.;QQHMJ*JET<2M4X=,,O07N)G&Z;=J$`UUQ;5_S6!NMJ
MQ8KBAO=%;PU-UE^M!9;3K#5`J7!L70F\IQXN./1J)YJ@*(+-\VXECY:05SG-
MF;UXS:F^-E[=OGP:K>^=^NU(Z[-&\$Q1K3G&S<1R>[RH!T15,E1\\0._!\<%
MXP+I&0?F9K?;:38[F8&LZN=E!E/+8=3O=QK=S0:3!SR#TR1>:RZL?XA_\7;3
MHNO-$CGTPHB]POEF+A1^RWM75Q]>=;+\+7>)G[TVS]^:U[Z=?]UA`2?(NOU"
MUA7C#-9=!X8F"3F*F_J5A.7B_J8:R+OD*,P-?(3W/WD!YK<O2`LC+`45UGJ.
M+R>CZ)=W]()#6N\BOMWH-EK/'A<%-%*-I-S8EHWF2KQT/;VD5WB3?]YPFKWA
ML-VIF*C2#O<_HK5D;M`<M+K=X2X']`6Q5]/8^NCY,]"M?R23<VUJ<</6):YB
MZ]T2$^R97/CG'^Z]XW_`.N@+LL4$5404D,3]_E/%(Q%!UU-JFY[GONCK=V66
M6R%$J.A[V39C;V%1N_].44=_P/NJK7*OJ[C7!>[IKJBGN\7<):[DOJ_#F%Y[
MT.AM8PE)93?/>JOJ#3YK27.`&GR!)=6VL*I*O,:;$'$0`]\T$&*K0TZ,ZM]N
MY9V+T>,M/(R][>2&J6*4*_I\J:&M);F=2K'=;'1R9+G@^]7CDTG%V]BU>XU6
M]I)L>6_['<I:T],=#CO]"GMJV4@PH"H7IW6E4EIO!*3;12YC!V_?,8LE]+&(
M+59&(ZRKD@%/O802BIX7RS;LMP:-=G:>1,LO/9#U0HX&G<:@V^DN'4CN.CE[
MFVQ;?W(ZW!_>U#W[Y'SS9NE,;^]ZK2_9\<N7*;>+S=;PJU:T\6ZA]G_UG;"?
MOF!J,_TBB!86P6\WS5;C4X8AJ^C;B%-><(2<8J(5I]J]W3!J'4=31:?\J@K`
M/SF83M5'5U<?+7/@U),O)=F&%)?$C58VAYO%)B%2PV&_WV[7H!<ZV`6-=>)^
MAMUA,WMA58/&%1JB-""SLF%Z>A/^=CKM9G?0JT$[=;%/ZNM8R+U.M]'O;Y=Z
MZQ]W9*QLHI2_3W5\D=0,;7*UA$S3""86TZ$)LM/[EE`F)H&\$G2Z1]!&##XP
M#1&,#S3D+YNG/7:&Y]T])/VRH3MV?7^.@&K!/0HJ?8[GSEA^%B0_>9/D`=MM
M_)0G;&,)2"+U%\$A`3_^\L,H3))PIOH5I)WQU[]8K?FW7RU*AQ\[ON0A_[B)
M:)WUSUN;L'KF1/=><(8M_F*9;=1G_\_)9!?#S_:7Z6,<XLQ")Z"<*OH;(2!F
MI+K[W^R.Q&XM2LS<F/<8!N5&SY=I_H+Q&+!S?\)=9U=US;6W:Z+>I($#9TRP
MFMXNG_T@?(J<^5]^X'\K9Z<HS%N5CY,,/F^ZS6WD0"10P<T>LNC];&P$-;:$
MD3/^>A^%:3`Y`VD*(Q"1\=AUI\`6L4OU>S\=U2;Q896QL='>L9I/S55L6E]9
M%%FY!3*6V9\;FD4_;L12<W2$K55G>,,7&%['AO.&#0>.'2W^%Y&MDT!_SP(-
MQW\;SO_')]!K;F^E^VH)>5/ZOZ/=\RZ,@G#*O2@#X[9R3%K-LUWHJ)7&:RW9
M.S1"JW5#CM*7T`UOFG9OT+6'K5WM=KL2KQWP8L5!\[1^3NNG;/UTVFU[T-WK
M4?'XUL\S-_).Q:A?S^$U<).MJ)^:G-K?J@:"K$F8CGRWIOXYV@/!F@PXZ#-#
MRQYVAW:SV]B36GLYL3T<2DX+Z'4MH&'?[K?W91?L6FR-#?QGNOW<(-BD&&:R
M_(I>(Y1:_]CDGEZ_?Z@W]I@[Y4T7N[O$:)];V>BFU?<J6Z/I$(&S3T$,IR"&
M4Q##*[Q`/@4QG((87EH&3T$,IR"&4Q##:SZA'LWQ\Q3$<!+H5R;0IR"&4Q##
MZ1+V=`E["F(X!3&<UL\IB.$4Q'`8&_DIB.$U'0A>V1WL*8CAM(!."^@4Q+`B
MB&'I=OH:[\'?&R=NB00K,&(9%??'5K=G#SM=<D/_V&RV[7:W5[_BN"HXGB_F
M77T=6C^.I"2NPX1[#N\#`LO%*_GW$K#OB_OH!JF;CQTQ'K^>RH?%L\\$U^KV
M.R80Z[*>]D+]IH![-0F/71(`#J>`N0XYAD=@=!<IY^=A6HVGQ<//!%A%`,UA
MVQS`DK[V-(*UF`_D=SN#P;9'L`X@U=(>Q>N'%4KU2K"H,I,XT:PG%5D*327K
MCV,H$A6"?/*2!^OCQ>T[4+U4D8PKJ]TCO%1`=:ITH7-4Z%%%EX1NE<&<JB*.
MGR0,=+&73*RG!S?`*J2(:3[AVFU8\MR+$X1G#\;>G&JC(U2VXSN1QR5Q%@@9
M:"7.-_R(SZ<^T^GB%QE*?0=,+0=K1JI?`U$\7CPU=<:JW!^]X8UI<>+C%H&P
M$^:[%TVP&`^5QX4O'%%^;NXDQ#?@D'B1?DYC_9.&;D_<\4,`ULK]H@8:5XW%
MI19UUDT^]<9>`>GJBXN@]^[D@T/3&QNOO.<W-D%=.FMVVX-^O]MKFH2OZFG'
M=-?`NCIK=KK]_J#;Z6]$]^^$[,_5<XL$TZ:'T)_TV#-1*X>-=JMG$IEK?4LT
MK0=W"A-N@I-7$R7-#,,\6&^#H=>-MT]0AWO97GC6(LWW=7>6VP^7UFWB3*=8
M5U7N(^]2WW?A+^L^]28,GHZ5-@J=97:3<.'XR4(^%JO]@9"VPTDZ3JQ(/#,7
M53;-]__0ZKS8!NPQ,]A5Q`Z3CG2-%E3:SH3.CP3'**GDTAAI!)03*./$@2.B
M@UK_Z<'#/2=2(\'J@/C3Q$KG-$YYPLGV!#N'V1'C.F:&P/5I,_L2EVT>BTHF
M\B?G'@Y<O(]3W+%!R(0KN7/-$]$'[[ZPR02B3"5B%(<!''D7EALGP!HX_!;G
MPJMB8*1^%FV*,B-4ZF)OPOM76'UPV,P(+'Z(T[GL&V?N[$&$P34S[<2@Y'R,
MM<N[#FA1)^$\<U#O=WCSAK9I79#49!GOQ$IV8*;P6/SO%,P(*KXN9`:_C)28
MS\-(6$E<.0;:4(#D8J+!2`>;ABR*!V=)H\S\)`R_6G/?&6?F\N\X]W+M>G@^
M3[S$YV.]Z!CD]@RZACD+PB!RIR!T%`S.5*`X@2S%'DR7$PES*8T043XA"TD+
M(TLKTR6[?`#&!%17!Q1"*B0?2^RP7A@!U\GO`+--$?.N&U>S5HCR&,Q"7&(@
M=UYL2K,3HQ]@4CE^,>!XIR.>A*ZH,+3VH"?RB$\"-D,\;61`A,H'U]ZCRQX7
MLS5>Y.:0KZ85#UEC)PC"Q!JY1160H%TNAR"[CG/\(4(5%3Z",XM,!P+X=D!'
MXQ;@@^9#T<2F0'*3)>0@+=!9.4'FH#YY(.-)&+A*^]N6-P5&+=#69],2YB8>
M>RCA8,;A%)(ACJL;[/@'#V2(9RTG7UX@S"F6+B1VIGH#`<,3$NYY\0,^/+7>
M.&])M2<@#[A\W"D,++&>2$[IN##AHP-UF6W/MMZ,WM)7H@:3X-\L/SS+F<]=
M+/-H,`;KCX!\IE1#BK9??%5T3V>MB3Q=O1F_-9>)Z$6V7;YJ+-.TI%;,X@CJ
M("5VXR7+U-QPLB=&L8H+E1?*&]>[#JRRK(:4+SXL)E%X[_I\_(H3=T8Y*ZJ=
M6@>P%<:GMG+5QB>*=[%90NJW8-*RHM^*_ZW9Z'>'IAV>:7L7Y*UU3!CV!R:<
M<`5UMU53G2<-'XS%V[^'8+^48S2O0^`@@W=<UL&.R%QKFGN]?JM3DTSQO0UF
M4^$H;;[X;-XU&[U>K]TM)VM;%*W'IF:GTV^O)NAV#/HZY=E\AV#K;AS#*044
M=.R)S7>T,+^H@0(MV[R>RA;-!M\MC$_?Y]GUSLQZM%3&$ZXBB[9_V%[H7V+X
M/1ECL('!-B5++E*)0O:[B6E)'J(PO>?-CLIZ6I=H;6")$2HW(LTQWA)_=R,\
MU\6X4]/M%&QJL</;H#:1\<SR?YP`K.F%)=(\S9T*AU%.,EEW:$0%8$O&,6]/
M8"+Y-`2T\%UT4])9"&^LV,YC,^@I3/T)FX;AF'VA\(FW6;++47=364K'0BO4
MY],VV#CR7"<,*3K5J>*2A3WNE%RZ27+I$459U<TC5?EU_<I[^,/+GI-LB/B[
M+DFH4"YXT?R)+YH_9"^:=Q24L(\8_]<L>.WC%;SF>5.%OI1D$;^D@!TKAW>=
MA?IB&3G?YQ(^VMSL-W\>52K^:2H.8RJ^^]1TZ<#;/+C_E+7[_6;M#ML=N]]J
M[FB9GY+03^*\WR3T8=ON-[K')\[/W\:./-O\F3!<+Y)A>B")KKM)8UU"QS87
MT![R@%]Z3DZB\;+L^>Z/"'B]YV-M5^?1\7Q9`AXC%S!*[,&)W`<X^[G1"<7J
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M5=#$OJ5K1U7MCOPDM>7+HYI<.N""7`=0F_&%"W(=@/G=M3N=MMWHO71!KMV+
M[>%0<EI`KV@!]>Q^"PS5UKXV[UV+[4:14NM')95&3'WT`B]QS_X@F.:K('&"
M>P_#6@BP<[TX*6Z*6M(-<3O'%AZU1635VN%1GF:^P\S'!XO?!BZACPNL=T8W
MI7(2B#D:>7'-L"GYYRBR?L[+&RV@4W33T1FHI\B24W33*;KI0&7P%-UTBF[:
M:).XRIL`V[H1/D6#?"?1(-V.W6\.[6'S@+-33O%-)XG^/B1Z1[?81^ZK-VO-
MFF?;G5YBOYCC<=W+O4,C]*#]@V^&]J`/_[5WA5F[*_':`2\VRY,^K9_O>OT,
M[&ZS">MGKX?#XUL_.[IT?VW'U<U1YS?DV`'?'Q[MR6!K]X<'<'CH=.Q!IV$W
M!OT7OD#<?Y3;:06=5M`V5E#/;C4&L()VE;RP;[G=Z`J^]H6WOGE/X-/9R,%+
M6KRN=8.8#KF%2W7$"'N'CUT:3SVO(NR@T>QVS3JUI7WLBM3U2L4.F\-.KS:I
MNF8]5NB<BY*A6/M]_``O62A+^*7C,_A:;+WQ!`Y;_/;L-AW%[K]3+$3ZX1'_
M]Q^?Z)ZF&.E02L5%%,',4R'3=PO]R`V7[+YX<J+)YQ3;NYY>*#KHN?@B31["
MB(IPKYC9?VHBB<:[Q=R]^.;%^>^9\BQSF_FJREU2/*NXNY5Q:6G"'X0T9>3$
MZ`;+^IK/B:XLZLNVKN>B^B^5.X^Q_/L-E53%;\*X6.AYTV&)CKB;JX`[H2[6
M6X!YQC=;C>YV&%]-X6MG^%(U4F!X8[@E2:_+<&L>>6.7U,LD]'TG8N1'4C7K
M:IH;:JHH<<]4!VV32:T??FN=%SA$/:^4)"D@%*9T%>!=->R$UHWO!+%U$_K>
M>&']0_R[+'ZL=$ZXZ8M@HAJF=D5SWU/\&'9<@*VCOW^QO`1(&&^IHZH-WX0J
M)8M(HMU9<M]U)K#INA,)\(4%KV,PAR:P<&+K/@2#+*#O#$&:\^("DIX>O/&#
M%8'4>K!^,&QMYCIQ&K&&0MF*W'%X'W!-\7":I<W]AG]CJ%MD.;Y?UH?E/!$A
M,V="-2TFT,\X"2..KW-G<S]<N,@<+QC[*5J=ZDL8!H8KAE(1<KO8;9S`"L(Q
M3QTO0K,V=6.S$/E5(*+^6HU&UZ9AW7ZXM+PXQAP]PR"Y3[V)ZR/FG>#$/`H?
MX2LK3N=SGY@`3WDS^3?77X>7'%@8-&SLW)',*>.Q29<VE6#XT('G<AESZC6F
MDN<4/.C%NA.TE5*@3'448YGV)]?WS98O!6B;K.<.)@#,BQZ>K?I.$\\'V8NI
MXW<^&/48D1KZ\,TGL-UQ(*Q84)GB=,Q":*-D%/\1@RI+W&CF!8H!>CXJV"'%
M@0K4N]8$9A&?O$?5;B'ZX#T7?6<:SC(TP/Q9#E6]Q_3\A4$'"PIK?\$<_!>>
M<6#*9RQ`(,GWT#<VYU@!&4_8]0.<]/P%R;7O?B.IC-/1OZ`7U*>/3N3A82+.
MU;F/C9^$Z+H@H2D,$-815KKWO1D&EX',VP:EN&*(?I/DQ]!W<%:2A87+E3B#
MC)61I,PS6R#V)2F()/X)4O,O;JQTQ4!?;C3V@-*1"[:Y!VLN-PA-C>Q-K#6>
M#_C>PSF.*#IY&H4S8!;T$.'Y#J?.H<4H^Y;=\<J>AW%R]H@K5:UHFG]38"1=
M>;(B+_YZ-L6JY1'*!Q"AECZRX\_SVW/K+B(]M:!'R#IR232L21JQ%.'N'8$]
M/`\#FO0YF0U*VLQ.+WQ8+^G]`\?M9F2X7!DQ8W@LR*:`M&_$*Y86(&@Y'.['
MB]MW:BW;%IR(P-8A<K$K0]!,01T[@87Z#>3+!]%DF:<7M.8C`L\+Y__B>7G]
M#5[9'F1\05^\.IT9;B]GMT`6C.`F<J<NL'=B75BT=U6;4_CK%:G>]S0W;+_]
M#0<`NR3]LM*V_R=818\P\(\I32:96XH$ZJ',VLJ<;,^Z/_S6+IR^ZA"W@B&U
M[<H-&=%M=`0CNHWN<XS/_$&_U>H,F\U-F7%I`*K'<F_%+1$!1%.?#1$W>@0-
M5SRL+.F)O_X81K?BY><Y7FI.=J'7`QCG6EZ;?K\U>/98>27S[Q:_ITZ=[%V`
M<P<"'IQ]<6'[F:2LO'YW`S?QQC$87J"@DA24]IJ+@!MG+(55JF")X^_=XI/S
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MBL)&#[[P?MY@\#4*8))$WBA-9#'@SV&`#(A"W\?'KC`WS8V34C:*YKEQU;1H
MV6SX+LPV*ULMO_A8SI%.M]WKM%KY\^2S:3ERSK6;K96<:[5ZK?:>.5=@TPTH
M@:`&5S:1C>:PU6D-.]UE(]P3M37FH]D9-!K]WF!S:C^'H.G>>_'8#_$RQ?K'
MLBNX0MOXMG[YL($;=I4<VS\7O*R9K+N7FC.K^][%U:!VM?)&?30<V=6EK+S*
MPOL@'<0#2H&<<U8+X57Q/^FS"Z?67/&0K.'\C8/Q,[\R<Q;6R)7>/K#GPL"U
MPLB:A;":8W:!.WR'-@K!#,0^]-4FO;VPH*'03VE/4I<%^9Y+WBX,:^I]HY[T
MI94>F!,L)#W98?(3>!6#MZZR>XMN:A-QR411CL!L>LL-QLCX>>0]>KY[[XH+
M)]Q((F^<O1>")J$A;S8/C7N98N?P_]88;2X;'T_G%*ZPL)Y`V_D+5,',7DT_
M_IIOI@;'@-]VEN%TGXQ71#1BT.[\]QN\H</;N9'KAT^53*4+5T$5/`.SGR9T
MIPZ;Z]M-IR+6IRM@'S;"XIII@RX_N9'"Y<[+!$`<UM*_("YE`47LS+UZGY>^
M,6-+)>I:A@IT\HV!*$UD:\8D6X'[A)=R>H6*&[$+O(2G\%<T40RE32>G-S*.
MH]7X5;V@'M($T=/JV>:O;^FJX<?V>=<"SOD@VOGU4&Q-=#EV(M93ELCMI'O&
M(,#[X_9/!E=@)CV8J0DNE1^;Y]V&#IO"=22>1/V`DBOY8Q;4S;#T@X.KAP*R
M@&&5Y'GD))`,`V4CKCA]=RS#"?`S6T8$T%31-[[IB+9B&;E`??_8.6]D!H.L
MB-!P-!^/\,2/CS=;P.5LT\A\M]9XRI:K_+,*Y>E%EM`5A0<'@LLB6@3$W6%(
MLF2)2.G%`:9R:!$^"FV/,#5.("/2+NXCEQTGU#BQ3_IBHJ4B@5?1B2^N[V<V
MQQ49%_=3E."%ZT0P1.C2_<;WZ?BT%QF+M+(#;%`_-C;]8_!9#$Y%7/5_9:WM
M33PG6EA_>%/WDS.W;L>>V"OA4'9N/;B^&8XBY3@K5;K3?"M9*HKR)IM]#7(G
M(Z_D!EA40?92^0.!\GVTRUA0V!"9.YAQX,TQ5(0$KEQ)>&Q[R(YBL@N\F$^5
M''H5Y%YY0QY;W),#XSVN%)YY<9I[$?X3%\/4*XS[7VF<T)(0*RROK=ZBL>1-
M=13=<CDFQ#FR3(0*E:LPIY0/8=X/S8(`#IO&P7)9@VT>VJ:,%I].!,OXC1)D
M&A-#,GMA5L7IGNV'&7HB*=:+1<$D9O74V]9C2))E&M?.'",(R=3%H`1A8II[
M8MYH*.R67BRCD6A-16&$\5V&X(J0)?=12+&#S^.JH$:@9S#&D1IO"LPR-_#\
M,B3*8(O``*>"'8U;-&M"993,'8].8)EVB+/R4?AEI((0UR0DGL',EA!R-&IU
MJ0E8IB\?0ZDH"\*+V@>D/4%9A=F=>8DX[)E/2F&FS9D$S_$W,/_*2#/C,I',
MV((#$UBK8KO0/Y9,)<?O>FC9I?Z$E:.Y7FN;S;SNT;XA3M$ZBUW897"#(<FB
MG0(:=;Q`L8N#]-ATP=#;(Y.BJ\+J]KU_8]BB7%2PXREGAK9*;%.UK375&!^)
MUIR,"Q;G9UE'!<_I:4!+OV@DQ-#8%!TQ]`;CL@J'C=J8N1>#NLKCRL44%9%!
M!X7<"CI4EW4,DX(E4J9U..[9L!_4T`7L[*/C^=++;2XX6Y@(R^EPXLWL@F=)
MY<Y<G^(&^^3WK./W;+:ZRO.9E3H2QH!,91DX;,C_"I?*1'I!>T.[U^S;[=8P
M?_Y&UX%AQ72'=J/?M)O#UH[E;E>,?J]CR),'C$.',20/L!L%&/U;`BC-&-*2
M9R)EYG^DM[DLK4>DSA#O?QPTFG:WRTW]V!LV[6&GAU[9>,[1X?["MB8I:X1,
M&+KACU6I-.*`(GRCYDP_<UBRLZ;=:I"DT3--NS$4+C<9")$E/(76P0H&U0;-
MM>0-639E[55*AFUUNB9CB%VP"I^<B%,ZZ10GTR8F=8+YZUX5ZMO)7$A/O/PJ
M,AM\$W^?5X_-QKE5X-NQ""BEOBUR2CQR*)3HQY[='C3L7J=!-H=.@W/%5;DS
MQ]T;)5MEPZ!;,#;]4!F-KI6+IS,56XU?G>0,7CZ;.=%7-S&\V58"DA\[XC9)
M]G,)JP%,S(]>\C_W;N2`]4ZOX'_697A.AH^1[$44.?<NYO`<`LL/S$JX9@GH
MYG=R-`T=D<#B@$WU[NJ+=4,1@4WK%D_!UCM,P'/A?$.9UM)6Y307VJ=:K8X]
M;#8Y%PQ_^^P("=+Q7?`<!E3!-%J?W`FEBBE7YYO/5[]_NGTK7:3%MTG2_NHZ
M/M@K\/!?WYY;?]+VP3F11)8Z11CR=HD9?W=.=.\F')@&&G<BW/=7,:77X=?P
M#Z[H6]B=T#L`-K,[L_#=V)11Q3"TZ9_"Z*M%[MG(=6:^1[FT>\L*O@&ECD1B
MAW$ZE_UA2N?9@U!<S<R[PI]1!&(A<4O">49F^YU?:3`_0^-*A<D,8ZPV86%7
MU@3.A7XX5SG!XC,Y.&?D>IK@\<59,,=!/WB8)DB9R,!A:FCB3>D2*?%HUH]@
MZ;[LT4?=$XA3M[AN4)<3K5\_A2,/CHEBN=R&T^0)G2XW'-AX-#N6T%<]J:\J
M!IZ]096_F3>EMKJ<!2&<N1/S[J;DXL7.W5_!5G/V/B?HA1NM-ZBW#$+4+YDK
M6W7XOQH[#Z!JQP]AZ-,I"S4BKBC0@)](K=YZ@>,1Y6$`*VGJ@8*#Z9,P/M$\
MC/AO<_B?Q'O9T<_3*$X=]OVR-TRQB08CWV*D'@<IIY,#J;AQ&,[=R&&CG4-&
MB!7('#<*W,0&<W7$)QD;5CB)7DH7>B(3;H;7K%((171M+)S)E%./3XNSJ!?@
M%/'`*.0!W3?S,"'U0#FO'KGP9K@)L8I!;>+#%))\TG@>2/#'V!V&[\5JH'`6
M!2OEB,Z;%?-$&Q!H%,)8P",>>E;I3LHF;RW*S)G[;>S#OOWHPKDK7`!'0/SQ
M8`(SY4&WTD]I2(\&\C)W/9QG'^_>T>$*#`=I2&@E6?\*/4K.=SD6@";6W!+,
M(Z8>B?"(+?1PL"U<%-@2K@7Y/?04XX6TGTGS]B)QB$6#SR%WUQPS9\!TP21Y
MF/P)IE/#EL]Y]X9TQZ9P.WC&'(=^+JQ@ZD5Q8OW85!X3S'[/MGN,\D-<Y_4=
M&&!<SI@!/AQ<[/[D[`G7HR%9."5YI4+7WUI6*@2$UAM=DY;_+N2$$1O4'#F^
MB*<CV8+U3EI!#T.8GBQYIO4A,`^4+('.PQ@T"@?31@D2A><4/%G#!/R//+(+
MX<U?!6!L7"P%0W+%43J?%)3R87]SQ^1=]J8&O1K[`/T<@N^IL%S=)?O''Z*W
M\GT$59MQ*Q>X]Z$PGY";-")T.:-XX!(@&@48A5KX!K9(S'8O!S1FZ#+A5^A.
M<@1BJR[/]#CINEW/XR_6&^>M4#L>7R%A?30ZH=G6F]%;CMY`3P^<UZ2C&W<+
MD#^QKXF+`)(/W1&=,)"7,'PQ(V[NZCV,U)R)>?W5>C-^2Y=8&.T')POTHJ,W
M7NSFW!".<1S&!*E%T4!XQ>"A//$M$^-(H-:0Z"3DL7>GF%Z"7Q?FC&\GBR$U
M@O")I('#+5DZQ>SPTC%,`1#&\4,0^N$]KZU5"U"@@F3'["3`G<!=9);RE&!V
MI-\1=I`I'(%@>8@?]$(6V@_9@W<?B1&M0;=@%%X)_<>X$N@#OCMSD+Z`$#"`
M9^5C_X4>?3-Y:\%A!IKM_B3YRY<6(CA+^",4"(>Q/_+),<'S&5U3F48A:%JZ
M](46[K2?X=Q84OFP7RV;0,S(%7?-F:OPB2=NO=3F-$T3C.GW`H0WD?.?W<*S
MYV:]P:'<%;89WJ.R"K)$=Y1IK1K#-_=X4A`SUPF,+1!#><?`>'&G#ZL#KY[T
M^W33KL-:(Y>+1)B.')N7-&.]X#X:Y2-@5+"#4111C^:-]Y:B9.(8AL#JR(B\
M`0*+IGMQ51;T-K;+#=,CN&9(EZ#@NY$@%64XHFJ=6?WS)HR$^AE#?W$8O<51
M":KTT$O'63B<P/++=.22FHV<"<L3V''"$>(O"G<'.L@-K]LY&@5^^W<:"C2J
M>(%G;!HLCI:4KZVXH8@&M0D;I8+Q0H6!\PHGI,111K?O5]+/MY._XDMOO$?L
M*'+#Z-X)1*$0E@&$VE=7QK#]WHN`/WV4PTXITE#P<<I/D*M1LRC[SM.#"'?*
MW#:746G>0HDXF0SCZ=:8%(@QAR,W<%D5`@_"IP",M3AFV9MZ4]!#0DU8;[J-
MG]Z6A>T4NJ)Q(K'UVA+OS\,GS8ULFPMSZ`P=%#UZ="@B?QBB!,FH_J2@^_B>
MSZK0$.C+A9GGL'A84NY,1/B36J#X!Q9S5A$CD%08#.)=.=',W&+.?#>XQXA/
M5M^P-&$W0!()+<6)\=Q7.)EZG%9M3),9=B==Q$M6\<2-QV`0L%4S]AVT97GE
MCT#3@GGBPL:%,5$,)$8"L-YTD"+(SP-&TL";N!-(O[E:;+$']KP3X28)!]:8
MG9R\7Z#5\O0`VTI(#'?$-1ELGP%N0Q-G<9:$9_"/)<[C(L!0,>QX+N\+D:X<
MHG`C$]&US7LDQZP+#`H*<^XJZ2W..9.JQLK688$UAILDNVQ*U5S)(5R8M&5G
M#NI16A9E<(1\5)>DMNQN(7UJ==#RCSKV`);A-$Q9OX\?X&&!.(#\,KLO-$IT
MX/(5-OT8SO"QOFR@?<-@E+JN"G>X.G8=RZ&CS8JG=C4E;"P[@7EG-]QLFEJ9
MC`@Z"#Z%>JJ4><<F/QPDP*R7@5'&D;(@?L`-U&Y!SI#*H'+J2\32\[(GW(#.
M0ASO\6!?&)(.I&*N\#6\%\!F[/N$N*F#Z,6P*(F%]A^TZH+J+)+"080O,,5!
MQ`#\<]0^3&=$L@?$(+0S8)*%+83IC5#%XUT]9R6)+)5R<L1;G__[]H/UZ;_N
MM,<##\P37D]D1-(>Z"P*>7)E*6K+!80<'9(:F@HI@-+[$:%O6HL'K`WE("DT
M39?.L5JEM(S%]@C:82QNY\IDJ882RRWA@UK:=P0/"N;PA$_`VC!&X#C6[@B&
M+Y%U1""(".*F<R!;`^H:`EGQ3J8]OI>A/7SNIG=%A);8FYJMT@O*YX[+SN(/
M4Y20444[XP;6X1,NAYV0=ANYL+9<1K(EZ%L99P#R@^RI$P)3%:*B0E[N\&#%
MMS<D;1>,BQQ;7\C3Y%"R67V$;&KN(IA08[(MW=0)$WMWM]]JYB+%;NGM"I\4
M`C.6;TFFJ2\!L..,F.YD)61`N0VM&Y(Y0O*G28Z%)TB$N.,J_T8@KF#U_]B#
M/;PC(NEV3_>/W7[7'D)WN^\*!W3/86[F[%5SHMWNV'W!B1]W3U^W/;3;C<8>
M9,4IB:^E49HEZ46HI1DYF;U6FTE/="RY&%M\\TG']3205UQ4RLB).8>])")U
MQ>*A,WYV9IK-GCW`F:D]D+)#AE3[L8B*)VJ=D8"]YD.VN6B4[>00TK;+3TT=
ML?5E[RN$XP$Y)(:K%Q_>1CMQ0@&TA.YM>$'`7CU+F#K:I>A:66-<H[,\(G,F
MXTC)V.'H6X@>F9N@;#%?@`"Z)3^UZ80`T7QQ)'DR<NF>FL*RA#][G$+O,S?*
MN.[!9A",@G4S<\$B16YI4T)?UZ`PXL0[Z@YM[/#UV,@)OD;I/!FC8P9S;#D#
M$FU:3\88R%?*:!#N"&`X.X/H=4V"="X:C-)_@>4_]J)Q.D./V3A[S)"=Q0(<
MVU8@U\K&1M:A\:R%Q9S@)\KW`0Y/TX@V?$Y:DP&UYN)>;EK4VND-,T,`D(NT
M/(+Z*AH/_!`]4P70NAI9J]7NM[IF2:9BNUNGJPYN%<(2#[O]]>CBLX:).[B,
MN$HXP1KU9X!ES785=3D@P.V25\*\(GF]8;_?[-8C[T]>Q!_DTEC'@H5WKZ?J
MS9.IN@M35<R/4EW9HY)A+DJX(7F3RJEI]8^*?-6,T5.H"NE4_/O%Q8TLX1*;
M1T?<+)ROKJ%0R7HV*@W0R<NH+P!TA9&H`:^L`9&71A?HK(,]?1<O$<YX&+@_
MT*&UXITD4_5#),+7'KL\"I=1&>$.G@JZ5'*-40R"7]+(IYD=G>_4Y<;&&:0<
ML"K=C^B+4GRL<4[-+CJUCO].0;M8-4%X@SXK+XU0)=?Z7LFVWCFQ-V8;"Z^A
MW0*@J&Q/-"=KPE%;1DO4#FQMHI7G@8IV!ZUNO],R%.MF5!PZ4]:J=M9M-OO=
M7F>X-::H8/P+C-UBXPK+;H0?,7+2NC(B*,M2>D;)MU]D$V8+T`"]:+S_?6;Y
M##&U0/BND*V6Y"L:Q#/KHU)`)J>SBAP=SY\X_^O#LA2Z[SYQ]<Z,_+"4RQ"=
MOQ2K[60"@N_A^!O+<C[R(@(W%`YC%$$,9I(2@?PB_)9.JLYYCAFQ7B=0F_?_
M21A^M>:^@][XP/H_3I!BQ'C)49:W[C*2)R%0C/>Y@8OA(G!>I5".J:\W5G%F
MFIKWNAQ92+L-5T\=BX`TS+HE!SO>[7/H@AOH\!S,)"4P&[V]\:866^*NNR2=
ML/[,=X;GW3VD6#"6*R:'B'K#J$CI<SQWQO*S(%F6&&XT?LH3MK'>T56'J^M&
MKU';>057S_KGK4VX.G.B>R\XPQ9_L<PVZG,Z6Q9Z'"*#8:C]RI+0&XYZ3)?@
M.]'9D@T1?]<E"17*I5H/+V?$QO6QGUOD^GL7O/;Q"E[SO"F'C7O\(0G8L7)8
M,K-@)QW1:A4[V!E__8O5FG];T?&K7<(C='-'BA/_FZM$(4<L.M]OS)==B^`;
M=1YXNR-)7%]*GK?63U.QAZE84U/HA(XSF,$P@FD9CUTX[6!X/MFX_=Y/1Z4[
MO@C7FXW)/\NG:V.>-%>Q9,E"J2T36R!CF7]DTTO[C5AJCHY,ESK#&[[`\(9X
M[]]J[FB9OXADG<3Y^Q7GSK!M]QO=XQ/GYV]C4_J_H]W&ZIK`&S/DI1;]?LFH
M7ITY.E:NSB5T;',![9X]+SXG)]%X6?9\]T>$SVYB^6&<0[<M094^'1].]M9:
MPWLSL!O#H;T[5^QASNH*M\AIH9P62IU0N&>O/N*3C'-KM>QNOV4/NJW36CR=
MJDZGJI/I?#I5G43C=*K:^:D*\_G-PU0F3G&DPF4G'&)Z,AU/IN-Z5E[C_'2\
M.JV1TQIYV>-5X[P].*W"XN;_,P42JT\J%6>3%`B5?K$TI+PJX8)>,M]1KQQ"
MCD4M"V97$3T[61^#\RR2P;))R\O2H:+'7.L4A(Z=J\"$1MQ%C`DJ3ERHOEPW
M">*R`E2>?C700M^6`,J;A(B4"H6T#8(M8)-\QD/A.GP*-4KD!,*3:@A>H.$M
MLZ69U2,F0%$!`=5(XL`\1,8+N!XG(6:/J02.K4T\II5[TX6<N!VDD=X9D)B2
MUS2O1U/-X4^-W;1$'FT#]"HP"S:J>1_8PT;+;O3[%?!8D7OOQ;P`IH0W>T;P
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MN(DMSLC;Y!W`SY0IA@4$*RKRF,CCO`06"EM<P.QGX?P0_1A8$-B&0F<<,NA&
M"GZK:??[;;O=,7$*$;U$E#!]EY$76Y>HM'YL@*`WF@988:8"C'S]UBA$INK`
M("Z:L;;52F[;S2ZOY-S[]M+%R!B#O!H5'*7,8N?BF[A(`P7]5[E<<PR4^L30
MAPB0XF-Y*\E4$_C3`'KA(KH(ELBH@(C6/D?@&04[[EA^Z"A0%Z.,EX;J="*/
ML`AI4(20J-%'!<QF5BV/%HI2C>K9S@+H2X!#64J7]H&QN0^8&W=::\,X'EQ/
MT):X,HTEP:72C4I$JGBRRD056[XPD6@V,F7;&(Q&['6$R%QDH5A'Q.@P4Y'[
M,V@7^,E-L'_1AUEV0=%*6((*J(C1&KS(1$0B`'LJ+:/`%\BT%-2:O7[*]5AH
M?.IX)>5H[Z@\,FNF,4(D)4^8^TJXS+(>@&C1M!T,P90P$;I]@4YA5)TH*BKD
MLZ8NSJ&M9L17]T7(HL9C6#_@C,!&:<<\@B)G+Y,,+L\"0O:C\@F4*%'9J:,:
M#3EABD5Z>?S+DB$*OWH2SF$\.!SQA4P!:9OGY2JE<DI:WNX=QF5F;DV!T&NS
M,*FU7(?/SJMJ/2>'LDQVCBB?<;5#<#`XKLLRM<DIRR\NK2I_\O2?//W+D4-;
M=K/7L;N]`W;&[RW)X]BTP-_+3H6[5@VGL)1GA:7L8`VW[$:S97<&>TP[?*&H
MEWR><P?SG%_?[O[A&^(N211">2CD8X;I0!''P4<WRIXJ-EKJ&_)V%[%PY8G^
M0!`A/",D]*'DQJY'Z4%;`AV$Q;8;O5T!E^Q;OG:D6H[<9&!4_S+WT4Z5QAX"
M:+>D--:E]&".'%O310=@T70']K#?MYO-7>5>[%MNOWN'Q?8S)X[41;&K<\BZ
M%L2>PN-/9_VM>?R67#)LYE-^\5/UJSO<?^\Y)\>VJ$K#GNSL=>YWOE\=C'U[
M-`?I=L<>#KIV<V<GZ=,VNWN-(%WK.U(&IWWVT(Z<S8'=ZO?L3J/WZKWHKV\?
MO^0X0U6#*-0528PH0R,(XSO?U`_E$+H+UY$,!SUMOD>WC*^"1U<$^F,DXA1+
M.W)].">A8,W3]OM:M]].LVMW.WNTF`_D!KOU.F^P986B?)TC52K53':#A1US
M(*SV:&WE-JHF<_=W&V5@U1_(OKX>H0>]\[=WNN_O6[9.U]?5U]?%@/O3Y?7I
M\OI03)G7?'F=1:<XU+2UNT*^%&?DE0?&RO0IS)F217$II>O'UGFG@?EAG(J?
M:8/P"N819D=R)_`=E9^?>0$_7L`]$/6"$W0OKJ[S".T%[GV(Z:Q(#=4!=L<R
M.\PCBRG"A'!;U$%6E>(9?"`=Q>Z_4VR*(0D(GT`SQ2R&3"F7W%@6`4&$'N83
MVHJL+4U/K>3W$R,AS&DP*657.M8['P38NAT_A#X\\@GD%%TY<TZ2BCQ*XIR%
M$]>W!7H#<,R'>1?9<:H>IU$0^A>#;BRB/";+$Z;(`L[`-B(S/'&@#A=-IE^S
M.;*R/R^N?LWWI@5>_`I:*O[*F<Z1R*YMG/?:L`H;/VEZ9&ZZM?!<+-#6&Y[W
M6L;OCR&ZM7S,\,Y(HB.J"V?2&8U<=>,]`WY!05W(45'J61ISVEE9DFZF4549
ME`I\4MXF^=B8B`7FNO.#.F,8UY#(5:_,*#Z>?-A2F`3B(:T'5AOM\V%;R+69
M0<QCQN3I\F;$Q'[^[]L/UJ?_NBM%_UBU$//7%_M;:^NN,`T)L<T%UCSOM%8L
ML'X?%^'R!;;6HBJ3>A2!5R/U*&I>QC6GT"UHB!4(%8(ID2NJ^&*B=U!(WA;P
M!G$FF;H,$J.0MRURTZ7(4VJZF"W8S016A=J$.`T7`2:2)YTGK5+9/82#V-I\
M[!Y;AQTL(BC(P`,[%IFJBZS#XZS"U<F!@]CB#\N9SX'5#"UATRX%4^V.(Q>?
M^0H&]]E#^&0@OR`<BX_EK5'7S",L:@U+G$X9`A(`1'AN5/`VT$5@.3.1$P]$
M.*%2V<+)%<IJV2Z6\+7!0'QT_7!.JXBP34!:434X$HW&!'%AU):$)5?1;+0M
M45Y`$<IW1A[21&L$K5C@D4^8-V`H$'M\9X1@6;!5HZKUB))?+<)*\/%8#7N5
M%]#K";X+^_TXQ6<<AO68>KY`99DXB6.C/IO)ZN"*K-^_?+Z^N6SFFHK9*IU[
MC#\0(=+7O]*(05G^=E'QO(,&KS5;`-=@!&$:@U2F7]V9YYP;*QMW(9>A74Q(
M$8.F.(7]15F[JDSY")%.6+!D%0]1>=RVL`P@ECB/K+$7`1?P/A&5FC--:@BN
MVO015P5Q%<9^.F&#`%6001HB,\SG+HP;N3N1`"=_!E13_C;!^P_K/>@^4'W8
M6QJ1!KZ$7<U'+"CL]G-X;ETV6V>-SJ#9+J`V_<US2%5?4#<9S*;8=;]*,X4!
ME(`.W&9!13H3!E22IQK!U=&BA+X;L>Q@+N]PL8%4?+6N$3,HJ\/?A4Y$&#3B
M!2:)1>H*3U0"**-DT0%%)8L;6?'G^>VY;-!L!+1-U^ZW.\A^V+@?<:!_WLI6
M^G:WV;`'_9[U1C#H+9&AGS#ZL9K-GX>]AMWI]ZTWM-H%+L_2O@>M_C:Z;OW<
M[;3A\:[LVC0#]2KPXU`M!3[1);Q;FVQ-Y]`BFUOX3%8T<`LE$\C.J`2A6\+Y
M/!28DT)4010D;!X\`%NR?%0T:P-+QN>2$+S,"^YIQBY@>XQ`Z3DT;"'Q'U+4
MN[`<!#M9?([&2+J(<UDUJ+_HH&9<?^10<<1)K`1PBOG:L[OMOMWO#PVT*7&8
MOG@>TM1%*=(4"P;W_>!,#&?`A!00(2#")_0^4+^BSI&--K.C`=L(4B>#Y28$
M&I6L[]Z#J$6X_T2D*[,X7[PA^][,2\02S^LS-83WDB@O"_58NCX\L43$#E$V
M+.Q'C"B'ZR7918]H`#T]*X5S5Y7%HF^X2JE\\@C*3%-5=J9S"-(-#E[^@O\F
MQ#9B+N].<$+'@X:6,=[T&$BPA'DPV4`9`A/A4=$'A3\Y@?V4QB<8&&=:\ZI5
M,@([3PER\8K3(T,V</D[VN%P2BKN2DWYN$7[I=@@.1[`[`G'RIHH539%T+0F
M;$%#>]CHL`:.$1F5CZ:X+L'V+<%9ZS0Q0_1H%+*!S+1D,4K3?4)N+;;37(0L
M_`KZ&SG"T(&PWC`EF[$*T6Q$?:9-?'7^*#?`]4%#$$33%-%&R^A0D0O=N8H.
MW$D2+T$-`-I4H#YG%,9X3(B2]_["+MME<G(5ZQ5>1%\+JJ7&H6Y(-)2X@NWJ
M/B*.+D'JQ:2B$>.6VT5+YQ9#[\#0B\%<G7A3:<B\N;B]?&L-&MVS;B/CR2I)
M29T["])G!IY;QHK.+P7;&*"Y'A(M!)+GVLM#5CBZH7)N<;;1Y6NQY*>$2%0X
M=TR`G??2V66<@[%;@U;#MCYB7W^CG?J3Z\1I=%R(@'<E##7VF>5@9^O@G*T:
M_0FZ;)?0912-(^W0$V)99EY.(=K;0"R[4-E6@4L&A@!&EJ8(6SB&X;&MV,\C
M#=D^F%"-HXD':W;M9JMIMUH'7,#Q%`I>,7G7F:P-XT1<P*#?DEHXA80?6AS5
M=Y21]9U$A=\9QS9])J:=?BL!G*=X[RT3>MC[N_1A[2G,\A3Q?2B`97@ZW8K"
M.$5\GR*^MX3XT.S;W?8KC/C^7KT5E2[.-_/(Q>M)JN8DG,V@E-YN#8/I2!T4
MAY)3?@(V.ZZE=B,*>]6,QBL+@/O.?0`'LZ<?S8;=&MH-V+`;C>&K=RV\OKWY
MO2MKZCC?+-]S1AR0GZG^9M3<PK#8,/R*(XS3F%[BDE^PE_..#OK&">X]BI_)
M[ONG+?T@MO0=:(`WS:;=[0[LUCXQ)P[@SJ=F%?)M.BV/W#ZYNOE""P'_>T]I
M0P'&CU`DK5.=>+%5!^:+^2/6=6`>&J$';86`!=(!%=3O[>J"8]_B=:KFLA*S
M@@/>ST0\H<H-XJ0:,SWH.1;(J93+P1R)7E.%F(-Q<^[`]_*:@"TN-@"VT+_7
MA;@8+31HQ&Z0+<I1-'8*=%&<Y".2@[!NS`SGV<<E=:4I4?))81\+C`@30\`A
M``C\8Q0^NJ):MY&=<V=4`)?]LC?]W,C1,<*_98WQ(C&ER2^($J"0!D++\9^<
M!49^9[$#UF`._#CC@O<+$>*M,^1"*?L@+Y%K2+\MHIQG.H1;1XZ+-RB7!Z/Y
M82FF/D-:HHQ&]Y16,(;=W4OD^HLQD5(V@QY/3GXZ*HFL*'2>G8OR:N?9Z/%Z
MM<[YG?4JG8N,NZ5USFT%+5`N2>7EOC4ULY"BW-$SY2\,F:F<R\-*<EIR]44S
M$2=&WC>P9/Y\_[U8;SI7#QH()I1KXWMC/&_CGX_0)::`2PU.F:TN;01>L&Z6
MO>Y;I?(K+*7,B5^ADW!J4+PRQWZ=%'K%#<U1W)!$!ED^(WX>N8_(`7@*9@+!
M`0S1RV9O@GY#T?>"E+GS&73U#'-48!-M'GIN7X6^RU.9H4GDY^4=N8:T9?TX
M"I6$EK1:WS#+(@.R^F@&$HUIK;&11XTOX?YA"*YDOYGI=%6>4>7HU*DH]=F`
MH7RA1M<VH0MPBMU`KTS.)_Q7&A@)A?E4+I4]9M,.)G6IS%>TD(E3#Y/YSWSO
M$?U:0(BO!@6<H)8BV.Z!#V&@=SKB<3AF*ZZ266"GAY'0#D0`ZU@"$Q+:&L>6
MX=*4,6%PK&937JS24^U\_V*Z%:S#!(U-T%WFR*A1>B#!ID>4W0BJY'_,G##X
M"?2]`![`W#!M&,..,$T1BNA1FKSP/_/08TB<))?2^]?P"0$5:LU9508>]3`)
MJU,"K3="/&IEFK\MS4Q;(8%GW880PN(U2>7JPIFN])0>E4UC9@6Z>AJEO&%"
M6^9HE<L%%(+%++#,R!'4Y4!//MU0Z!2\L`)^AW)FP`R!AJ/8,N<;-X%,QB=M
M:#;]`V(:N.:F7+9MP1K`*3=L,5L:H_>D#LWE1UL]'K)3WXE,`!SL0X#5P/(&
MDB:$"6((QW)X'A/?AOMG-<I+3HS-2,@41B)LF6%$%W]Q#,*@\SWS1!=)@P=-
M"S\CS2HEE[Z.8U/A5>@";03E`=HX?3K.YJ2N:3"1$EAF&I$0YO1JR96F4,`\
MY5KS4?5H!"DKCFWJ"C@<0E9K,%I;K2%FM0&O$JD.3&<!:JEBXK*4G%5YR`:"
M!"8@*WU5(%$%:9%]GO%[E.0`&[H3EBLS$3T-BL6."F"O/-XH\P*9G>7&B%.]
M6;HD^,ZDQIUVDCUB/>=>6QJ+H`MAI?-&K>9?9;A'X3?ZRE_PX;HR`?U'?9/!
MSH*L,`);WKMCMC_;*DD:^9=_40I);@9C0\PB-Z-&\;RE!_'`W@F0U$1#68#B
MA4.80Y`UQIK&_G':'%/T<@J^@,%0^7[.+3%RC?XG:23G&=@8(4*'R[5I_D\:
MN%:[02SI+,_O%^,7QQ`V)`PVER]XM>ARVW/YG!!S3=`6\K/Q`F-Y&4O[2FXA
MAWZ4>*$3]#+,F;DCG051N'!\Z>BD?=?Q76/+0L@#M(5)!-!#%;F9PZP\^(*^
M0(5`1H;:7(K'=X5`+,$R.S_A_V+Z+79\7/B'MX0MB3(N/(/6C<(=UJYFW"N@
MU=1/"S&"AVIT7I?XO$N`8\@YCRJ$K,35.(I9KSXK#%CAUMI\M#YZ_@S&\$<R
MR0!+23:;\'+S-,)L[D0;7+(1[7U7<-$MN]GN$:R2PHL6H$N,$%J",-WN,@Z3
MX<O+OXL;]X^J)A1KS?B!UXJPH>-T-BMN`H5S5%H+L=)4XM<%`%]A7I<,BVPD
MX=OT$#*6+S,JZ"\LU;*___/G4?+M%R+6I%61>@<2_`XLHZ^__3__R[+^\_\]
M._ODP(:?SM#J&Z/+ZIZ-VW$:$9RJ@`;2EP6AGS)$%RH68<^A+4Z8+SCM.M_O
M[%;?TWQ`:$7K'Y]H]_G_SLZX?R16$'"C^[^>7G+O'ZAS`DZYGM[*GB\27%+P
MA>[U+H,-$^`Z_>).__+#&/?81K?124+Q5^^?FBBBZ6XQ=R^^>7'^>Z;T!Q`!
MC]OZL]'H_`!6Q1CL(S]&J(K?&N>-+G-\RX-0L_,YI=T:A11^'8-95(^I_-[U
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M*^_%"U<!/?U%/?Q,)K?[S<&@Q^2O[&N_`UES'AJMII3K^@/)K,9K='V)U?B'
M\*&37KN``]D7\LDLZ(O5RU2\C@_#R^+=YVO\5K_=[RY;NY7]'M"(U]NGMSQB
M!,HFS\8[<O;?1"XA&GY9JGSI#7I!//]\+5RZ893VL_=QK">1S6:GM_Y8;C#,
MW9W$UD?T0GZ8S?UPX;K6-=<,LCZ(PC@9_2W?P5?D&^(%]?PS#:I6MR$FIDYG
M^Q_-)B+VC)&\I\(E8)37'HE\0W4PWLK$='J-LHFI[.T%QO/<J5D]%E*FM,KQ
MX"1N!#*5PLQ1X-,W\/!U<`N/7D_-0\YSEWRK(=?\LE[V0?A:7&\WA[U6=PW"
MW\EH&J..D@VZ-K3@@#ASK`].%%#IBALW8K^RC?K8&Y,+][WG8^2$.3;9H-$>
MM$:-R;:@*6J)VH$=3;2RWLC;.1_D6>.\/>"!;T["4;!EJ227L*79V1I;=!!]
MF5:1OVZX537+-4BA5:WY5("&J-_G2/?^F;@*@7U9F'X7PI8H<VW]X4UA>63*
M5RSS:MU$8&$G[L>4[K')H:7ZH4Z4/ZO[WSR$;`>&YI;423A@./]3,@_8[_(#
M@LQ;7]#B6&]0FB1JVVA9MTO-;FV\2Z\(FJWSKMH2:E*FS[X/(GY3\H.+";Z!
M\]@D]'TGBG7%E[?KL@E:DF)_/15;TUTH;P(O171KD4D;LZ9=O#$XUUM_+7(J
M10COI2;/$I1;:&";H\VOZG[#L',*/:N!42DM&0'(]X7WO#SUV9NN[\4%G3DB
M>E?49,`3$YV,8WTT_NPFXDZJ?*#+M]A!<]"2Y[7Z/;WTP-K-UJJ!#8>#]K"]
M\<#4*5O&YG'^0:6[-7>ZA4Y6.HY7&]'-P;`KK(!5[>^/\!J\[W0Z@W9[3<)O
MQP_N)`5QN9Z"F2\"L#)'Z(+GXP,'15G_N",YPVMPB^[!,RI!-GP]E<V:K>;H
M$TU2@^I:?>7._]O2)-V-"U/4#UOI=+=9_@QLD$^4`R#BR3JV-4T3+`OK5#G#
MI;2A>,&W\3CR1BJU\(EJ.RZK$;(Z]&AWD65<?T1D-B-O?[`XUUO5(:E?EV2P
M?EF2#/J`,8^;5BH1E/2>@:TPIM"BYS.>OWAR,?P9._<GW/5_8W6M#Q@7OE$F
M_A9`#K93FN0E>)=7@CM*X#\$V/0CD&0S\G9[N$'[$?#5^#L'RG0T&_:)LW-P
M.'^'L"(8?1%L@\W`5%X:TN[UX=,<#?C,H&WWFMT=+>!CPO<]I&6\8CY>/?+N
M:ZZ^TVQBQ/G^%MS!XN,>TH);@13XZO?-5XQ(N_<%=]KA:BRX_FF'.^UPQ[W#
M;5C'ZF!6X1V61W>FT.#V?"6'!(9Z*A*WXT4^V!G&^^LL$7<X*Q^1D[>RZ$^%
MWHX?`?D`3(9N:X!X)7O2)GNL\I:%/\YFD#__)MP(_""\U`7P@$)Q;F`W&2^J
MKN#ETQ17PX\>T>7Z-O%-H&/\(3.67:!JY.9'@CDTFRP6^`X^IE!Y50@/IG3*
M+\=E.9])2$C-WL1S*"X+7Q#1`?,0(4L0*_,IC+X2(!D#VU@!Q70CVEF6+@.[
M`<T12AL?.3ZAH,0/;A9.4)+U(%#3"$&+X7LDS!(0%[GW'D)D$`QP&LB/.JB,
M!C"?@^!3*S,G^NHFL@$!',&/5H(SR+"B:JG6>;,BW]U$4XB\^"L'2Z6!R(<G
M\)@5JT@T98`+?,&&+H+)GV8SI_6UA_6UQK1F%YRQ$@G23"-$FSC;5%PBB;,K
M+0_J9`4J`UZ""A*ZT!AA**=3>HQ`,$4?B`E)`-9,Y-0+8)UYC*T\$8"..90L
MV:X`J[)&*8,7(307(G<QS`.#H7!X#_3RB\!CXZXP=2`'?\N++(O.B?!YSMQ-
M8?-3V!!(Y<R=T*L3]Q&C9#7VWZ^B#6/IAR.:DX_O+WB`8>3"]*!&2'T'QK%@
M++1'1A?GA;^<DA(*BBB$)90(5`O0>T\@BNZ,D1P5MJJ$A6+H.0.V^%<"&W,3
MAJPAQ"?U+`AGBO.11@("%:-C$="5@0!%EPPD+.NQ8WRM)R@4<<:,ZSH3#!*D
MRTZJF6H@\PC!0?!!@9R'P-@,SP\ZEX`M]3,DDC-G@6!CW)8[*>E&%1(`F7L,
M(XK)XJ`R;`0(Y2%I)LC^>1KIDPR8YTV)Z@^8X[*<1\?S#4T/+R%T.[V1QHS7
MD^>'PI#,O0NB-1NE4<RX2H*3P/$XT>)=(M-QB4C%UAO\4L&FP+9"6&UO60#N
M$=B1\5,>7,='F-G)#!94G`@@=2=-'A!`DV"OYQS6+!\=X\N(`>H%"&\?"91.
M9F88W8-X_$\%0'UVL]ML\RGF6IBH3]*^J&-"R@8RT>.8`70R*?>TY:V>PLQ.
M9VYT<EN[=P.01M]?9.W-)UT20L)F%5#2&+%*J14R)AW2<&$@H(7X&7,/^PR_
M29,NWPEH2;7;EH2\JBW/T=LCK-AL\0EJ"IY`0'L.=5<[,EN0O\).&5'\*RXX
MEP`L"<]Z'L:Q)[4?:DA)"VK*0""JQ6Z2^&Z.>HD;EH'9EF\3^)@B3&.2$3CU
M<P:"&E@!MI:,@1#*"9"-B6:L.D46H4UR<8>*6@R*5II7`S@U87"CS*F`RWNP
MTJ0V2PO&X"<)RPN"XII`FD+59T\>JG1'O*)V1U8UKJ.:=')X$"!&,"IR!&J+
M1.[^)'7/+B:/.-2)=8E&PYW&9[X*QN<V3\-_>;`!@HTVDH'75U>E^3#<S2?N
M123;OT_+L!LP)^8CH:S_@1@8&H&?RTB\6WQR_A5&E[X3QY0L(ZE$(C6-0.+?
M@3XB3U-WY94ET^33!KHZF::"[#K<(Z9=XG'TLYM&83SV$&0WUG`)N*?^U9DX
M"#NB6":ZVC,/D58D-4.I!$@`.@693-,_OZ",TWN"ECI,;3:VPE6%.BFHLZT_
M`X\2V'CQ7\)&`ZH\\)Q]BZ$@3-"EJ;J>:IKJ2E\]-HFO;$L#`SZ7/Z))W>#*
M/,:]\*@$&K')/"H0O)P[&VFTE^#4.DIM/3#)[7#,)I8=$F=J<F&P"1<*6OGO
M%U\^OL#@88>?KJ.$2\;?VFC\`L;U,,?/Q-4<?V=_>N/@%4>I-93A69MXUMY(
M=4BC6QD\8+JCIS&[(?V9.`\OP"<@#O&%I8T31N9FA#35%*?V)IRYAF/`Y2)Q
ML[;@[;M/7UY"9)":\2)Q#7OO=C2+5@M'S05EX(/9F$B+Q6<00663O46#=G%#
MV,XNSQ!U#+:6<5XHHV]S1FQ@ENR;077MD0+3&B_#M,/EVKI'TZ5<4UI'[MPW
MSH(@7#:WYR0(.3?TTHN.CY.-C.[)4KB:%]O9H+;.EXVVIC*E]"SF;/^HM#\!
MVE0I]6K+E/!02,GYY%`,`#D&84%6F\?\GGC->`M>VI&A7&/O,KT-I:35';8N
M&ZY%XJ,N]OJ2#)&D:<J0,**KMKJISZ<*;%03M$)BAA`&P<<PC9:`H1!&J?&R
M>!=?Q3<WP71I-IMJ1.OUMO$@[QXBU]ULE/3J_H9)W6TRS@N,*1=3"F*Y_F"I
M`>(T1@!L-N!!IQSRIDZ7FT_N4[CAU#Z58:7M:F*?-/S9Q8PK0LH!ZN)$;$]M
MZ,#/8.A2#Q)Q2+8OC-@]>^VS[.P6JAH,&Q+B:2G9]=FWR6:P8X8]<Q/H&9OE
M=GA4;2?LF!.U[8/ANF,F/8&7Z;%BLFV4?]I$++!),(/U"SN^GJ@I'M67$DL(
MKL^G[=G?>^/?5B\MFLC1UDLS](@XNMIAMVV6KNO'W!?;-O9H;EWFGG<;NV_%
M][Q[6;XKZ'>WQ[[MAU#LBZ,["*@H"NH6=YMGV[H'R=A5#&R_-`,+]ZJ'SM$-
MKEW7Y?0:)\_/&*)[]^3Z<%;^!"QY6(8H6W$LQ#:X"6YA(_#B=J_97><LFN]4
M#?YSF%!L/V.P8^%*-\*ZY!AEJ&#8-S"AN5V&=K\+[V2C^D"R7SOZMYNA*DJX
M@K(-6;/9AOLB;*JSZ_YVTUN;85]<#/2G_(V0L]"XE#?'^3XXCS*Q`8-\GT*,
MK`5)??Z]O>P6WKL(%C?4YQUT^5?H4;0YN7L*KZ-/870`E_I+;D[6&HE&CQ<7
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M-)C`WW`R>KM^L*39T5U(CC]4NM#)E>CC*OBKZF`+>_?S`BAE8;DUZ2XQ\X%Q
M;!EY;OSL1!#9ZE7P1;;YDEDR19="-V>D&X2NXLWZ(K439CS/35UG_,IKI3+^
MTWACM_T7T<:?I4>*_0X^Z_HT*%LQ]&?N8SOAQ/-#T:G<6=[)5I\IVW+^;I<M
MV_+T9I*?EO"&R>#2E!+9XHN`0L!24=Y$I.&*7%_X>GF])VY0MH<UIKFU3&-?
M1%O'5NAIB\`!N/X<9KXCF3_5[DP)?"%A*<:9N:!$<S4ARXL[R3]'D?5S/H.:
MD-:XFOQ:A9;`I%Z[TM*SRBIMB*)8,H5G_?/6)I.8*11EME'`)LK,%-7Q!;N/
M9K4P/;6`_UZVRE*9R&P)I^\P8.D'ST#I?`GYTO<@7)GS0E5\Q4J/$C)"NV#Q
MG$&("C]V.TU[L`JH^=5#WQ\,H.?Q8/]V[6:K:;=:K1.H_M&IB^L,TLP$<:N\
M40K'('DHD/@I)X#^5PO0/[!;_9[=::RH>O+]8O0?VZ*^@Q4;.^SCT8!RM-.?
ML/T/D=##WM_M;G-H#QLKB@F>T/V/VA"@(@`Y/P*>3D]U`4YU`0[%4FEW[&&S
M;W?;NSIIO&!I@._56U'IXGPSCUQ$L0X<A(;V_7!,2NGM9EZRU^.@.)3:?$OH
M.)WT#W"I<:1F;!P(,$O?]]UQ@O`%\P@A59,%2TBL`:]#Z^'#+3O\OW,?P,'L
MZ4>S8;>&=@,V[$9C^.I="Z]O;U8Y)XGSS<1\CCR*AJ6M>N)-X2&\A<9@DE$8
M?L41QFE,+XV<V(NQC`SOZ)ZZW<Y?;9ZV](/8TG>@`=XTFW:W.[!;.RL.>)AW
M/F^7C'9'3LLCMT^N;K[00L#_WDLD^`DGC)">B`D=?Z<.S!?S1ZSKP#PT0@_:
M"@$+I`,JJ-_;U07'OL5K1Q[,([=7V(,I+0NLT16<P:EF[,:Q#NWC`DM4C(EB
MKI]E@6S(V`-V<Q[`SOG";LX#L)D.QLVY`]_+L@JHSX@-S0>LT@VH.+Y4QZQ^
M62=FU6CR%+9:(VPU,:;`+.>T-'*5XB'7"5^50Q2[1!+.83PX'/&%%/&VR9I3
MK.M+Q+J:`I&$4B!.0:^9"3JYJK81]/I.!+U^YWZE@['.CL;TZK;L9J]C=WN[
M*CY_NN':G18HK8&Y:]5PI'=9KSB>M64WFBV[,VB^^CNG[\2Q\^$;^7"P5CG\
MS/'I$W',4(5L^[_*DJ6/C#VC+<^3;^<P*3UH2Z"#N5!VH[>K:ZL7],&<HEZ7
M1KUR">J=*HU3W.OQ.(0/P*+I#NQAOV\WFR_M$#[%UFQ)[^0X\_VZ*`XE].44
MS7I<"^ABV27#UD+$3X?[9VV%>UI4IUUI2XM*WM&-P]D,#&$)'.$DUM3Q(CY?
M?^?[U<'8MT=SD,9HAD'7;N[L)'W:9G>O$:1K?4?*X+3/'MJ1\SL"A7A]^_@E
M(COY/KNSPJD5IDF<.`$>\:TP`_@BUO=WOJD?RB%T%ZXCNX%N[%6P7J?-]P"7
M\57PZ,8)A2E[@>5,IY[O.8FPR!'-Y;3]OM;MM]/LVMU]IDP=R`WV*P5D$J"M
MZ+,R<YETDK4!V,2`C!0(JSU:6[F-.L$V;9G0@][YVSO=]T^@38>@5S(I3X8O
M_'1Y?;J\/A13YC5?7J_.9MHT:T@E-%W=?*&<F24IT;:P+%1T'.$^JO*/U04P
MK^98]NR]J+\YP8)S%[I9&L"ET>:RBH]8R.`/]][Q/P2)ERRH6$%ED?A\L9QF
MO],=]'L]9MRF5"F6"6<E5D3U9.Z)&\W.+OE:@ZHI6.\T1U2(,!:=>(!IF;O0
M\C@NY9EH7+>-Q297%B;*LT9VF>M1U!^Z34!*<$A$ZO7T-@&)X/H/-`3Z^IVJ
M@MG^;V9<*6DKN7)HHX<!=6L-J"3?UZJ=[[OQFJ%>1:9B,+D*;KA'63P#)5=W
MIW(9][:4VIUAL]]MBW+M6R965_QRHJ_`O+]QP.U4)?>)%79+%X=RO966]J(&
MZ/WKJ:CUPH_SNP6VM)N-1K/>PK@LXU,[5_VD?3X4E6%6D:+K)HD"FQ%6UX5Q
M(9Y^[/@N12:#X&')H3BK9"[TX*LE2K3[!9J]#CZ[R2VV>3V]$2VN+R'UV'11
MLTA,1Y146DZE+O2J"W(#6V[3$>QT'D+X$1&6DBMW4E5BQ[;^2";GY:5=5>,P
M*-4TM6PT7)-CY;5TDDE-OHC=JAY)F[#G.DH>N"3591C-0Z&S=\X6ZA:+4!F]
MKE5_:DV.E(7@4J75QY5:>JVMB_K)6U[4R[.U\_+];'G5WP$8QV`;&_IZ31JW
MP<@5V]UNN/:</6U3'NT1TVP)4R45=\ZW/R0-%TP"%O%ZKPBX"MY!]W^CWN'A
M=]CW=4`-YTN%J1)=6V;^6;/9[0Y:';%;[I)T-4N79OR1B,?'V\I8JTLZ`Z&L
MI[.9NN<LROAZ*L+<]J^HU[M0:S`\B%P:/5Y/"P*W94MXU:H8=)L],2_/)EV7
MP\/H#F79"7.,FZS!S:HSEED8#SH0YI9)[S9T[7HGIZ4&8NN\(\JW5M!;BV'K
M6X//X\YVK,#->5%93D8'$&5!(0S_R,9[E.[T+GRONI0]9OHSW3'[<V\,6OU>
M1QJ,VZ96UZJ7"<XR?!/G>W-^KZ4YN>]W0@L)4V\W;'^.L=5J]CK=WD`4HM\"
MS7GO2C;WO#`C(J!V+U,B*;H+;P0]V0$3+8<X2]!FJS-H9EQ`VQY%<=[V9V7(
M+@_>PLCJK6>17>ZT2W8C^8;7ZT!$NN24MP9]^BY`!03%%1%!ZS'*:.\JN%"M
M72187WWW7.G`R4*>*Y:2H@\&M0(;MRE+9H_7TVO=G][&7U2P^&90G`&>0VO>
MC+C8DAE1;;9Q1_LP&>I;:MUFJ]EJM4P#83OVP1:J+VS,:-'W13"YQIZOC(YO
M1+]?J%MQ/7D7_A6&C5WNC_.M8:/9;S2&PH6X`XJU$J'#&&@/>2,61A:U9EN?
M4Z24CG'N.(V\!%<"S,'(%?;!!@<Z<?H2G5U'U!5W!(<HU<U=^,Y]@:->,S</
M@XQ"69=TQ>,ED"W_$5<"M6Q3<3,%UU/#Y4RR<<O'5^@[LYI?4HEWD.G2D;,U
MNC4DZBQ,`RK]G#$DT5UG\;8;1NOQEELT:(3VL#G9VCZ-U,P.N(HP'H+O!5]_
MF89A$H2)^P=\L+[15U&(`28/23+_Y>>?GYZ>SK^-(O\\C.Y_;C4:[9_QYY_Q
MP1_$\\EB#L_#.-U@XDY^H,;SS8M'?6?D^G_YX:/X]NP*ENM9\X<U.I8-9CN'
MPT\(YR+\=N9#+PA1Z@9G?][^\-L?WM3]Y,RMV^RU&FY`ZJ?0)Q;!;U?!&'Z+
M7.OI(?3]Q5GX%,""54<ACV\YBVWB>__Y<V;(&3[XX5@0_!#A#/[O[,@%7_C+
M?_HC/SL\*OH5@@3\7,K<BVAL4:347WYHGC?DJTXT7L%0\<3/4V><G.49BW<`
MI12%E?/'Q$*K>4++1]\J&WWKX$;?VG3T.7G`%0;?_^?/2`;\\?\'4$L#!!0`
M```(`!Q(K$2I682^JA$``/SN```4`!P`8G1X+3(P,30P,S,Q7V-A;"YX;6Q5
M5`D``P?&<%,'QG!3=7@+``$$)0X```0Y`0``[5U9D^.V$7Y/5?Z#,GZ><VTG
MN^6)2W/M3M78FM+.NI(G%X:$))0I0@$HC>1?'X`")9'$R4,$)WG90^@#W?C0
M:)S\Z>?U/!JL(*$(Q]<GEV<7)P,8!SA$\?3Z9$E/`0T0.OGYGW_]RT]_.SW]
M#&-(0`+#P>MF<(=H$&&Z)'#P%4?+A$F@@^?QZ.'QZ7YP=?;CV<79Q>`6+S8$
M36?)X/+CQQ\&IX.KB\L/@Y<9GE,<#\9PF3#=@V$0P&A)SP;#*!JDY'1`((5D
M!<.STU.N/4+Q'Y_X'Z^`P@&K=4P_K2FZ/IDER>+3^?G;V]O9VX<S3*;G5Q<7
ME^?_^N7I:S"#<W"*8IJ`.(`G`T;_B:8_/N$`)*G)!^SK5Q)E`CZ<[W0I*?C_
M3C.R4_[3Z>75Z8?+LS4-3T05>;&%DHQ\7:(7-C'O?3Q/2W>D3!#2B-Z9S;PW
M&&S]1W`$QW`RX']_&S_NN%\13M`<HC@X"_#\G!>?#RF%R2V.$X)>T\8=3@F$
M<Q@G=S`!***L(JG09+.`UR<4S1<1S'Z;$3BY/GE-ULPME]]??-@ZY3L+F>=5
MJQL$>!DG]!ELP&L$AW'(?B%+&#XA\(HBE"!(:U3<17I5$\9X`Z)D,WJ-T#1%
M)U-S!R>0$*XG@#&%#[".%:X*JAKR&#/D31%W%&_P&C562JI:M?O_+-&B'HC+
M(JI6AO6$D#L]9/^@.$(A#ZU?$_8G%T]'DUM`9P\1?J/?8K`,$2NM4-]*6EHS
M:;3@(P@?*QCX;O%\0>",,:`5?,*T73NM53=J_`V(>!C^.H,,OXW;IY)^:$(`
MHF`9I98_L?_G-,-U`IG877VX'8W9F-8AJT6$@YSFB`_!F.2-%HK3D6P"Z&LZ
MG+$T9`K`@@UKEU?G,$IH]@OWS]7IQ:48<[\3/_^^C169Y`B\PNCZ)/]C@A)N
M:/;C>;=5O5VR$!PGTAH7RG(5WY55J'\)7^R'WU\("&$VV+%>\ID`]H\Q#"!:
M\8'O5S9\2^OJSB@,<6',6WD`ZR')&PQ(D*EA_\QANIPH"8ISNIS/4VFG#+SS
MC']"\%S5%+B&W0>U_S3(B1\D>.`B%I,0DNN3#SQW?X,\>1:)?&>@Y@,*#['L
M+SY8KD#$`_`PN06$;-C,XC<0+6$!0$X\PH>6/!["IHJU>L182A1@^=X?L#S&
M*U933#8,TP5,R(J$,_)%'K:PIN[ZALPSBO:Z]*>]G@E<`!3>KQ<\#6"0&R4S
M2'3CF`.'\)`5AX>-[FZI'@M6\@1$K@P0.;Z##CWCZ`-NO-Q,CWI"<7+*.NS]
M.HB6?/'L,\;A&XJB4D2S9]E%.AL6G]JZ@I$*"-A)$LCXT1]D''337W$<2*.B
MED:X14'C4V/;F*%H706K?RG*'5Q@BE@VI6]1$YGPAIK,IW:U-$;1M&INT;H_
M^-.ZSP0O($DVSQ&;8[$Q=K>^5TY(;4AW*8R.U*>6=C!*T=IZ"9;Y2?5%B\(2
M=KJX%]-EE+!1@J]GE[JI'?FNNYK(?6I,1^.4W=<DQ;]%AX.=&%;?KPD._ICA
MB-62<C@FFP(*;,F%H\SDG1E>KLQC+'*D9TQ2'";;#3>^<O2">33F6W`X8E69
MLA0+$DB+D:Y9H<*)30GMS-6_H!B3M-I2IZF*A?GEXNXB1\/MBXW&YR)-,]IY
MI"IK;7*X::N#&CN;L>-TN641!,LY;TJX78[([:2Q=L3S=#^-C?VCR0M8%S<U
MJG%GVQZNW#[UL-QZ2"TW&#I3NGKBJL"_:=<+@8`NR28U4+9GH";8;2Z5"7Q%
MA-$8BT:7R9"MCIQVV[!C?G`BAN$](#&+Y_0`JRSS1`$J#JSV#,)7-@R^`L'9
M6`M@V,CT<68NYB'*"*"AV&\EE"E\;7JS.19M+17BW^HY&Y#F.%:VK*HXV_HM
M%?O:I@9#+!JT+,&_''<8AHC;`*)G@,+'^!8L4`**VQ\&JBS)4U'YVL1V9MDD
M;2I!ELLM_9Y!&J=!+<TA97HMX^4Q'6Z]8B5U90/+-SGWFVHC=VRU6GB]V"@_
M\Z`F*"\HUCG%U]0&US9C&,,5C)=0;I*>J+!:7B3RHMM(3FQ8&:4"_L%)#94<
M#T=JBZL,BO.H[IS[91M[3E^A4MU\"_PX">_YX%397\J!IH:3NADTE&<(M#3E
MH4-]>N#8IUULC#,3'IY[L3*S(XQ+:HX=[%,!?,^P.Q^C$.=?2K0?`>/DEOV-
M$LU!&3-I*9^0D7J,!0<;[="@%^A?GI'5]P6L;6*#+7D!%VKR'F##TE8W?*B%
M6N[P]"!M<':53>;@T)U^.B]ZZHG]_ZA7[JI<;.QPJ;>X]YCM.S9P5*4EZ?N%
MYF:E=Q:06;7W^[X%'TK+A`<*95V>TYR@1%+Y<L'^#.:NH,-;`MQW#"[B%L<-
MC.&DM,-IH-K=!5!0=1?!)<['MN;DHO5>T/;DOT*`B,P7'FUG[WO'`W,)?]X"
MQ4O6Y_=A^09.,($[FR"]7R<$,%-0#,CFD3F56H6Z(VC*(:TE3=W-5+>UYW51
M!$(-138WE5%T9M%GPO1ONT[!$DF)L"!7TMVI.!!!*I9+RR?M%:79>;AB:8='
M6=)*\$ZRO:-=.KFB*-\=5"F5=[BEIW`Z-MN1WYK+R]D>0"GQ^[>$(=['$74M
MMJ2T,&O&0J&?;:BSP-B`!6;_%AP.*\TO!U)]5"F22$++GL3+]K2PQM2J<A'^
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M_!N6LUZ9LT'V(J">;/]FEH+,<P18VF</`;5`_V8?GP&*>0@>Q7QF/YKDGI79
MO2E33-R=F++\W9+)<[14LMT>.[;B/;R<=*1LQG;`/69.HZF3APFX[OC`,?:Y
MC4<06JJ$ATTA/P.$->=K\J'DD%V\"K9C\S"G/JQNA5-GE?EEIZJJG!SS`AIU
MO:!'4`7ILG[5]=2ZK0.*1?_K?-MP'4JMXV,^J7KWYH$%;32-MS>%@LT+`3$%
M06IZ'*;_VWHMRW^&!%%F^]V2<"=!@G"H>-SHB!H/I[IM:WR77>?X;=5VASR*
M1?XM':C,_A83""+T)PR_X"A],7H_GX$!,RZ]&%"[;S>EQM"AZZOYG^K%#;=*
M5UVWOAF&R;EG-UDDGR+SZR,V6_>RQN$OK<$[N/V[>+*C`JOVDS8JUBYG3[R*
M;(JW0@P`-YMOK%$?XP<V\8T#AL(A&UY6*3C+TR9'QOU\R9JQRRLJ`81ANF"P
M73/+O<A7\(4E]?XRBYZZT^FA:Z-B5_.+,T5+A6(A0J_(OZG+894?*5WRK^NQ
MZ+A_"$P#)2V]!$P*^C[#R<8%#0%*H4I`ZA]^0BI[-?GK#+"$8WLG5H,H';D$
M4'+R/N/)P@$-P4FN2:#I8VN?4#BLPOU\$>$-A*-%NLA]OX8D0'2?Y4D`8F*1
M@$3-TF>@6#JB(;"HM35Y@E\*&/X5"/Y&8;8W*((?1VTQDMB0"K_H2?L&#`?#
M:P!"KZ71UY^-H>,.$1@PMAT@`W/L,/)(@H>&IV\@J>**AL*'1IV/;T'+<J[\
M6\=LXKS]`?*/45NGR;9"M+FS64B?D5G968UGV6;]`KM_]VAKO=*"$*ZQ6I)?
MKW30+C;VK+7Z=XGW?C)A46TT8>%L!N(I'(,$CF*Y#PKAH0JK<+@;:_^06,,U
MM;#HIM>_BZN*OK0[>.ZZ4*IAU"^42AF;R@&'<[[=\6?:QJ-)]A*9]BM\+BS9
M*[)6+-X-L[HFPY4<83.H2K2F[\Q::6LRJCL`1MQBYG5@O5N\.&"-'2.W%D8:
M[O>!*%OW-`XNC>+6ERGD-1I+WK8V$FK1,^[ZN'B#0)$8W3@FQIY^"_@.+MB<
M&*6U+2!$5K3_HO-!4=]0H#&L1KOGI?JWPU9,-A]CFR?8"YBH)V3_U%HE(7W#
M62/.JH'(JOHS[)H6%(X)WOD"(,+/S(PF3SB>/J$5#+>?;_X"H_`!DV^E0RE.
M/!DT[7AZA\0*KJ@#/#MU&<X\"I+_OR31.A:;OD'A@,OJURL:.=9@D;"G*[HW
M+%;S55[6B<R9NY9#FL(K./J&(W<W-);4*Y19KL/W_05L_Z%A?4FH1OAH]HJ?
M-#24\[?T)=$Q#"!:\;!E3,X5],H\O$3?MY9W=4&CV75)59;@?-_(882VIX$.
MN%*S&*=X[PM=1D>T,GV38>R#UQ@3XV2V&B8NZ+/Y9WH/9#LU,*+.18@2AW9"
M^H_,"LYJ%*MV^C/T-G-<JZ'O1>9R/385`/$4\=42&4KMB*5Y>)FX;ZAS,KZQ
M[+NLQ[\KFHI=QQD@4]N-X3RM?D<XH^TW@/2F-[\'G*F1'1GM^LW.`$]C5-Q"
MDK[2;T&Z>[%31]HW[#@87@,Z>BW9\.51Y$G/0:=K$_QV+1MS95M[>J+LPP`*
MHKX!Q<K8&A!1R6_R#DM;>?ECS)#,M-GL]$EHE5EVCK9O@'$QO=&<.:<FBRT_
M>)0:9P'0\+6SPA=.[;Z-9J3N&XS<S*]U\L"@*(.21Z^1E<&?O=TJ/DGJ<@;!
MS*H,5#K6O@&NAF,:#6,ZK1D431MJ?3@B7OG$<AN7%:1:_3N%I*@]'_EHE>/A
M&D;]\7`I8U,[-^*IFLT=7&"*Q)Y`Z5*@@2I+PU54WH4G75M@6W-M(I%$49J(
MJQ3X=TOB&6S2!X!>\#!@G9[`W%/#+!RH7G]V9\PN\3DP]@U9E9U2`VPN.FW?
MZ.STX1YK!+IS*A_T>4\8K.R6.B!T46JY2M[CS,N<#+21>4FU&IQ]W%?H=B"X
M@PE`$>WLB3DE.LL?OK`AW<<5#6F7(59>K?2;>+;FYHA-!@OB3E^W-[<:=C2W
M^&2]4H,(B5K)_CW,/@R"Y9S;!\/#.R3LWQ%,&RT.#S>P;,?IIL5F.Y"-B?4?
MI2VYT`G/S=7!E(4>=TPJ[N)W/30]H)@!);VI4*Q:>7"R(\[>>#(0=Q9X-!4[
M0-TANNS=8!!@=HU20'=AP[+5<0..R84(O=[T2:P*^FR_R>@'(&4YDRVY&6R=
MYTV-0,N8.]4"4CY_4BTI'W<0$7?K1Z\1F@(Q&DINX7<]MNQ?G:`)W7Z5@(_-
M^RT2Q<:ID;ZP=:JA;VIE6_;&P4%8$3N/_X:`O#`IQ<-*%;D+9EIS=]>?[5L0
MU_5*KH<;]1[N%UOK:_UU%/L:/>`EJ0RJ0V9G3&V9WQVD)#YI$U%;=:T_@V)7
MH5_9@//R!J,5_`7'R:R87]03X@2PLI!W!32#C]H"7%EMDQOB-8`WG"20I-V!
M95J54">5X`2Y@H1WA3>==]H"6T%GDX?*ZV9B;[AZ'K;G=<_"..^[PI7<(ZUF
M8%R;5YM)-F_(=#WALJGCK73J58%SOS!NS]GE9@.OTPV.EU3C`S7-WEH937>]
MO4K#83M;<_W;08]8OI?)]^_&VO9:IF4OL2,^_,"?=5_H`6:<K*\#'I,B_]ZB
M+AAH%6.MPFE_T6)E;<T0(U7@U4IMNH;,/RF?OKG$FVM*(*QW)D6:%K_@!$1B
MZR,.^3UT'$!*QY"R;"J8I0O$*QCA=%-4'-T+U;4K0+<EZ0(%C4MO[),G(.%'
MH[+;^_QYK"B"0;($4;;A/.8`8U5-=YI>\!<&449#K3W;IHK=$=@V5'07D-H"
M(SY*:^1"7L.F;`_HMF%"ZPM(CPO"K153P/#;@JGG]M+T#K)U=ZHK)KLP55G,
MN^P6#7FU;>A7KV:3\Q+MJM4+6&?9S$9\SGG[A::)^+;-8WR#\1^_04*7E!'?
M`(KH*/X,"8[+1QRV3E$L<K6IJK`FUHZJ=]F5CM@Z;7>W=DVI^CUS4<#_>`44
MLE_^"U!+`P04````"``<2*Q$#SA=F78A```RUP$`%``<`&)T>"TR,#$T,#,S
M,5]D968N>&UL550)``,'QG!3!\9P4W5X"P`!!"4.```$.0$``.U=6W/<-I9^
MWZK]#UK-LRS+GLQL7..=:MT2U4B62I(GNT\IB$2K,6$3'9"4U//K%V`3W;S@
M1A!H@HY?$KEY<'`.O@]WX.!O?W];)@<OD&0(IY\/3]Z]/SR`:81CE#Y_/BRR
M(Y!%"!W^_7_^\S_^]E]'1S_!%!*0P_C@:7UPCK(HP5E!X,$#3HJ<:L@.[NYO
M+Z^N+PX^O/O+N_?OWA^<X=6:H.=%?G#RXX\_'!P=?'A_\O'@<8&7&4X/[F&1
MT[P/9E$$DR)[=S!+DH-2/#L@,(/D!<;OCHY8[@E*?_O$_O,$,GA`K4ZS3V\9
M^GRXR//5I^/CU]?7=Z\?WV'R?/SA_?N3X_^]N7Z(%G`)CE":Y2"-X.$!E?^4
ME3]>XPCDI<NUY&]/).$*/AYO\Y)*L'\=<;$C]M/1R8>CCR?OWK+XL#*1?3;(
MA(N_=>0KGVCI_7A<?MV*4D5(H;KF=BF?GVR%ZX(_E/^*\T-:R`<'FV(F.('W
M<'[`_O_U_FJ;[@GA'"TA2J-W$5X>L\_'#\53!G\O8)I?O-#_9.<P!RC):*ZE
MJGR]@I\/,[1<)9#_MB!P_OGP*7^C97;RY_<?-R7V)ZFF8TO3OJ:@B!%EZQW!
MEY@LP55*V8:6ERBE!8-`<I7.V<^,"(_4*'B#TWR17:0QC&\`B18?3YB!LS1F
MI+5WS),=ML4RRS*8G]$L"'HJ:^WLF>:YI$5N[Z*!3EMS+WXO4+ZV-ZV5WKK4
MH@@7E)5W8`V>$DC!H+^0`L;7"#RA!.4(#N!^+^VV+MSC-4CR]>U3@IY+LM%L
MSN$<$L+RB6":P4LXQ(N^&=@Z0NL/2)\1*RC&NP$62S4-8>MJ6%WJJK`O)]:0
M8C*@]G15V!IS2YY!BOY=\N(49"B[G=^Q/IXB4%'EH5@N`5G?SA]@`J/\`3VG
M:(XBD.95]:"#DCN<H&A05?-D1QB=U"-K/<;OH[@9[KLH:P?U*GWV#/9F]U#N
MN5^P]J&G?E>]@K6],D6#^P1KBSH:PFB$K?WQ8T88A<+_/WJQ[`RQ+9CVC,S!
MI"Z4CG+T+M)'Y^BT6QPZ8[.>JOGMB3WUP=Y[7W_]KKL>UT%?ZZ"7'=*_.IAK
M#9EDA=*'C=YWV1<$;<MBQNR8_I%1;3%;KGZ@1I2-&K7J#&2+RP2_9MOVW,);
MJUR\N72[8JOR;/V=%O,97JX(7-`$Z`5>X\ROG\99.W7^%"1L:?MA`6F3L>N7
M`:%&+6!.296X<M8HJSTXY]<?>Q?.<50P+E#X+V@5SM>U49"%S6IU=2/IB(K;
M6?U9-W6[Q8'2_#A&R^-*YA@D!M20;*KPO1*VU_-#:6ZIS8%5]&]6:W!Z%,,Y
M*!*#3LS81H%NMQ;C)4`&6-L87*EV86^IZF@)ET^0N#2VJ=>!I0MJ%(F*)WBT
M+0B']@JUUZVF)$$I8O7MFOZSD3%\RR&;S?"LF;D#&@=?N5JW>R,9H>A,O%LT
MN"_?JX6Z495+8WP.:%W:*9D\N,Q",CURZX5J'N@R)ZM9L4L#^B\GN,:RO<;B
MU#O#!267>?I<F7-IIWHQ--S&RW\CYG]#P$M[Z#LCDYVH$=I&WV;8;GKNIQWS
MG;/_K?AP:RX_3E$:R\U-<-2P,6&'-S$13H#*R<\<9$_E#*C(CIX!6-&9T,F'
M8YCD&?^%+3I\.'I_4IW6_%/U\Z^TR.D@.%_?)6`S:^$UG184O*+CT.W2:`*>
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M6JA8)/7?J/W:9:8D4#V3;Y=`OWX(F$+-#2M?'.H4@1\6L6SJ?>!H/-K:=M,8
MIU:<D7RMBJ;S-;3AM*!IP#JGC/#>*69X=Q0&T4+<@_19-"SI_%XY7OM]<D,,
MF4^V`XF:OB!J:6F/L(8*OM3QW$O-5';S76BPRNHZ8MND6TC"JV`Z4#K]R1BP
MB+I.'2[*CE"&3##=V@TU=5DLA>@(OU5.MKZ-U*&)J@=6&]Y!9R/%\&DE"Z+N
MW(`W.3ZB;QR?YK?`\%$8KL*GF2R4^H-)>9`FAP1FTG5IK=RN7LGD@O'Q]C6%
M)%N@U1T=H+"-A6=XNMX<FM%X;9!24@[*E".Q6X\I'E($]9H@S:IJM\RS"*)5
MXQN*]S""Z(4-)K_`_*P@`@J9B%8%IA8-F20]G#1FA5IG$(WG3P0T#!0S0"-5
ME8M4*F3<S5PSAERJKD+[X[B5/DGP*SMN>8G).2Z>\GF1=$DJ:05LTO)FH5_:
MD/DRI!C,&XY^F53<^G-0PS#1SJ921C+L&&//TFI8H=N7[#6`:.X]_K#OO<<,
M1N^>\<MQ#-&&`?2/-O#TIU^OX3-(-N?8!<MWDJ]5V72^CKJ4IT83ZYQ1`;U=
MJNNH<#@2-$5LD[UPUT7TB2^?-SZ-MT(G`P$KK:^#T])0KHDW4H:+26>9:Q14
M1`MTAK`HU^DTP#A8KNO<K*,__#K+V$E"D)TBG"\@`2M8Y"C*A*L]1K)\R*.6
M'6F((ZPDN)]G==#J^LJ!BUK/P+HE!/`B.X-)4K:U:7F^$B1W.;S.8_$NH9DT
MKV`ZZ<!@[.>="DBM)A]U\3:-<+3.X1DF*[RY=R4$42M7.:B0"PPX4X]4D"ET
M#)Q\BL$B^<(,+:T@ATLA&!I>ICXI`5,H&3BE$R+&:C2=,\(OL"`XBQ"D$\Q,
MUE":"5=>ZH0#0Z^7;RH$=8KJTS=7*-+Y/Z7,8ZUWO4HC\=:N7I)O]*HD`P//
MW"L5<DHM%6Q_<0G;Z>:BR"Q#X!HMV5T6(68ZL<HUN5A@:!GZHX)*KJ+"Z:\N
M<6+7!Y9@]5!59EG=THGQ-0ZI6&`X&?JCPDFNHL+IOSWB).O&=&)BG,+MN@S]
MZ8%3M[OZT0=._#D$7862RK60$L@%"I7.(Q.L!#KX7/K]N#M*U.`8,>M>X`.,
M"E+>1+UXBY(BAO$E+2`6-:/8W'R\G5\`DJ+T.;N#Y&$!"+R6G-5PK98ORCA3
M.]4"GRW9)I+;TF[J=%/47.=(==HY_["?4JZW':YL+M?QW-@:Q$F7W6'J@5ZI
M[VJZ5-ZYT>E&^5[W4'U4(:^E[:LNN39Z>O=1!_I]NA8K$.PX[R$G-_V;.J=`
M+K4XK63#>\`>Z(@OT[CPQT'OJ/8CB#Y3;.`7L!3?US055]:=NOAX)PSVP5%I
M59"6F,.^266AG-QUR[Y%AG:.)@3#4=%YBT!(JCS/,3)-@[G>]9#CZ+?;5;E\
M(USYD@OP:8!`(*AYL:#9P@9^Z=FR4UP.I`4*@VB+?@&$'?L6HBO\5A5`Z]L$
M,%5YTQ?.EJX@*NLC@2`KR+JDFA!/A415#D*)"6"K]ZPOPD*-W;,H?SMN%0J=
M/O_F.S2P\)5"+Q$QO>=D]&+G"#$QQXY<>,D<AM>4H'&[B&3[#GV25)7"+,EH
M+9K</&D`PSY)M(400`C#7J!B*__K+:-)=JQU-,O&QY'9JO[N[J:V#P[)OO/C
M0MWO$X%6YYD-C@*=7@ZJ+\M&NFI?MZ%WQ1MZ)K)\HJN6G0BP?3RV`5FCW\<!
MVUF:%B"I<KRA!45[Z?).(&S75P/)[:J&0G(J4!M[:P6T2KN/4[F[`=.&3'<`
MQ2U\52+;8S$BD8D@:N"?#91BM5[.Y&ZZ@"HZRAU8UQ]=;':J8IEFQ]J6F0B,
M)AX.Z&#;>GV<TF73EDM,'@HZM2G)(QTC&4CRL;%*<B+0FGMK-1)6:?=QR'?3
MR%?!IBIZG1?B;E4JU>A2!5(3@=;,2_NN5*!YX'E@A^OR5UE6P/B\(.S!!4@0
MCLO-A^R6W5X4K=,;):BOVVL23(0DO7VWX8M))@./*'NESC]!4L`>S.G*JXE3
MEY\V;Z2>.Z1-/8^A9Z558X5[F$%:<HNOF62((!!HC@P:`A,!5NO;@'%`0RF'
MSNT"&(R+B-EVE6[ZI=H#W]O+<W*1[:TYD<A$`#3PSVJL+E3+072Z('8/T?*I
M(-GF!2K\\+0DB++G#&?Y51JQV$C4U)^+-*9_Y(LNOE:IM]#W3#T95@PI%3O"
M],R1<\GI6ML-2F"6XQ16L\MN[%#)]VW0JL[WB2"N\\P&4X%.CIK3I;/MA)%V
M^F58M%7.^H\S2A64L\.:.ECM%?"1FH6"B1!C<-E8C>4L,N74<KJBUYRU;M8/
M+T"T^#\Z,IFE,;LX#L$\EP7L-D_7#.9MDFXB_+$M";L&QS@OSA:GRX85&;^N
MZ+B'3D38?L'M_!*1++]D3X5O%K5:3.F5IBH;PS0388A-"=BPPS`?S@RG*XW;
M\3!MQ6;I^@[D;)BS`/G/8)MU_/B*;\D-)IU]>*O$[=F)8>*)D&90F0R:T1AF
MR&GD--K!%YS3G#8+&X_X$9(E2JDAM8?$&\0Q%:^*12\^$7+T]-N&#OHL.`'&
M7:/DY_'81"J;/64Y`5&;)DJ9JHPD,A,AA(F'-BR0Z.7G?IRN,PI.5M(1#LFK
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M6P)6^U@],N/,^NMT`CHIG#I=WX!_87*6@$P4H,DBI?Z>93=E(`&4C)FFO'6H
M*QEQL"-=WNHKB((\@PBUH+!X9Z\T"HQE:CT#Q:G'BV)D0R8U!PW*Q["A;!N@
M(:(XXS\>&3O!=D*EHRA@T7[XJ(Q'Y)>1OIZG^@60N2RNS%P8I*/^(;PAOK(9
MP0JW#*$4Z:^"S<Q;$4B<KIK/XA=VKB!F+X(\PFB1X@0_KV7!S@VE^0TCG?3T
M8.Y7``.QUV;FY;J^+--?4+[X!R(HW5UWN^I'$KT&'7%4&KXA,AD7E"^"J0SP
M$C*@CR%H..O0<-JA/PCOQ$6U3^*A%O.<+K#?PQ7!Y4&I%_@33.'F1:6,NEGD
M4/(ZE7&*[8DV@Q33HU'_@AC(&J,,?81)X"\4\O5Z6G+E?0_E(X]JX=9+CS+A
MZ;&BE_L#":'+RT>D!?'3>3L#?@8QR)`XIJ956N53A=*TTR/.D,(9R*.>6?N(
M[/`(7T`[2),XCJ=6D(?S5`A.CQW&;@^D@BH?'\_!58\$<K)A\C6EYA+*MO7M
M_&L.%JK7%DU3-1]?U*>:'CWL"F0@5XPS]?$^'7^QO,J]GO492-`<DQ0!\4RI
M?TH^0>J3<GHDLB^8H=.A/AE[B0G!+=A-NUB_]Q,DDK>QC>5;S%'(3Y<OIH7@
MB"6*[+P$G:BNH=TM`.T3NSOCLL_-JW^USQ/<X];X:+^1W57L8TVWGHMP2T\N
M($!Q_%UB*1S8P)4Z6&U%;4@<[=JZ`J6S3S@B+*+=TGZX*'<]S9#QM7M99G%U
M1L50!!)A#Z@2X>@(14;JYQ3U`AMY(T-GUT&)E7BI.V5.R``@B4P#H8Y,P!"I
M_3'%J*/%7R5"1B@9P30IG!P!)4/*=OO-S0&B>SJ:$8T%.[_S'9#=[Q,<_<F\
MLA_VU32&@Z=XMZO[I8[I7FJB<BS8!0>KK*YCMDVZA22HU[F,0.D,HL:`1306
MU.&B'/W)D`GF<;PJ<(\0'>&W9KBDD3LP4?7`:L,[Z&RD:D&,@JH[5<QU,3ZB
M;QR?YK?`\%$8KL*GF:Q;?_;YCMDLBEB0JXP.>EAG.$MC^@LIV%TX\(22\C&V
MO3QQEJ_MG_D2#W<)>@$YO"S2&*7/UY*'NC12?,`KDQKO`E?YMBD=DL;L]5/:
M\&_>3V,O(3Z7FV2GZYU(-:*=O0(2;\J:'=,@11GXK@QM_+@`:?4BYBR.2UA!
M<HXR=H>H(%`6^&5D*_C5LK&L&&N^H^$L#@68QJQ*;'1YR6TL8X/H&N](=6FT
MC#_^I6!XW\XWP>KO`"G#C]-FN71-7R,=:=NV>P.UA5M#W!:4(=,'9QK$8)O6
MTB5.G=#5A2I^(&N0JG")ZK"(#%DZ+,<@%E!J+FQ,GQ7Y`A/T;]A^$\U`LDNP
MKN0D^*-QL#\]N@H'G@GWA/[F50\=\DTI&>I<:D*("QVS19LK&WBPVQ/2MT6>
MY:!T0P>W0%2&>4-T0L#+7;1%OZ%QX'GN/;R_57ZL)@,7;Y!$*.NT`_8*3-[G
MDB@(ET2#B\-TUF>1S\"3WFX(-TM*Y3`6SUNK:%$MDO5+Q$_I&28*ETQ6;AL2
MR%1W&*\$VJYQ5)7@)RJ89U?III+\1'#6>8/$7PY#U]E4.83+7?\%ZGM]3&6(
MCS/POP!29B7K::7?=R$GVM_#I8?.&4-P!6J&GBCWL2ZIF46;"0M7%:<TE^[E
MIM6:H'1&;7V&W!\;Y',M0VD%'R8RX^KGZ`!&B.9=;I]!W.6Z&8'C1%[).Q(=
M)&L24T!/YE!OQ&J*ACXPZ/^-X2_PM?S2&4KV26/PUG`M3;ADL'%ZV%2WK7KH
MVX8^6OIS]()BF,;WU#5J=42'EN"Y\P19CR3"-E^6)%RV6+ALU?K+-`]]K'`/
M7#G'20+(YA&]/H01I3-A33/=1*FC<-X%?YKJ_;QA2#;O6I5=X>V\FH,^XKN"
M1.P,/9O#@G3=/8?5)]7N7)99JI#98..X,1<,E7MYL[`U*CK#Z0LD.3M^O_F3
M'5:^9VL9ZG&F/IUX]*E*%S(?[)RW&ZFJU'MY@/`:S2D1^:)'"WCQQ\K!]L=P
M(52Z88A36\?0QP!51V39W))V$I49HJC_>L'F05FAX%ZC^INUO&9.F3>V4GV-
M!_U\Q^8W.`XMBAL@%1`>@@[@]I@!@-C`+P&\`I4UA!NJ?%RG/0/9XBJ=)_@U
M$]Y$EW[GYQ>ZWT<,#B`O?ZQW15[W^'4D@88@,.E<J!H/%6%L@'ZPJ(,#F`'C
M*SK`(^TCHP6\3<6W\V2?>5RVSN>11A;RJH"U3M31Z.@IXZAUTONH)%4NCZ]8
MA43G<Q.)VN>`D9`Y88I$+;V/.G%&1_4TPRLZIL]HBDP2_U(EM`UT*18*$1LC
MA[0(R;0$<;*YN;PCCN&@$!$NI(4,J8$S6D#%.AP>5<Y@].X9OQS'$&V0I'^T
M`:0__7H-GT%RD5*[UX(1N.0KG_^VOTY@[*WVR'S@W='C\!Z,*7:;[(5C/]&G
MRL?FI_%&X3(DL-+Z.D(M#0R69DJ'M^D<8](9O(Z"BF@4;@B+<O2M`<;7J)N'
M/V115Q>0@!4L6`!X97A*I6PK-*5$=J0^2EA)<#_/ZJ#5]=6#24KT^!BLWY)\
M489K/\-DA4EYJ%"(GEZ01\]7"`:&F[%/*M!42GQ4.1Y?7PN83J[UVL$$X#+T
M2(F67(>/-W3N(<OLL5:99:]X&4CR8$(JR<`@,_=*!9I2BX\':-C&RQ*L'JI7
M!V28Z<1JFU9BL<#0,O1'!95<A8\W8*I@[[,,@6NT1#F,A3CIQ)JA^`5B@>%D
MZ(\*)[F*(.[SW24@98&V15M4@D]\0:/Q:0)38X4O/3:D&DK"6)^J3!*'4!9^
M;$$X_F19B`W6F-]`K::@CI.'J?)>D.H&NAX'*^%&EA%8ZOTK)5R^)M`\>A$[
MTXE>(,M4V(5IY?BBAEQNK+,RXOJ"S7T2H;3KR11:?$R8:Y>265;T^WLA8%JY
M^I%YL5QP@)GZI`9,H<5'#>MF=V((V(DA8"<3`DSL4U_`3EJ`U48;>XU;R0(X
MG^$T)^BI*`N:OP[F.(RD/*-K24C)'BFV2YX&*4*[0;0Y0-KS"I$DD4D@C?$O
M$?4!5A=(P^1&D4%^VD`:@NM%H03L^8)Y/+$6=Y0R@FAO-9EI,,/$00LB2-2&
M$3.0O9^U/=!\2^[1\R+?1I>#$24N"S5\!I($QJ=K?O"Y$FRW+HZT<2X-U381
MUCDM-!M^#C7`QS*]H5&/^!2*H\C9IN]'OGKZ;XINTH+Q1[!ZEF'$*Q39S0."
ME'>X=E=!^K2(ABI43-2JF#`9^Q6/*SYJ<_6Q6U+E<O&V0IN=ST=(EBT**66:
M$7K:,M,@@8F#%BA+U/IX['YS<?=V7C>*/3K*CZJV9Z*&XGP:JA6?!LX]W;:`
M7)^#CS?I=_?_:6]6/&4H1H"LR_'^UI!N9*9>B?CROF&B:?#!J@@L6&&:3Q`!
M">\(CB",LY*V=#`$4M8;U::0;1Z9RF]/F&OE)\*>GH[;$$>?Q<!P?8XBG\;_
M*K*\?&GC$>_>UK@#*+Y*S\`*Y2"IK49Q5\YPUAFONE#%NZU!JJ9!0H?%9=/=
M#<I]:#A#85]X"=!F?8N_32"<G&NDJA*12DV#&V9.6L`N5>SE6?L;0'Z#>95?
M=4:I:@++S%O0FHKG_"$YG?@TP.[IM@7J^AR&AA]TTQG)WW7]FL%YD;#CB.WF
MH$<2WC88)9D&=RS<MVDUC'(9&AQ1?.0:KT&2KUFLJ]OT"\P?0`*SVSD=7L5%
MU!F"&$KSH]<ZZ6EPH)_3%O!K,P@CRJ%U3.UMITC+HUA6S\RE\0W,%SC&"7Y>
MNWXKL7^.0^.U]\EQ&K3??^';;.3OP\BA@2/%!ZT@03`[K<U8J;?LP'*U($H]
MR#8WL.5%T:XN#E7R^N!$Y40([[[X;!CMQ`HO82KYOLLN&&+36!X>;QB+/>?2
MW)5QG\LTN+Z?0K;?&7)OF)=PG1=O$63;E;6UZM*&A\U<\`62AJG&=<"Y7G[>
MW9W>:?#<5T%:,-NA*5["C#[B'"0-$^YA!-F<U)BV0U3P@%96*J9!1@?%8\$[
MNUR]!$^MM^&;A=%'O-OU^[K"*;.S6"Y+,V_G'0/%IUZ'ZVN>D!VB;QI,=%UP
M]B=OAYC0B!#K>I#K@I].=+4&K-\T+UT6V(#!YT`^.@ZBFD8P2:I<:V\:W3XE
MZ+G?L-*)KFUHUD&ZIL%'EP5FTT8.RY[ST>D%P<UYK7)C^RJ=S><H02"'V2QG
M6]<MOAG)5L6CD9T&7_HX;,$'C7J.][C1#$Z+C-J<9;/H]P)EI8/,/-IBLA_H
M+'T37*.<MH.(?V[O-`W4PF.4V&J9!MW<%)(%$:TSYA1U&G^HG.&4EF<V"XZV
MR>LSUE[)IT&N@<5B.U/ME2.GDX>=&?<;,^[W9?Y`VS)![,JXV93YX'139C<4
M?,3G**N6%OE,9C!U?:GGX12=JY\&J3T7JP7#W5O$Z6Z[X^)V.$KK[A-*-W.F
MW:CE'M+9%3L\(!^!FB=L#3I-$DZ#K=9%,6!H:9(79YC3?9`[F@%E_"R-;UE8
MX:LTIU-P&.4%2.X(7D&2KS?7#BM;'O'/M&>@,IEQH^HS"WZ7Q$L6TZ#K'HK7
MYL:*%ZMX%7"Z3W->O?WP"-ZN$7A""8N33F@53)_9?9MS-*??6<32J_04X]_^
M"4E69%3X%&0HNTU_@@2GK8.L&9\9MJK"/K*J,/.;U32JQAZ+VZ**^+6.A\)P
MNEUTM2*T1I]?O+'#AS!F^P2U[LJX1QBJAB^B6JN9!GT=%9/-TJMUSIQV;E\-
MVRV54+.NTO(Z9$:[C@S24E\P4^$+3/"J//!:50&;%3&7VKL+9FZT3X.[?@MU
MV'*;&X,XTT>^Y"0XV<VJ;<3&5-T0'J;B[8N/4O%IL+&GVT.N0DISX'P9=[]*
M9.<]RGZ[I$ZQ03J!6<ZNYACP1I5,P1]QLNGRR*`8'/%)G!/GU;C7I53\/T<O
M*(9I;,@K53*#=JF9;+J\,B@&Q^U4,R?.*]O=)O^\^B=FAT78M*DGL\0)#;C5
M3CA]=BF+PC&_VGEQAKF-@"6UL_'"AC84<_,]#ET8YDK:)Q]`D@QB03]7;8*`
MZ#+@>)=;)/G)IRC!='+Y^3`G+`HM^X$FAF_Y15*F^GR8P6?1G.?[ZZO:)V9,
MP>[U!*M&J>H=U@#?_&PYVOST_1W6[^^PVL#R_1W6[^^P?G^']0__#BO;R#PK
M"/P""X*SZKW#ZSP6HF8FS"\B:(0#0Z^7;RH$=8I\1'XO=]B$D`F^5#XTO@0&
MAMQJ5<DW4OEX4/4>+XNDR"Y1LI36$:7,-@"34"8P$$P\4;YW*TX_,":XJX>`
MZ+R>S0>JN.;EV5'!3$HKMWWN1RHWE=F5J:L]YUD*M2&]YE*:)1SURP6:CPTT
M!,:;E>EAQ`8^U4&6:JR]"]#0%,;K3/UQ[4R)1D16-+.SA%8YT^L)KH.9G\O'
MMTH#S\1C5:E`(ZA`4V"D'EA1';&!)W4\NZIVE_J;*L*HI3O#9CH89SH89U.!
M4>Q)+QAGCB:%SF$\U<%XJH/Q="HPBCWI!>.ISUDAOR0B?BE6\K45UF+L5V'5
M8*A]T"/12=^=->[S)=BO*2ABE,/XCN!+3):@/#^!EI<H!6F$0'*5SMG/++='
M"CR\H4/O17;!,KEA9\,^GC`2S-*8_N\C?SV6.^+<7!:&`_Y>T,'#Q0L[0F__
M7*VC25W3GFO)H[8Z,3ZEDXI]?^AD[\V`%K.!KYO(]/=[TF3<L93D\=SRC$//
MMXW%:;9K'49I`F:*C=>F;#'4'<BPC<6&>(#D!44P8Z$.%Q!T7@55"FV';V*A
M@$E@Y)<IZC)E/H9U-^`-+8OE[HDN%KRR((09]GN!\C5_Z`0GY9I<-LL?:==-
M?T#/*9JCB(YX:A%`6G![TKY]N\2Q]H`)YK<D39GIW(H@GIG=F+Z)"K^+OG3[
MFD*2+=!JYVW["$??=/QTAWFZ@!EIZ[TIUWKH#V07B/;5]W!51;1N=-C"EYK,
M$]3'2IH$`1.FM[^]1DD:Q0-?G?5/D;+E[,&0AKP!02KYB?)#Y*T+>E1Z?;Q*
MR]]79_U=M.C4?MGGRKGNYX"1T_AB"E1731`OPEH_/\/]V;T,N6F-9@7MTPCZ
M=R=.PAYR&OH$DDE.`3-U?R5LW#KYM"B(UW%+L^X(G<N*Z-[X4&=G]2%T,HGL
M[X5]I<#+:[#M%G4;=6:6Y]3S<D`]/X.$_:-ZB:YV'5S38]DID_1O?94%3`NG
MY63;=_;-U,O3M=RHJS3+09*4,8TO,;D`T:*R4T(Q?8(6C50))D`58W_[TD&E
M>.ASM;H6A\4P/P=KQ<"W+=%M&W82$T!1[I%%+=YI&OHDK)?]4-&M4I6(>!]T
MC/NC1CV[WA/C/EZHJO'8ZS[OA+HC`,U/=,99+26AP59JU//-2M0%K!#[IB#&
M[ARS3%,8>[]=ZX2'7K5R<K0#.-JL`5.,M_Y\LUBM!/2@#CD/AKUS-GA\X(4G
MGP<@KS[^;(%],&>@6Q8*3_DI9<28CWSB3U^%NVAKC_])E0J0EA^0EIT%K'YG
M_WD"&:2__#]02P,$%`````@`'$BL1+RC@$8*E0``D6L(`!0`'`!B='@M,C`Q
M-#`S,S%?;&%B+GAM;%54"0`#!\9P4P?&<%-U>`L``00E#@``!#D!``#MO7ES
MY+:6+_C_1,QWP/C-FRY'J.R2?)?Q?:_S16HI6]$J22VI[-=1,=%!92(EMIE$
MFF2J2O?3#P`NR04K<9"$5!71?5U*G@69^/W..5@(_,__]66=H"><Y3%)__6[
MPQ_>?8=PNB#+.'WXU^^V^=LH7\3Q=_]K]G_^'__S_WK[]A><XBPJ\!+=/Z/3
M.%\D)-]F&-V29%M0"SFZOKEZ?WYQAHY^^-L/[WYXAT[(YCF+'QX+=/CSSW]%
M;]'1N\.?T-TC6><D13=X6U#?:+Y8X&2;_X#F28*X>(XRG./L"2]_>/N6>4_B
M](]_L/^YCW*,:*O3_!]?\OA?OWLLBLT_?OSQ\^?//WS^Z0>2/?QX].[=X8__
M^\/%[>(1KZ.W<9H74;K`WR$J_X^<?WA!%E'!OW)+_<M]EM0&?OJQ\2658'^]
MK<7>LH_>'AZ]_>GPAR_Y\KNJB>RQ@9-:_,M`OOI.]-?[^4?^M!&EAF*%Z>9K
MTU\/H?+WRTB";_`*L?]^O#F7:O_\(Y/X,<7%172/$^J2JQ?/&_ROW^7Q>I/@
M^K/'#*_$=I(L:\RP7^=G]NL<_HW].O]M9_E'E^8],"S>D2)*8-K)[0W;.G#C
MWNA+J)]6U>1+R%^9\A3OX5=NN7%O]#7.8K(\2Y?^&]YW!=7XVR+*]@"5H3/W
M+^"_U8*F)NRC"_JOCE_\I<#I$B]KS\RV(G9RUSS8<LN-;;+H6$U8%B&9\.MP
M@SE>_/!`GGY<XI@:/CQB_WC+_O'VW6&5*/X;_>@_YVO:.OK_Q?LD>JC-\6_R
MK]\)GQ5QP;Y`[]F/W=8R_4Y[:4HEVVR!>QX&+?C/Y#ZQ^J4Z'5TV369TG5"W
MK+C`Z=N/M]^A>"F3G34?(?;9__QQU^;A]YQGW:Z)LD7=(/I/S9>H)'Y<$)HO
M-\7;SO=9960MZP6B^?&JWX+;^P?JB*&"((GNC_L!W<DVRYA?6L9%R7_@**/!
MZY2RJH<.G5CU'>5B#JB4&84"J,:^#*M*M5GU%)6/$7N.J`!B$M."6-N5Q/QG
M[T);IE&C7&UQ3X`_)8LM8UJ3J@5H5\I4WUDBXX!SH44HD*N,RQ`NUYG5CU#Y
M+!!HJ_N-&/[,75`+Q6M$*VSM"<YG*6WN\RE91W':PY3H4?7=NH\<,-LV!`55
M@4T90@>BL_(3]*G\[/^;%H_"'B#J7ZZ+OK94#;JAYEZQ]CM.DG]+R>?T%D<Y
M2?'R/,^W.!."3R/;0:-4UAF>$LNP>%4[40-8I5LCFLF\_8,)H5H*E6(A8%S7
MT<2R/T0LD*AU::&TO5>>_$:2;4J'TL_OXP1GN9`?$ID.+P8RSGSH683E@=BX
M&O\BG1KWS3-4/@P![;)N(X:_L@C=/?$NJH6V]HKFJG:_P1N2%7'Z<%M$Q58,
M:K5H!]LR46>(BPW#(EWI0PUXA6J-^WH`V<B@4B@$_&MZF-CUA(@-8JTN*526
M]\H-3LH36OD_D.Q92`FA1(<)/0EG`G3LP>)>9%H-]Z%&C7+^!-6/0L"VN*N(
MT6\K0G)'N`M@@9V]XO8&/\1YD45I<1FM^U!2B720VQ=QAF[7("QVA;;5X!6H
MU.C=/4+L60CPE708,?N!10#N2G<1++*TW[*$)H`L2L[3)?[R;U@<?"4RW4*D
M+^->@70M`I<>0N.:FD.@TQ0;Y3/$'R+Z-`0HR_J-&/[,PKJB*]XK*$2V]@MG
MLEZ3]+8@BS]N'R.*L:MMP39PL)TX8FP;*'2!KE1P1[W"/#`%])XT?-`9:,C!
M!1&7/$"E+&H)!\$5$QR0,3TE9)%"MT<IK9<]+_OL%I_>TT_Z`UB-5&_I9R`%
ML/C3LPF]_",VKUL`$FGMEH#:2YS\>1B+0+(^),8_N'@AJ*?07PH2VIL$Y.6B
ME![F`CDAT#MR8%!O6?4#]J$#,[CW]0:`KY8^@X.\J#^%H)?\]"K8MU3$P!_8
MW!/T+_!#E)0Y9_XE[@->\K3ZIH.G#N#NV8*"M-BL#,@BZ1G_L$K@Z!/[?.+5
M45FG$.TOV45H3[#&I5!_SX'XCIJ5Q-[VHUZX+1\!1%AF"#JHMFSJXF@CN@N=
M[*,P8F7G]R?JWTT<$9E4/PCN-!V1MHKR>_Z]MOG;ARC:E'##29'7G_1Q5WW\
MG_/%@FQ3-B%^39)X$>-\?L_F:!9%#REZP>I[JP1'HE3?6`C<&GL1(=E0>7:5
M/41I_$_^)LD!.HYR&H+("EVS5U?2HOJ8CGC0[7:]9NN8].$M3O"B0+?Q0QJO
MX@6;0-RY0;4?&J4K3Q-':@.D$-L^[7)*KL,89FIY:L[EU]%S=)_@>;JDGV1;
MO+R(H_LXB0O:U&JY2DQ"&\TN*\TT86AJXLN6M\7PQ1TA>2U\&[#9V-JL5D";
M4H-3.2IU4+)3"H*A5C`:4M:V?X4<-C$B(+6Y[_UB^=`&S$\XNR?]-Z2<X'P(
MB^?#;X!6=O(4B#[<-Z2/@.LJ&[^`6#YJ8?FZA>5*";6T#NKM-%\3J(^F!/51
MX-78[KWU._RE.*:M^6-$9::P8E&E":WL(20(_-I6;T`)3]X2UW@ALVP<.L*/
M&"H06D8/#2+L`XG`H&U0D;9I.H98U82N"531!D_D.#1G1_O\CT_,".)6PIBO
MF)@U#D6E/]H,B\W]Y^4;O,#Q$VOY)2[4TR(JT5Z&%8L"!0F1<0\SE"H_)F27
MJL_NLFB)V3"OI'76"(;!5&4_"^BHZP\QY41:(E[)K4_.G8KR1I.)1O.&GJ8(
M/7)$Z,$B%2JG]\*@@Z0#Y7G)=G)./\`+!O8LKQV3=)LKIM#E,CO0BV3<,3^T
M:CT!/CQ3:8![J1<-["5ZL[J2NR^?30YZ1?\1BY][`/FA>`_Q,GN^@`$Y<I![
M&(6*PQTLJH?AS)HYXD->B8\$R,15]':]3=C)5Z=X0PNYF*\QTW\GF/V#C0;6
M[(VX<DGZ.B,;G!7/UQ01!7UV]N<VWJR%4134["[P`IEUIR1(0XS#N^H8M`&7
M(9NF83^<JUG+&EJVS$T>+V"13/RB:!"40#STXAA@JP,B(F0Z!6W4OCAXV"5A
MV]X!:BR6LW<MFP>HMDK_Q>R6.Y0:T]\(;(6^E\7@0(J7J^(19R=D3;_-(T[S
M^`F?IPNRQA<DSR]Q<;6ZB[[(:Q0;[6$I8J8-%^A,_`%/E8QP;1BTC"UV0A-A
M6FC15D,QU_OQ34(UOP\FYEA!2QQ:;/M;&D!,#$GBA'D;IHL&RV7,PE647$?Q
M\CP]B39Q$25]UJNE:G;+I%Q9++8+RE:E"R4K%9JS$Y(667R_9>Q;E`\FYIBF
M(XG5K][CC%BAPPV5S0DY\%_;O&"Y.;\C-YC]?#%?=]BQ]8Z<1/DCS>E/\1(O
MCY\_YI@V_VK#;F&(TX?YHHB?^)J?;*._1Q<-^WRX<*8N?*-@>>^M?>J@X<GM
MK&69$2^K;:,4%X@E>10594CB>PJHR'%,[N(U/D#4]P_L`R:YH+XI:VG8BE-$
M:J<H:KS^8^HXYI%/9'_X[4=0>&_=\.OKVX01NR7IA9]]P`^AY$=1LLM83DA>
M]-]0A3`EBL76IB!CKJ5S^)4S]\88!](QYMFNC#1G<8VD=&A$/T91PO%*8Q^E
M3EQIL%?&,!W"%Q.?RP,"4EF`<P"+(I!96I4&K%&MFYA+<+.C``WQ2:3#0>FQ
M,X*8%59(5'8.RH-\RK.3EP>H-H:XM6_\$@(H3()-.I%9QVE^K-%Q1"L5-M>"
M:3AGW^+L"_MGG]AV2G4Z-U1R#39&;N!3M(U;90PQ-S3CH'K+KMQ;\AG)6@CA
M4FKB*&"'$N+2ASUB&^EW*&SA<6\`A<M[5BYAT,ER65,#<ND*J&UY=/:U`%66
M@CPB=>JT\IDEN?<D.R7;^V*U38:[DB7[(,?HMI*,A2X`E8V]>4DYMMYUW+:S
M-VM4T(ID:%DI-=OSIZ>U/8X(0/<..6YLID]U2__[!C1HBK+V#(KFPSZ<:ZUF
MSSG:Z86RI73O$%?DL?U@?-*LUMJ:<K4Z3PL*OIB]N);G>#@3:B1<YRV-L"NO
ME>9!UX),/"EYJS<P:\NP.<6XD4(1%YOZ>E6CGB=C^J='.Z5>AV<&'@+AU2E>
M84KWY0DM<!^PFE8262&K!K*@I.I9AZ_V#+R9\TJD/Z#5LA)"2;Q@@XH#E)'G
M*"F>^2;+?'N?+[)XPZ4S_(33[>1OX!AA0\H[11>J:-=3D[-.:-\W".$J-!-/
M3@@\'$*PED*5V&O#EZR<`@/8I.526L3+.-D6\1.^Q8MMQM>\S[XLDNT2+]_3
MGY3-7&R+JO5G49;&Z4-^C3,^MT&_VW8X.0!ILTX3,#9=F0S1"M!2#K!!RK@`
MYF?&3+VM;:&\O.("5Y80(S&?)Z]L\1S'A%F*8[MZ-C@KE=";.*W4I][/"XIW
MXA%NO0@&8;X3Z>#:^U(#XD6<XO,"KP<E,;!9F+#8,CMM9&P:$E!P[+?)8WSL
MNIJUK:&=.736B9(GW2A9VV1W192+.>@3LXNXX:E/28*&/UR4%$(/-%`V'@!C
M9:_5@85+=D-?]RIZ91@<BBO#6UO<2]C:.?`?C@:^[,-,SX0L?!SPBR/1IU(T
MR(`@`(*6Z.+.,B'P3E-/S+Z7P`AG'#>.G\4&!!?9[,$33!6C]C1M8:-J6T"U
MCD$S/98_6N_2BBB$NX7VP1.X<L<4D*`5D,HI8%&D_V[3A6V^AE.MD<K>G5/)
MU*%2+.,:Y$160<.3PH$RL$CU9B<?;V[.+N_0_/;V[.YVXA"@[#EB\4/W:"<2
M[Q!&;F]BJ"LQK@0W,*K'PEF_VB<RKP=S[S7&8-"KAZTI7N5`52+4O7OAUM&$
MINWZEJV4E4O\P5RM-:*?98M?%AT]Z?)6.SZJTJTJS<*F5^LXI+VT2F#=.*=6
M[P8R'VA1;?T*8G^.L'-DF=0P@THS)V`\\K+Q4F39JHN;8!3*IDCK[E4&(I/^
MG3X,">./,/``8=%3J#&.,55PN;J;7P14ILOAI@LC0WP!!@X/$<,\5'1B1/B=
MI`P&XEZ:DO[\HM:KU;Q[I>AS^;^R.Z'LE*H?PE3)$;%F;L!'7%9N5:"W,#3[
M!:<XF_HX*TLP$)>NZG+*3+_-.1N/>\,A6&2U<PD#0AJ9F[N>=^('Y>7-S^A3
M]=]@[D3:!UHE*<`G7"=-(=L\3G&>SQ=_;N,\K@Y>?4^R=72>KMA_^-&LXDFW
M<<IU2K%4=J6TE3O(.>I1GI4$MS<X^YA&VV7,=CM24<1ET7E*,V.\1N_C-$H7
M,1VIM]316W1'@8;1!Y(6CSDZ2]D&H0^4I8_HI\,#1/'T%_XN`/W'3\%,18U$
M)('`22]@6-GI!(X1+0@I?N1U:V_*%T/T04.F(8\40PWX\-#W`5]V&ONTC`9"
M*[/JC_R`'5`8'$VE&%!S4]5)6D+VE34L%/O:#_#@ZDQS?P"H8Q5F)8E:H@>M
M+%1)OV9`RFI*+X@,K)ILFM@Y)=,B)PCU##)#3\\C33N>/%>.2J=C"3NT-;ML
M3KM]BN*D/NJ6RJQ)]7;,(TF6-,.%RULQ<`S9*^U3<PIW3)@26>`W)#:S<^O8
MF)9^D.'E&1W7%L^M`T!%I\(Z6I$SW<P*/.]-_'J.`A9-L(P)QI9GO^",W<K#
M)L)1M#.`,EQ>EE$,SH7=L%,L[Y_K`[.#BQQ6L%3'$5N,:*.*B4%-C#%OT^01
MYX2L[^.T'.?NOL!-B2Q5D#%7[,45$T6@4*)WY2-Z&'LU"1B&QCIG0[.YHOH"
MG<E/J1V!%P'A[7I2S'&]#1&M33U/QF1V"/X\7;+_L(N[GJ*$'9$[+TZB+'N.
MTX??HF0P,V2E4_V:ACJ.U#7R8LO:#<YBLKPMHJQ0S1+9^%9QU]S.;%Z@>_P0
MIVP3/%L;HJQ%96NG9:T=0(A#_W6Y:J3>IJF%OWTATVH"23MU:>46!)6'W\V8
M$$\C_'(5O!-_[:B4S!_Y@^5P#LD;+H_L0^99JKR*V,HU"#:/>,C$K,#YFH+E
MT;YA>;0_6/X$57];>01!XT^M2,G_T1(_0%&!:@W$55X[2G_:-TI_"J[L5F\(
MM-)1EMW0VP&-O(`OR]IXM2>L<"_@BZIL#+9;67><"3<5>ZTL_.T+DF`+ME8>
M0?!XJ$P@H6X.]`]6JS(<`JU3+N5*&LD+V_-TD>$HQZ>X_*]90E&JJO.*1-4/
MEX7.P%]Y&>%\!+GEYF:79W?HY-?YY2]GZ/P2G<QO?T7SR]/R'V?__O'\M_G%
MV>7=[<3WE(["DI[<VCXVHKC0B@'3%=[W#&G?64KI&!+/FIS%]5"MB-[4JA.?
M\+EO=-ME,'!XAY?/)!O;S8352Q!0&]?5YB&7"HT\C9BBZ!ZO\J(2C6JGN'G'
M&,T\"':"FWB8CE!)E.=7J]^C+(O2XBJ[B1\>B[,O.%O$.;[.X@5N'N;5T_ZJ
MO8N)FGRC3+A2<H134**.]Z^D[UBSLUH(;9@4FP7_7,KQP[27)$FBK'7$]M19
MUP5V!`X&O;`PPEHG6(QNS=0AA%]E*CS652[0I7]'`(;<+9,>J#NT;D#,OM*,
M?\[85EX''<8)K(H^&W)'\BL+F=&2%>!^8&EJ5'>)>+E=W^.,-K,Y//`D2A*\
M/'X>DR/MK:G2I8TU'YG3W+_W)&K=%.M\:NEA5LJW4FJ.8GZ5>#CW5$!!5)=:
MQ^'$(,N:&]8F7-LV3A>ER'H=EQ?7LR$&X:^HXW01#VY=,Y"LHXM*TC5RR&V#
M1@6M&R7C-=JSED"YWM<6F9C%!MU,K/NCQSZY4H=9.MN3LH:DG/GS#YA174`6
ML4"+(WT!`&IT34(S0FA=1P2!TJS\O(S":(X^E<^FKECE?49,?^4ASKNR?7B+
M+$V,:EY!7Y+K*!-NSE;)=+`]D`&!=\\J/,+%#O0@%^G5."_+LP.TB3+TQ#<4
M!3D?HNS:`044/2%B04]\2`2AO1"XP,]^SZ^V15[07$U3D)P24M$A,P2B<`09
M&(??':5W9L@9L7J?.M5%?F0G%M#`QP0`8OXH.TI*HX&6A$T2ZYYQ!K>8;.#(
M!62'`Y1]%?"2K?X"X6O2U=U=VS3%BZ9N`2]9?%8K(PH5>8V2DEV9<H"B;?%(
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M0-POFF2P4U(FA+[M$'+"B2XGG.ARP@E\3CCQFA-.QN2$$T%.""X7]/M*G`L$
MOZXT%YPH<\%):+F@V5/!^5:O$\S3Y14[3NHTSA<)R;>,BI+=_`"F!"M<]J8`
M%\)LG?L<S(YMC.G:VBCS-9U+K6`.J`?!HF1)S@43\I4[6ZNR!;YQK9N8,C[&
M[Z,;XI,ONYD`;N,`[?8=WE:%(;54GAC"IUZY,=2R]HUB.@R%R;&)IS$V&7[$
M:1X_X?+<XTM<7*WNHB_TKV2[Y-?F9/R8PZ+(XOMMP8ZBOB.7M/M)6E`HT#8]
M\(M,<"[(^SZL[TH!6.ONH0ZR/?`OO'MIGR8F@GN<G5Q]N+XY^_7L\O;\MS-T
M<74[\=V3OD!.]H*L04B$=-2+DO#?(3S&0M8K/MJV9[J65<W.*BK-HC?L=/WO
M:9&#"U;A4`\'J/&!*B>H[85AJ>L'U8Z^\=\!IR\Y`$Q;.5%$T%;Q(Z!OXOR/
MDPPOXX+]:U`%:26;BD8AZ1SKI+8]3$WH?*G#D%I[UA'@^U467`)E5&3J8*#O
M:V+=*7V.2I6Z?-/8]@LHP$2H]>.`IL,>G!![<(!*H>J/8`]<`P6;-"-`H&WB
M2)W3GEORIEW@/+][C-+?'VDZ>;[ZG.+E[?8^CY=QE#W3`3O]#NS#+'^,-W6J
M.5NM\*+(KU8G5/$!YS1M28_RW(>O7;;PZ<L]//AKG8^,Y;VUFBCEV?^LNO3G
M7VC"K)59ZFQOVZRW^J]07.0HKWT&\&;D/EA%)@#O(-;Z<]N+UKZ_7^CA`[(^
M\=_226-'62/M?!P@Y@455!J5?A!WA':>^&(%]84:9\UH_0!5_EB<J3R6$P&?
M[OA`/Z3ZZI6%'7F-]TKB3C!UIN;$=P-1494'?KZ[PKC?&FO$:>XZ]=EU%J>+
M>).4)<RB+1]0(#$Y$-NP6Q0L5IU^K;7N&55^4N^8`]FU^OW$%_!4`"C"3!*%
M`\2F#=/L%L[;B(8)79#6"38A6B[H3"69:=A=G!HO:A(IE6?L.8O'.9.8FB7:
M'B6VOWV?(#*=+CW4EB?F1G67O9`.O6<=!C3/0$!?63/&^<\ESE/\P*[@5!<B
M0_MZA+?EPP-UOU\&.!;\G"+H5F)#M';TH3L8L"(06+;JV\-=YU:?OK3NE>9N
MT_X-(#OC["E>X/SJ"6>/.!J^?*02ZF;E@1!,1NZ9]9"-Q1X,,K%(<5;_A1:/
M4?801LR2=N`P"2M^;F$"[LD+DJ_0XF2P/\4KG&75S=&2MRB4,M6O()%QQ+S0
M*OC\@,J+"O9RO=E\S3:4_+-<V:41?5F)(EITX33':(4#VC>M[F!BT1]=3@C%
MVY10V/.%'+",K_0P"C:T`JB?H?+^]]<#$$EM,!XA4]8*G4:=;#,V8SQ/EVR_
M6/F'*H"JY$7!5"P/20^1!_!-X*8>C9DCM3&[8VT)B##*'I>11]<I"AZ)5*6<
MDOO9!\3\1&.5-V=\#:+T:T6:2<@&@5H0H;P<G:@G9LV$^T%<(@Q%+Z%Y?S6R
MRIT1M^0&=KRJJ^3JH/1\F[!SP'G1'`C;U`@044W;3Q*:"?6$'%-X\`XV^$"N
M=.6&M$X(+Z7"76'S`3E=:`?`7`A!O9I:W+W^JIG@T,KW0KM"'HAP4@^0\WZF
MSDQ(I[8QNR'/45(\HZO[)'XH9T?*PT,K-EY4@?]]B-,C>G@(2&C4@V(:2E5%
M3-3X"8"+:5%NS=<.DU6B`P:*1,'(-S3NAW=2/V:4DZCODAS[Z`"EY3N/=9F^
M*=]Y"X5;BCX7TDK=-S)&#;7$9))9GYQ'Y0N,=]&7LR\;%BJ/<8I7L8Q*&ND>
MFZ320(22V/?!*;4K$UJI+.R8%9>O%1?1%W1?"H3!)UW'"RAET#MB5DD41<12
M^IB<6X,<JIL(T"OH*D;X"0&Y"UN>/>'LGIA-"VB=CJH=>],#-L5C&"PTP(=)
MR6@Q72#7-2H:_4P;J-V`3QWHW;FCL3V%4&]MV8FB3\%-'_B`HF8:`1*+`4TG
MG&@&+R(A<1HX`1^PM,UZG"(X&3%(&2B*IWO9RY^++-[P\)Z56@>ACEF$72VG
MD:!CE,PY48U0AA8G)PBMZ^9YCHO\:H/9"_GI`SMMYR3*LN<5R3Y'V;)_P^P(
MS1Z5C#2!^&7@R]O"B[EO$SJ:6@M_H&.#'`$S+;M43%<#(R(.&_O>+WS!ZS$+
MOX#8;5=H5`65.@>HT4),#77TOB9(:XHWOY@.H9PS:.HI#7EY$2_&9ZV^!?OL
MM;.POS!0^YPRF_7:`!09.E95V>T`K?"26@ED(]D8J(V+#:*^'QTB:F,C0T6W
M+=/@?XITV/?O`?QCTN,!JBU\S:1P3YR`K'@AB?2VB`IV'/D%;4TR/IL*S=BG
MU)Z9_<65CN,IDZNH(4!!9FA:G69S)L\^"F72?C0.QX46*29&AY>.Q9$Q1M"J
M"6DR10X6-L(71\9E8VZ&SYIR0]_H`Y.>O?`GD$1]$4?W<1(7,<ZU^[!TXL/$
M*Q&'BQQ"!SX6.C2^#..`W,2.[BP9)I7<,]^D%0R/U;TOYJNVAZ2T%&I*Z*?P
M,B'+-B2/B[P,#0IVJ<4:5LG$G-DD-NQE=XC2E9I$"M59_71JIFAZDMC]ZGUF
MB#6ZC%!9]0@4P(),[60L1@YW(&F*J9W$Z\"-M-)Q`\ZTE<HFPXN8;^X:QLW!
MHUVL;#URAWUCS,,0?6!<@_"N^*S]"<+E)LK)T3SL%Z+_/0>@W7VO+E![VL#=
M"QG)!H9M^O;P-72N/"09]>Z4H><LRE(ZDLNO<<9O43R.\GA!1W"G<;(M!M?0
M&TI7/X-6VA'4&ON0`R0S5RK@FUB8'<]OST_0_/(4G9Y??+P[.^47[J'KLQMT
M<O7AP]4ENOUU?G/&+ZI?DB2)LAS1P7AYD\#$=]:;8H.,ZL`NLS2*;;(9^0B&
M?NHW\0VE)?2#?A=?8Q^\BC#S9\-!X>OX?,JQ(558G#)X#=JB5]2<4KP';>3#
M/[K`BAA#7X[0HJ5.+86H6'G/=+AOX/O!GJ14@@7?I`45OS+A:G7V9<'O3+B)
M"GR5GD3Y(TTZ[#]G?V[CIRBAP\[^MN`QJG6LMU)UI::%,]`BS-ZODK*VYF:E
M!GN;&%<Z*&-K4>6_<T3+_`75*P]P8?_`.PL3DWD,M(A[E_=8;F&E0WEK[]/1
MG[9DLZ8-^8#9W?1]AHN?UB3N/W7E:=<>*!6%II5L$VC,F@_1I_+CJ7.>I'^(
MT8_:`WM7L(-GD8U)(5L\2PZ)$3]L`;;]$`"O.W/0<!U8UJ&UIS`K/POF?!9)
MSQ"3WW.(U)U<'ZA]"Q/C]`,N'LGR/'W">;%NWUE%ZT%V)6KTT(>7M5X'W49Z
M(,`W\`3/"7.G>KJ8VIKM_L[[=V(^$;[O)\>+;<87NMGUF3FZQRN2841AF.84
MB6Q"M=Q*MX@C=B$>FQ![W*;+#"^+QWSJF3!KP`U(:XD%$9\-3`RI;NQWLBCP
M/HJSWZ)DB^=YOEWS%V9S=JS&HL#+WT@2%7Q'":L0>V2S5ZQ^51M%QT!@[LK#
MO@5KYZJ(8&EL5C^C`:!^&!:I1\"'N'9LE];F-MJ\MO6\5P2#S>#9NX4#[^%W
M,Z:`N`9JJ1R@!M4[+<34OAXH2^;[]H'E*6<!12V]B?,_WF<8UY>K&N8HE9HB
M0XG5/+!;Y`A\[<?2L2VYI:9F[,G;%7V$XNI9.>47?&Y2PD9#9UV7ZKDLLJ!C
MLMSK'E'K-2.IG$)!5I&-F`IB.LWEX($F(Q_8M4A$D.`-+0G5Z?(.9VN+`5);
MW&!85(I[+"69@[TD&8'#L95C8V(WV*%-6H='/V&G&U:`_8XQ+_N8IFFQM_.R
M!XSM99#2=N8*,),!R=VK1=Z($<<8Z(4:V$_CIWB)TZ7E#)A(S2#0=]4\DK'M
M:,]S7P+78QDZ,#6K/T'/,4Z6X0\KE'@Q9*JL+\T)V[9@2MRAUSW"=2\Y1.04
M"JDF.:7!<IBC"A_0'9%L(+`;1/*Y6KV/TRAE*W#G:5YD6[9@5%V*(\L\)CK]
MM*/6@2*QRHN_D8:!5R,&:^V4['WB["4KM*JE4;P3#X2R1A@1\=6T"R5<5:D+
MB:KWMR]PPJ<7$X\@R.PF%@K-1ARUY,/=)NT?MKH<`X[;2;-+G,8%OHB?V*T9
M!457?)]@_K[NQQROMLE%O!H,:RQ4ZMQBI.+*7@,GD!MZ+/PIF6MJ9K9[C*+J
M9?,M%T$)E9F8EC:@(.,[K<=)`^T.)8V]!4C(_$/T7R0[26C?7T9K?$K64=Q_
M?7VDMI:F$FUOC!7ZVP]Y5:['\5AN<58JO>5:J,7O^C`)KHFX*F*ZZ%.I/742
M'@DS(^)K^]XT!@@-F84#11M"C`R_9"3OO]UD*J[G?B7NC^S<`?R@S\SA2$[O
M3`SS<K#D[':\&1L'G6-,/ZYIR+>6ESW@#&[\9NC,%62'^E3!95\G\F0C,F#H
MA3D.RR_B%)\7>&T1X`<J^B#?4O%'P,;)GDJYOK^1-.R:T3`1?6+BB,N'6Z8-
M$6+&26$/&M.RT3:D9L];B.P\?MZ5BO,OL05)99IZK@XU_5&V[VM/S)6X'4E@
MH34=C^^?.\.O3TPQ7$)+T63&:U4W&].[;\20Y6+?(9)]OEALU]LD*O!ROF:7
M!/Y3=(;@>`-ZZDL-^(L`$I?&@>#G,A"D^(&9&#EB4S=B9%A0&9VU'J*H]338
M"*##EED@,.AMXW@@L648%I0MF03N^Q@V:MS#(]U@:-FFPOP;%4:-2+UQ(=!1
MZR4N)$=<V"GI4V)'R5]<:+G94PT\]#B2_7U#HI7$%!?!'+5AB1`S-DOZSYC`
M+7U#T@X\!LI3*WY:\=(S'ZV7#$@1)2,+T)V[\214D2]DQMDS;2S#S)GENPRL
M7.RCY&NY<L.602EW^1J19E^-64-MTBJ+9#A^2$_XY0F+Y[O=H3R_1''*SL\]
MYL?UW$5?^J'<7K..ZS::KBPT]P6_2&SM6TE12VNS2@$M*HW.B4L)6\.*TT6R
M7?);#1$I'G%676_XXYOJZ/ZI7UH9`3'BW/<]HIL;Z;#>UO=^<0Z7>NS]`H+\
M<(?R6@6U=!!30F^8VO<'];EC5/5K0K4L?^T%UF%FMGR>+OF?"9_HR-4']3O;
MT68]K1UOL4'C>8\9T:PEXT*'B6U)MBPUT`,%]X\\9;+CH$_(>I/A1YH@:5''
M)S>2Z;?'.*/4*,18`,8TWFA,FD4?HW9-2:,])%S#5GCCD"89E]QIVPCW/:!@
MR&2=O??%IBDS>UUJ7*6W48*O5M<9V>"L>+ZFN"Z:\[A[++93JGYN4R7'R&+F
M!G)EP,JC*F)8&"IOXZ'9-*>2Y8NK7]CZ=P#;FBW!05RZKLMD,_TV;6T\3D=1
MG.(L2F@<F2_7<1JSE8J"5DMGY;Q"GYMFTC4I==*N;%3;][`WQ<RCDH8&%F:5
M$,_#44=L8O89=C\9U4<]OJD5.T0S\>$?:V"5HZ$O1Y@==G'6E4-G(5P)Z@=O
MDE(-%G"3EEV$+#_'"6M??R%#/8-BKUA'>@M%5R(:NP(MPVR]*LEI9RRT5\M&
MH(2X]E^/JL8V.JRU]!PB?T_C?)&0?)MAR;ZJ4;IZ%HMT_1%YZ&U/7)8Z'DEG
MB;TAHX/9=34./V;\5G>K,<6'9@Q9+O,_'=$S.A+,;_`"QT\1;68YPS.@M%JJ
M)J],RI6F8KO@*PYJ/TK^*31GY4.4-4\GII>F+XG5#]^CC%BA0PZ537]`@1L9
MJ7V,1,EA`Y/=XX-J:GSBC5(P>)&->)P`,^D(A[VM?9V153P,EH,G38!L/7'&
M>F,+?/OIT+8:UEWIV1VS3^/=$TZW.(1=I:(>(=J?LH_41JB+SIXN;+<"AJV!
M78L^Y>&)S<B7'[VDWI0&'I/NG#+`G*\W49SQR_@R6C9N2!XE5ZL+DC[P_:$F
MDRDN)JJ?:YP)1Q*,<0I>#3HT0L6LT69G.TVV()90C;<)WUX=PHR,$]0(7-=W
M63[&6CL<C&_-1`P`RQ<N#?`!_\,N_C-4*S,N,/7J58/Z_8)0MXM,S1-).IR*
M*($DV'Y+?\7)\CW)/@Y6GZUTABE4I0,7,>1>(.<P;1P:1@2-G=ZFD`Q]SM@[
M1F2U8D$`U]L9@B&X`4+$C#;K0"F#Y>H2RNK\34=1_HH)Z_;W],<](6D1I]LX
M?;C:X*S<;E9N(2_E[J(O.#_[4F01R99Q&F7/_,RF2]I95)-V'&W?PWEU45N?
MV/X]U>'`IR?7(.*O;>"3%/[;JHQ:GKW/+JYN;]'QV?NKFS-T?GER]>$,W<W_
M-_WD\NS]^=W$,6X/9"%[1V4OGOISVHG"OK];V!$!;KSBOYT3A@,V^N&:U0MJ
MB/$0[=R@G9_ZU;5*GKMB=S6UG)5G0AZ@KK_F<MAOL<4#OE]C<)ET\,:;?%M$
MM(FTA)5L1=%(=2HR@11([!S8!1V$*5WH(Y98<W9R=7EZ=GE[=HKHOVZO+LY/
MYW?TC]L[^I\/9Y=WM^CJ/;JZ/KN9WYU3`32_9)(?KF_.?J5JY[^=(5Z^O-FF
MT79)QVC+[X/97:*#Q"`V*/M/1.N!PI"2$IL3LXD&`.WF+@/)#JLDDB#,$MJ&
M9Y?*C9YA<NU9.T4'Q@]U!P\XHNT)$4^$2D.N*&Q/SY=JN_4Q3O%P(X!&JL^3
MOA041[IV/;R2HO9D1!&!9DV/(OI":UK^>2#,D'2GB!7RWU["B*Z"D`TBF_ZP
M`CQ"D_H8"9/#=ABM7QE!;RJ)B<^D@4&,<@PQ%C+3U^ZT69K="QJQ?OP$WX4@
M,0R_TT#MR(@9DK<VZ@B*I]X>H.M+$17,E_DE&D(N>%FN5QB'#Z!CEMV5NJT0
M&O#*.1"$=.%T)(8F#J@9CG)\BLO_GJ=7[(0V-G-3;I:]B*/[.(F+&/?O!1FC
MN@N\%JKN##-V!CP$M/6KX:&=N1E_SG=[(9I(UBC9"4S.1WOD$/<>'=#6V$J/
MRI;>`V+W?+$@V\ZF>"VKY2I2-HM4P%D\=.)G@&KJUHZ\$C.S^O/62S\!;(.W
M0H62J>I>TS%TJ*UFILS;GL`(6<`9.X3`85G8<1'TIA;^GAW@VN#S)I"7TGQ#
M4U[T><%F6,5@W<;KZ)DUD)T9L5AD6QHS+<I"&R/:E*(VXHW7*K=^BT:+%HQC
MOM;P+B=M2M'R:)]2..2JT@IX1J'!%`:FL4)ESRQZZ%L44#BI=@^D#R?1)BZB
M1+Y2:*DH'U=*%>%'E1)7GL>4:J^6(TJ5L=G)([6$<WZ,>RU8GP#!(D(K$OPC
MM%"@!9!Z>&G0M=K!I<2&9FBI]!P0M:\SO(GBY2E>83H(7E;+!C0L\<%QN3E<
M2W,;(U+*FQD!I[^)V[T,4"T:8A<=C`W/*DE4W>]0AH?RZH=JCB2,-P_=`*@,
M&;9PT(4/$WOJ4&+>HLFXX7&\;-,$/[20CZEKNM1KT(PMY>3M_!M+<JM!^/YH
M$M9`_3Q]HE&59";C<8&L-)EV9,'C0LOZ7E+CT)\=U?OZL_J#Y]`H*NIC)1,E
M7:'C6TM-3:N!?=]@\IA+!)Z<<"3/#"W!UX8PXY`^%F+3!FC9X7WR+4O&&DVP
M-M!P9IG6A^WTQA/.[HEN5Y.I5S7MS*R$=D*M#1+(Z*[JLTZKW.6>H:_]P`\P
MU!O[`T#>80=Z56VZDT6?`MI`Y1.2TDS@`Y,A9876G:WEMK`3DA?Y>;F/9'E'
M;G"*/U]E9U\*G"XU^6*4+4DFL;0%3'(K[QYVU+JWQB8VV-N?7=.!3UJ@!1,,
M*RZ,`Z$B8HS&@CJ46)E5!9D1[9N:+=Z2Y:B6>*6**,$>(*Z%:C76NUR1G0I4
MJH:\D3DTOAGF[ND(%U*^O\3%V1=V%W:</M0GO6O2NDI%DKW%*L!A1^0$=J';
MV)]-")&:&0X"@]AU:0$&!:MUG:7FKDA;15&YMRF)R(^>*-_"J*;T:3N'Y%.*
M[0@G$7,GF=`P,+%4/C1DDJO.FE-$WE2KOM__&'/!,(BD[EABUPD#P@@U>B11
M6)V<&-=1+!A@#A[U"%`^`@(],^8#Z"V[)N!NQ&<G4?Z(^+KL<INQK4[%(T8;
MG,5DB5:T6(P#.?1(T$T"./=_7C&$F90(MCOM":%:+;7I7OU5BS40EHDYPUEL
MV,-$A=*1&NL*U7#6-#4=2>Q^]#[@Q1I=\*NL>L0)X!!=[60L2`Y;*`EYM`R#
M(.D8UPU"TXY,JW:Q\73^B)>L4&>5^]7J!N<X>Q)L(S'6Z(=8E084B^0^_`5>
MK4\C>FFL[(A6WF5>"J--1I;;1<'.M'Z;Q\7D[V"9@T-$.K/>D]!/KBQDHL[7
M?A`)'^+U_@#@V`W\M2R_[Y"="HKY_2*UPFO&I"XG@((RB$QALH5%+]K/#7XV
MK<B->]FMHG5GQ#S%_I2P"G+CU7^S;I`P2+O<K[/N&47P$7ST;A.=?JN&"'1[
M"2RR=,'9$5I!A&/1[/7P43_<PLQ2[XS!3M@-[!K!OC4#'5:<E$XPBW\_"5@'
M$\E][>FQ:'#TKU927A@`OK(KM>T%QR./_E5KMV)Y..?^ZGM7';U-WJ>5*FE"
M=R!OS+9>RQ=?E"X7J'X)D8`C(X8FK6=+='?M2%VH2"!1JJX'KE\A#>;D"477
M$=,?NPOWH6P;Y3)+7M``5N?*S=M#@=:TK0>!7'?N`@-)R3H&!U.6IZT6[<[#
MDP>ZH<PPUK5EX`"^L^HSX@V\&"*]IU?%/7YO;U@G.:K[4HQZ\4\OQ?U.7`+]
MOCU?(/$1"(<>1B&D'PYW3U\Z//1QT1(?@43'*EY+QDMZ06E-"#9:DIN&'"QI
MO=C5!KT#BS[>W)Q=WJ&+\_GQ^<7YW?G9;3!\D/6KLE+0CY/D.NK"(;Q1THZV
M>I+(957UA`^J#*U[8HO4D74"Z7+FXNKRE[=W9S<?@F2-HJ-UV<2*.T,U;7()
MCT'S='E;D,4?CR19XBP_^W,;%\]Z,AFI#7FE48.CF-(1^&X/2\>&[-.;FK7H
MQR_)._OWC^=W_Q$,$\U0(B:E<0]*^:FT(*&J@=<]@M3':,+(*11"NV,.?F95
M*13,O/2^T*H?HWB!:R`C&6$[+;.+95;Q3E2?<T(JAR[<K&:*KN[F%^@EYHXQ
M+!R?*VQ(MY?<L-><`)$+E#G@=4)M9*"WQ=JT@7W!3VR]P4\XW?;!+'G:A.W>
M4V?*=.S!#J1%IM5T&&K,J@_1"D\_$2_N&6+T<_;QW!'LPE=@8S*P?HB^Q.OM
M^@->W^.L!R+AL^I[]IXYPK1C#1*D(L,JB`[E9]5'Z%/YX<0%N;A/B,%/V05H
M1ZP-3X'^=.",4SDX1<]J<':?N8*S;0T4G`+#2G`.Y&?51Z&`4]@GQ."G[(&S
M+=8!YU!_2G"2C)8;]?N]=X*;X)0R.["*9-Q!.[0*#%ZI`PV()7HS-A%,TH*Z
M3MB[XLUI")^XS/385G0EL?CE!U@?BO<P+[,7#/8UL-<@'ASL/G$^`N)"=(=Q
M](&TIQ2`-L>R"L:!(?@B3O%Y@=?]=W:U<A),M^2`P=U8]HGROA,;N'=UY5&=
MR2$N&%AH'_:Q@@W"[E#3HE%1\:-G-QBB7'U.<98_QIMK3#&;%M$#/GZ^C@2;
M%$=H2LBDU`2FE\*73\+IW=I04&=M=AR3NWB-42.(WL0I>MRFRPPOB\?\^[`8
M:0(=!4<-^U3-6H41%8^UOB=C]B4NV/E,UQEYBI=X>?S\,<?+\_1]G$;I@H;J
M^:*(G\II5O&&A_$&JE]ZC`%'NMN[A&3]:.\J\H\T.CN9W_Z*WE]<_7Z+WM]<
M?4#OSR_GER?GE[^@^<G=^6]\Z6OB2P@=$$:@^KP;%>QMM8/#V):$%B/8.V)Y
MT6FP66Q0**IC@E#13RP0N`)?S+9V/2(`R(R5I_)MJ0R['B>NI5#4B`5)>A5T
M]&37=*H1R04V#,@M];Q7](*MB]N[A8/N(1U-X@)Q_-8JZ/X9O?E8@OE[U"BB
M^5>(9LGB^C[@/.6"NWE6'5W`CBY<]UBP[BM)R5W#5*G5M!$E^H(?']LB^JJ6
M#CU9J2`TJC*%J$C'5:(^DY7$G>]DI7`+!V%]LFH40T]67M!LEZQ`X1Q@LA*D
M5;M9%P,#UB,LW[,N"I=[F'71>X>I7-6S+N>7OYW=WKV$61<3A(TJ74?/NBAL
MC:MDPYYUN=K@+'*)$08&U#%":<!/C%"XW$.,T'L?$2-T1@<QXNKZ[&;^(F*$
M"<+T,<*PSXUBA,*608S0MF3*&%%>A')!<L&X=OALQ^SV,W?2[JSY&(`.K&OX
MUI.?79[=H8NKVULTO[N[.3_^>#<_OCA#=U?H^/SJ[OS#V0%-P"<_3,XE07<1
M@U]YP("=6`_<?7WH?H<<L@TM6W5Z-?!*V(\0%446WV^+>E-=M>Y]P.XN?'&]
M+A\Q&79[@.,>08`=7<N,KF'V6+OL:Y).[AJF8.E-TM6K2:26#'V"3@6?404*
M1&$RKB#Q.4$G<>=[@D[A%@Z^^@FZ1C'T"3HO:+:;H`.%\\2):I<UYZWZX8YT
MM[)*-K^/UA<5Z&;ZD,6<B4?C)/9S&0%2_!`5>'FG.RAF;$.,RT-CF_(*,@UQ
M&_]XS,GJ35L8*$I2$U/2LM6\'5.0P,^HQ\8[./0[HZ>$Q=D=\-]^0[Z@[Z>&
M_K3)\O-\L2#;E.5PFMQ3^L\%7N.TR,OK^M0WC8Y5;U*EK;ISD+!S"'Z4VL@&
MJ*/$").SL]4*+_A591EFV]J39Q3G^986SNP$D^:S:$DV!?NP\<#V<[1<3!T]
M1N*/P&"B'SKL+'4CQYA63$`'P)0YSCDT%WC"_(QV>JBK&.[EKE.A7YHY]PO_
M2?,F[14Z'-XM0:?+9J\*?^M/MK!KJU=G2G,]UYA@Z@ET]=;2J3(&6-F:W7Z\
MOKXX^W!VR0Z-NSWY]>STX\49NGJ/+J\NWY8+N;OW:BY/@]SO80TJXMC?/>*;
MFN@PWL[OE$QO)L7+VO[LRX8=`#5DMEINQV29G#MSQ9;AURPTGC3T5.A6UWR0
MXA%G=(3*'O_X!I<"WQ^@%$\]7-7V,K'LD`&5Q"H]ZJCL^H017/6G\S(:0X?\
MR(+=0E8I@-Y4(A._&0T'(%D5YHR@B>LJ<</D]929O"[Z0M9/:@_`=9.1LU%D
MZM9)5W>_GMVPS397'\Y^?'/VOZ_/+F_/;K^?OO0Q['\36AF5.FI5(Y8%4MHT
MBW=5LV2#%JU<]1LIY!Q));4,22:=$Q6)U+JSFBX3LT7?D<3R-^^R0ZK29H7&
M;CALT+%`AWYXU(]=M]75\S)'5HAOU^]5Q3[Q[+"\QU0PMX"W$M8@Q;C0*E@1
M+K5NW?&TZ-YMMCE[X;TOJ:SMNW_*2OJJ6WD(=IDK)/HA#7#'N<`F^/R$W(<1
ML/M[T/F^7`:J>GLD24/!MGH'LN:WEL!;O!E9:LL/'N!CG-VN=*E:*\[5,POL
MX<33"FZ`T`4\*T1,&O2RARB-_\DI>D)92I)XR?^8I\MK"D1V?AO[\VI5S35'
MR2W]I%QH.HWS14+R;8;9M13Q0QJOXD64%JV%*;8(%>-<MAUB*O=UN-Z[>U?N
M[[G!MHGF"6?W1+VA8Z*OH`Q=4S1IUO9Z@(ZC/,[9[I*VPP.^M^1VNUY'V3-[
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MJ"RB8F<$O6&OR7W_XP,U%D!HVQ.S^H%R?]`51%V_S@<Q?!_?]66$$ZL"Q&0B
M='_-#B"N''X++"$$%E4]]^HB2XBUYL<TPU$2_Q,O?R7)DC:[_BY7Z2VFS"A/
MW',N,*'<:*I*=S>>8K]KP_S,2/AKZ)@(#^)ZMK/"CU`(,WB#T<$@8D-"SRQ*
MNWHT"<TPWRI@MN^KO(-JZU2,/QQ0'K$5G:<H3MBY'6]7)'N;1PE&>6,Q@-?0
M7DM@L*S?7DID&%9J(86&(]\S25"-G"HF'-43X!W[W>U^!Z@5-BI7B/FJGK,H
MLG.(*H^H=(E*GP?LL"&V6$S]?HLGH-!^7?'D:.J1W_!--M'`32[5'G>)I""B
MY=`N^*RYU(4V4DDTJS@3X(ONN@[M$UK]ZPOH.%08L$EF<UHNL!,K4NK@^4-$
MA\EQE.2WV\TF82Q.EQ]PMGB,TF6<4^(O64"@H>`A74OV++C::O-JO"T(]HWU
M[F=FPK$U6CH[V9\UVN@1)_S(XN(QSI9H$V7%,RL<%CN-`**`,TC[L0("*X*(
M,M;L(.ZXM6]J-L'N+'%MB5<J-3M5&B,'J#%S@&I#?+-ERQ3:,ENH9>P`_9*%
M,=L7%-E4P_,@V#;YDLA%'-W'":_AU;L3E8+M-"X1A(@J0M,^WHG1.=,&!;ER
M:^,BXAL7DYUH`/15=W.?F]H.$?!.J#,@E<*R5R3!)A^EF_$@:M)&2R*P78Y`
M.%(%<$<@31YZYXM%ML7+5@-/%)O#=<*=7>)R89#MP#+SGO:-:]SI]P@K#514
MBDJAP,*QOML'NX9-.D>T>UBF-]Q&K/;@'6'`.\]UKMS@M=N+7N&K$[)/@HG7
MP$!3[E.'0=J4\?LZ>F:+JZS`YVVD-;_DZ#$#R>HG4DHZDDIA&W*.6>]&12:=
M]JQZR2M'E20?%@MXA3[5>A._=6C2^<2ZE[J44BBU^:2U/267^*M]=V2^^',;
M9_@Z8Y/FQ?-UPE[L2Y=G]-.-8`+:7G''-&-%=^(9NAIY-)JJ>K)VKF&GC;'9
M]99-?.28+0_C^M'D=+0%#''MR@%9#6WTN&OE>:^8!:O&[-W"P956:;4"^^$K
M%53K'""N51[_<?;U@5E2S>T#S9-6>;1!E]$:GY)U%*?]["-\6&>8WD-71G;,
M@59L(LM*7@T59NPSQ#Y$G\J/IRZ[Q%U#3'[0'L([<AT4"RQ,#M3YE[A_1J+H
M40^DY2,@B#)C/@#:LFL"ST:\#4[V82#0['2'`)C]GU$,2R8E`N5.>SI(4EN8
MCM67MP59_/%;E&S[R%%(U``52;CB=&@3%*Y2\TK42K1FS0.4/T89W[E-V"X+
M],1D:#VR+1Y)QK=P'AV\>_>._7\EBB)^?-D'"LI']-/A`:(=]1=>P)SB!5[?
MXZS^]*?_@?Y>:K*G:9RT+](CVR(OV/HENU'=V.(!HBW88':E,DZ>)Z:<`F?$
M&!@]`@Z%.SR4V0J$CK<<(?,&/$IFRH2%)!T*@_*U;QY\P<'(G3F5A08$K*XI
MNZ/S&UINE)].?#"K(1BD3%)UF8I4?3TYO\0>O.,.;N!KY,H-=(<BU'TM<),-
M7P'Q-NDPM=.ZT_@I7N)T>1,5^!IG[!K<Z$%=>ZE5A'%>I@+*.K$3?^6:TI\Y
M_Q1FVB1DHFA9R:*,"G,6/F[3)7U>/(;%1`U&I'S4]Z&*E&)M.355W@+AYR6Y
MCC+]>&@H)N1A6PR4>SO#_O@V\&'.L9ZJ(+DUHR3.JB5)DBC+T88.4KA$4.02
M=+:44.*.49%HIR$G3M]J*&39LF'EU:I,N743Y^F2;P_8'08J77V'L2:FGKTU
M6(;:^O<\6!K;'@O2C_+0B@VE8CC;`X#0*8\5+A!1AA1;PXK(,ZZ-TU/)T_AO
M=%L\\Z@S@N1F#E!IB%^$4&5=:@R5J8;-"Y8[WUH&OU'/#%(A<R^<H6[9[',^
M66TPA=D55$Q?UH(>II!*T_Y*:H$7VXFCEK*@K*Z6!H*>+^IUM&:N:-@E^FFB
M4D<W1=2V'`AE>@/D4SXLFJ_9MDJ;*2*1GLD\45?/YV11V]/>9HP$3D=/&PUL
M]<FXFSL2#G##(J8)?DSGD&1=:S&1U#9A/)LT]!L(J<MH<[5;J35(A@)I14;L
M2'M(BRW[>UG2&_JSS9)]"_)4V5]%#SIUBF"AR9^2OM,GT9:B+I,.?/C'H-?E
M/8$O1P`*%OB^)M19+/&-AUTX(Y\/?+N-,LQW182QO18!)5-IU%_)U;%O3IJ6
MVNP69^PMH1U?YN6$!OI42@4U-]'K1RDMAK^[B@JEM!S_;6M38GX3Q<OJ0O)Z
M6J*\Q4;\JK2%QHX1>@UW@NA\`//%T)V&/D969I4@PO6E\KS@X3-_]3OY(=S-
M90,-,KKO!IS3*?<H:.9K0D;&)"N/=[S!BX3V*[]_C]\(L/RO;5ZPUS9.<;[(
MX@W[<$#/<>H-5VW5G8EKY]##V&54`]2\'F%RUA>=FLLC<41@^K;/<CM+7<J/
M:<4$L`8<#HUS#HWIPR&H#\J;:Y_1I^J_P5Q?.Q7@I<.J_2)^VH$766"\S-_3
MCO@0IR2+BV<^.GPDR9+&[T&*,Q-O4II.W)GK:@>PA:>1+S63#4S,:BG$V('X
M[09DA19DO29I,_FQ0OGV/H^7<91-_@:*(2;(N'[KDU.MV26CB9<@N,<6TR+Z
M$U^M3G@_\V&J@GQ*>0'[)/*`]!-Z\'!ZH:E/4Q[*;<SFRV7,@G24\#,>BF>T
MB#9Q0?_,HCC'RW!XIX:#A'C:'I,S3Z@JHY["SS[P!UC;&7ISAMYA/PG$E>0@
M$;Q6"$I+,V@,NM\%8^3&ZE(7@X&SH4MG)!Y]]4B4W%D"C\0I;Q$1-[`[:3Y/
ME^4'F#XTKT],C2B+%KT1+R36N?4UO+!N@3W/C0Q+AB*;[FM>(3+?&'7:<&"#
M`9,0H;.GCQMF+0HBEMQ2Q+`&&QYY9Z\IB!I:3<!0H?'E*SZ8N34-"B;6>I&@
M>,1--`CE^+L1X)&0WZ)7Y8S7&)'1W,AW0-R^RW"4;[-G74&@D)9RN"<-SMN.
M?;]<%;FRX^?0@B0[%Y5@<'6Y"@)*)DK[2<>^CJ*:<0(?4[)L%1?L$L(AH7H/
M=MQI'KC3I#)EO=Y+BBC1#%N[IC4,:`O/+L_NT,75[>WD>.[W`-']=@.45C(]
M0'8T03L1<@:L9]:\!P]I%^*B?TLK_3/9\LV*UR3CBVGSHLCB^VW!C\"FOQ"[
MUH*D!6U;PL3.TX*6NOGTQ88Q#.1365H<3+PR*"Y!/N9XM4TNXM7PB`=CC5W8
MTFNX4T'GP\/&%E.?&OX869GMBLHM?X(2^FAR@AAC@8SNK`&C=,H]JIGYV@\`
M(8.TJ3\`])5+%>USI+O'2!^@4AY=O'),RL.\!U`&F1AH>I<>5&*NHDL-'15?
MU&PY`1X7FOH;1<V^F5F+AJMMEL;%-BO/+EC%7XK`CBRP@(@).R5=:,C.EK81
M/0?>PJ/G'?4L/NO=7$-'SK:&+V[N?.R%F@-WHYC9LZ++F4P\E./F+=!APDMQ
M]QG2<J=LQ,J^K_!(:9LP;;.E_U2YUSP)D20E&3+\3#@J#3KD0*L$&'KV*_>\
MLRWO?,>[*=\D:CK:#=1\L:_G:'\S&6+'HP@I,K7C9:!DE`'#A).*3C.D9L^"
M$4.%7O>(2_\3'!*G4*#43W6$^X+-?E!L.P<"!.-09T,L9D$L9C^\SGKX6//3
M.1L[U3&8XDAQJ-FBW<.&DQ?C)BU,)RO\1O_*@?^(WW+D@J+#UPTCV[!LB:,@
MP^]%G.+S`J\%6R@,%72AN*7@BT>-B[T,KOO>1C&J:T1=,*%/3!IQ\5`KI"$L
M3(@G[#A#]C6Z1ASL>0J/B+]DPGU,!L(Z`E;"OLC'S>]O0-UV-XIY.P/Z99]`
MR=;M?A.B#3K)D&1<SXA@+0_>D>:_8.JX<H.9?CC,15\?U&S+J1%8"[*DLIX\
MM9XVW<.$Z013I2"3I++IT1<6X<=--;E,E=K-+NUI>G3/$Z,P4Z)6DZ'HTQW?
MP1O^'"@`)&TS@@,F@\P,Q\]LI5UT/[NYABXWM#5\T7+G8R\#[H&[4;3L63';
M6A+"9?$6V#!AI+CS#!FY4S:B9-]7>)3<76]C7;8I5'4D%:KZ8JO`F9_SAFS=
MCZ*QS%SP*^$JN)CP5M.-A@066#%BLM3[GE'KOPA4.(8$K+8PW.G1&C'XZM`3
MNFTK1F!X3UE%WE"DB6K%P>?53]/ZW)&3C27(ZJYO5,6EKNR,_QE$+3;\[8GF
M9^OBMA%I@[*G-RW@A'=*")ZT00=T@T3+%CCPC.^+Z$O7X`MBC[FH'_H`U-T`
MT1(:@#"(^QYN\((\I/Q`R:O5:76$SPU^PNG@LG03T1JH2E%7Y"J,@\^?&CA3
M`ERG/JL_1%GYZ<1SI$:=3.P[HT<+A5:')UKKGK$$5@";.'(!4GFT>BW"3EQI
M@%5)O2Y<24I5*&!-6HKB'--?])%6S*>T10GA-7-U0\D@)AO(-D%9*>O,)(5U
MX[#\<\FD%#]$!5ZJ`[/>GYI0.OU9+<*'BLN=T-1,,NER,J)G^E12J'6YI+7O
M&UN`8=K`DQ.L#GNX:DFA2NRUX4L:JZ$`%FRT+E\+L(G970V3R%UK^.18Z<-#
M<6WJ<S3E6E9>8CSOP<&4=</^LJ!>]9Z0*0';OO:#P?U$^ZX_```:1/YP7];R
MB](Q&6(T3*?-%D44IWAY%F5IG#[D\\5BN]XFK-BEHY!X$?=?SS)7:'*%7L&9
MICH7H#.*IM[4%#4R,FM]3C,$?S`U[XS[GXSMH3[I=+I=SIEYFI!Q?%#/SE3]
M)8O28K#`(WO>\&GPW)D^/8NP;!$;5Y-#I#/C_T8Q/QIS:A+(^H@8_JQ]B/=$
MNX@6VID:P*T9*_6I$<;R78"KY&$`+_?@86!AYM&`%1H;LWIR,=O)!4$6@_X?
MDL>LBX1DDJL*R*7SLP_``8XB#+TYH^UP![>68,B#!E]0E`X8H+$XZ6"!/$=)
M\2Q9C14^K&-Z[Z$KGSKF0,L5D64E3X8*L_*S&%=7#FPRLMPN"G[UP-2KJ>).
M(B8_;0_9';D.C`46)H,LN[8@KYKR"R'+?'C@B$JD^LYB$4<0BXQ"0EEA7P5H
MJ=KLMKHZ(ZLGC2I@3XQI9?\1\]^[BV^1=!OE<FM!8%T-<S7"H<'MX\`<L7U3
M7#>0OB/\GMH@=KK(.D@"86/T*H`+=<2-P"98-2NQ;=G5NTKU`%U.?7+-N)Z6
ME)AV73UE^=AKCN105XV4.%Z!'>`JL>LK+]N=:*[2G-V<_79V^?'L]A]!85MU
M&JO!;ZV$NNCD5:7-Z9"_>,3++;M`ZWB;QRG.\_GBSVV<\T%>?OS<^DLVB^9B
MHN;,*!.NA!KA%'SZS:$12CZ.-3O[F$;;9<P6=:XS@MZ3;!VA\W3%_CO]A)T3
MU`A<U_?(/\):)S*,;LU$#("KH!P:X`/^M!:K5=EPLE9&;>T#=/_<_B"X@Q*F
M)HFL&IR()9/6E4V;W\<I#:H7\1->GJ<%Q6U,,3//<USD'#[2G&JJ.,BD>D6P
MZ*%S!5JCVGHUBQ-&QCK!H=1XRU703@>52E54""84&,-(&`!L.EC&>IT-,=?-
M/`=`\'E:Q,LXV1:TJ;=XL<UB-LU^]H5=CXF7;(G\A*PWVR(J7Z2H-X%<X^R6
M7?.K#@*0Q@>!`L8X6#"!:(Z?@`/8,K.@!.:P$[C:5M'.+*KMEDM#+<M,J;:-
MJ''$K8<6X4`Y(HR"T,B414H(/^)H"O<-0HBXBP79ID5^'3VS=LW3)?TDV^+E
M11S=QPG_:KS%^HF+\::&T72$*;C8:>W<XX3&Z,88!L=QYF>U'MJ4BGR#>52J
MHF2G&TQ<&X]-<11SPH@T9EE;E42HD:V;F$(>9D3&-\0G?WHS)`V9KEMDJNR@
MEJ&`)TG"X)=VTF1:@KV,211]HK>V8#VMXB.M&_OT<'S>^%;`3+STLG=KHB7B
M0J&$$7MDC9IIL4K*QL;&S;WX2L%6?CUD7FO_'I!^.&*R,<3L.@4MM+ETG[P(
M(W/*SZ96SCN:J0URI$X-+%*H'?F9!33R:181#$QUHH#)@>W!,-\0.T*ZF_>K
MC.)J"V)>FWB=CLML`NXXRO&23='A-.=S=/,L8^?CE4=:[T1H<<\^FG^.,OXM
MBN?S-"^R+?LPORH><7;W&*57&[YT.E\N^:IIE.P.&\UE6^"F;44=::9JA6O@
MFJ;=H'%PTJ^@#*L3MFSV>Y25;\>&<@G]U$0E872,.$M,TZ!.TIGR-PDLAQFE
M&*,,X"E`^X^?H\-;52,6=+#Q]IX]1(O6TQ!#D'F$L"6PGE]!PM^`])=;=OSQ
MU6K';2Z7S[?%(\GB?^(E5)EF[LFU%#/Q-%6YI6];$"65<3.]E$V&WF?',;F+
MUQ@]1D]T$+NIF;JA'?=(;:*HT4<Y-X#>Q&GUS^]#C&"P-((HE.SP"E0,Z9V"
M%#RFW^WE1?6J8"M/SCE/KW$6DZ7HMF6/'ERCN,K#5-%;WB;XS2[>VN@E9&N\
MEG5D%:-S],#$*(M??C@VX`%$&#8#'E#XE3L#";NZ[Q(FN>$6`_VU;P)FL\5$
MIE8-$3N#II9Q]F)36ZYR@+B'`U3Y8->"\ZDN&A9*/T%<%/ZR@X-LR?)%1H=)
MESQ9>Z^S>!!YA@_:M4_U`"*J<5/@X\.V56T$V0F7O$<;]@%/Y$N2)%&6HPW.
MRJ0>0D[O=DN?;8,?5,`1+C.`=DOSY0T/WD=Q]EN4;-G.@NVZFMQ-EQ\P'??0
M7B0/S]!K=/8>78</-AZGJCC,VQC.\,*ZS5Z*$LM6S'['\<,C'7&\C9YP%CWP
M'7ZUWLM?6!O!+HBZ8QQ\@<H0<^<@98GM=WT9(67Z08U]>P.()S"#'N83<:>H
MY97OO&KY_1:=]LN$KR$\33Z*&GS%<M1'6WQ.\9>R=TC93KE<>'.3@P5E4:FQ
MX"6B*WWNJ>@S:8-]T-5;?5%["\S@I8U;QOUM$H:4QO1AQ:`MTV#><U5BY-\#
MX!550ST#RI-_H\^W8N?!GBL_+5&L$K9OIDR:4(NHX+7!U>HDRA_?)^2S=(NU
M@6B=(I6BKG%!81QT>E/O1\ESG?KLY.KR].SR]NP4T7_=7EV<G\[OZ!^W=_0_
M'\XN[V[1U7MT,K_]%;V_N/K]%KW9UD<@?A].76\""F+?>3U>*K0Z!-1:#X%H
M[^,T2A=QE%R3\E@X/>&T*D/B*53@""AUXHF(.G^&A%2;D1'S>'XQOSPY0[>_
MGIW=!4]'/63$M#3J4BD]I=H2FFJ\34_7DR3*\ZL5'VW,O\2#+5`ZN3XQAW)0
M;.Q;]D)!B1,CW@EU9_Q3]A)AN<GG$WL2"HNDG2JBCNKWE_"EKR(DB=CNA,R@
M[:C6V3]@M@=R0`F90,.%H8`S"?HF8=$OL:Z&O5"IVLMV5:\>E8\F![RTRXCI
MC]R'>%^VBVVQI6E!?9[G6[P\W69Q^E#N'.&3HI?X,W\R#/T6.FWHZW4@V*#S
M`DX00X=:SAC9F?&):[PL-X.B:,W.#@J`1,9XZ//*IKL$5-.I#]AGYF]?0+2:
MM#,Y',C&,0@B#[^;76=D@?&RNL*.7UW'ZIH-C5,XRRA6R\W*KQVELKDU;S"=
M=OY,WLCRX_<DN\794[RP2B!278-$(M#UR..!MWTE%IGCL706VYN=D/6:U"\:
MH)@+H17)$"59ODT*:@3EE4:XU);CR9#BRFXV9_K`C"GC)?Y#(W[Y#AA_]]V,
M[0(%-<4["GYXW7(!OXILZG($C?M&Q-P-Y[4A<T3H22KI,R-FMG0-Z#CPM!<0
MPBWK&KMS1^!A/=PO)5$IVKR=4DH?("[_>K%H5Q`Z@7'R4O`&U^^/#U.8*"&8
MR+?S@5H>@HDJ#^"EG8$S+0NU-IHTP*G8O-^_+,FXJ<CXQ.0#(*$1(OH<-.TT
M`0-5J@,"ZOV$69!9SN%)E$P*,^^S>#TW/DY6MG$\.DGVYO/*/%F5:!UJOI""
M;<SDB:(O+7*ES>R)T./>@+J?(@YB@D]HR:B8HSJE1)BS`:!@'5/9.:(UU`JO
M;*I%B==5,*CQ:@6/15[I8E]57L?;V#*O9<2DS@LLF9AAP[#:&_:>>;E7ZIK6
M>VU/819\[17FLR\X6\3Y\#"ZT09,"D&)`9^Y5NAROS-XJB:,3L-RH[-Z'P6N
M/PZ,X./@99J,M1UND9>%MHQSM*(EDR!^/Y6FTCT\W(&/RZEMMT[,^7H9,Z:4
M]429R4M<R1*<Q:K64-Y@W=KKFM;.P[X2XL#CV(5IS8+6`5I'V1^X"&8&TP@.
MALO.XQ:T=JJFR\O>E[.Z7GRGIZ$W9_!IIC^X<,A+60`8'+&S:1P()\\`CR19
MTK!7'^K/KF%F3249?T6C*++X?EOP*Z7()>T)DA:T5VA3'LY3&BYQ7DA?:?)A
MO)U;`(U#!`*PYH!/RD"W3!M@8!W.SO[]X_G=?P00:N#AW(]+7D`DB&%@?@8!
M#_@;O/#@Z"4H>@F&@01!ZY*=%%&B+=FAFN4_\I41[XY]*X2YE=<0]_S%.]]Q
M#CZ^P0T]0)H".SX!:])^F%:/="IC_X)*<P>H,8@JBZAMDH&B:Q355K^QU1AP
M+X>N80W2M#6%MC[P$'[VD+='Y>!V/N5S:0W5P\RN9MRSR7IJ2GC*1IXSR[@L
MH8CX@_!^3:$2Q&NF(]%A'&7U\`@K^EV2`N^NE1S<W2X-BAH]::R4ZH%S1N+)
MU[9/"]]V-%/9FIT%&75UX%#2S:#?="24F%!S4^EWG^CT&.@U7L&`*4L+3`7M
M=-"G<$Y5W!N(C5,)-(HG33S;^YQ6B+0&.'NB_Y-+$XU.KDXL<CE7JLHL^T@<
M&E]*/BIU9[O'J'P^,;VT_4HLNZ#''IE*ARUJNSZ!`Q?3=5Y&8^90`)J0`C08
M@F0!V!E"(058V3*R1DP27N&6=B6&01=IU3YL"-)=.!70(Y33*W7=JN"&P1*G
M1$-%C%"6';O-NJ/^3LDZBE,U+X9R8F*TY6"9L;/LD1H#)Q;<Z.D.R(&8`/I4
MBH1%#T'ORODA[@@E078J"H;T[89"D8LXQ><%7@_>R-*(B0G2$H/E1V/8(SWZ
M/BS8T54=DN,3$T!<(BQN#/M53@UA'RB9T6@HB-&S&@HO&%]%QQBKI>1I`^8(
M8[%=SRG#]/ABA:8L781PAK&F1]6I0G-^L5A!DR9".+NXURJVKJ-A0EM$0H-2
M!)@#S*A/`K3LVZ"_41,D`_XP,-AWND^!^?[/K09\O1ZHMQ8*U,4G=:MDQ&"'
M.J];9-4CW,U/[9;J"0`?QMG=RDZ40UY[@K=(7`'Z,,[QWFXV"7\),DKJ&V#.
MTQ7)UI'JHA4[K889AEK.7#'R`\L>&Y=J/IE;FMU^O+Z^X%<?S2_0Z?GMR<75
M[<>;L\XU2.C\\OW5S8?YW?G5Y3^F9IX=;(A3G_;9:62@RU<+GY,Q^"Z+EGB>
M+OF[4//%@IWKGM_@!8Z?6%85WNEII5/]CH8ZCMPU\@+^0JJ-5Q5YS>W,ZJ<H
M:Q[SZPBCA*(LHA3B1R8OR?:^6&T3%%7BTQ+8#C?$H5N[Y#52;U/7PM^^``NV
M%&CE$02MA]_-N"P':/F"9@/?G?Q!L%=G^H>M9&W1'VZG7'.\RW"4;[-GO@M%
M=%"K7*#))4,!9Q[V31IGB9]+SJ7X(2KP4ITG)$[4-!,JS>K/J^.WH@(M2%[\
M`QV^._CK7_YV</C3WSG?Z)]_^_GO!W\__&M]B@&5_$!1_XA^.CQ`M(_^4B:.
M`IU2H/!!1_7@IP.:7?(-7K`[5).)MPLJ0$%,N['/KKYLETIB2UYP!AC<9>;M
M(7;8PAA_4ATZ\')Q(`VS]D`()H`*ST%42(A"*-!)AP*;D(-DN7EC;+</+^S%
MSV".,5/UG0SANI,(!<)2B`=QUF"G1<*Y5(6$".)`\Z@"FQY&DS(?QCAO3Z/N
M8GC9[V',HJJZ3X9RW0RJ0%B*<L7L*1`F_.3TKOT1@!AD]5<!")/,;HR(*7/[
MQQQ?K<[R(E[3P40_K8L?5E^Y_]`1U5USX$%.:%X%9X'"C'[&+OS#]:?3(EC2
M.\3D-^W"MBO71JS(`GA'@T4NL6F[7CYLNKGY.-R9HC$0D(0N&PQ,&;!^C]A!
MJ.+U;N&SZFOVGCF"N&,-/%B)K*M0/)2?51^%4GZ)>X88_*!=E';$VB`5Z$-W
M,5B8$EJVZM_#IH-?;/]*PI!Y!T\:A'#\\%C@Y?P)9]$#OMRR1EVM^(CG:EOD
M192R`T>.HSQ>S-/E:9QLB\'Q]&Y&ZK`VTH@K.4:Y]?!NHE-#E)P;;WCV^]GY
M+[_>G9VB^6]G-_-?SM#EQP_'9S=\G\/5AP]7E^CVU_G-V2VZ^GAW>S>_/#V_
M_.4?Z'A^>WZ"Z%_H]/SB(U,/9H[($:H$$CB]>#'*7B>P.+1H,A;!Y2*G)O@A
M$,MNE3*JM%&ISLKR:EJI9>(`<2-\6:DR\XTNLOPZ(5_&9>S[X@M+PW]Y]U.5
MA.D'_WF\S>,4Y_E\\><VSF-^QOYU1OAFI]:>)]G[^V/5J]_27GUDH!CS56V3
M[)(LMGS3&+/2^Z(._D6A8;2YV5E:Q!E&R]V9'#02;#*"N`);-M[2LHU]2#84
MEN6=,6Q'4H38J#6+HP3=5YY1M'.-J$A.'V.N&U/D/L7+;90DSRA>*S7I$/DQ
M*A`%_<X#>Y/N$:/HX2'CB_,_3!N&1J.<N".O&W5L+;%X,[X%>R:;<RYV<0Q)
M,YIW:S74UD-4\3WG64LSH#,7IL"Y)+WN$^C#=.H;Z4=`@S<7_Y"`/_IN]C&-
MMLN8E3A4&-4H9_%\C=[':90N6&!OX_XMNJ.%"48?2%H\YN@L75)EP08GMJ'I
MZ^/%T?2\.((K,^=YCHL3=CPL.R62;:*GF9UOL9>\:6*N4/T^)@H.+->;!\M@
MYJYD%#:U,.."J"V)&M%@#CNQ@`(9U5E=ANF5:TX9N_'/(MGXS$)#RR.849B!
M?>B!E[E+>T+UAE=W=-2"!T,L-GY24FVSS?(M6X2@R/K\&-,,6%2&BF>TJ'7H
MV&J!LX*=,Q(Q:_PZ0OQE\<CN,^1.JHW"=`2V:-WP._'HR0:#6@(;C)$,E/4,
MAAL)&?KPG#J,QSO&)C3)(YA!C3_X62>0L?AS&Z`8.K$:DTA7WBT=.J+P2(W"
MUPH\R=@`'GB`(X`/T9=XO5U?8PI2FJH?<'ZU.MEF[)CX\B3;\F*_U2U)>(/R
M>7$7K]D'\4,:K^(%38]W693FM*QJI?D*YYZL5[\ON'4'-@.W!;K6\M,\69CP
MX6UV@S?T]\=LS\^ZM(\V.P>\N"I=5'=@E-?)LL_SV@U[*:N@COB'.U>HV/E"
MR_):4%;H;?C-EA.7:;XH1+SCMAL%@1W5$=-+^\.*`R`EJ*=V[3$"T-+V@S_>
M?R/Y2%"^5):[%>\>&@17Z'MJW!ZY?N25ZWS?V>,V769X63Q.O??LY7%?,LYY
M.=P''#_5VX.8A\7CX`TCV>/JEQL^=HA)?6/08PB)?5E8$(K3*GY%0Q?KV[39
M\594$A-7VM*^(OK?M\N$OF0-9;$%X"X'*1=EAFTZFQ9LEX,^?GE=+*ET;/K8
MK=80680K%F36;7KZZ'7TM"2OV?2TQ\QR@Q-V'LX=F1=LK8E%:IH(RX6GZXPL
MMXOB%#_AA&S8(TT>&F=,DK5LC0%RP<ZU[XPXJC6F1!MAO#UG-DRW*"LM,CSS
M;9V-75YH5TN:F](T6NYL!S='!H1N26@8CS%U'+&S*XLZ8UHW*0&]U"?CFN&/
M>L+:9S3AOK%+"*`PZ05;[-G[]U<:CFN+/Y()R\XVR;X1S`U!81+,0XU]GN9%
ME"3,0_Z>9&?1XK%JGZ2.UBOT:F65`D"XD)OW5?-J/>IXKS$@KEWCEA+?6H<C
MMBNOU`ND"C7`!AG3>V(VRG7[C--Y\0Y#T,I/[\H-@)T*3@F[UXDZ394%!3N8
M:DGM`[XBTOMS`]_15PX^304"!3X_LW7L[?#3Z%FQ%-27&,ZK[21@QA*U/8\S
M8#T7!F5_1T,Z5\6DT)**T<K^SVU<[=N/JG,3V%Y^)K#)X@5?\SV."5O^:W;:
M5UOORS>7+__C]@Q]^+>[0"H%$12&5;RH[Z25>2TL*+>[=N!Q!3VQT[=MB:C^
M%$R#HY?:]_IY#\/.!YNA:!OU,NW0=V`)@?X$P8N'@'YD;@@!T'=(^>D0.0V\
M[):,:(.W1;S(A0<8&LDV;[PI99W>O%!8AG_+3>],_KJ%3G<V3_DCENXV4?I<
MO:86Y^7K:21)\/(`+6G67!3),SL-A)T!4OYU@.Z?44S3[29BFVE^0.PMN6V^
MC1*FO"S/#V&YMC+%K)+/*:7N8[QAC&)GC_P7R=@^K#>$YF/TUW?__7M.-6J(
M[([*04^D8/\IWWKC;C;D<WG\76U['3VC*,D)PE_BO$"?X^*1VD]PGE.YW1XP
M?@)*W8:#LAK^$JTW[+J;^^J=O&A1'%#-**>?1<V;3]QB^5OQ=CR29,EVHE`+
M7'&;L1G!!16?_+T\$XX02RCW7TE1J.U>1M':]DE"H#?O#+R,IA]_VZZ403VA
M0,ZMA`63],TZ"#0!OI!]$:_P.MHT.P+/TX4P'6GEJN^ID'-@@-0J=`K2.9+A
M7ZWW+?6\NM2CYP.Q@&XW2$A5Z@"AL>F+:"!I1NMA%,5H>F'//T0;U`@<("H2
M2'*!@8LDJ;CAQ6V(JS0--]#5NAF%FB,9:GYX5;"1#(7=8`,X++[!B^<"W[5*
M'5D58B!9?4>EI`/>%7:A:Q&]*QGH=9K?ZI%75X^8,(-80;@;+!1*=;C0VO5'
M.Y#*Q,#'2,(=LB6;$RJ!VB)!91HX_$B*%'<``8YZS_(3G"3\<,>4A]\HN2[P
M1;$49AU#Z>K[:J4=:*"Q#9V!S-S)2&&B_2T3O;I,9,H68@WI;D#1*-9!Q<B^
M7TJ"9"=#/PYDI%GJ[!8Q,=210U3PAP-$94-)5O`0DR0M.(QYF+)=Q)C^0KDL
M:^G$>A.V0S&`68&^45_3M1(_NDD!H=JWE/3J4I*6"L0<MN(YE+Y&?PI%;-$3
MPT#G:64.QG"K/4M;/0\JKT#@1#-'.P8H_G*';K5/)B;.';!K?7VCGG.'[4J?
M4.U;[GCMN4,[`Z^"K3(D2*??Q18],<Q'[K!>XA/K"7)'0!-H$#@QRQU60`',
M'5?I@K`)NA.2;4AYL98P>6CEJF^GD',`M]0J=/[0.9*!7*WW+8.\N@RBYP.Q
M@&XW-$A5ZMB@L>F+:"!I1.MA%,5H(F'/^7),2R"0-`(#%DDB<4,+Y)V=,6$'
M3\[S.+J(U^S.+6$FT8G5=W!*Q5PN19,8A4XC&C_2.\Y4:M^2R*M+(EHJ$'/8
M]NYCDV@T]ZXI+7IB&,Q%FAH'8[C%+L:L7IMDSP]0)1%(^H"`B>P^2P><.-Y/
MJ;`,M\50YV4,6HY>/UIDMSPZH`5P:R%;ESO99O@2;S.2:U;,S(2K[ZD3=L"[
MVC1T`6+D309^`^5OQ<BK*T8,B4)LX=P-(6J].I"86/?*19!2Q<S->!;2LH5O
M[&!2J",6U`(<-+`DI0P4LMS*&KU]N.+&S-=X?!U]G?B2%#]0^`(LA*ZRXM%L
M]EXK6$_?*P1=IA6E9L$G\'6>I-.+:L5O!<^K*W@,2$%LX-N;EI7J-/.R&JO>
M^`8SCZ]U,8YI;":?"80ZE0\$&MEDOB-J`*?S3_@!8K?\_+#S/-_BY7N2W0RO
M5M#*U6-KN9Q+O26S"CZBUCB2EEE*/7XS^RJ*L]U-7MV#VV*NPN,OO_<K3E%*
MT1GE-/>D3SCG\9Y&?[2*TRA=\+\61?Q$D\KD%PKID4$L.K%7C<E4FD),;=,7
MY&`&CCH/H\#&AHLJ;+T&L,C&ADYH`0RJ\S7)BOB?/,A<K4[996`97IZ0--\F
MC,KO\>`*-1N5^N@P(Q67PXL,'(`?)&;N4WJ@D:D)'I:C!UK3/D2T#(G69%N>
MH4\+^FW&+W^IHS#^LL%ICM&"8N>!LBEZB-B!M0A'64KE<A:Q=Q?%\%/Y$XX7
MS#]>D)P;7E:-895UU1JTPI.'<"OPD7'@Z!VF9*#=G*ED[&D/6(<YK\O"F2O*
MV>E=+5$5"E\O"&5'>GE`H?<T(BC.]8+*E.%<GLO-[B<]&!3H&L4)4P&?+`J1
M>J*RS*RG35C6KLMT5KU!TV,T-RGD=9KRR#U])0^%&:O0;`X:P#!\RT)`7#R?
MX@W)X^(&+W#\A)<]L&FDJF\GE7*`N,0F=.A5NY%!7*7%@VZ*"U1-=*P2\OG'
M-V1;L']\CZ(\)XN8WW+%9YOSRA1E`;?%8C,W%MQ-C3HL$...ZY)"HE`S0FG/
M#\!``JC&_@AHT=!Y*T/+2X>&)&".QX;;4KC",-P:N,;)"(0<"1"RB>+E`0M(
M+QTBDK7M\1`!7,T^3Q<96TP\Q>5_S]-?LBBMO$7W21]CQO+5=S60=T"[UCIT
MUC5U**.`F3[/Q'$EBMXL*^'OVYDUH[#(^%Q!-;+A%]3P@5).Y3#:IDNV@,6N
M)\+9.F?UZ@-;Q^:W'4;)`1WZE&M9^(`M$Z^HYK*L;!]8DZ:>!#,'&AF!A2X3
MM:HU)PU]^$8T2)HW]N2$99KZSP5`IH-R+ER5`4SZ-<)-4AS`XLVM8#!R858Z
M_%P"+N63-DM9\6#LT`EWM*#X&@`F*2U@`09Y;X]PEN`B7K`Y/#9G.T^7-^0Y
M2HIGXU4YK;9RME6A#3[/)?6UGWE9G7N[>3&UM0EG<).R87P-A>_2R,JVA;NT
MIT>P<N[."%8F\WE20^I)/HW__=+(XQRRUB\@@?JSS5<K5.NA2A'QGJ&JJ-+E
M'WQM^+::L/8!<+?R:X1#N'F<D<X!87ZD6%1IQ_&O#=62NFY_J/96\]VR[>G'
MM-1<7F>83?%I%]"5&L+:3J(!1E.A?;\UG,JE&1_E%O9?JT4]SO-W%M`]:QS:
ME*T+;R%>C4,AU[5`4=%;J"RFM,*/?]![J+B4OASA+EC'Y[*("Z-*&MT$MJ0/
MB3ZCF@D"?I"UD=2)KWI(Z=`1A(*ZA\?`M\,8^%I!:%3B0(`0L)2YSL@"XV7^
MGOXV9^M-0IXQOMHP__G9%YPMXGRP$<5&I?HES%0<B&7B`+J<L?`IXY:Q"5[0
MM':Q#/:NL%JD*G.:72L,[ZA^;Q*7]JK%MKAZJQ*1TAM[RS.FM4Z!U]3#(V8T
M39ZITB+9+OFD$_\#Y[0"C[Z@>YSB55P<5*^O,N=4@2UUL_="'Z,GMIH7)?$_
M64'%YJOXTA[](Z<X9@MTR?/$A9`5B,DXD'7#@(EV'0?,/>V!,R#5D(TS5[;0
M>J@614P6U<*HDD:-^.L%H:0B\H%"MYK(U`M<463CT16+M"QJT%?%VCH4OV;T
M24HA'^CS5`R=\E,72-:X7.BK(:V.H!Q2Z`"12NK!9T&D<VK"*[4-#R51[;"I
MBL(AJ!Y:`H8:];R<H5)U$44UOO:!9?!"1>O-&<6#4J6!8,"E"CP6#8H5.##"
ME2M*-W[J%:U+9TC2BJ4?!T.L6.!!:%"SP($0L&IA"US74;R\2F^C!%^MVH<0
M]`!L(EI]>[6H`X%4AJ$K$@-?,KYH57?U1_5"T:``6=&:GT]ZLK,RJ)'AL2RA
MO5=DA`]BUX]=-JFT:A+I+7N$'T@18>)D+/!HR<!7PI7(>CTPDI0&$#AR*P1T
MUB%W&)OX&HNGHZ\+3Y(L#X$GP)Q^O*7#4ISG\\6?6SI"9>F-EA;O2;:.SJJ-
M"=<XXZZ/HSQ>S-/E:9QLB\'TA+NA^B(5!T,NY_N/=@M=2SBW1'I)@)MA7H=L
M,L)>EUI';,M)O."++LM2B+\`':>4SKS(*`E=OEM5;VJ)<A27IX#>5VUA[+^/
MTVHI-VO_F:/':(GN,4[Y(:8)9CZBHE3'#W'*6EP>-QI$30/```*)Q=Y="*-M
M-K<E.+9J,G+"W./BW`0_M&1WP=1<:EDX8,-)Q(V@V@JB9A"W<X".&_96MKYQ
M1U$$3DT>QZMKG'P#7F[CW`X_%**%Z25-70FA%-J41V8W!2EZ*TAT;^(4+4F2
M1%F^RW3??V.0HNR=FD&`)3/?+57.M5U3--+GA\)#[+5R]4DZ<CF7TRQD5L%/
MT]$XDAYIH=2;749KO-O?7,X/HPT5I%5B_,!+1%K]42(RQ:E/R='V-+'HE-Y1
M%S*5YK`+M4U?$((Y+T?G811XV)DY'#6E`&(2'":!G,D.`Q?9Z3E.>'$\04=E
M&O`,'9V;4:BA50#'R!`ZKPDUL@-UG%`#NC,F?HH*?+4M\GB)WV_Y/2%W@M-T
M](+-'ABYH-/RK,PLX`X!G0OY&JQ:<U8)H$H"52+H$Q>:&.D&74NL.J&_SBI3
MVBVN:LP"H[WR,/\2]]=1Y0)=='<$W%'=,@>-9H%I#8H'&@UZ&]2R9V&`5M13
MQ.BW%8*T)=P#Y]",'U!>T$'7>8'7:F0.I(3P;$F!8;2QZ0FH`_MF:.VI#2'+
M!!"7"`JXPXX4HE?\JZL@W&B(<=PW"'8K4)0_GO-MF_DI64=QV@.4]'E]"]#P
MN<M5+'UK8*"56I9>O2)6F+'/4?4`?2H?37UAHK2/B,G/VKM:I2_;7*DB,0*%
MQ+LL2A>/^"K%PMDBV>.J]</'#C#L&P-#H<RP#(1B^5GU,2(T1(8Q^)+V#C'X
M1;L`[(O6^).8`(;?W6>B@M_@<1=^K<?N\&N,0<-O8%@#OYY\`S_Z>5CP&_8.
M,?A%A?!K1'OPZYL`[F:X22"9=9N^/MKU=?&B^UHRJV/3UX!S."<X*VC^/.?W
M_9$L%P8<M5!=?4F$G"Z\%IF$J\.4YN5W6\NU9M7#ZOY$^C00H&IZD!C_WOU[
MJT4*N_NJ%>:@`/Q[E/%SG&4'$TB?5]]$\-P!L0-KT"MX,@<RM(KE9Y=;WE%D
MA3Y7`KO7.88;T.D_HX+='!T511;?;XMZ`JZ@JCF[$Y3M`*.8)\D37^G+\RV-
M6JTUP904K=?\T3+.%PFAOB9>#)2#@QCT9Y<+`]&:!A(;T"@#"8E2RU;XHH'P
M]P&L7F)/2\*>75>[569"DW"EF=2\58<?B3J<;[TI=XI/O-]F7.=+"C6[S@<L
MU<[^W,;%\SG]EFD1/V&VM">LUK1RU?=1R#G@56H5.A/J',D`K-9K]K)@+L;V
M2)=RLOTL/_$'$^<Q?9<3B][IXEVJ4N->8],7ED#RG=;#*!0=\NT)/U4_'6JD
M0MJB``,928)TPXQ;PE2:ADN<6C>CD'/TU2!'DEW=D.-UY^@[PYVC[X395B$'
MNHOKW;YVCKXSRK9J/:N=H^^"VSG:[VGIIBY!I^CV=+W3[>EZ!Y1DE98][1Q]
M9Y9D-8KBG:/O`@F3,'`QWCEJ@Q?HG:/O?"18K9M1J"D3[+L7M'-T#&J,=X[:
MH`8PN5[$*WRUJ@?,/8R)'U;?I/_0`<==4]`)4VA=!EF!,'^#-Z&?L_3(IF+K
MB=J)LZ"D=XCN-^TBL2M7PT^D#=K!(.E,;-:\:]D.LW):G?9L5?)$#QG&Z\F/
MP;;M7$EV,NU=T(V0U74?Y<D+)R1]PED1WR>X_&=.?^4;QM4>3JSUFLV2QGI.
MVR<-O4!'+UO'\HV6-G9XS,O8GRC:;)*XG%MEP6^)[PM^/,%FFVU(CO/R"AUV
MY6N<UHM5:;.H59VD5$7.:BJON<D]3JG5W2'5W/;G.$G0/;NZ@[=P\I4I>UP2
M!\CT-X,:FMAM#[7RN2]"`.TPMO0(0@6^"[F^(:I$\P%JJ=1_,"7$M;X&N$HW
M+_O$J^O)D!:N($^'M'0+@EHZN#JIWL?GPZO%#J/9UX)1Z8&1/C$*^U+?`M<O
MYU^MJG,J[\@U!?ACE%/OZTV4/@_**"NMW1LG9EIN;Z"8^(`OH&S<*MY3,;8R
MX\+E&4OL^.H$5Z=B\$]:M5&48+Y_AW,T+Q\O2D.3%SUV*"*CNWCP]HN)@=;;
M,.;^]@-=J)>I;/P!@);-X7*,MC+%AL,XQ&-;_,-3_G:6)WSZ&X'?DF1X*X)4
M0CRJ+B7@JB]FS_-(N>7"L*1J-&9WI(B25J3>]$8`/%2G]:5*?$\FOU6)'[N7
M4S.3AV]Y_XI+J7Z'*&LF)BRICG9VX,'B8Q39MFT)$\'(D/?]2^UZLS&=0=^#
MCM-JHU8C,IK![HGQF*SMPA(#1Q(,A+/C<CP>S,9/!G@`'!/=9=$2SQ<+=FT,
MNT3Z%SZ#?</OCV&E]"4N3K99-KSAV5YQ]PZ?L:+;:U^&;J#3IK5GQ;MB-H;8
M?:3L\I_E%I?W_BRV=!RT9C?_L!-MDQBS%0LVT_Q`R))_F./LB194>3_C+G$2
M4\I3"C(A!LCJ5NB4G7.7T)IVF^5\^-4<H,MN`*!"[%W99QQE3+&E0&BA6VYX
M63POV!Q?O$()21]P=L#/ZV7I/TG(9_YJ!6OBDFSOB]4V05'U_0_XT8>[.XYR
M_CVWZ1*7CMA\.2\C'@AM><H[*#F@+<TVA+V:<<!:M**:R_*0WX<05AQ'D(BX
MP'OP7IZAC=8;>U9>]\9?J/=V+5W",+=\UW>)&ZQSJ)<`K:[RXK,:C"B+4NWK
M@*W\W6&ON'5^W]C"%^B;R)9^8=![9(9>'N>_#MC*7X/V"EO`JO"T*CLO:'&0
MYIBZ/B%IODU8!F>W0O1@;RI>_1YZ<0?ZZ8Q#5WN&_F1<,U*?G419]LRJI[KV
MB9H=`/=1PHNF_!&7==2R'CTEI4E.QT5CE-W2E-<76;./X[QHC#U%R19W7IUE
M[[O6>Q7B;(DV45;$N"PCF^J15V;E;H9U3"L^OB6!C5C*FR=9\7@<D[MXC=$\
MCR.NW&I1;:<L\0;M7S6WM5`?$3MV.<,HBQ\>R_TW6RI2E%=";+(8%U'V3(O!
MQ6-*$O(0UULE6FV?N.8S)@NQ!W0WX.@TZS!CYL$S)T$J.%-'+FRDU=JI`<5>
M'\@DU1@DR@#G[&\7CWBY9=<6G7W9X$6!EW1X3/G_3Q[(>XUA(O0__&S-._RE
M.*9^_N@!&<Y@_=H,@$&7O>[.[L%?Q(%JD73[/(R#&?ULFT19?=;#-FMV,N.\
MB-?\1L3HX2'CEYRQG-WX0+BT6LYQ"#-=OKW_+]HVGNS:FDP#1S1I5ZY6[-VY
M?+M@]V_RH$,;$R5\\F7J%`=(%>(#K+U7!YQM-^\8`+5R<E;#O!L%UA2_?&8K
M]94A=+5"M2G4MM5D.5190Y6YZJAJQ"PB;G+JMVP"Y9[L;:_`R.?X_AA(&P!?
M-`-KCU\*'O'%BQW;1,/8Z8OJ4*DE>R4N,&J!KEKBB)9=S_REOFM"(?(L*]M-
M1)N5296HTY2PW##\ZJ/6EWS>5Z,Z.^T4O-6$+RL^-URZO&6SWL;S+W3H5UDL
M-V0>L"-GDBVO5KOW@N]FF6CUF\?+.,KJ2:;5MF#N-J1@5FF!^YED?W`+T2;F
MFXK8_?.3K^,9@(S8@:$_>2S7VDT7ZRQ[Q##0"IS>R5CT\E6V-AS1IU(JG-H-
M$D;2M3-W'+FNCZFM0ZZ(Z3V-1=-1'TVO!SG2Y2MWY,"?[GL;/Z3Q*EY$:7$3
MYW^P5;*/]%?BS]ADO[HX<#/2/1W8VHC[Z<&6+J%+#:=6:,X@'F/4J#RI;*!\
MYP!ES`.?Q-^V?4Q<5#B"DT!!17@NLJ6]WKG)HUHS"5\@3^,>Z1Z>*:W3O`UH
M$%Z=-#4SU$>&[YT:;O78>+^0.\C=6@%/D2,KBGS==)`4C%/1`;#(K$]TZ;Q@
MMB:IP;S3&-7>N?UFJ@`'<)LX@BX>1_C6G=MM;,IZ'NMSZ[R?3>6CF<)ZW5-;
MHW!,W/`E/I7<Q$K_P')SSWND$>AU!C9.H0C4O@1!QHCPJL9](EESNX)/*,/<
MR6#J#?ZZ!AO/4(`^,@#TUP->S>T0/L$+6+M=I0NR>"YPM2SYGOZ,M_?K+!8>
M=6TF7/T>.F$'^JE-0]=@1MYD'#-0GMT6>(T6.$EVIT#R%P51AC<966X7_`#X
M!YSB(EZP:Y9RVKIM,?G4FR$<B&VG=0FEUJLI9&+=*^)`RA4S-^.Q1DL2)G1"
MA9HM6DP,W1Y_N#D/Y`1D:%A)J@PH7`'NQIXOG]A;*LL3&@ONZI<SV%4'O]-H
M\&]Q1@?ZV_MJI\^Y,$([6*A^G5$6')@UPA]T@!_?!!D3QUJ<W6#.S;M'G$4;
MO.7Q_DTS)'[^OI4A^,OH&W;^*2O''LLRC%T\%26M#6)5`F%9`SUNUQ%_0;VV
M7;Y)%$</*<G9GY4P6D?9'WCRU[Y=L$Q`P-4-&".,U5%D=#OV3RR0/.;@&YA2
M-./5FHBIHITNNUSGAX.RTN(&T,X""B493D<"2=K</PNF2K#B,9"+B3$I%F*\
M-,;AI$G6;&PUVN2W-#LVPDB*<%>`.828V"'&0(T.QSK=?ZXU'$F.MSDRV[[(
M=`M,!HB$"\0&V.O95\)$.GRP6]A=`22]G1D/B[(KHP35$YS5QSOL4DCGW?C^
M53`E67Z/<WX`18KFR7:=QN@&YYA"^1&]WYW3]>;W^<W[[Z=?!.WW*%'UQ6#B
M?-5%;U\+#`Q02XLKLVC:EYRQS@HDX)GVF7RI3MEI@('DIC49_DLU%WY>3X4+
M(XR%1O6MC#0<8&A@'SI8F;N4P=?4@KZJSD<N=$P<UVQP1$9U=)=4!LHUVXS]
M^`<M2%"U\.4(UT.&UQ;J:E'4R`82H?VA3Q+3X>&WCQD<N\D:NWD9GU,P>YYM
M<9M8L8KV36G;C?6R`>(!'R$&.ORS'.F-GN$P'+[YGK?8UQ2%XVR$T<1#B:M`
M@CD\P&QG#:P1!AF\TW0;)1_B-%YOUS?D.4J*Y]-M'YD:J3I8RZ1<^""V"1Z<
ME6ZD+%!H\7LSU^6CZO3+\JX0IH*R4I@=!3YU?-5T+3'NAQ[:Q0H-RE7V_.`%
M)FZJ[8]`"HN3)2AJM+3`\=*Q(0N%H\$!.7M1&K[&%$DT,CSTX21]7L],#)^[
M#.GZUL!G'20.I(,VH3P/:YOF,Q;2:KANHN<UOZFAO-N`76"7%EFT*!BV^7;:
MA[+FS+>+1W80<*7`7RFAV*=%:U*NRV5QDK#72:JS<OE;:^6M#<5N\8*PXWD+
MFB1QZ8$=HXNS8NK[\N2H(08=W1OV]46;09[8!C3\8.8/9):M@,?F!LK/#]#N
MR4OL:MD0WZJOW=Z5$)J$>R%":MZJQX^:'F<7U5+VI_R:S,[2/HL,S6'>;_A"
M?[K,\+)XG/JRI7'8D+S`8(<-P%<1ZBVV&)=7]%Q'<?\"095(]2W$(@[X%1F$
M3I<*'S(82U5XTBSX38+52("?"I_AA)^X2SNSGIAA9P5.G,"4'4K,.J`+7Y%T
MC6"Y)0_X`,EG*N.VR*!9K=GSC_$!JB["8H]?+@@D"6X,"MS2G,PJ7*93>;#%
MPE&-A?H@?AXD7BX,)+EL#`P`,UJ5,3]$7]C8\KH<@8@'?F*9[N"O+^->E'4M
M>AH$"IUHJC.!SJSZK#6_]6TP**@")4@BAATO+`:[XKV"4&3+!S0A!XABZ]:@
M;`\4:WA6CU\R%M2C1DLP@(P>AV;!1Y!B%]:0.-H%JGYX>LF04`\6+2$!F&++
MV=LJEW]@QQWAE*UHT;0N7%922G:6EB22SLL%0KM^EIA4KM2+!W+->OV@3J&"
M<>5ZI\5JRR#6G-3]3JPZ2+2\(%3J+C$H[/H#%>`ZE-+'2#CMUJ/JH6E+A@U3
M7PMVE&M3+N!Q2Z\:XW!)UL#12`@=-1"2Q)_7`B%)"G:'D+\K4=F-=>U+,*I;
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M_.^7/GNNW3I^`8DSHGKCNE\;O)T+.%=\[ZN$:QQ.4<-UG`.BO*SB_O:U@=:Y
MCG,%+>A=;TERLLWP)=YF)%_$F/[.>=T4^OO^&BVC/"Z$+\J.TFUN=K/2=;J$
MQ\(3=`4WQKG\QAU;6[/YXL]M3#^K#AQCQ5:4Y[C(J_O:D@054?:`V04=_)Z-
MR>]E&X,HXMC1_;MU+,SLKM2Q]KU/2`-=M3;"*QB8^<5J%*],"76TNH=25XJ!
MO+J[7T!++T_;!Z(!WWLS2XGS%2V/^`1'_#1NBD%HP6J:H6?!>RG9\3?-=(.H
M"6XUY=#B^&F'B-DJ5XOBU5>U6"0&LU65*T77F$*W8\RNV!6T8__,VN-,A-`W
M,*?L9B2X>K6J1`U\K?AWFIZ`),`^IBD&3B$O(75H`C`1COC+;AGFF>)K!;;3
M%`8DL*=9E/I,QB])[73M%Z28[GZF&S^3"1>C&N<`<XV5+9"%J)Q^FGYU*U$M
MP-K/>79Q-'K"\S,9,=U9^]XG8_:]_K3S"L:5,6M/G\G7!&?W52<'/.]MQ:ET
M-\EZT\XU&*K+M::_?DTP=5]G<H`IY.M6M*Q8-J[G]<F>94;O8=Q(MG[E2BWK
M\H:#RC+X:U<&SJ2O.6AU9S>LY_G=NU$I+#ACM7P[>NIWKHRZGECV4.^]!Y5:
M\^:#WK9/;,&\?67B932JV!M8%9CJ"J.1JHX(>4U8DKV'!0(FQW>Q=.8!W\8R
M<34:4D<[2,GBTVN"E.R]+!!(`>9N5BB\)]GNQA_I890&DM5W54HZ<$%A%SIG
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M'3#$\F'PMA%FHVTF/G'LM44)&=V%77H9&JBY9N5O/]`$"=Z6_@!`2<,ZE;ZC
MTKLQ*&$G1F#T<0#.0$*]?Y!*DH`_E$)>:IK385X<U2]4MGV>1$F\(ED:1^+;
MJ>TUZ^U2-IHN6Q+,_8!OI;)V+=VO8&EI=M94[+VKJUD*R?`#OVJB>@>_FU%V
M]J;>@#4"6L2ISWN;'\R--%LA;/WN#]<PV[CL?0(AFFWQJC3JI'/0RS8[M4!R
MSOX`+-L1YAW!CKO%[)P![AVS=PR$XZ,ACLN#(KYAN=_+^\8RY!;SRO-N,9[U
M\2\X(ZFRBM+*]VHGA3P`+:76?=5).H<Z#JKU6S51:Q])>=W6`F=%%*=H$Q5E
M9?0YQ4MT_RRJCTA"LFA)_B5O/ZC-X3^W[,]'DBSC]"$/X10C<W"1$?TO9JE4
MM<]-C0_?*`:MBK2>G/#;KH!V@F7RX**!90I8N&DJ'!B\`8ZH+^DP?L&V8,5D
M>4?N<+:.4QI;FEG>'F!-Q:MOKQ=W(([..'3T-_0G(X^1.K]0..62;/,I%:UV
M(CW0")[2((U(MBS14M06@EG<,@8'L>_`+IUTFC6;S#QXQB!([#9UY((^&KDO
M^]`3H.SU@4P2M"%1!ABRJ\O]KA^C',^_Q/T-J[+'U7<;/G:`?]\8=,B5V)>!
M7"@^.XWS14)R=@`B+8N;^VO9GDP<+1[1@GJ-V5;-#=.;.(9*>X_H?_$N>ON2
M-5K%%H!!`!+S9(9MNI_&M/JF3/XY^L2>3%QZCNED28RRZ65/,>B4L$O@%%&H
M*R"(0[4`$`A+<SYC4<>#"1Q;"B\W'O7Z40#6X2\O1VLI*\)KVPHX),`C4]>T
M'1B&T:E\%E!\LNET@QAETNN`<>H&+[<+1NCW))NGS]=\VNSN,2I^C9[JQ>OE
MW6=RE7T@61]$XY2K[VZK[')OMY4KZ+@XRKOTJF][8[-&!_&)T9).#UF45N_Q
M1.ES-5^*"FJIG@*ESSX3.IQ&:VJI-=.:3QQQ1Z*.N&*A=]FXE9WF%O(1WO<*
M?)#H/\XM'.0/VYAG94,?X8]44PCSKPO9DG2T+VA#EMLL09Z?5(6A<&E.)5*7
MW$(1EPI+8!"\[);[D-9:,I475GJK>I28]4"O$!-(-Z68U)('@,`4X0KCMM!@
MA3@OP,]1_3"092H7%,CJ\1$P``]FL4$TD\ATPME`QAFN\3X"FMB)&K8BG9<8
MTF3=2@Q[083F6`5GH2T?.`&,:Q+KU@C91;9`0]M8-"B#FRT<X,.;47PS"G`>
M(MQ^0MRH&/=J@IP9KFW#G!K8G@*=YT@W+M2I8UVHP6XT*M3ASAH6\&M!'S<D
M/<_S;41_@JO5^SC+"W9;134T%B\/F>ET5XQT.NXK!FH/GM:5C)QJ5A<,;/`-
M1E%S"%(]75IN,EI'2XRV&S:36EGA9RDR._1_=W-*4T^1VJ&'C.Q<X2*&6KVW
MKF'B:Q]PA5SS,O/F#-36RI@!(%\S'-6+:L!X!$P+'VC*66_7-^0Y2HKG\MRU
M,UJLL</RY^ER=YE4#]G6>M7O8J'GP#EC+]!IPM:QC(%V=F:5.,I*>98PHOL$
MEV4W/]N.G;M2-%H39P9[\!"'?NTRTMA$S4I+G_M"+4BVL/8(@M?#(6"K6D>&
MUZ\!KI(,XA>O@)FD>1<B3A]N\`+'FX*=('N2X65<L&CT(4YP7I`45WFNOR5V
MO('J%QMCP(&N]NZ@L\WH%LAH/-+@K)8MSY7)6U;0HM%%ZUIY-S>TJ>XS#N7E
M"`<,$@A4=+EO;ZL.`F-;L7<Z@*2Q\:YAB4`36UN1'4Q<T8)D:B)\I;"7Y+Q]
MXQYT/*5.<KH<!INBO&<@VP0CR1_U)`*?VF+[`]F,:'C90<L"B]@NA3!\9/87
M>*WCJBQL?AA$Q)?8T](2WJ:K0?=5Q^O[;99S[MR1V_MU%K-H2/+B/%ULV0F\
MY^FOS;47/>B,U&YV5EMJ.^TPM?(%O[=ZC'OY3E-[:_6%"5FMNRQ+#JK#CHS@
M2I-OF!Z')N+<Q?U]I5:&=AM+1_C?+Z2!=DV/\@L(9KYONJ7%>N#V^,/-^1#2
M85W;LW^$2[=.[POB/MX!.D_+J:L8#Q.27*3_/D]'!.+EA99!;^_F#'UH7T?H
MJW3?LZFG5_E%>Q']O\V&#H_X&)2=&A!0::WLV_Z[!9*^D+Q`T)(>O"8PL.0!
M*K!OLPB,VX+D4(@2^O#E0D#W$HD%!MP.(919A3MM4.7!%@E',B2$EEG'(T-R
M`.`89,#?/%M?B_%QL/5*+M"]9[8CX'ZU8\L<=):3>M#<Y-A7X'NC=E=^LMS&
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MT#+6M9_*V+$UZ@CC9%Q?'Q<[\X`E<A`ULC/8"33D1,%JK-UNO')KW:1\!"R9
M79OACXF[POFN1SAQ[5Q;"K1V#H=:R@IZ>FY!U-$N_J%+:=>V^&/8D9!A]\^H
MOEHYZ)HZ'$(I*^OI"05=7Y^T"ICF(A3N5E1`ZZ7;%;)*VC4JR&U[J7&U[I3$
MUFC/YJA\*XQD*%\\XN66_GN3D:>8;5U`<6OM9E/>*\@^II#BQE';.IJ'-$UK
M`!=BW:<"7LH5.\33V?>+2;@Z3^_'`8UUI2:!5560A5"%@:)+54>!P`MPF?#W
M*&.GYN>'PB,+)4^K[S5XZ@#ZGBWHP"LV+X.V2'I6?\CZ:4._!3]T+B]81HX*
M%)7#]VC!2J)-%B^F/I%0UG5$^WMW4=L3K%$JU(?M?Y`@)[%KT?.'NZX_#.1<
M0?N^E80D\\YU&WP)#,*-IB3&+;KXJ,7NE]K#DK&&>0\#C@;.-^QLF-.S+QM^
M0P([@HPO`N0QSV?2!-=#CJN9ZI<8;\8!\6.=0B<^QW;(2.1DMGZ_E*S0^?4-
MGTPX1;@R51[]%^V,O8RM),Y8)7"XZ4:`L1;K4.'6HHDH!%([N#;`!WEH-6+`
MF0,E5;XQ15(.34D5MP++Q3-<)>;:"A^$.>*$^7^B]>9_*`CSC1*2^G%*2@!6
MI%6]2YL1E[/B[,9N\62'6*8[Y=&7<1\:=2UZFOX0.M&,DP0ZL_+:<_:*Y^?'
M>/&(/I>B_,!F2B[,5`*9_Y#T)C'\\86#J:YX;T@ELN4#'I"S(V+KUL#8S92@
MW4-$,\;Z)4-!/75BB060:92A6?#)%+$+:T3L)E;*H/`Z$*&>:K%$!&"2NR-%
ME%1[+M/E>7J=D07.\_H%/I:'\1-.R(:_BE3ORC2=C?%DO?H-P:T[T`RX+=#)
MW$_S9-SVX6W&C3:O%:6\E-B4AG=OWK+/ESO;N]>/7L2$D"^Z$.\8[48U8$=U
M//32_K`X#U*A>6K7'ME^Z$CWD.>R7A[))=7LRV&Y6P7MH4%VM3?S+ZN]/35N
MCUP_$G+]K3'7O[%Y)/9>*IL!1S\?HNP/7/P6)5M\M3J.21&O\0E9KTEZ^QAE
M@^,?3<7KD]2UXBY':FN,0X\@#/U)C]TV49_=/<8YHIXQB@N\IMS?,/KS#52/
M[-I!9@,],2/U:U0+;F.WIXI]AFFDJ!XOHV?VBA7?Q\IF$>A'E_]Q>S;U*>ZF
M."+V?=T[^%NCV9P#;N3!,UQA#H0W=.0"5'9<?(G%WVHLUF\YE**HE'U]*).=
M+P\(,[=BS<0#W,RGJ3<7L!TU8'OJ@ZT3_-B!8TN2)%%67EN1,PL3GSOF`X*2
M^@42@H`51G4)VDU4X*OT$A>W48+SJQ4M@]@)GX/SI<VDZZ.F==(NI\BJ;4-7
M%V;NI(?+&FAK:HOZG.J,VF!U1+E(69X&\3E.$G;M\2:*EZR*2"D7<^:B/#)B
M0U72]E%'NX,DIC[2VA!.Q+K/>T?9JA6;4VU-[/O%+,Q)V&9^'-#*SL=N`[(#
M.G8==R7[VN`E.T0;#%^.1VOK'0">LFWFS`%E1X8H"^LL4WC4R0[H!D,=8#UQ
MW1P[?;6ZW=[G\3*.LN=;5@$V$R9XV<.NG5+U*Y@JN5Q,;^0"NM:P\BJ]H-[<
MB*;R:!TD3CF7-[:JLGZQL\;>IB_G-]AQH!/7%I:8(F-[O'>;O9%^<YV]A;>]
MP!BD_+!SYP[@0[YYKX71G3CB\JBE\+I!*:E/?*'2K5HQ]P-7M-CY=,?F41^;
MRO@95!WC&ZN2JL875J'WI/7/(\'QD^W&LY$FVKO+K$VXKC-;.O2R3VQ<&Y1+
MQF-,5LO"B_Y)>%SW!6WH&@M#`@,+P3*OI;7.6NZHEDS`"KB=5".=0_/A4$V(
MX+<\340#U>:E/?,`8!O2"*]PQ9U+"Z#9<"1F0_DVT=>+=M7FGCVC'?+2'UR>
M5G<7?;F(H_LXB8OG>1;G<?KPGO[DI_&*/L>T0\[38T+^^(V">)M3X>,HC_.K
ME"_%G-.B)WV([Q-<[4:J5FMZ3-N'J_J2(:^N7"XG\M@PZ()U#VV57HGDV_6L
M]H"*Z`M*:A\H*IV4ZXS+Q@W;(7U/':$G[HDKW3-?;&*_7,F,&W?]^UDF+I3W
M0CNR7WCWKG[RZ+6Y,LK[-PLXJL!<E;:'1DX53P[W&E"^Q1-P8+^^@.(V(O+=
M.KB1TSY:.E58.?H65EYD6)$,%5]#6`$<>K:WAI[SR84[LEL(84?3L*'Q=EV>
MCWVU&HR)>W$+S%[5:P#V'"*PLW?HX2!4@V3!%,8^OT!^%<79;DMWO96[W*M<
M'8I#Z=):S^3G3RU:YIF>8-*7AM>4AK`H?Z3_?,)YP6(P>WMN%:=1NN!_+8KX
M*2YB//6]]'!T(!X0V8V,SJ;K\`?4QJEY"S+@`FN)5\;2H=,)&$&_,4Z!I9`I
MYS9:`6D"W)`$K#E>B4<'%^QEI_/6RT[<X`%[1V.70;]12@&5D"D%6*F_IVBH
M7NMJ-ZK'1(U4]5M)I1SX+[$)70&KW<C(JM+2[%_NUK&<GG5ZI*-ZS-^8.DZB
MQ1_H]I&P-PL^X*R@GS&5,DO2%+E=;]@_IRY'=>@@QEW9)9U$H::2TIX?R($4
M;QK[(\!&"RWV=/=>=?7RYGD`Z_KNX)!4.>/1X5:1*`S#U1D:)R,P<E1AI!MS
MFIH\Q/>@W:$CR>;CH0.8>?E\G/`N*,&3JOV=)PX8;MF!SJ1#TS*P]B5G-VR"
MD[\A1JO6#:9&258?21+$VSNBCB'*7[2+NY90C;6!'ERO@B0K@4W#_J1)J5R6
M"..>'_.^D^0;?>>YY96>,;A<(C!LV(5'+[4+)7%?WX6@9UBLM\DV?Q\GZ_RB
M6`HCO5*F.:]"*./T0K;`(OS9%'(G\K>O93JS>4IH&LAX9HC2Y^JD"3K"XG.$
MM'!A>[F7<8871?+,KF2-T_JO`_8&:$S'71N:R]/B!\36$;;YMMP&NRRO/EJ1
MK#;%K)+/*:748[SADY%H'?T7R=CB[!OR1!OQUW?__?LZ,9%MD1=1RL_*>B)\
MU8"_0E6ZV9#/)=9JV^OH&45)3A#^$N<%^AP7C]0^'>#E5*[[4FO3A@/>.OPE
M6F\2S+\-MQ8MB@.J24>+![LMZZ7%\K?B[:"CQR7+JM0"5]QF!5KB!16?_)@-
M%?:)(53[+Y\+Q'>OG$MM^2`3T*$9"NO6-.('9/!GB#\\0/3Q#X%$=S<\2,_`
M&`,(U_,N)&8A3[E0N+"&Q='KA87TD(HQL``L#J[ND_BAO)V`G-)$4+X26M\5
MV7EOH'WOO.F+G+[,5[\BO'D'ND$W!KH0\M0^&<N]N.-;+Z+F+DG2^&"<639>
MZNN)\A?VPJDWNA#_$.T&-FA/=4ST\PT"8SU(Q>:K8?OD.ZT3KV04KRT?H(YM
MU#(>\DNU+Y'JDMKV)7'=K:+VT2*K8IP.^N^)O!SWU;Y]<OY(P?EZ,TGMX1N%
M1Z/MY5(8</1SB[,8Y\?57ICJ6!RW$0^DR:J/8$PZA#V(!D"/9@#;)(MN8"YZ
MHY;2+CKN'@#^LD8JH#`G?F#6#7$0UNNP!M?2`%@),MJ`;(QO/M)1A9""+W0D
M$3(5)2.&$+GH-C*`:@7<U#QDBWPSDM;\\YQ^FSC*=]DQ#^`2EI"Y)2GE0^06
M8,E>CQWNR#6EXF.4XVXC.6B<JWC/7JH>\^;%_<)QZ#9!E_]^FZFY]=R+U]X@
MH5G!H%3<5,[JV%@5+76(?&%#!]_<(GL#LO`R>&B'O>OD_7R?,`,&R,C$<_LF
M"!5T_/*[(CH<]]^U>Y&CFI<?)21CGY<;)MQ&2!X;!C=H\MS("8+%D218A#G>
M>OFLEXS*7B[K/8S=($[B`;'5&X?M_P0>)\^^QE0^3MYQMRTX=:<9(WTU!^[`
MH)X`@T\<ZIR.)P!HVY2T!!VY>#E8!\#XKK!XN>?IA$4HS9!A6D;!E/\!G)T#
MTA1OO*K.S(G7[2V.`1V7$Q9C-.7VM(R!OE2+.\G'K&>,56]?IF6E[GI3BH4S
MZ#)XI'_E%2FVYJK;47BVI./VG=[+F.(?#3?B#@'!U2D6ECK7IEBW8,^HA[LD
M:X1C2+P?R@$?\ASU%#!778BU)YP#7(1EZ1'X$JP1WB'1?B1'^]>'9]655WO"
M,V"9=LXGD)CA_#R=KU9Q$D<%SN?4>=ZOR8QDJU]%(^M`1Z5EZ-+*Q)F,:7K=
M&?M7?1Q&W(BSP=,B(3F?,MS@+";+']![?C)'(Q*G?,8O6CY%E!U\I21J7!R@
M>(7(IIHXS_DT1OK<.O"C.@R$+:.PXQ/KNQ*XV<5CQ`[(H#4;OT>A>*P:PMI8
MG2%R@!XRLMV@?+MX;+GE)VBPT]#BISCGCED3V27RM$]Y(T*9E31#,K$$7#<@
M*-5J]AO8]DD5D'K,R,MHDM!*JR7#<=_".6,*%7Q-:)+42S!P<JN$M.;ARAXC
M5Z-!==0&U5>`*4G-`H,IR-M/6#)+DFJ*ZFIW0-3NM3SC&2006_6M)VZV7$YQ
M=_$,70U!-$9Z?+NS[=Y^U$7+(#]ZHW7<6.L8CA<Q/06#90(,J=Y![RYFFT/>
MW=LV)=E@KBB!:(4WFK&K28R8%?(\6%A\DEU&$@2A'"\A<74/>`$)1%.\T>K(
ME%:L8ZOEUF\<TL[*A<$AP`I9[N@B3O%Y@==YCX86&M5O9Z3A$!0,[$-7KN8N
M90PWM3"[J"\NR7<WE]0[\\J#<QFCV$S&(MDN\9(//U$1W2>8GWR;XYT,FYS;
MYN5&I66<EY."U"K)N#Q579&LVJM$LRU9L*'9LCS)=DG6$36]YH<PYFB):1M*
M;X0VD&1HS>8$HR_EY"$K@,LV3!M5;-!*1L&I&R`,E.LP8.S'/S5`ZDP+7XZD
M.&1O2[-:L+-I91=G/W'.</&)STSU!S])D0>/OV'!YGC:$/QA0_!G#4U]U%"`
M)PWY/VC(USE#\Y=_SI"'\Q>\GC($>/A""&<,A73$T!Y.&`(\8&C^>@X8"I&#
MRN.%0B(AQ.%"^SU;2'/2*&"3/)-1<+;0O'DU/L4\4[+W5]BL!%^I9!_\WW_]
MR^'!__ONW3?B6<T/A4<\P+FBZZA@J[;S='G%;K4Y3PN<)'A1;*/D.F/;@XKG
MF_CAL<AO<,+F#>[(K_0+4)G<N)[WZ:+J*3\N'(*;CP9!#P$\ME$6_;RYG%66
M^6ZR\GZFN&4<;2KK*./FZ7B!VV>\?#R[16SJENHN_MS&+^9U!*^T(ON!<3?0
M^O!61UY_WR3`*`$R,O'9N'W'AT.0`!'R<.8E1P/)@.<EA@.W(9&O5L$MD/ML
MX;Z#PA%(4/A&>V=4OGS:0VYO36B2N5I5KVE?9;P]EUNV0'NUNL6+;<9?CK@C
MQ[A[87N]I76L?KV-U5[?9>^/K3?P[:HC&R#=Y#/*'E_CR#=X$:]B&E]2+L^F
M;/)&@PY'H@+A:/&(%LQ'YZ@@DM4AJKTAZ"%^PGP44]Y2R__)Q1"%,$I)45ZQ
MV]DVU!RE5KW8@\MC4#*VXSVJF[B@D3%>X`/$-B%EZ!ZO2$;'2C0@9@7;3["D
MW)EZ-^QH&A``9/8V&-F::C85C6O#OOD(LZ-UK&=0)K*=JS6[*DV&<*Y[@"X;
M7MZV>$G[JF+)Q&^Z3H-YV<[4O8+><0?J&)>`NT['N@>%/BV'=_AN']3=H)N]
MIMFL.M`'@^5`MOY0WXC^)J[/ZOW^:V2%;*_I7ED!6):>?5E@UH"F!*[6*&Y_
M8X<W73WAK+.48;PX`&ZW^KT![3H$%K!60)>]T`V312)8/[/2'']S:V>PG)7[
ME[P^0I,:Y2?T[;8DO(CY?'@F$(\@[(8U,!=UN`-N<R@4!JF4P5NT%_(>CF5O
MR+/N+X.SD@H];-*Z5?2@38&K],&;M1?J'HVE[C=R6H#K)9$3\F4UOK.[U2[J
MZSWMO_)(B9V)^DTU0_'Z-36MN,N+.!KCX"^HF?F3OHACHCZ[>XQSE-3OI^U>
M3\O+^GEW=$(['3?;[_FL<5P99.^1\26S:FXYX.+;&%;$ONM[+_-H-)LW>8P\
M>$8OS#MDAHY<<,O>'FN@V19$3!+5HJ\/9+)7Q@!1YE:)F7B`*[!,O;E@[:B-
MM4XTZT2_UX<U2:D"B;6FL&C_>A?T7_3#^B/Z/_=1CNDG_S]02P,$%`````@`
M'$BL1(,.>U2D0```^AL$`!0`'`!B='@M,C`Q-#`S,S%?<')E+GAM;%54"0`#
M!\9P4P?&<%-U>`L``00E#@``!#D!``#M?5MSXSBRYOM&['_P]CQ755?WG#FG
M)Z;WA'RK=HS+<MBN[CU/$S0%29BF"#5!NJS^]0N0A,0+[@1%0.67NHB)3&3B
MPSV1^8__?MTD9R\@PQ"E/W_W\?WWWYV!-$8+F*Y^_J[`[R(<0_C=?__?__V_
M_O%_WKW[!%*013E8G#WOSBXACA.$BPR</:*DR`D'?';_,+^^N;TZ^^']W]Y_
M__[[LPNTW65PM<[//O[TTW^<O3O[X?N//YX]K=$&H_3L`10YD7TVBV.0%/C]
MV2Q)SDIR?)8!#+(7L'C_[AV5GL#T][_3/YXC#,Y(K5/\]U<,?_YNG>?;OW_X
M\/7KU_=??WR/LM6''[[__N.'__?Y]C%>@TWT#J8XC](8?'=&Z/^.RQ]O41SE
MI<J-XJ_/6<(8_/AA+TM(0?_WCI&]HS^]^_C#NQ\_OG_%B^_J*M+/&D(8^6N/
MOM:)6.^G#^77/2EA!"6L]VH3ZYV=5?;+4`(>P/*,_OWEX498^J</E.)#"O+;
MZ!DD1&19/-]MP<_?8;C9)H#]ML[`DL\GR;(]&VJ=GZAU/OZ-6N<O!\X?AE1O
M1;'XA/(H<5//DE^_KCTQPRM]Y\JTLBK?N;0RZ:?@"%9NB!E>Z7N00;2X2A?C
M5[PKRE7E'_,H.P)4^L*&*S!^K0VJ^@Q1#C<`IO'[&&TJYH_%,P9_%"#-KU[(
M'_@2Y!%,L+K*S_DKJ=''OW[_8S7:_T7(R;9J7]*H6$#:,!FZ1MDFNDG)3`DW
MUS`E@SJ,DIMT27^FD]@3J13XC-)\C0G^P.)SE,7K'S_2"L[2!9UP[14;J1ZV
M9IEA#/(+(B*#S^6*8[8B,C?$Y/8J:O"TK>[5'P7,=_95ZY2WMEH<HX*@\C[:
M1<\)((U!?LD*TG]@]`P3F$,P`/M&W&U5>$"[*,EW\^<$KDJP$3&78`FRC,J)
M08K!-1BBA:D`6T5(_XG2%:2&HK@;4&,AIR%HW0[K2WT6]G:B`RG*!O2>/@O;
MRLRS593"/TM<G$<8XOGRGNY/2`O44'DL-ILHV\V7CR`!<?X(5RE<PCA*\[I[
MD`W5/4I@/*BKC50//R:I)SIZ3#]'L6JXGZ*L%52S''-FL*^V`?.1YP5K'0SY
MNYH5K.LK8C1X3K"N48^#'X.PM3[C5,,/H["_)S?+H2*N]G8.-G6^3)233Y%C
M3(Y.I\6A.S;KK=JX,_%(<_#HL^]X\ZZ[&=?!7.M@EATROSK8:PW99/DRATT^
M=]D;@HQE"XKL!?D')MP6](SSD52B'-1(K2XBO+Y.T%>\'\\MM+62,II*\RV]
M4:1WA\3,%VBSS<":%(`OX!;A<?74%NU4^?,HH==RCVM`AHS#O!QEI%)KD!-0
M:9R9ZRFK)>H(RHVKC[T*ER@N*!9(\U^1+ISO&JL@BSK+V34KN6V,+K?DAY8L
M\)H#NNYBTFA5[=4HI3*Y"8I;HA)Z#8XRA5[DAW_)9,R><9Y%\7[R2NBMS,_?
MF10AGZF2>D4^F.M46Z^\7\(@?K]"+Q\6`'X@>OY`_T$5_N'=]Q_KV_N_D)_^
M5=7@`:P@%9SF=]$&=%24D=0J\4G:*C3A,,O:ZI#%-^-(_MG"0O_.OZ;XL"V[
M^+MX#9,]C)89VA@V"M+2L%G[OY_I"#C+T1F?,<H6(/OYN^^I'PKA6Z_W*F,+
MM2Y53II7@4?"Q@71,Z-[IP5X_2?8<<$AH&FAHT<3&#SD.@[!1X]S#9"/O@/D
MHLBHC:\A)I/L_X`H(UOI2S*'=3"B(JM-*"8+!BF:FMJ!1<R\QLL/ON.E4N\W
MD"3_3-'7]!%$&*5@<8-Q`3+NP**@;0TP0MI@X&.B\Y`!1RBA!M*/80#I5Y20
M32G9L5[#!&28"R`!30LX/9K``"/7<0A0>IQK@/PU#(#4(^8#V**,'E[0?7'!
MQXF<M+V0$9`&AAHMC0<M:P0":@S]1Q@8*I%_0:;95>/HL`4=+D4+,1V*P(`B
MTV\(/CI\:UC\+0Q87*#-!J6/.8I_?UP3@^-YD5-7=/JF@#_`:!1H#S/2`H%A
MR$#[04..5$R-L/_T'6%,Y\-*_YK\TIVW%%2=PZ8>53``TM/3#C5"WC54_BLL
MJ%3^[6JP<.BX<&G1!0H8L:XN(-/B7H/FIU!`\T38"G#2_-2!1O4I.#1P-!H&
M@(HA.ZKS_C!W1NJ\*(&;1-T5"O=;;:3.MV#:7::37<-W.+*6]_Z4ENFW?[S%
M.:*5TG0&@`Y-,(C0T7'8D-#AS!`R]%SV'Q]ZIKTE/XQVU6IR+3T,PLL(/Y>:
M%_C=*HJV%8Y!DF/V2Q?0]<__VKLXS)=[][Y[A*'DJM:D2`T'O2(#^[&]$2J/
M+(&Z_(]L5.]\G%B%^JA(JHF`IJ50CV8RO:A[$76X(7]1W[67*"'UPK/\(LJR
M'=F-_AHE1>^>S*0,NS33*S/9("UO.V2G='N4YHHH+\ST6-M?Q^>]=]P3(&WO
MFW@'NAV']ZDV8?N3O_"0J*")@C:'*:[6N;Y&3UFT`,QQF:#T$_4/P0\@!@2H
MSPD@M:V5Z32J><':7B8%_06$M?J:<#'A;W_O[L7(<9^!;0075Z];NMHCNL[S
M-<A:ENE@SZ!$;76M$OZBS5QA39AI,9[Z.M[1LDZVG),MXWP&A@,(\!O;XFH]
M[P7MF<QB2E,)EN\\DPEM=>`QM2?ED+$7;4&6[^Z3J#I?8`]<^JLX'=+]:"LC
M]1`;!KJI(")GY<VZK_.^JWR4D>(BH1X2S6=D[&!.DYR=T2G)/02!H8XJ(*C9
M3>TO:3]L7((M/7["E=9W*(VY4ZR*;(\6$9F7*-'228T.$1O[U=8+R)[1].OY
MQA)2B`PI36U"`8V'F-#11@4(`8\!RS$?]G;=9[MD$KQZC9.">L)\0FCQ%29)
M!QHF1?:G2#I%/`2.A:XJ'.FQG-KY<>B6CKN7XV[BO&QW;GWU-A]#/!2]V*$9
MW7\AQ052VV8ZK`^6=+%_\V*0;827H,_GJ=OA&B5$)5P%RA#<9YD6JTVN7\P'
M@\BO]-2$?:7]N=S3B3<B./LR+\D&59.2DXTQ&NV*AEBA/>R(I96#C8D4^Y'(
MD\4_V_4^@!>0%H`//SE1YPRA2^0YJ+1T,\&/B.'4KW-=#L_*85DY''N/"Z=C
MBF3HL+D%]&%9:+P:X=I4:YFH*XIOZ5,X]F]H=3AL4*^1Q+3]?LFC]6!62O,+
M\C?,)6>6:M+>#,4C]:$G21H,&:DJ[$!]">TYB\<YW'[#]'J*7KDV$&!)1=[!
MDY@\'$QIJFR)*S'W<%=%Y0&P#JK4A,T#]&"1I*VF(89D?.W74)YLOW3PHV/3
M8%$S`F#D6+&XISN%];9R*>ADR<V3$NX(3Y^%P[P,B%EY`U!7`)`V`ZDR%WPU
M)7.\EU$&!2Y]G>VA)941KCM&7^F;M+[RNZ=!3TA[YU7@;GH"^81HMZ*AO%%"
MJK(JPY,#+-K_C<-\_[+)+?,IG9@KP)0:\9[52"@.3LI]B@GOZ49I=Z1CB>ZU
MGLN:U&[/_1J$NRUMQ!OA/N@2?&Y,(>W/)X@YA0W&!EQ??+C+F-EB4=ZH1\E]
M!!<WZ46TA7G4=>-14+'K1!'5"4)0SR)C(U%8BW"7/[,X+C9%0I^'EYO[5GAY
M8B^T*8/,WX%\OGR*7OMWX3:E#_?A9J5/$=B#+#@ZX$UK%^YSIP>:9#`%BZLH
M2XDU<$/U2["$,>RN[?4+U(VE4^`$$6YLI[%!K5.AJ8.DVN/X*0,1+K*=<$4K
M)M@_,NX3G"`NE788&X>\"ECX%G-SF7MTG*(\$E$>:YPD_)1V&!M^O`J,X1Y]
M1/!]ABG*2M-4ZG:@)_I<&[S_^01AI[#!V*#KBY\ZHNO4)\>CG!B/<E)\DOUA
M%'L??^BVJ[1]B-Q@KV%'O9&QOUQS7:UP]^$JJXD=,J3DF@]P`D.SH?9._`H$
M@@*/?6+ZLL[R`9C=FSM]8?8W(_W7>!['+&VG!GT+8.KQ>/W-/:!\<RB9O`G:
M+@IWB`P7:J^2/AG7M:1)=H+[(4V;'-?)I%F-<#U-VCI5R6UF1;Y&&?SS,$UR
ML2DBYB*T3WSR.%78Y[AH[5<F7'\5GF9EIDD=O+8))5AEA-\(3KEVF0*CK"+A
MNJ_PM!*G<=.DEB#5CP1NQX6K;IZWXV"6EPXNP&.NAE.C<'TJI>D[H)[XRE3'
M&D=T1>6L20/T%NEE6Q0N2#4H^Y#\)I:B^I8Y(CR%B]``P];UU.*N0!54(G">
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MKVO"`8&C]F\V?:@NTZKU>=]R6GL]`5N.!4\AFO0%PF13RU]2<;_M#XM;WWP&
M@4P-[:;O,+%83OGU3OI31G;B]QE:]N)*<+[4QFI]\;G%Q2IHMW>+Q1CA^8\9
MG;@ZCDE7=:KH7D(F%IQ81<=B$XOI)MPE8$"PLYZEBTO221-4YFVM*]C;,6C0
M[G</4MK)>H&ZK9"9HNV>(61?[2RD;"TF0\_&1I`2[1.:[6>Q@2FDFN?P!?#1
MI$G-QE`5M=^(,E/6`%-*QL'/N#WU5:.O:M3U'2LJA0S0P6%E,2>W\?`4R!Y&
M=U;67MI(&(9[&+!7ZA`53M2_^A3='M:D"`(:0I7,0=%D-<8!P1$Q<8=2U%:K
M1KQ@_:M-7QM7@W[*Y,WEE7^K7OU3,A79(4FS@&RR[J'?6$A;S79O44JH4S8+
M.(=[)O0I@BD=`.8I/?":+\DVF-@AW]TG$5GF_U'`<KW?708;%6*K8<U"8:#,
MR@06F-.5$^Z=7QGLM6^+[HPNIVIF4N)1A0$J/24M4"1D'.XMH5!OW8E>=X(/
M!3RZBEK`1\(Z\.Q*&@MOTY6B]C)<@W&X[V@.6POJE%!E\"F(H@=WP7.P1%D=
MV/LI>@7XZI5H332&:93M;HB]L%84PR-(:KG_C23)YRYP/!-K=YY1JQ1X:-J]
MSO5X<@Y2T+_[4U"U,,^A\A^O*M4,L<9A9_%6QZ]SZNK2DW.`UO^P#U1P^.`S
M!(0*:+=ZD\,8P4N/N58&^6&\M`@4;%V>K:W-R_N,K:'FT%\AF@NJD?J3_55)
M[\G)U("5@5$&M(!`Y`0@AT,@FY=&/HQ3HKP_UV0A!U?I19EB-MX]95&*B05H
M.Z:+\G]):2MV6#;+(":]XK+(Z)LYD$&T$"25.J+$YA'5V!)]!O[Q3:Y_,7:,
MJK%.&NI1+<<^7](,1`D-_?$+2N@[U<:I-8B)%<I'DH,[I2LQBIXX7$R(W<^Q
M<0?WN>'U81W-XG#[!63/:/IE$,<L3+TAF2,.X4+&X'Z(,.*6N\^=:EQ3&CBN
M.ZX&ZT).C_>/V(%8VCTR-)0A+LXC#&/JR@J3(N]%==*DKEM%2>TS8,U4U0:@
MDBT#5(#AZWXC2\`U46)&)H=H!>Z*S3/(YLM2ST8$'SG$AC&IF\.6B<^`=&(8
M;9S:2F/PM;B0XRTIO`OF<1'A]76"OGH0MZ,1AF5?*W6B"R%I/\$%AW3*\RY:
MG?L,O4#2H.>[+Z21;M*]H^:,;#9?JA6OP)W1FL'AY,R8P=OQH*U?AWUK&9T<
MFLL1'RH&Z-LX6_R[P'DYM#VA!T!6N#%,0$N])S2LWXTI@F6N'T7$9(UR"0B(
M8E@BM&-,WJ?:".U/DW7<49L;22W0[MEC5(3V_78%`N[Z&[K-_;/48[XD&]HH
M74&RU9UA#'I19?2(67=4$)\L-HVL=!RTJJHTA5/T<_Y*0?G7[W^L(4E^Z,#Q
MLJX)7847"57O&O2>")H4X4)35.0;`:B6Q::`J:AB4[AB&X"UCBU'ZTIVQ'7(
M,6W<*DM+(2PI_8VA6=>.4P);4L<!WN+#W%(,@/[0?^^D)I3"]V':=TW3()5C
MG2E!^=!\)17@Z;-@#EE'V4IWZ="FE:\9&.TW!EJ^C29=);`:V3\%&7_H+(-?
MGT=$R_L,;".H'D.E);C0%)3X1@"J8Z\I8"JHUX`'%-ZYG[[Y2T_:#]PZ6X_5
M*^P]M0-,],*N]D$9[Y^L]7F'N7(B=ATG(#I9-&M9Y3B0%57%<0Z8HUXM5)75
M>_^F2;V_@%!0GRQDS>QTK&L*19TLGL%X`N*;#5E&996+PBU*5[?P!2RJ`^U?
M0+*X1MF77HP#HS+L8:=>F9.%M8W-C@-NS9H->.PS-<:IL58I[)[0<%-]:)#N
MP[?*2$\6R`86.@Y^Y14:\/S%B[TA,0[-G`<N0?5WPQP7T1;F42).,658\/`$
M7[N@1V:9Q3$J"+8('`!\H7LAI4'$182FX!69TL_5M(F1E1UZCJZ:8NMH!AKB
M)@SLS#UP[->Z3'1C`"X!O1!9/?K@826W@%M,]60%'].YK^--2N8T(@WV;F"T
M:(7(:]$&CSJQYFX1UY(S.&*T?VBK#]C9@HK%"DL7Y0M*KF/;,"9"?.HQ"1ZX
M%K9RBVB]"ECX5/@.=;8@N8]V=/*@B0+B."NH:\D^YZ[V8E*'B7)Y*6<2/-0M
M;#7.$E1>@7#=-SCVJ4.RQF50B=P$V>JBXIVCI&CP*-:VBUOLRL0Z#N!Y0L=6
MUL<A1SJ$-:C>@$`34X]+^B_$^BX.A@6-'QJ>,/BMK7<T;P;MZHT2(B*8MYA'
M>/_GXDGG.-5T_+SFB(VN]6+<J)]J-9Y,K%F_.X5TM`)MZ3D.'O+H78.!?"Z2
M,I@N5F^TJSOP+/ZC@!EHI0(A.R91MA;S@BS6KT%!W\9O'1"@`;;1&I4EE2@C
M#!L(]^T^IH[!MKL$6X1A?=+?"W>CH&)>@"*J0$&EI[4+!`DEV4_-7ERR$S/$
M`"S*V/Z<O$>RP<Z\Y"&RN7[)0)%I;QTGXYV)](`S$VD;QWH]8[V."1:YUK9Q
M`5P3X8$G1!JX,])?>SO9&4G%A9L23Z#M-4PCLG&WWQEI,)"/*%(&KI:6S6GB
M:K--T`Z`^9;B!%^]@BR&N+?.-"G"F>[%17P;+75:$%G90VN<E(CO3O!BL?8G
M%F.\9&W6^9+LP6)2;%_G6`TW91D.WB1E3@!PNA9QC3B)W!/:#MU@7!"+D,7S
M!=IL4%J^P)7@4TK/P::`_@1PJ6,)UY@4R/0FU@\-RW(?P05++US7DCX-[.Y.
M=$AK*\I)`X62@?XN4"07%[S35_\LX(G>LQ?93C6@2:B%)SD=ZD`1:&8%UT,9
M5V*X'EG\4?J>Z5#J-TL7U0^`?-2?:'692&=?-9,30+&US<:;I]45"3<I<U/C
MSS!%].J@G%'6*"$Z<9*`:I%S<,PG/P'$:MC!-3;Y(NU#[$R-0GV+6)]J69]F
M!8M1:]NX0*N)</NP-Z=P/JY_`NOD?%PJ+MP;MJOE$L3$%%>O\3I*5^"!&&>>
M4@.0^9K^1>\17\AZ->T]B;(IRA(^&17U'J$#+&&&33-!]O=G4Z.2KU&5E;#K
M3MY!I4U1EF?/J*CWJ!Q@"3-4F@FRW^=ZD0>/KZS@\E"/6`H_#]PE!14CTV26
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M<;-QVZ-AAND<-.N*+[NPF=@IGD1RO6N:/AO[>G)R8RCIV#I?3!<6CG05'H`9
MB8AOX-VRY<!N>.F@+\51LH-C)TR?9ZLHK9.=T&3PN/0/.+1VNG@L-ILHV\V7
MCR`!<?X(5RE<PI@^9ZI"&M'1"B4PII=?DR6/ZE5%L"!0$[+</!+"R:;\9FL=
M,MQ7[=1LMOFRAFF4["&.+R&.$X2+C`:?DC;C$X'1>=)W!II*?-TDQQ<_77@6
M-4S1Y.W1"=4BK#(=28]?5?LUT@O(GE'')_[8XS*+];F;;$C=UZ!A?5'<;R7E
M_BQ$0CGAN4ZO5J(14(=4K*L/(XM.8R$C1;NQYH3\J_,?&=^P^^SA;?>$[H_\
MU^:"GJM-?W"`5-%/Z?K)KYNZ5]L455G$KUZOW]!HD#G:8X%2:NT(:B`M[!'B
MAG!*5Y#&?ZUB&T_563XAM/@*DX38NULGY71O5;;&AV'9*:]Z!)43KPRT2QPN
MAM0E)ALQ[%H9V1BB/6@8":ZOE-0"PQXWZA3S\^<$KMBNB9.,?K+AI),#23F$
M:--W<A-*Z"?/R=BKFVBDT"^@TMZ'<4*_*9&%ZNVA02FKF3E1)B/LT4`KE/R$
M01QII3"K592(CF(U*`]A&L64DW5\G690CP8#N;1/J\VY3+<CT6A]Y,H\G6V)
M6'092MA69-BC"MUWY=,=-U;B!4,%_R-[M=+Y.*U#1OU\L:K4'<HU%@3&Y9J.
M&'KE)NOF@I9#]EJW^W*;_]Z50H]OV!VVW.U<H#3/X'-1-N4J`\#R_)'KW2&6
M(+I=U2[`YBV-`JY\5<2RA'.S?@FE/CYT1H/F03;:=RX$E=+*V59'BLN`:L?N
MIE_2J%C`'"SN,W1-?3)+%UBXV=]S-EPUGPA\P6=BC#6^HD(^DS9=__B10IDL
M0\A?/TXV/Y\7&*8`XS*0-RYS'Q\44GF$VQ6N465:V-5XP9&+B>!E1[!H\+`M
M+M9:47RR8<6R==%@&[7'&[-JT+''7'S8*X;'XAF#/PK"\(K>PDYW2-"MB/`A
MB9QL_W)$1#;APYEVE81+?Q6=0$4?NKVR=9"^?MWW)'S.U6,'(<>P.Z=;3\PW
MC\PC+8NJENK4;5?]*5P:&!5B"P+-0I[[+%KI;N)IJ"M@LB#-CMY>-YTHY7#3
M(=V_OY"1>@XM`SU-`"5G.UG@9?Y[')#E$4P;4\,#Q+_3D^XO:5Q]R]GL(,;+
M("8,299,?,>8"]L8H<]2H'WL*]YB:((![@L&\^45)NND*.^]7^1_K,W;_>@Y
MI*2ZF$"ERVA`HA8?9KCZ`I\F\R385T]SVO2U:37H/4>.J<8F8-+@/2!DE`_X
M$L3'DD^-)F7D\<L"PYJ-YD;SG!Y_^U@J7F#N*8L6U*-@GJ]!QAP-JJ2&U->@
M4K>#.:,RM>4URWB..1O-33"GR=\^;(87F"/[EYA8)"M-0A>/%Z3ZL%Q&]C>*
M*LK#/E%,Z3FJ]+4TW"6*N0X(">P#@O:/MN23HXJL^S`NM"E04S\3U(A9UI#Y
MKT`A(WS5(X>0:3'5*ZS0(&:IOPGD]$74$/PI4`A*'I+(06A>4/VZ*30@6MO`
M!(HF0M@YZ_0QCUH)@N1(TB'=K]AEI)ZCQ4!/L_6YC"U#A"='[[]%61;1"VET
M7V3Q.L*@D1!/#A.;HK4YS8IZ#J,!=C"!E9D8!C.+DW0OIL$+A//YDN8V4YUM
M*0GWFS\QH><(T];1;.LG9LK0$V"VA^Z4?`U3F(-;^`(6E9I4;WR3Q@55Z0D]
M@!1\G6=7I>-+;VOH@)?@W;0A+\\1ZM)29CO107(9SD.]#+C/(,JJH)L/($XB
MC,O;UA(6BW\7."\C4@`<9[!,OMS;M]H5W^]?38M[CN*!]C#;SYJ*8E@-]1+A
M@1B'/@PH@P"\@`25V_>KURV-`\"]0C`HL;\<U2CA.0C-M3:[(-7@SJ`6ZMW!
M-<H`7*47=-!/R<*&K)LQT9\ZRA.]R_\F4>4W+UU;#N;#\F[;\_$<K*XL9`+A
M`3(9L,.]THC1!CQ%KZHK#3G9?DDJ(O,<=9KZF2TD12P99D*]TRA#;9]'&"PN
MT(8.\U7$TFWMGG]37@"2!3,]6<?<>7@`!_80Q(:#YR`<;A43?%I)8]`-]2[D
M9K.-8%9&.L\N(=XB'"7SY2U*5^4.3^=69`@+-DQ:L?`<O0[L8C2\6HECWL"A
MOG9@09TN2.==J0XR]8@[P;5$Q)ZCSTA7$YRI&#-$'?_VQ5&\F2A+B>HT'VHY
M(\@AI4G-(M*HJ#T'E9FV)JA2<F:P"O6VY9H,SF76GD8@^YN4&*#8'/Q9NYMC
MDS)L(ZQ7QG.@V6ANM,'5X\]`%^I+B3OPM6&'#*7DGS%HJ"@?W&R+LUQIQL4]
M1^5`>Y@`U%P4PZJ3BY:PW[@_E5'\WEZX'_&A\2W`^&D=I;^M49+LYE]3L*`!
M&>`"DD:[+_L=_3'#:[AEJ3ZOEDO2DJ2IR5(R)4O).R`,N'446;RGSNYE>3[&
M'=/2UH^MW=<KY$!B>T?=B<>]MR0CG+H9.[0;N[+[,+:X22.B&:5W4/*0$^GS
M7:^<B;O^6]H0Q0U1O`:+(JFVF\Q]BMN&PH!@]AS8#9$-A_#2C`PWU,"T(U85
M"#M$F68:DHD'J3"3D7#?%!PP1OV*XAPL9AN4Y?4.NF/ZVO5(<W@9RK`WVM@S
M#"-WB7/36>0V<5&'D)=#.JD9IMX=?3/Y3PY@U&X6];!DSZHW(-FP\CT=BD-#
M&>5$&28WZ"%'')_>=J#Y5G(MX-*#M&IM@I,'D$0Y];I*,21XJ`)E@)B"8R$=
M'=PP:UIA`+.0DC>XLIEU7H<!%9@L/*L$SV6<>"=@'L2IA61+3D'!V(6U[#%L
M*=UE8-BP<Y9,O"(_Z<PEKI?RO)08Y[O&_]1+>',6O:6["8L`TYXXL-70U"=V
M50AY(>_6]^02Y!%,WIQ/CO5,2WF*JT'9?:SEU=41.[PC]:J6'?-MN<!(5[<(
MXXLHRW:D(W^-LD4W%K9%R<Y)ME;)R<99G99%0\S0'DLEXII^\5IB`L\Q8:#K
M);$9SF%LC\TN!W.,'CB<$%8%9AD+LP=QDR6V.#IV'XD9Z4'F+:E-8@]@+AMS
M%'?8G!"4908:"\\=F?99,<2@]LZW4W\I9/6NF\?5?J*;.LI5XV:#J+Z`24$?
M_SZ"N,C*NXRKUS@IR#[CFC0`?3!<5-::+[M/F<I3#O&]ED/F_9LN)\PG:X*!
MU2>;52Z#V2OL+I6/((GMIL:4Y%E+W44;0-8-$>Q&Q=(EE]JL23[=*$%#0U8Q
M`O!GL'D&6;>G"PE8;^403#>/Z#8,TM"L,XDH6)>'3QR6X<X@=3A1+BRXW]JA
M6X,"@TP?<QQTN`6^XVA%*^:B04+!BP(=%#+4NIGC@\LS]"7\$98@R'CJU6D;
M)W4LKU65=7,\&1RQ>4=:\0M;=(RU:QL,;C42M[\C3<)=1PPTRRU,P4T.-H[W
M/#VV;C8X#;:A&GRVH:<E;JW=YNG&U(QGJ%->'X'#1T.NG9U.@OM:.QCQ6&W?
MID7GTZ)H>/-\#FQ4VW[7-#4H-*-#CGF&:A0XTG%%'#?<$2?.SS!%1.<=B[G`
M._J6TM36%]`,U`N#^/T*O7Q8`%BI1/[1U83\]*];L(J2*]*4^8YS5"SX6M>\
M]_5(=:Y$<@];>9]8/+K6)W<^T=0G-,+G$-'\J=$6D`X1\X]'M6CW?LU2VLF&
M*ZZ!D9EN[?&FR;'R-Y9RFF)KPVWY*WP!DJ3LM6FI2I3<Y^`V7W#;7I.:855%
M[5W[F^DG1X"2UQ23!A<#\S1&\2X'%RC;HLH3GMOZ2KK:+A(Z[UI<5R=Y6TNX
MV)]QNF[E+%_K-;.2D+6SA-"_AM;52M'2$C9U4Q\U/QBWJ>G`<U%DX`X4&<)D
M\9O&`(O&=#UB%FE-0>Q=LQMI)V]Z%:NZ^2VB.3IN_@=``?K46';<I#&W[34H
M]TF$))3>M;J^7O(FE_*IV]LB]93C]CZOGDC,,(QNX8:^]>(VMHJ,O702DGG7
MS)H:R=M8S*1N8(N$3XX;^!8NP2;:/M9CCJ@WJ\C8AE=(YET#:VHD;V`QD[J!
M+1(?C=O`HJE:1<9O8)^G9TV-C!JX/R5;9"D:J8%14CY15G9A(5VGB3ETWK:Q
M2B>]1N9PJ5O9:4*?(]I-=#R)I`>!;6MU>)3G#ZVRX=XWR4^?D>IXMVTG+K,2
M7ETFX3H?='6\%7@3*.D$1_NW'MSW=^NTCQU]#S*:]"M:@?,ZK+1":XV2`CM(
M2WK37?JMBH880=Z=;ILWY49"PNUN+(H6V2L"^$+'DSN05WDX!0^XI:3M)]P"
M4K_19:"F`9SD7,.]@?U$_:8;6O&AHZ!BP95%5'X#1D\Y`ZP(&8[A<7S,L29)
MT->(;'*N47:)BN=\623]?B$8?&S*LM'(K*S?:!MB")/QRDR,_>6!%YL8Y2I=
M=[6IN5Z7L#MU+RH==QP39R@!ORDN+EV_`Q;GE)"^\-4KUGN[JRKF7ZJ3\]T3
MD<UQF3(HH4IVTBSAGP5HW;@^6`8EE.E>&B6F2Y+*:L-W[.%_98X\W:_^9:WA
MM`I2J:69I.;`NCQ6Z[(,]V3-I)-+DP")>H2F@0_BY'F`&F+"-;KQ+".SO'`T
M%OF\RV5*S=^4%>YIS0/-),>9\'J_,[^'P^_3UIGOO]'_TJPW?[@^[C$MW!0;
M;MVYWPY'K<UODW56GGV1O.KMGM=@4"^UFP7#[4:?HU=QP_*^L89M?_.N8255
MES=LNV"X6]#^.(ADPPS'*&P>;Q7ZMN9KT61B/RLW.(9[TBU4LW<6I-J#B0Z/
M=`KXI_X7#)9%0AT<=/7OEU`9H%G"OPT']YS67'O-_4;KF%9+RAC!7ST?PXS[
MW@A;COZAKJO32.\.=2T/'^T>O:I$3/&0P<T8.Z>/[>B+W0RL08KA"ZAB75ZC
M#,!56MVVQ+LREPTQ"RR#Q9?_2TH;?HI@2@./SC*(B1DOBXP:$V00+>Y`/E\^
M1:^=,?J($MFSFV-(]+R['-_J)CWM*+6S?V["RS_K45_]DF8@2N"?8/$+2A9$
M<V:.>=J($#2X@[H2H^B5P\4$VA4=V]=%_QM>)?LW/U[XCX@'(&:)<[!$-*Q%
MMQ=9E*P;SJBDYUBWMX()?(VDV#]2FCZ/STWZ0IBA;#=U"IY#1=2Y:924^]PT
M$LH)L_#4M:*9[C'9$'Q":('+`>Z!-&WV`KJ',`8ENIK+2DR8#$'=@LA&[787
MEXBI0O!KL`\\YTPY#>\5_1R5$5$2_%ALMPDL\Q-_!EF\CM(%Q&1N7M`YF\S6
MJW33]UYTPJNY5+/GY3MR79K*"-,#!8><97-_@C+U3"8\VA%EKM>E5QTP>S"W
M">M&AE53]3E%5!9H%?'/")\RLG#45;]%K%*\)O;O6H'7B+*C;9[6FG<*#5'2
M(^U:1.`S.]F_%)NB3*!\"4C]8UC:A_P[`?5QUFR#LKS.T2FT1@>.KMD>WE(Y
M8AL,Q$>RI%UG<%<9BR7"3U6W2<&*RI^ZX\A,9C`U&4Q)`8'60&/'HW(I8,#;
M,)1'R=27O/HK.86IM1+,*:6I['T*">>:HUFG]_(^[1-(-C^%@1>).A:X:',+
M>=]W0SBE*_B<@"I[Y=3;/WJ*]!4F";%\KVJJHTVKLNSAL5G9Z2Y`8`IS<`M?
M0*^>XDVB62%V[:%9R$=3\+:*NN1J]:?>+AHV)S+6O3TBZHDK[WV48@+?-DH4
M;.P1FGL!?1`J&*AA*61P&D#5L\\(T!4*#GXS)S>/T21B-'F<"B15VSHG\#N%
MK9W=RDQI?*V-GI%L=5N<PK9/K*'0D]^DB'(,\,*7?P1,:OKU.T0DQ\<_P'<U
MS6EUONS:I'O&KD7,3LX5Q.&ASTC]@;A3R7+TIN'89QX/:!<E^6[^G,!55)_?
M7[+:PQBD&%P#,/E1"*O2`W@!:0&4QQ_:]/MC/"6]!Q%P)+.Q/`:.;L%>%!QU
M00\G;GR^^QS]&V47280Q)SR`14GU4KY?TD?+'.K83SFMMHZLM-I"_-*N@G+_
M%F5+[@OV_H>ZJLT//N[!I-9&$L6T-UX\"72N:W+V)KG9;/%"`_`M:.:6)Q"O
M4Y2@U4X4>UV3FBV-5-0AXL/,!(-!HQ3G38HT84U_@_GZGS"#Z6-!UD/EXN?&
M#%UJ#BK$R3B<%`JU334>,F55\";5FU'MX7"XPN%XA=\,8/G&.BYB80>RTZ>L
M>P#;#"V*F.9A_@124.7:PL0Z12Z(?:5?8I_#3*-$B/@S-\5@N&F)]"8C'LO/
MR8XGB,$?GS<9?^C3(^[D.A41AP@G(P,,1I)*FC=I]OCY'P^U_B5:1!CRXZM:
ME97FW!26#1%Q0\PS&("&PKW)"O@$7J*ZFK-5!H`PN*^:L#:EC#!$6&DK/AA#
M,DG>9!FL,UTR:*/L2TITS`BV=_/EESQ:R]*&ZI9J9Q%5EPH15W8F&0PR;;'>
MI#V<X?(-*!M-F_6]B!*X1%D*(_[^T[PDVW::E`P1??:F&;[)-!$]1EK&X5`\
M[(+IW/X)9-TT\!T`*ND[L)/0APPV73,X@YA$(#L5#C":K,T]HMR/2^."3;M-
MNE50N'/Q19]"J%_MRV]YVRBNAD41,U72%<W2E^K-A=Q]M*,KX_MUA+E99P2?
MV3/'WN<QZL7/!B,DX-3-]3UUR?3F@I#!.$JXLY6,A-602S+=\S.Q19&6/IUW
M9SUVY0-$+AM_ND-9/:C1L@*:5M/V:+QN6[E&^HW;X^/-G7%=/ZWFU6K?P!K8
M60N+FCC`8-#"&0YIS#%BD^US)W%8?&OK,<4B8LBBJ\\Z7*?QMT1(;XF0WA(A
MO25">DN$])8(:<39V#05DLXTW$^&%&"28HFBMX)T2"9%U+[UMQZD1'I[22D_
M$^XWJXL'E#H"C=]-3G^:4K]+NP=93'5==9$C_,Y6BOWOP6!"I9L=`#A<709K
M<G"IMRF?+G8]+V8;&EV_>Z&G0[M_]RJE#086)CK;040A84#@A3'@DJ9%E-1U
M_1S!-`<I=9J^!MVQ0H.2045&&0Y0M/6UA(F,O[T3^A@@.3QAKD!\'\%%!QTR
MDMI,?))@\*"AH1T0^(SM'<7'0$`][=5;V?K0C[^8X-.T%Q1=FF!`H*/CH(5%
ME_-DV96X,*!!#*Y1=G!$$:XL-2C95D1&&0PP]/6UW'C(^+M,>.1J25$?9]:P
MOBSXRPDA56LIP:$*!AAZ>@Y90G!X3^%?[2A,1X[BWV\P+L"BF6[N<4T:!)?9
M5#HXTB_`PG)H%`@&7<;:VP%-1XR]A[47@3@%*OX:)04PP%V?7@Z[)GWHJ!/J
M[A1T32E^^5/7<S1-5D9LOOZ"!8LB#D%[+=0B"`852NT&K7Q:;`>X.X^R.P+E
MLU^4WJ35+`Q[*0-E)/NWV#R28)I?0T/+G1&7,8.`)\>N#P!NG@O"M\P9C\KG
MN@2U%PCG-VE,TY82)7\IT@7Y1[[NH\.J]!XXAJ4#PM00N]C"S5`F0^+T04X^
MPP3@'*6@/C[HPDSX?>]:T_L>#%14NMF!@<.5-??T`4+VAP%D;?0`8@"W.9TI
M+TAU8$X]`U1XL&?`%K46#()!U&#K6"Y[+<0R3$X?5J1]&%$=:%]%\?I_R.)M
MEBZ>R+(=1,M<Y/&G7Z[M#:A3+AC@V=K"=HC3EL9@-GW@D1KZ7[9D54AVB/3>
MC#I*93B_)@K7-RH=B!F5:;]A4I4)!EHV-K"#E:8D!JGI8X?LMQEDL)VEN_LH
MI^N_=93_$NWKNWCZBN;99Y3U'&FL"G<W?IJ%@T';(*L,W"QJBF3XFSX4R1W*
M2?6J,ZXG]`2R#4Q)[??^(QW$Z9+7UE23!X,J0\WM<*06PI!SU)`B;N/`TSTM
M5L1^Y])TXKUW:%SU"$X$_6;^@*O7+?WY#KSF3U]!\@(^H[1_M#*,24=14R:3
M]2EYZR%'9FEW+:[,*K>EG:S)4KL-0"-=-9/IQ0J$G;)&V-N7#1UR?",X1=I>
MA%^>NP:5)URZ*U#+TN8@JTJ?!,PXAG`/M$J(7UZ_^M6_1D7WJ,:NL#'0JL*G
M@#..&9S#K)+AE]NP7NUG]&RI5($LRJV@QN5@A+<.A]!!)S.(4^1U!-G[++^`
M[!E-[P34,L<%O>LK,[;?H>KBK[<)UZ;G;9CX]/YC3U=90Z1)V`YP@O8A5ZGI
M`8?.UMON5$/`F:V#G?I1>?\.V^+M\$CAZ1KB'&>?F&#\4"<+1`.2ZO$'%:',
M\D+50):CE[O'SC\YBV-Z;8?OHQW5@PR?Y)>LH--W]`P32%VFIDX^6=<-L\I%
MB>CH48/R<#TGIIPN^6R[-2ZX2P<Y$7O^("":,EB7LFF0IG*]V%TBSN53!P''
M<,/DU#WT'*4%!E@($C'-`2,\F@`@HE3-%"$\AI.=\;E!2>GHWA_,^7#1(V9I
M>A3$O@/(2%DC)*DX3W:6-\KTQ%TL:,U9.B7Y$YF\I._(LS?#D"E/+F;`R5]O
MBWSLU>O5'P7,=U.O3ZM:"):D_(]UJW8_.G-RR^!+E(-YD6.X`-=%NH#IBI>B
M7$W(ULL20L>UKIGS0IH+"=JU;!$XRU@6X?5-NDS05\R-:B[\SC*/];\[2UZ5
M12G9JLY3?CQ/T6>6J*KW>;)A5&Q#I%2C/4+V.)6)I7H<O(FW55?MZ2N2-6'O
M<[L)&Y^];D*1&OI-V.#@UU7\!<C(9)3>I"_4TS[#@@2&,J)]ID(^D9\MJZ62
M1ON*^(0;F_*>U;9\E<R/6R\AV<]L/!(_L:"AC@82^%S"/>66+%Z0>O706?_W
M>)5]I\\CW`BY&BM3I+$BY-J-P[1"7)_9U*>$&,3O5^CEPP+`:L@A_^B.-.2G
M?]V"591<I3G=3O07SH*O++Q:]^N1ZER)Y"ZF>9_8GJGUR75&.YH6<@VR:`L*
MFH5;FLU.2MO)9">@G:Q[<0V,S'1K]ZTFQV;N.0$G;U;>\RQ?ESFS+U"V15FI
M#3^5N9*0G8]*"+UK<&VMY*TM8^--$B&6'5W9TBJZ3K[Z(-I94R=%,XNY3+%"
M%SS'HS5\:HPY-VG,3W2BIMP_M)-0>M?6^GK)6UO*Q_%*?$B,V2781-O'.MF\
MJ+%59/M8LR(R[YI94R-Y&XN9V/MD.F[@.E7W#,/H%FY@#A:RW.I"LKR53)U#
MYET#:VHD;V`QDS$BQ![1:J)-#9)N']K&ZO"@]FJ7/?4-M'QG:+)[[G$*-YW;
M?1*E-`LS[PJ*\XD=T;4^35YY?NI=[L>.`J[WUM4M)YE9")3@"Z!BN`.XDJYU
M:\JEFZZW\0V+]+7J]+46OW)<$O/QZ[EK>5X[WU(]:"7)]^^YS:VD:\8_Y=-Y
MV-RZ6JF:6\+'KQNO?D4_:C;W1\WF_AA4<_.U,F_NC\,WUEXLT[@S)E),17QS
M[3/S=HJ>^B)-LN@PNM]HL?'FO*9][7(KR->GH.(Z`#6HIHL.3B.=GT>8/IW:
MT*>/-:PRFG>1QH,YWQU(ZM!7LZ]1MF#S/<ZSH@S65SJ7/JVCM!HF\&RQ@/0?
M47)XO2)Z&#%Q+=C0/E4MIN[?0M0B7YI&=K]\VPHR.55UI[Z)=>4!<E?0:7V^
MK%(@W$=9&99^EBY*>ZB[LB-N7+\2"VZ>6+6J\:S(URB#?QY<B+E&$Q%S;=(G
MGG`T<=/T/1\=A4&Z@\.@6O1]>_K2)]O0C@=-NB;+HW(\U<`FAUH"SA;UJ:)3
M;)*CP+,EWJ\=^*&Z94T?42(>_GH4/5@U*$X+2B+51X1/0Z3]=LN3"">RI#IW
MX&OYI1<FWJ2,1KJC1IE3P*:->9RC5;,2]M?]GN"W;:I+^`(7(%T\D&V.,!6E
M21'N]"PJ<@K@M3#.R!.UJ`Y3.#(<`;.7*$FBC)N>W;B<#GK;Y4X>PA(S'1?'
M[8K8.VVX/[8MPUR7BLZ7]2'.$[HOLG@=84"/AZ)TUS_&-2EU.-;5*W4:J+0Q
MT0B8U*R&?0YAYXALK;LO4$J6'CF-U%3]$Q,%'JB!Y+LC=3G^GDE6[C1P:6>F
ML?=7LHK8IS,>8Z-.?2WGR]\B>EC>2ZG%_]CP2FU^/`4\215V#IJN-/NDPY[<
M&<ONE-S>$6C?#0T6&WC()3(E;E#JY);'!2OVD'P0*Q^,J;C<T:#LF\*C:QTG
M;8U,[-#NT4/DE^^.97+#O;;MJ54=DJG`UZ82`8]1G1[HN/J/##@F\W3F#]6E
MH0ZI"'M^7!>.!D#=BT+G*.1=$88:ZD]P*U#?:!V<5?'5*\ABB'OCHCT#^3V0
ME$'P8!YL-;<0MZG.9)E$',6X3$KF]>%"S]&M3E_1`;M9(18:0K-0\*"VLHY;
M(.M6P?ZJR`OP6CMGUMWX4WDX<I-6W?Q3AG#O1G\\"4.=A&42@N]#X]O=\<PQ
M1GW'>+!L?YK+SA)%*R#A]]K@G._!PU2ELUN0<:397T;Y\5A*?;;K\&10^V!W
MF,S0'[!91*+KM]S0<'2WIY#I1Q`,&VD9F1OLHL6P834NHU!S]-`\0Q<HS3/X
M7)2MQ'*)VT<^%P3!$PD2W%+H%]B'PU,7<!?23R2+%PE=DUJIAWU,]+>PCV]A
M']_"/KZ%?7P+^^BXJ2]`DER0)>D=*,@^L@YT=IOSHXCI$>]CM,N)O6MV(^WD
M3:]BY5?>\D\@$_1OSI=:_]87[YI27&]YN[7*^97V^P%MBJ3`US#9"/NGE(9%
MZ^33>->$.KK(&U/`88QC["/:ZRVRG]0\NEL5P_!^"K:R&'\!>O<\$K5+Y2Z2
M"./YLCS<XNRAE'3[ZVHAW73^)(VJ\'-6"0G8`H=#,+%[3%FE"_[:34C0<H5I
M$TQWYBXV/M+0I7.4WF-V.+=M,PFWRS:TF:G:?Z9J_UDX[<_7Q;#]9U-NRYRW
M_[FJ_<]5[7\>3OOS=3%L__/A^S+'VW)V>\</%RGXVKD[G3XTI+P5Y5KH-&&/
MPQA;MB/:2[V>0AKKDK;EA#S+/L#A]4VL_757KL:[``EC;\[\Q&K<"@),&I10
M7@+=^A!X4N:[:1BP15!(QU/7AY`M)DVK<L+5B\NB(5'I7]L/OF(Q7GD2?*7I
M0(*8TPAW]2:@X;QE:]"$@BP=%:V`)&`<\%J_FEKJU<\\>X"K=;[W/0(QZ2UE
M%OLH2<#B?,=6235A=UASQ*U]*&+/+1BX.C6;';"'5L&;[8ZF)D_H'/`?&MJ6
M-T-ML_R)X51HFC&1V10:^-,8KL;,][8,%W,(L&`R$&NRD.%8R2)H*)L9R!V:
ME7*]21%75^WJ=0LK)Y0GD&WX)TI\FO:Y4I<F%/3HJ&@%#P%COQYD5"'2YLNF
M.M?$C#?I"\`-%FS#KTG.=OM*\E!08JBX%6#4,L9XJ3$@=M@^7B29O(MG#!<P
MRG;EAFJO0C^JO%$A%C5,LU`H:+(R@A6F="5-%O3+5=!/%`.PP&5W(2O'**63
M;V.'WT6A+OT^;)V2/ACL&:IN!SNU$/M@8EX@;K;X=X'S,BG+$SJD8;F/X.(F
MO8BV,(^2QE$E,\(%PKT%O@M6;,(=Q"H4"#LTF-U$/4A^#?R?_)C$KR-8G7RR
MYXG<@Q0%56U,(54HP-)3TPHS0M;LO-F33*2?H^QWD-<UK?-@U^-V6>T.,'3)
M:].IR4.!BJ'B5IA1RV#@"35ZUS5,80YNX0L9)8EUTA6-2%M:YPL&RR*A$4B[
M0Y%!$38N:14)!7D6!K`;L;3D,`1.?UGP@'91DN]H!/AY>@?RQR@!>+XD2]%%
M$?<679K4^]<1"NI0P&.FMA5NE"(89$(]T[>.T[)?`Q!+%ILZ@V.Z^`SR-5J@
M!*UZS_R'1A`RES@THI")Q.FF'4XE:3RK.`<+SBFX+GEW&2PDG\Z3\(A`0L:&
MZW@HCE_7UL)<6,?`,ROR%'R`^/=K,GB3B1T0H^=TL-8`O:R8!/S\8M]R)]`P
MI#>=@5_7P,,&RWI],Y>0P4S`*Z8Q([2+?<N=0L.0WG0*?EV#3U@I4_57E!#[
M)K!:VAMT#'Y!C:[1+?C6.13&]*Y[=&L[3D9,?[?;Q]^XV?G4'Z.:;,5P_$#!
MW..B1Y!!@,\;=Y+$3C3^7>VL0W3'517%1NQNTQVR9/MP)RR#Z2[N#6C7'YS4
M@P'>$U<OYHIX2$?85I,EAAO6!T:6TGG+ZEQ**#WE.&8>XO?HOFJL/WGB_G;U
M&@/J_]OPHRIK_UA=V)$%2TM)[1[DG"^+!NF.;RB]9"Q36O4+AY5A/<&3')U/
M*(^25N4?0`SHQ:$VZ(>PJ!O%CD4H4'9@("O4VLEE`#V^=Q__'5ECYJG\;I[0
MP1OVRQ:E5,-BLRD5G"][JG70ZHQ?^XGN$'ZAX-BUZ88\_1U2"89P3]SXV*++
M!;J=\.HLU$\<U2Y--FC1/0S-/WCBA'A!W663I*YO(T?@_#F!*[/EM!->;)P>
MQBL4-+LTF=WX/*P"#,W'OYSDHKEZOU6ZB]^DL^42)C#*`9[EU"&\@U8MVMJT
M"MI0T&:BLA6:%`(86D)-.WI>8*(MQK/XCP+B\BT"58R,\_0'HLI5&7RV/&2)
M8O:YZP\YD$O=/M9<0@&K&S-9P=A:-`.XJ^1'`P\*2G6QS=FR;?'F`8%1\5!0
M.=`P]@<#1C(9#KVZ`'1__^?^^N^;NOWSY/+/S=W?#Q9W?X-=@?BY>_8KYR=T
M"7%]`LVVC8.A/Q9[EB?(.?M0.L7(AK7J(>[KQ+J+Q=6>)YYS;'5&QHUGF%9`
M.BS4'D!",VG+%M[Z!3MK;9V"H:#=VAB#5M0ZTAA"+:[<'"^B[TFM2#=CZ6.I
M6W:2@#@OHN0^0UN0Y;LJUE2MP!/ZA4QGA`9KC^9CBF`1-481$0K.CV!@N[@=
MH]2+]1U/;@,OZPH\1:^W,'HNW5-G&>GUZ8K&*[F$2_*=IF:[2<\1^OU74H4"
M$^+S"$,\3\MD8)T7L9CMP3L=Z1BBZO8>5U0H'>N(!K?J8./6CW4T3RXE;[89
M&4DNJ3-XBL&"WD0UYE?MV6@H&W9<;LTF%/`[,I3=(;NU;/8FP).[Q\:Y%E'H
M)BU#66$RX6%`&FQ-E00O($';T@F^[GHV1Y@NN?=/.-UP#P7YXYIUZ/FHFRJQ
M?F)SJTGKXN_3F5X:%I/6MTS(HB7"<2!T+XS->W"FVS1FMFX^$E-*<)1>Z!\?
M>I8F[?E[]8W[J=4*X)7L?Q:'I5ZK'9ZK"$PPC=_':%,)_Y)&Q0*2G1#IWM<H
MVT3E*VFXN89IE,8P2F[2)?VY/`LCLP[X3&RPQE=4R&<Z#OSXD<Y`9#0@?_UX
M"?(()OB[J0^Q&C/W0:^]'H(@)7:%Q1?'TL*3G_,U*HI931_(@)[V<K08E!`;
MHU]BLJ'%LIWYE^<*2[2'&C/)@COSOL3`XWO(=+P#^4U*!BMPB["&QX>\G`8Z
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M7L+-QRQ(/%U&;S#,#<XO(T\-WBWC-=)L]-9'FR;W@#,YE^]Z'D'V`F.`:6B0
M-8AZR6VE1/O(`GPBK]&CI9D^7$3LO$ES_#EZA9MB<\C51J/$%!DUX=4?!<QW
M+'$,2LJ[,SS+G^"&_@!7*5S"."(+E,.SKPY.1N*^S^CBF+O7R!S7EOJ0=EZ/
MP-,L5TI782</SWWG7U-2N37<'NS4Z1O&Y5@L+?UR7N/95G]]I!I(F"(SLL.E
MX0/8UO'N6JL2;MHL_0+-1:&B@-=(,];8<#FH8&V?==EG;)6CO`&T6O0:R*KI
M@P463U\WN*HYVR=D=KR$O"OH*>E\22?U>-T;;T2?:YOT/WO=Y`IM]%NXSRCP
M/,C6@;R9)0[93*N1<U:0B3N#?_:N[(\@:6@J*AU)7N/\>#8V&!3'K)-]3NC)
M9VFJRWT&X]YTW/O0A'7]P7\4\C0P!$W-PC[]\<A3YOY)XRS/(YB6VY3E!<CH
M?^KDA0V/?<4$:\=,,!V;,O,:3DXM93_5FXKU+$TS4^<FQ7F4)&5PLVN4747Q
MNM90`%!U@0X(906"`)JVQN9@DK&>+C6S:K2C@10OHYUDC]"EZ(]+!XH@,"#6
MR6H$.?`:D/Y8W,K^NE3TC3S`IZ+!S/%5W70&[+M2<OQ2E&^J1$QYCBE'>CY5
M?Z%_/).E/?GE_P-02P,$%`````@`'$BL1#PKB*H*$@``U+T``!``'`!B='@M
M,C`Q-#`S,S$N>'-D550)``,'QG!3!\9P4W5X"P`!!"4.```$.0$``.T=VW+K
MN.V],_T'U4_;F74N)V<OR6RVXR3.'D^3V&/[[+9/'5JB;<Z12"]))7&_OB`E
M6?>;G3CTU$^610`"")`$0`KZY1^OGFL]8RX(H]>=\Y.SCH6IS1Q"%]<=7W21
ML`GI_./7O_[EE[]UN[]ABCF2V+%F:^N."-MEPN?8FC#7ET!!6*/Q\'[PT+<^
MG?QX<G9R9MVRU9J3Q5):YY>7/UA=Z]/9^84U73)/,&J-L2_AV5;/MK'KBQ.K
MY[J6!A<6QP+S9^R<=+OJZ:_B2MA+["%+(K[`\@EY6*R0C:\[2RE75Z>G,\(D
M\3"A]HG-O%-XT.>SBXMS$,C%'J;RGG'O#L^1[\KKSI\^<LF<8*=C00]0<?4J
M-H1>7EY.7BY.&%\`D;/STW\]/DSTHR/8F7RM?VH`"ETHURL<$Y\C,=.DHQ:%
M\JE[=MZ-D5Q"OZ6X>9UQ-^+GXE0USY#`&]9S\"'WT.67I[IU`PJ$2`5I0H5$
MU,9)>$=N$)+`/YP&C1$HH<]89$`%MD\6[/DT:"N0E/I>,3>.Y*>J>TX!`G-B
M;Q`8;8##:#>#YV!2S!HT)/D"4[,L96R(4B:1,FI]*[RY6A$Z9^$=N*?Z]BK2
MQQC/+=W;5XJ+ZXX@WLI57:GO+3F>7W?`=+J1C?QGQ?$)L!=!<.;B"MVHYM.5
M&A8T8.PA?FY$`G$[1R5G#$"$K3"7!(POMJ73MY+*1FY;J0#%]EV3A7+PO*U0
M@$(H,5@F%\W:R@0HV'U?<12=*0A@J8NOXT'93*OYN6.VK^;V'G7Z5!*Y'L#P
MY)ZVI(Y%G.M.)<3FT='#8YW]>@93_]D9K%@1A>0EHHX5D+,2]'XYS1+)TO<%
M=H;T5WV='<HA=@A2A9D9+LT1TR99C!?>C=2PBW9N&74P!?)P(9A+'.4ZW"!7
MK3"3)<92?*7(=XA4R[!25AN$2MV!YK3N)M"].%3>[?#IKO\TZ=^IJ\GP87#7
MF\*?F]Y#[^FV;TV^]/O3B?6='SWA[T=U;JW.$>+0%TLL"0C76K=I[&07@`\:
M-%ICX.BJO4ZU,UEE-^>[VXWU74J`HQTUL:--CXOA?+A248:*)V#6OF4>=,D2
M$,@S?F"BT9RQ#;5*P_C4?$*93.'GL?\$1C&\MX:C_K@W'0"`U7M2D(^C<?\+
MH`U^[UL/P\EQQMG%4FZ16-Z[[*6U410@5NK_8EO]W_8F7ZS[A^$?1T57*'K(
M%XB2_VI&;Y`@H*%10F@8N!/?\Q!?#^<3".=M.2$+"O&[C<"SLVWF@R]&%R/0
MM`W>96`#;TRSTCQ^C'S%."?2M9(,?&]I%BPVMY),?*\]R9`/U1AP8B58L6)>
MK(B9H_FDS6=`GT%`QM>!YN._-4K[E%?:!O?8Q^D^[O_IDY6:^8(^CO_6]/%%
MOH\WN,<^SMJQ1'1!9B[N"0$><63.F;LU/?ZYR*HC$A;2-(X]G^[Y,5LC5ZZ'
M,Y<LHN7A#L\QY]AY(+;R)>YQM+(T!:[1TP]Y/864K9BT7B`BXE9(W5+DCRI,
MJS!<)\4(K9$:*]2!.]Q7*D$SXA*Y\0P:0=8H[\>\\B*R5DA7JRZD;"5('Q67
M7UGD.EY69.VZ_5/QFB*/BW9V3*C)'F(@R<E,[]#U%ASC>!6O:*]1P<\%]J^(
M64EJUH;<43%IQ<2Y+L[4QB2"%1ISXMT3BJA-D)M(*T^7T(F/T*U+T8>PUGE$
MW%Y>G*L\/DQ=:D,U4.8;TZPQ@,N\`6P8@!B'69H%*^3!VC"13)@#CF;$"CBQ
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MTWN)C>^P1,1]E^`X(FUD='RY[^@X[(VC.9>=E4E98NYN=<@5`M?JO.J`S5%%
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MZBHZ75#)^8^[\R%;\R"W>7ZZ4^6*M]=$A*2OWD(7R6I93?I`HZA_W0A/]<2%
MZHD=N/A\RE49GH8,:&CUV,_=LY^[YV?M%)"K_-7PJ1&">O`/VTE:7-NKR?.3
MF$\!XLXC(%^=K!TGV[-173YN>Z="T]IFIL[/#&$M*&#5EEW\NG(116J_YQ[^
M-Y\MDE3Z,9&*/@O+_&D>KSLWOB`4"]&S__2)T!Z@@&!F'D1T<02'7^6-R^QO
M@8\]DZ__:8\9U-L*2M-=R>C^0&)/^9,@,SC0DD@=W?_&F;^Z[NA"?%<08GD=
MBQ+758FXZX[D/H`C@.8@]G5GCEQ=YD\#K\!FF#/5SW+\H*1)N?SE68Y>2#Z6
MN`EL(&/`"=PC=/$&\@7_WU:\`HTV`C91B8_HE7B^-\+<5G'3`JO*)=JUDT$R
M\'?D^G@XW]3?[,DIQ)1P(]X=GW)$!3!"HHIHJD?>G'#8>]!UJX#FQW8<3/0S
MS(=SQ2-,."*6/-^2M&Q")5Y@_I[,!XN_;,[[&+O*;9NRGH2@FRI(4!;FZ@_,
M2XYORSO\C%V6J,Y0)&E;.GONE^9*':@>=%U=R>>>\3ZREZ&,>>&K8(T5$#A4
M!7COT+K8<./&I`@1_8]>=U2:$(D;PN02<[3"\'A;/&+%?7)*K@1+3<8.\\!$
M/W2Y>2!S\%I6F^EP0.VL1!4@IDDSQO9:XFFBWPODJ00R3:*^N,6NJU/45(,B
M=R3Q@W2R4M4"FB999%8VP1`QB@*1RB$,EZ5B$.4A3)-E2&VF!L@MXQ`9:>"L
M,!4@IDES$VQ&]`1!#\13.S]98<HA3)-%#7#P9?$3]CD3Y>.F#LXTN89<+FM-
MK@+&-'ENF><Q.EDB#@-="!\[X*"-4RYL!4C2\P$8+!%?[\?S"=IF0>7:ZX[-
ML4,JW/F>Q[@,SS@/Y]$!+%67TG?5D>6XK)3VBQI!&R.\@V?M94_KN`KF4.2<
M8-OG^OS/B@DBP77"Y#FJ1:J$+`4X%`EA)>88"7R'@]\!\`-1;""(XB&6M0&H
M,5)O-W@39SU[U`F/6C89QQ6(QG1)JR$]D<S^=@-*=D8<KQ"I'-LEP(<B^8@S
M&V-'W'/F];V5R]88#U<ZUNN_8FX3D1SQS:`/4?8[PK$M&=](8U<*7P%^*-*K
M$3H">QW2"7+Q<)YT2V*AJZ&,D;5NRBO8_HA.PO41I^"#B!'F6BSUPI:MSL`3
MUY=)_>]"(Y5)UB`?F]#2LU9@O"/H0K5QG/6Z*T!,<[I''-9@B8>^%,3!]SY5
MN<1I>@&O@MEB&\B15\NUVA7P9UJ5[RI8R&WOE8B<0*FV[01Q(`2F(DRR[D.0
M!QA'ZEFETB0`#-NB4R7V!W2NBNS?:<-/Q'7Y)M,&2KA+,*0X.]KS+8;R/GUA
M);PG6DSC/=R0&NBS?8SG-@[*VDV3XP_$5=13Y!H6-*6&;I#N^-!%+]@$AD@.
M;D&@JE:U7":]',0T7>37Y[/Z)?S,5&E4CGPXCXPHG3M/WC=O;Q#"OB`.#ISB
M6P:#&.)#>$QPJ1;6L:*17.P:HR3E7?D?[3;"*FWCR,E5'R'2T<^4C7QN+R$&
M5A\B0G2=6M:;(>S70:X]KI#1T(2Y3JGZ@L;]3G:U`J@-=1R]%`F1B,Y6B3A=
M]81E>#0FM8XVQMEWY+<1N%V0F\E1Z6]E%>>HZR$/1&3U55_'5[%Z_W6%;0@_
MDPFKC)@*!'YT'%1PQNPM:*56&D..H$U5#M?G:[U`ZNHJZP+IJZ%,E"OT(Q/G
MV<9$?%-C^2N8CFZ340'E(HFWQ3>Q+R*?(;78J-Q5I<[;89DH=[1!'Z7E.?,F
M,X^3LHW\,CC3/,2>\ZSF/T?M<$^QO:3,90OEJO]!Y/*?A(/9^C,W$&:0.YFU
M#?)!]T!.W]MAF]8',#[G6<F2]TSC=XQ7P2E4B"9_PQ0'1\X"+G))F$;`IDE8
M:E>-#=!8R8`1Y#X2JDZ5A_N:=WXBIUP*8(JK6+<M$O(<GYA/V&*^*16C??QQ
M^'C?&9Q2"%G4-E4R<5#4:HIB:GSXL/.C%QK0.GT(OJ39%.%JSQ_H81,JZ%'Y
ME%A57U"ZRHZM$B!C]AW;A9_ZB$0B@`HCIG]CQ.^9STN#T5H\4S3_9MVAZVYL
MTQ\AXH%T2/%IS=@A_X(<)(AL=LBS%,VT=;69-GMSB;DV<?"&VII"!OE`S*&%
MF;^PK4;'"SN8SNC!M1/GXS8O;^K5/'D:JQ+,%&'KUD2EM'O&XQ"LR">K!#+,
M.VMFE$_X54Y?L/L<%IQJ:]1Y?%,47F/=4_R,LC:;V]>N@#%M3@_?I(BTQ?A7
M2O1.EEP/YU\E6I:\>E&/8)JDT4M^(>=)MF^12^:,4X+*W@QLA&2JQ/&\HYR,
MWS#/OZK1`-0TZ9[`#O4>I<)A4\P]0I'$F6_*ZI=5:R$-W)T.@L.1RF1GSH_E
M6K8X:K6GTV,)5K.GKHK:3#.Q,=9)/49AFNO1]0B,ALKI$LDOZ#F:`1WPS8;\
MD?%D#J8EGC%A<9VWH[4UN'4))39RLY-(<:MI2@VX)-5"Y)H-E:).#//E"*:!
MKRN8AX3PE1D.Y_>$"ZDBP'"LY&:-.G!C!E2--YE.00>QCZH*H6*^'G74^^X8
MJ9`X42RE.8HI+G7=K+)Q.F#ETJ=65KH\QJU&4SP\$E>=KZ0X5']B-=P&UQCK
MJ.N8"KE-%JLN28Z)-_.Y"&H>,;UYK53&A!Q072O2&=`O/G7@(A5:MD;<:VA=
M>[1KXQ4,:#!Z"18%/D.JU2P)PCS&&`NLBBE_3<[,16UF<7_';%^GF*C3IU(?
M%][43\N7(6L&O87K_>Z%R((7G6`,J+<Z@S)+ZD@<<7"`#M,DXPXXH"6'QW8B
M8N+)FO#KO:I"6)";VJECMJ=C;-^4?^6R4=DZPU_&BHZ&Y=Z4RS68YAP/5LJE
MNPMSIH[R>A,O,99K)/'Z^]843'$>:YR)4(<@(.%A)4SNY52<;38OWS-E$KGA
MS$O!C=$O+0L1+:?ZVTZ;<GB;N;F!!;PYX0,QC$?$OV$95HX,D];%KTK70Z;\
MF(]_R2&,_<;JM5CZA*5ZPUM_K%.?04OZE'6`9CEH\:[8<*X^\T`<@L)3W!M;
M3+W8WQ#>+"GU@,SZ"[H`2^/AW!K[0,9LM'<X1:_1I[_6/4Y4;!\4;YA#NSHT
M,:`WC'W['7/A"P`.OE9+]79%]G.'T926WZ%\GZ<<2%?GBUE!0+T90\I/T*_1
M>%Y8+B5G755UL5J3,B9U4;O=CPB/JA$G!$Z$P64`AJTAA;N`1N_WC9GGN[ZX
M)ZY75$"OI-DT*>)/8$[9'1'A(A5%(JF)/1EH-E@9WI[R@4QE$R"!Q4WB?9]=
MNO%MJ!U(U^7?FDJ+'[WFO'5OOML##JR#=UQB=R1S,,MK(EAM:6CM,0_$@H+:
M(GJ+9T![\SFXJQ#.B9Y4VQ[).H>58`<B[*V"<MW0DE7-)Z"B"@LEOG+=P!AV
M)',@G54N0D&=ID;`ANUF!$O%FZ[K_Q_+>G#@2.7[ANI[!JK`O.MB6_K('7$&
M#Y#K,5DL9?P5CB]8EZ(737KR?:@?2-?>NDB(36&;(=>21E_#"`OK@IU-V0W.
MAH9;H*8&Y,<7)U'E,I4(B>R:5NDDB'B?,4\-JB;&](8D#\2"@B,["8G5.4'.
MO*B(6*I@;0VD,8Y=0F;]9=K@PVKP[W]02P$"'@,4````"``<2*Q$!7&.85_7
M```S30<`$``8```````!````I($`````8G1X+3(P,30P,S,Q+GAM;%54!0`#
M!\9P4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!Q(K$2I682^JA$``/SN
M```4`!@```````$```"D@:G7``!B='@M,C`Q-#`S,S%?8V%L+GAM;%54!0`#
M!\9P4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!Q(K$0/.%V9=B$``#+7
M`0`4`!@```````$```"D@:'I``!B='@M,C`Q-#`S,S%?9&5F+GAM;%54!0`#
M!\9P4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!Q(K$2\HX!&"I4``)%K
M"``4`!@```````$```"D@64+`0!B='@M,C`Q-#`S,S%?;&%B+GAM;%54!0`#
M!\9P4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!Q(K$2##GM4I$```/H;
M!``4`!@```````$```"D@;V@`0!B='@M,C`Q-#`S,S%?<')E+GAM;%54!0`#
M!\9P4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!Q(K$0\*XBJ"A(``-2]
M```0`!@```````$```"D@:_A`0!B='@M,C`Q-#`S,S$N>'-D550%``,'QG!3
E=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(```/T`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventory (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory of finished products on-site</a></td>
        <td class="nump">$ 223,665<span></span></td>
        <td class="nump">$ 165,771<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Inventory held by third party on consignment</a></td>
        <td class="nump">$ 12,923<span></span></td>
        <td class="nump">$ 12,923<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.2.Q2 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">4. Intangible assets</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Intangible assets</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54,719,918</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54,719,918</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated amortization</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(9,879,831</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(8,511,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Intangible assets, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">44,840,087</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">46,208,085</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis.&#160; BioTime recognized $1,367,998 and $642,573 in amortization expense of intangible assets during the three months ended March 31, 2014 and 2013, respectively.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16265-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 44, 45, 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A
M;FEZ871I;VY?0F%S:7-?;V9?4')E<V5N=&$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y);G9E;G1O<GD\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%<75I<&UE;G0\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G1A;F=I8FQE7V%S<V5T<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)O>6%L='E?
M3V)L:6=A=&EO;E]A;F1?1&5F97)R93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D%C8V]U;G1S7U!A>6%B;&5?86YD7T%C8W)U961?
M3#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET
M>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%S<V5T
M7T-O;G1R:6)U=&EO;E]!9W)E96UE;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y5;F%U9&ET961?4')O7T9O<FUA7TEN=&5R:6U?
M1FD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S
M97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D]R9V%N:7IA=&EO;E]"87-I<U]O9E]0<F5S96YT83$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ871I;VY?
M0F%S:7-?;V9?4')E<V5N=&$R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^17%U:7!M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?87-S971S7U1A8FQE
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)O>6%L
M='E?3V)L:6=A=&EO;E]A;F1?1&5F97)R93$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R
M=65D7TPQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M07-S971?0V]N=')I8G5T:6]N7T%G<F5E;65N=%]4/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^56YA=61I=&5D7U!R;U]&;W)M85])
M;G1E<FEM7T9I,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D]R9V%N:7IA=&EO;E]"87-I<U]O9E]0<F5S96YT83,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E;G1O<GE?1&5T86EL
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6EP
M;65N=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^26YT86YG:6)L95]A<W-E='-?1&5T86EL<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)O>6%L='E?3V)L:6=A=&EO;E]A
M;F1?1&5F97)R93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R=65D7TPR/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:71Y7T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!<W-E=%]#
M;VYT<FEB=71I;VY?06=R965M96YT7T0\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y5;F%U9&ET961?4')O7T9O<FUA7TEN=&5R:6U?
M1FDR/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B
M<V5Q=65N=%]%=F5N='-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E
M=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R
M="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-
M"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T
M=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN
M9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM
M/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@
M8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO
M<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,X
M,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\S.#$Y,V$X-%\W,V$T7S0V8F%?8CDS-U\T
M9CED,C!B96%E,S@O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,4=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT
M:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%Y(#`Y+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I
M;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B="24]424U%($E.0SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#
M96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S`P,#`X-S8S-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG+2TQ,BTS,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!796QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE
M<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=.;SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R+#$T.2PS,CD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O
M8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=1,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"U1
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q+`T*"0DR,#$T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?
M-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E
M864S."]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/3T%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@
M0D%,04Y#12!32$5%5%,@*'5N875D:71E9"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0U524D5.5"!!4U-%5%,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C,W+#@S-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PT
M.34L-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S-BPU.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-S@L-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D92!A8V-O=6YT<R!A;F0@9W)A;G1S
M(')E8V5I=F%B;&4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#$X+#(W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDY."PS.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R
M(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4U-"PQ,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(W-RPT,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PR-#8L.#$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY-#DL
M.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPY-3DL,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPY.3<L-S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!L:6-E;G-E(&%N
M9"!C;VYS=6QT:6YG(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0Q."PY-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-#0L.#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#(X+#@R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.2PQ,CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QO;F<M=&5R
M;2!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#`V
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0T+#@T,"PP.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPR,#@L,#@U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@05-3
M1513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPY-#DL.#DU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3<L-S(Y+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($Q)04))3$E42453/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT-#,L,#8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,C(L-C(T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!L:6-E;G-E(&%N9"!S=6)S8W)I<'1I;VX@<F5V96YU92P@8W5R<F5N
M="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S<L
M-3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,U+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C(P+#8U-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.34W+#DP,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,3TY'+51%4DT@3$E!0DE,251)15,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT+"!N
M970@;V8@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR."PP-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-2PY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D('1A>"!L:6%B:6QI='DL
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,C@L-3(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M."PR-S<L-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!L;VYG('1E<FT@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-#0Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DU+#DX-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPY-C4L,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PU,#DL-3(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@
M8V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^15%52519/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M9F5R<F5D('-H87)E<RP@;F\@<&%R('9A;'5E+"!A=71H;W)I>F5D(#(L,#`P
M+#`P,"!S:&%R97,@87,@;V8@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R
M(#,Q+"`R,#$S.R`W,"PP,#`@86YD(&YI;"!I<W-U960@86YD(&]U='-T86YD
M:6YG(&%S(&]F($UA<F-H(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q
M,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S+"!N;R!P87(@=F%L=64L(&%U
M=&AO<FEZ960@,3(U+#`P,"PP,#`@<VAA<F5S(&%S(&]F($UA<F-H(#,Q+"`R
M,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,SL@-CDL-C$W+#,R.2!I<W-U960@
M86YD(#4Y+#`W,2PQ.3(@;W5T<W1A;F1I;F<@87,@;V8@36%R8V@@,S$L(#(P
M,30@86YD(#8W+#0Q,BPQ,SD@:7-S=65D(&%N9"`U-BPW,30L-#(T(&]U='-T
M86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,3$L.30S+#0R,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,RPT-38L-#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT<FEB
M=71E9"!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M,RPY-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,RPY-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@
M:6YC;VUE+RAL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-#0L,S0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8R+#@Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,34S+#@W-RPU-C$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30U+#<W."PU-#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4<F5A<W5R>2!S=&]C:R!A="!C;W-T.B`Q,"PU-#8L,3,W(&%N9"`Q,"PV
M.3<L-S$U('-H87)E<R!A="!-87)C:"`S,2P@,C`Q-"!A;F0@870@1&5C96UB
M97(@,S$L(#(P,3,L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#(L,S<R+#4T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,RPP,S,L.34W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-H
M87)E:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.2PR-#(L.30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30L.#`P+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N8V]N=')O;&QI;F<@:6YT
M97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#$R,2PR
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-RPT-C$L-34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-2PS-C0L,C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L,C8R+#,R,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1/5$%,($Q)
M04))3$E42453($%.1"!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-3<L.30Y+#@Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-3<L-S(Y+#<U,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?-S-A-%\T-F)A
M7V(Y,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S."]7;W)K
M<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"04%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@0D%,04Y#12!3
M2$5%5%,@*'5N875D:71E9"D@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D5154E463PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S:&%R97,L('!A<B!V86QU92`H
M:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S:&%R97,L(&%U=&AO<FEZ960@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-H87)E<RP@:7-S=65D("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<VAA<F5S(&]U='-T86YD:6YG("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<VAA<F5S+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<VAA<F5S+"!A=71H;W)I>F5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<VAA<F5S+"!I<W-U960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8Y+#8Q-RPS,CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPT,3(L,3,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<VAA<F5S+"!O=71S=&%N9&EN9R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3DL,#<Q+#$Y,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#<Q-"PT,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S
M=7)Y('-T;V-K("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PU-#8L,3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`L-CDW+#<Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?-S-A-%\T-F)A7V(Y
M,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S."]7;W)K<VAE
M971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q14%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/
M1B!/4$52051)3TY3($%.1"!#3TU04D5(14Y3259%($Q/4U,@*'5N875D:71E
M9"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4D5614Y515,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!F965S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y-"PU,#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,T.2PX,C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O
M>6%L=&EE<R!F<F]M('!R;V1U8W0@<V%L97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDW+#@X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P-RPU.3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(&EN8V]M93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<U+#8U.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+#,R-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L
M92!O9B!R97-E87)C:"!P<F]D=6-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3@L-3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C8L-S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8V+#8S-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q-"PT-S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M<W0@;V8@<V%L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S
M,2PY,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3@R+#<T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E<RP@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,S0L-S(Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,Q+#<R-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%6%!%3E-%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-#`U+#,Y,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#,Y-2PT.#@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,RPV-C<L,3<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#$V+#$T-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L,#<R+#4V
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#@Q,2PV,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#$S-RPX-#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PS-SDL.3`Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY/5$A%4B!)3D-/344O*$584$5.4T53*3H\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="`H97AP
M96YS92DO:6YC;VUE+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L,S@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDT,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!O;B!S86QE(&]F(&9I>&5D(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PU-S8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!I;F-O;64O*&5X<&5N<V4I+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<W+#<T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(X+#`U-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!I;F-O
M;64O*&5X<&5N<V4I+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8P+#<X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(X+#8S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,3U-3($)%1D]212!)3D-/344@5$%8($)%
M3D5&250\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#`W-RPP
M-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH."PT,#@L-30U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YC;VUE('1A>"!B96YE9FET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T.2PP,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL-S(X+#`S,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#0P."PU
M-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<R!A='1R:6)U=&%B;&4@=&\@;F]N8V]N=')O;&QI;F<@
M:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C(Y
M+#`Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8X.2PR.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.150@3$]34R!!5%1224)55$%"3$4@5$\@0DE/5$E-
M12P@24Y#+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PP.3DL
M,#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<L-S$Y+#(V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-L871I;VX@
M*&QO<W,I+V=A:6X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P
M-"PU.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30X+#0S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!L;W-S(&]N(&%V86EL86)L92UF
M;W(M<V%L92!S96-U<FET:65S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L-C4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU04D5(14Y3259%($Q/4U,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PR,#8L,C4T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPU-S`L
M.#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0D%324,@04Y$($1)3%54140@3$]34R!015(@0T]-34].(%-(05)%
M("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XQ-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y714E'2%1%1"!!5D5204=%($Y5
M34)%4B!/1B!#3TU-3TX@4TA!4D53($]55%-404Y$24Y'.B!"05-)0R!!3D0@
M1$E,551%1"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3@L,C4W+#0R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4Q+#$W-2PV-#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,X,3DS83@T7S<S831?-#9B85]B.3,W
M7S1F.60R,&)E864S.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M.#$Y,V$X-%\W,V$T7S0V8F%?8CDS-U\T9CED,C!B96%E,S@O5V]R:W-H965T
M<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%,TE"1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@
M0T%32"!&3$]74R`H=6YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3
M($923TT@3U!%4D%424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@871T<FEB=71A
M8FQE('1O($)I;U1I;64L($EN8RX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H."PP.3DL,#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H-RPW,3DL,C8S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU
M<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@871T<FEB=71A8FQE('1O
M($)I;U1I;64L($EN8RX@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97!R96-I871I;VX@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4V+#DT-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,RPS-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO
M;B!O9B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PS-C<L.3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C0R+#4W,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E
M9F5R<F5D(&-O;G-U;'1I;F<@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,38L,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,38L,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R
M960@;&EC96YS92!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-RPS-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-RPS-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!D969E<G)E9"!R96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#`T,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#(R,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M;W)T:7IA=&EO;B!O9B!D969E<G)E9"!L:6-E;G-E+"!R;WEA;'1Y(&%N
M9"!S=6)S8W)I<'1I;VX@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T,BPY.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@<W1O8VLM
M8F%S960@<')E<&%I9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,2PQ-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<R!A;&QO8V%B;&4@=&\@;F]N+6-O;G1R
M;VQL:6YG(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#8R.2PP,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C@Y+#(X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`Q+#4U-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y,2PY
M-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(&EN8V]M92!T87@@8F5N969I=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PS-#DL,#(V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@<V%L92!O
M<B!W<FET92UO9F8@;V8@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3<L-#`R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!R96-E:79A8FQE+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(T+#0T,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X,BPY,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R96-E:79A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#(L,3(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<Q+#@X-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-RPX
M.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPY.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-S4L,C(T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(T,RPW.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(W-BPR
M,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3`Q+#,Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R(&QO;F<@=&5R;2!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@U+#<Q-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@P-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PS-3<L,C<Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L,#(Q+#8X,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D535$E.1R!!0U1)5DE42453
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C,Q+#DR,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T.38L,3(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5C=7)I='D@9&5P;W-I="!P
M86ED+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y.2PV
M.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-30L-#(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-3(W+#8Q."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-3`L-34Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M05-(($9,3U=3($923TT@1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@
M;W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1I<F5C=&]R(&]P=&EO;G,@97AE<F-I<V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@L,3@R+#4U.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#8Y.2PS-#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E97,@<&%I
M9"!O;B!S86QE(&]F(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(Q,BPP-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S$Y+#8R-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M<V%L92!O9B!T<F5A<W5R>2!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Y.2PT-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#8P,BPY,C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L
M92!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!C;VUM
M;VX@<VAA<F5S(&]F('-U8G-I9&EA<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S`L-3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN
M86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#$R."PT.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPQ,3,L,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@
M<F%T92!C:&%N9V5S(&]N(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P,2PR-#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT-C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M150@0TA!3D=%($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,Z/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T,BPS-38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#4T-BPS-C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!!3D0@0T%32"!%455)5D%,14Y44SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!="!B96=I;FYI
M;F<@;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PT.34L-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PS-#DL.38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!="!E;F0@;V8@=&AE('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPV,S<L.#,T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX.38L
M,S,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-54%!,14U%3E1!3"!$25-#3$]355)%($]&($-!4T@@
M1DQ/5R!)3D9/4DU!5$E/3CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9'5R:6YG('1H92!P97)I;V0@
M9F]R(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#0W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%,(%-#2$5$54Q%($]&($Y/3BU#
M05-(($9)3D%.0TE.1R!!3D0@24Y615-424Y'($%#5$E6251)15,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<R!I<W-U960@9F]R(&-O;G-U;'1I;F<@<V5R=FEC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RPR.#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R
M97,@:7-S=65D(&9O<B!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(T,BPW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E
M864S.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.#$Y,V$X-%\W
M,V$T7S0V8F%?8CDS-U\T9CED,C!B96%E,S@O5V]R:W-H965T<R]3:&5E=#`V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G
M86YI>F%T:6]N+"!"87-I<R!O9B!0<F5S96YT871I;VXL(&%N9"!3=6UM87)Y
M(&]F(%-E;&5C="!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W)G86YI>F%T:6]N+"!"87-I<R!O9B!0<F5S96YT871I;VXL(&%N9"!3=6UM
M87)Y(&]F(%-E;&5C="!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]R9V%N:7IA=&EO;BP@0F%S:7,@;V8@4')E<V5N=&%T:6]N
M+"!A;F0@4W5M;6%R>2!O9B!396QE8W0@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/C$N($]R9V%N:7IA=&EO;BP@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N+"!A;F0@4W5M;6%R>2!O9B!396QE8W0@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY'96YE<F%L
M/"]F;VYT/B`F(S@R,3$[($)I;U1I;64@:7,@82!B:6]T96-H;F]L;V=Y(&-O
M;7!A;GD@96YG86=E9"!I;B!T=V\@87)E87,@;V8@8FEO;65D:6-A;"!R97-E
M87)C:"!A;F0@<')O9'5C="!D979E;&]P;65N="X@0FEO5&EM92=S('!R:6UA
M<GD@9F]C=7,@:7,@:6X@=&AE(&9I96QD(&]F(')E9V5N97)A=&EV92!M961I
M8VEN93L@<W!E8VEF:6-A;&QY(&AU;6%N(&5M8G)Y;VYI8R!S=&5M("@F(S@R
M,C`[:$53)B,X,C(Q.RD@8V5L;"!A;F0@:6YD=6-E9"!P;'5R:7!O=&5N="!S
M=&5M("@F(S@R,C`[:5!3)B,X,C(Q.RD@8V5L;"!T96-H;F]L;V=Y+B8C,38P
M.R!296=E;F5R871I=F4@;65D:6-I;F4@<F5F97)S('1O('1H97)A<&EE<R!B
M87-E9"!O;B!S=&5M(&-E;&P@=&5C:&YO;&]G>2!T:&%T(&%R92!D97-I9VYE
M9"!T;R!R96)U:6QD(&-E;&P@86YD('1I<W-U92!F=6YC=&EO;B!L;W-T(&1U
M92!T;R!D96=E;F5R871I=F4@9&ES96%S92!O<B!I;FIU<GDN)B,Q-C`[(&A%
M4R!A;F0@:5!3(&-E;&QS('!R;W9I9&4@82!M96%N<R!O9B!M86YU9F%C='5R
M:6YG(&5V97)Y(&-E;&P@='EP92!I;B!T:&4@:'5M86X@8F]D>2!A;F0@=&AE
M<F5F;W)E('-H;W<@8V]N<VED97)A8FQE('!R;VUI<V4@9F]R('1H92!D979E
M;&]P;65N="!O9B!A(&YU;6)E<B!O9B!N97<@=&AE<F%P975T:6,@<')O9'5C
M=',N)B,Q-C`[($)I;U1I;64@86YD(&ET<R!S=6)S:61I87)I97,@<&QA;B!T
M;R!D979E;&]P('-T96T@8V5L;"!P<F]D=6-T<R!F;W(@<F5S96%R8V@@86YD
M('1H97)A<&5U=&EC('5S92XF(S$V,#L@07-T97)I87,@0FEO=&AE<F%P975T
M:6-S+"!);F,N("@F(S@R,C`[07-T97)I87,F(S@R,C$[*2!A8W%U:7)E9"!T
M:&4@<W1E;2!C96QL(&%S<V5T<R!O9B!'97)O;B!#;W)P;W)A=&EO;B`H)B,X
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M=7)E(&%N9"!M>6]C87)D:6%L(&EN9F%R8W1I;VXN)B,Q-C`[($]N8V]#>71E
M($-O<G!O<F%T:6]N("@F(S@R,C`[3VYC;T-Y=&4F(S@R,C$[*2!I<R!D979E
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M;W9E<BUS96%S(&UA<FME=',N)B,Q-C`[($]R=&AO0WET92!#;W)P;W)A=&EO
M;B`H)B,X,C(P.T]R=&AO0WET928C.#(R,3LI(&ES(&1E=F5L;W!I;F<@=&AE
M<F%P:65S('1O('1R96%T(&]R=&AO<&5D:6,@9&ES;W)D97)S+"!D:7-E87-E
M<R!A;F0@:6YJ=7)I97,N)B,Q-C`[(%)E0WET92!4:&5R87!E=71I8W,L($EN
M8RX@*"8C.#(R,#M294-Y=&4@5&AE<F%P975T:6-S)B,X,C(Q.RD@:7,@9&5V
M96QO<&EN9R!T:&5R87!I97,@=&\@=')E870@82!V87)I971Y(&]F(&-A<F1I
M;W9A<V-U;&%R(&%N9"!R96QA=&5D(&ES8VAE;6EC(&1I<V]R9&5R<RP@87,@
M=V5L;"!A<R!P<F]D=6-T<R!F;W(@<F5S96%R8V@@=7-I;F<@8V5L;"!R97!R
M;V=R86UM:6YG('1E8VAN;VQO9WDN)B,Q-C`[($-E;&P@0W5R92!.975R;W-C
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M8VQE<F]S:7,N)B,Q-C`[($QI9F5-87`@4V-I96YC97,L($EN8RX@*"8C.#(R
M,#M,:69E36%P(%-C:65N8V5S)B,X,C(Q.RD@;6%R:V5T<RP@<V5L;',@86YD
M(&1I<W1R:6)U=&5S(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI
M8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^1V5N94-A<F1S/"]F;VYT/CQS=7`@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ93H@<VUA;&QE<CL@
M=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[/"]S=7`^+"!T:&4@
M;&5A9&EN9R!H=6UA;B!G96YE(&1A=&%B87-E(&%N9"!A;B!I;G1E9W)A=&5D
M(&1A=&%B87-E('-U:71E('1H870@:6YC;'5D97,@/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
M4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY'96YE
M0V%R9',\+V9O;G0^/'-U<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3L@9F]N
M="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X="UT;W`[)SXF
M(S$W-#L\+W-U<#XL('1H92`\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I
M=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DQI9F5-87`@1&ES8V]V97)Y
M/"]F;VYT/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ
M93H@<VUA;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[
M/"]S=7`^(&1A=&%B87-E(&]F(&5M8G)Y;VYI8R!D979E;&]P;65N="P@<W1E
M;2!C96QL(')E<V5A<F-H(&%N9"!R96=E;F5R871I=F4@;65D:6-I;F4L(&%N
M9"!-86QA0V%R9',L('1H92!H=6UA;B!D:7-E87-E(&1A=&%B87-E+CPO9&EV
M/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
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M('=I=&AO=70@<F5G=6QA=&]R>2`H1D1!*2!A<'!R;W9A;"P@86YD(&%R92!T
M:&5R969O<F4@<F5L871I=F5L>2!N96%R+71E<FT@8G5S:6YE<W,@;W!P;W)T
M=6YI=&EE<R!W:&5N(&-O;7!A<F5D('1O('1H97)A<&5U=&EC('!R;V1U8W1S
M+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY(97AT96YD/"]F;VYT/CQS=7`@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ93H@<VUA;&QE<CL@=F5R
M=&EC86PM86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[/"]S=7`^+"!F<F]M('1H
M92!S86QE(&]F('!R;V1U8W1S(&9O<B!R97-E87)C:"P@86YD(&9R;VT@<F5S
M96%R8V@@9W)A;G1S+B8C,38P.SPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P
M=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE('5N875D:71E9"!C;VYD96YS
M960@8V]N<V]L:61A=&5D(&EN=&5R:6T@8F%L86YC92!S:&5E="!A<R!O9B!-
M87)C:"`S,2P@,C`Q-"P@=&AE('5N875D:71E9"!C;VYD96YS960@8V]N<V]L
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M=')U8W1I;VYS(&9R;VT@1F]R;2`Q,"U1(&%N9"!296=U;&%T:6]N(%,M6"XF
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M)B,Q-C`[(%1H928C,38P.V-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S
M(&]F($1E8V5M8F5R(#,Q+"`R,#$S(&ES(&1E<FEV960@9G)O;2!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&%N;G5A;"!A=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&%S(&]F('1H870@9&%T92XF(S$V,#L@5&AE(')E<W5L=',@;V8@;W!E
M<F%T:6]N<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q-"!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(&]P
M97)A=&EN9R!R97-U;'1S(&%N=&EC:7!A=&5D(&9O<B!T:&4@9G5L;"!Y96%R
M(&]F(#(P,30N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A
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M9V4@0V]M;6ES<VEO;B`H)B,X,C(P.U-%0R8C.#(R,3LI(&5X8V5P="!F;W(@
M=&AE)B,Q-C`[8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@87,@;V8@1&5C
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M+"`R,#$S+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M4')I;F-I<&QE<R!O9B!C;VYS;VQI9&%T:6]N/"]F;VYT/B`F(S@R,3$[($)I
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M+71O<#H@,W!T.R!M87)G:6XM8F]T=&]M.B`S<'0[)SX\8G(@+SX\+V1I=CX\
M=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D
M97(M;&5F=#H@;65D:75M(&YO;F4[('=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93L@8F]R9&5R+7)I9VAT
M.B!M961I=6T@;F]N93LG/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O
M<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO
M;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^4W5B<VED:6%R>3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG
M:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D9I96QD(&]F($)U<VEN97-S/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P+C$R
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D)I;U1I;64@/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SY/=VYE<G-H:7`\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@.2XY)3L@=F5R=&EC86PM
M86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O
M<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
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M(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`S,"4[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED
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M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N
M93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^4F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C
M:6%L:7IA=&EO;B!O9B!H=6UA;B!T:&5R87!E=71I8R!P<F]D=6-T<R!F<F]M
M('-T96T@8V5L;',@<&]T96YT:6%L;'D@:6X@=&AE(&9I96QD<R!O9B!N975R
M;VQO9WDL(&]N8V]L;V=Y+"!O<G1H;W!E9&EC<RP@86YD(&-A<F1I;VQO9WD\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@
M;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXW,2XV)3PO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY54T$\+V1I=CX\
M+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I
M=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^15,@0V5L;"!);G1E
M<FYA=&EO;F%L(%!T92!,=&0\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^4W1E;2!C96QL('!R;V1U8W1S(&9O<B!R97-E87)C:"P@:6YC;'5D
M:6YG(&-L:6YI8V%L(&=R861E(&-E;&P@;&EN97,\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/G!R
M;V1U8V5D('5N9&5R(&-'35`\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXQ,#`E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/E-I;F=A<&]R93PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M('=I9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z
M(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY/;F-O0WET92!#;W)P;W)A=&EO;CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M
M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O
M<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE
M9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY#86YC97(@9&EA9VYO<W1I8W,\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-2XS)3PO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D
M97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B
M;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C
M,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY54T$\+V1I=CX\+W1D/CPO
M='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N
M93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD
M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3W)T:&]#>71E($-O<G!O<F%T
M:6]N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D
M:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]R=&AO<&5D
M:6,@9&ES96%S97,L(&EN8VQU9&EN9R!C:')O;FEC(&)A8VL@<&%I;B!A;F0@
M;W-T96]A<G1H<FET:7,\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,3`N
M,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXQ,#`E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`S
M,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
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M969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D
M:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/D%G92UR96QA=&5D(&UA8W5L87(@9&5G96YE
M<F%T:6]N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DUU;'1I
M<&QE('-C;&5R;W-I<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY087)K:6YS;VXF(S@R,3<[<R!D:7-E87-E/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M
M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^-C(N-24\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@
M<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^27-R865L/"]D:78^/"]T9#X\+W1R/CQT<CX\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E
M<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D
M:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/E)E0WET92!4:&5R87!E=71I8W,L($EN8RX\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@
M;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5F%S8W5L87(@9&ES
M;W)D97)S+"!I;F-L=61I;F<@8V%R9&EO=F%S8W5L87(M<F5L871E9"!D:7-E
M87-E<RP@:7-C:&5M:6,@8V]N9&ET:6]N<RP@=F%S8W5L87(@:6YJ=7)I97,\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4W1E;2!C96QL+61E
M<FEV960@96YD;W1H96QI86P@86YD(&-A<F1I;W9A<V-U;&%R(')E;&%T960@
M<')O9V5N:71O<B!C96QL<R!F;W(@<F5S96%R8V@L(&1R=6<@=&5S=&EN9RP@
M86YD('1H97)A<&5U=&EC<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q
M,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/CDT+C@E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY":6]4:6UE($%S:6$L($QI;6ET960\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z
M(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@
M;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^4W1E;2!C96QL('!R;V1U8W1S(&9O<B!R97-E87)C
M:#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU
M;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C@Q)3PO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY(;VYG($MO;F<\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3&EF94UA
M<"!38VEE;F-E<RP@26YC+CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`T
M.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY'96YE=&EC+"!D:7-E87-E+"!A;F0@<W1E;2!C96QL(&1A=&%B87-E
M<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU
M;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C<S+C(E/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO
M;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M
M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E5303PO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`S,"4[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
M4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY,:69E
M36%P(%-C:65N8V5S+"!,=&0N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@
M=VED=&@Z(#0Y+CDX)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O
M<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO
M;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/E-T96T@8V5L;"!D871A8F%S93PO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG
M:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q*3PO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@=&]P
M.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT
M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY)<W)A96P\+V1I=CX\
M+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M3&EF94UA<"!3;VQU=&EO;G,L($EN8RX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE9G0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
M:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M<FEG
M:'0Z(&UE9&EU;2!N;VYE.R<^36]B:6QE(&AE86QT:"!S;V9T=V%R93PO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$P
M+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+7)I9VAT.B!M961I
M=6T@;F]N93LG/B@Q*3PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E
M<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=VED=&@Z(#DN.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O
M<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[)SY54T$\+W1D/CPO='(^
M/"]T86)L93X\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M,C=P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#(W<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T5&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^
M/'1D('-T>6QE/3-$)W=I9'1H.B`R-W!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&%L:6=N.B!R:6=H=#LG/B@Q*3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B!A=71O.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SY,:69E
M36%P(%-C:65N8V5S+"!,=&0N(&%N9"!,:69E36%P(%-O;'5T:6]N<RP@26YC
M+B!A<F4@=VAO;&QY+6]W;F5D('-U8G-I9&EA<FEE<R!O9B!,:69E36%P(%-C
M:65N8V5S+"!);F,N/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=CX\8G(@
M+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
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M9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H92!5+E,N("@F(S@R,C`[1T%!4"8C
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M<"!38VEE;F-E<RP@86YD($QI9F5-87`@4V-I96YC97,L($QT9"X@87,@0FEO
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^0V5R=&%I;B!S
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M:61A=&5S.R!T:&5I<B!A8FEL:71Y('1O(&1E=F5L;W`@;F5W('-T96T@8V5L
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M:7(@=&AE<F%P975T:6,@<')O9'5C=',@86YD(&UE9&EC86P@9&5V:6-E<R`H
M86YD(')E;&%T960@=')E871M96YT*2!F<F]M(&=O=F5R;FUE;G0@:&5A;'1H
M(&%D;6EN:7-T<F%T:6]N(&%U=&AO<FET:65S+"!P<FEV871E(&AE86QT:"!C
M;W9E<F%G92!I;G-U<F5R<RP@86YD(&]T:&5R(&]R9V%N:7IA=&EO;G,N/"]D
M:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/E5S92!O9B!E<W1I;6%T97,\+V9O;G0^("8C.#(Q,3L@
M5&AE('!R97!A<F%T:6]N(&]F(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN
M86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W:71H($=!05`@<F5Q
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M;G-E<R!D=7)I;F<@=&AE(')E<&]R=&EN9R!P97)I;V0N)B,Q-C`[($%C='5A
M;"!R97-U;'1S(&-O=6QD(&1I9F9E<B!F<F]M('1H;W-E(&5S=&EM871E<RX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S
M-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E)E=F5N=64@
M<F5C;V=N:71I;VX\+V9O;G0^("8C.#(Q,3L@0FEO5&EM92!C;VUP;&EE<R!W
M:71H(%-%0R!3=&%F9B!!8V-O=6YT:6YG($)U;&QE=&EN(&=U:61A;F-E(&]N
M(')E=F5N=64@<F5C;V=N:71I;VXN)B,Q-C`[(%)O>6%L='D@<F5V96YU97,@
M8V]N<VES="!O9B!P<F]D=6-T(')O>6%L='D@<&%Y;65N=',N)B,Q-C`[($QI
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M)B,Q-C`[(%)O>6%L=&EE<R!C;VYS:7-T('!R:6UA<FEL>2!O9B!R;WEA;'1I
M97,@96%R;F5D(&]N('-A;&5S(&]F(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^2&5X=&5N9#PO9F]N
M=#X\<W5P('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q.R!F;VYT+7-I>F4Z('-M
M86QL97([('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<#LG/B8C,3<T.SPO<W5P
M/B!A;F0@87)E(')E8V]G;FEZ960@87,@<F5V96YU92!I;B!T:&4@<75A<G1E
M<B!I;B!W:&EC:"!T:&4@<F]Y86QT>2!R97!O<G1S(&%R92!R96-E:79E9"!F
M<F]M('1H92!L:6-E;G-E92P@<F%T:&5R('1H86X@=&AE('%U87)T97(@:6X@
M=VAI8V@@=&AE('-A;&5S('1O;VL@<&QA8V4N)B,Q-C`[(%=H96X@0FEO5&EM
M92!I<R!E;G1I=&QE9"!T;R!R96-E:79E('5P+69R;VYT(&YO;G)E9G5N9&%B
M;&4@;&EC96YS:6YG(&]R('-I;6EL87(@9F5E<R!P=7)S=6%N="!T;R!A9W)E
M96UE;G1S('5N9&5R('=H:6-H($)I;U1I;64@:&%S(&YO(&-O;G1I;G5I;F<@
M<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,L('1H92!F965S(&%R92!R96-O9VYI
M>F5D(&%S(')E=F5N=65S('=H96X@8V]L;&5C=&EO;B!I<R!R96%S;VYA8FQY
M(&%S<W5R960N)B,Q-C`[(%=H96X@0FEO5&EM92!R96-E:79E<R!U<"UF<F]N
M="!N;VYR969U;F1A8FQE(&QI8V5N<VEN9R!O<B!S:6UI;&%R(&9E97,@<'5R
M<W5A;G0@=&\@86=R965M96YT<R!U;F1E<B!W:&EC:"!":6]4:6UE(&1O97,@
M:&%V92!C;VYT:6YU:6YG('!E<F9O<FUA;F-E(&]B;&EG871I;VYS+"!T:&4@
M9F5E<R!A<F4@9&5F97)R960@86YD(&%M;W)T:7IE9"!R871A8FQY(&]V97(@
M=&AE('!E<F9O<FUA;F-E('!E<FEO9"XF(S$V,#L@268@=&AE('!E<F9O<FUA
M;F-E('!E<FEO9"!C86YN;W0@8F4@<F5A<V]N86)L>2!E<W1I;6%T960L($)I
M;U1I;64@86UO<G1I>F5S(&YO;G)E9G5N9&%B;&4@9F5E<R!O=F5R('1H92!L
M:69E(&]F('1H92!C;VYT<F%C="!U;G1I;"!S=6-H('1I;64@=&AA="!T:&4@
M<&5R9F]R;6%N8V4@<&5R:6]D(&-A;B!B92!M;W)E(')E87-O;F%B;'D@97-T
M:6UA=&5D+B8C,38P.R!-:6QE<W1O;F4@<&%Y;65N=',L(&EF(&%N>2P@<F5L
M871E9"!T;R!S8VEE;G1I9FEC(&]R('1E8VAN:6-A;"!A8VAI979E;65N=',@
M87)E(')E8V]G;FEZ960@:6X@:6YC;VUE('=H96X@=&AE(&UI;&5S=&]N92!I
M<R!A8V-O;7!L:7-H960@:68@*&$I('-U8G-T86YT:79E(&5F9F]R="!W87,@
M<F5Q=6ER960@=&\@86-H:65V92!T:&4@;6EL97-T;VYE+"`H8BD@=&AE(&%M
M;W5N="!O9B!T:&4@;6EL97-T;VYE('!A>6UE;G0@87!P96%R<R!R96%S;VYA
M8FQY(&-O;6UE;G-U<F%T92!W:71H('1H92!E9F9O<G0@97AP96YD960L(&%N
M9"`H8RD@8V]L;&5C=&EO;B!O9B!T:&4@<&%Y;65N="!I<R!R96%S;VYA8FQY
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M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO9F]N=#X@
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M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY!8V-O=6YT<R!R96-E:79A8FQE(&%N9"!A
M;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B`F(S@R,3$[)B,Q-C`[(%1O
M=&%L('1R861E(')E8V5I=F%B;&5S(&%M;W5N=&5D('1O(&%P<')O>&EM871E
M;'D@)#8P,"PT,#`@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXD-3<U+#DP,"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^86YD(&=R86YT<R!R96-E:79A8FQE(&%M
M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)#,S-"PW,#`@86YD("0\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-3,Y+#,P,#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
M4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX@87,@
M;V8@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S+"!R97-P
M96-T:79E;'DN)B,Q-C`[(%-O;64@;V8@=&AE<V4@86UO=6YT<R!A<F4@9&5E
M;65D('5N8V]L;&5C=&EB;&4[(&%S('-U8V@@0FEO5&EM92!R96-O9VYI>F5D
M(&%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N=',@;V8@87!P<F]X:6UA
M=&5L>2`D,3$V+#@P,"!A<R!O9B!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB
M97(@,S$L(#(P,3,N)B,Q-C`[($)I;U1I;64@979A;'5A=&5S('1H92!C;VQL
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M9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^0V]N8V5N=')A=&EO;G,@
M;V8@8W)E9&ET(')I<VL\+V9O;G0^("8C.#(Q,3L@1FEN86YC:6%L(&EN<W1R
M=6UE;G1S('1H870@<&]T96YT:6%L;'D@<W5B:F5C="!":6]4:6UE('1O('-I
M9VYI9FEC86YT(&-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O;G-I
M<W0@<')I;6%R:6QY(&]F(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',N)B,Q
M-C`[($)I;U1I;64@;&EM:71S('1H92!A;6]U;G0@;V8@8W)E9&ET(&5X<&]S
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M9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY);G9E;G1O<GD@)B,X
M,C$Q.SPO9F]N=#X@26YV96YT;W)I97,@87)E('-T871E9"!A="!T:&4@;&]W
M97(@;V8@8V]S="!O<B!M87)K970N)B,Q-C`[($-O<W0L('=H:6-H(&EN8VQU
M9&5S(&%M;W5N=',@<F5L871E9"!T;R!M871E<FEA;',L(&QA8F]R+"!A;F0@
M;W9E<FAE860L(&ES(&1E=&5R;6EN960@:6X@82!M86YN97(@=VAI8V@@87!P
M<F]X:6UA=&5S('1H92!F:7)S="UI;BP@9FER<W0M;W5T("@F(S@R,C`[1DE&
M3R8C.#(R,3LI(&UE=&AO9"X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^17%U:7!M96YT/"]F
M;VYT/B`F(S@R,3$[($5Q=6EP;65N="!I<R!S=&%T960@870@8V]S="XF(S$V
M,#L@17%U:7!M96YT(&ES(&)E:6YG(&1E<')E8VEA=&5D('5S:6YG('1H92!S
M=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R(&$@<&5R:6]D(&]F(#,V('1O(#$R
M,"!M;VYT:',N)B,Q-C`[(%-E92!.;W1E(#,N/"]D:78^/&1I=CX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DEN
M=&%N9VEB;&4@87-S971S/"]F;VYT/B`F(S@R,3$[($EN=&%N9VEB;&4@87-S
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M87,@86X@87-S970N)B,Q-C`[($EF(&%N9"!W:&5N(&1E=F5L;W!M96YT(&ES
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M($%30R`X,#4M-3`L('-U8V@@:6YT86YG:6)L92!A<W-E=',@<F5L871E9"!T
M;R!I;BUP<F]C97-S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="`H)B,X,C(P
M.TE04B9A;7`[1"8C.#(R,3LI(&%R92!E>'!E;G-E9"!U<&]N(&%C<75I<VET
M:6]N+B!3964@3F]T92`X+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY4<F5A<W5R>2!S=&]C
M:R`F(S@R,3$[/"]F;VYT/B!":6]4:6UE(&%C8V]U;G1S(&9O<B!":6]4:6UE
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/E=A<G)A;G1S('1O('!U<F-H87-E(&-O
M;6UO;B!S=&]C:R`\+V9O;G0^)B,X,C$Q.R!":6]4:6UE(&=E;F5R86QL>2!A
M8V-O=6YT<R!F;W(@=V%R<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET
M:"!E<75I='D@9FEN86YC:6YG<R!A<R!A(&-O;7!O;F5N="!O9B!E<75I='DN
M)B,Q-C`[($YO;F4@;V8@=&AE('=A<G)A;G1S(&ES<W5E9"!B>2!":6]4:6UE
M(&%S(&]F($UA<F-H(#,Q+"`R,#$T(&EN8VQU9&4@82!C;VYD:71I;VYA;"!O
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M<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^0V]S="!O9B!S86QE<SPO9F]N=#X@)B,X,C$Q
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M('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
M4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/E!A=&5N="!C;W-T<R`F(S@R,3$[/"]F;VYT/B!#;W-T<R!A<W-O
M8VEA=&5D('=I=&@@;V)T86EN:6YG('!A=&5N=',@;VX@<')O9'5C=',@;W(@
M=&5C:&YO;&]G>2!D979E;&]P960@87)E(&5X<&5N<V5D(&%S(&=E;F5R86P@
M86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S('=H96X@:6YC=7)R960N)B,Q
M-C`[(%1H:7,@86-C;W5N=&EN9R!I<R!I;B!C;VUP;&EA;F-E('=I=&@@9W5I
M9&%N8V4@<')O;75L9V%T960@8GD@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG
M(%-T86YD87)D<R!";V%R9"`H=&AE("8C.#(R,#M&05-")B,X,C(Q.RD@<F5G
M87)D:6YG(&=O;V1W:6QL(&%N9"!O=&AE<B!I;G1A;F=I8FQE(&%S<V5T<RX\
M+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^4F5C;&%S<VEF:6-A=&EO;CPO9F]N=#X@)B,X,C$Q
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M9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/B`F(S@R
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M(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^1F]R96EG;B!C=7)R
M96YC>2!T<F%N<VQA=&EO;B!G86EN(&%N9"!#;VUP<F5H96YS:79E(&QO<W,@
M)B,X,C$Q.SPO9F]N=#X@26X@8V]U;G1R:65S(&EN('=H:6-H($)I;U1I;64@
M;W!E<F%T97,L(&%N9"!T:&4@9G5N8W1I;VYA;"!C=7)R96YC>2!I<R!O=&AE
M<B!T:&%N('1H92!5+E,N(&1O;&QA<BP@87-S971S(&%N9"!L:6%B:6QI=&EE
M<R!A<F4@=')A;G-L871E9"!U<VEN9R!P=6)L:7-H960@97AC:&%N9V4@<F%T
M97,@:6X@969F96-T(&%T('1H92!C;VYD96YS960@8V]N<V]L:61A=&5D(&)A
M;&%N8V4@<VAE970@9&%T92XF(S$V,#L@4F5V96YU97,@86YD(&5X<&5N<V5S
M(&%N9"!C87-H(&9L;W=S(&%R92!T<F%N<VQA=&5D('5S:6YG(&%N(&%P<')O
M>&EM871E('=E:6=H=&5D(&%V97)A9V4@97AC:&%N9V4@<F%T92!F;W(@=&AE
M('!E<FEO9"XF(S$V,#L@4F5S=6QT:6YG('1R86YS;&%T:6]N(&%D:G5S=&UE
M;G1S(&%R92!R96-O<F1E9"!A<R!A(&-O;7!O;F5N="!O9B!A8V-U;75L871E
M9"!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92!O;B!T:&4@8V]N9&5N<V5D
M(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T+B8C,38P.R!&;W(@=&AE('1H
M<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,RP@8V]M
M<')E:&5N<VEV92!L;W-S(&EN8VQU9&5S(&9O<F5I9VX@8W5R<F5N8WD@=')A
M;G-L871I;VX@;&]S<R!O9B`D,3`T+#4Y,"!A;F0@9V%I;B!O9B`D,30X+#0S
M-RP@<F5S<&5C=&EV96QY(&%N9"!U;G)E86QI>F5D(&QO<W,@;V8@)#(L-C4P
M(&]N($=E<F]N(&-O;6UO;B!S:&%R97,@:&5L9"!B>2!!<W1E<FEA<R!A<R!O
M9B!-87)C:"`S,2P@,C`Q-"X@5&AE('5N<F5A;&EZ960@9V%I;B]L;W-S(&9R
M;VT@=&AE($=E<F]N('-H87)E<R!I<R!A(&-O;7!O;F5N="!O9B!C;VUP<F5H
M96YS:79E(&QO<W,@8F5C875S92!T:&5S92!S:&%R97,@87)E(&-O;G-I9&5R
M960@82!M87)K971A8FQE(&5Q=6ET>2!S96-U<FET>2!T:&%T)B,Q-C`[87)E
M(&%V86EL86)L92!F;W(@<V%L92X@1F]R('1H92!T:')E92!M;VYT:',@96YD
M960@36%R8V@@,S$L(#(P,30@86YD(#(P,3,L(&9O<F5I9VX@8W5R<F5N8WD@
M=')A;G-A8W1I;VX@;&]S<RP@:6YC;'5D960@:6X@;W1H97(@:6YC;VUE+RAE
M>'!E;G-E*2PF(S$V,#MA;6]U;G1E9"!T;R`D,3`L,C$R(&%N9"`D,C$L.3<W
M+"!R97-P96-T:79E;'DN/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O
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M>'!E8W1E9"!T;R!B92!T86ME;B!I;B!A('1A>"!R971U<FXN)B,Q-C`[($9O
M<B!T:&]S92!B96YE9FET<R!T;R!B92!R96-O9VYI>F5D+"!A('1A>"!P;W-I
M=&EO;B!M=7-T(&)E(&UO<F4M;&EK96QY+71H86XM;F]T('-U<W1A:6YA8FQE
M('5P;VX@97AA;6EN871I;VX@8GD@=&%X:6YG(&%U=&AO<FET:65S+B8C,38P
M.R!&;W(@,C`Q,RP@07-T97)I87,@=VEL;"!F:6QE('-E<&%R871E(%4N4RX@
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M<R!A<R!O9B!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,R!R97-P96-T:79E;'DN
M)B,Q-C`[($)I;U1I;64@9FEL97,@:71S(&EN8V]M92!T87@@<F5T=7)N<R!I
M;B!T:&4@52Y3+B!F961E<F%L(&%N9"!V87)I;W5S('-T871E(&%N9"!L;V-A
M;"!A;F0@9F]R96EG;B!J=7)I<V1I8W1I;VYS+B8C,38P.R!'96YE<F%L;'DL
M($)I;U1I;64@:7,@;F\@;&]N9V5R('-U8FIE8W0@=&\@:6YC;VUE('1A>"!E
M>&%M:6YA=&EO;G,@8GD@;6%J;W(@=&%X:6YG(&%U=&AO<FET:65S(&9O<B!Y
M96%R<R!B969O<F4@,C`Q,"XF(S$V,#L@06YY('!O=&5N=&EA;"!E>&%M:6YA
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M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^02!D969E<G)E
M9"!I;F-O;64@=&%X(&)E;F5F:70@;V8@87!P<F]X:6UA=&5L>2`D,2PS-#DL
M,#`P('=A<R!R96-O<F1E9"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"P@;V8@=VAI8V@@87!P<F]X:6UA=&5L>2`D,2PQ-3$L
M,#`P('=A<R!R96QA=&5D('1O(&9E9&5R86P@86YD("0Q.3@L,#`P('=A<R!R
M96QA=&5D('1O('-T871E('1A>&5S+B8C,38P.R!!(&1E9F5R<F5D(&EN8V]M
M92!T87@@8F5N969I="!O9B!A<'!R;WAI;6%T96QY("0S+#(X,"PP,#`@=V%S
M(')E8V]R9&5D(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,RP@;V8@=VAI8V@@87!P<F]X:6UA=&5L>2`D,BPX,#`L,#`P('=A<R!R96QA
M=&5D('1O(&9E9&5R86P@86YD("0T.#`L,#`P('=A<R!R96QA=&5D('1O('-T
M871E('1A>&5S+B8C,38P.R!.;R!T87@@8F5N969I="!H860@8F5E;B!R96-O
M<F1E9"!T:')O=6=H(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/E-E<'1E;6)E<B`S,"P@,C`Q,SPO9F]N=#X@8F5C875S92!O9B!T:&4@
M;F5T(&]P97)A=&EN9R!L;W-S97,@:6YC=7)R960@86YD(&$@9G5L;"!V86QU
M871I;VX@86QL;W=A;F-E(&AA9"!B965N('!R;W9I9&5D+CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O
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M;'5E<RXF(S$V,#L@26X@36%R8V@@,C`P-2P@=&AE(%-%0R!I<W-U960@861D
M:71I;VYA;"!G=6ED96QI;F5S('=H:6-H('!R;W9I9&4@<W5P<&QE;65N=&%L
M(&EM<&QE;65N=&%T:6]N(&=U:61A;F-E(&9O<B!V86QU871I;VX@;V8@<VAA
M<F4M8F%S960@<&%Y;65N=',N)B,Q-C`[($)I;U1I;64@:&%S(&%P<&QI960@
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M=&EO;B!E>&5R8VES92!B96AA=FEO<G,N)B,Q-C`[(%1H92!E>'!E8W1E9"!T
M97)M(&]F(&]P=&EO;G,@9W)A;G1E9"!I<R!D97)I=F5D(&9R;VT@:&ES=&]R
M:6-A;"!D871A(&]N(&5M<&QO>65E(&5X97)C:7-E<R!A;F0@<&]S="UV97-T
M:6YG(&5M<&QO>6UE;G0@=&5R;6EN871I;VX@8F5H879I;W(N)B,Q-C`[(%1H
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M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
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M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
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M<V5A<F-H('!R;V1U8W1S+B8C,38P.R!3964@3F]T92`U+CPO9&EV/CQD:78^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
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M('1H92!P97)I;V0N)B,Q-C`[($1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E
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M=&DM9&EL=71I=F4N)B,Q-C`[($1I;'5T960@;&]S<R!P97(@<VAA<F4@9F]R
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30L(&%N9"`R
M,#$S(&5X8VQU9&5S(&%N>2!E9F9E8W0@9G)O;2`Q,"PU-#8L,3,W('1R96%S
M=7)Y('-H87)E<RP@-2PT.3$L,S`Q(&]P=&EO;G,@86YD(#DL-S4Q+#8Q-2!W
M87)R86YT<R!A;F0@,BPS-C`L.38X('1R96%S=7)Y('-H87)E<RP@-"PW-S$L
M,S`Q(&]P=&EO;G,@86YD(#@Q-BPV,3(@=V%R<F%N=',L(')E<W!E8W1I=F5L
M>2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D9A:7(@
M=F%L=64@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S/"]F;VYT/B`F(S@R,3$[
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M86QA;F-E('-H965T<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^169F96-T(&]F(')E8V5N
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DEN=F5N=&]R>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5N=&]R>2!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXR+B!);G9E;G1O<GD\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D)I;U1I;64@:&5L
M9"`D,C(S+#8V-2!A;F0@)#$V-2PW-S$@;V8@:6YV96YT;W)Y(&]F(&9I;FES
M:&5D('!R;V1U8W1S(&]N+7-I=&4@870@:71S(&-O<G!O<F%T92!H96%D<75A
M<G1E<G,@:6X@06QA;65D82P@0V%L:69O<FYI82!A="!-87)C:"`S,2P@,C`Q
M-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L(')E<W!E8W1I=F5L>2XF(S$V,#L@
M1FEN:7-H960@9V]O9',@<')O9'5C=',@;V8@)#$R+#DR,R!W97)E(&AE;&0@
M8GD@82!T:&ER9"!P87)T>2!O;B!C;VYS:6=N;65N="!A="!-87)C:"`S,2P@
M,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,N/"]D:78^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6EP;65N=#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6EP;65N="!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SXS+B!%<75I<&UE;G0\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%T
M($UA<F-H(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@97%U:7!M
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M<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/DUA<F-H(#,Q+"`R,#$T/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
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M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)SY$96-E;6)E<B`S,2P\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/C(P,3,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
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M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
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M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/C0L-#,Q+#4X-CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N
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M;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+V1I
M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@Q+#0S,RPX-3,\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(L.34Y+#$U,#PO9&EV/CPO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(L.3DW+#<S,SPO9&EV/CPO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY$97!R96-I
M871I;VX@97AP96YS92!A;6]U;G1E9"!T;R`D,C4V+#DT-2!A;F0@)#$Q,RPS
M-38@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30@
M86YD(#(P,3,L(')E<W!E8W1I=F5L>2XF(S$V,#L\+V1I=CX\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,X,3DS83@T
M7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S.#$Y,V$X-%\W,V$T7S0V8F%?8CDS-U\T9CED,C!B
M96%E,S@O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^26YT86YG:6)L92!A<W-E=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G1A
M;F=I8FQE(&%S<V5T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C0N
M($EN=&%N9VEB;&4@87-S971S/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY!="!-87)C:"`S,2P@,C`Q-"!A;F0@
M1&5C96UB97(@,S$L(#(P,3,L(&EN=&%N9VEB;&4@87-S971S(&%N9"!I;G1A
M;F=I8FQE(&%S<V5T<R!N970@;V8@86UO<G1I>F%T:6]N('=E<F4@8V]M<')I
M<V5D(&]F('1H92!F;VQL;W=I;F<Z/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T
M.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/DUA<F-H(#,Q+"`R
M,#$T/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
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M,G!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY$96-E;6)E<B`S
M,2P\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C(P,3,\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[
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M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
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M.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C4T+#<Q.2PY
M,3@\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
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M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/C4T+#<Q.2PY,3@\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\
M='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@-S8E
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M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*#DL.#<Y+#@S,3PO9&EV
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
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M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/C0T+#@T,"PP.#<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R
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M:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D
M/CPO='(^/"]T86)L93X\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
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M<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N
M9"`R,#$S+"!R97-P96-T:79E;'DN/"]D:78^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E)O>6%L='D@3V)L:6=A=&EO;B!A;F0@1&5F97)R960@
M3&EC96YS92!&965S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F]Y86QT>2!/8FQI9V%T:6]N(&%N9"!$969E<G)E
M9"!,:6-E;G-E($9E97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!/8FQI9V%T:6]N(&%N
M9"!$969E<G)E9"!,:6-E;G-E($9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXU+B!2;WEA;'1Y($]B;&EG
M871I;VX@86YD($1E9F5R<F5D($QI8V5N<V4@1F5E<SPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^0FEO5&EM
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M:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E=!4D8@3&EC96YS928C.#(Q,CM2
M97-E87)C:"!0<F]D=6-T<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P
M=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@2F%N=6%R>2`S+"`R,#`X+"!"
M:6]4:6UE(&5N=&5R960@:6YT;R!A($-O;6UE<F-I86P@3&EC96YS92!A;F0@
M3W!T:6]N($%G<F5E;65N="!W:71H(%=I<V-O;G-I;B!!;'5M;FD@4F5S96%R
M8V@@1F]U;F1A=&EO;B`H)B,X,C(P.U=!4D8F(S@R,C$[*2XF(S$V,#L@5&AE
M(%=!4D8@;&EC96YS92!P97)M:71S($)I;U1I;64@=&\@=7-E(&-E<G1A:6X@
M<&%T96YT960@86YD('!A=&5N="!P96YD:6YG('1E8VAN;VQO9WD@8F5L;VYG
M:6YG('1O(%=!4D8L(&%S('=E;&P@87,@8V5R=&%I;B!S=&5M(&-E;&P@;6%T
M97)I86QS+"!F;W(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('!U<G!O<V5S
M+"!A;F0@9F]R('1H92!P<F]D=6-T:6]N(&%N9"!M87)K971I;F<@;V8@<')O
M9'5C=',@=7-E9"!A<R!R97-E87)C:"!T;V]L<RP@:6YC;'5D:6YG(&EN(&1R
M=6<@9&ES8V]V97)Y(&%N9"!D979E;&]P;65N="XF(S$V,#L@0FEO5&EM92!O
M<B!294-Y=&4@5&AE<F%P975T:6-S('=I;&P@<&%Y(%=!4D8@<F]Y86QT:65S
M(&]N('1H92!S86QE(&]F('!R;V1U8W1S(&%N9"!S97)V:6-E<R!U<VEN9R!T
M:&4@=&5C:&YO;&]G>2!O<B!S=&5M(&-E;&QS(&QI8V5N<V5D(&9R;VT@5T%2
M1BXF(S$V,#L@5&AE(')O>6%L='D@=VEL;"!R86YG92!F<F]M(#(E('1O(#0E
M+"!D97!E;F1I;F<@;VX@=&AE(&MI;F0@;V8@<')O9'5C=',@<V]L9"XF(S$V
M,#L@5&AE(')O>6%L='D@<F%T92!I<R!S=6)J96-T('1O(&-E<G1A:6X@<F5D
M=6-T:6]N<R!I9B!":6]4:6UE(&%L<V\@8F5C;VUE<R!O8FQI9V%T960@=&\@
M<&%Y(')O>6%L=&EE<R!T;R!A('1H:7)D('!A<G1Y(&EN(&]R9&5R('1O('-E
M;&P@82!P<F]D=6-T+B8C,38P.R!":6]4:6UE('!A:60@;&EC96YS:6YG(&9E
M97,L('1O=&%L:6YG("0R.34L,#`P(&EN(&-A<V@@86YD($)I;U1I;64@<W1O
M8VLL(&%N9"!R96EM8G5R<V5D(%=!4D8@9F]R(&-E<G1A:6X@8V]S=',@87-S
M;V-I871E9"!W:71H('!R97!A<FEN9RP@9FEL:6YG+"!A;F0@;6%I;G1A:6YI
M;F<@=&AE(&QI8V5N<V5D('!A=&5N=',N)B,Q-C`[($EN(&%D9&ET:6]N+"!"
M:6]4:6UE('!A>7,@5T%21B`D,C4L,#`P(&%N;G5A;&QY(&%S(&$@;&EC96YS
M92!M86EN=&5N86YC92!F964N)B,Q-C`[(%1H92!L:6-E;G-I;F<@9F5E<R!L
M97-S('1H92!A;6]R=&EZ960@<&]R=&EO;B!W97)E(&EN8VQU9&5D(&EN(&1E
M9F5R<F5D(&QI8V5N<V4@9F5E<R!I;B!":6]4:6UE)B,X,C$W.W,@8V]N9&5N
M<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($UA<F-H(#,Q
M+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RX\+V1I=CX\9&EV/CQB<B`O
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M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!*=6QY(#$P
M+"`R,#`X+"!294-Y=&4@5&AE<F%P975T:6-S(&5N=&5R960@:6YT;R!A($QI
M8V5N<V4@06=R965M96YT('=I=&@@061V86YC960@0V5L;"!496-H;F]L;V=Y
M+"!);F,N("@F(S@R,C`[04-4)B,X,C(Q.RDL('5N9&5R('=H:6-H(%)E0WET
M92!4:&5R87!E=71I8W,@86-Q=6ER960@97AC;'5S:79E('=O<FQD=VED92!R
M:6=H=',@=&\@=7-E($%#5"8C.#(Q-SMS("8C.#(R,#L\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%#
M5$-E;&QE<F%T93PO9F]N=#XF(S@T.#([)B,X,C(Q.R!T96-H;F]L;V=Y(&9O
M<B!M971H;V1S('1O(&%C8V5L97)A=&4@=&AE(&ES;VQA=&EO;B!O9B!N;W9E
M;"!C96QL('-T<F%I;G,@9G)O;2!P;'5R:7!O=&5N="!S=&5M(&-E;&QS+B8C
M,38P.R!294-Y=&4@5&AE<F%P975T:6-S('!A:60@04-4(&$@)#(U,"PP,#`@
M;&EC96YS92!F964N)B,Q-C`[(%)E0WET92!4:&5R87!E=71I8W,@:&%S(&%S
M<VEG;F5D(&ET<R!R:6=H=',@=6YD97(@=&AE($QI8V5N<V4@06=R965M96YT
M('1O($)I;U1I;64N)B,Q-C`[($)I;U1I;64@=VEL;"!P87D@86X@."4@<F]Y
M86QT>2!O;B!S86QE<R!O9B!P<F]D=6-T<RP@<V5R=FEC97,L(&%N9"!P<F]C
M97-S97,@=&AA="!U=&EL:7IE('1H92!L:6-E;G-E9"!T96-H;F]L;V=Y+B8C
M,38P.R!/;F-E(&$@=&]T86P@;V8@)#$L,#`P+#`P,"!O9B!R;WEA;'1I97,@
M:&%S(&)E96X@<&%I9"P@;F\@9G5R=&AE<B!R;WEA;'1I97,@=VEL;"!B92!D
M=64N)B,Q-C`[(%1H92!L:6-E;G-E('=I;&P@97AP:7)E(&EN('1W96YT>2!Y
M96%R<R!O<B!U<&]N('1H92!E>'!I<F%T:6]N(&]F('1H92!L87-T('1O(&5X
M<&ER92!O9B!T:&4@;&EC96YS960@<&%T96YT<RP@=VAI8VAE=F5R(&ES(&QA
M=&5R+B8C,38P.R!4:&4@)#(U,"PP,#`@;&EC96YS92!F964@;&5S<R!T:&4@
M86UO<G1I>F5D('!O<G1I;VX@:7,@:6YC;'5D960@:6X@9&5F97)R960@;&EC
M96YS92!F965S(&EN($)I;U1I;64F(S@R,3<[<R!C;VYD96YS960@8V]N<V]L
M:61A=&5D(&)A;&%N8V4@<VAE970@87,@;V8@36%R8V@@,S$L(#(P,30@86YD
M($1E8V5M8F5R(#,Q+"`R,#$S+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P
M=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@075G=7-T(#$U+"`R,#`X+"!2
M94-Y=&4@5&AE<F%P975T:6-S(&5N=&5R960@:6YT;R!A($QI8V5N<V4@06=R
M965M96YT(&%N9"!A(%-U8FQI8V5N<V4@06=R965M96YT('=I=&@@04-4('5N
M9&5R('=H:6-H(%)E0WET92!4:&5R87!E=71I8W,@86-Q=6ER960@=V]R;&0M
M=VED92!R:6=H=',@=&\@=7-E(&%N(&%R<F%Y(&]F($%#5"!T96-H;F]L;V=Y
M("AT:&4@)B,X,C(P.T%#5"!,:6-E;G-E)B,X,C(Q.RD@86YD('1E8VAN;VQO
M9WD@;&EC96YS960@8GD@04-4(&9R;VT@869F:6QI871E<R!O9B!+:7)I;B!0
M:&%R;6$@0V]M<&%N>2P@3&EM:71E9"`H=&AE("8C.#(R,#M+:7)I;B!3=6)L
M:6-E;G-E)B,X,C(Q.RDN)B,Q-C`[(%1H92!!0U0@3&EC96YS92!A;F0@2VER
M:6X@4W5B;&EC96YS92!P97)M:70@=&AE(&-O;6UE<F-I86QI>F%T:6]N(&]F
M('!R;V1U8W1S(&EN(&AU;6%N('1H97)A<&5U=&EC(&%N9"!D:6%G;F]S=&EC
M('!R;V1U8W0@;6%R:V5T<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
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M($QI8V5N<V4L(%)E0WET92!4:&5R87!E=71I8W,@<&%I9"!!0U0@82`D,C`P
M+#`P,"!L:6-E;G-E(&9E92!A;F0@=VEL;"!P87D@82`U)2!R;WEA;'1Y(&]N
M('-A;&5S(&]F('!R;V1U8W1S+"!S97)V:6-E<RP@86YD('!R;V-E<W-E<R!T
M:&%T('5T:6QI>F4@=&AE(&QI8V5N<V5D($%#5"!T96-H;F]L;V=Y+"!A;F0@
M,C`E(&]F(&%N>2!F965S(&]R(&]T:&5R('!A>6UE;G1S("AO=&AE<B!T:&%N
M(&5Q=6ET>2!I;G9E<W1M96YT<RP@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&-O<W1S+"!L;V%N<R!A;F0@<F]Y86QT:65S*2!R96-E:79E9"!B>2!294-Y
M=&4@5&AE<F%P975T:6-S(&9R;VT@<W5B;&EC96YS:6YG('1H92!!0U0@=&5C
M:&YO;&]G>2!T;R!T:&ER9"!P87)T:65S+B8C,38P.R!/;F-E(&$@=&]T86P@
M;V8@)#8P,"PP,#`@;V8@<F]Y86QT:65S(&AA<R!B965N('!A:60L(&YO(&9U
M<G1H97(@<F]Y86QT:65S('=I;&P@8F4@9'5E+B8C,38P.R!4:&4@;&EC96YS
M92!W:6QL(&5X<&ER92!I;B!T=V5N='D@>65A<G,@;W(@=7!O;B!T:&4@97AP
M:7)A=&EO;B!O9B!T:&4@;&%S="UT;RUE>'!I<F4@;V8@=&AE(&QI8V5N<V5D
M('!A=&5N=',L('=H:6-H979E<B!I<R!L871E<BXF(S$V,#L@5&AE("0R,#`L
M,#`P(&QI8V5N<V4@9F5E('!A>6UE;G0@;&5S<R!T:&4@86UO<G1I>F5D('!O
M<G1I;VX@:7,@:6YC;'5D960@:6X@9&5F97)R960@;&EC96YS92!F965S(&EN
M($)I;U1I;64F(S@R,3<[<R!C;VYD96YS960@8V]N<V]L:61A=&5D(&)A;&%N
M8V4@<VAE970@87,@;V8@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q
M+"`R,#$S+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E5N9&5R('1H92!+
M:7)I;B!3=6)L:6-E;G-E+"!294-Y=&4@5&AE<F%P975T:6-S(&AA<R!P86ED
M($%#5"!A("0U,"PP,#`@;&EC96YS92!F964@86YD('=I;&P@<&%Y(&$@,RXU
M)2!R;WEA;'1Y(&]N('-A;&5S(&]F('!R;V1U8W1S+"!S97)V:6-E<RP@86YD
M('!R;V-E<W-E<R!T:&%T('5T:6QI>F4@=&AE(&QI8V5N<V5D($%#5"!T96-H
M;F]L;V=Y+"!A;F0@,C`E(&]F(&%N>2!F965S(&]R(&]T:&5R('!A>6UE;G1S
M("AO=&AE<B!T:&%N(&5Q=6ET>2!I;G9E<W1M96YT<RP@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT(&-O<W1S+"!L;V%N<R!A;F0@<F]Y86QT:65S*2!R96-E
M:79E9"!B>2!294-Y=&4@5&AE<F%P975T:6-S(&9R;VT@<W5B;&EC96YS:6YG
M('1H92!+:7)I;B!496-H;F]L;V=Y('1O('1H:7)D('!A<G1I97,N)B,Q-C`[
M(%)E0WET92!4:&5R87!E=71I8W,@=VEL;"!A;'-O('!A>2!T;R!!0U0@;W(@
M=&\@86X@869F:6QI871E(&]F($MI<FEN(%!H87)M82!#;VUP86YY+"!,:6UI
M=&5D("@F(S@R,C`[2VER:6XF(S@R,C$[*2P@86YN=6%L;'DL('1H92!A;6]U
M;G0L(&EF(&%N>2P@8GD@=VAI8V@@<F]Y86QT:65S('!A>6%B;&4@8GD@04-4
M('5N9&5R(&ET<R!L:6-E;G-E(&%G<F5E;65N="!W:71H($MI<FEN(&%R92!L
M97-S('1H86X@=&AE("0U,"PP,#`@86YN=6%L(&UI;FEM=6T@<F]Y86QT>2!D
M=64N)B,Q-C`[(%1H;W-E('!A>6UE;G1S(&)Y(%)E0WET92!4:&5R87!E=71I
M8W,@=VEL;"!B92!C<F5D:71E9"!A9V%I;G-T(&]T:&5R(')O>6%L=&EE<R!P
M87EA8FQE('1O($%#5"!U;F1E<B!T:&4@2VER:6X@4W5B;&EC96YS92XF(S$V
M,#L@5&AE(&QI8V5N<V4@=VEL;"!E>'!I<F4@=7!O;B!T:&4@97AP:7)A=&EO
M;B!O9B!T:&4@;&%S="!T;R!E>'!I<F4@;V8@=&AE(&QI8V5N<V5D('!A=&5N
M=',L(&]R($UA>2`Y+"`R,#$V(&EF(&YO('!A=&5N=',@87)E(&ES<W5E9"XF
M(S$V,#L@5&AE("0U,"PP,#`@;&EC96YS92!F964@<&%Y;65N="!L97-S('1H
M92!A;6]R=&EZ960@<&]R=&EO;B!I<R!I;F-L=61E9"!I;B!D969E<G)E9"!L
M:6-E;G-E(&9E97,@:6X@0FEO5&EM928C.#(Q-SMS(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@8F%L86YC92!S:&5E="!A<R!O9B!-87)C:"`S,2P@,C`Q-"!A
M;F0@1&5C96UB97(@,S$L(#(P,3,N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4F5#>71E(%1H97)A<&5U
M=&EC<R!,:6-E;G-E(&9R;VT@4D=)/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S
M-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!&96)R=6%R>2`R.2P@,C`P
M.2P@4F5#>71E(%1H97)A<&5U=&EC<R!E;G1E<F5D(&EN=&\@82!3=&5M($-E
M;&P@06=R965M96YT('=I=&@@4F5P<F]D=6-T:79E($=E;F5T:6-S($EN<W1I
M='5T92`H)B,X,C(P.U)'228C.#(R,3LI+B8C,38P.R!);B!P87)T:6%L(&-O
M;G-I9&5R871I;VX@;V8@=&AE(')I9VAT<R!A;F0@;&EC96YS97,@9W)A;G1E
M9"!T;R!294-Y=&4@5&AE<F%P975T:6-S(&)Y(%)'22P@0FEO5&EM92!I<W-U
M960@=&\@4D=)(#,R+#(U.2!C;VUM;VX@<VAA<F5S+"!H879I;F<@82!M87)K
M970@=F%L=64@;V8@)#4P+#`P,"!O;B!T:&4@969F96-T:79E(&1A=&4@;V8@
M=&AE(%-T96T@0V5L;"!!9W)E96UE;G0N)B,Q-C`[(%1H:7,@)#4P+#`P,"!P
M87EM96YT(&QE<W,@=&AE(&%M;W)T:7IE9"!P;W)T:6]N(&ES(&EN8VQU9&5D
M(&EN(&1E9F5R<F5D(&QI8V5N<V4@9F5E<R!I;B!":6]4:6UE)B,X,C$W.W,@
M8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($UA
M<F-H(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RX\+V1I=CX\9&EV
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY/
M;F-O0WET92!,:6-E;G-E(&9R;VT@4T)-4DD\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
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M96%R8V@@26YS=&ET=71E("@F(S@R,C`[4T)-4DDF(S@R,C$[*2!T;R!U<V4@
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M<B!T:&%T(&]F(&$@=&AI<F0@<&%R='DN)B,Q-C`[($)I;U1I;64@87-S:6=N
M960@=&AE(%-"35))(&QI8V5N<V4@=&\@3VYC;T-Y=&4@9'5R:6YG($IU;'D@
M,C`Q,2XF(S$V,#L@3VYC;T-Y=&4@=VEL;"!P87D@4T)-4DD@82!R;WEA;'1Y
M(&]F(#0E(&]N('1H92!S86QE(&]F('!H87)M86-E=71I8V%L('!R;V1U8W1S
M+"!A;F0@,3`E(&]N('1H92!S86QE(&]F(&%N>2!R97-E87)C:"UU<V4@<')O
M9'5C=',@=&AA="!/;F-O0WET92!D979E;&]P<R!U<VEN9R!O<B!I;F-O<G!O
M<F%T:6YG('1H92!L:6-E;G-E9"!T96-H;F]L;V=Y.R!A;F0@,C`E(&]F(&%N
M>2!P87EM96YT<R!/;F-O0WET92!R96-E:79E<R!F;W(@<W5B;&EC96YS:6YG
M('1H92!P871E;G1S('1O('1H:7)D('!A<G1I97,N)B,Q-C`[(%1H92!R;WEA
M;'1I97,@<&%Y86)L92!T;R!30DU222!M87D@8F4@<F5D=6-E9"!B>2`U,"4@
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M87(N)B,Q-C`[($]N8V]#>71E('=I;&P@<F5I;6)U<G-E(%-"35))(&9O<B`R
M-24@;V8@=&AE(&-O<W1S(&EN8W5R<F5D(&EN(&9I;&EN9RP@<')O<V5C=71I
M;F<L(&%N9"!M86EN=&%I;FEN9R!P871E;G0@<')O=&5C=&EO;BP@<W5B:F5C
M="!T;R!/;F-O0WET928C.#(Q-SMS(&%P<')O=F%L(&]F('1H92!C;W-T<RXF
M(S$V,#L@3VYC;T-Y=&4@:6YC=7)R960@;F\@<F]Y86QT>2!E>'!E;G-E<R!T
M;R!D871E(&%S(&]F($UA<F-H(#,Q+"`R,#$T+CPO9&EV/CQD:78^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D-E;&P@0W5R
M92!.975R;W-C:65N8V5S($QI8V5N<V4@9G)O;2!(861A<VET/"]D:78^/&1I
M=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
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M;F5R871I=F4@9&ES96%S97,N)B,Q-C`[($-E;&P@0W5R92!.975R;W-C:65N
M8V5S('!A:60@2&%D87-I="`R-#DL,#4X($YE=R!)<W)A96QI(%-H96ME;',@
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M.B`Q,'!T.R<^268@5&5V82!0:&%R;6%C975T:6-A;"!);F1U<W1R:65S($QT
M9"X@*"8C.#(R,#M4979A)B,X,C(Q.RD@97AE<F-I<V5S(&ET<R!O<'1I;VX@
M=&\@;&EC96YS92`\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]P4F5G96X\+V9O;G0^/'-U<"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3L@9F]N="US:7IE.B!S;6%L;&5R.R!V97)T
M:6-A;"UA;&EG;CH@=&5X="UT;W`[)SXF(S$W-#L\+W-U<#X@;W(@/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY/<%)E9V5N/"]F;VYT/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$[(&9O;G0M<VEZ93H@<VUA;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M
M=&]P.R<^)B,Q-S0[/"]S=7`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXM4&QU<SPO9F]N=#X@=6YD
M97(@=&AE('1E<FUS(&]F(&$@4F5S96%R8V@@86YD($5X8VQU<VEV92!,:6-E
M;G-E($]P=&EO;B!!9W)E96UE;G0@*'1H92`F(S@R,C`[5&5V82!,:6-E;G-E
M($]P=&EO;B!!9W)E96UE;G0F(S@R,C$[*2P@0V5L;"!#=7)E($YE=7)O<V-I
M96YC97,@=VEL;"!P87D@2&%D87-I="`S,"4@;V8@86QL('-U8FQI8V5N<VEN
M9R!P87EM96YT<R!M861E(&)Y(%1E=F$@=&\@0V5L;"!#=7)E($YE=7)O<V-I
M96YC97,L(&]T:&5R('1H86X@<&%Y;65N=',@9F]R(')E<V5A<F-H+"!R96EM
M8G5R<V5M96YT<R!O9B!P871E;G0@97AP96YS97,L(&QO86YS(&]R(&5Q=6ET
M>2!I;G9E<W1M96YT<RX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
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M<'0[)SY/<%)E9V5N/"]F;VYT/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$[(&9O;G0M<VEZ93H@<VUA;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M
M=&]P.R<^)B,Q-S0[/"]S=7`^(&]R(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3W!296=E;CPO9F]N
M=#X\<W5P('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q.R!F;VYT+7-I>F4Z('-M
M86QL97([('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<#LG/B8C,3<T.SPO<W5P
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^+5!L=7,\+V9O;G0^(&ET<V5L9B!O<B!S=6)L:6-E;G-E
M<R!T:&4@2&%D87-I="!P871E;G1S('1O(&$@=&AI<F0@<&%R='D@9F]R('1H
M92!C;VUP;&5T:6]N(&]F(&1E=F5L;W!M96YT(&]R(&-O;6UE<F-I86QI>F%T
M:6]N(&]F(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^3W!296=E;CPO9F]N=#X\<W5P('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q.R!F;VYT+7-I>F4Z('-M86QL97([('9E<G1I8V%L
M+6%L:6=N.B!T97AT+71O<#LG/B8C,3<T.SPO<W5P/B!O<B`\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/D]P4F5G96X\+V9O;G0^/'-U<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3L@
M9F]N="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X="UT;W`[
M)SXF(S$W-#L\+W-U<#X\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L
M:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/BU0;'5S/"]F;VYT/BP@0V5L;"!#
M=7)E($YE=7)O<V-I96YC97,@=VEL;"!P87D@2&%D87-I="!A(#4E(')O>6%L
M='D@;VX@<V%L97,@;V8@<')O9'5C=',@=&AA="!U=&EL:7IE('1H92!L:6-E
M;G-E9"!T96-H;F]L;V=Y+B8C,38P.R!#96QL($-U<F4@3F5U<F]S8VEE;F-E
M<R!W:6QL(&%L<V\@<&%Y('-U8FQI8V5N<VEN9R!F965S(')A;F=I;F<@9G)O
M;2`Q,"4@=&\@,S`E(&]F(&%N>2!P87EM96YT<R!#96QL($-U<F4@3F5U<F]S
M8VEE;F-E<R!R96-E:79E<R!F<F]M('-U8FQI8V5N<VEN9R!T:&4@2&%D87-I
M="!P871E;G1S('1O(&-O;7!A;FEE<R!O=&AE<B!T:&%N(%1E=F$N)B,Q-C`[
M($-O;6UE;F-I;F<@:6X@2F%N=6%R>2`R,#$W+"!(861A<VET('=I;&P@8F4@
M96YT:71L960@=&\@<F5C96EV92!A;B!A;FYU86P@;6EN:6UU;2!R;WEA;'1Y
M('!A>6UE;G0@;V8@)#$P,"PP,#`@=&AA="!W:6QL(&)E(&-R961I=&5D('1O
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M,#`L,#`P+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^268@5&5V82!D;V5S(&YO="!E>&5R8VES92!I=',@;W!T
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M;VYT+7-I>F4Z(#$P<'0[)SY/<%)E9V5N/"]F;VYT/CQS=7`@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ93H@<VUA;&QE<CL@=F5R=&EC86PM
M86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[/"]S=7`^(&]R(#QF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M3W!296=E;CPO9F]N=#X\<W5P('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q.R!F
M;VYT+7-I>F4Z('-M86QL97([('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<#LG
M/B8C,3<T.SPO<W5P/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI
M8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^+5!L=7,\+V9O;G0^+"!(861A<VET
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M<&%T96YT<RXF(S$V,#L@2&%D87-I="!W:6QL(')E8V5I=F4@)#(U,"PP,#`@
M=7!O;B!T:&4@96YR;VQL;65N="!O9B!P871I96YT<R!I;B!T:&4@9FER<W0@
M4&AA<V4@22!C;&EN:6-A;"!T<FEA;"P@)#(U,"PP,#`@=7!O;B!T:&4@<W5B
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M9F]R('-A:60@;6EL97-T;VYE('!A>6UE;G0L(&5X8V5P="!T:&%T('1H92`D
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M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^0FEO5&EM92!,:6-E;G-E(&9O<B!T
M:&4@56YI=F5R<VET>2!O9B!5=&%H/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S
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M)B,Q-C`[(%5N9&5R('1H92!,:6-E;G-E($%G<F5E;65N="P@=&AE('-C;W!E
M(&]F('=H:6-H('=A<R!E>'!A;F1E9"!B>2!A;B!A;65N9&UE;G0@9'5R:6YG
M($%U9W5S="`R,#$R+"!":6]4:6UE('=I;&P@<&%Y(&$@,R4@<F]Y86QT>2!O
M;B!S86QE<R!O9B!P<F]D=6-T<R!A;F0@<V5R=FEC97,@<&5R9F]R;65D('1H
M870@=71I;&EZ92!T:&4@;&EC96YS960@<&%T96YT<RXF(S$V,#L@0V]M;65N
M8VEN9R!I;B`R,#$T+"!":6]4:6UE('=I;&P@8F4@;V)L:6=A=&5D('1O('!A
M>2!M:6YI;75M(')O>6%L=&EE<R!T;R!T:&4@97AT96YT('1H870@86-T=6%L
M(')O>6%L=&EE<R!O;B!P<F]D=6-T<R!S86QE<R!A;F0@<V5R=FEC97,@=71I
M;&EZ:6YG('1H92!P871E;G1S(&%R92!L97-S('1H86X@=&AE(&UI;FEM=6T@
M<F]Y86QT>2!A;6]U;G0N)B,Q-C`[(%1H92!M:6YI;75M(')O>6%L='D@86UO
M=6YT<R!A<F4@)#(L-3`P(&EN(#(P,30@86YD("0S,"PP,#`@96%C:"!Y96%R
M('1H97)E869T97(@9'5R:6YG('1H92!T97)M(&]F('1H92!,:6-E;G-E($%G
M<F5E;65N="XF(S$V,#L@0FEO5&EM92!S:&%L;"!A;'-O('!A>2!T:&4@56YI
M=F5R<VET>2!O9B!5=&%H(#,P)2!O9B!A;GD@<W5B;&EC96YS92!F965S(&]R
M(')O>6%L=&EE<R!R96-E:79E9"!U;F1E<B!A;GD@<W5B;&EC96YS92!O9B!T
M:&4@;&EC96YS960@<&%T96YT<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D)I;U1I;64@=VEL;"!P87D@=&AE
M(%5N:79E<G-I='D@;V8@571A:"`D-2PP,#`@=7!O;B!T:&4@:7-S=6%N8V4@
M;V8@96%C:"!O9B!T:&4@9FER<W0@9FEV92!L:6-E;G-E9"!P871E;G1S(&ES
M<W5E9"!I;B!T:&4@52Y3+BP@<W5B:F5C="!T;R!R961U8W1I;VX@=&\@)#(L
M-3`P(&9O<B!A;GD@<&%T96YT('1H870@=&AE(%5N:79E<G-I='D@:&%S(&QI
M8V5N<V5D('1O('1W;R!O<B!M;W)E(&]T:&5R(&QI8V5N<V5E<R!F;W(@9&EF
M9F5R96YT('5S97,N)B,Q-C`[($)I;U1I;64@=VEL;"!A;'-O('!A>2!A("0R
M,C4L,#`P(&UI;&5S=&]N92!F964@=VET:&EN('-I>"!M;VYT:',@869T97(@
M=&AE(&9I<G-T('-A;&4@;V8@82`F(S@R,C`[=&ES<W5E(&5N9VEN965R960@
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M;B!I;G1O(&$@:'5M86X@<&%T:65N="X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US='EL
M93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY":6]4:6UE($QI8V5N
M<V4@9G)O;2!#;W)N96QL(%5N:79E<G-I='D\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($%U9W5S="`R,RP@
M,C`Q,2P@0FEO5&EM92!E;G1E<F5D(&EN=&\@82!,:6-E;G-E($%G<F5E;65N
M="!W:71H($-O<FYE;&P@56YI=F5R<VET>2!F;W(@=&AE('=O<FQD=VED92!D
M979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@=&5C:&YO;&]G
M>2!F;W(@=&AE(&1I9F9E<F5N=&EA=&EO;B!O9B!H15,@8V5L;',@:6YT;R!V
M87-C=6QA<B!E;F1O=&AE;&EA;"!C96QL<RX\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D-O<FYE;&P@=VEL;"!B
M92!E;G1I=&QE9"!T;R!R96-E:79E(&$@;F]M:6YA;"!I;FET:6%L(&QI8V5N
M<V4@9F5E(&%N9"!N;VUI;F%L(&%N;G5A;"!L:6-E;G-E(&UA:6YT96YA;F-E
M(&9E97,N)B,Q-C`[(%1H92!O8FQI9V%T:6]N('1O('!A>2!A;FYU86P@;&EC
M96YS92!M86EN=&5N86YC92!F965S('=I;&P@96YD('=H96X@=&AE(&9I<G-T
M(&AU;6%N('1H97)A<&5U=&EC('!R;V1U8W1S(&1E=F5L;W!E9"!U;F1E<B!T
M:&4@;&EC96YS92!I<R!S;VQD+B8C,38P.R!":6]4:6UE('=I;&P@<&%Y($-O
M<FYE;&P@82!M:6QE<W1O;F4@<&%Y;65N="!U<&]N('1H92!A8VAI979E;65N
M="!O9B!A(')E<V5A<F-H('!R;V1U8W0@<V%L92!M:6QE<W1O;F4@86UO=6YT
M+"!A;F0@=VEL;"!M86ME(&UI;&5S=&]N92!P87EM96YT<R!U<&]N('1H92!A
M='1A:6YM96YT(&]F(&-E<G1A:6X@1D1!(&%P<')O=F%L(&UI;&5S=&]N97,@
M9F]R('1H97)A<&5U=&EC('!R;V1U8W1S(&1E=F5L;W!E9"!U;F1E<B!T:&4@
M;&EC96YS92P@:6YC;'5D:6YG("AI*2!T:&4@9FER<W0@4&AA<V4@24D@8VQI
M;FEC86P@=')I86P@9&]S:6YG(&]F(&$@:'5M86X@=&AE<F%P975T:6,@<')O
M9'5C="P@*&EI*2!T:&4@9FER<W0@4&AA<V4@24E)(&-L:6YI8V%L('1R:6%L
M(&1O<VEN9R!O9B!A(&AU;6%N('1H97)A<&5U=&EC('!R;V1U8W0[("AI:6DI
M($9$02!A<'!R;W9A;"!O9B!T:&4@9FER<W0@:'5M86X@=&AE<F%P975T:6,@
M<')O9'5C="!F;W(@86=E+7)E;&%T960@=F%S8W5L87(@9&ES96%S93L@86YD
M("AI=BD@1D1!(&%P<')O=F%L(&]F('1H92!F:7)S="!H=6UA;B!T:&5R87!E
M=71I8R!P<F]D=6-T(&9O<B!C86YC97(N/"]D:78^/&1I=CX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
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M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
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M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^07-T97)I87,@3&EC
M96YS92!F<F]M(%=!4D8\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
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M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^26X@
M8V]N<VED97)A=&EO;B!O9B!T:&4@<FEG:'1S(&QI8V5N<V5D+"!!<W1E<FEA
M<R!H87,@86=R965D('1O('!A>2!705)&(&%N('5P9G)O;G0@;&EC96YS92!F
M964L('!A>6UE;G1S('5P;VX@=&AE(&%T=&%I;FUE;G0@;V8@<W!E8VEF:65D
M(&-L:6YI8V%L(&1E=F5L;W!M96YT(&UI;&5S=&]N97,L(')O>6%L=&EE<R!O
M;B!S86QE<R!O9B!C;VUM97)C:6%L:7IE9"!P<F]D=6-T<RP@86YD+"!S=6)J
M96-T('1O(&-E<G1A:6X@97AC;'5S:6]N<RP@82!P97)C96YT86=E(&]F(&%N
M>2!P87EM96YT<R!T:&%T($%S=&5R:6%S(&UA>2!R96-E:79E(&9R;VT@86YY
M('-U8FQI8V5N<V5S('1H870@:70@;6%Y(&=R86YT('1O('5S92!T:&4@;&EC
M96YS960@<&%T96YT<R!O<B!S=&5M(&-E;&P@;&EN97,N/"]D:78^/&1I=CX\
M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
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M-C`[(%=!4D8@86QS;R!H87,@=&AE(')I9VAT('1O('1E<FUI;F%T92!T:&4@
M;&EC96YS92!A9W)E96UE;G0@:68@07-T97)I87,@8G)E86-H97,@=&AE(&QI
M8V5N<V4@86=R965M96YT(&]R(&)E8V]M97,@8F%N:W)U<'0@;W(@:6YS;VQV
M96YT(&]R(&EF(&%N>2!O9B!T:&4@;&EC96YS960@<&%T96YT<R!O<B!S=&5M
M(&-E;&P@;&EN97,@87)E(&]F9F5R960@=&\@8W)E9&ET;W)S+CPO9&EV/CQD
M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/D%S=&5R:6%S($QI8V5N<V4@9G)O;2!T:&4@56YI=F5R<VET>2!O9B!#86QI
M9F]R;FEA/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL
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M86YD(&$@;6EN:6UU;2!A;FYU86P@<F]Y86QT>2!O9B`D-2PP,#`@<W1A<G1I
M;F<@:6X@=&AE('EE87(@:6X@=VAI8V@@=&AE(&9I<G-T('-A;&4@;V8@82!P
M<F]D=6-T(&-O=F5R960@8GD@86YY(&QI8V5N<V5D('!A=&5N="!R:6=H=',@
M;V-C=7)S+"!A;F0@8V]N=&EN=6EN9R!F;W(@=&AE(&QI9F4@;V8@=&AE(&%P
M<&QI8V%B;&4@<&%T96YT(')I9VAT('5N9&5R('1H92!A9W)E96UE;G0N)B,Q
M-C`[(%1H92!R;WEA;'1Y('!A>6UE;G1S(&1U92!A<F4@<W5B:F5C="!T;R!R
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M<FUI;F%T92!I;B`R,#(T+B8C,38P.R!4:&4@=6YI=F5R<VET>2!M87D@=&5R
M;6EN871E('1H92!A9W)E96UE;G0@:6X@=&AE(&5V96YT(&]F($%S=&5R:6%S
M)B,X,C$W.R!B<F5A8V@@;V8@=&AE(&%G<F5E;65N="XF(S$V,#L@07-T97)I
M87,@8V%N('1E<FUI;F%T92!T:&4@86=R965M96YT('5P;VX@-C`@9&%Y<R<@
M;F]T:6-E+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/D%S=&5R:6%S(%-U8FQI8V5N<V4@9G)O;2!'97)O
M;CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M92!O9B`D-C4L,#`P+"!A;F0@=VEL;"!P87D@1V5R;VX@86X@86YN=6%L(&QI
M8V5N<V4@;6%I;G1E;F%N8V4@9F5E(&]F("0Q,"PP,#`@9'5E(&]N(&5A8V@@
M86YN:79E<G-A<GD@;V8@=&AE(&5F9F5C=&EV92!D871E(&]F('1H92!496QO
M;65R87-E(%-U8FQI8V5N<V4L(&%N9"!A(#$E(')O>6%L='D@;VX@<V%L97,@
M;V8@86YY('!R;V1U8W1S('1H870@07-T97)I87,@;6%Y(&1E=F5L;W`@86YD
M(&-O;6UE<F-I86QI>F4@=&AA="!A<F4@8V]V97)E9"!B>2!T:&4@<W5B;&EC
M96YS960@<&%T96YT<RXF(S$V,#L@5&AE(%1E;&]M97)A<V4@4W5B;&EC96YS
M92!W:6QL(&5X<&ER92!C;VYC=7)R96YT;'D@=VET:"!T:&4@97AP:7)A=&EO
M;B!O9B!'97)O;B8C.#(Q-SMS(&QI8V5N<V4N)B,Q-C`[(%1H870@;&EC96YS
M92!W:6QL('1E<FUI;F%T92!D=7)I;F<@07!R:6P@,C`Q-R!W:&5N('1H92!L
M:6-E;G-E9"!P871E;G1S(&5X<&ER92XF(S$V,#L@5&AE(%1E;&]M97)A<V4@
M4W5B;&EC96YS92!M87D@86QS;R!B92!T97)M:6YA=&5D(&)Y($%S=&5R:6%S
M(&)Y(&=I=FEN9R!'97)O;B`Y,"!D87ES('=R:71T96X@;F]T:6-E+"!B>2!!
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M3F]T92`X+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#0U<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#0U<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%S(&]F($UA<F-H
M(#,Q+"`R,#$T+"!F=71U<F4@86UO<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&QI
M8V5N<V4@9F5E<R!D97-C<FEB960@86)O=F4@=V%S(&%S(&9O;&QO=W,Z/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\=&%B;&4@86QI9VX],T1L969T
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#0U<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`V."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/EEE87(@16YD960\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D1E9F5R<F5D($QI
M8V5N<V4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R!W:61T:#H@-C@E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY$96-E;6)E<B`S,2P\+V1I=CX\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
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M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^.#,L-C$U/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
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M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD
M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,3$Q+#`P,#PO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`V."4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,C`Q-CPO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$Q,2PP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@-C@E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/C(P,3<\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3$L,#`P/"]D:78^/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
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M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#8X)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N
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M='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^
M/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.#$Y,V$X-%\W,V$T
M7S0V8F%?8CDS-U\T9CED,C!B96%E,S@O5V]R:W-H965T<R]3:&5E=#$Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C;W5N
M=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S
M(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C8N
M($%C8V]U;G1S(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#0U<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/D%T($UA<F-H(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@
M86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<R!C;VYS
M:7-T960@;V8@=&AE(&9O;&QO=VEN9SH\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT
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M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ
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M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/BAU
M;F%U9&ET960I/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,G!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D
M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D1E8V5M
M8F5R(#,Q+#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q
M,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#)P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T
M<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@-S8E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@+3<N,G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@-RXR<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/D%C8V]U;G1S('!A>6%B;&4\+V1I=CX\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@
M4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#4R
M-RPS,S`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I
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M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@
M.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/C,L.#@W+#DU,#PO9&EV/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^06-C<G5E9"!B;VYU<V5S/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^,C(Y+#DP-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-C`P+#`P,#PO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^
M3W1H97(@86-C<G5E9"!L:6%B:6QI=&EE<SPO9&EV/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M,BPV.#4L.#(X/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/C(L,C,T+#8W-#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/C4L-#0S+#`V,SPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/C8L-S(R+#8R-#PO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXW+B!%<75I='D\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
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M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY"
M:6]4:6UE(&ES(&%U=&AO<FEZ960@=&\@:7-S=64@,BPP,#`L,#`P('-H87)E
M<R!O9B!P<F5F97)R960@<W1O8VLN)B,Q-C`[(%1H92!P<F5F97)R960@<VAA
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M<W5E9"!S97)I97,@;V8@86YY('!R969E<G)E9"!S:&%R97,N)B,Q-C`[(%1H
M92!B;V%R9"!O9B!D:7)E8W1O<G,@;6%Y+"!B>2!R97-O;'5T:6]N+"!I;F-R
M96%S92!O<B!D96-R96%S92`H8G5T(&YO="!B96QO=R!T:&4@;G5M8F5R(&]F
M('-H87)E<R!O9B!S=6-H('-E<FEE<R!T:&5N(&]U='-T86YD:6YG*2!T:&4@
M;G5M8F5R(&]F('-H87)E<R!O9B!A;GD@<V5R:65S(&]F('!R969E<G)E9"!S
M:&%R97,@<W5B<V5Q=65N="!T;R!T:&4@:7-S=64@;V8@<VAA<F5S(&]F('1H
M870@<V5R:65S+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%S(&]F($UA
M<F-H(#,Q+"`R,#$T+"!":6]4:6UE(&AA<R`W,"PP,#`@;W5T<W1A;F1I;F<@
M<')E9F5R<F5D('-H87)E<RXF(S$V,#L@3VX@36%R8V@@-"P@,C`Q-"P@0FEO
M5&EM92!S;VQD(#<P+#`P,"!S:&%R97,@;V8@82!N97=L>2!A=71H;W)I>F5D
M(%-E<FEE<R!!($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R`H)B,X,C(P
M.U-E<FEE<R!!(%!R969E<G)E9"8C,38P.U-T;V-K)B,X,C(Q.RD@9F]R("0S
M+C4@;6EL;&EO;BXF(S$V,#L@5&AE(%-E<FEE<R!!(%!R969E<G)E9"!3=&]C
M:R!C87)R:65S(&$@8W5M=6QA=&EV92!A;FYU86P@,R4@<')E9F5R<F5D(&1I
M=FED96YD(&]R("0Q+C4P('!E<B!S:&%R92P@:6X@<')E9F5R96YC92!T;R!"
M:6]4:6UE(&-O;6UO;B!S:&%R97,N)B,Q-C`[($5A8V@@<VAA<F4@;V8@4V5R
M:65S($$@4')E9F5R<F5D(%-T;V-K(&ES(&-O;G9E<G1I8FQE+"!A="!T:&4@
M96QE8W1I;VX@;V8@=&AE(&AO;&1E<BP@:6YT;R!":6]4:6UE(&-O;6UO;B!S
M:&%R97,@870@82!C;VYV97)S:6]N('!R:6-E(&]F("0T+C`P('!E<B!S:&%R
M92P@82!C=7)R96YT(&-O;G9E<G-I;VX@<F%T:6\@;V8@,3(N-2!C;VUM;VX@
M<VAA<F5S(&9O<B!E86-H('-H87)E(&]F(%-E<FEE<R!!(%!R969E<G)E9"!3
M=&]C:RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
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M87)Y($QI9F5-87`@4V-I96YC97,L($EN8RX@:&5L9"!B>2!":6]4:6UE(&%T
M('1H92!R871I;R!O9B`Q,BXU('-H87)E<R!O9B!,:69E36%P(%-C:65N8V5S
M(&-O;6UO;B!S=&]C:R!F;W(@96%C:"!S:&%R92!O9B!":6]4:6UE(%-E<FEE
M<R!!(%!R969E<G)E9"!3=&]C:RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DEN(&%D9&ET:6]N('1O('1H92!P
M<F5F97)R960@9&EV:61E;F0L('1H92!397)I97,@02!0<F5F97)R960@4W1O
M8VL@=VEL;"!B92!E;G1I=&QE9"!T;R!P87)T:6-I<&%T92!W:71H($)I;U1I
M;64@8V]M;6]N('-H87)E<R!I;B!A;GD@9&EV:61E;F1S(&]R(&1I<W1R:6)U
M=&EO;G,@;VX@8V]M;6]N('-H87)E<R`H;W1H97(@=&AA;B!D:79I9&5N9',@
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M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^06QL(&]U='-T86YD:6YG(%-E<FEE<R!!(%!R
M969E<G)E9"!3=&]C:R!W:6QL(&%U=&]M871I8V%L;'D@8F4@8V]N=F5R=&5D
M(&EN=&\@8V]M;6]N('-H87)E<R!O;B!-87)C:"`T+"`R,#$Y+"!O<B!I9B!H
M;VQD97)S(&]F(&$@;6%J;W)I='D@;V8@=&AE(&]U='-T86YD:6YG('-H87)E
M<R!O9B!397)I97,@02!0<F5F97)R960@4W1O8VLL('9O=&EN9R!A<R!A(&-L
M87-S+"!A<'!R;W9E(&]R(&-O;G-E;G0@=&\@82!C;VYV97)S:6]N+B8C,38P
M.R!4:&4@8V]N=F5R<VEO;B!P<FEC92!I<R!S=6)J96-T('1O('!R;W)A=&$@
M861J=7-T;65N="!I;B!T:&4@979E;G0@;V8@82!S=6)D:79I<VEO;B!O<B!R
M96-L87-S:69I8V%T:6]N(&]F('1H92!C;VUM;VX@<VAA<F5S(&EN=&\@82!G
M<F5A=&5R(&YU;6)E<B!O9B!S:&%R97,L(&$@<W1O8VL@9&EV:61E;F0@<&%I
M9"!I;B!C;VUM;VX@<VAA<F5S+"!O<B!A('-T;V-K(&-O;6)I;F%T:6]N(&]R
M(')E8VQA<W-I9FEC871I;VX@;V8@=&AE(&-O;6UO;B!S:&%R97,@:6YT;R!A
M('-M86QL97(@;G5M8F5R(&]F('-H87)E<RX\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E1H92!397)I97,@02!0
M<F5F97)R960@4W1O8VL@=VEL;"!B92!E;G1I=&QE9"!T;R!V;W1E('=I=&@@
M8V]M;6]N('-H87)E<R!O;B!A;&P@;6%T=&5R<R!S=6)M:71T960@=&\@8V]M
M;6]N('-H87)E:&]L9&5R<R!F;W(@87!P<F]V86PN)B,Q-C`[($5A8V@@<VAA
M<F4@;V8@4V5R:65S($$@4')E9F5R<F5D(%-T;V-K('=I;&P@8F4@96YT:71L
M960@=&\@82!N=6UB97(@;V8@=F]T97,@97%U86P@=&\@=&AE(&YU;6)E<B!O
M9B!C;VUM;VX@<VAA<F5S(&EN=&\@=VAI8V@@:70@8V]U;&0@=&AE;B!B92!C
M;VYV97)T960N)B,Q-C`[(%1H92!397)I97,@02!0<F5F97)R960@4W1O8VL@
M=VEL;"!A;'-O('9O=&4@87,@82!S97!A<F%T92!C;&%S<R!O;B!C97)T86EN
M(&UA='1E<G,@869F96-T:6YG('1H;W-E('-H87)E<RX\+V1I=CX\9&EV/CQB
M<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
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M<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
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M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY":6]4:6UE(&ES(&%U=&AO<FEZ960@=&\@:7-S=64@
M,3(U+#`P,"PP,#`@8V]M;6]N('-H87)E<R!W:71H(&YO('!A<B!V86QU92XF
M(S$V,#L@07,@;V8@36%R8V@@,S$L(#(P,30L($)I;U1I;64@:&%D(&ES<W5E
M9"`V.2PV,3<L,S(Y(&-O;6UO;B!S:&%R97,@86YD(&]U='-T86YD:6YG(#4Y
M+#`W,2PQ.3(@8V]M;6]N('-H87)E<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D1U<FEN9R!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S+"!":6]4:6UE
M(')E8V]G;FEZ960@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V5S
M(&]F("0X,#$L-34T(&%N9"`D-CDQ+#DT-BP@<F5S<&5C=&EV96QY+"!D=64@
M=&\@<W1O8VL@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@9&ER
M96-T;W)S+B8C,38P.R!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,RP@0FEO5&EM92!G<F%N=&5D(#$L,C`U
M+#`P,"!A;F0@,2PP.3`L,#`P(&]P=&EO;G,L(')E<W!E8W1I=F5L>2P@=6YD
M97(@:71S(#(P,3(@17%U:71Y($EN8V5N=&EV92!0;&%N+CPO9&EV/CQD:78^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^1'5R:6YG
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30L(#0U+#`P
M,"!O<'1I;VYS(&%N9"!N;R!W87)R86YT<R!W97)E(&5X97)C:7-E9"X\+V1I
M=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E864S.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.#$Y,V$X-%\W,V$T7S0V8F%?
M8CDS-U\T9CED,C!B96%E,S@O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^07-S970@0V]N=')I
M8G5T:6]N($%G<F5E;65N=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T($-O;G1R:6)U=&EO;B!!9W)E96UE
M;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^07-S970@0V]N=')I8G5T:6]N($%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^."X@/"]F
M;VYT/D%S<V5T($-O;G1R:6)U=&EO;B!!9W)E96UE;G0\+V1I=CX\9&EV/CQB
M<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($IA;G5A
M<GD@-"P@,C`Q,RP@0FEO5&EM92!A;F0@07-T97)I87,@96YT97)E9"!I;G1O
M(&%N($%S<V5T($-O;G1R:6)U=&EO;B!!9W)E96UE;G0@=VET:"!'97)O;B!#
M;W)P;W)A=&EO;B`H)B,X,C(P.T=E<F]N)B,X,C(Q.RD@<'5R<W5A;G0@=&\@
M=VAI8V@@0FEO5&EM92!A;F0@1V5R;VX@86=R965D('1O(&-O;F-U<G)E;G1L
M>2!C;VYT<FEB=71E(&-E<G1A:6X@87-S971S('1O($%S=&5R:6%S(&EN(&5X
M8VAA;F=E(&9O<B!S:&%R97,@;V8@07-T97)I87,@8V]M;6]N('-T;V-K+B8C
M,38P.R!4:&4@=')A;G-A8W1I;VX@8VQO<V5D(&]N($]C=&]B97(@,2P@,C`Q
M,RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY4<F%N<V9E<B!O9B!":6]4:6UE($%S<V5T<SPO9&EV/CQD
M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^56YD
M97(@=&AE($%S<V5T($-O;G1R:6)U=&EO;B!!9W)E96UE;G0L($)I;U1I;64@
M8V]N=')I8G5T960@=&\@07-T97)I87,@."PY,#(L,#<W($)I;U1I;64@8V]M
M;6]N('-H87)E<R!R96=I<W1E<F5D(&9O<B!R92US86QE('5N9&5R('1H92!3
M96-U<FET:65S($%C="!O9B`Q.3,S+"!A<R!A;65N9&5D+"!W87)R86YT<R!T
M;R!S=6)S8W)I8F4@9F]R(&%N9"!P=7)C:&%S92`X+#`P,"PP,#`@861D:71I
M;VYA;"!":6]4:6UE(&-O;6UO;B!S:&%R97,@*'1H92`F(S@R,C`[0FEO5&EM
M92!787)R86YT<R8C.#(R,3LI(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O
M9B!F:79E('EE87)S(&%T(&$@<')I8V4@;V8@)#4N,#`@<&5R('-H87)E+"!S
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M(&ES<W5E9"!T;R!":6]4:6UE(#(Q+#<W,RPS-#`@<VAA<F5S(&]F(&ET<R!3
M97)I97,@0B!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,#`Q('!E<B!S
M:&%R92`H)B,X,C(P.U-E<FEE<R!"(%-H87)E<R8C.#(R,3LI+"!A;F0@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@,RPQ-3`L,#`P(%-E<FEE<R!"(%-H87)E<RP@
M97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D(&]F('1H<F5E('EE87)S(&9R;VT@
M=&AE(&1A=&4@;V8@:7-S=64@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#4N
M,#`@<&5R('-H87)E+B8C,38P.R!);B!A9&1I=&EO;BP@0FEO5&EM92!C86YC
M96QL960@07-T97)I87,F(S@R,3<[(&]B;&EG871I;VYS('1O(')E<&%Y('1H
M92!P<FEN8VEP86P@86UO=6YT(&]F(&$@;&]A;B!I;B!T:&4@86UO=6YT(&]F
M("0U+#`P,"PP,#`@87)I<VEN9R!F<F]M(&-A<V@@9FEN86YC:6YG('!R;W9I
M9&5D('1O($%S=&5R:6%S(&)Y($)I;U1I;64@9'5R:6YG(#(P,3,@<')I;W(@
M=&\@=&AE(&-L;W-I;F<@;V8@=&AE(&%S<V5T(&-O;G1R:6)U=&EO;B!T<F%N
M<V%C=&EO;B!U;F1E<B!T:&4@07-S970@0V]N=')I8G5T:6]N($%G<F5E;65N
M="X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/D)E8V%U<V4@07-T97)I87,@:7,@82!S=6)S:61I87)Y(&]F($)I
M;U1I;64L('1H92!T<F%N<V9E<B!O9B!A<W-E=',@9G)O;2!":6]4:6UE('=A
M<R!A8V-O=6YT960@9F]R(&%S(&$@=')A;G-A8W1I;VX@=6YD97(@8V]M;6]N
M(&-O;G1R;VPN)B,Q-C`[($YO;BUM;VYE=&%R>2!A<W-E=',@<F5C96EV960@
M8GD@07-T97)I87,@=V5R92!R96-O<F1E9"!A="!T:&5I<B!H:7-T;W)I8V%L
M(&-O<W0@8F%S:7,@86UO=6YT<R!W:71H($)I;U1I;64N)B,Q-C`[($UO;F5T
M87)Y(&%S<V5T<R!W97)E(')E8V]R9&5D(&%T(&9A:7(@=F%L=64N)B,Q-C`[
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M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY4:&4@87-S971S('1R86YS9F5R<F5D(&)Y($)I;U1I;64@86YD
M('1H92!R96QA=&5D(&-O;G-I9&5R871I;VX@<&%I9"!W97)E(')E8V]R9&5D
M(&%S(&9O;&QO=W,Z/"]D:78^/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`S
M<'0[(&UA<F=I;BUB;W1T;VTZ(#-P=#LG/CQB<B`O/CPO9&EV/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B
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M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^07-T97)I
M87,@4V5R:65S($(@<VAA<F5S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-3(L,38T+#4V.#PO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`X."4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W
M+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^5V%R<F%N=',@=&\@<'5R8VAA<V4@
M07-T97)I87,@4V5R:65S($(@<VAA<F5S/"]D:78^/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M,BPP,3(L-#@Q/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
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M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^-"PX,#`L,#8S/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
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M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@
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M-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E
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M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#@X)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TW+C)P=#L@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z
M(#<N,G!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY!<W-E=',@=')A;G-F97)R960@
M8GD@0FEO5&EM93H\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
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M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD
M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,3@L,C<V+#0P-CPO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`X."4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W
M+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^0V%N8V5L;&%T:6]N(&]F(&]U='-T
M86YD:6YG(&]B;&EG871I;VX@=&\@0FEO5&EM93PO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/C4L,#`P+#`P,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^26YV
M97-T;65N="!I;B!A9F9I;&EA=&5S+"!A="!C;W-T/"]D:78^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^-#$U+#4T,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^1V5R;VX@87-S970@86-Q=6ES:71I;VX@<F5L
M871E9"!T<F%N<V%C=&EO;B!C;W-T<R!P86ED(&)Y($)I;U1I;64\+V1I=CX\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/C,P,"PP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
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M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T
M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXU."PY-S<L
M,3$R/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/"]T
M86)L93X\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/E1H92!F86ER('9A;'5E(&]F('1H92!!<W1E<FEA<R!397)I97,@0B!S
M:&%R97,@:7-S=65D('=A<R!E<W1I;6%T960@870@)#(N-#`@8F%S960@;VX@
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M:&4@=V%R<F%N=',[(')I<VLM9G)E92!R871E(&]F(#`N-C,E.R`P)2!E>'!E
M8W1E9"!D:79I9&5N9"!Y:65L9#L@-CDN-C(E(&5X<&5C=&5D('9O;&%T:6QI
M='D@8F%S960@;VX@=&AE(&%V97)A9V4@:&ES=&]R:6-A;"!C;VUM;VX@<W1O
M8VL@=F]L871I;&ET>2!O9B!":6]4:6UE(&%N9"!'97)O;BP@=VAI8V@@=V5R
M92!U<V5D(&%S($%S=&5R:6%S)B,X,C$W.R!C;VUM;VX@<W1O8VL@9&]E<R!N
M;W0@:&%V92!A('1R861I;F<@:&ES=&]R>3L@82!S=&]C:R!P<FEC92!O9B`D
M,BXT,#L@86YD(&%N(&5X97)C:7-E('!R:6-E(&]F("0U+C`P+CPO9&EV/CQD
M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^0FEO
M5&EM92!C;VUM;VX@<VAA<F5S('=E<F4@=F%L=65D(&%T("0S+CDS('5S:6YG
M('1H92!C;&]S:6YG('!R:6-E('!E<B!":6]4:6UE(&-O;6UO;B!S:&%R97,@
M;VX@=&AE($Y94T4@34M4(&]N($]C=&]B97(@,2P@,C`Q,RXF(S$V,#L@5&AE
M(&9A:7(@=F%L=64@;V8@=&AE($)I;U1I;64@5V%R<F%N=',@=V%S(&-O;7!U
M=&5D('5S:6YG(&$@0FQA8VL@4V-H;VQE<R!-97)T;VX@;W!T:6]N('!R:6-I
M;F<@;6]D96PL('=H:6-H('5T:6QI>F5D('1H92!F;VQL;W=I;F<@87-S=6UP
M=&EO;G,Z(&5X<&5C=&5D('1E<FT@97%U86P@=&\@=&AE(&-O;G1R86-T=6%L
M('1E<FT@;V8@9FEV92!Y96%R<RP@=VAI8V@@:7,@97%U86P@=&\@=&AE(&-O
M;G1R86-T=6%L(&QI9F4@;V8@=&AE('=A<G)A;G1S.R!R:7-K+69R964@<F%T
M92!O9B`Q+C0R)3L@,"4@97AP96-T960@9&EV:61E;F0@>6EE;&0[(#<W+C8S
M)2!E>'!E8W1E9"!V;VQA=&EL:71Y(&)A<V5D(&]N(&AI<W1O<FEC86P@8V]M
M;6]N('-T;V-K('9O;&%T:6QI='D@;V8@0FEO5&EM93L@82!S=&]C:R!P<FEC
M92!O9B`D,RXY,SL@86YD(&%N(&5X97)C:7-E('!R:6-E(&]F("0U+C`P+CPO
M9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M="US:7IE.B`Q,'!T.R<^1V5R;VX@07-S971S($%C<75I<VET:6]N/"]D:78^
M/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
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M,3,@*'1H92`F(S@R,C`[5FEA0WET92!!<'!E86PF(S@R,C$[*2!S965K:6YG
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M=FEN9R!54R!P871E;G0@-RPU,3`L.#<V("A6:6%#>71E*2!A;F0@55,@<&%T
M96YT(&%P<&QI8V%T:6]N(#$Q+SDV,"PT-S<@*$=E<F]N*2P@86YD(%4N4RX@
M4&%T96YT($EN=&5R9F5R96YC92`Q,#4L.#(W(&EN=F]L=FEN9R!54R!P871E
M;G0@-RPU,3`L.#<V("A6:6%#>71E*2!A;F0@55,@<&%T96YT(&%P<&QI8V%T
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M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY!<R!C;VYS:61E
M<F%T:6]N(&9O<B!T:&4@86-Q=6ES:71I;VX@;V8@87-S971S(&9R;VT@1V5R
M;VXL($%S=&5R:6%S(&ES<W5E9"!T;R!'97)O;B`V+#4S-RPW-SD@<VAA<F5S
M(&]F(%-E<FEE<R!!(&-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("0P+C`P,#$@
M<&5R('-H87)E("@F(S@R,C`[4V5R:65S($$@4VAA<F5S)B,X,C(Q.RDL('=H
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M:&%R97,@=&AE(#@L,#`P+#`P,"!S:&%R97,@;V8@0FEO5&EM92!787)R86YT
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M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
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M;B!T:&4@86UO=6YT(&]F("0U-#$L.#`P+CPO9&EV/CQD:78^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&%S<V5T<R!C;VYT
M<FEB=71E9"!T;R!!<W1E<FEA<R!B>2!'97)O;B!D:60@;F]T(&EN8VQU9&4@
M=V]R:V9O<F-E(&]R(&%N>2!P<F]C97-S97,@=&\@8F4@87!P;&EE9"!T;R!T
M:&4@<&%T96YT<RP@8FEO;&]G:6-A;"!M871E<FEA;',L(&%N9"!O=&AE<B!A
M<W-E=',@86-Q=6ER960L(&%N9"!T:&5R969O<F4@9&ED(&YO="!C;VYS=&ET
M=71E(&$@8G5S:6YE<W,N)B,Q-C`[($%C8V]R9&EN9VQY+"!T:&4@86-Q=6ES
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M;G-A8W1I;VXL($]C=&]B97(@,2P@,C`Q,RP@:6X@86-C;W)D86YC92!W:71H
M($%30R`X,C`L($9A:7(@5F%L=64@365A<W5R96UE;G0N/"]D:78^/&1I=CX\
M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@87-S
M971S(&%C<75I<F5D(&9R;VT@1V5R;VX@86YD('1H92!R96QA=&5D(&-O;G-I
M9&5R871I;VX@=V5R92!R96-O<F1E9"!A<R!F;VQL;W=S.CPO9&EV/CQD:78^
M/&)R("\^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G5&EM
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M8F]T=&]M.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#@X)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M("TW+C)P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#<N,G!T.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY!<W1E<FEA<R!397)I97,@02!S:&%R97,L(&YE="!O9B!S:&%R92!I
M<W-U86YC92!C;W-T<R!O9B`D-30Q+#@P,#PO9&EV/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
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M.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C$U+#$R,2PR
M,C(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.#@E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M87)G:6XM
M;&5F=#H@-RXR<'0[(&9O;G0M<VEZ93H@,3!P=#LG/D]B;&EG871I;VX@=&\@
M9&ES=')I8G5T92!":6]4:6UE(%=A<G)A;G1S/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^,3@L,C<V+#0P-CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^5')A;G-A8W1I;VX@86YD(&]T:&5R(&-O<W1S
M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z
M(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4Q.2PY,#0\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R!W:61T:#H@.#@E.R!V97)T:6-A;"UA;&EG;CH@8F]T
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M-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXS-"PY,3<L-3,R/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
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M;VYT+7-I>F4Z(#$P<'0[)SY!<W-E=',@86-Q=6ER960@9G)O;2!'97)O;B`H
M<')E;&EM:6YA<GD@86QL;V-A=&EO;BDZ/"]D:78^/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I
M9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^4&%T96YT
M<R!A;F0@;W1H97(@:6YT96QL96-T=6%L('!R;W!E<G1Y(')I9VAT<R!R96QA
M=&5D('1O(&A%4R!C96QL<SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
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M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(Y+#`Q-RPP,#D\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.#@E.R!V97)T:6-A
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M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#$Q+#4U."PR-#,\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^*3PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.#@E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@-RXR
M<'0[(&9O;G0M<VEZ93H@,3!P=#LG/DE04B9A;7`[1"!E>'!E;G-E9"!U<&]N
M(&%C<75I<VET:6]N/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
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M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I
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M=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/C,T+#DQ-RPU,S(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/"]T<CX\+W1A8FQE/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^5&AE(&9A:7(@=F%L=64@;V8@=&AE($%S=&5R
M:6%S(%-E<FEE<R!!('-H87)E<R!I<W-U960@=V%S(&5S=&EM871E9"!A="`D
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M="US:7IE.B`Q,'!T.R<^5&AE(&9A:7(@=F%L=64@;V8@=&AE(&]B;&EG871I
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M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M;6]R92!R96QI86)L>2!D971E<FUI;F5D+CPO9&EV/CQD:78^)B,Q-C`[/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^07-S971S(&%C<75I<F5D
M(&9R;VT@1V5R;VX@8V]N<VES="!P<FEM87)I;'D@;V8@<&%T96YT<R!A;F0@
M;W1H97(@:6YT96QL96-T=6%L('!R;W!E<G1Y(')I9VAT<R!R96QA=&5D('1O
M(&A%4R!C96QL<R!W:&EC:"!!<W1E<FEA<R!I;G1E;F1S('1O(&QI8V5N<V4@
M=&\@=F%R:6]U<R!P87)T:65S(&EN=&5R97-T960@:6X@<F5S96%R8V@L(&1E
M=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!H15,@8V5L;',@
M=&5C:&YO;&]G:65S+"!A;F0@25!2)F%M<#M$+"!W:&EC:"!I;F-L=61E<R!B
M:6]L;V=I8V%L(&UA=&5R:6%L<RP@<F5A9V5N=',L(&-L:6YI8V%L('1R:6%L
M(&1O8W5M96YT871I;VXL(&9I;&5S(&%N9"!D871A(')E;&%T960@<')I;6%R
M:6QY('1O(&-E<G1A:6X@8VQI;FEC86P@=')I86QS('!R979I;W5S;'D@8V]N
M9'5C=&5D(&)Y($=E<F]N+"!W:&EC:"!'97)O;B!D:7-C;VYT:6YU960@:6X@
M3F]V96UB97(@,C`Q,2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V1I=CX\+V1I=CX\9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#,V<'0[)SY);G1A;F=I8FQE(&%S<V5T<R!R96QA=&5D('1O($E0
M4B9A;7`[1"!R97!R97-E;G0@=&AE('9A;'5E(&]F(&EN8V]M<&QE=&4@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT('!R;VIE8W1S('=H:6-H('1H92!C;VUP
M86YY(&EN=&5N9',@=&\@8V]N=&EN=64N)B,Q-C`[($EN(&%C8V]R9&%N8V4@
M=VET:"!T:&4@86-C;W5N=&EN9R!R=6QE<R!I;B!!4T,@.#`U+"!S=6-H(&%S
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M870@9&\@;F]T(&-O;G-T:71U=&4@82!B=7-I;F5S<R`H<W5C:"!A<R!T:&4@
M86-Q=6ES:71I;VX@;V8@87-S971S(&9R;VT@1V5R;VXI+"!I;B!A8V-O<F1A
M;F-E('=I=&@@=&AE(&%C8V]U;G1I;F<@<G5L97,@:6X@05-#(#@P-2TU,"P@
M<W5C:"!I;G1A;F=I8FQE(&%S<V5T<R!R96QA=&5D('1O($E04B9A;7`[1"!A
M<F4@97AP96YS960@=7!O;B!A8W%U:7-I=&EO;BX\+V1I=CX\9&EV/CQB<B`O
M/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
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M(&]F('!A=&5N=',N)B,Q-C`[(%1H92!A;6]U;G1S(&%L;&]C871E9"!T;R!P
M871E;G1S(&%N9"!O=&AE<B!I;G1E;&QE8W1U86P@<')O<&5R='D@<FEG:'1S
M('1H870@07-T97)I87,@:6YT96YD<R!T;R!L:6-E;G-E('=E<F4@8V%P:71A
M;&EZ960@87,@:6YT86YG:6)L92!A<W-E=',@86YD(&%R92!B96EN9R!A;6]R
M=&EZ960@;W9E<B!A;B!E<W1I;6%T960@=7-E9G5L(&QI9F4@<&5R:6]D(&]F
M(#$P('EE87)S+B8C,38P.R!4:&4@86UO=6YT<R!A;&QO8V%T960@=&\@25!2
M)F%M<#M$('=E<F4@97AP96YS960@870@=&AE('1I;64@;V8@86-Q=6ES:71I
M;VX@;V8@=&AE(')E;&%T960@87-S971S(&EN(&%C8V]R9&%N8V4@=VET:"!T
M:&4@<F5Q=6ER96UE;G1S(&]F($%30R`X,#4M-3`N)B,Q-C`[(%1H92!A;&QO
M8V%T:6]N('=A<R!B87-E9"!O;B!T:&4@<F5L871I=F4@9F%I<B!V86QU92!O
M9B!A<W-E=',@96QI9VEB;&4@9F]R(&-A<&ET86QI>F%T:6]N(&%N9"!T:&4@
M9F%I<B!V86QU92!O9B!A<W-E=',@<F5P<F5S96YT:6YG($E04B9A;7`[1"!B
M969O<F4@87-S97-S:6YG('1H92!D969E<G)E9"!T87@@;&EA8FEL:71Y(&%R
M:7-I;F<@9G)O;2!T:&4@9&EF9F5R96YC92!I;B!B;V]K('9E<G-U<R!T87@@
M8F%S:7,@;VX@1V5R;VX@:6YT86YG:6)L92!A<W-E=',@86-Q=6ER960L('=H
M:6-H(&UA;F%G96UE;G0@97-T:6UA=&5D('1O(&)E(&%P<')O>&EM871E;'D@
M97%U86PN)B,Q-C`[($%C8V]R9&EN9VQY+"`D,3<L-#4X+#<V-B!W87,@8V%P
M:71A;&EZ960@87,@;V8@1&5C96UB97(@,S$L(#(P,3,L(&%N9"`D,3<L-#4X
M+#<V-B!W87,@97AP96YS960N)B,Q-C`[(%1H97-E(&%M;W5N=',@87)E('!R
M96QI;6EN87)Y(&%S(&UA;F%G96UE;G0@:&%S(&YO="!Y970@8V]M<&QE=&5D
M(&$@9&5T86EL960@87-S97-S;65N="!A;F0@=F%L=6%T:6]N(&]F('1H92!A
M8W%U:7)E9"!A<W-E=',N)B,Q-C`[(%-U8V@@87-S97-S;65N="!A;F0@=F%L
M=6%T:6]N(&ES(&5X<&5C=&5D('1O(&)E(&-O;7!L971E9"!D=7)I;F<@=&AE
M('%U87)T97(@96YD:6YG($IU;F4@,S`L(#(P,30N)B,Q-C`[($%C8V]R9&EN
M9VQY+"!T:&4@86UO=6YT<R!I;F-L=61E9"!I;B!C87!I=&%L:7IE9"!I;G1A
M;F=I8FQE(&%S<V5T<R!A;F0@97AP96YS960@25!2)F%M<#M$(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$S(&%R92!S=6)J96-T('1O(&%D:G5S=&UE;G1S('=H
M:6-H(&-O=6QD(&)E(&UA=&5R:6%L+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I
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M="!S86QE<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY3=&]C:R!A;F0@5V%R<F%N="!0=7)C:&%S92!!
M9W)E96UE;G0@=VET:"!2;VUU;'5S/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S
M-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!*86YU87)Y(#0L(#(P,3,L
M(&EN(&-O;FYE8W1I;VX@=VET:"!E;G1E<FEN9R!I;G1O('1H92!!<W-E="!#
M;VYT<FEB=71I;VX@06=R965M96YT+"!!<W1E<FEA<R!E;G1E<F5D(&EN=&\@
M82!3=&]C:R!A;F0@5V%R<F%N="!0=7)C:&%S92!!9W)E96UE;G0@=VET:"!2
M;VUU;'5S($9I;&US+"!,=&0@*"8C.#(R,#M2;VUU;'5S)B,X,C(Q.RD@<'5R
M<W5A;G0@=&\@=VAI8V@@4F]M=6QU<R!A9W)E960@=&\@<'5R8VAA<V4@,BPQ
M,S8L,#`P(%-E<FEE<R!"(%-H87)E<R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA
M<V4@,S4P+#`P,"!A9&1I=&EO;F%L(%-E<FEE<R!"(%-H87)E<R!F;W(@)#4L
M,#`P+#`P,"!I;B!C87-H('5P;VX@=&AE(&-O;G-U;6UA=&EO;B!O9B!T:&4@
M86-Q=6ES:71I;VX@;V8@87-S971S('5N9&5R('1H92!!<W-E="!#;VYT<FEB
M=71I;VX@06=R965M96YT+B8C,38P.R!/;B!/8W1O8F5R(#$L(#(P,3,L('1H
M92!S:&%R97,@86YD('=A<G)A;G1S('=E<F4@:7-S=65D(&EN(&5X8VAA;F=E
M(&9O<B`D-2PP,#`L,#`P(&EN(&-A<V@N/"]D:78^/"]D:78^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E5N875D:71E9"!0<F\@1F]R;6$@26YT
M97)I;2!&:6YA;F-I86P@26YF;W)M871I;VX@+2!4:')E92!-;VYT:',@16YD
M960@36%R8V@@,S$L(#(P,30@86YD(#(P,3,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY5;F%U9&ET960@4')O($9O
M<FUA($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N("T@5&AR964@36]N
M=&AS($5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N
M875D:71E9"!0<F\@1F]R;6$@26YT97)I;2!&:6YA;F-I86P@26YF;W)M871I
M;VX@+2!4:')E92!-;VYT:',@16YD960@36%R8V@@,S$L(#(P,30@86YD(#(P
M,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXY+B!5;F%U9&ET960@4')O($9O<FUA($EN=&5R:6T@1FEN86YC:6%L
M($EN9F]R;6%T:6]N("8C.#(Q,3L@5&AR964@36]N=&AS($5N9&5D($UA<F-H
M(#,Q+"`R,#$T(&%N9"`R,#$S/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S
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M:6]N('1O;VL@<&QA8V4@;VX@2F%N=6%R>2`Q+"`R,#$S+B8C,38P.R!4:&4@
M<')O(&9O<FUA(&EN9F]R;6%T:6]N(&1O97,@;F]T(&YE8V5S<V%R:6QY(')E
M9FQE8W0@=&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<R!T:&%T('=O=6QD(&AA
M=F4@;V-C=7)R960@:&%D('1H92!E;G1I=&EE<R!B965N(&$@<VEN9VQE(&-O
M;7!A;GD@9'5R:6YG('1H92!P97)I;V1S('!R97-E;G1E9"X\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`T.2XU
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B
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M97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA
M<F=I;BUR:6=H=#H@,2XQ<'0[)SXR,#$T/"]D:78^/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/C(P,3,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/BA5;F%U9&ET
M960I/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,G!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
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M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@-S8E.R!V97)T:6-A;"UA;&EG
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M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
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M;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DE
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXT.3,L-S`U/"]D:78^/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
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M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED
M=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
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M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
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M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B@X+#`Y.2PP,30\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
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M)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`W-B4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W
M+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`W
M-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I
M;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^3F5T(&QO<W,@<&5R
M(&-O;6UO;B!S:&%R92`F(S@R,3$[(&)A<VEC(&%N9"!D:6QU=&5D/"]D:78^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#`N,30\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^*3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
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M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXQ
M,"X@4W5B<V5Q=65N="!%=F5N=',\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DEN($UA>2`R,#$T+"!":6]4:6UE
M(')A:7-E9"`D-BPS.#`L-C0P(&]F(&%D9&ET:6]N86P@97%U:71Y(&-A<&ET
M86P@=&AR;W5G:"!T:&4@<V%L97,@;V8@0FEO5&EM92!C;VUM;VX@<VAA<F5S
M)B,Q-C`[:6X@)B,X,C(P.V%T+71H92UM87)K970F(S@R,C$[('1R86YS86-T
M:6]N<R!T:')O=6=H($-A;G1O<B!&:71Z9V5R86QD("9A;7`[($-O+BP@87,@
M0FEO5&EM92=S('-A;&5S(&%G96YT+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/D]N($UA>2`U+"`R,#$T+"!":6]4:6UE('=A<R!A=V%R9&5D(&%N(%-"
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M)SY0=7)E4W1E;3QS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M
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M.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^3&EF94UA<"!3;VQU=&EO;G,L($EN8RXF(S@R,3([36]B:6QE
M($AE86QT:"!3;V9T=V%R92!0<F]D=6-T<SPO9&EV/CQD:78^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@36%Y(#8L(#(P,30L
M($QI9F5-87`@4V]L=71I;VYS+"!);F,N("@F(S@R,C`[4V]L=71I;VYS)B,X
M,C(Q.RDL(&$@;F5W;'D@9F]R;65D('-U8G-I9&EA<GD@;V8@3&EF94UA<"!3
M8VEE;F-E<RP@96YT97)E9"!I;G1O(&$@0V\M1&5V96QO<&UE;G0@86YD($]P
M=&EO;B!!9W)E96UE;G0@*'1H92`F(S@R,C`[06=R965M96YT)B,X,C(Q.RD@
M=VET:"!T:&4@26-A:&X@4V-H;V]L(&]F($UE9&EC:6YE(&%T($UO=6YT(%-I
M;F%I+"!A(&YO;G!R;V9I="!E9'5C871I;VX@8V]R<&]R871I;VX@*"8C.#(R
M,#M-="!3:6YA:28C.#(R,3LI+"!P=7)S=6%N="!T;R!W:&EC:"!3;VQU=&EO
M;G,@86YD($UT(%-I;F%I(&AA=F4@86=R965D('1O('=O<FL@8V]O<&5R871I
M=F5L>2!T;R!D979E;&]P(&EN=&5R;F5T+"!W96(M8F%S960L(&UO8FEL92!U
M<V5R(&]R(&-O;G-U;65R('-O9G1W87)E('!R;V1U8W1S('1O('!R;W9I9&4@
M=7-E<G,@=VET:"!I;F9O<FUA=&EO;B!T:&%T(&UA>2!P;W1E;G1I86QL>2!A
M:60@=&AE;2!I;B!I;7!R;W9I;F<@;&EF97-T>6QE(&%N9"!H96%L=&AC87)E
M(&1E8VES:6]N<R!A;F0@;W5T8V]M97,N/"]D:78^/&1I=CX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY3;VQU=&EO;G,@86YD($UT
M(%-I;F%I('=I;&P@;&EC96YS92!T;R!E86-H(&]T:&5R+"!O;B!A(&YO;BUE
M>&-L=7-I=F4L(')O>6%L='D@9G)E92!B87-I<RP@8V5R=&%I;B`F(S@R,C`[
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M('1O('=A:79E(&-O;&QE8W1I;VX@;V8@=&AE(&9I<G-T("0Q+#`P,"PP,#`@
M;V8@;W9E<FAE860@8VAA<F=E<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
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M<F-I<V5S(&ET<R!O<'1I;VX@=6YD97(@=&AE($%G<F5E;65N="`H=&AE("8C
M.#(R,#M,:6-E;G-E($%G<F5E;65N="8C.#(R,3LI(&%R92!S=6)J96-T('1O
M(&YE9V]T:6%T:6]N(&)Y('1H92!P87)T:65S+"!B=70@=VEL;"!I;F-L=61E
M(&-E<G1A:6X@<')O=FES:6]N<R!S<&5C:69I960@:6X@=&AE($%G<F5E;65N
M="P@:6YC;'5D:6YG('1H92!O8FQI9V%T:6]N(&]F(%-O;'5T:6]N<R!T;R!P
M87D@370@4VEN86DZ("AA*2!R;WEA;'1I97,@;VX@;F5T('-A;&5S+"`H8BD@
M82!P97)C96YT86=E(&]F(&%N>2!C;VYS:61E<F%T:6]N(')E8V5I=F5D(&)Y
M(%-O;'5T:6]N<R!F<F]M(&ET<R!S=6)L:6-E;G-E97,@86YD(&1I<W1R:6)U
M=&]R<R!O9B!T:&4@<')O9'5C=#L@*&,I(&%L;"!R96%S;VYA8FQE('!A=&5N
M="!A;F0@;&EC96YS:6YG(&-O<W1S(&EN8W5R<F5D('!R:6]R('1O('1H92!E
M9F9E8W1I=F4@9&%T92!O9B!T:&4@9&5F:6YI=&EV92!,:6-E;G-E($%G<F5E
M;65N="!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&QI8V5N<V5D('!A=&5N="!R
M:6=H=',@86YD(&-E<G1A:6X@;W1H97(@36]U;G0@4VEN86D@=&5C:&YO;&]G
M>2!A;F0@8F%C:V=R;W5N9"!I;G1E;&QE8W1U86P@<')O<&5R='DL(&%N9"!A
M;&P@<F5A<V]N86)L92!A='1O<FYE>28C.#(Q-SMS(&9E97,L(&5X<&5N<V5S
M+"!O9F9I8VEA;"!F965S+"!A;F0@;W1H97(@8VAA<F=E<R!I;F-I9&5N="!T
M;R!T:&4@<')E<&%R871I;VXL('!R;W-E8W5T:6]N+"!A;F0@;6%I;G1E;F%N
M8V4@;V8@;&EC96YS960@<&%T96YT(')I9VAT<SH@86YD("AD*2!U<"!T;R`U
M)2!O9B!T:&4@=&AE;B!C=7)R96YT(&5Q=6ET>2!V86QU92!O9B!3;VQU=&EO
M;G,@870@=&AE('1I;64@;V8@82`F(S@R,C`[4VEG;FEF:6-A;G0@5')A;G-A
M8W1I;VXN)B,X,C(Q.R8C,38P.R!4:&4@<&5R8V5N=&%G92!T;R!B92!P86ED
M(&ES('-U8FIE8W0@=&\@9&EL=71I;VX@8F%S960@;VX@9G5T=7)E(&EN=F5S
M=&UE;G0@:6X@4V]L=71I;VYS(&%N9"!T:&4@86UO=6YT(&]F('!E<G-O;FYE
M;"!C;W-T(&]V97)H96%D(&-H87)G97,@=V%I=F5D(&)Y($UT(%-I;F%I('5N
M9&5R('1H92!!9W)E96UE;G0N)B,Q-C`[(%1H92!T97)M("8C.#(R,#M3:6=N
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M;&QY(&]W;B!L97-S('1H86X@9FEF='D@<&5R8V5N="`H-3`E*2!O9B!T:&4@
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M:6]N<R!I<W-U97,@<V5C=7)I=&EE<R`H;W1H97(@=&AA;B!T:')O=6=H(&%N
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M969T.R!F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/DQI9F5-87`@4V-I96YC97,@4W1O8VL@4'5R8VAA<V4@06=R965M96YT/"]D
M:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY!;'-O(&]N($UA>2`V+"`R,#$T+"!":6]4:6UE(&5N=&5R960@:6YT;R!A
M(%-T;V-K(%!U<F-H87-E($%G<F5E;65N="!W:71H($QI9F5-87`@4V-I96YC
M97,@=&\@<')O=FED92!F:6YA;F-I;F<@9F]R(%-O;'5T:6]N<R8C.#(Q-SL@
M<')O9'5C="!D979E;&]P;65N="!C;W-T<R!U;F1E<B!T:&4@06=R965M96YT
M('=I=&@@370@4VEN86DN)B,Q-C`[($)I;U1I;64@=VEL;"!P=7)C:&%S92`R
M+#4P,"PP,#`@<VAA<F5S(&]F($QI9F5-87`@4V-I96YC97,@8V]M;6]N('-T
M;V-K(&9O<B`D-2PP,#`L,#`P(&EN(&9O=7(@=')A;F-H97,@9'5R:6YG(#(P
M,30N)B,Q-C`[($QI9F5-87`@4V-I96YC97,@=VEL;"!U<V4@=&AE('!R;V-E
M961S(&9R;VT@=&AE('-A;&4@=&\@<')O=FED92!C87!I=&%L('1O(%-O;'5T
M:6]N<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/D)I;U1I;64@=VEL;"!A;'-O(&AA=F4@86X@;W!T:6]N('1O
M('!U<F-H87-E('5P('1O(&%N(&%D9&ET:6]N86P@.2PU,#`L,#`P('-H87)E
M<R!O9B!,:69E36%P(%-C:65N8V5S(&-O;6UO;B!S=&]C:R!F;W(@)#(N,#`@
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M,C`@=')A9&EN9R!D87ES+B8C,38P.R!4:&4@;G5M8F5R(&]F('-H87)E<R!O
M9B!,:69E36%P(%-C:65N8V5S(&-O;6UO;B!S=&]C:R!T:&%T($)I;U1I;64@
M;6%Y('!U<F-H87-E('=I;&P@8F4@<F5D=6-E9"!T;R!T:&4@97AT96YT('1H
M870@3&EF94UA<"!38VEE;F-E<R!R86ES97,@8V%P:71A;"!F<F]M(&]T:&5R
M('-O=7)C97,@9F]R('!R;V1U8W0@9&5V96QO<&UE;G0@=6YD97(@=&AE($%G
M<F5E;65N="!W:71H($UT(%-I;F%I+CPO9&EV/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
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M.B`Q,'!T.R<^+#PO9F]N=#X@,C`Q-"`H=6YA=61I=&5D*2XF(S$V,#L@4W5B
M<V5Q=65N="!E=F5N=',@:&%V92!B965N(&5V86QU871E9"!T:')O=6=H('1H
M870@9&%T92X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R
M,&)E864S.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.#$Y,V$X
M-%\W,V$T7S0V8F%?8CDS-U\T9CED,C!B96%E,S@O5V]R:W-H965T<R]3:&5E
M=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5U!!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY/<F=A;FEZ871I;VXL($)A<VES(&]F(%!R97-E;G1A=&EO;BP@86YD(%-U
M;6UA<GD@;V8@4V5L96-T(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0F%S:7,@;V8@4')E<V5N
M=&%T:6]N+"!A;F0@4W5M;6%R>2!O9B!396QE8W0@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY'96YE<F%L/"]F;VYT/B`F(S@R,3$[($)I;U1I;64@:7,@82!B:6]T96-H
M;F]L;V=Y(&-O;7!A;GD@96YG86=E9"!I;B!T=V\@87)E87,@;V8@8FEO;65D
M:6-A;"!R97-E87)C:"!A;F0@<')O9'5C="!D979E;&]P;65N="X@0FEO5&EM
M92=S('!R:6UA<GD@9F]C=7,@:7,@:6X@=&AE(&9I96QD(&]F(')E9V5N97)A
M=&EV92!M961I8VEN93L@<W!E8VEF:6-A;&QY(&AU;6%N(&5M8G)Y;VYI8R!S
M=&5M("@F(S@R,C`[:$53)B,X,C(Q.RD@8V5L;"!A;F0@:6YD=6-E9"!P;'5R
M:7!O=&5N="!S=&5M("@F(S@R,C`[:5!3)B,X,C(Q.RD@8V5L;"!T96-H;F]L
M;V=Y+B8C,38P.R!296=E;F5R871I=F4@;65D:6-I;F4@<F5F97)S('1O('1H
M97)A<&EE<R!B87-E9"!O;B!S=&5M(&-E;&P@=&5C:&YO;&]G>2!T:&%T(&%R
M92!D97-I9VYE9"!T;R!R96)U:6QD(&-E;&P@86YD('1I<W-U92!F=6YC=&EO
M;B!L;W-T(&1U92!T;R!D96=E;F5R871I=F4@9&ES96%S92!O<B!I;FIU<GDN
M)B,Q-C`[(&A%4R!A;F0@:5!3(&-E;&QS('!R;W9I9&4@82!M96%N<R!O9B!M
M86YU9F%C='5R:6YG(&5V97)Y(&-E;&P@='EP92!I;B!T:&4@:'5M86X@8F]D
M>2!A;F0@=&AE<F5F;W)E('-H;W<@8V]N<VED97)A8FQE('!R;VUI<V4@9F]R
M('1H92!D979E;&]P;65N="!O9B!A(&YU;6)E<B!O9B!N97<@=&AE<F%P975T
M:6,@<')O9'5C=',N)B,Q-C`[($)I;U1I;64@86YD(&ET<R!S=6)S:61I87)I
M97,@<&QA;B!T;R!D979E;&]P('-T96T@8V5L;"!P<F]D=6-T<R!F;W(@<F5S
M96%R8V@@86YD('1H97)A<&5U=&EC('5S92XF(S$V,#L@07-T97)I87,@0FEO
M=&AE<F%P975T:6-S+"!);F,N("@F(S@R,C`[07-T97)I87,F(S@R,C$[*2!A
M8W%U:7)E9"!T:&4@<W1E;2!C96QL(&%S<V5T<R!O9B!'97)O;B!#;W)P;W)A
M=&EO;B`H)B,X,C(P.T=E<F]N)B,X,C(Q.RD@=&AA="!H860@8F5E;B!U<V5D
M(&EN($=E<F]N)B,X,C$W.W,@:$53(&-E;&P@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT('!R;V=R86US(&9O<B!T:&4@9&5V96QO<&UE;G0@;V8@<')O9'5C
M=',@9F]R(&AU;6%N('1H97)A<&5U=&EC<R!I;B!T:&4@9F]L;&]W:6YG(&9I
M96QD<SH@;F5U<F]L;V=Y+"!O;F-O;&]G>2P@;W)T:&]P961I8W,L(&%N9"!H
M96%R="!F86EL=7)E(&%N9"!M>6]C87)D:6%L(&EN9F%R8W1I;VXN)B,Q-C`[
M($]N8V]#>71E($-O<G!O<F%T:6]N("@F(S@R,C`[3VYC;T-Y=&4F(S@R,C$[
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M<W1I8R!A;F0@;W9E<BUS96%S(&UA<FME=',N)B,Q-C`[($]R=&AO0WET92!#
M;W)P;W)A=&EO;B`H)B,X,C(P.T]R=&AO0WET928C.#(R,3LI(&ES(&1E=F5L
M;W!I;F<@=&AE<F%P:65S('1O('1R96%T(&]R=&AO<&5D:6,@9&ES;W)D97)S
M+"!D:7-E87-E<R!A;F0@:6YJ=7)I97,N)B,Q-C`[(%)E0WET92!4:&5R87!E
M=71I8W,L($EN8RX@*"8C.#(R,#M294-Y=&4@5&AE<F%P975T:6-S)B,X,C(Q
M.RD@:7,@9&5V96QO<&EN9R!T:&5R87!I97,@=&\@=')E870@82!V87)I971Y
M(&]F(&-A<F1I;W9A<V-U;&%R(&%N9"!R96QA=&5D(&ES8VAE;6EC(&1I<V]R
M9&5R<RP@87,@=V5L;"!A<R!P<F]D=6-T<R!F;W(@<F5S96%R8V@@=7-I;F<@
M8V5L;"!R97!R;V=R86UM:6YG('1E8VAN;VQO9WDN)B,Q-C`[($-E;&P@0W5R
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M=6QT:7!L92!S8VQE<F]S:7,N)B,Q-C`[($QI9F5-87`@4V-I96YC97,L($EN
M8RX@*"8C.#(R,#M,:69E36%P(%-C:65N8V5S)B,X,C(Q.RD@;6%R:V5T<RP@
M<V5L;',@86YD(&1I<W1R:6)U=&5S(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^1V5N94-A<F1S/"]F
M;VYT/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ93H@
M<VUA;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[/"]S
M=7`^+"!T:&4@;&5A9&EN9R!H=6UA;B!G96YE(&1A=&%B87-E(&%N9"!A;B!I
M;G1E9W)A=&5D(&1A=&%B87-E('-U:71E('1H870@:6YC;'5D97,@/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY'96YE0V%R9',\+V9O;G0^/'-U<"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3L@9F]N="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X
M="UT;W`[)SXF(S$W-#L\+W-U<#XL('1H92`\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DQI9F5-87`@
M1&ES8V]V97)Y/"]F;VYT/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[
M(&9O;G0M<VEZ93H@<VUA;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P
M.R<^)B,Q-S0[/"]S=7`^(&1A=&%B87-E(&]F(&5M8G)Y;VYI8R!D979E;&]P
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M.B`Q,'!T.R<^0FEO5&EM92!I<R!F;V-U<VEN9R!A('!O<G1I;VX@;V8@:71S
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M;B!B92!S;VQD('=I=&AO=70@<F5G=6QA=&]R>2`H1D1!*2!A<'!R;W9A;"P@
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M="US:7IE.B`Q,'!T.R<^0FEO5&EM92!P<F5V:6]U<VQY(&1E=F5L;W!E9"!B
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M/CQS=7`@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$[(&9O;G0M<VEZ93H@<VUA
M;&QE<CL@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P.R<^)B,Q-S0[/"]S=7`^
M+"!F<F]M('1H92!S86QE(&]F('!R;V1U8W1S(&9O<B!R97-E87)C:"P@86YD
M(&9R;VT@<F5S96%R8V@@9W)A;G1S+B8C,38P.SPO9&EV/CQD:78^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE('5N875D:71E
M9"!C;VYD96YS960@8V]N<V]L:61A=&5D(&EN=&5R:6T@8F%L86YC92!S:&5E
M="!A<R!O9B!-87)C:"`S,2P@,C`Q-"P@=&AE('5N875D:71E9"!C;VYD96YS
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M:"!T:&4@:6YS=')U8W1I;VYS(&9R;VT@1F]R;2`Q,"U1(&%N9"!296=U;&%T
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M965N(&UA9&4N)B,Q-C`[(%1H928C,38P.V-O;G-O;&ED871E9"!B86QA;F-E
M('-H965T(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S(&ES(&1E<FEV960@9G)O
M;2!T:&4@0V]M<&%N>28C.#(Q-SMS(&%N;G5A;"!A=61I=&5D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&%S(&]F('1H870@9&%T92XF(S$V,#L@5&AE(')E<W5L
M=',@;V8@;W!E<F%T:6]N<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@
M;V8@=&AE(&]P97)A=&EN9R!R97-U;'1S(&%N=&EC:7!A=&5D(&9O<B!T:&4@
M9G5L;"!Y96%R(&]F(#(P,30N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T
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M;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H)B,X,C(P.U-%0R8C.#(R,3LI(&5X
M8V5P="!F;W(@=&AE)B,Q-C`[8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@
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M8V5M8F5R(#,Q+"`R,#$S+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&QE<R!O9B!C;VYS;VQI
M9&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F
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M(')E9FQE8W1S($)I;U1I;64F(S@R,3<[<R!O=VYE<G-H:7`L(&1I<F5C=&QY
M(&]R('1H<F]U9V@@;VYE(&]R(&UO<F4@<W5B<VED:6%R:65S+"!O9B!T:&4@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&ET<R!S=6)S:61I87)I97,N/"]D:78^
M/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`S<'0[(&UA<F=I;BUB;W1T;VTZ
M(#-P=#LG/CQB<B`O/CPO9&EV/CQT86)L92!B;W)D97(],T0P(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B!M961I=6T@;F]N93L@=VED
M=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&)O<F1E<BUT;W`Z(&UE9&EU
M;2!N;VYE.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/'1R/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,S`E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY3=6)S:61I87)Y/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#0Y+CDX
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S
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M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X
M('-O;&ED.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B
M;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M
M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^0FEO
M5&EM92`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D]W;F5R
M<VAI<#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE
M9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[('=I
M9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S
M;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)SY#;W5N=')Y/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O
M<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO
M;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/D%S=&5R:6%S($)I;W1H97)A<&5U=&EC<RP@26YC+CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N
M;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D
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M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/C<Q+C8E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DN
M.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P
M,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I
M9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY%4R!#96QL($EN=&5R;F%T:6]N86P@4'1E($QT9#PO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG
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M9F]N="US:7IE.B`Q,'!T.R<^<')O9'5C960@=6YD97(@8T=-4#PO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG
M:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C$P,"4\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R
M+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P
M,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4VEN9V%P;W)E/"]D:78^/"]T
M9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M
M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI
M9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E
M<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]N8V]#>71E($-O<G!O
M<F%T:6]N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R
M=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D-A;F-E
M<B!D:6%G;F]S=&EC<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@
M<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q,"XQ
M,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/C<U+C,E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DN.24[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`S
M,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
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M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
M:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N
M93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^3W)T:&]P961I8R!D:7-E87-E<RP@:6YC;'5D:6YG(&-H
M<F]N:6,@8F%C:R!P86EN(&%N9"!O<W1E;V%R=&AR:71I<SPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D
M97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z
M(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C$P,"4\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!W:61T:#H@.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P
M,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^55-!/"]D:78^/"]T9#X\+W1R/CQT
M<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O
M<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@
M;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/D-E;&P@0W5R92!.975R;W-C:65N8V5S
M($QT9"X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M
M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@-#DN.3@E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^06=E+7)E
M;&%T960@;6%C=6QA<B!D96=E;F5R871I;VX\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^375L=&EP;&4@<V-L97)O<VES/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/E!A<FMI;G-O;B8C.#(Q-SMS(&1I<V5A
M<V4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I
M=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXV,BXU)3PO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N
M;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R
M+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY)<W)A96P\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4F5#>71E
M(%1H97)A<&5U=&EC<RP@26YC+CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY687-C=6QA<B!D:7-O<F1E<G,L(&EN8VQU9&EN9R!C87)D:6]V
M87-C=6QA<BUR96QA=&5D(&1I<V5A<V5S+"!I<V-H96UI8R!C;VYD:71I;VYS
M+"!V87-C=6QA<B!I;FIU<FEE<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^
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M<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O
M<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H
M=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^.30N."4\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R
M+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P
M,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^55-!/"]D:78^/"]T9#X\+W1R
M/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O
M<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H
M=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D)I;U1I;64@07-I82P@3&EM:71E
M9#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU
M;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY3=&5M(&-E;&P@
M<')O9'5C=',@9F]R(')E<V5A<F-H/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED
M=&@Z(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^.#$E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DN
M.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/DAO;F<@2V]N9SPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT
M;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N
M;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY,:69E36%P(%-C:65N8V5S+"!);F,N/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O
M<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R=&EC86PM86QI9VXZ('1O
M<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H
M=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D=E;F5T:6,L(&1I<V5A<V4L(&%N
M9"!S=&5M(&-E;&P@9&%T86)A<V5S/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED
M=&@Z(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^-S,N,B4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^55-!/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL
M969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M
M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/DQI9F5-87`@4V-I96YC97,L($QT9"X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4W1E;2!C96QL(&1A
M=&%B87-E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$P+C$R
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM
M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^*#$I/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DN.24[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/DES<F%E;#PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUR
M:6=H=#H@;65D:75M(&YO;F4[)SY,:69E36%P(%-O;'5T:6]N<RP@26YC+CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
M;&ED.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SY-;V)I;&4@
M:&5A;'1H('-O9G1W87)E/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P
M.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^*#$I/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.2XY)3L@=F5R
M=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S
M;VQI9#LG/E5303PO=&0^/"]T<CX\+W1A8FQE/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TR-W!T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M87)G:6XM
M;&5F=#H@,C=P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&-L
M87-S/3-$1%-01DQI<W1486)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@<W1Y;&4],T0G=VED=&@Z(#(W<'0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#L@=F5R=&EC86PM86QI9VXZ('1O<#L@86QI
M9VXZ(')I9VAT.R<^*#$I/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(&%U=&\[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@=F5R=&EC
M86PM86QI9VXZ('1O<#LG/DQI9F5-87`@4V-I96YC97,L($QT9"X@86YD($QI
M9F5-87`@4V]L=71I;VYS+"!);F,N(&%R92!W:&]L;'DM;W=N960@<W5B<VED
M:6%R:65S(&]F($QI9F5-87`@4V-I96YC97,L($EN8RX\+W1D/CPO='(^/"]T
M86)L93X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
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M871I;VX@4RU8+B8C,38P.R!!<R!O9B!-87)C:"`S,2P@,C`Q-"P@0FEO5&EM
M92!C;VYS;VQI9&%T960@07-T97)I87,L(%)E0WET92!4:&5R87!E=71I8W,L
M($]N8V]#>71E+"!/<G1H;T-Y=&4L($5322P@0V5L;"!#=7)E($YE=7)O<V-I
M96YC97,L($)I;U1I;64@07-I82P@3&EM:71E9"`H)B,X,C(P.T)I;U1I;64@
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V5R=&%I;B!S:6=N:69I8V%N="!R:7-K<R!A;F0@=6YC97)T86EN
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^0V5R=&%I;B!S:6=N:69I8V%N="!R:7-K<R!A
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M:71Y('1O(&1E=F5L;W`@;F5W('-T96T@8V5L;"!R97-E87)C:"!P<F]D=6-T
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M9'5C=',@86YD(&UE9&EC86P@9&5V:6-E<R`H86YD(')E;&%T960@=')E871M
M96YT*2!F<F]M(&=O=F5R;FUE;G0@:&5A;'1H(&%D;6EN:7-T<F%T:6]N(&%U
M=&AO<FET:65S+"!P<FEV871E(&AE86QT:"!C;W9E<F%G92!I;G-U<F5R<RP@
M86YD(&]T:&5R(&]R9V%N:7IA=&EO;G,N/"]D:78^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@
M97-T:6UA=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY5<V4@;V8@97-T:6UA=&5S/"]F;VYT
M/B`F(S@R,3$[(%1H92!P<F5P87)A=&EO;B!O9B!C;VYD96YS960@8V]N<V]L
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M<W1I;6%T97,N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(')E8V]G;FET:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY2979E;G5E(')E8V]G;FET:6]N/"]F;VYT/B`F(S@R,3$[
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M(&%D=F5R=&ES:6YG('!E<FEO9',N)B,Q-C`[($]T:&5R(&QI8V5N<V4@9F5E
M<R!U;F1E<B!C97)T86EN(&QI8V5N<V4@86=R965M96YT<R!W97)E(')E8V]G
M;FEZ960@9'5R:6YG('!R:6]R('!E<FEO9',@=VAE;B!E87)N960@86YD(')E
M87-O;F%B;'D@97-T:6UA8FQE+B8C,38P.R!2;WEA;'1I97,@8V]N<VES="!P
M<FEM87)I;'D@;V8@<F]Y86QT:65S(&5A<FYE9"!O;B!S86QE<R!O9B`\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/DAE>'1E;F0\+V9O;G0^/'-U<"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3L@9F]N="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X
M="UT;W`[)SXF(S$W-#L\+W-U<#X@86YD(&%R92!R96-O9VYI>F5D(&%S(')E
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M;64@<F5C96EV97,@=7`M9G)O;G0@;F]N<F5F=6YD86)L92!L:6-E;G-I;F<@
M;W(@<VEM:6QA<B!F965S('!U<G-U86YT('1O(&%G<F5E;65N=',@=6YD97(@
M=VAI8V@@0FEO5&EM92!D;V5S(&AA=F4@8V]N=&EN=6EN9R!P97)F;W)M86YC
M92!O8FQI9V%T:6]N<RP@=&AE(&9E97,@87)E(&1E9F5R<F5D(&%N9"!A;6]R
M=&EZ960@<F%T86)L>2!O=F5R('1H92!P97)F;W)M86YC92!P97)I;V0N)B,Q
M-C`[($EF('1H92!P97)F;W)M86YC92!P97)I;V0@8V%N;F]T(&)E(')E87-O
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M(&%S(')E=F5N=64@=VAE;B!E87)N960N)B,Q-C`[(%)E=F5N=65S(&9R;VT@
M=&AE('-A;&4@;V8@<F5S96%R8V@@<')O9'5C=',@87)E('!R:6UA<FEL>2!D
M97)I=F5D(&9R;VT@=&AE('-A;&4@;V8@:'ED<F]G96QS(&%N9"!S=&5M(&-E
M;&P@<')O9'5C=',N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]F;VYT/B`F(S@R,3$[($)I;U1I;64@8V]N<VED97)S(&%L;"!H:6=H;'D@
M;&EQ=6ED(&EN=F5S=&UE;G1S('!U<F-H87-E9"!W:71H(&%N(&]R:6=I;F%L
M(&UA='5R:71Y(&]F('1H<F5E(&UO;G1H<R!O<B!L97-S('1O(&)E(&-A<V@@
M97%U:79A;&5N=',N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE
M(&%N9"!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY!8V-O=6YT<R!R96-E:79A8FQE(&%N9"!A;&QO=V%N8V4@9F]R(&1O
M=6)T9G5L(&%C8V]U;G1S/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/B`F(S@R,3$[)B,Q-C`[(%1O=&%L('1R861E(')E8V5I
M=F%B;&5S(&%M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)#8P,"PT,#`@86YD
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXD
M-3<U+#DP,"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^86YD(&=R86YT<R!R96-E:79A8FQE(&%M;W5N=&5D('1O(&%P<')O
M>&EM871E;'D@)#,S-"PW,#`@86YD("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^-3,Y+#,P,#PO9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX@87,@;V8@36%R8V@@,S$L(#(P
M,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S+"!R97-P96-T:79E;'DN)B,Q-C`[
M(%-O;64@;V8@=&AE<V4@86UO=6YT<R!A<F4@9&5E;65D('5N8V]L;&5C=&EB
M;&4[(&%S('-U8V@@0FEO5&EM92!R96-O9VYI>F5D(&%L;&]W86YC92!F;W(@
M9&]U8G1F=6P@86-C;W5N=',@;V8@87!P<F]X:6UA=&5L>2`D,3$V+#@P,"!A
M<R!O9B!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,N)B,Q
M-C`[($)I;U1I;64@979A;'5A=&5S('1H92!C;VQL96-T86)I;&ET>2!O9B!I
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M=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DEN=F5N=&]R>2`F(S@R
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M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O
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M,RX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y
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M(&EM<&%I<FUE;G0N)B,Q-C`[($%C<75I<F5D(&EN+7!R;V-E<W,@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&EN=&%N9VEB;&4@87-S971S(&%R92!A8V-O
M=6YT960@9F]R(&1E<&5N9&EN9R!O;B!W:&5T:&5R('1H97D@=V5R92!A8W%U
M:7)E9"!A<R!P87)T(&]F(&%N(&%C<75I<VET:6]N(&]F(&$@8G5S:6YE<W,L
M(&]R(&%S(&%S<V5T<R!T:&%T(&1O(&YO="!C;VYS=&ET=71E(&$@8G5S:6YE
M<W,N)B,Q-C`[(%=H96X@86-Q=6ER960@:6X@8V]N:G5N8W1I;VX@=VET:"!A
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M;"!L:79E<R!A="!T:&%T('!O:6YT(&EN('1I;64N)B,Q-C`[($AO=V5V97(L
M('=H96X@86-Q=6ER960@:6X@8V]N:G5N8W1I;VX@=VET:"!A;B!A8W%U:7-I
M=&EO;B!O9B!A<W-E=',@=&AA="!D;R!N;W0@8V]N<W1I='5T92!A(&)U<VEN
M97-S("AS=6-H(&%S('1H92!A8W%U:7-I=&EO;B!O9B!A<W-E=',@9G)O;2!'
M97)O;BDL(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@86-C;W5N=&EN9R!R=6QE
M<R!I;B!!4T,@.#`U+34P+"!S=6-H(&EN=&%N9VEB;&4@87-S971S(')E;&%T
M960@=&\@:6XM<')O8V5S<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@*"8C
M.#(R,#M)4%(F86UP.T0F(S@R,C$[*2!A<F4@97AP96YS960@=7!O;B!A8W%U
M:7-I=&EO;BX@4V5E($YO=&4@."X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY4<F5A<W5R>2!S=&]C:R`F(S@R,3$[/"]F;VYT
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('1O('!U<F-H
M87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5V%R<F%N=',@=&\@<'5R
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M(&EN(&-A<V@N)B,Q-C`[($EF($)I;U1I;64@=V5R92!T;R!I<W-U92!W87)R
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M<&5R871I;VYS+CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!S86QE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0871E;G0@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/E!A=&5N="!C;W-T<R`F(S@R,3$[/"]F;VYT
M/B!#;W-T<R!A<W-O8VEA=&5D('=I=&@@;V)T86EN:6YG('!A=&5N=',@;VX@
M<')O9'5C=',@;W(@=&5C:&YO;&]G>2!D979E;&]P960@87)E(&5X<&5N<V5D
M(&%S(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S('=H96X@
M:6YC=7)R960N)B,Q-C`[(%1H:7,@86-C;W5N=&EN9R!I<R!I;B!C;VUP;&EA
M;F-E('=I=&@@9W5I9&%N8V4@<')O;75L9V%T960@8GD@=&AE($9I;F%N8VEA
M;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H=&AE("8C.#(R,#M&05-"
M)B,X,C(Q.RD@<F5G87)D:6YG(&=O;V1W:6QL(&%N9"!O=&AE<B!I;G1A;F=I
M8FQE(&%S<V5T<RX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I
M9VX@8W5R<F5N8WD@=')A;G-L871I;VX@9V%I;B]L;W-S(&%N9"!#;VUP<F5H
M96YS:79E(&YE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY&;W)E:6=N(&-U<G)E;F-Y
M('1R86YS;&%T:6]N(&=A:6X@86YD($-O;7!R96AE;G-I=F4@;&]S<R`F(S@R
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M<V]L:61A=&5D(&)A;&%N8V4@<VAE970N)B,Q-C`[($9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S+"!C;VUP<F5H
M96YS:79E(&QO<W,@:6YC;'5D97,@9F]R96EG;B!C=7)R96YC>2!T<F%N<VQA
M=&EO;B!L;W-S(&]F("0Q,#0L-3DP(&%N9"!G86EN(&]F("0Q-#@L-#,W+"!R
M97-P96-T:79E;'D@86YD('5N<F5A;&EZ960@;&]S<R!O9B`D,BPV-3`@;VX@
M1V5R;VX@8V]M;6]N('-H87)E<R!H96QD(&)Y($%S=&5R:6%S(&%S(&]F($UA
M<F-H(#,Q+"`R,#$T+B!4:&4@=6YR96%L:7IE9"!G86EN+VQO<W,@9G)O;2!T
M:&4@1V5R;VX@<VAA<F5S(&ES(&$@8V]M<&]N96YT(&]F(&-O;7!R96AE;G-I
M=F4@;&]S<R!B96-A=7-E('1H97-E('-H87)E<R!A<F4@8V]N<VED97)E9"!A
M(&UA<FME=&%B;&4@97%U:71Y('-E8W5R:71Y('1H870F(S$V,#MA<F4@879A
M:6QA8FQE(&9O<B!S86QE+B!&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,RP@9F]R96EG;B!C=7)R96YC>2!T<F%N
M<V%C=&EO;B!L;W-S+"!I;F-L=61E9"!I;B!O=&AE<B!I;F-O;64O*&5X<&5N
M<V4I+"8C,38P.V%M;W5N=&5D('1O("0Q,"PR,3(@86YD("0R,2PY-S<L(')E
M<W!E8W1I=F5L>2X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87AE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^26YC;VUE('1A>&5S("8C.#(Q,3L\+V9O;G0^($)I;U1I;64@86-C
M;W5N=',@9F]R(&EN8V]M92!T87AE<R!I;B!A8V-O<F1A;F-E('=I=&@@1T%!
M4"!R97%U:7)E;65N=',L('=H:6-H('!R97-C<FEB92!T:&4@=7-E(&]F('1H
M92!A<W-E="!A;F0@;&EA8FEL:71Y(&UE=&AO9"P@=VAE<F5B>2!D969E<G)E
M9"!T87@@87-S970@;W(@;&EA8FEL:71Y(&%C8V]U;G0@8F%L86YC97,@87)E
M(&-A;&-U;&%T960@870@=&AE(&)A;&%N8V4@<VAE970@9&%T92!U<VEN9R!C
M=7)R96YT('1A>"!L87=S(&%N9"!R871E<R!I;B!E9F9E8W0N)B,Q-C`[(%9A
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M>"!P<F]V:7-I;VX@=VET:"!":6]4:6UE)B,X,C$W.W,N)B,Q-C`[($)I;U1I
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M<G,@8F5F;W)E(#(P,3`N)B,Q-C`[($%N>2!P;W1E;G1I86P@97AA;6EN871I
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M=&5X="UI;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D$@9&5F97)R960@
M:6YC;VUE('1A>"!B96YE9FET(&]F(&%P<')O>&EM871E;'D@)#$L,S0Y+#`P
M,"!W87,@<F5C;W)D960@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@@,S$L(#(P,30L(&]F('=H:6-H(&%P<')O>&EM871E;'D@)#$L,34Q+#`P
M,"!W87,@<F5L871E9"!T;R!F961E<F%L(&%N9"`D,3DX+#`P,"!W87,@<F5L
M871E9"!T;R!S=&%T92!T87AE<RXF(S$V,#L@02!D969E<G)E9"!I;F-O;64@
M=&%X(&)E;F5F:70@;V8@87!P<F]X:6UA=&5L>2`D,RPR.#`L,#`P('=A<R!R
M96-O<F1E9"!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L
M(&]F('=H:6-H(&%P<')O>&EM871E;'D@)#(L.#`P+#`P,"!W87,@<F5L871E
M9"!T;R!F961E<F%L(&%N9"`D-#@P+#`P,"!W87,@<F5L871E9"!T;R!S=&%T
M92!T87AE<RXF(S$V,#L@3F\@=&%X(&)E;F5F:70@:&%D(&)E96X@<F5C;W)D
M960@=&AR;W5G:"`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY397!T96UB97(@,S`L(#(P,3,\+V9O;G0^(&)E8V%U<V4@;V8@=&AE(&YE
M="!O<&5R871I;F<@;&]S<V5S(&EN8W5R<F5D(&%N9"!A(&9U;&P@=F%L=6%T
M:6]N(&%L;&]W86YC92!H860@8F5E;B!P<F]V:61E9"X\+V1I=CX\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#,V<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4W1O8VLM
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M;VYS+"!B87-E9"!O;B!E<W1I;6%T960@9F%I<B!V86QU97,N)B,Q-C`[($EN
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M)B,Q-C`[($-O;G-I<W1E;G0@=VET:"!T:&]S92!G=6ED96QI;F5S+"!":6]4
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M-C`[(%1H97-E('9A<FEA8FQE<R!I;F-L=61E+"!B=70@87)E(&YO="!L:6UI
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M)B,Q-C`[($%L=&AO=6=H('1H92!F86ER('9A;'5E(&]F(&5M<&QO>65E('-T
M;V-K(&]P=&EO;G,@:7,@9&5T97)M:6YE9"!I;B!A8V-O<F1A;F-E('=I=&@@
M<F5C96YT($9!4T(@9W5I9&%N8V4L(&-H86YG97,@:6X@=&AE('-U8FIE8W1I
M=F4@87-S=6UP=&EO;G,@8V%N(&UA=&5R:6%L;'D@869F96-T('1H92!E<W1I
M;6%T960@=F%L=64N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F(&QO;F<M
M;&EV960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!L:6-E;G-E(&%N9"!C;VYS=6QT:6YG(&9E97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
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M<V5D(')E<V5A<F-H('!R;V1U8W1S+B8C,38P.R!3964@3F]T92`U+CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DQO<W,@<&5R('-H87)E
M/"]F;VYT/B`F(S@R,3$[($)A<VEC(&YE="!L;W-S('!E<B!S:&%R92!I<R!C
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M8V]M;6]N('-H87)E<RP@<W5C:"!A<R!O<'1I;VYS(&%N9"!W87)R86YT<R`H
M=7-I;F<@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"D@86YD('-H87)E<R!I
M<W-U86)L92!I;B!F=71U<F4@<&5R:6]D<RP@97AC97!T(&EN(&-A<V5S('=H
M97)E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV92XF(S$V,#L@
M1&EL=71E9"!L;W-S('!E<B!S:&%R92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"`S,2P@,C`Q-"P@86YD(#(P,3,@97AC;'5D97,@86YY(&5F
M9F5C="!F<F]M(#$P+#4T-BPQ,S<@=')E87-U<GD@<VAA<F5S+"`U+#0Y,2PS
M,#$@;W!T:6]N<R!A;F0@.2PW-3$L-C$U('=A<G)A;G1S(&%N9"`R+#,V,"PY
M-C@@=')E87-U<GD@<VAA<F5S+"`T+#<W,2PS,#$@;W!T:6]N<R!A;F0@.#$V
M+#8Q,B!W87)R86YT<RP@<F5S<&5C=&EV96QY+CPO9&EV/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!V86QU92!O9B!F:6YA;F-I86P@:6YS=')U;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/D9A:7(@=F%L=64@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S/"]F;VYT/B`F
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C="!O9B!R
M96-E;G1L>2!I<W-U960@86YD(')E8V5N=&QY(&%D;W!T960@86-C;W5N=&EN
M9R!P<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^169F96-T(&]F(')E8V5N
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0F%S:7,@;V8@4')E<V5N=&%T
M:6]N+"!A;F0@4W5M;6%R>2!O9B!396QE8W0@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0F%S:7,@
M;V8@4')E<V5N=&%T:6]N+"!A;F0@4W5M;6%R>2!O9B!396QE8W0@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE)W,@
M;W=N97)S:&EP(&]F(&]U='-T86YD:6YG('-H87)E<R!O9B!I=',@<W5B<VED
M:6%R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^5&AE(&9O;&QO=VEN9R!T86)L92!R969L96-T<R!":6]4:6UE
M)B,X,C$W.W,@;W=N97)S:&EP+"!D:7)E8W1L>2!O<B!T:')O=6=H(&]N92!O
M<B!M;W)E('-U8G-I9&EA<FEE<RP@;V8@=&AE(&]U='-T86YD:6YG('-H87)E
M<R!O9B!I=',@<W5B<VED:6%R:65S+CPO9&EV/CQD:78@<W1Y;&4],T0G;6%R
M9VEN+71O<#H@,W!T.R!M87)G:6XM8F]T=&]M.B`S<'0[)SX\8G(@+SX\+V1I
M=CX\=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B
M;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93L@8F]R9&5R+7)I
M9VAT.B!M961I=6T@;F]N93LG/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M
M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^4W5B<VED:6%R>3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P
M,#`P,"`R<'@@<V]L:60[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M
M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D9I96QD(&]F($)U<VEN97-S/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO
M;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P
M+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D)I;U1I;64@/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY/=VYE<G-H:7`\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R
M+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@.2XY)3L@=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
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M;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`S,"4[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
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M(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@
M;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^4F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!C;VUM
M97)C:6%L:7IA=&EO;B!O9B!H=6UA;B!T:&5R87!E=71I8R!P<F]D=6-T<R!F
M<F]M('-T96T@8V5L;',@<&]T96YT:6%L;'D@:6X@=&AE(&9I96QD<R!O9B!N
M975R;VQO9WDL(&]N8V]L;V=Y+"!O<G1H;W!E9&EC<RP@86YD(&-A<F1I;VQO
M9WD\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I
M=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXW,2XV)3PO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N
M;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R
M+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY54T$\+V1I
M=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M
M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^15,@0V5L;"!)
M;G1E<FYA=&EO;F%L(%!T92!,=&0\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^4W1E;2!C96QL('!R;V1U8W1S(&9O<B!R97-E87)C:"P@:6YC
M;'5D:6YG(&-L:6YI8V%L(&=R861E(&-E;&P@;&EN97,\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/G!R;V1U8V5D('5N9&5R(&-'35`\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXQ,#`E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN
M.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/E-I;F=A<&]R93PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT
M;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N
M;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY/;F-O0WET92!#;W)P;W)A=&EO;CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D
M97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z
M(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY#86YC97(@9&EA9VYO<W1I8W,\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N
M93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,3`N,3(E.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R
M+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-2XS)3PO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@=&]P
M.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT
M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY54T$\+V1I=CX\+W1D
M/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@
M;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R
M+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3W)T:&]#>71E($-O<G!O
M<F%T:6]N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R
M=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D]R=&AO
M<&5D:6,@9&ES96%S97,L(&EN8VQU9&EN9R!C:')O;FEC(&)A8VL@<&%I;B!A
M;F0@;W-T96]A<G1H<FET:7,\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M,3`N,3(E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXQ,#`E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY#96QL($-U<F4@3F5U<F]S8VEE;F-E<R!,=&0N/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E
M<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#0Y+CDX)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@
M;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%G92UR96QA=&5D(&UA8W5L87(@9&5G
M96YE<F%T:6]N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/DUU
M;'1I<&QE('-C;&5R;W-I<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY087)K:6YS;VXF(S@R,3<[<R!D:7-E87-E/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL
M969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CL@=VED=&@Z(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D
M:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^-C(N-24\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z
M(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@.2XY)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+71O
M<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R
M<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^27-R865L/"]D:78^/"]T9#X\+W1R/CQT
M<CX\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M(&YO;F4[(&)O
M<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#,P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@
M;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/E)E0WET92!4:&5R87!E=71I8W,L($EN
M8RX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I
M=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5F%S8W5L87(@
M9&ES;W)D97)S+"!I;F-L=61I;F<@8V%R9&EO=F%S8W5L87(M<F5L871E9"!D
M:7-E87-E<RP@:7-C:&5M:6,@8V]N9&ET:6]N<RP@=F%S8W5L87(@:6YJ=7)I
M97,\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^4W1E;2!C96QL
M+61E<FEV960@96YD;W1H96QI86P@86YD(&-A<F1I;W9A<V-U;&%R(')E;&%T
M960@<')O9V5N:71O<B!C96QL<R!F;W(@<F5S96%R8V@L(&1R=6<@=&5S=&EN
M9RP@86YD('1H97)A<&5U=&EC<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/CDT+C@E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@;65D:75M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN
M.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P
M,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`S,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY":6]4:6UE($%S:6$L($QI;6ET960\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D
M97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I
M=6T@;F]N93LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^4W1E;2!C96QL('!R;V1U8W1S(&9O<B!R97-E
M87)C:#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE
M9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C@Q)3PO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE9&EU;2!N
M;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R
M+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY(;VYG($MO
M;F<\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O
M;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V
M97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93LG/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3&EF
M94UA<"!38VEE;F-E<RP@26YC+CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&UE9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`T.2XY."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY'96YE=&EC+"!D:7-E87-E+"!A;F0@<W1E;2!C96QL(&1A=&%B
M87-E<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&UE
M9&EU;2!N;VYE.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C<S+C(E
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@;65D:75M
M(&YO;F4[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D
M97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E5303PO
M9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@
M<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`S,"4[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY,
M:69E36%P(%-C:65N8V5S+"!,=&0N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#0Y+CDX)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@;65D:75M
M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/E-T96T@8V5L;"!D871A8F%S93PO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q,"XQ,B4[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M
M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q*3PO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y+CDE.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY)<W)A96P\+V1I
M=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O
M;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,S`E.R!V
M97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE
M.R<^3&EF94UA<"!3;VQU=&EO;G,L($EN8RX\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE9G0Z
M(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@-#DN.3@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M<FEG:'0Z(&UE9&EU;2!N;VYE.R<^36]B:6QE(&AE86QT:"!S;V9T=V%R93PO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUL969T.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z
M(#$P+C$R)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+7)I9VAT.B!M
M961I=6T@;F]N93LG/B@Q*3PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#DN.24[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[)SY54T$\+W1D/CPO
M='(^/"]T86)L93X\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`M,C=P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#(W<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T5&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M='(^/'1D('-T>6QE/3-$)W=I9'1H.B`R-W!T.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&%L:6=N.B!R:6=H=#LG/B@Q*3PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B!A=71O
M.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SY,
M:69E36%P(%-C:65N8V5S+"!,=&0N(&%N9"!,:69E36%P(%-O;'5T:6]N<RP@
M26YC+B!A<F4@=VAO;&QY+6]W;F5D('-U8G-I9&EA<FEE<R!O9B!,:69E36%P
M(%-C:65N8V5S+"!);F,N/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6EP;65N="`H5&%B;&5S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0L(&9U<FYI='5R92!A;F0@
M9FEX='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL
M>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY!="!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L
M(#(P,3,L(&5Q=6EP;65N="P@9G5R;FET=7)E(&%N9"!F:7AT=7)E<R!W97)E
M(&-O;7!R:7-E9"!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#0Y+C5P=#L@9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,G!X('-O;&ED.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SY-87)C:"`S,2P@,C`Q-#PO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4
M:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^*'5N875D:71E9"D\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^1&5C96UB97(@,S$L/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXR,#$S/"]D:78^/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^17%U:7!M
M96YT+"!F=7)N:71U<F4@86YD(&9I>'1U<F5S/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-"PV-#4L
M,#<W/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\
M='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@-S8E
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M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*#$L-C@U+#DR-SPO9&EV
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
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M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T
M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#DU.2PQ
M-3`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T
M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#DY-RPW
M,S,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,S@Q.3-A.#1?-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B
M85]B.3,W7S1F.60R,&)E864S."]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE
M(&%S<V5T<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN=&%N9VEB;&4@87-S971S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,S9P=#L@
M9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^070@36%R8V@@,S$L(#(P,30@86YD($1E
M8V5M8F5R(#,Q+"`R,#$S+"!I;G1A;F=I8FQE(&%S<V5T<R!A;F0@:6YT86YG
M:6)L92!A<W-E=',@;F5T(&]F(&%M;W)T:7IA=&EO;B!W97)E(&-O;7!R:7-E
M9"!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV/CQD:78^/&)R("\^/"]D:78^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
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M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY-87)C:"`S,2P@,C`Q
M-#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^*'5N875D:71E
M9"D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^1&5C96UB97(@,S$L
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXR,#$S/"]D:78^
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^26YT86YG:6)L92!A<W-E=',\+V1I=CX\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@
M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
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M.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO
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M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/'1R
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#<V)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TW+C)P=#L@9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE
M9G0Z(#<N,G!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY!8V-U;75L871E9"!A;6]R
M=&EZ871I;VX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B@Y+#@W.2PX,S$\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^*3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*#@L-3$Q+#@S,SPO9&EV/CPO
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^26YT86YG:6)L92!A<W-E=',L(&YE=#PO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.
M97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXT
M-"PX-#`L,#@W/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O
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M,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M-#8L,C`X+#`X-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED
M=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)O
M>6%L='D@3V)L:6=A=&EO;B!A;F0@1&5F97)R960@3&EC96YS92!&965S("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F]Y86QT>2!/8FQI9V%T:6]N(&%N9"!$969E<G)E9"!,:6-E
M;G-E($9E97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&QI
M8V5N<V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#0U<'0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#LG/D%S(&]F($UA<F-H(#,Q+"`R,#$T+"!F=71U<F4@86UO
M<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&QI8V5N<V4@9F5E<R!D97-C<FEB960@
M86)O=F4@=V%S(&%S(&9O;&QO=W,Z/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V1I=CX\=&%B;&4@86QI9VX],T1L969T(&)O<F1E<CTS1#`@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@.#`E.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M;6%R9VEN+6QE9G0Z(#0U<'0[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V."4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/EEE87(@16YD960\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/D1E9F5R<F5D($QI8V5N<V4\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-C@E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SY$96-E;6)E<B`S,2P\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,G!X('-O;&ED.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
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M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^.#,L-C$U/"]D:78^
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^,3$Q+#`P,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`V."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R<^,C`Q-CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C$Q,2PP,#`\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@-C@E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(P,3<\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DE.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXQ,3$L,#`P/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
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M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
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M.R!P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT
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M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,X,3DS83@T7S<S
M831?-#9B85]B.3,W7S1F.60R,&)E864S.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\S.#$Y,V$X-%\W,V$T7S0V8F%?8CDS-U\T9CED,C!B96%E
M,S@O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E
M9"!,:6%B:6QI=&EE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S(%!A>6%B;&4@86YD
M($%C8W)U960@3&EA8FEL:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L
M92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#0U<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/D%T($UA<F-H(#,Q+"`R,#$T
M(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@86-C;W5N=',@<&%Y86)L92!A;F0@
M86-C<G5E9"!L:6%B:6QI=&EE<R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN
M9SH\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9&EV/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
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M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P
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M97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/BAU;F%U9&ET960I/"]D:78^/"]T9#X\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
M<'@@<V]L:60[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("<G5&EM97,@
M3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/D1E8V5M8F5R(#,Q+#PO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE
M<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
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M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W
M(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z
M(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#4R-RPS,S`\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C,L
M.#@W+#DU,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA
M<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^06-C<G5E9"!B
M;VYU<V5S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,C(Y+#DP-3PO9&EV/CPO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@
M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^-C`P+#`P,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`W-B4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W
M+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^3W1H97(@86-C<G5E9"!L:6%B:6QI
M=&EE<SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,BPV.#4L.#(X/"]D:78^/"]T9#X\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(L,C,T+#8W-#PO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C4L-#0S
M+#`V,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C8L-S(R
M+#8R-#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%S<V5T($-O
M;G1R:6)U=&EO;B!!9W)E96UE;G0@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E="!#;VYT<FEB
M=71I;VX@06=R965M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T<R!4<F%N<V9E<G)E9"!B
M>2!":6]4:6UE(&%N9"!296QA=&5D($-O;G-I9&5R871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M
M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@87-S
M971S('1R86YS9F5R<F5D(&)Y($)I;U1I;64@86YD('1H92!R96QA=&5D(&-O
M;G-I9&5R871I;VX@<&%I9"!W97)E(')E8V]R9&5D(&%S(&9O;&QO=W,Z/"]D
M:78^/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`S<'0[(&UA<F=I;BUB;W1T
M;VTZ(#-P=#LG/CQB<B`O/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
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M-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`X."4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W
M+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^07-T97)I87,@4V5R:65S($(@<VAA
M<F5S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^-3(L,38T+#4V.#PO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^5V%R<F%N=',@=&\@<'5R8VAA<V4@07-T97)I87,@4V5R:65S
M($(@<VAA<F5S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD
M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^,BPP,3(L-#@Q/"]D:78^
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
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M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-"PX,#`L,#8S
M/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E
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M1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L
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M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
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M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DE
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@
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M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#DE
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
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M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#DE.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXS-"PY.#4L,38S/"]D:78^/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/'1R
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#@X)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z("TW+C)P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#<N,G!T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY":6]4:6UE(%=A<G)A;G1S+"!A="!F86ER('9A;'5E/"]D:78^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^,3@L,C<V+#0P-CPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^0V%N8V5L;&%T:6]N(&]F(&]U='-T86YD:6YG(&]B;&EG871I
M;VX@=&\@0FEO5&EM93PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C4L,#`P+#`P,#PO
M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`X."4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T
M.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^26YV97-T;65N="!I;B!A9F9I
M;&EA=&5S+"!A="!C;W-T/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N
M)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-#$U+#4T,SPO
M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE
M<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T
M.R<^1V5R;VX@87-S970@86-Q=6ES:71I;VX@<F5L871E9"!T<F%N<V%C=&EO
M;B!C;W-T<R!P86ED(&)Y($)I;U1I;64\+V1I=CX\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C,P
M,"PP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\
M='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.#@E
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M93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT
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M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S
M<V5T<R!!8W%U:7)E9"!F<F]M($=E<F]N(&%N9"!296QA=&5D($-O;G-I9&5R
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@
M)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY4:&4@87-S971S(&%C<75I<F5D(&9R;VT@1V5R;VX@86YD('1H
M92!R96QA=&5D(&-O;G-I9&5R871I;VX@=V5R92!R96-O<F1E9"!A<R!F;VQL
M;W=S.CPO9&EV/CQD:78^/&)R("\^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R!F;VYT+69A
M;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M87)G
M:6XM;&5F=#H@-RXR<'0[(&9O;G0M<VEZ93H@,3!P=#LG/D-O;G-I9&5R871I
M;VX@<&%I9"!T;R!'97)O;CH\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO
M=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
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M(&YE="!O9B!S:&%R92!I<W-U86YC92!C;W-T<R!O9B`D-30Q+#@P,#PO9&EV
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$U+#$R,2PR,C(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F
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M;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^,3@L,C<V+#0P-CPO9&EV/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`X
M."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M
M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I
M;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^5')A;G-A8W1I;VX@
M86YD(&]T:&5R(&-O<W1S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CL@=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4Q.2PY,#0\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.#@E.R!V97)T
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M861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I
M;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N
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M;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
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M960@9G)O;2!'97)O;B`H<')E;&EM:6YA<GD@86QL;V-A=&EO;BDZ/"]D:78^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[('=I9'1H.B`X."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G
M+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^4&%T96YT<R!A;F0@;W1H97(@:6YT96QL96-T=6%L('!R;W!E
M<G1Y(')I9VAT<R!R96QA=&5D('1O(&A%4R!C96QL<SPO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/C(Y
M+#`Q-RPP,#D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
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M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*#$Q+#4U."PR-#,\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9&EV/CPO=&0^
M/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@.#@E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M
M87)G:6XM;&5F=#H@-RXR<'0[(&9O;G0M<VEZ93H@,3!P=#LG/DE04B9A;7`[
M1"!E>'!E;G-E9"!U<&]N(&%C<75I<VET:6]N/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@
M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R
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M:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T
M:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/C,T+#DQ-RPU,S(\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?
M-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E
M864S."]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY5;F%U9&ET960@4')O($9O<FUA($EN=&5R
M:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N("T@5&AR964@36]N=&AS($5N9&5D
M($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S("A486)L97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^56YA=61I=&5D
M(%!R;R!&;W)M82!);G1E<FEM($9I;F%N8VEA;"!);F9O<FUA=&EO;B`M(%1H
M<F5E($UO;G1H<R!%;F1E9"!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5;F%U9&ET960@4')O($9O<FUA($EN9F]R;6%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,S9P=#L@9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O
M;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&9O
M;&QO=VEN9R!U;F%U9&ET960@<')O(&9O<FUA(&EN9F]R;6%T:6]N(&=I=F5S
M(&5F9F5C="!T;R!T:&4@87-S970@86-Q=6ES:71I;VX@=&AR;W5G:"!T:&4@
M07-S970@0V]N=')I8G5T:6]N($%G<F5E;65N="!W:71H($=E<F]N(&%S(&EF
M('1H92!T<F%N<V%C=&EO;B!T;V]K('!L86-E(&]N($IA;G5A<GD@,2P@,C`Q
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M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA
M;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#<@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT
M.B`U+C5P=#LG/E1H<F5E($UO;G1H<R!%;F1E9"!-87)C:"`S,2P\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#$N,7!T.R<^,C`Q-#PO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE
M=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXR,#$S/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&UA<F=I;BUL969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXH56YA=61I=&5D*3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^*%5N875D:71E9"D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
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M;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Y)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^.3,T+#<R,3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^-#DS+#<P-3PO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`W-B4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S
M($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`W+C)P
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[('=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`W-B4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY
M.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&UA<F=I;BUL
M969T.B`W+C)P=#L@9F]N="US:7IE.B`Q,'!T.R<^3F5T(&QO<W,@879A:6QA
M8FQE('1O(&-O;6UO;B!S:&%R96AO;&1E<G,\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
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M;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2
M;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+V1I
M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9&EV/CPO=&0^/'1D
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M/"]F;VYT/C(R+#4W,BPX-3(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^*3PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T
M:#H@-S8E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R!F;VYT
M+69A;6EL>3H@)R=4:6UE<R!.97<@4F]M86XG)RP@5&EM97,L('-E<FEF.R!M
M87)G:6XM;&5F=#H@-RXR<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CL@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@
M.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E<G1I
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M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@
M.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#LG/B@P+C$T/"]D:78^/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B<G+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/BD\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CL@=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("<G
M5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH/"]F;VYT/C`N,S@\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[('=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("<G5&EM97,@3F5W(%)O;6%N)R<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9&EV/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,S@Q.3-A.#1?-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B
M85]B.3,W7S1F.60R,&)E864S."]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$551$-)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA
M=&EO;BP@0F%S:7,@;V8@4')E<V5N=&%T:6]N+"!A;F0@4W5M;6%R>2!O9B!3
M96QE8W0@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CY-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!I
M;F-O;64@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PS-#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(&EN8V]M92!T87@@8F5N969I="P@9F5D97)A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-3$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T87@@
M8F5N969I="P@<W1A=&4@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Y."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;VYC;VYT<F]L;&EN9R!);G1E<F5S="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&4@86-C;W5N
M=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C`P+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S4L.3`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F%N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S,T+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,SDL,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L.#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q-BPX,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL
M(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-L871I
M;VX@*&QO<W,I+V=A:6X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P-"PU.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30X+#0S
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5N<F5A;&EZ960@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,BPV-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-A8W1I;VX@;&]S<R!I;F-L=61E9"!I
M;B!O=&AE<B!I;F-O;64O*&5X<&5N<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$P+#(Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C$L.3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17%U:7!M96YT(%M-96UB97)=('P@36EN:6UU;2!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y
M+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0@=7-E9G5L(&QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S-B!M;VYT:',\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT(%M-96UB97)=
M('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0@=7-E
M9G5L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,C`@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S=&5R
M:6%S($)I;W1H97)A<&5U=&EC<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG($EN=&5R97-T(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE($]W
M;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<Q+C8P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%4R!#96QL($EN=&5R;F%T:6]N86P@4'1E+BP@3'1D+B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG
M($EN=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y":6]4:6UE($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3VYC;T-Y=&4@0V]R<&]R871I;VX@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;VYC;VYT
M<F]L;&EN9R!);G1E<F5S="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0FEO5&EM92!/=VYE<G-H:7`@*&EN(&AU;F1R961T
M:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2XS,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)T:&]#>71E($-O<G!O
M<F%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3F]N8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H
M=6YD<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#96QL($-U
M<F4@3F5U<F]S8VEE;F-E<RP@3'1D+B!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG($EN=&5R97-T(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE
M($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8R+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y294-Y=&4@5&AE<F%P975T:6-S+"!);F,N(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N8V]N=')O;&QI;F<@26YT
M97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H=6YD<F5D=&AS*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30N.#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@07-I82P@3&EM:71E9"!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL
M:6YG($EN=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y":6]4:6UE($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:69E36%P(%-C:65N8V5S+"!)
M;F,N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N
M8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H=6YD
M<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,N,C`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI9F5-87`@4V-I
M96YC97,L($QT9"X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY.;VYC;VYT<F]L;&EN9R!);G1E<F5S="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO5&EM92!/=VYE<G-H:7`@
M*&EN(&AU;F1R961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EF94UA<"!3;VQU=&EO;G,L($EN8RX@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;VYC;VYT<F]L
M;&EN9R!);G1E<F5S="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0FEO5&EM92!/=VYE<G-H:7`@*&EN(&AU;F1R961T:',I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS
M=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@3W!T:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R
M;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T
M:79E('-H87)E<R!E>&-L=61E9"!F<F]M(&-O;7!U=&%T:6]N(&]F(&1I;'5T
M960@;&]S<R!P97(@<VAA<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L-#DQ+#,P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-S<Q+#,P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I
M97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@
M4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%N=&DM9&EL=71I=F4@<VAA<F5S(&5X8VQU9&5D(&9R;VT@8V]M<'5T
M871I;VX@;V8@9&EL=71E9"!L;W-S('!E<B!S:&%R92`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW-3$L-C$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$V+#8Q,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y(%-H
M87)E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N
M=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I
M;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-H87)E<R!E
M>&-L=61E9"!F<F]M(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@;&]S<R!P97(@
M<VAA<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#4T-BPQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#,V,"PY-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#4^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@
M("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C
M;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^3&EF94UA<"!38VEE;F-E<RP@3'1D
M+B!A;F0@3&EF94UA<"!3;VQU=&EO;G,L($EN8RX@87)E('=H;VQL>2UO=VYE
M9"!S=6)S:61I87)I97,@;V8@3&EF94UA<"!38VEE;F-E<RP@26YC+CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139!04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^26YV96YT;W)Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);G9E;G1O<GD@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2!O9B!F:6YI<VAE
M9"!P<F]D=6-T<R!O;BUS:71E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(R,RPV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$V-2PW-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2!H96QD(&)Y('1H
M:7)D('!A<G1Y(&]N(&-O;G-I9VYM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$R+#DR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L.3(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A*04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^17%U:7!M96YT("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6EP
M;65N="P@9G5R;FET=7)E(&%N9"!F:7AT=7)E<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP
M;65N="P@9G5R;FET=7)E(&%N9"!F:7AT=7)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T+#8T-2PP-S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#0S,2PU.#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M
M=6QA=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PV.#4L.3(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#0S,RPX-3,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT+"!N970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.34Y+#$U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY
M-RPW,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<')E8VEA=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(U-BPY-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q,RPS-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E,04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YT86YG:6)L92!A<W-E=',@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YT86YG:6)L92!A<W-E=',L(&YE="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4T+#<Q.2PY,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U-"PW,3DL.3$X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!A;6]R
M=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL.#<Y
M+#@S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH."PU,3$L.#,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#@T,"PP.#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L,C`X
M+#`X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT86YG:6)L92!A<W-E=',L('5S969U;"!L:69E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L,S8W+#DY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C0R+#4W,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,X,3DS83@T7S<S831?-#9B
M85]B.3,W7S1F.60R,&)E864S.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S.#$Y,V$X-%\W,V$T7S0V8F%?8CDS-U\T9CED,C!B96%E,S@O5V]R
M:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%639#2SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY2;WEA;'1Y($]B;&EG871I;VX@86YD($1E9F5R<F5D
M($QI8V5N<V4@1F5E<R`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$P/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY54T0@*"0I
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^5T%21B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^5T%21B!;365M
M8F5R73QB<CY-:6YI;75M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^5T%21B!;365M8F5R73QB
M<CY-87AI;75M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^061V86YC960@0V5L;"!496-H;F]L
M;V=Y+"!);F,N(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY!9'9A;F-E9"!#
M96QL(%1E8VAN;VQO9WD@26YC+BP@=VET:"!+:7)I;B!3=6)L:6-E;G-E($D@
M6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D%D=F%N8V5D($-E;&P@5&5C:&YO
M;&]G>2!);F,N+"!W:71H($MI<FEN(%-U8FQI8V5N<V4@24D@6TUE;6)E<ET\
M8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/E)E<')O9'5C=&EV92!'96YE=&EC<R!);G-T:71U
M=&4@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D]N8V]#>71E($QI8V5N<V4@
M1G)O;2!30DU222!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D-E;&P@0W5R92!.975R;W-C:65N
M8V5S($QI8V5N<V4@1G)O;2!(861A<VET(%M-96UB97)=/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CY#96QL($-U<F4@3F5U<F]S8VEE;F-E<R!,:6-E;G-E($9R;VT@2&%D
M87-I="!;365M8F5R73QB<CY)3%,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY#96QL($-U<F4@3F5U<F]S8VEE
M;F-E<R!,:6-E;G-E($9R;VT@2&%D87-I="!;365M8F5R73QB<CY-:6YI;75M
M(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY#96QL($-U<F4@3F5U<F]S8VEE
M;F-E<R!,:6-E;G-E($9R;VT@2&%D87-I="!;365M8F5R73QB<CY-87AI;75M
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^5&5V82!,:6-E;G-E($%G<F5E;65N="!;365M8F5R
M73QB<CY0:&%S92!)($-L:6YI8V%L(%M-96UB97)=/&)R/E531"`H)"D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CY4979A($QI8V5N<V4@06=R965M96YT(%M-96UB97)=/&)R/E!H87-E($E)
M($-L:6YI8V%L(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY4979A($QI8V5N
M<V4@06=R965M96YT(%M-96UB97)=/&)R/E!H87-E($E)22!#;&EN:6-A;"!;
M365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^0FEO5&EM92!,:6-E;G-E($9O<B!4
M:&4@56YI=F5R<VET>2!O9B!5=&%H(%M-96UB97)=/&)R/E531"`H)"D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CY!<W1E<FEA<R!,:6-E;G-E($9R;VT@56YI=F5R<VET>2!O9B!#86QI9F]R
M;FEA(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY!<W1E<FEA<R!3=6)L:6-E
M;G-E($9R;VT@1V5R;VX@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YI=&4M3&EV
M960@26YT86YG:6)L92!!<W-E=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1A;F=I8FQE(&%S<V5T<RP@=7-E9G5L(&QI9F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R,"!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R
M,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y(')A=&4@;VX@
M<V%L92!O9B!P<F]D=6-T<R!A;F0@<V5R=FEC97,@*&EN(&AU;F1R961T:',I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD
M960@;&EC96YS92!A9W)E96UE;G0@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R.34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,C0Y+#`U.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06YN=6%L(&QI8V5N<V4@;6%I;G1E;F%N8V4@9F5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&EC96YS:6YG(&9E97,@<&%I9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-87AI;75M(')O>6%L='D@<&%Y;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9E97,@9F]R('-U8FQI8V5N<V4@*&EN(&AU
M;F1R961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N
M-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%N;G5A;"!M:6YI;75M(')O>6%L='D@9'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&ES<W5E9"`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#(U
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&ES<W5E9"P@;6%R:V5T('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9E97,@9F]R(')E<V5A<F-H('5S92`H:6X@:'5N
M9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D=6-T:6]N(&EN(')O
M>6%L=&EE<R`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM
M8G5R<V5M96YT('1O(%-"35))(&9O<B!C;W-T(&EN8W5R<F5D("AI;B!H=6YD
M<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B;&EC96YS:6YG(')E8V5I
M<'1S(&9O<B!C<F5D:71A8FQE(&UI;&5S=&]N92!P87EM96YT<RX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;FEM=6T@<F]Y86QT>2!A;6]U;G0@96%C:"!Y96%R(&%N
M9"!T:&5R96%F=&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G0@=7!O;B!I<W-U86YC
M92!O9B!F:7)S="!F:79E(&QI8V5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2961U8W1I;VX@
M9F]R(&%N>2!P871E;G0@=&AA="!H879E(&QI8V5N<V5D('1W;R!O<B!M;W)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]T:6-E('!E<FEO9"!T;R!T97)M:6YA=&4@86=R965M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<V,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SDP(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06UO<G1I>F%T:6]N
M(&]F(&1E9F5R<F5D(&QI8V5N<V4@9F5E<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#XR,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,RPV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H97)E869T97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,2PX-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U,C@L-#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.#$Y,V$X-%\W,V$T7S0V
M8F%?8CDS-U\T9CED,C!B96%E,S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,S@Q.3-A.#1?-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X+U=O
M<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139%04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,
M:6%B:6QI=&EE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+#4R-RPS,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,L.#@W+#DU,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!B;VYU<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,CDL.3`U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPV.#4L.#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,S0L-C<T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+#0T,RPP-C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-S(R+#8R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?
M-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E
M864S."]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"34%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>2`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F5F97)R960@4VAA<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-H
M87)E<RP@<VAA<F5S(&%U=&AO<FEZ960@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S:&%R97,L(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;6UO;B!3:&%R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA
M<F5S+"!A=71H;W)I>F5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<RP@<VAA<F5S(&ES<W5E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-CDL-C$W+#,R.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPT,3(L,3,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<VAA<F5S+"!S:&%R97,@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y+#`W,2PQ.3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L
M-S$T+#0R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<R!E>&5R8VES960@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E
M9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`X,#$L-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V.3$L.30V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!G
M<F%N=&5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(P-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!E>&5R8VES960@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5R:65S(%!R969E<G)E9"!!(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')E9F5R<F5D
M(%-H87)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S:&%R97,L(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<VAA<F5S('-O;&0@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&5S(&]F('!R969E<G)E9"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:R!D:79I9&5N9"!R871E("AI;B!H=6YD<F5D
M=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-H87)E(&1I=FED96YD("AI;B!D;VQL87)S('!E<B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92!C;VYV97)S:6]N('!R:6-E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@8V]N=F5R<VEO;B!R871I;SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)I;V0@;V8@;W!T:6]N(&%G<F5E;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S@Q.3-A.#1?
M-S-A-%\T-F)A7V(Y,S=?-&8Y9#(P8F5A93,X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,X,3DS83@T7S<S831?-#9B85]B.3,W7S1F.60R,&)E
M864S."]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)4T)+/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%S<V5T($-O;G1R:6)U=&EO;B!!9W)E
M96UE;G0@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T
M+B`P,2P@,C`Q,SQB<CY#;VUM;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`P,2P@,C`Q,SQB<CY787)R86YT<R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/D%S=&5R:6%S($)I;W1H97)A<&5U=&EC<R!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$T/&)R/D%S=&5R:6%S($)I;W1H97)A<&5U=&EC<R!;365M8F5R73QB<CY#
M;VUM;VX@0VQA<W,@0B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D]R=&AO0WET92!#;W)P;W)A
M=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/D-E;&P@0W5R92!.975R;W-C:65N8V5S+"!,
M=&0N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^1V5R;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY'97)O;B!;
M365M8F5R73QB<CY#;VUM;VX@0VQA<W,@02!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/E)O;75L
M=7,@1FEL;7,L($QT9"X@6TUE;6)E<ET\8G(^0V]M;6]N($-L87-S($(@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^07-S970@0V]N=')I8G5T:6]N($%G<F5E;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&1U<FEN9R!P97)I;V0@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PY
M,#(L,#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$L-S<S+#,T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L-3,W+#<W.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3,V+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G1S(&ES<W5E9"`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#$U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A
M;G1S('1O(&)E(&ES<W5E9"!B>2!!<W1E<FEA<R!T;R!397)I97,@02!C;VUM
M;VX@<VAA<F5H;VQD97)S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@
M<')I8V4@;V8@=V%R<F%N="`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@97AP:7)A=&EO;B!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT
M(&]F(&-O;G1R:6)U=&EO;B!F<F]M(&EN=F5S=&]R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C
M96YT86=E(&]F('-U8G-I9&EA<GD@<W1O8VL@8V]N=')I8G5T960@*&EN(&AU
M;F1R961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@
M8V]M;6]N('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M."PQ.#(L-34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$L-CDY+#,T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-A
M8W1I;VX@8V]S=',@86QL;V-A=&5D('1O(&ES<W5A;F-E(&]F(&5Q=6ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30Q+#@P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER('9A;'5E(&]F('-H87)E<R!I<W-U960@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUA<FME="!V86QU92!O9B!":6]4:6UE(&-O
M;6UO;B!S=&]C:R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N.3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG
M:6)L92!A<W-E=',L('5S969U;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!R871E
M(&]N(&YE="!S86QE<R!O9B!P<F]D=6-T<R`H:6X@:'5N9')E9'1H<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^5V5I9VAT960M879E<F%G92!A<W-U;7!T:6]N<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K
M+69R964@:6YT97)E<W0@<F%T92`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C0R)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C8S)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M:79I9&5N9"!Y:65L9"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!V;VQA=&EL:71Y("AI;B!H=6YD<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<W+C8S)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XV,B4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-T97)I
M87,@4V5R:65S($(@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4R+#$V-"PU-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('1O('!U<F-H
M87-E($%S=&5R:6%S(%-E<FEE<R!"('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`Q,BPT.#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8V5S<R!O
M9B!C;VYT<FEB=71E9"!A<W-E="=S('9A;'5E(&]V97(@8V]N<VED97)A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@P,"PP
M-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&-O;G-I9&5R871I;VX@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#DW-RPQ,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PY
M,3<L-3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)I;U1);64@8V]M;6]N('-H87)E<RP@870@9F%I<B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PY.#4L
M,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y":6]4:6UE(%=A<G)A;G1S+"!A="!F86ER('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#(W-BPT,#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A;F-E;&QA=&EO;B!O9B!O=71S=&%N9&EN9R!O8FQI9V%T:6]N
M('1O($)I;U1I;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT(&EN(&%F9FEL:6%T97,L
M(&%T(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#$U+#4T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V5R;VX@87-S970@86-Q=6ES:71I;VX@<F5L871E
M9"!T<F%N<V%C=&EO;B!C;W-T<R!P86ED(&)Y($)I;U1I;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@87-S971S('1R86YS9F5R<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4X+#DW-RPQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S=&5R:6%S(%-E<FEE
M<R!!('-H87)E<RP@;F5T(&]F(&ES<W5A;F-E(&-O<W0@;V8@)#4T,2PX,#`\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#$R
M,2PR,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3V)L:6=A=&EO;B!T;R!D:7-T<FEB=71E($)I;U1);64@5V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X+#(W-BPT,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5')A;G-A8W1I;VX@86YD(&]T:&5R(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Q.2PY
M,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&%T96YT<R!A;F0@;W1H97(@:6YT96QL96-T=6%L('!R;W!E<G1Y
M(')I9VAT<R!R96QA=&5D('1O(&A%4R!C96QL<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL,#$W+#`P.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!T87@@;&EA8FEL:71Y(&%R:7-I;F<@9G)O;2!D:69F97)E;F-E(&EN(&)O
M;VL@=F5R<W5S('1A>"!B87-I<R!O;B!'97)O;B!I;G1A;F=I8FQE(&%S<V5T
M<R!A8W%U:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3$L-34X+#(T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^25!2)F%M<#M$(&5X<&5N<V5D('5P;VX@
M86-Q=6ES:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$W+#0U."PW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!A;F0@:6XM<')O
M8V5S<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-Q=6ER960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0L.3$W+#4S
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14A%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^56YA=61I=&5D(%!R;R!&
M;W)M82!);G1E<FEM($9I;F%N8VEA;"!);F9O<FUA=&EO;B`M(%1H<F5E($UO
M;G1H<R!%;F1E9"!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^56YA=61I=&5D(%!R;R!&;W)M82!);G1E<FEM($9I;F%N
M8VEA;"!);F9O<FUA=&EO;B`M(%1H<F5E($UO;G1H<R!%;F1E9"!-87)C:"`S
M,2P@,C`Q-"!A;F0@,C`Q,R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y,S0L-S(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T.3,L-S`U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<R!A=F%I;&%B;&4@=&\@8V]M;6]N('-H87)E:&]L9&5R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#`Y.2PP,30I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R
M,BPU-S(L.#4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92`M(&)A<VEC
M(&%N9"!D:6QU=&5D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U004<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`P-2P@,C`Q
M-#QB<CY3=6)S97%U96YT($5V96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA>2`P-BP@,C`Q-#QB<CY3=6)S97%U96YT
M($5V96YT(%M-96UB97)=/&)R/E1R86YC:&4\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#$T/&)R/E-U8G-E<75E;G0@179E
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CY3=6)S97%U96YT($5V96YT(%M-96UB97)=/&)R
M/E1R86YC:&4\8G(^26YT86QL;65N=#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&5Q=6ET>2!C87!I=&%L(')A:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#$X,BPU-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q
M+#8Y.2PS-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BPS.#`L-C0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07=A<F1E9"!G<F%N="!A;6]U;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(T+#DQ,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W9E<FAE860@8VAA<F=E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<&5R8V5N=&%G97,@;V8@8W5R
M<F5N="!E<75I='D@=F%L=64@;V8@<V]L=71I;VYS(&%T('1I;64@;V8@<VEG
M;FEF:6-A;G0@=')A;G-A8W1I;VX@*&EN(&AU;F1R961T:',I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E
M<R!O9B!O=71S=&%N9&EN9R!V;W1I;F<@<V5C=7)I=&EE<R!O=VYS(&)E9F]R
M92!T<F%N<V%C=&EO;B!B96YE9FEC:6%L;'D@*&EN(&AU;F1R961T:',I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K('!U<F-H87-E(&1U<FEN9R!P97)I;V0@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@<'5R8VAA<V4@9'5R:6YG('!E<FEO9"P@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!T<F%N8VAE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE(&AA=F4@;W!T:6]N('1O('!U<F-H
M87-E(&%D9&ET:6]N86P@<VAA<F5S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@<')I
M8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!T<F%N8VAE<R!R96QA
M=&5D('1O(&%T=&%I;FUE;G0@;V8@8V5R=&%I;B!P<F]D=6-T(&1E=F5L;W!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!I;G-T86QL;65N=',@9F]R(&5A8V@@=')A;F-H93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=')A
M9&EN9R!D87ES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<R,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N
M:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S,X,3DS83@T7S<S
=831?-#9B85]B.3,W7S1F.60R,&)E864S."TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">$ 2,527,330<span></span></td>
        <td class="nump">$ 3,887,950<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
        <td class="nump">229,905<span></span></td>
        <td class="nump">600,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
        <td class="nump">2,685,828<span></span></td>
        <td class="nump">2,234,674<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">$ 5,443,063<span></span></td>
        <td class="nump">$ 6,722,624<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedBonusesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EY6CK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees (Details)<br></strong></div>
        </th>
        <th class="th" colspan="10">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="8">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>WARF [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>WARF [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>WARF [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Advanced Cell Technology, Inc. [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Advanced Cell Technology Inc., with Kirin Sublicense I [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Advanced Cell Technology Inc., with Kirin Sublicense II [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Reproductive Genetics Institute [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>OncoCyte License From SBMRI [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Cell Cure Neurosciences License From Hadasit [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Cell Cure Neurosciences License From Hadasit [Member]

</div>
          <div>ILS</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Cell Cure Neurosciences License From Hadasit [Member]

</div>
          <div>Minimum [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Cell Cure Neurosciences License From Hadasit [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Teva License Agreement [Member]

</div>
          <div>Phase I Clinical [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Teva License Agreement [Member]

</div>
          <div>Phase II Clinical [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Teva License Agreement [Member]

</div>
          <div>Phase III Clinical [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>BioTime License For The University of Utah [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Asterias License From University of California [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Asterias Sublicense From Geron [Member]

</div>
          <div>USD ($)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RoyaltyPercentage', window );">Royalty rate on sale of products and services (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="nump">8.00%<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="nump">3.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.00%<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmendedLicenseAgreementAmount', window );">Amended license agreement amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 295,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"> 249,058<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 65,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicenseFeeAmountPaid', window );">Licensing fees paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RoyaltyMaximumPayment', window );">Maximum royalty payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FeesForSublicensePercentage', window );">Fees for sublicense (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.50%<span></span></td>
        <td class="nump">1.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AnnualMinimumRoyaltyDue', window );">Annual minimum royalty due</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common shares issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,259<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common shares issued, market value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FeesForResearchUse', window );">Fees for research use (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ReductionInRoyalties', window );">Reduction in royalties (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ReimbursementToSbmriForCostIncurredInHundredths', window );">Reimbursement to SBMRI for cost incurred (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MilestonePayments', window );">Milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">225,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SublicensingReceiptsForCreditableMilestonePayments', window );">Sublicensing receipts for creditable milestone payments.</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MinimumRoyaltyAmountEachYearAndThereafter', window );">Minimum royalty amount each year and thereafter</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentUponIssuanceOfFirstFiveLicense', window );">Payment upon issuance of first five license</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore', window );">Reduction for any patent that have licensed two or more</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NoticePeriodToTerminateAgreement', window );">Notice period to terminate agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">60 days<span></span></td>
        <td class="text">90 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsAbstract', window );"><strong>Amortization of deferred license fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths', window );">2014</a></td>
        <td class="nump">83,615<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearTwo', window );">2015</a></td>
        <td class="nump">111,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearThree', window );">2016</a></td>
        <td class="nump">111,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearFour', window );">2017</a></td>
        <td class="nump">111,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
        <td class="nump">111,843<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Total</a></td>
        <td class="nump">$ 528,458<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmendedLicenseAgreementAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amended license agreement amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmendedLicenseAgreementAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AnnualLicenseMaintenanceFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual payment related to license maintenance fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AnnualLicenseMaintenanceFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AnnualMinimumRoyaltyDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum amount of annual royalty due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AnnualMinimumRoyaltyDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized after the fifth fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseFeesAmortizationExpenseNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseFeesAmortizationExpenseYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseFeesAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseFeesAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FeesForResearchUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage fee for the use of research findings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_FeesForResearchUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FeesForSublicensePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of fees for sublicense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_FeesForSublicensePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LicenseFeeAmountPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount paid related to license fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_LicenseFeeAmountPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment made in phases per the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_MilestonePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MinimumRoyaltyAmountEachYearAndThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum royalty payable each year and thereafter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_MinimumRoyaltyAmountEachYearAndThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NoticePeriodToTerminateAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The notice period to be given in order to terminate agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_NoticePeriodToTerminateAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentUponIssuanceOfFirstFiveLicense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of payment to be made upon issuance of first five licenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PaymentUponIssuanceOfFirstFiveLicense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction in payment granted to any patent that licensed two or more sublicenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ReductionForAnyPatentThatHaveLicensedTwoOrMore</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ReductionInRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction in royalty fees as applicable to the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ReductionInRoyalties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ReimbursementToSbmriForCostIncurredInHundredths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount reimbursed for cost incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ReimbursementToSbmriForCostIncurredInHundredths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_RoyaltyMaximumPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_RoyaltyMaximumPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_RoyaltyPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_RoyaltyPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SublicensingReceiptsForCreditableMilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Receipts from sublicensing creditable milestone payments per the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_SublicensingReceiptsForCreditableMilestonePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCostsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCostsCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, issued and outstanding (in shares)</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
        <td class="nump">69,617,329<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">67,412,139<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
        <td class="nump">59,071,192<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">56,714,424<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
        <td class="nump">45,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 801,554<span></span></td>
        <td class="nump">$ 691,946<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
        <td class="nump">1,205,000<span></span></td>
        <td class="nump">1,090,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsExercised', window );">Warrants exercised (in shares)</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series Preferred A Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, issued and outstanding (in shares)</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PreferredSharesSold', window );">Preferred shares sold (in shares)</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sales of preferred shares</a></td>
        <td class="nump">$ 3,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate (in hundredths)</a></td>
        <td class="nump">3.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred share dividend (in dollars per shares)</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PricePerShareOfOptionsToPurchaseCompany', window );">Share conversion price (in dollars per share)</a></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PreferredSharesConvertibleConversionRatio', window );">Common stock conversion ratio</a></td>
        <td class="nump">12.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LifeOfWarrants', window );">Period of option agreement</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LifeOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The life of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_LifeOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PreferredSharesConvertibleConversionRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PreferredSharesConvertibleConversionRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PreferredSharesSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of preferred shares of an entity that have been sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PreferredSharesSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PricePerShareOfOptionsToPurchaseCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PricePerShareOfOptionsToPurchaseCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants exercised during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_WarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage rate used to calculate dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockDividendRatePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount per share used to calculated dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockDividendRatePerDollarAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EISBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Contribution Agreement (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="3">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 01, 2013

</div>
          <div>Common [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 01, 2013

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Asterias Biotherapeutics [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Asterias Biotherapeutics [Member]

</div>
          <div>Common Class B [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>OrthoCyte Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Cell Cure Neurosciences, Ltd. [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Geron [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Geron [Member]

</div>
          <div>Common Class A [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Romulus Films, Ltd. [Member]

</div>
          <div>Common Class B [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetContributionAgreementLineItems', window );"><strong>Asset Contribution Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,902,077<span></span></td>
        <td class="nump">21,773,340<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,537,779<span></span></td>
        <td class="nump">2,136,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="nump">3,150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued', window );">Number of warrants to be issued by Asterias to Series A common shareholders (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.00<span></span></td>
        <td class="nump">$ 5.00<span></span></td>
        <td class="nump">$ 5.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantExpirationTerm', window );">Warrant expiration term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmountOfContributionFromInvestor', window );">Amount of contribution from investor</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfSubsidiaryStockContributed', window );">Percentage of subsidiary stock contributed (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
        <td class="nump">8,182,559<span></span></td>
        <td class="nump">11,699,340<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transaction costs allocated to issuance of equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FairValueOfSharesIssued', window );">Fair value of shares issued (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MarketValueOfBiotimeCommonShares', window );">Market value of BioTime common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.93<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RoyaltyRateOnNetSalesOfProducts', window );">Royalty rate on net sales of products (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.42%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.63%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">77.63%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">69.62%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement', window );">Asterias Series B shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,164,568<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement', window );">Warrants to purchase Asterias Series B shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,012,481<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement', window );">Excess of contributed asset's value over consideration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,800,063<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TotalConsiderationReceivedAssetContributionAgreement', window );">Total consideration issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,977,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,917,532<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution', window );">BioTIme common shares, at fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,985,163<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution', window );">BioTime Warrants, at fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,276,406<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CancellationOfOutstandingObligationAssetContributionAgreement', window );">Cancellation of outstanding obligation to BioTime</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_InvestmentsInAffiliatesAtCost', window );">Investment in affiliates, at cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">415,543<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Geron asset acquisition related transaction costs paid by BioTime</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TotalAssetsTransferredAssetContributionAgreement', window );">Total assets transferred</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,977,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement', window );">Asterias Series A shares, net of issuance cost of $541,800</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,121,222<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement', window );">Obligation to distribute BioTIme Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,276,406<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction and other costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,519,904<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement', window );">Patents and other intellectual property rights related to hES cells</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,017,009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired', window );">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(11,558,243)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement', window );">IPR&amp;D expensed upon acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,458,766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement', window );">Total assets and in-process research and development acquired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,917,532<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmountOfContributionFromInvestor">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This line item represents the amount of contribution received from investor in relation to asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmountOfContributionFromInvestor</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetContributionAgreementLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetContributionAgreementLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CancellationOfOutstandingObligationAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cancellation of outstanding obligation under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_CancellationOfOutstandingObligationAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ClassOfWarrantOrRightNumberOfSecuritiesToBeIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of common shares issued to subsidiary upon consummation of asset contribution in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_CommonSharesIssuedToSubsidiaryUponConsummationOfAssetContribution</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredTaxLiabilityArisingFromDifferenceInBookVersusTaxBasisOnGeronIntangibleAssetsAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of contributed asset's value over consideration under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ExcessOfContributedAssetSValueOverConsiderationAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FairValueOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This line item represents the fair value of share issued based on Black Sholes Merton valuation assumptions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_FairValueOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_InvestmentsInAffiliatesAtCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cost of the investment at close of period. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_InvestmentsInAffiliatesAtCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of IPR and D expensed upon acquisition under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_IprAndDExpensedUponAcquisitionAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MarketValueOfBiotimeCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This line item represents the market value of the common stock at the end of the day trading on the NYSE.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_MarketValueOfBiotimeCommonShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of obligation to distribute warrants received under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ObligationToDistributeWarrantsConsiderationTransferredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patents and other intellectual property rights related to hES cells acquired under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PatentsAndOtherIntellectualPropertyRightsRelatedToHesCellsAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfSubsidiaryStockContributed">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This line item represents the percentage of subsidiary stock contributed by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_PercentageOfSubsidiaryStockContributed</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_RoyaltyRateOnNetSalesOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This line item represents the royalty rate at which Geron will be paid on net sales from patents acquired from Geron.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_RoyaltyRateOnNetSalesOfProducts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of Series B common stock received under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_SeriesBCommonStockConsiderationTransferredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of Series A common stock received under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_SeriesCommonStockConsiderationTransferredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total assets and in process research and development acquired under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_TotalAssetsAndInProcessResearchAndDevelopmentAcquiredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TotalAssetsTransferredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total assets transferred under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_TotalAssetsTransferredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TotalConsiderationReceivedAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total consideration received under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_TotalConsiderationReceivedAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantExpirationTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period in which warrant issued expire.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_WarrantExpirationTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of warrants issued to subsidiary upon consummation of asset contribution in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_WarrantsIssuedToSubsidiaryUponConsummationOfAssetContribution</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of warrants to purchase Series common B shares received under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_WarrantsToPurchaseSeriesBCommonSharesConsiderationTransferredAssetContributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917927&amp;loc=d3e1043-128460<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 59<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationAcquisitionRelatedCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance value per share of no-par value common stock; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNoParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">3. Equipment</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following:</div><div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Equipment, furniture and fixtures</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,645,077</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,431,586</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated depreciation</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,685,927</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,433,853</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Equipment, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,959,150</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,997,733</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Depreciation expense amounted to $256,945 and $113,356 for the three months ended March 31, 2014 and 2013, respectively.&#160;</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenues, net</a></td>
        <td class="nump">$ 934,721<span></span></td>
        <td class="nump">$ 493,705<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss available to common shareholders</a></td>
        <td class="num">$ (8,099,014)<span></span></td>
        <td class="num">$ (22,572,852)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="num">$ (0.38)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionsProFormaRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 6,637,834<span></span></td>
        <td class="nump">$ 5,495,478<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump">236,588<span></span></td>
        <td class="nump">178,694<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TradeAccountsAndGrantsReceivableNetCurrent', window );">Trade accounts and grants receivable, net</a></td>
        <td class="nump">818,275<span></span></td>
        <td class="nump">998,393<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">1,554,114<span></span></td>
        <td class="nump">1,277,405<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">9,246,811<span></span></td>
        <td class="nump">7,949,970<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
        <td class="nump">2,959,150<span></span></td>
        <td class="nump">2,997,733<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseAndConsultingFees', window );">Deferred license and consulting fees</a></td>
        <td class="nump">418,958<span></span></td>
        <td class="nump">444,833<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump">428,827<span></span></td>
        <td class="nump">129,129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
        <td class="nump">56,062<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
        <td class="nump">44,840,087<span></span></td>
        <td class="nump">46,208,085<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">57,949,895<span></span></td>
        <td class="nump">57,729,750<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">5,443,063<span></span></td>
        <td class="nump">6,722,624<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred license and subscription revenue, current portion</a></td>
        <td class="nump">177,594<span></span></td>
        <td class="nump">235,276<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">5,620,657<span></span></td>
        <td class="nump">6,957,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
        <td class="nump">28,054<span></span></td>
        <td class="nump">35,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net</a></td>
        <td class="nump">6,928,522<span></span></td>
        <td class="nump">8,277,548<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
        <td class="nump">8,441<span></span></td>
        <td class="nump">195,984<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
        <td class="nump">6,965,017<span></span></td>
        <td class="nump">8,509,529<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively</a></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013</a></td>
        <td class="nump">211,943,421<span></span></td>
        <td class="nump">203,456,401<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Contributed capital</a></td>
        <td class="nump">93,972<span></span></td>
        <td class="nump">93,972<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income/(loss)</a></td>
        <td class="num">(44,341)<span></span></td>
        <td class="nump">62,899<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(153,877,561)<span></span></td>
        <td class="num">(145,778,547)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost: 10,546,137 and 10,697,715 shares at March 31, 2014 and at December 31, 2013, respectively</a></td>
        <td class="num">(42,372,546)<span></span></td>
        <td class="num">(43,033,957)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
        <td class="nump">19,242,945<span></span></td>
        <td class="nump">14,800,768<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
        <td class="nump">26,121,276<span></span></td>
        <td class="nump">27,461,553<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
        <td class="nump">45,364,221<span></span></td>
        <td class="nump">42,262,321<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND EQUITY</a></td>
        <td class="nump">$ 57,949,895<span></span></td>
        <td class="nump">$ 57,729,750<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseAndConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amounts as of the balance sheet of deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DeferredLicenseAndConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TradeAccountsAndGrantsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_TradeAccountsAndGrantsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 41, 42<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 42, 45<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1. Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">General</font> &#8211; BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (&#8220;hES&#8221;) cell and induced pluripotent stem (&#8220;iPS&#8221;) cell technology.&#160; Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.&#160; hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products.&#160; BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use.&#160; Asterias Biotherapeutics, Inc. (&#8220;Asterias&#8221;) acquired the stem cell assets of Geron Corporation (&#8220;Geron&#8221;) that had been used in Geron&#8217;s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction.&#160; OncoCyte Corporation (&#8220;OncoCyte&#8221;) is developing products and technologies to diagnose cancer.&#160; ES Cell International Pte Ltd. (&#8220;ESI&#8221;), a Singapore private limited company, and BioTime&#8217;s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets.&#160; OrthoCyte Corporation (&#8220;OrthoCyte&#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries.&#160; ReCyte Therapeutics, Inc. (&#8220;ReCyte Therapeutics&#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.&#160; Cell Cure Neurosciences Ltd. (&#8220;Cell Cure Neurosciences&#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.&#160; LifeMap Sciences, Inc. (&#8220;LifeMap Sciences&#8221;) markets, sells and distributes <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">GeneCards</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, the leading human gene database and an integrated database suite that includes <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">GeneCards</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, the <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Discovery</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries.&#160; Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.&#160; BioTime&#8217;s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hextend</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, from the sale of products for research, and from research grants.&#160;</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime&#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X.&#160; In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made.&#160; The&#160;consolidated balance sheet as of December 31, 2013 is derived from the Company&#8217;s annual audited financial statements as of that date.&#160; The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) except for the&#160;consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements.&#160; Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods.&#160; It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&#8217;s Form 10-K for the year ended December 31, 2013.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Principles of consolidation</font> &#8211; BioTime&#8217;s consolidated financial statements include the accounts of its subsidiaries.&#160; The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.</div><div style="margin-top: 3pt; margin-bottom: 3pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"><tr style="height: 33px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Subsidiary</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Field of Business</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">BioTime </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Ownership</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Country</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias Biotherapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">71.6%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ES Cell International Pte Ltd</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research, including clinical grade cell lines</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">produced under cGMP</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Singapore</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OncoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cancer diagnostics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75.3%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OrthoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Orthopedic diseases, including chronic back pain and osteoarthritis</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cell Cure Neurosciences Ltd.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Age-related macular degeneration</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Multiple sclerosis</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Parkinson&#8217;s disease</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">62.5%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ReCyte Therapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">94.8%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr style="height: 13px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime Asia, Limited</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">81%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hong Kong</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Genetic, disease, and stem cell databases</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">73.2%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Ltd.</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell database</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1)</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;">LifeMap Solutions, Inc.</td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;">Mobile health software</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;">(1)</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;">USA</td></tr></table><div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;">(1)</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td></tr></table></div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">All material intercompany accounts and transactions have been eliminated in consolidation.&#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the accounting and reporting requirements of SEC Regulation S-X.&#160; As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&#8220;BioTime Asia&#8221;), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime&#8217;s condensed consolidated balance sheets.</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Certain significant risks and uncertainties</font> &#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition.&#160; Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Use of estimates</font> &#8211; The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ from those estimates.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue recognition</font> &#8211; BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition.&#160; Royalty revenues consist of product royalty payments.&#160; License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods.&#160; Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable.&#160; Royalties consist primarily of royalties earned on sales of <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hextend</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place.&#160; When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&#160; When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&#160; If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned.&#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounts receivable and allowance for doubtful accounts</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> &#8211;&#160; Total trade receivables amounted to approximately $600,400 and </font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$575,900 </font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">and grants receivable amounted to approximately $334,700 and $</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">539,300</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> as of March 31, 2014 and December 31, 2013, respectively.&#160; Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013.&#160; BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience.&#160; An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position.&#160;&#160;If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</font></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents.&#160; BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions.&#160; Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Inventory &#8211;</font> Inventories are stated at the lower of cost or market.&#160; Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Equipment</font> &#8211; Equipment is stated at cost.&#160; Equipment is being depreciated using the straight-line method over a period of 36 to 120 months.&#160; See Note 3.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Intangible assets</font> &#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&#160; Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business.&#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition. See Note 8.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&#160; BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Warrants to purchase common stock </font>&#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity.&#160; None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&#160; If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the &#8220;FASB&#8221;) regarding goodwill and other intangible assets.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets.&#160; Additionally, we have carved out the loss on sale of fixed assets amount from other expenses.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development</font> &#8211; BioTime complies with FASB requirements governing accounting for research and development costs.&#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Foreign currency translation gain and Comprehensive loss &#8211;</font> In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date.&#160; Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period.&#160; Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet.&#160; For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that&#160;are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense),&#160;amounted to $10,212 and $21,977, respectively.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect.&#160; Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized.&#160; The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.&#160; For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities.&#160; For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias&#8217; tax provision with BioTime&#8217;s.&#160; BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively.&#160; BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions.&#160; Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.&#160; Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws.&#160; Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&#160; No tax benefit had been recorded through <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">September 30, 2013</font> because of the net operating losses incurred and a full valuation allowance had been provided.</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock-based compensation &#8211;</font> BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&#160; In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments.&#160; BioTime has applied the provisions of this guidance in such valuations as well.&#160; Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model.&#160; BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables.&#160; These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Impairment of long-lived assets &#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&#160; If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&#160; The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products.&#160; See Note 5.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Loss per share</font> &#8211; Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period.&#160; Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive.&#160; Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Effect of recently issued and recently adopted accounting pronouncements </font>&#8211; There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Contribution Agreement (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetContributionAgreementAbstract', window );"><strong>Asset Contribution Agreement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock', window );">Assets Transferred by BioTime and Related Consideration</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The assets transferred by BioTime and the related consideration paid were recorded as follows:</div><div style="margin-top: 3pt; margin-bottom: 3pt;"><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Consideration transferred to BioTime:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Asterias Series B shares</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">52,164,568</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warrants to purchase Asterias Series B shares</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,012,481</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Excess of contributed assets&#8217; value over consideration</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,800,063</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total consideration issued</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">58,977,112</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Assets transferred by BioTime:</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">BioTime common shares, at fair value</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,985,163</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">BioTime Warrants, at fair value</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,276,406</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Cancellation of outstanding obligation to BioTime</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">5,000,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Investment in affiliates, at cost</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">415,543</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Geron asset acquisition related transaction costs paid by BioTime</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">300,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total assets transferred</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">58,977,112</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock', window );">Assets Acquired from Geron and Related Consideration</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The assets acquired from Geron and the related consideration were recorded as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Consideration paid to Geron:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Asterias Series A shares, net of share issuance costs of $541,800</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,121,222</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Obligation to distribute BioTime Warrants</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,276,406</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Transaction and other costs</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,519,904</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total consideration paid</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,917,532</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Assets acquired from Geron (preliminary allocation):</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Patents and other intellectual property rights related to hES cells</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">29,017,009</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(11,558,243</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">IPR&amp;D expensed upon acquisition</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">17,458,766</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total assets and in-process research and development acquired</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,917,532</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetContributionAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetContributionAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the assets acquired and related consideration recorded under the asset contribution agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetsAcquiredAndRelatedConsiderationRecordedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the assets transferred and related consideration recorded under the asset contribution agreement..</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetsTransferredAndRelatedConsiderationRecordedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUDCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred income tax benefit</a></td>
        <td class="nump">$ 1,349,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred income tax benefit, federal</a></td>
        <td class="nump">1,151,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred income tax benefit, state taxes</a></td>
        <td class="nump">198,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
        <td class="nump">600,400<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
        <td class="nump">334,700<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">539,300<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
        <td class="nump">116,800<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">116,800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation (loss)/gain</a></td>
        <td class="num">(104,590)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">148,437<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss</a></td>
        <td class="num">(2,650)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss included in other income/(expense)</a></td>
        <td class="nump">$ 10,212<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 21,977<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment useful life</a></td>
        <td class="text">36 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment useful life</a></td>
        <td class="text">120 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Asterias Biotherapeutics [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">71.60%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">ES Cell International Pte., Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">OncoCyte Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">75.30%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">OrthoCyte Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cell Cure Neurosciences, Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">62.50%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">ReCyte Therapeutics, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">94.80%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">BioTime Asia, Limited [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">81.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">LifeMap Sciences, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump">73.20%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">LifeMap Sciences, Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">LifeMap Solutions, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="nump">5,491,301<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">4,771,301<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="nump">9,751,615<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">816,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Treasury Shares [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="nump">10,546,137<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,360,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3-4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a(1)<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5074-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Section Appendix E<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrantsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestOwnershipPercentageByParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 13, 20, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32157-110900<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a-c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669646-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2. Inventory</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime held $223,665 and $165,771 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2014 and December 31, 2013, respectively.&#160; Finished goods products of $12,923 were held by a third party on consignment at March 31, 2014 and December 31, 2013.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred shares, par value (in dollars per share)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized (in shares)</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="nump">2,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued (in shares)</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
        <td class="nump">69,617,329<span></span></td>
        <td class="nump">67,412,139<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
        <td class="nump">59,071,192<span></span></td>
        <td class="nump">56,714,424<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
        <td class="nump">10,546,137<span></span></td>
        <td class="nump">10,697,715<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance value per share of no-par value common stock; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNoParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance value per share of no-par value, nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockNoParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">BioTime's ownership of outstanding shares of its subsidiaries</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.</div><div style="margin-top: 3pt; margin-bottom: 3pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"><tr style="height: 33px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Subsidiary</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Field of Business</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">BioTime </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Ownership</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Country</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias Biotherapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">71.6%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ES Cell International Pte Ltd</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research, including clinical grade cell lines</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">produced under cGMP</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Singapore</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OncoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cancer diagnostics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75.3%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OrthoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Orthopedic diseases, including chronic back pain and osteoarthritis</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cell Cure Neurosciences Ltd.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Age-related macular degeneration</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Multiple sclerosis</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Parkinson&#8217;s disease</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">62.5%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ReCyte Therapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">94.8%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr style="height: 13px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime Asia, Limited</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">81%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hong Kong</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Genetic, disease, and stem cell databases</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">73.2%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Ltd.</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell database</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1)</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;">LifeMap Solutions, Inc.</td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;">Mobile health software</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;">(1)</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;">USA</td></tr></table><div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;">(1)</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td></tr></table></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4M<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591554-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>May 09, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">BIOTIME INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000876343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">72,149,329<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Equipment, furniture and fixtures</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following:</div><div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Equipment, furniture and fixtures</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,645,077</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,431,586</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated depreciation</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,685,927</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,433,853</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Equipment, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,959,150</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,997,733</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1EAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>REVENUES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fees</a></td>
        <td class="nump">$ 294,504<span></span></td>
        <td class="nump">$ 349,824<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties from product sales</a></td>
        <td class="nump">97,886<span></span></td>
        <td class="nump">107,599<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant income</a></td>
        <td class="nump">575,659<span></span></td>
        <td class="nump">90,326<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sale of research products</a></td>
        <td class="nump">98,586<span></span></td>
        <td class="nump">66,724<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump">1,066,635<span></span></td>
        <td class="nump">614,473<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
        <td class="num">(131,914)<span></span></td>
        <td class="num">(182,749)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total revenues, net</a></td>
        <td class="nump">934,721<span></span></td>
        <td class="nump">431,724<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>EXPENSES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="num">(8,405,393)<span></span></td>
        <td class="num">(5,395,488)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="num">(3,667,171)<span></span></td>
        <td class="num">(3,416,145)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
        <td class="num">(12,072,564)<span></span></td>
        <td class="num">(8,811,633)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(11,137,843)<span></span></td>
        <td class="num">(8,379,909)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME/(EXPENSES):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (expense)/income, net</a></td>
        <td class="num">(8,384)<span></span></td>
        <td class="nump">943<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
        <td class="num">(8,576)<span></span></td>
        <td class="num">(1,523)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income/(expense), net</a></td>
        <td class="nump">77,746<span></span></td>
        <td class="num">(28,056)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income/(expense), net</a></td>
        <td class="nump">60,786<span></span></td>
        <td class="num">(28,636)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX BENEFIT</a></td>
        <td class="num">(11,077,057)<span></span></td>
        <td class="num">(8,408,545)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="nump">1,349,026<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
        <td class="num">(9,728,031)<span></span></td>
        <td class="num">(8,408,545)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
        <td class="nump">1,629,017<span></span></td>
        <td class="nump">689,282<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</a></td>
        <td class="num">(8,099,014)<span></span></td>
        <td class="num">(7,719,263)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation (loss)/gain</a></td>
        <td class="num">(104,590)<span></span></td>
        <td class="nump">148,437<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities, net</a></td>
        <td class="num">(2,650)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">COMPREHENSIVE LOSS</a></td>
        <td class="num">$ (8,206,254)<span></span></td>
        <td class="num">$ (7,570,826)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="num">$ (0.15)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)</a></td>
        <td class="nump">58,257,427<span></span></td>
        <td class="nump">51,175,649<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591552-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of operating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 10<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591551-111686<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 13, 20, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32157-110900<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a-c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669646-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591551-111686<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">7. Equity</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Preferred Shares</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime is authorized to issue 2,000,000 shares of preferred stock.&#160; The preferred shares may be issued in one or more series as the board of directors may by resolution determine.&#160; The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.&#160; The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of March 31, 2014, BioTime has 70,000 outstanding preferred shares.&#160; On March 4, 2014, BioTime sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock (&#8220;Series A Preferred&#160;Stock&#8221;) for $3.5 million.&#160; The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares.&#160; Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In connection with the sale of the Series A Preferred Stock, BioTime also entered into an Option Agreement with each purchaser of Series A Preferred Stock entitling them, for a period of five years, to exchange their shares of Series A Preferred Stock for shares of common stock of BioTime&#8217;s subsidiary LifeMap Sciences, Inc. held by BioTime at the ratio of 12.5 shares of LifeMap Sciences common stock for each share of BioTime Series A Preferred Stock.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion.&#160; The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval.&#160; Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted.&#160; The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares.&#160; After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Common Shares</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime is authorized to issue 125,000,000 common shares with no par value.&#160; As of March 31, 2014, BioTime had issued 69,617,329 common shares and outstanding 59,071,192 common shares.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the three months ended March 31, 2014 and 2013, BioTime recognized stock-based compensation expenses of $801,554 and $691,946, respectively, due to stock options granted to employees and directors.&#160; During the three months ended March 31, 2014 and 2013, BioTime granted 1,205,000 and 1,090,000 options, respectively, under its 2012 Equity Incentive Plan.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the three months ended March 31, 2014, 45,000 options and no warrants were exercised.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">6. Accounts Payable and Accrued Liabilities</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following:</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accounts payable</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,527,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,887,950</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued bonuses</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">229,905</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Other accrued liabilities</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,685,828</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,234,674</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">5,443,063</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">6,722,624</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Unaudited Pro Forma Information</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013.&#160; The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.</div><div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 5.5pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.1pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Revenues, net</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">934,721</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">493,705</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Net loss available to common shareholders</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(8,099,014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(</font>22,572,852</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Net loss per common share &#8211; basic and diluted</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(</font>0.38</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1392-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1486-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br> -Appendix F<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 68<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Intangible assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Intangible assets</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54,719,918</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54,719,918</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated amortization</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(9,879,831</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(8,511,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Intangible assets, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">44,840,087</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">46,208,085</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">10. Subsequent Events</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In May 2014, BioTime raised $6,380,640 of additional equity capital through the sales of BioTime common shares&#160;in &#8220;at-the-market&#8221; transactions through Cantor Fitzgerald &amp; Co., as BioTime's sales agent.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On May 5, 2014, BioTime was awarded an SBIR Phase 1 Small Business Grant in the amount of $224,911 from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH). Under this grant entitled &#8220;Cell Targeting Peptides for Isolating Patient Specific Stem Cells&#8221; BioTime will work on streamlining <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">PureStem<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174; </sup></font>cell line development and developing improved assays for monitoring stem cell differentiation.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Solutions, Inc.&#8212;Mobile Health Software Products</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On May 6, 2014, LifeMap Solutions, Inc. (&#8220;Solutions&#8221;), a newly formed subsidiary of LifeMap Sciences, entered into a Co-Development and Option Agreement (the &#8220;Agreement&#8221;) with the Icahn School of Medicine at Mount Sinai, a nonprofit education corporation (&#8220;Mt Sinai&#8221;), pursuant to which Solutions and Mt Sinai have agreed to work cooperatively to develop internet, web-based, mobile user or consumer software products to provide users with information that may potentially aid them in improving lifestyle and healthcare decisions and outcomes.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Solutions and Mt Sinai will license to each other, on a non-exclusive, royalty free basis, certain &#8220;background&#8221; intellectual property for joint use in product development.&#160; Solutions will pay Mt Sinai for the use of Mt Sinai personnel based on their direct salaries plus an overhead charge, but Mt Sinai has agreed to waive collection of the first $1,000,000 of overhead charges.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Solutions will have an option to acquire a world-wide license to use Mt Sinai&#8217;s background intellectual property and other intellectual property developed by Mt Sinai alone or jointly with Solutions in the joint development project for the purpose of developing and commercializing the product.&#160; The terms of the license agreement that will be executed if Solutions exercises its option under the Agreement (the &#8220;License Agreement&#8221;) are subject to negotiation by the parties, but will include certain provisions specified in the Agreement, including the obligation of Solutions to pay Mt Sinai: (a) royalties on net sales, (b) a percentage of any consideration received by Solutions from its sublicensees and distributors of the product; (c) all reasonable patent and licensing costs incurred prior to the effective date of the definitive License Agreement in connection with the licensed patent rights and certain other Mount Sinai technology and background intellectual property, and all reasonable attorney&#8217;s fees, expenses, official fees, and other charges incident to the preparation, prosecution, and maintenance of licensed patent rights: and (d) up to 5% of the then current equity value of Solutions at the time of a &#8220;Significant Transaction.&#8221;&#160; The percentage to be paid is subject to dilution based on future investment in Solutions and the amount of personnel cost overhead charges waived by Mt Sinai under the Agreement.&#160; The term &#8220;Significant Transaction&#8221; will mean the first to occur of a single transaction, or series of related transactions, consisting of or resulting in any of the following:&#160; (i) an assignment, other than to LifeMap Sciences, of the definitive license agreement; (ii) an initial public offering of securities by Solutions (or its successor) or other transaction resulting in any of Solutions&#8217; securities being traded on a nationally recognized stock exchange or automated quotation system; (iii) a sale, license or other disposition of all or substantially all of Solutions&#8217; assets; or (iv) a reorganization, consolidation or merger of Solutions, or sale or transfer of the securities of Solutions, where the holders of Solutions&#8217; outstanding voting securities before the transaction beneficially own less than fifty percent (50%) of the outstanding voting securities, or hold less than fifty percent (50%) of the voting power of the voting security holders of the surviving entity after the transaction.&#160; A Significant Transaction shall not be deemed to occur as a result of a bona fide, arm&#8217;s-length equity financing for cash in which Solutions issues securities (other than through an initial public offering described in clause (ii) above) representing more than fifty percent (50%) of the voting power of its security holders to venture capital or other similar professional investors who do not actively manage day-to-day operations of Solutions.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences Stock Purchase Agreement</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Also on May 6, 2014, BioTime entered into a Stock Purchase Agreement with LifeMap Sciences to provide financing for Solutions&#8217; product development costs under the Agreement with Mt Sinai.&#160; BioTime will purchase 2,500,000 shares of LifeMap Sciences common stock for $5,000,000 in four tranches during 2014.&#160; LifeMap Sciences will use the proceeds from the sale to provide capital to Solutions.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime will also have an option to purchase up to an additional 9,500,000 shares of LifeMap Sciences common stock for $2.00 per share in two tranches related to the attainment of certain product development milestones by Solutions.&#160; If BioTime exercises its option it may pay for those LifeMap Sciences shares in up to three installments for each tranche, in cash or in BioTime common shares at the then current market value determined as of the date the option is exercised based on the average closing price of BioTime common shares on the NYSE MKT for the preceding 20 trading days.&#160; The number of shares of LifeMap Sciences common stock that BioTime may purchase will be reduced to the extent that LifeMap Sciences raises capital from other sources for product development under the Agreement with Mt Sinai.</div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">These condensed consolidated financial statements were approved by management and the Board of Directors, and were issued on May 12<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font> 2014 (unaudited).&#160; Subsequent events have been evaluated through that date.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Contribution Agreement<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetContributionAgreementAbstract', window );"><strong>Asset Contribution Agreement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetContributionAgreementTextBlock', window );">Asset Contribution Agreement</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8. </font>Asset Contribution Agreement</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On January 4, 2013, BioTime and Asterias entered into an Asset Contribution Agreement with Geron Corporation (&#8220;Geron&#8221;) pursuant to which BioTime and Geron agreed to concurrently contribute certain assets to Asterias in exchange for shares of Asterias common stock.&#160; The transaction closed on October 1, 2013.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Transfer of BioTime Assets</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Asset Contribution Agreement, BioTime contributed to Asterias 8,902,077 BioTime common shares registered for re-sale under the Securities Act of 1933, as amended, warrants to subscribe for and purchase 8,000,000 additional BioTime common shares (the &#8220;BioTime Warrants&#8221;) exercisable for a period of five years at a price of $5.00 per share, subject to pro rata adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions; a 10% common stock interest in BioTime&#8217;s subsidiary OrthoCyte; a 6% ordinary share interest in BioTime&#8217;s subsidiary Cell Cure Neurosciences; and a quantity of certain hES cell lines produced under &#8220;good manufacturing practices&#8221; sufficient to generate master cell banks, and non-exclusive, world-wide, royalty-free licenses to use those cell lines and certain patents pertaining to stem cell differentiation technology for any and all purposes.&#160; In return, Asterias issued to BioTime 21,773,340 shares of its Series B common stock, par value $0.0001 per share (&#8220;Series B Shares&#8221;), and warrants to purchase 3,150,000 Series B Shares, exercisable for a period of three years from the date of issue at an exercise price of $5.00 per share.&#160; In addition, BioTime cancelled Asterias&#8217; obligations to repay the principal amount of a loan in the amount of $5,000,000 arising from cash financing provided to Asterias by BioTime during 2013 prior to the closing of the asset contribution transaction under the Asset Contribution Agreement.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Because Asterias is a subsidiary of BioTime, the transfer of assets from BioTime was accounted for as a transaction under common control.&#160; Non-monetary assets received by Asterias were recorded at their historical cost basis amounts with BioTime.&#160; Monetary assets were recorded at fair value.&#160; The difference between the value of assets contributed by BioTime and the fair value of consideration issued to BioTime was recorded as an additional contribution by BioTime, in additional paid-in capital.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The assets transferred by BioTime and the related consideration paid were recorded as follows:</div><div style="margin-top: 3pt; margin-bottom: 3pt;"><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Consideration transferred to BioTime:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Asterias Series B shares</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">52,164,568</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warrants to purchase Asterias Series B shares</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,012,481</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Excess of contributed assets&#8217; value over consideration</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,800,063</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total consideration issued</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">58,977,112</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Assets transferred by BioTime:</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">BioTime common shares, at fair value</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,985,163</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">BioTime Warrants, at fair value</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,276,406</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Cancellation of outstanding obligation to BioTime</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">5,000,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Investment in affiliates, at cost</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">415,543</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Geron asset acquisition related transaction costs paid by BioTime</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">300,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total assets transferred</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">58,977,112</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The fair value of the Asterias Series B shares issued was estimated at $2.40 based on the Asterias enterprise value as determined on January 4, 2013, at the time the Asset Contribution Agreement was negotiated and executed by its parties, and as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.&#160; The fair value of the warrants to purchase Asterias Series B shares was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions:&#160; expected term equal to the contractual term of three years, which is equal to the contractual life of the warrants; risk-free rate of 0.63%; 0% expected dividend yield; 69.62% expected volatility based on the average historical common stock volatility of BioTime and Geron, which were used as Asterias&#8217; common stock does not have a trading history; a stock price of $2.40; and an exercise price of $5.00.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime common shares were valued at $3.93 using the closing price per BioTime common shares on the NYSE MKT on October 1, 2013.&#160; The fair value of the BioTime Warrants was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of five years, which is equal to the contractual life of the warrants; risk-free rate of 1.42%; 0% expected dividend yield; 77.63% expected volatility based on historical common stock volatility of BioTime; a stock price of $3.93; and an exercise price of $5.00.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The investment in OrthoCyte and Cell Cure Neurosciences stock represents a non-monetary asset and was recorded at BioTime&#8217;s historical cost because BioTime is a common parent to Asterias and those two BioTime subsidiaries.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Geron Assets Acquisition</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Asset Contribution Agreement, Geron contributed to Asterias certain patents, patent applications, trade secrets, know-how and other intellectual property rights with respect to the technology of Geron directly related to the research, development and commercialization of certain products and know-how related to hES cells; certain biological materials, reagents, laboratory equipment; as well as clinical trial documentation, files and data, primarily related to GRNOPC1 clinical trials for spinal cord injury and VAC1 clinical trials for acute myelogenous leukemia. Asterias assumed all obligations related to such assets that would be attributable to periods, events or circumstances after the Asset Contribution Agreement closing date, including those related to an appeal filed in the United States District Court in Civil Action No. C12-04813 (the &#8220;ViaCyte Appeal&#8221;) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office&#8217;s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving US patent 7,510,876 (ViaCyte) and US patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving US patent 7,510,876 (ViaCyte) and US patent application 12/543,875 (Geron).&#160; Asterias also assumed the patent interferences upon which the ViaCyte Appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte, Inc. patent filings in Australia and in the European Patent Office.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As consideration for the acquisition of assets from Geron, Asterias issued to Geron 6,537,779 shares of Series A common stock, par value $0.0001 per share (&#8220;Series A Shares&#8221;), which Geron had agreed to distribute to its stockholders, on a pro rata basis, subject to applicable legal requirements and certain other limitations (the &#8220;Series A Distribution&#8221;).&#160; Asterias is also obligated to distribute to the holders of its Series A Shares the 8,000,000 shares of BioTime Warrants contributed to Asterias by BioTime.&#160; Asterias will distribute the BioTime Warrants as promptly as practicable after notice from Geron that the Series A Distribution has been completed.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In addition, Asterias agreed to bear certain transaction costs in connection with the Geron asset acquisition.&#160; Such transaction costs were allocated to acquisition of assets in the amount of $1,519,904 and issuance of equity in the amount of $541,800.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The assets contributed to Asterias by Geron did not include workforce or any processes to be applied to the patents, biological materials, and other assets acquired, and therefore did not constitute a business.&#160; Accordingly, the acquisition of the Geron assets has been accounted for as an acquisition of assets in accordance with the relevant provisions of Accounting Standards Codification (ASC) 805-50.&#160; Total consideration payable by Asterias, including transaction costs, has been allocated to the assets acquired based on relative fair values of those assets as of the date of the transaction, October 1, 2013, in accordance with ASC 820, Fair Value Measurement.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The assets acquired from Geron and the related consideration were recorded as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Consideration paid to Geron:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Asterias Series A shares, net of share issuance costs of $541,800</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,121,222</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Obligation to distribute BioTime Warrants</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,276,406</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Transaction and other costs</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,519,904</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total consideration paid</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,917,532</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Assets acquired from Geron (preliminary allocation):</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Patents and other intellectual property rights related to hES cells</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">29,017,009</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(11,558,243</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">IPR&amp;D expensed upon acquisition</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">17,458,766</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Total assets and in-process research and development acquired</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">34,917,532</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The fair value of the Asterias Series A shares issued was estimated at $2.40 based on the estimated Asterias enterprise value as determined by parties at the time the Asset Contribution Agreement was negotiated and executed by its parties on January 4, 2013, as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The fair value of the obligation to distribute BioTime Warrants equals the fair value of such warrants, which was computed as noted above under &#8220;Transfer of BioTime Assets.&#8221;&#160; Because the fair value of the BioTime Warrants is expected to always be equal to the fair value of the obligation to distribute them at any date on which those values are determined, the remeasurement of those values will not result in a charge or credit on the statement of operations.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The difference between the fair value of assets contributed by Geron and the fair value of consideration issued to Geron was recorded as an additional contribution by Geron, in additional paid-in capital, because the fair value of the assets transferred by Geron was more reliably determined.</div><div>&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Assets acquired from Geron consist primarily of patents and other intellectual property rights related to hES cells which Asterias intends to license to various parties interested in research, development and commercialization of hES cells technologies, and IPR&amp;D, which includes biological materials, reagents, clinical trial documentation, files and data related primarily to certain clinical trials previously conducted by Geron, which Geron discontinued in November 2011.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div></div><div><div style="text-indent: 36pt;">Intangible assets related to IPR&amp;D represent the value of incomplete research and development projects which the company intends to continue.&#160; In accordance with the accounting rules in ASC 805, such assets, when acquired in conjunction with acquisition of a business, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&amp;D are expensed upon acquisition.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The values of the acquired assets were estimated at October 1, 2013 based upon a preliminary review of those assets which took into account factors such as the condition of the cells, cell lines and other biological materials being contributed, the stage of development of particular technology and product candidates related to patents, patent applications, and know-how, the intended use of these assets and the priority assigned to the development of product candidates to which those assets relate, and the assessment of the estimated useful lives of patents.&#160; The amounts allocated to patents and other intellectual property rights that Asterias intends to license were capitalized as intangible assets and are being amortized over an estimated useful life period of 10 years.&#160; The amounts allocated to IPR&amp;D were expensed at the time of acquisition of the related assets in accordance with the requirements of ASC 805-50.&#160; The allocation was based on the relative fair value of assets eligible for capitalization and the fair value of assets representing IPR&amp;D before assessing the deferred tax liability arising from the difference in book versus tax basis on Geron intangible assets acquired, which management estimated to be approximately equal.&#160; Accordingly, $17,458,766 was capitalized as of December 31, 2013, and $17,458,766 was expensed.&#160; These amounts are preliminary as management has not yet completed a detailed assessment and valuation of the acquired assets.&#160; Such assessment and valuation is expected to be completed during the quarter ending June 30, 2014.&#160; Accordingly, the amounts included in capitalized intangible assets and expensed IPR&amp;D as of December 31, 2013 are subject to adjustments which could be material.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias is also obligated to pay Geron royalties on the sale of products, if any, that are commercialized in reliance upon patents acquired from Geron, at the rate of 4% of net sales.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock and Warrant Purchase Agreement with Romulus</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On January 4, 2013, in connection with entering into the Asset Contribution Agreement, Asterias entered into a Stock and Warrant Purchase Agreement with Romulus Films, Ltd (&#8220;Romulus&#8221;) pursuant to which Romulus agreed to purchase 2,136,000 Series B Shares and warrants to purchase 350,000 additional Series B Shares for $5,000,000 in cash upon the consummation of the acquisition of assets under the Asset Contribution Agreement.&#160; On October 1, 2013, the shares and warrants were issued in exchange for $5,000,000 in cash.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetContributionAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetContributionAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetContributionAgreementTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for Asset Contribution Agreement pursuant to which the entity contributes certain assets in exchange for shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AssetContributionAgreementTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BusinessAcquisitionsProformaInformationTextBlock', window );">Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">9. Unaudited Pro Forma Interim Financial Information &#8211; Three Months Ended March 31, 2014 and 2013</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013.&#160; The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.</div><div style="text-align: left; text-indent: 49.5pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 5.5pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.1pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Revenues, net</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">934,721</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">493,705</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Net loss available to common shareholders</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(8,099,014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(</font>22,572,852</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Net loss per common share &#8211; basic and diluted</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(</font>0.38</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BusinessAcquisitionsProformaInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entire disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_BusinessAcquisitionsProformaInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">General</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">General</font> &#8211; BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (&#8220;hES&#8221;) cell and induced pluripotent stem (&#8220;iPS&#8221;) cell technology.&#160; Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.&#160; hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products.&#160; BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use.&#160; Asterias Biotherapeutics, Inc. (&#8220;Asterias&#8221;) acquired the stem cell assets of Geron Corporation (&#8220;Geron&#8221;) that had been used in Geron&#8217;s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction.&#160; OncoCyte Corporation (&#8220;OncoCyte&#8221;) is developing products and technologies to diagnose cancer.&#160; ES Cell International Pte Ltd. (&#8220;ESI&#8221;), a Singapore private limited company, and BioTime&#8217;s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets.&#160; OrthoCyte Corporation (&#8220;OrthoCyte&#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries.&#160; ReCyte Therapeutics, Inc. (&#8220;ReCyte Therapeutics&#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.&#160; Cell Cure Neurosciences Ltd. (&#8220;Cell Cure Neurosciences&#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.&#160; LifeMap Sciences, Inc. (&#8220;LifeMap Sciences&#8221;) markets, sells and distributes <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">GeneCards</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, the leading human gene database and an integrated database suite that includes <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">GeneCards</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, the <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Discovery</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries.&#160; Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.&#160; BioTime&#8217;s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hextend</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, from the sale of products for research, and from research grants.&#160;</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime&#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X.&#160; In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made.&#160; The&#160;consolidated balance sheet as of December 31, 2013 is derived from the Company&#8217;s annual audited financial statements as of that date.&#160; The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) except for the&#160;consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements.&#160; Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods.&#160; It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&#8217;s Form 10-K for the year ended December 31, 2013.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Principles of consolidation</font> &#8211; BioTime&#8217;s consolidated financial statements include the accounts of its subsidiaries.&#160; The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.</div><div style="margin-top: 3pt; margin-bottom: 3pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="border-bottom: medium none; border-left: medium none; width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; border-top: medium none; border-right: medium none;"><tr style="height: 33px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Subsidiary</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Field of Business</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">BioTime </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Ownership</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Country</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias Biotherapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">71.6%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ES Cell International Pte Ltd</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research, including clinical grade cell lines</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">produced under cGMP</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Singapore</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OncoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cancer diagnostics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75.3%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OrthoCyte Corporation</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Orthopedic diseases, including chronic back pain and osteoarthritis</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">100%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cell Cure Neurosciences Ltd.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Age-related macular degeneration</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Multiple sclerosis</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Parkinson&#8217;s disease</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">62.5%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ReCyte Therapeutics, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">94.8%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr style="height: 13px;"><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime Asia, Limited</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell products for research</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">81%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hong Kong</div></td></tr><tr><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Inc.</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Genetic, disease, and stem cell databases</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">73.2%</div></td><td style="border-bottom: medium none; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">USA</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 30%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">LifeMap Sciences, Ltd.</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 49.98%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stem cell database</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 10.12%; vertical-align: top; border-top: #000000 2px solid; border-right: medium none;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1)</div></td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #cceeff; width: 9.9%; vertical-align: top; border-top: #000000 2px solid; border-right: #000000 2px solid;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Israel</div></td></tr><tr><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 30%; vertical-align: top; border-right: medium none;">LifeMap Solutions, Inc.</td><td style="border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff; width: 49.98%; vertical-align: top; border-right: medium none;">Mobile health software</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 10.12%; vertical-align: top; border-right: medium none;">(1)</td><td style="border-bottom: #000000 2px solid; text-align: center; border-left: #000000 2px solid; background-color: #ffffff; width: 9.9%; vertical-align: top; border-right: #000000 2px solid;">USA</td></tr></table><div style="text-align: left; text-indent: -27pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; align: right;">(1)</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td></tr></table></div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">All material intercompany accounts and transactions have been eliminated in consolidation.&#160; The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the accounting and reporting requirements of SEC Regulation S-X.&#160; As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&#8220;BioTime Asia&#8221;), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime&#8217;s condensed consolidated balance sheets.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock', window );">Certain significant risks and uncertainties</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Certain significant risks and uncertainties</font> &#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition.&#160; Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Use of estimates</font> &#8211; The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ from those estimates.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue recognition</font> &#8211; BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition.&#160; Royalty revenues consist of product royalty payments.&#160; License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods.&#160; Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable.&#160; Royalties consist primarily of royalties earned on sales of <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Hextend</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place.&#160; When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured.&#160; When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period.&#160; If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated.&#160; Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned.&#160; Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable and allowance for doubtful accounts</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounts receivable and allowance for doubtful accounts</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> &#8211;&#160; Total trade receivables amounted to approximately $600,400 and </font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$575,900 </font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">and grants receivable amounted to approximately $334,700 and $</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">539,300</font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> as of March 31, 2014 and December 31, 2013, respectively.&#160; Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013.&#160; BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience.&#160; An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position.&#160;&#160;If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents.&#160; BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions.&#160; Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Inventory &#8211;</font> Inventories are stated at the lower of cost or market.&#160; Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Equipment</font> &#8211; Equipment is stated at cost.&#160; Equipment is being depreciated using the straight-line method over a period of 36 to 120 months.&#160; See Note 3.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Intangible assets</font> &#8211; Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment.&#160; Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business.&#160; When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset.&#160; If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&#160; However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition. See Note 8.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TreasuryStockPolicyTextBlock', window );">Treasury stock</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet.&#160; BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsToPurchaseCommonStockPolicyTextBlock', window );">Warrants to purchase common stock</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Warrants to purchase common stock </font>&#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity.&#160; None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&#160; If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent costs</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred.&#160; This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the &#8220;FASB&#8221;) regarding goodwill and other intangible assets.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets.&#160; Additionally, we have carved out the loss on sale of fixed assets amount from other expenses.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development</font> &#8211; BioTime complies with FASB requirements governing accounting for research and development costs.&#160; Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation gain/loss and Comprehensive net loss</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Foreign currency translation gain and Comprehensive loss &#8211;</font> In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date.&#160; Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period.&#160; Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet.&#160; For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that&#160;are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense),&#160;amounted to $10,212 and $21,977, respectively.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect.&#160; Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized.&#160; The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.&#160; For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities.&#160; For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias&#8217; tax provision with BioTime&#8217;s.&#160; BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively.&#160; BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions.&#160; Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.&#160; Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws.&#160; Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes.&#160; A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes.&#160; No tax benefit had been recorded through <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">September 30, 2013</font> because of the net operating losses incurred and a full valuation allowance had been provided.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock-based compensation &#8211;</font> BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values.&#160; In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments.&#160; BioTime has applied the provisions of this guidance in such valuations as well.&#160; Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model.&#160; BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables.&#160; These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&#160; The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior.&#160; The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant.&#160; Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Impairment of long-lived assets &#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable.&#160; If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets.&#160; If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred license and consulting fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.&#160; The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products.&#160; See Note 5.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Loss per share</font> &#8211; Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period.&#160; Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive.&#160; Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Effect of recently issued and recently adopted accounting pronouncements</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Effect of recently issued and recently adopted accounting pronouncements </font>&#8211; There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for certain significant risks and uncertainties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_CertainSignificantRisksAndUncertaintiesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TreasuryStockPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for an entity's treasury stock, including common shares issued to subsidiaries for future potential working capital needs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_TreasuryStockPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsToPurchaseCommonStockPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for an entity's warrants to purchase common stock, including common shares issued to subsidiaries for future potential working capital needs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_WarrantsToPurchaseCommonStockPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 2110<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number SOP94-6-1<br><br> -Paragraph 7, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14537-108613<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 113<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6487554&amp;loc=d3e32600-158583<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13531-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 14<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 140<br><br> -Paragraph 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 97-2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 5, 6, 16-19<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 96-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959686&amp;loc=d3e355033-122828<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197414<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408645&amp;loc=d3e63676-111659<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfSalesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredChargesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 8, 10, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175856<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175826<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175892<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 5, 7-20, 80<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-18, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 4, 11-23, 26, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-15, 26, 30-37<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 4<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 6-34, 43, 47, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS142-3<br><br> -Paragraph c<br><br> -Subparagraph c<br><br> -Appendix A1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Paragraph 3, 5-10, 15, 16, 17<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4492-108314<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4556-108314<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 69-75<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section C<br><br> -Paragraph 5<br><br> -Chapter 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 06-11<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TradeAndOtherAccountsReceivablePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following:</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accounts payable</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,527,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,887,950</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued bonuses</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">229,905</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Other accrued liabilities</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,685,828</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,234,674</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">5,443,063</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">6,722,624</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Equipment, furniture and fixtures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, furniture and fixtures</a></td>
        <td class="nump">$ 4,645,077<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,431,586<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="num">(1,685,927)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,433,853)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
        <td class="nump">2,959,150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997,733<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 256,945<span></span></td>
        <td class="nump">$ 113,356<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3IBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to BioTime, Inc.</a></td>
        <td class="num">$ (8,099,014)<span></span></td>
        <td class="num">$ (7,719,263)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">256,945<span></span></td>
        <td class="nump">113,356<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump">1,367,998<span></span></td>
        <td class="nump">642,573<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfDeferredConsultingFees', window );">Amortization of deferred consulting fees</a></td>
        <td class="nump">16,279<span></span></td>
        <td class="nump">16,280<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees', window );">Amortization of deferred license fees</a></td>
        <td class="nump">27,375<span></span></td>
        <td class="nump">27,375<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfDeferredRent', window );">Amortization of deferred rent</a></td>
        <td class="num">(5,040)<span></span></td>
        <td class="num">(2,222)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred license, royalty and subscription revenues</a></td>
        <td class="num">(280)<span></span></td>
        <td class="num">(42,996)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfStockBasedPrepaidRent', window );">Amortization of stock-based prepaid rent</a></td>
        <td class="nump">21,146<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss allocable to non-controlling interest</a></td>
        <td class="num">(1,629,017)<span></span></td>
        <td class="num">(689,282)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">801,554<span></span></td>
        <td class="nump">691,946<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
        <td class="num">(1,349,026)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Loss on sale or write-off of equipment</a></td>
        <td class="nump">8,576<span></span></td>
        <td class="nump">1,523<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenues</a></td>
        <td class="num">(57,402)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="num">(24,441)<span></span></td>
        <td class="num">(82,916)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncreaseDecreaseInGrantReceivable', window );">Grant receivable</a></td>
        <td class="nump">202,122<span></span></td>
        <td class="nump">371,886<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num">(57,894)<span></span></td>
        <td class="nump">2,981<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(375,224)<span></span></td>
        <td class="num">(243,798)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(1,276,211)<span></span></td>
        <td class="num">(101,319)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
        <td class="num">(185,717)<span></span></td>
        <td class="num">(7,806)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(10,357,271)<span></span></td>
        <td class="num">(7,021,682)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
        <td class="num">(231,921)<span></span></td>
        <td class="num">(496,128)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SecurityDepositReceived', window );">Security deposit paid, net</a></td>
        <td class="num">(299,697)<span></span></td>
        <td class="num">(54,423)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump">4,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
        <td class="num">(527,618)<span></span></td>
        <td class="num">(550,551)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromEmployeeOptionsExercised', window );">Employee options exercised</a></td>
        <td class="nump">12,500<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromDirectorOptionsExcercised', window );">Director options exercised</a></td>
        <td class="nump">46,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
        <td class="nump">8,182,559<span></span></td>
        <td class="nump">11,699,340<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FeesPaidOnSaleOfCommonShares', window );">Fees paid on sale of common shares</a></td>
        <td class="num">(212,046)<span></span></td>
        <td class="num">(319,625)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Proceeds from sale of treasury shares</a></td>
        <td class="nump">599,472<span></span></td>
        <td class="nump">1,602,921<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock</a></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of common shares of subsidiary</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">130,502<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">12,128,485<span></span></td>
        <td class="nump">13,113,138<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
        <td class="num">(101,240)<span></span></td>
        <td class="nump">5,463<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS:</a></td>
        <td class="nump">1,142,356<span></span></td>
        <td class="nump">5,546,368<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>CASH AND CASH EQUIVALENTS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At beginning of the period</a></td>
        <td class="nump">5,495,478<span></span></td>
        <td class="nump">4,349,967<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At end of the period</a></td>
        <td class="nump">6,637,834<span></span></td>
        <td class="nump">9,896,335<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
        <td class="nump">8,472<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for consulting services</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">77,280<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CommonSharesIssuedForRent', window );">Common shares issued for rent</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 242,720<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfDeferredConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmortizationOfDeferredConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred license fees and royalty fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmortizationOfDeferredLicenseFeesAndRoyaltyFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmortizationOfDeferredRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfStockBasedPrepaidRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of amortization of stock based prepaid rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_AmortizationOfStockBasedPrepaidRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CommonSharesIssuedForRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of common shares issued for rent in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_CommonSharesIssuedForRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FeesPaidOnSaleOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with fee paid on sale of common shares during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_FeesPaidOnSaleOfCommonShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncreaseDecreaseInGrantReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period for amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_IncreaseDecreaseInGrantReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromDirectorOptionsExcercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their Director options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ProceedsFromDirectorOptionsExcercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromEmployeeOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ProceedsFromEmployeeOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SecurityDepositReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow/(outflow) associated with security deposit received during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_SecurityDepositReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of amortization of deferred charges applied against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDeferredCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 26<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743430&amp;loc=d3e92212-112881<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7, 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591551-111686<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow contributed by noncontrolled interest that purchase additional shares or otherwise increase their ownership stake in a subsidiary of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromMinorityShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfTreasuryStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Royalty Obligation and Deferred License Fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">Royalty Obligation and Deferred License Fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">5. Royalty Obligation and Deferred License Fees</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products.&#160; BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing.&#160; The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired.&#160; BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">WARF License&#8212;Research Products</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;).&#160; The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development.&#160; BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF.&#160; The royalty will range from 2% to 4%, depending on the kind of products sold.&#160; The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product.&#160; BioTime paid licensing fees, totaling $295,000 in cash and BioTime stock, and reimbursed WARF for certain costs associated with preparing, filing, and maintaining the licensed patents.&#160; In addition, BioTime pays WARF $25,000 annually as a license maintenance fee.&#160; The licensing fees less the amortized portion were included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ReCyte Therapeutics Licenses from ACT</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc. (&#8220;ACT&#8221;), under which ReCyte Therapeutics acquired exclusive worldwide rights to use ACT&#8217;s &#8220;<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ACTCellerate</font>&#8482;&#8221; technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells.&#160; ReCyte Therapeutics paid ACT a $250,000 license fee.&#160; ReCyte Therapeutics has assigned its rights under the License Agreement to BioTime.&#160; BioTime will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology.&#160; Once a total of $1,000,000 of royalties has been paid, no further royalties will be due.&#160; The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later.&#160; The $250,000 license fee less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On August 15, 2008, ReCyte Therapeutics entered into a License Agreement and a Sublicense Agreement with ACT under which ReCyte Therapeutics acquired world-wide rights to use an array of ACT technology (the &#8220;ACT License&#8221;) and technology licensed by ACT from affiliates of Kirin Pharma Company, Limited (the &#8220;Kirin Sublicense&#8221;).&#160; The ACT License and Kirin Sublicense permit the commercialization of products in human therapeutic and diagnostic product markets.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The technology licensed by ReCyte Therapeutics covers methods to transform cells of the human body, such as skin cells, into an embryonic state in which the cells will be pluripotent.&#160; Under the ACT License, ReCyte Therapeutics paid ACT a $200,000 license fee and will pay a 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the ACT technology to third parties.&#160; Once a total of $600,000 of royalties has been paid, no further royalties will be due.&#160; The license will expire in twenty years or upon the expiration of the last-to-expire of the licensed patents, whichever is later.&#160; The $200,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Kirin Sublicense, ReCyte Therapeutics has paid ACT a $50,000 license fee and will pay a 3.5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the Kirin Technology to third parties.&#160; ReCyte Therapeutics will also pay to ACT or to an affiliate of Kirin Pharma Company, Limited (&#8220;Kirin&#8221;), annually, the amount, if any, by which royalties payable by ACT under its license agreement with Kirin are less than the $50,000 annual minimum royalty due.&#160; Those payments by ReCyte Therapeutics will be credited against other royalties payable to ACT under the Kirin Sublicense.&#160; The license will expire upon the expiration of the last to expire of the licensed patents, or May 9, 2016 if no patents are issued.&#160; The $50,000 license fee payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ReCyte Therapeutics License from RGI</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On February 29, 2009, ReCyte Therapeutics entered into a Stem Cell Agreement with Reproductive Genetics Institute (&#8220;RGI&#8221;).&#160; In partial consideration of the rights and licenses granted to ReCyte Therapeutics by RGI, BioTime issued to RGI 32,259 common shares, having a market value of $50,000 on the effective date of the Stem Cell Agreement.&#160; This $50,000 payment less the amortized portion is included in deferred license fees in BioTime&#8217;s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OncoCyte License from SBMRI</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Through BioTime&#8217;s acquisition of the assets of Cell Targeting, Inc. during March 2011, BioTime acquired a royalty-bearing, exclusive, worldwide license from the Sanford-Burnham Medical Research Institute (&#8220;SBMRI&#8221;) to use certain patents pertaining to homing peptides for preclinical research investigations of cell therapy treatments, and to enhance cell therapy products for the treatment and prevention of disease and injury in conjunction with BioTime&#8217;s own proprietary technology or that of a third party.&#160; BioTime assigned the SBMRI license to OncoCyte during July 2011.&#160; OncoCyte will pay SBMRI a royalty of 4% on the sale of pharmaceutical products, and 10% on the sale of any research-use products that OncoCyte develops using or incorporating the licensed technology; and 20% of any payments OncoCyte receives for sublicensing the patents to third parties.&#160; The royalties payable to SBMRI may be reduced by 50% if royalties or other fees must be paid to third parties in connection with the sale of any products.&#160; An annual license maintenance fee is payable each year during the term of the license, and after commercial sales of royalty bearing products commence, the annual fee will be credited towards OncoCyte's royalty payment obligations for the applicable year.&#160; OncoCyte will reimburse SBMRI for 25% of the costs incurred in filing, prosecuting, and maintaining patent protection, subject to OncoCyte&#8217;s approval of the costs.&#160; OncoCyte incurred no royalty expenses to date as of March 31, 2014.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cell Cure Neurosciences License from Hadasit</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit Medical Research Services and Development, Ltd. (&#8220;Hadasit&#8221;) under which Cell Cure Neurosciences received an exclusive license to use certain of Hadasit&#8217;s patented technologies for the development and commercialization for hES cell-derived cell replacement therapies for retinal degenerative diseases.&#160; Cell Cure Neurosciences paid Hadasit 249,058 New Israeli Shekels as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;) exercises its option to license <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> or <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-Plus</font> under the terms of a Research and Exclusive License Option Agreement (the &#8220;Teva License Option Agreement&#8221;), Cell Cure Neurosciences will pay Hadasit 30% of all sublicensing payments made by Teva to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If Teva does not exercise its option and Cell Cure Neurosciences instead commercializes <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> or <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-Plus</font> itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> or <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-Plus</font>, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology.&#160; Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents to companies other than Teva.&#160; Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year.&#160; If Cell Cure Neurosciences or a sublicensee other than Teva paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If Teva does not exercise its option under the Teva License Option Agreement and instead Cell Cure Neurosciences or a sublicensee other than Teva conducts clinical trials of <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup> or <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">OpRegen</font><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-Plus</font>, Hadasit will be entitled to receive certain milestone payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents.&#160; Hadasit will receive $250,000 upon the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial.&#160; These milestone payments are creditable by Cell Cure Neurosciences against sublicensing receipts that are payable to Hadasit at the time of each milestone payment for said milestone payment, except that the $1 million milestone payment shall only be creditable by Cell Cure Neurosciences if it received the sublicensing receipts in the amount of $50 million.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime License for the University of Utah</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Through the merger of Glycosan into OrthoCyte during March 2011, BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products.&#160; Under the License Agreement, the scope of which was expanded by an amendment during August 2012, BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents.&#160; Commencing in 2014, BioTime will be obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount.&#160; The minimum royalty amounts are $2,500 in 2014 and $30,000 each year thereafter during the term of the License Agreement.&#160; BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses.&#160; BioTime will also pay a $225,000 milestone fee within six months after the first sale of a &#8220;tissue engineered product&#8221; that utilizes a licensed patent.&#160; A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime License from Cornell University</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On August 23, 2011, BioTime entered into a License Agreement with Cornell University for the worldwide development and commercialization of technology for the differentiation of hES cells into vascular endothelial cells.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cornell will be entitled to receive a nominal initial license fee and nominal annual license maintenance fees.&#160; The obligation to pay annual license maintenance fees will end when the first human therapeutic products developed under the license is sold.&#160; BioTime will pay Cornell a milestone payment upon the achievement of a research product sale milestone amount, and will make milestone payments upon the attainment of certain FDA approval milestones for therapeutic products developed under the license, including (i) the first Phase II clinical trial dosing of a human therapeutic product, (ii) the first Phase III clinical trial dosing of a human therapeutic product; (iii) FDA approval of the first human therapeutic product for age-related vascular disease; and (iv) FDA approval of the first human therapeutic product for cancer.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">BioTime will pay Cornell royalties on the sale of products and services using the license, and will share with Cornell a portion of any cash payments, other than royalties, that BioTime receives for the grant of sublicenses to non-affiliates.&#160; The potential royalty percentage rates to be paid to Cornell will be in the low to mid-single digit range depending on the product.&#160; BioTime will also reimburse Cornell for costs related to the patent applications and any patents that may issue that are covered by the license.</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In conjunction with the License Agreement, BioTime also entered into a Sponsored Research Agreement under which scientists at Weill Cornell Medical College will engage in certain research for BioTime over a three year period beginning August 2011.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias License from WARF</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products.&#160; The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells.&#160; The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines.</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire.&#160; Asterias may terminate the license agreement at any time by giving WARF prior written notice.&#160; WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time.&#160; WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias License from the University of California</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Geron assigned to Asterias its Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents.&#160; Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement.&#160; The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement.&#160; Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias&#8217; affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent.&#160; The license agreement will terminate on the expiration of the last-to-expire of the university's issued licensed patents.&#160; If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024.&#160; The university may terminate the agreement in the event of Asterias&#8217; breach of the agreement.&#160; Asterias can terminate the agreement upon 60 days' notice.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias Sublicense from Geron</div><div><br /></div><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado&#8217;s University License Equity Holdings, Inc. relating to telomerase (the &#8220;Telomerase Sublicense&#8221;).&#160; The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of VAC1 and VAC2 as immunological treatments for cancer.&#160; Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents.&#160; The Telomerase Sublicense will expire concurrently with the expiration of Geron&#8217;s license.&#160; That license will terminate during April 2017 when the licensed patents expire.&#160; The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party. See Note 8.</div><div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of March 31, 2014, future amortization of deferred license fees described above was as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; margin-left: 45pt; font-size: 10pt;"><tr><td valign="bottom" style="width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Deferred License</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fees</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2014</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">83,615</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2015</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2016</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2017</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Thereafter</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,843</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Total</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">528,458</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 5<br><br> -Paragraph 83, 84<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
        <td class="nump">$ 54,719,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 54,719,918<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num">(9,879,831)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,511,833)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
        <td class="nump">44,840,087<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,208,085<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump">$ 1,367,998<span></span></td>
        <td class="nump">$ 642,573<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>72</ContextCount>
  <ElementCount>256</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPolicies</Role>
      <ShortName>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/Equipment</Role>
      <ShortName>Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssets</Role>
      <ShortName>Intangible assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Royalty Obligation and Deferred License Fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees</Role>
      <ShortName>Royalty Obligation and Deferred License Fees</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Asset Contribution Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AssetContributionAgreement</Role>
      <ShortName>Asset Contribution Agreement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013</Role>
      <ShortName>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>070100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>080100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>080300 - Disclosure - Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquipmentTables</Role>
      <ShortName>Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Royalty Obligation and Deferred License Fees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables</Role>
      <ShortName>Royalty Obligation and Deferred License Fees (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080800 - Disclosure - Asset Contribution Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AssetContributionAgreementTables</Role>
      <ShortName>Asset Contribution Agreement (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Tables</Role>
      <ShortName>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndSummaryOfSelectSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquipmentDetails</Role>
      <ShortName>Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Royalty Obligation and Deferred License Fees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails</Role>
      <ShortName>Royalty Obligation and Deferred License Fees (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090802 - Disclosure - Asset Contribution Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AssetContributionAgreementDetails</Role>
      <ShortName>Asset Contribution Agreement (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/UnauditedProFormaInterimFinancialInformationThreeMonthsEndedMarch312014And2013Details</Role>
      <ShortName>Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element btx_FeesForResearchUse had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element btx_FeesForSublicensePercentage had a mix of decimals attribute values: 1 3.</Log>
    <Log type="Info">Element btx_RoyaltyPercentage had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_CommonStockNoParValue had a mix of decimals attribute values: 0 4.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Process Flow-Through: 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</Log>
    <Log type="Info">Process Flow-Through: 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>btx-20140331.xml</File>
    <File>btx-20140331.xsd</File>
    <File>btx-20140331_cal.xml</File>
    <File>btx-20140331_def.xml</File>
    <File>btx-20140331_lab.xml</File>
    <File>btx-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Royalty Obligation and Deferred License Fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock', window );">Amortization of deferred license fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 45pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of March 31, 2014, future amortization of deferred license fees described above was as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; margin-left: 45pt; font-size: 10pt;"><tr><td valign="bottom" style="width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Deferred License</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fees</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2014</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">83,615</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2015</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2016</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2017</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Thereafter</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">111,843</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 68%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Total</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">528,458</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the estimated aggregate amortization expense for deferred license fees subject to amortization for each of the five succeeding fiscal years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
